

0000320335-24-00006010-Q GLOBE LIFE INC. 2624110620241106170109170109170109 0 0000320335-24-000060 10-Q 105 20240930 20241106 20241106 GLOBE LIFE INC. 0000320335-6311 630780404 DE 1231 10-Q 34 001-08052 241432007 3700 SOUTH STONEBRIDGE DRIVE MCKINNEY TX 75070 972-569-4000 3700 SOUTH STONEBRIDGE DRIVE MCKINNEY TX 75070 TORCHMARK CORP 19920703 TORCHMARK CORP SAVINGS & INVESTMENT PLAN 19820825 LIBERTY NATIONAL INSURANCE HOLDING CO 19820701 10-Q 1 gl-20240930.htm 10-Q (Q3 2024) gl-20240930000032033512/312024Q3FALSEhttp://fasb.org/us-gaap/2024#RealizedInvestmentGainsLosseshhttp://fasb.org/us-gaap/2024#OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParenthttp://fasb.org/us-gaap/2024#RealizedInvestmentGainsLosseshhttp://fasb.org/us-gaap/2024#OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParenthttp://shareholders.usdiso4217:USDxbrli:sharesgl:segmentxbrli:puregl:issuergl:laongl:commercial_member-01-012024-09-300000320335us-gaap:CommonStockMember2024-01-012024-09-300000320335gl:JuniorSubordinatedDebenturesMember2024-01-012024-09-3000003203352024-10-3100003203352024-09-3000003203352023-12-310000320335gl:PartnershipInterestFairValueOptionMember2024-09-300000320335gl:PartnershipInterestFairValueOptionMember2023-12-310000320335us-gaap:LifeInsuranceSegmentMember2024-07-012024-09-300000320335us-gaap:LifeInsuranceSegmentMember2023-07-012023-09-300000320335us-gaap:LifeInsuranceSegmentMember2024-01-012024-09-300000320335us-gaap:LifeInsuranceSegmentMember2023-01-012023-09-300000320335us-gaap:HealthInsuranceProductLineMember2024-07-012024-09-300000320335us-gaap:HealthInsuranceProductLineMember2023-07-012023-09-300000320335us-gaap:HealthInsuranceProductLineMember2024-01-012024-09-300000320335us-gaap:HealthInsuranceProductLineMember2023-01-012023-09-300000320335us-gaap:OtherInsuranceProductLineMember2024-07-012024-09-300000320335us-gaap:OtherInsuranceProductLineMember2023-07-012023-09-300000320335us-gaap:OtherInsuranceProductLineMember2024-01-012024-09-300000320335us-gaap:OtherInsuranceProductLineMember2023-01-012023-09-3000003203352024-07-012024-09-3000003203352023-07-012023-09-3000003203352023-01-012023-09-300000320335us-gaap:PreferredStockMember2023-12-310000320335us-gaap:CommonStockMember2023-12-310000320335us-gaap:AdditionalPaidInCapitalMember2023-12-310000320335us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000320335us-gaap:RetainedEarningsMember2023-12-310000320335us-gaap:TreasuryStockCommonMember2023-12-310000320335us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000320335us-gaap:RetainedEarningsMember2024-01-012024-03-310000320335us-gaap:TreasuryStockCommonMember2024-01-012024-03-310000320335us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000320335us-gaap:PreferredStockMember2024-03-310000320335us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000320335us-gaap:RetainedEarningsMember2024-03-310000320335us-gaap:TreasuryStockCommonMember2024-03-310000320335us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300000320335us-gaap:RetainedEarningsMember2024-04-012024-06-300000320335us-gaap:TreasuryStockCommonMember2024-04-012024-06-300000320335us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000320335us-gaap:PreferredStockMember2024-06-300000320335us-gaap:CommonStockMember2024-06-300000320335us-gaap:AdditionalPaidInCapitalMember2024-06-300000320335us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000320335us-gaap:RetainedEarningsMember2024-06-300000320335us-gaap:TreasuryStockCommonMember2024-06-300000320335us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000320335us-gaap:RetainedEarningsMember2024-07-012024-09-300000320335us-gaap:TreasuryStockCommonMember2024-07-012024-09-300000320335us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300000320335us-gaap:PreferredStockMember2024-09-300000320335us-gaap:CommonStockMember2024-09-300000320335us-gaap:AdditionalPaidInCapitalMember2024-09-300000320335us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300000320335us-gaap:RetainedEarningsMember2024-09-300000320335us-gaap:TreasuryStockCommonMember2024-09-300000320335us-gaap:PreferredStockMember2022-12-310000320335us-gaap:CommonStockMember2022-12-310000320335us-gaap:AdditionalPaidInCapitalMember2022-12-310000320335us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000320335us-gaap:RetainedEarningsMember2022-12-310000320335us-gaap:TreasuryStockCommonMember2022-12-3100003203352022-12-310000320335us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000320335us-gaap:RetainedEarningsMember2023-01-012023-03-3100003203352023-01-012023-03-3100003203352023-04-012023-06-300000320335us-gaap:TreasuryStockCommonMember2023-01-012023-03-310000320335us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000320335us-gaap:PreferredStockMember2023-03-310000320335us-gaap:CommonStockMember2023-03-310000320335us-gaap:AdditionalPaidInCapitalMember2023-03-310000320335us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000320335us-gaap:RetainedEarningsMember2023-03-310000320335us-gaap:TreasuryStockCommonMember2023-03-3100003203352023-03-310000320335us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300000320335us-gaap:RetainedEarningsMember2023-04-012023-06-300000320335us-gaap:TreasuryStockCommonMember2023-04-012023-06-300000320335us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300000320335us-gaap:PreferredStockMember2023-06-300000320335us-gaap:CommonStockMember2023-06-300000320335us-gaap:AdditionalPaidInCapitalMember2023-06-300000320335us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000320335us-gaap:RetainedEarningsMember2023-06-300000320335us-gaap:TreasuryStockCommonMember2023-06-300000320335us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000320335us-gaap:RetainedEarningsMember2023-07-012023-09-300000320335us-gaap:TreasuryStockCommonMember2023-07-012023-09-300000320335us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000320335us-gaap:PreferredStockMember2023-09-300000320335us-gaap:CommonStockMember2023-09-300000320335us-gaap:AdditionalPaidInCapitalMember2023-09-300000320335us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000320335us-gaap:RetainedEarningsMember2023-09-300000320335us-gaap:TreasuryStockCommonMember2023-09-3000003203352023-09-300000320335us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-06-300000320335gl:FuturePolicyBenefitsMember2024-06-300000320335us-gaap:AccumulatedTranslationAdjustmentMember2024-06-300000320335us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-06-300000320335us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-07-012024-09-300000320335gl:FuturePolicyBenefitsMember2024-07-012024-09-300000320335us-gaap:AccumulatedTranslationAdjustmentMember2024-07-012024-09-300000320335us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-07-012024-09-300000320335us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-09-30

[illegible]

[illegible]

[illegible]

[illegible]

gaap:PensionPlansDefinedBenefitMembergl:GuaranteedAnnuityContractMember2024-09-300000320335us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMembergl:GuaranteedAnnuityContractMember2024-09-300000320335us-gaap:PensionPlansDefinedBenefitMembergl:GuaranteedAnnuityContractMember2024-09-300000320335us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ShortTermInvestmentsMember2024-09-300000320335us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ShortTermInvestmentsMember2024-09-300000320335us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ShortTermInvestmentsMember2024-09-300000320335us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMembergl:OtherMember2024-09-300000320335us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMembergl:OtherMember2024-09-300000320335us-gaap:PensionPlansDefinedBenefitMembergl:OtherMember2024-09-300000320335us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMember2024-09-300000320335us-gaap:FairValueInputsLevel12And3Memberus-gaap:PensionPlansDefinedBenefitMember2024-09-300000320335us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMember2024-09-300000320335us-gaap:PensionPlansDefinedBenefitMember2024-09-300000320335us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ExchangeTradedFundsMember2023-12-310000320335us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ExchangeTradedFundsMember2023-12-310000320335us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ExchangeTradedFundsMember2023-12-310000320335us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMembergl:EquityExchangeTradedFundMember2023-12-310000320335us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMembergl:EquityExchangeTradedFundMember2023-12-310000320335us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMembergl:EquityExchangeTradedFundMember2023-12-310000320335us-gaap:PensionPlansDefinedBenefitMembergl:EquityExchangeTradedFundMember2023-12-310000320335us-gaap:PensionPlansDefinedBenefitMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-12-310000320335us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-12-310000320335us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-12-310000320335us-gaap:PensionPlansDefinedBenefitMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-12-310000320335us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMembergl:OtherBondsMember2023-12-310000320335us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMembergl:OtherBondsMember2023-12-310000320335us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMembergl:OtherBondsMember2023-12-310000320335us-gaap:PensionPlansDefinedBenefitMembergl:OtherBondsMember2023-12-310000320335us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMembergl:GuaranteedAnnuityContractMember2023-12-310000320335us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMembergl:GuaranteedAnnuityContractMember2023-12-310000320335us-gaap:PensionPlansDefinedBenefitMembergl:GuaranteedAnnuityContractMember2023-12-310000320335us-gaap:PensionPlansDefinedBenefitMembergl:GuaranteedAnnuityContractMember2023-12-310000320335us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ShortTermInvestmentsMember2023-12-310000320335us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ShortTermInvestmentsMember2023-12-310000320335us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ShortTermInvestmentsMember2023-12-310000320335us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMembergl:OtherMember2023-12-310000320335us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMembergl:OtherMember2023-12-310000320335us-gaap:PensionPlansDefinedBenefitMembergl:OtherMember2023-12-310000320335us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMember2023-12-310000320335us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMember2023-12-310000320335us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMember2023-12-310000320335us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMember2023-12-310000320335us-gaap:PensionPlansDefinedBenefitMember2023-12-310000320335us-gaap:PensionPlansDefinedBenefitMemberus-gaap:QualifiedPlanMember2024-09-300000320335us-gaap:PensionPlansDefinedBenefitMemberus-gaap:QualifiedPlanMember2023-12-310000320335us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMemberus-gaap:NonqualifiedPlanMember2024-09-300000320335us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMemberus-gaap:NonqualifiedPlanMember2023-12-310000320335gl:A585SeniorNotesDueSeptember152034Memberus-gaap:SeniorNotesMember2024-08-230000320335gl:A585SeniorNotesDueSeptember152034Memberus-gaap:SeniorNotesMember2024-08-232024-08-230000320335gl:TermLoanCreditAgreementMember2024-08-140000320335gl:TermLoanCreditAgreementMember2024-08-150000320335gl:TermLoanCreditAgreementMember2024-08-152024-08-150000320335gl:SeniorNotesDueSeptember152028Member2024-09-300000320335gl:SeniorNotesDueSeptember152028Member2023-12-310000320335gl:SeniorNotesDueAugust152030Member2024-09-300000320335gl:SeniorNotesDueAugust152030Member2023-12-310000320335gl:SeniorNotesDueJune152032Member2024-09-300000320335gl:SeniorNotesDueJune152032Member2023-12-310000320335gl:A585SeniorNotesDueSeptember152034Member2024-09-300000320335gl:A585SeniorNotesDueSeptember152034Member2023-12-310000320335gl:JuniorSubordinatedDebenturesDue2057Member2024-09-300000320335gl:JuniorSubordinatedDebenturesDue2057Member2023-12-310000320335gl:JuniorSubordinatedDebenturesDue2061Member2024-09-300000320335gl:JuniorSubordinatedDebenturesDue2061Member2023-12-310000320335gl:TermLoanDueNovember112024Member2024-09-300000320335gl:TermLoanDueNovember112024Member2023-12-310000320335gl:TermLoanDueNovember112024Member2024-09-300000320335gl:TermLoanDueNovember112024Member2023-12-310000320335us-gaap:FederalHomeLoanBankBorrowingsMember2024-09-300000320335us-gaap:CommercialPaperMember2024-09-300000320335us-gaap:CommercialPaperMember2023-12-310000320335srt:SubsidiariesMembergl:SeniorNotesDueJune152032Membersrt:ConsolidationEliminationsMember2024-09-300000320335gl:TermLoanDueNovember112024Member2024-01-012024-09-300000320335us-gaap:SeniorNotesMember2024-01-012024-09-300000320335gl:JuniorSubordinatedDebenturesDue2056Member2024-09-300000320335us-gaap:LineOfCreditMember2024-03-290000320335us-gaap:LineOfCreditMember2024-03-292024-03-290000320335us-gaap:ShortTermDebtMember2024-09-300000320335us-gaap:ShortTermDebtMember2023-12-310000320335us-gaap:ShortTermDebtMember2023-09-300000320335us-gaap:CommercialPaperMember2024-01-012024-09-300000320335us-gaap:CommercialPaperMember2023-01-012023-09-300000320335us-gaap:FederalHomeLoanBankBorrowingsMember2024-09-300000320335us-gaap:AssetPledgedAsCollateralMemberus-gaap:EstimateOffFairValueFairValueDisclosureMember2024-09-300000320335us-gaap:FederalHomeLoanBankBorrowingsMember2023-12-310000320335gl:AmericanIncomeExclusiveMembergl:AnnuitySegmentMember2024-07-012024-09-300000320335gl:AmericanIncomeExclusiveMember2024-07-012024-09-300000320335gl:DirectResponseMembergl:LifeSegmentMember2024-07-012024-09-300000320335gl:DirectResponseMembergl:HealthSegmentMember2024-07-012024-09-300000320335gl:DirectResponseMembergl:AnnuitySegmentMember2024-07-012024-09-300000320335gl:DirectResponseMember2024-07-012024-09-300000320335gl:LibertyNationalExclusiveMembergl:AnnuitySegmentMember2024-07-012024-09-300000320335gl:LibertyNationalExclusiveMember2024-07-012024-09-300000320335gl:UnitedAmericanIndependentMembergl:LifeSegmentMember2024-07-012024-09-300000320335gl:UnitedAmericanIndependentMembergl:AnnuitySegmentMember2024-07-012024-09-300000320335gl:UnitedAmericanIndependentMember2024-07-012024-09-300000320335gl:FamilyHeritageMembergl:LifeSegmentMember2024-07-012024-09-300000320335gl:FamilyHeritageMember2024-07-012024-09-300000320335gl:DistributionChannelOtherMembergl:LifeSegmentMember2024-07-012024-09-300000320335gl:DistributionChannelOtherMembergl:HealthSegmentMember2024-07-012024-09-300000320335gl:DistributionChannelOtherMembergl:AnnuitySegmentMember2024-

A has been subject to such filing requirements at the past 90 days. AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA Yes A A No A Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA Yes A A No A A Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act. Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company  If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. A Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). A A A Yes A A No A A Indicate the number of shares outstanding of each of the issuers classes of common stock, as of the latest practicable date. Class A Outstanding at October 31, 2024 Common Stock, \$1.00 Par Value\$ 83,945,064 GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc. Table of Contents PagePART I. FINANCIAL INFORMATIONItem 1.Condensed Consolidated Financial StatementsCondensed Consolidated Balance Sheets1Condensed Consolidated Statements of Operations2Condensed Consolidated Statements of Comprehensive Income (Loss)3Condensed Consolidated Statements of Shareholders' Equity4Condensed Consolidated Statements of Cash Flows6Notes to Condensed Consolidated Financial Statements7Note 1a Significant Accounting Policies7Note 2a New Accounting Standards8Note 3a Supplemental Information about Changes to Accumulated Other Comprehensive Income9Note 4a Investments11Note 5a Commitments and Contingencies21Note 6a Policy Liabilities23Note 7a Deferred Acquisition Costs43Note 8a Liability for Unpaid Claims46Note 9a Postretirement Benefits47Note 10a Earnings Per Share49Note 11a Debt50Note 12a Business Segments52Note 13a Subsequent Events75Cautionary Statement58Item 2.Managements Discussion and Analysis of Financial Condition and Results of Operations59Item 3.Quantitative and Qualitative Disclosures About Market Risk90Item 4.Controls and Procedures90PART II. OTHER INFORMATIONItem 1.Legal Proceedings90Item 1A.Risk Factors91Item 2.Unregistered Sales of Equity Securities and Use of Proceeds94Item 5.Other Information94Item 6.Exhibits95Signatures 96As used in this Form 10-Q, Globe Life, the Company, we, our, us, and ourselves refer to Globe Life Inc., a Delaware corporation incorporated in 1979, its subsidiaries and affiliates. GL Q3 2024 FORM 10-QTable of Contents PART Ia FINANCIAL INFORMATIONItem 1. Condensed Consolidated Financial StatementsGlobe Life Inc. Condensed Consolidated Balance Sheets (Unaudited) (Dollar amounts in thousands, except per share data)September 30, 2024December 31, 2023Assets:Investments:Fixed maturities\$ available for sale, at fair value (amortized cost: 2024a \$19,084,454; 2023a \$18,924,914), allowance for credit losses: 2024a \$7,132; 2023a \$7,115\$18,334,570A \$17,870,206A Mortgage loans381,315A 279,199A Policy loans691,072A 657,020A Other long-term investments (includes: 2024a \$979,397; 2023a \$795,583 under the fair value option)1,221,888A 835,878A Short-term investments100,501A 81,740A Total investments20,729,346A 19,244,034A Cash134,549A 103,156A Accrued investment income284,952A 270,396A Other receivables651,871A 630,223A Deferred acquisition costs6,386,682A 6,009,477A Goodwill490,446A 481,791A Other assets878,974A 832,413A Total assets\$29,556,820A \$28,051,499A Liabilities:Future policy benefits at current discount rates: (at original discount rates: 2024a \$17,402,917; 2023a \$16,984,615)\$19,814,913A \$19,460,353A Unearned and advance premium264,644A 254,567A Policy claims and other benefits payable530,399A 514,875A Other policyholders' funds469,288A 236,958A Total policy liabilities21,079,244A 20,466,753A Current and deferred income taxes619,970A 494,639A Short-term debt437,418A 486,113A Long-term debt (estimated fair value: 2024a \$2,202,644; 2023a \$1,491,229)2,323,676A 1,629,559A Other liabilities457,887A 487,632A Total liabilities24,198,153A 23,564,696A Commitments and Contingencies (Note 5)Shareholders' equity:Preferred stock, par value \$1 per sharea \$5,000,000 shares authorized; outstanding: 0 in 2024 and 2023a A A Common stock, par value \$1 per sharea \$320,000,000 shares authorized; outstanding: (2024a \$102,218,183 issued; 2023a \$102,218,183 issued)102,218A 102,218A Additional paid-in-capital543,255A 532,474A Accumulated other comprehensive income (loss)(2,484,743) (2,772,419)Retained earnings8,225,030A 7,478,813A Treasury stock, at cost: (2024a \$17,942,902 shares; 2023a \$8,426,854 shares)(1,747,135) (854,283)Total shareholders' equity4,638,625A 4,486,803A Total liabilities and shareholders' equity\$29,556,820A \$28,051,499A See accompanying Notes to Condensed Consolidated Financial Statements. 1 A A A A A GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc. Condensed Consolidated Statements of Operations (Unaudited) (Dollar amounts in thousands, except per share data) Three Months EndedSeptember 30,Nine Months EndedSeptember 30, 2024202320242023Revenue:Life premiums\$18,638A \$788,099A \$2,438,385A \$2,342,429A Health premiums353,955A 331,236A 1,046,617A 982,916A Other premiumsa A A A A Total premium1,172,593A 1,119,353A 3,485,002A 3,325,345A Net investment income284,964A 266,926A 853,178A 785,275A Realized gains (losses)(2,192) (2,193) (26,580) (79,963)Other income42A 50A 192A 185A Total revenue1,455,407A 1,384,118A 4,311,792A 4,031,842A Benefits and expenses:Life policyholder benefits(1,454,502A 515,676A 1,493,165A 1,536,317A Health policyholder benefits(2,221,926A 1,931,704A 6,299,676A 5,801,676A Other policyholder benefits11,756A 9,578A 32,830A 27,488A Total policyholder benefits688,184A 179,044A 2,155,671A 2,144,481A Amortization of deferred acquisition costs104,310A 95,757A 305,703A 282,159A Commissions, premium taxes, and non-deferred acquisition costs149,693A 138,677A 447,605A 414,933A Other operating expense104,874A 85,870A 297,196A 256,074A Interest expense31,388A 25,955A 91,413A 76,640A Total benefits and expenses1,078,449A 1,065,303A 3,297,588A 3,174,287A Income before income taxes376,958A 318,815A 1,014,204A 857,555A Income tax benefit (expense)(73,964) (61,732) (198,638) (161,602)Net income \$302,994A \$257,083A \$815,566A \$695,953A Basic net income per common share \$3.45A \$2.72A \$8.96A \$7.29A Diluted net income per common share \$3.44A \$2.68A \$8.93A \$7.20A (1) Net of total reinsurance including both the impact of assumption changes and the effect of actual to expected experience adjustments, resulting in a gain of \$70.6 million for the three months ended September 30, 2024, and a total reinsurance gain of \$11.3 million for the same period in 2023. (2) Net of a total reinsurance gain of \$87.8 million for the nine months ended September 30, 2024, and a total reinsurance gain of \$16.5 million for the same period in 2023. (2) A A Net of total reinsurance including both the impact of assumption changes and the effect of actual to expected experience adjustments, resulting in a loss of \$9.6 million for the three months ended September 30, 2024 and a total reinsurance gain of \$7.8 million for the same period in 2023. Net of a total reinsurance loss of \$3.1 million for the nine months ended September 30, 2024, and a total reinsurance gain of \$8.3 million for the same period in 2023. See accompanying Notes to Condensed Consolidated Financial Statements. 2 A A A A A GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc. Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) (Dollar amounts in thousands) Three Months EndedSeptember 30,Nine Months EndedSeptember 30, 2024202320242023Net income \$302,994A \$257,083A \$815,566A \$695,953A Other comprehensive income (loss):Investments:Unrealized gains (losses) on fixed maturities:Unrealized holding gains (losses) arising during period869,743A (1,068,091) 301,715A (932,301) Other reclassification adjustments included in net income(2,408) 851A 2,580A 82,866A Foreign exchange adjustment on fixed maturities recorded at fair value(954) (1,603) 546A 603A Total unrealized investment gains (losses)866,381A (1,065,637) 304,841A (848,832) Less applicable tax (expense) benefit(181,941) (223,782A) (68,018) 178,250A Unrealized gains (losses) on investments, net of tax684,440A (841,855) 240,823A (670,582) Future Policy Benefits:Change in discount rate on future policy benefits(1,247,366) (1,687,316) 631,614A 1,272,631A Less applicable tax (expense) benefit261,946A (354,334) (13,360) (267,252) Future policy benefit adjustments, net of tax(985,420) 1,332,976A 50,254A 1,005,379A Foreign exchange translation:Foreign exchange translation adjustments, other than securities, net of tax5,764A (6,226) (3,681) (3,192) Pension:Pension adjustments118A 35A 354A (336) Less applicable tax (expense) benefit(25) (7) (74) 70A Pension adjustments, net of tax93A 28A 280A (266) Other comprehensive income (loss) (295,123) 484,932A 287,676A 331,339A Comprehensive income (loss) \$7,871A \$742,006A \$1,103,242A \$1,027,292A See accompanying Notes to Condensed Consolidated Financial Statements. 3 A A A A A GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc. Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Dollar amounts in thousands, except per share data) Preferred StockCommon StockAdditional Paid-In CapitalAccumulated Other Comprehensive Income (Loss)Retained EarningsTreasury StockTotal Shareholders' EquityBalance at December 31, 2023 sae A \$102,218A \$532,474A \$(2,772,419) \$7,478,813A \$(854,283) \$4,486,803A Comprehensive income (loss)a ae A ae A ae A \$305,183A 254,217A ae A \$559,400A Common dividends declared (\$0.2400 per share)a ae A ae A ae A ae A \$22,603A ae A \$22,6

The following Tax Disclosures are as of December 31, 2023, and add disclosures and requirements to disaggregated information related to the effective tax rate reconciliation and information on income taxes paid. The disclosures will enhance the assessment of the entity's operations and related tax risks. This standard is effective for the Company for annual periods beginning on January 1, 2025, and will be implemented on a prospective basis. The Company does not expect the standard will have a material impact on the Condensed Consolidated Financial Statements.

8.A.1. A. A. A. A. GL Q3 2024 FORM 10-Q Table of Contents

Globe Life Inc. Notes to Condensed Consolidated Financial Statements (Dollar amounts in thousands, except per share data)

Note 3Ae "Supplemental Information about Changes to Accumulated Other Comprehensive Income Components of Accumulated Other Comprehensive Income: An analysis of the change in balance by component of Accumulated Other Comprehensive Income is as follows for the three and nine month periods ended September 30, 2024 and 2023:

Three Months Ended September 30, 2024

Available for Sale Assets Future Policy Benefits Foreign Exchange Pension Adjustments Total Balance at July 1, 2024 \$(1,271,213) \$(911,717) \$(4,726) \$(1,964) \$(2,189,620) Other comprehensive income (loss) before reclassifications, net of tax \$686,343A (985,420) \$5,764A \$(293,313) Reclassifications, net of tax \$(1,903)A \$(A) 93A (1,810) Other comprehensive income (loss) \$684,440A (985,420) \$5,764A 93A (295,123) Balance at September 30, 2024 \$(586,773) \$(1,897,137) \$1,038A \$(1,871) \$(2,484,743) Three Months Ended September 30, 2023

Available for Sale Assets Future Policy Benefits Foreign Exchange Pension Adjustments Total Balance at July 1, 2023 \$(1,249,399) \$(1,696,801) \$1,353A \$950A \$(2,943,897) Other comprehensive income (loss) before reclassifications, net of tax \$(842,527) 1,332,976A (6,226)A \$(A) 484,223A Reclassifications, net of tax \$672A \$(A) 28A 700A Other comprehensive income (loss) \$(841,855) 1,332,976A (6,226) 28A 484,923A Balance at September 30, 2023 \$(2,091,254) \$(3,663,825) \$(4,873) \$978A \$(2,458,974) Nine Months Ended September 30, 2024

Available for Sale Assets Future Policy Benefits Foreign Exchange Pension Adjustments Total Balance at January 1, 2024 \$(827,596) \$(1,947,391) \$4,719A \$(2,151) \$(2,772,419) Other comprehensive income (loss) before reclassifications, net of tax \$238,785A 50,254A (3,681)A \$(A) 285,358A Reclassifications, net of tax \$2,038A \$(A) 280A 2,318A Other comprehensive income (loss) \$240,823A 50,254A (3,681) 280A 2,877,676A Balance at September 30, 2024 \$(586,773) \$(1,897,137) \$1,038A \$(1,871) \$(2,484,743) Nine Months Ended September 30, 2023

Available for Sale Assets Future Policy Benefits Foreign Exchange Pension Adjustments Total Balance at January 1, 2023 \$(1,420,672) \$(1,369,204) \$(1,681) \$1,244A \$(2,790,313) Other comprehensive income (loss) before reclassifications, net of tax \$(736,046) 1,005,379A (3,192)A \$(A) 266,141A Reclassifications, net of tax \$65,464A \$(A) 266A 65,198A Other comprehensive income (loss) \$(670,582) 1,005,379A (3,192) 266A 31,339A Balance at September 30, 2023 \$(2,091,254) \$(3,663,825) \$(4,873) \$978A \$(2,458,974) A. A. A. A. GL Q3 2024 FORM 10-Q Table of Contents

Globe Life Inc. Notes to Condensed Consolidated Financial Statements (Dollar amounts in thousands, except per share data)

Note 4e "Investments Portfolio Composition: Summaries of fixed maturities available for sale by amortized cost, fair value, and allowance for credit losses at September 30, 2024 and December 31, 2023, and the corresponding amounts of gross unrealized gains and losses recognized in accumulated other comprehensive income (loss) are as follows. Redeemable preferred stock is included within "Corporates, by sector."

At September 30, 2024

Amortized Cost Allowance for Credit Losses Gross Unrealized Gains Gross Unrealized Losses Fair Value (1%) of All Fixed Maturities (2) Fixed maturities available for sale: U.S. Government direct, guaranteed, and government-sponsored enterprises \$397,969A \$(A) \$38A \$(21,026) \$376,981A 2A States, municipalities, and political subdivisions \$3,253,819A \$(A) 49,409A (424,989) 2,508,279A 16A Foreign governments \$1,794A \$(A) 17A (8,995) 31,926A \$(A) Corporates, by sector: Industrials \$8,115,835A (7,132) 258,165A (508,089) 7,858,779A 43A Financials \$1,014,169A \$(A) 171,762A (229,903) 8,866,028A 26A Utilities \$2,140,610A \$(A) 109,998A (72,371) 2,178,237A 12, corporates \$15,270,614A (7,132) 539,925A (880,363) 14,923,044A 81A Collateralized debt obligations \$36,685A \$(A) 5,798A \$(A) 42,483A \$(A) Other asset-backed securities \$83,573A \$(A) 1A (1,677) 81,897A 1A Total fixed maturities \$19,084,454A \$(7,132) \$595,188A \$(1,337,940) \$18,334,570A 100A (1) Amount reported in the balance sheet. (2) At fair value. At December 31, 2023

Amortized Cost Allowance for Credit Losses Gross Unrealized Gains Gross Unrealized Losses Fair Value (1%) of All Fixed Maturities (2) Fixed maturities available for sale: U.S. Government direct, guaranteed, and government-sponsored enterprises \$398,450A \$(A) \$7A \$(32,306) \$366,151A 2A States, municipalities, and political subdivisions \$3,296,305A \$(A) 47,346A (403,329) 2,940,322A 16A Foreign governments \$4,453A \$(A) 1A (10,348) 34,106A \$(A) Corporates, by sector: Industrials \$8,016,126A (7,115) 213,078A (566,847) 7,655,242A 43A Financials \$1,028,151A \$(A) 112,368A (388,340) 7,52,179A 27A Utilities \$2,017,967A \$(A) 73,925A (94,130) 1,997,762A 11A corporates \$15,062,244A (7,115) 399,371A (1,049,317) 14,405,183A 81A Collateralized debt obligations \$37,110A \$(A) 5,036A \$(A) 42,146A \$(A) Other asset-backed securities \$86,352A \$(A) 3A (4,057) 82,298A 1A Total fixed maturities \$18,924,914A \$(7,115) \$451,764A \$(1,499,357) \$17,870,206A 100A (1) Amount reported in the balance sheet. (2) At fair value. 11 A. A. A. A. GL Q3 2024 FORM 10-Q Table of Contents

Globe Life Inc. Notes to Condensed Consolidated Financial Statements (Dollar amounts in thousands, except per share data)

The Company has exposure to real estate investment trusts with an average rating of BBB+, which had a fair value of \$429 million (2% of the total fixed maturity portfolio) and \$425 million (2% of the total fixed maturity portfolio) at September 30, 2024 and December 31, 2023, respectively. A schedule of fixed maturities available for sale by contractual maturity date at September 30, 2024, is shown below on an amortized cost basis, net of allowance for credit losses, and on a fair value basis. Actual disposition dates could differ from contractual maturities due to call or prepayment provisions. At September 30, 2024

Amortized Cost, Net Fair Value Fixed Maturities Available for Sale: Due in one year or less \$11,956A \$11,456A Due after one year through five years \$748,300A 771,458A Due after five years through ten years \$841,477A 1,912,103A Due after ten years through twenty years \$954,088A 8,827,993A Due after twenty years \$7,301,254A 6,587,150A Mortgage-backed and asset-backed securities \$120,287A 124,410A \$19,077,322A \$18,334,570A Analysis of Investment Operations: "Net investment income" for the three and nine month periods ended September 30, 2024 and 2023 is summarized as follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023

Change 2024 2023 Change Fixed maturities available for sale \$245,313A \$237,609A 3A \$738,626A \$704,095A 5A Policy loans \$13,296A 12,446A 7A 39,196A 36,435A 8A Mortgage loans \$7,668A 5,363A 43A 21,337A 13,919A 53A Other long-term investments \$11,992A 14,630A 37A 58,608A 38,753A 51A Short-term investments \$3,083A 1,396A 8,396A 4,811A 289,352A 271,444A 7A Investments \$163,798,013A 9A Less investment expense \$(4,388) (4,518) (3) (12,985) (12,738) 2A Net investment income \$284,964A \$266,926A 7A \$853,178A \$785,275A 9A (1) For the three months ended September 30, 2024 and 2023, the investment funds, accounted for under the fair value option method, recorded \$19.1 million and \$14.0 million, respectively, in net investment income. For the nine months ended September 30, 2024 and 2023, the investment funds, accounted for under the fair value option method, recorded \$55.1 million and \$37.2 million, respectively, in net investment income. Refer to Other Long-Term Investments below for further discussion on the investment funds. Selected information about sales of fixed maturities available for sale is as follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2023

Fixed maturities available for sale: Proceeds from sales (1) \$163,221A \$46,210A \$674,125A \$192,034A Gross realized gains \$2,042A 261A 6,086A 308A Gross realized losses (1,856) (67,018) (15,824) (\$77,879) (1) As of September 30, 2024 and 2023, the Company had \$0 and \$27 thousand of unsettled trades, respectively. 12 A. A. A. A. GL Q3 2024 FORM 10-Q Table of Contents

Globe Life Inc. Notes to Condensed Consolidated Financial Statements (Dollar amounts in thousands, except per share data)

An analysis of "Realized gains (losses)" is as follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2023

Realized investment gains (losses): Fixed maturities available for sale: Sales and other (1) \$257A \$(66,767) \$(9,716) \$(77,730) Provision for credit loss \$(A) 65,008A (16) (7,500) Fair value option \$(A) change in fair value (3,683) 868A (22,777) 7,954A Mortgage loans (1,376) (59) (3,530) (4,918) Other investments (16) 880A 1,135A 502A Realized gains (losses) from investments (4,818) (70) (34,904) (81,692) Other gains (losses) \$2,626A (2,123) 8,324A 2,7

[illegible]

expected experience(103,922)(219,723)(26,533)8882(364,060)Adjusted balance at January 1, 2023
4,157,066A \$5,497,311A 1,044,768A 443,746A 11,142,891A Issuances(1)557,844A 450,361A 92,894A 21,756A 1,122,855A Interest accrued(2)147,968A 214,988A 40,362A 17,071A 420,389A Net premiums collected(3)(388,288)(461,367)(100,093)(34,542)(984,290)Effect of changes in the foreign exchange rate(631)â€”â€”â€”â€”(631)Ending balance at original discount rates4,473,959A \$5,701,293A 1,077,931A 448,031A 11,701,214A Effect of change from original to current discount rates(155,254)(31,118)(17,702)(1,499)(206,573)Balance at September 30, 2023 4,438,705A \$5,670,175A \$1,059,229A \$446,532A 11,494,641A Balance at January 1, 2024 \$4,681,888A \$6,052,651A 1,129,716A \$478,052A 11,342,307A Beginning balance at original discount rates4,523,329A \$5,664,259A 1,077,831A 443,949A 11,709,368A Effect of changes in assumptions on future cash flows(82,348)(28,366)(29,292)(982)(140,988)Effect of actual variances from expected experience(173,180)(226,062)(29,381)(9,292)(437,915)Adjusted balance at January 1, 2024
4,267,801A \$5,409,831A 1,019,158A 433,675A 11,130,465A Issuances(1)616,527A 398,034A 90,517A 18,126A 1,123,204A Interest accrued(2)164,917A 220,485A 41,610A 17,213A 444,225A Net premiums collected(3)(341,412)(415,625)(101,687)(33,960)(1,003,989)Effect of changes in the foreign exchange rate(4,101)â€”â€”â€”â€”(4,101)Ending balance at original discount rates4,632,427A \$5,572,725A 1,049,598A 435,054A 11,689,804A Effect of change from original to current discount rates204,567A 421,888A 54,498A 35,513A 716,466A Balance at September 30, 2024 \$4,836,994A \$5,994,613A \$1,104,096A \$470,567A \$12,406,270A (1)Issuances represent the present value, using the original discount rate, of the expected net premiums related to new policies issued during each respective period.(2)The interest accrual is the interest earned on the beginning present value of the expected net premiums, as well as the interest on actual net premiums earned during the period, using the original interest rate.(3)Net premiums collected represent the product of the current period net premium ratio and the gross premiums collected during the period on the in-force business.25 A A A A A GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc.Notes to Condensed Consolidated Financial Statements(Dollar amounts in thousands, except per share data)LifePresent value of expected future net premiumsAmerican IncomeDTCLiberty NationalOtherTotalBalance at July 1, 2023
\$4,472,847A \$5,988,577A 1,110,017A \$471,279A \$12,042,720A Beginning balance at original discount rates4,399,053A 5,700,354A 1,071,561A \$445,475A 11,616,443A Effect of changes in assumptions on future cash flows14,265A 36,170A 5,178A 8,419A 64,032A Effect of actual variances from expected experience(34,571)(91,120)(10,938)(7,232)(143,861)Adjusted balance at July 1, 2023 4,378,747A \$5,645,404A 1,065,801A 446,662A 11,536,614A Issuances(1)181,823A 136,611A 32,045A 7,143A 357,622A Interest accrued(2)51,119A 72,515A 13,707A 7,414 143,082A Net premiums collected(3)(131,329)(153,237)(33,622)(11,515)(329,703)Effect of changes in the foreign exchange rate(6,401)â€”â€”â€”â€”(6,401)Ending balance at original discount rates4,473,959A \$5,701,293A 1,077,931A 448,031A 11,701,214A Effect of change from original to current discount rates(155,254)(31,118)(17,702)(1,499)(206,573)Balance at September 30, 2023 4,323,705A \$5,318,705A \$1,059,229A \$446,532A 11,494,641A Balance at July 1, 2024
\$4,635,903A \$5,810,518A \$1,085,233A \$449,883A 11,981,537A Beginning balance at original discount rates4,648,111A 5,670,288A 1,080,642A 437,551A 11,836,592A Effect of changes in assumptions on future cash flows(82,348)(28,366)(29,292)(982)(140,988)Effect of actual variances from expected experience(59,483)(103,089)(12,113)(1,970)(176,655)Adjusted balance at July 1, 2024 4,506,280A \$5,538,833A 1,039,237A 434,599A 11,518,949A Issuances(1)203,828A 110,993A 30,298A 5,969A 351,088A Interest accrued(2)55,750A 73,134A 13,836A 5,709A 148,429A Net premiums collected(3)(138,552)(150,235)(33,773)(11,223)(333,783)Effect of changes in the foreign exchange rate5,121A â€”â€”â€”â€”â€”5,121A Ending balance at original discount rates4,632,427A 5,572,725A 1,049,598A 435,054A 11,689,804A Effect of change from original to current discount rates204,567A 421,888A 54,498A 35,513A 716,466A Balance at September 30, 2024 \$4,836,994A \$5,994,613A \$1,104,096A \$470,567A \$12,406,270A (1)Issuances represent the present value, using the original discount rate, of the expected net premiums related to new policies issued during each respective period.(2)The interest accrual is the interest earned on the beginning present value of the expected net premiums, as well as the interest on actual net premiums earned during the period, using the original interest rate.(3)Net premiums collected represent the product of the current period net premium ratio and the gross premiums collected during the period on the in-force business.25 A A A A A GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc.Notes to Condensed Consolidated Financial Statements(Dollar amounts in thousands, except per share data)LifePresent value of expected future policy benefitsAmerican IncomeDTCLiberty NationalOtherTotalBalance at January 1, 2023 \$9,119,104A \$9,225,451A \$3,429,256A \$3,976,150A \$25,749,961A Beginning balance at original discount rates8,409,761A 8,477,892A 3,272,980A 3,403,704A 23,564,337A Effect of changes in assumptions on future cash flows13,444A 34,407A 6,156A 11,661A 65,568A Effect of actual variances from expected experience(109,386)(227,639)(27,482)(17,962)(382,469)Adjusted balance at January 1, 2023
8,313,719A 8,284,660A 3,251,654A 3,397,403A 23,247,436A Issuances(1)557,844A 450,362A 92,894A 21,756A 1,122,856A Interest accrued(2)335,349A 342,208A 130,712A 152,378A 960,647A Benefit payments(3)(296,133)(332,391)(53,294)(86,008)(967,828)Effect of changes in the foreign exchange rate(819)â€”â€”â€”â€”(819)Ending balance at original discount rates8,909,960A 8,644,837A 3,321,966A 3,485,529A 24,362,292A Effect of change from original to current discount rates80,477A 228,607A (46,234)282,118A 544,968A Balance at September 30, 2023 \$8,990,437A \$8,873,444A \$3,275,732A \$3,767,647A \$24,907,260A Balance at January 1, 2024
\$10,163,627A \$9,714,516A \$3,605,392A \$4,239,623A \$27,723,158A Beginning balance at original discount rates9,061,833A 8,656,752A 3,328,252A 3,506,859A 24,563,696A Effect of changes in assumptions on future cash flows(104,498)(50,106)(41,836)(2,027)(198,467)Effect of actual variances from expected experience(187,711)(241,231)(34,722)(12,841)(476,505)Adjusted balance at January 1, 2024 8,769,624A 8,365,415A 3,261,694A 3,491,991A 23,888,724A Issuances(1)611,802A 398,032A 90,518A 18,127A 1,118,479A Interest accrued(2)367,403A 355,850A 134,020A 157,318A 1,014,591A Benefit payments(3)(326,318)(439,992)(159,219)(103,998)(1,029,527)Effect of changes in the foreign exchange rate(8,768)â€”â€”â€”â€”(8,768)Ending balance at original discount rates9,413,743A 8,679,305A 3,327,013A 3,563,438A 24,983,499A Effect of change from original to current discount rates1,091,042A 1,082,717A 275,358A 717,751A 3,166,868A Balance at September 30, 2024 \$10,504,785A \$9,762,022A \$3,602,371A \$4,281,189A \$28,150,367A (1)Issuances represent the present value, using the original discount rate, of the expected future policy benefits related to new policies issued during each respective period.(2)The interest accrual is the interest earned on the beginning present value of the expected future policy benefits, as well as the interest on actual benefits and expenses paid during the period, using the original interest rate.(3)Benefit payments represent the release of the present value, using the original discount rate, of the actual future policy benefits incurred during the period due to death, surrender, and maturity benefit payments based on the revised expected assumptions.26 A A A A A GL Q3

[illegible]

[illegible]

Globe Life completed the issuance of \$450 million principal amount of 5.85% Senior notes due SeptemberÂ 15, 2034. Total proceeds received by the Parent from the issuance, net of the underwritersâ€™ discount, were \$445 million. The proceeds were used for general corporate purposes, which included open market purchases of shares of its common stock under its share repurchase program. On AugustÂ 15, 2024, Globe Life amended its term loan agreement increasing the principal amount from \$170 million to \$250 million, an increase of \$80 million. The amendment extends the maturity date from NovemberÂ 11, 2024 to AugustÂ 15, 2027. The following table presents information about the terms and outstanding balances of Globe Life's debt.

Selected Information about Debt IssuesAs ofSeptember 30, 2024December 31, 2023InstrumentIssue DateMaturity Date Coupon Rate ParValueUnamortized Discount & Issuance CostsBookValueFairValueBookValueSenior notes09/27/201809/15/20284.550%\$550,000Â (3,180)\$546,820Â \$550,088Â \$546,283Â Senior notes08/21/202008/15/20302.150%400,000Â (2,983)397,017Â 344,796Â 396,670Â Senior notes(1)05/19/202206/15/20324.800%250,000Â (3,828)246,172Â 248,443Â 245,873Â Senior notes08/23/202009/15/20345.850%450,000Â (5,188)444,812Â 464,881Â Â€"Â Junior subordinated debentures11/7/201711/17/20575.275%125,000Â (1,561)123,439Â 109,657Â 123,427Â Junior subordinated debentures06/14/202106/15/20614.250%325,000Â (7,633)317,367Â 236,730Â 317,306Â Term loan(2)05/11/202308/15/20276.593%250,000Â (1,951)248,049Â 248,049Â Â€"Â Total long-term debt2,350,000Â (26,324)2,323,676Â 2,202,644Â 1,629,559Â Term loan(2)Â€"Â Â€"Â 169,549Â FHLB borrowings17,000Â Â€"Â 17,000Â 17,000Â Â€"Â Commercial paper426,908Â (6,490)420,418Â 420,418Â 316,564Â Total short-term debt443,908Â (6,490)437,418Â 437,418Â 486,113Â Total debt2,793,908Â (\$32,814)\$2,761,094Â \$2,640,062Â \$2,115,672Â (1)An additional \$150Â million par value and book value is held by insurance subsidiaries that eliminates in consolidation. (2)Interest calculated quarterly using Secured Overnight Financing Rate (SOFR) plus 135 basis points. The commercial paper has the highest priority of all unsecured debt, followed by senior notes then junior subordinated debentures. The senior notes are callable under a make-whole provision, and the junior subordinated debentures are subject to an optional redemption five years from issuance. Interest on the 4.25% junior subordinated debentures and the term loan are payable quarterly while all other long-term debt is payable semi-annually. Credit facility: On MarchÂ 29, 2024, Globe Life amended the credit agreement dated SeptemberÂ 3, 2021, which provides for a \$1 billion revolving credit facility that may be increased to \$1.25 billion. The amended credit facility matures MarchÂ 29, 2029 and may be extended up to two one-year periods upon the Company's request. Pursuant to this agreement, the participating lenders have agreed to make revolving loans to Globe Life and to issue secured or unsecured letters of credit. The Company has not drawn on any of the credit to date.50 Â A Â A Â A Â A GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc. Notes to Condensed Consolidated Financial Statements(Dollar amounts in thousands, except per share data)The facility is further designated as a back-up credit line for a commercial paper program under which the Company may either borrow from the credit line or issue commercial paper at any time, with total commercial paper outstanding not to exceed the facility maximum of \$1 billion, less any letters of credit issued. Interest is charged at variable rates. In accordance with the agreement, Globe Life is subject to certain covenants regarding capitalization. As of September 30, 2024, the Company was in full compliance with these covenants. The following tables present certain information about our commercial paper borrowings. Credit FacilityÂ€"Commercial PaperAs ofSeptember 30, 2024December 31, 2023September 30, 2023Balance of commercial paper at end of period (par value)\$426,908Â \$319,000Â \$251,000Â Annualized interest rate5.56Â %5.71Â %5.65Â %Letters of credit outstanding\$115,000Â \$115,000Â \$115,000Â Remaining amount available under credit line\$458,092Â \$316,000Â \$384,000Â Credit FacilityÂ€"Commercial Paper ActivityÂ Nine Months Ended September 30, 20242023Average balance of commercial paper outstanding during period (par value)\$375,851Â \$296,816Â Daily-weighted average interest rate (annualized)5.80Â %5.33Â %Maximum daily amount outstanding during period (par value)\$633,425Â \$477,700Â Commercial paper issued during period (par value)1,482,556Â 1,480,000Â Commercial paper matured during period (par value)(1,374,648)(1,514,000)Net commercial paper issued (matured) during period (par value)107,908Â (34,000)Federal Home Loan Bank: FHLB membership provides certain of our insurance subsidiaries with access to various low-cost collateralized borrowings and funding agreements. The membership requires ownership of FHLB common stock, as well as the purchase of activity-based common stock equal to approximately 4.1% of outstanding borrowings. Globe Life owned \$32.4 million in FHLB common stock as of September 30, 2024 and \$22.3 million as of December 31, 2023. The FHLB stock is restricted for the duration of the membership and recorded at cost (par) as required by applicable guidance. The FHLB stock is included in "Other long-term investments" in the Condensed Consolidated Balance Sheets. Borrowings with the FHLB are subject to the availability of pledged assets at the insurance subsidiaries of Globe Life. As of September 30, 2024, Globe Life's insurance subsidiaries maximum borrowing capacity under the FHLB facility was approximately \$781 million, net of outstanding funding agreements and short-term borrowings, on pledged assets with a fair value of \$1.4 billion. As of September 30, 2024, \$372 million in funding agreements were outstanding with the FHLB, compared to \$138 million as of December 31, 2023. This amount is included in "Other policyholders' funds" in the Condensed Consolidated Balance Sheets. In addition, the Company had \$17 million in short-term borrowings from the FHLB as of September 30, 2024, compared to \$0 as of December 31, 2023, this amount is recorded in "Short-term debt".51 Â A Â A Â A Â A GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc. Notes to Condensed Consolidated Financial Statements(Dollar amounts in thousands, except per share data)Note 12Â€"Business Segments Globe Life is organized into four segments: life insurance, supplemental health insurance, annuities, and investments. In addition, other expenses not included in these segments are reported in "Corporate & Other." Globe Life's reportable insurance segments are based on the insurance product lines it markets and administers: life insurance, supplemental health insurance, and annuities. These major product lines are set out as reportable segments because of the common characteristics of products within these categories, comparability of margins, and the similarity in regulatory environment and management techniques. There is also an investment segment that manages the investment portfolio and cash flow for the insurance segments and the corporate function. The Company's chief operating decision makers evaluate the overall performance of the operations of the Company in accordance with these segments. Life insurance products marketed by Globe Life include traditional whole life and term life insurance. Health insurance products are generally guaranteed renewable and include Medicare Supplement, cancer, critical illness, accident, and other limited-benefit supplemental hospital and surgical products. Annuities include fixed-benefit contracts. The following tables present segment premium revenue by each of Globe Life's distribution channels. Premium Income by Distribution ChannelThree Months Ended September 30, 2024LifeHealthAnnuityTotalDistribution ChannelAmount% ofTotalAmount% ofTotalAmount% ofTotalAmerican Income\$427,839Â 52Â %\$31,277Â 9Â %\$459,116Â 39Â Direct to Consumer246,425Â 30Â 18,072Â 5Â Â€"Â Â€"Â 264,497Â 23Â Liberty National93,625Â 12Â 47,277Â 13Â Â€"Â Â€"Â 140,902Â 12Â United American1,608Â Â€"Â 149,510Â 42Â Â€"Â Â€"Â 151,118Â 13Â Family Heritage1,684Â Â€"Â 107,819Â 31Â Â€"Â Â€"Â 109,503Â 9Â Other47,457Â 6Â Â€"Â Â€"Â Â€"Â 47,457Â 4Â \$818,638Â 100Â \$353,955Â 100Â Â€"Â \$1,172,593Â 100Â Â Three Months Ended September 30, 2023LifeHealthAnnuityTotalDistribution ChannelAmount% ofTotalAmount% ofTotalAmount% ofTotalAmerican Income\$400,214Â 51Â \$30,535Â 9Â Â€"Â Â€"Â \$430,749Â 39Â Direct to Consumer247,858Â 32Â 17,153Â 5Â Â€"Â Â€"Â 265,011Â 24Â Liberty National188,199Â 11Â 46,643Â 14Â Â€"Â Â€"Â 134,842Â 12Â United American1,802Â Â€"Â 137,077Â 42Â Â€"Â Â€"Â 138,879Â 12Â Family Heritage1,561Â Â€"Â 99,828Â 30Â Â€"Â Â€"Â 101,389Â 9Â Other48,465Â 6Â Â€"Â Â€"Â 48,465Â 4Â \$788,099Â 100Â \$331,236Â 100Â Â€"Â \$1,119,335Â 100Â 52 Â A Â A Â A GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc. Notes to Condensed Consolidated Financial Statements(Dollar amounts in thousands, except per share data)Nine Months Ended September 30, 2024LifeHealthAnnuityTotalDistribution ChannelAmount% ofTotalAmount% ofTotalAmount% ofTotalAmerican Income\$1,265,417Â 52Â 92,495Â 9Â Â€"Â Â€"Â 1,357,912Â 39Â Direct to Consumer743,304Â 31Â 54,070Â 5Â Â€"Â Â€"Â 797,374Â 23Â Liberty National176,599Â 11Â 142,612Â 14Â Â€"Â Â€"Â 419,211Â 12Â United American5,009Â Â€"Â 440,375Â 42Â Â€"Â Â€"Â 445,384Â 13Â Family Heritage4,945Â Â€"Â 317,065Â 30Â Â€"Â Â€"Â 322,010Â 9Â Other143,111Â 6Â Â€"Â Â€"Â Â€"Â 143,111Â 4Â \$2,438,385Â 100Â \$1,046,617Â 100Â Â€"Â \$3,485,002Â 100Â Â Nine Months Ended September 30, 2023LifeHealthAnnuityTotalDistribution ChannelAmount% ofTotalAmount% ofTotalAmount% ofTotalAmerican Income\$1,182,346Â 50Â \$89,656Â 9Â Â€"Â Â€"Â \$1,272,002Â 38Â Direct to Consumer744,132Â 32Â 51,576Â 5Â Â€"Â Â€"Â 795,708Â 24Â Liberty National126,030Â 11Â 140,518Â 14Â Â€"Â Â€"Â 400,554Â 12Â United American5,533Â Â€"Â 407,137Â 42Â Â€"Â Â€"Â 412,670Â 13Â Family Heritage4,554Â Â€"Â 294,029Â 30Â Â€"Â Â€"Â 298,583Â 9Â Other145,828Â 7Â Â€"Â Â€"Â 145,828Â 4Â \$2,342,429Â 100Â \$982,916Â 100Â Â€"Â \$3,325,345Â 100Â Due to the nature of the life insurance industry, Globe Life has no individual or group that would be considered a major customer. Substantially all of Globe Life's business is conducted in the United States. Â The measure of profitability established by the chief operating decision makers for the insurance segments is underwriting margin before other income and administrative expenses, in accordance with the manner in which the segments are managed. It essentially represents gross profit margin on insurance products before insurance administrative expenses and consists primarily of premium less net policy benefits, acquisition expenses, and commissions. Required interest on policy liabilities is reflected as a component of the investment segment (rather than as a component of underwriting margin in the insurance and annuity segments) in order to match this cost with the investment income earned on the assets supporting the policy liabilities. Â The measure of profitability for the investment segment is excess investment income, representing the income earned on the investment portfolio in excess of policy requirements. Other than the required interest on the insurance segments, no other intersegment revenues or expenses are recognized. Expenses directly attributable to corporate operations are included in the Â€"Corporate & Other" category. Stock-based compensation expense is considered a corporate expense by Globe Life management and is included in this category. All other unallocated revenues and expenses on a pretax basis, including insurance administrative expense and interest on debt, are also included in the Â€"Corporate & Other" segment category. Â Globe Life holds a sizable investment portfolio to support its insurance liabilities, the yield from which is used to offset policy benefit, acquisition, administrative, and tax expenses. This yield or investment income is taken into account when establishing premium rates and profitability expectations for its insurance products. From time to time, investments are sold or called, or experience a credit loss event, each of which are reflected by the Company as realized gain (loss)Â€"investments. These gains or losses generally occur as a result of disposition due to issuer calls, compliance with Company investment policies, or other reasons often beyond managementâ€™s control. Unlike investment income, realized gains and losses are incidental to insurance operations, and only overall yields are considered when setting premium rates or insurance product profitability expectations. While these gains and losses \$3 Â A Â A Â A GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc. Notes to Condensed Consolidated Financial Statements(Dollar amounts in thousands, except per share data)are not relevant to segment profitability or core operating results, they can have a material positive or negative result on net income. For these reasons, management removes realized investment gains and losses when it views its segment operations. Management also removes non-operating items unrelated to the Company's core insurance activities when evaluating those results. Therefore, these items are excluded in its presentation of segment results because accounting guidance requires that operating segment results be presented as management views its business. All of these items are included in Â€"Other operating expense" in the Condensed Consolidated Statements of Operations for the appropriate year. See additional detail below in the tables. The following tables set forth a reconciliation of Globe Life's revenues and operations by segment to its major income statement line items. See Note 1Â€"Significant Accounting Policies for additional information concerning reconciling items of segment profits to pretax income. Three Months Ended September 30, 2024LifeHealthAnnuityInvestmentCorporate & OtherAdjustmentsConsolidatedRevenue:Premium\$818,638Â \$353,955Â Â€"Â Â€"Â \$1,172,593Â Net investment incomeÂ€"Â Â€"Â Â€"Â 284,964Â Â€"Â Â€"Â 284,964Â Other incomeÂ€"Â Â€"Â Â€"Â 424Â Â€"Â 424Â Total revenue818,638Â 353,955Â Â€"Â 284,964Â 424Â 1,457,599Â Expenses:Policy benefits454,502Â 221,926Â 5,716Â 6,040Â Â€"Â Â€"Â 688,184Â Required interest on reserves(203,875)(27,717)(7,829)239,421Â Â€"Â Â€"Â Â€"Â Amortization of acquisition costs90,070Â 13,852Â 388Â Â€"Â Â€"Â 104,310Â Commissions, premium taxes, and non-deferred acquisition costs90,758Â 58,931Â 4Â Â€"Â Â€"Â 149,693Â Insurance administrative expense(1)Â€"Â Â€"Â Â€"Â 88,465Â 730Â (3)89,195Â Parent expenseÂ€"Â Â€"Â Â€"Â 3,210Â 3,236Â (2)3,646Â Stock-based compensation expenseÂ€"Â Â€"Â Â€"Â 9,233Â 4Â 9,233Â Interest expenseÂ€"Â Â€"Â Â€"Â 31,388Â Total expenses431,455Â 266,992Â (1,721)245,461Â 132,296Â 3,966Â 1,078,449Â Subtotal387,183Â 86,963Â 1,721Â 39,503Â (132,254)(3,966)379,150Â Non-operating itemsÂ€"Â Â€"Â Â€"Â Â€"Â 3,966Â (2)3,966Â Measure of segment profitability (pretax) \$387,183Â \$86,963Â 1,721Â \$39,503Â \$(132,254)\$Â€"Â 383,116Â Realized gains (losses) (2,192)Legal costs and proceedings(3,329)Non-operating expenses(637)Income before income taxes per Condensed Consolidated Statements of Operations \$376,958Â (1)Administrative expense is not allocated to insurance segments. (2)Non-operating expenses. (3)Legal costs and proceedings.54 Â A Â A Â A GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc. Notes to Condensed Consolidated Financial Statements(Dollar amounts in thousands, except per share data)Three Months Ended September 30, 2023LifeHealthAnnuityInvestmentCorporate & OtherAdjustmentsConsolidatedRevenue:Premium\$788,099Â \$331,236Â Â€"Â Â€"Â \$1,119,335Â Net investment incomeÂ€"Â Â€"Â Â€"Â 266,926Â Â€"Â Â€"Â 266,926Â Other incomeÂ€"Â Â€"Â Â€"Â 50Â Â€"Â 50Â Total revenue788,099Â 331,236Â Â€"Â 266,926Â 50Â 1,386,311Â Expenses:Policy obligations515,676Â 193,790Â 6,854Â 2,724Â Â€"Â Â€"Â 719,044Â Required interest on reserves(194,199)(26,732)(9,353)230,284Â Â€"Â Â€"Â Â€"Â Amortization of acquisition costs82,523Â 12,816Â 418Â Â€"Â Â€"Â 95,757Â Commissions, premium taxes, and non-deferred acquisition costs84,011Â 54,662Â 4Â Â€"Â Â€"Â Â€"Â 138,677Â Insurance administrative expense(1)Â€"Â Â€"Â Â€"Â 74,585Â Â€"Â 74,585Â Parent expenseÂ€"Â Â€"Â Â€"Â 2,581Â 1,137Â (2)3,718Â Stock-based compensation expenseÂ€"Â Â€"Â Â€"Â 7,567Â 4Â 7,567Â Interest expenseÂ€"Â Â€"Â Â€"Â 25,955Â Â€"Â 25,955Â Total expenses488,011Â 234,536Â (2,077)233,008Â 110,688Â 1,137Â 1,065,303Â Subtotal300,088Â 96,700Â 2,077Â \$33,918Â (110,638)(1,137)321,008Â Non-operating itemsÂ€"Â Â€"Â Â€"Â Â€"Â 1,137Â (21,137Â Measure of segment profitability (pretax) \$300,088Â \$96,700Â 2,077Â \$33,918Â (110,638)\$Â€"Â 322,145Â Realized gains (losses) (2,193)Non-operating expenses(1,137)Income before income taxes per Condensed Consolidated Statements of Operations \$318,815Â (1)Administrative expense is not allocated to insurance segments. (2)Non-operating expenses.55 Â A Â A Â A GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc. Notes to Condensed Consolidated Financial Statements(Dollar amounts in thousands, except per share data)Nine Months Ended September 30, 2024LifeHealthAnnuityInvestmentCorporate & OtherAdjustmentsConsolidatedRevenue:Premium\$2,342,429Â \$982,916Â Â€"Â Â€"Â \$3,325,345Â Net investment incomeÂ€"Â Â€"Â Â€"Â 785,275Â Â€"Â Â€"Â 785,275Â Other incomeÂ€"Â Â€"Â Â€"Â 185Â Â€"Â 185Â Total revenue2,342,429Â 982,916Â Â€"Â 785,275Â 185Â 4,110,805Â Expenses:Policy obligations1,493,165Â 629,676Â 17,786Â 15,044Â Â€"Â Â€"Â 2,155,671Â Required interest on reserves(605,397)(82,300)(24,358)712,055Â Â€"Â Â€"Â Â€"Â Amortization of acquisition costs263,753Â 40,774Â 1,766Â Â€"Â Â€"Â 305,703Â Commissions, premium taxes, and non-deferred acquisition costs270,347Â 177,246Â 12Â Â€"Â Â€"Â Â€"Â 447,605Â Insurance administrative expense(1)Â€"Â Â€"Â Â€"Â 251,072Â 1,646Â (3)252,718Â Parent expenseÂ€"Â Â€"Â Â€"Â 9,166Â 6,722Â (2,3)15,888Â Stock-based compensation expenseÂ€"Â Â€"Â Â€"Â 28,590Â Â€"Â 28,590Â Interest expenseÂ€"Â Â€"Â Â€"Â 91,413Â Â€"Â 91,413Â Total expenses1,421,868Â 765,396Â (5,384)727,099Â 380,241Â 8,368Â 3,297,588Â Subtotal1,016,517Â 281,221Â 5,384Â 126,079Â (380,049)(8,368)1,040,784Â Non-operating itemsÂ€"Â Â€"Â Â€"Â Â€"Â 8,368Â (2)3,368Â Measure of segment profitability (pretax) \$1,016,517Â \$281,221Â 5,384Â \$126,079Â \$(380,049)\$Â€"Â 1,049,152Â Realized gains (losses) (26,580)Legal costs and proceedings(5,764)Non-operating expenses(2,604)Income before income taxes per Condensed Consolidated Statements of Operations \$1,014,204Â (1)Administrative expense is not allocated to insurance segments. (2)Non-operating expenses. (3)Legal costs and proceedings.56 Â A Â A Â A GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc. Notes to Condensed Consolidated Financial Statements(Dollar amounts in thousands, except per share data)Nine Months Ended September 30, 2023LifeHealthAnnuityInvestmentCorporate & OtherAdjustmentsConsolidatedRevenue:Premium\$2,342,429Â \$982,916Â Â€"Â Â€"Â \$3,325,345Â Net investment incomeÂ€"Â Â€"Â Â€"Â 785,275Â Â€"Â Â€"Â 785,275Â Other incomeÂ€"Â Â€"Â Â€"Â 185Â Â€"Â 185Â Total revenue2,342,429Â 982,916Â Â€"Â 785,275Â 185Â 4,110,805Â Expenses:Policy obligations1,493,165Â 629,676Â 17,786Â 15,044Â Â€"Â Â€"Â 2,155,671Â Required interest on reserves(605,397)(82,300)(24,358)712,055Â Â€"Â Â€"Â Â€"Â Amortization of acquisition costs263,753Â 40,774Â 1,766Â Â€"Â Â€"Â 305,703Â Commissions, premium taxes, and non-deferred acquisition costs270,347Â 177,246Â 12Â Â€"Â Â€"Â Â€"Â 447,605Â Insurance administrative expense(1)Â€"Â Â€"Â Â€"Â 251,072Â 1,646Â (3)252,718Â Parent expenseÂ€"Â Â€"Â Â€"Â 9,166Â 6,722Â (2,3)15,888Â Stock-based compensation expenseÂ€"Â Â€"Â Â€"Â 28,590Â Â€"Â 28,590Â Interest expenseÂ€"Â Â€"Â Â€"Â 91,413Â Â€"Â 91,413Â Total expenses1,421,868Â 765,396Â (5,384)727,099Â 380,241Â 8,368Â 3,297,588Â Subtotal1,016,517Â 281,221Â 5,384Â 126,079Â (380,049)(8,368)1,040,784Â Non-operating itemsÂ€"Â Â€"Â Â€"Â Â€"Â 8,368Â (2)3,368Â Measure of segment profitability (pretax) \$1,016,517Â \$281,221Â 5,384Â \$126,079Â \$(380,049)\$Â€"Â 1,049,152Â Realized gains (losses) (26,580)Legal costs and proceedings(5,764)Non-operating expenses(2,604)Income before income taxes per Condensed Consolidated Statements of Operations \$1,014,204Â (1)Administrative expense is not allocated to insurance segments. (2)Non-operating expenses. (3)Legal costs and proceedings.56 Â A Â A Â A GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc. Notes to Condensed Consolidated Financial Statements(Dollar amounts in thousands, except per share data)Nine Months Ended September 30, 2023LifeHealthAnnuityInvestmentCorporate & OtherAdjustmentsConsolidatedRevenue:Premium\$2,342,429Â \$982,916Â Â€"Â Â€"Â \$3,325,345Â Net investment incomeÂ€"Â Â€"Â Â€"Â 785,275Â Â€"Â Â€"Â 785,275Â Other incomeÂ€"Â Â€"Â Â€"Â 185Â Â€"Â 185Â Total revenue2,342,429Â 982,916Â Â€"Â 785,275Â 185Â 4,110,805Â Expenses:Policy obligations1,493,165Â 629,676Â 17,786Â 15,044Â Â€"Â Â€"Â 2,155,671Â Required interest on reserves(605,397)(82,300)(24,358)712,055Â Â€"Â Â€"Â Â€"Â Amortization of acquisition costs263,753Â 40,774Â 1,766Â Â€"Â Â€"Â 305,703Â Commissions, premium taxes, and non-deferred acquisition costs270,347Â 177,246Â 12Â Â€"Â Â€"Â Â€"Â 447,605Â Insurance administrative expense(1)Â€"Â Â€"Â Â€"Â 251,072Â 1,646Â (3)252,718Â Parent expenseÂ€"Â Â€"Â Â€"Â 9,166Â 6,722Â (2,3)15,888Â Stock-based compensation expenseÂ€"Â Â€"Â Â€"Â 28,590Â Â€"Â 28,590Â Interest expenseÂ€"Â Â€"Â Â€"Â 91,413Â Â€"Â 91,413Â Total expenses1,421,868Â 765,396Â (5,384)727,099Â 380,241Â 8,368Â 3,297,588Â Subtotal1,016,517Â 281,221Â 5,384Â 126,079Â (380,049)(8,368)1,040,784Â Non-operating itemsÂ€"Â Â€"Â Â€"Â Â€"Â 8,368Â (2)3,368Â Measure of segment profitability (pretax) \$1,016,517Â \$281,221Â 5,384Â \$126,079Â \$(380,049)\$Â€"Â 1,049,152Â Realized gains (losses) (26,580)Legal costs and proceedings(5,764)Non-operating expenses(2,604)Income before income taxes per Condensed Consolidated Statements of Operations \$1,014,204Â (1)Administrative expense is not allocated to insurance segments. (2)Non-operating expenses. (3)Legal costs and proceedings.56 Â A Â A Â A GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc. Notes to Condensed Consolidated Financial Statements(Dollar amounts in thousands, except per share data)Nine Months Ended September 30, 2023LifeHealthAnnuityInvestmentCorporate & OtherAdjustmentsConsolidatedRevenue:Premium\$2,342,429Â \$982,916Â Â€"Â Â€"Â \$3,325,345Â Net investment incomeÂ€"Â Â€"Â Â€"Â 785,275Â Â€"Â Â€"Â 785,275Â Other incomeÂ€"Â Â€"Â Â€"Â 185Â Â€"Â 185Â Total revenue2,342,429Â 982,916Â Â€"Â 785,275Â 185Â 4,110,805Â Expenses:Policy obligations1,493,165Â 629,676Â 17,786Â 15,044Â Â€"Â Â€"Â 2,155,671Â Required interest on reserves(605,397)(82,300)(24,358)712,055Â Â€"Â Â€"Â Â€"Â Amortization of acquisition costs263,753Â 40,774Â 1,766Â Â€"Â Â€"Â 305,703Â Commissions, premium taxes, and non-deferred acquisition costs270,347Â 177,246Â 12Â Â€"Â Â€"Â Â€"Â 447,605Â Insurance administrative expense(1)Â€"Â Â€"Â Â€"Â 251,072Â 1,646Â (3)252,718Â Parent expenseÂ€"Â Â€"Â Â€"Â 9,166Â 6,722Â (2,3)15,888Â Stock-based compensation expenseÂ€"Â Â€"Â Â€"Â 28,590Â Â€"Â 28,590Â Interest expenseÂ€"Â Â€"Â Â€"Â 91,413Â Â€"Â 91,413Â Total expenses1,421,868Â 765,396Â (5,384)727,099Â 380,241Â 8,368Â 3,297,588Â Subtotal1,016,517Â 281,221Â 5,384Â 126,079Â (380,049)(8,368)1,040,784Â Non-operating itemsÂ€"Â Â€"Â Â€"Â Â€"Â 8,368Â (2)3,368Â Measure of segment profitability (pretax) \$1,016,517Â \$281,221Â 5,384Â \$126,079Â \$(380,049)\$Â€"Â 1,049,152Â Realized gains (losses) (26,580)Legal costs and proceedings(5,764)Non-operating expenses(2,604)Income before income taxes per Condensed Consolidated Statements of Operations \$1,014,204Â (1)Administrative expense is not allocated to insurance segments. (2)Non-operating expenses. (3)Legal costs and proceedings.56 Â A Â A Â A GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc. Notes to Condensed Consolidated Financial Statements(Dollar amounts in thousands, except per share data)Nine Months Ended September 30, 2023LifeHealthAnnuityInvestmentCorporate & OtherAdjustmentsConsolidatedRevenue:Premium\$2,342,429Â \$982,916Â Â€"Â Â€"Â \$3,325,345Â Net investment incomeÂ€"Â Â€"Â Â€"Â 785,275Â Â€"Â Â€"Â 785,275Â Other incomeÂ€"Â Â€"Â Â€"Â 185Â Â€"Â 185Â Total revenue2,342,429Â 982,916Â Â€"Â 785,275Â 185Â 4,110,805Â Expenses:Policy obligations1,493,165Â 629,676Â 17,786Â 15,044Â Â€"Â Â€"Â 2,155,671Â Required interest on reserves(605,397)(82,300)(24,358)712,055Â Â€"Â Â€"Â Â€"Â Amortization of acquisition costs263,753Â 40,774Â 1,766Â Â€"Â Â€"Â 305,703Â Commissions, premium taxes, and non-deferred acquisition costs270,347Â 177,246Â 12Â Â€"Â Â€"Â Â€"Â 447,605Â Insurance administrative expense(1)Â€"Â Â€"Â Â€"Â 251,072Â 1,646Â (3)252,718Â Parent expenseÂ€"Â Â€"Â Â€"Â 9,166Â 6,722Â (2,3)15,888Â Stock-based compensation expenseÂ€"Â Â€"Â Â€"Â 28,590Â Â€"Â 28,590Â Interest expenseÂ€"Â Â€"Â Â€"Â 91,413Â Â€"Â 91,413Â Total expenses1,421,868Â 765,396Â (5,384)727,099Â 380,241Â 8,368Â 3,297,588Â Subtotal1,016,517Â 281,221Â 5,384Â 126,079Â (380,049)(8,368)1,040,784Â Non-operating itemsÂ€"Â Â€"Â Â€"Â Â€"Â 8,368Â (2)3,368Â Measure of segment profitability (pretax) \$1,016,517Â \$281,221Â 5,384Â \$126,079Â \$(380,049)\$Â€"Â 1,049,152Â Realized gains (losses) (26,580)Legal costs and proceedings(5,764)Non-operating expenses(2,604)Income before income taxes per Condensed Consolidated Statements of Operations \$1,014,204Â (1)Administrative expense is not allocated to insurance segments. (2)Non-operating expenses. (3)Legal costs and proceedings.56 Â A Â A Â A GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc. Notes to Condensed Consolidated Financial Statements(Dollar amounts in thousands, except per share data)Nine Months Ended September 30, 2023LifeHealthAnnuityInvestmentCorporate & OtherAdjustmentsConsolidatedRevenue:Premium\$2,342,429Â \$982,916Â Â€"Â Â€"Â \$3,325,345Â Net investment incomeÂ€"Â Â€"Â Â€"Â 785,275Â Â€"Â Â€"Â 785,275Â Other incomeÂ€"Â Â€"Â Â€"Â 185Â Â€"Â 185Â Total revenue2,342,429Â 982,916Â Â€"Â 785,275Â 185Â 4,110,805Â Expenses:Policy obligations1,493,165Â 629,676Â 17,786Â 15,044Â Â€"Â Â€"Â 2,155,671Â Required interest on reserves(605,397)(82,300)(24,358)712,055Â Â€"Â Â€"Â Â€"Â Amortization of acquisition costs263,753Â 40,774Â 1,766Â Â€"Â Â€"Â 305,703Â Commissions, premium taxes, and non-deferred acquisition costs270,347Â 177,246Â 12Â Â€"Â Â€"Â Â€"Â 447,605Â Insurance administrative expense(1)Â€"Â Â€"Â Â€"Â 251,072Â 1,646Â (3)252,718Â Parent expenseÂ€"Â Â€"Â Â€"Â 9,166Â 6,722Â (2,3)15,888Â Stock-based compensation expenseÂ€"Â Â€"Â Â€"Â 28,590Â Â€"Â 28,590Â Interest expenseÂ€"Â Â€"Â Â€"Â 91,413Â Â€"Â 91,413Â Total expenses1,421,868Â 765,396Â (5,384)727,099Â 380,241Â 8,368Â 3,297,588Â Subtotal1,016,517Â 281,221Â 5,384Â 126,079Â (380,049)(8,368)1,040,784Â Non-operating itemsÂ€"Â Â€"Â Â€"Â Â€"Â 8,368Â (2)3,368Â Measure of segment profitability (pretax) \$1,016,517Â \$281,221Â 5,384Â \$126,079Â \$(380,049)\$Â€"Â 1,049,152Â Realized gains (losses) (26,580)Legal costs and proceedings(5,764)Non-operating expenses(2,604)Income before income taxes per Condensed Consolidated Statements of Operations \$1,014,204Â (1)Administrative expense is not allocated to insurance segments. (2)Non-operating expenses. (3)Legal costs and proceedings.56 Â A Â A Â A GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc. Notes to Condensed Consolidated Financial Statements(Dollar amounts in thousands, except per share data)Nine Months Ended September 30, 2023LifeHealthAnnuityInvestmentCorporate & OtherAdjustmentsConsolidatedRevenue:Premium\$2,342,429Â \$982,916Â Â€"Â Â€"Â \$3,325,345Â Net investment incomeÂ€"Â Â€"Â Â€"Â 785,275Â Â€"Â Â€"Â 785,275Â Other incomeÂ€"Â Â€"Â Â€"Â 185Â Â€"Â 185Â Total revenue2,342,429Â 982,916Â Â€"Â 785,275Â 185Â 4,110,805Â Expenses:Policy obligations1,493,165Â 629,676Â 17,786Â 15,044Â Â€"Â Â€"Â 2,155,671Â Required interest on reserves(605,397)(82,300)(24,358)712,055Â Â€"Â Â€"Â Â€"Â Amortization of acquisition costs263,753Â 40,774Â 1,766Â Â€"Â Â€"Â 305,703Â Commissions, premium taxes, and non-deferred acquisition costs270,347Â 177,246Â 12Â Â€"Â Â€"Â Â€"Â 447,605Â Insurance administrative expense(1)Â€"Â Â€"Â Â€"Â 251,072Â 1,646Â (3)252,718Â Parent expenseÂ€"Â Â€"Â Â€"Â 9,166Â 6,722Â (2,3)15,888Â Stock-based compensation expenseÂ€"Â Â€"Â Â€"Â 28,590Â Â€"Â 28,590Â Interest expenseÂ€"Â Â€"Â Â€"Â 91,413Â Â€"Â 91,413Â Total expenses1,421,868Â 765,396Â (5,38

[illegible]

premium (defined in the following section) increased 13% to \$507 million for 2024 compared to \$449 million in 2023. Life insurance premium income increased 4% to \$2.44 billion over the prior-year total of \$2.34 billion. Life net sales rose 9% to \$450 million for the first nine months of 2024. First-year collected life premium increased 9% to \$342 million. Life underwriting margin, as a percent of premium, increased to 42% for 2024 from 38% in 2023. Underwriting margin increased to \$1.02 billion in 2024, compared to \$887 million for the same period in 2023. Health insurance premium income increased 6% to \$1.05 billion over the prior-year total of \$983 million. Health net sales rose 11% to \$171 million for the first nine months of 2024. First-year collected health premium rose 21% to \$165 million. Health underwriting margin, as a percent of premium, was 27% for 2024 and 29% for 2023. Health underwriting margin increased slightly to \$281 million for the first nine months of 2024, compared to the same period in 2023. Excess investment income, the measure of profitability of our investment segment, increased 33% during the first nine months of 2024 to \$126 million from \$95 million in the same period in 2023. Excess investment income per common share, reflecting the impact of our share repurchase program and increased net investment income, increased 41% to \$1.38 from \$0.98 when compared with the same period in 2023. Insurance administrative expenses increased 12% in 2024 when compared with the prior-year period. These expenses were 7.2% as a percent of premium during 2024 compared to 6.7% in 2023. For the nine months ended September 30, 2024, the Company repurchased 9.7 million Globe Life Inc. shares at a total cost of \$910 million for an average share price of \$93.36. 64 A A A A A A A A A A GL Q3 2024 FORM 10-Q Table of Contents GLOBE LIFE INC. Management's Discussion & Analysis The discussions of our segments are presented in the manner we view our operations, as described in Note 12a. "Business Segments. We use three measures as indicators of premium growth and sales over the near term: annualized premium in force, net sales, and first-year collected premium. Annualized premium in force is defined as the premium income that would be received over the following twelve months at any given date on all active policies if those policies remain in force throughout the twelve-month period. Net sales is calculated as annualized premium issued, net of cancellations in the first thirty days after issue, except in the case of Direct to Consumer, where net sales is annualized premium issued at the time the first full premium is paid after any introductory offer period (typically 1 month) has expired. Management considers net sales to be a better indicator of the rate of premium growth than annualized premium issued since annualized premium issued excludes cancellations, and cancellations do not contribute to premium income. First-year collected premium is defined as the premium collected during the reporting period for all policies in their first policy year. First-year collected premium takes lapses into account in the first year when lapses are more likely to occur, and thus is a useful indicator of how much new premium is expected to be added to premium income in the future. First-year collected premiums are lower than net sales over the prior 12 months because premiums are not collected on lapsed policies after the date of lapse. Cancellations are not included in lapses. Approximately 90% of our premiums are collected monthly; however, other premium payment options such as quarterly and annual are offered by the Company and may be elected by the policyholder. The majority of premiums are paid by way of automatic draft or electronic payment from our policyholders and to a lesser extent from other payment methods such as check, credit card, and worksite payroll deduction. See further discussion of the distribution channels below for Life and Health. 65 A A A A A A A A A A GL Q3 2024 FORM 10-Q Table of Contents GLOBE LIFE INC. Management's Discussion & Analysis LIFE INSURANCE Life insurance is the Company's predominant segment. During 2024, life premium represented 70% of total premium and life underwriting margin represented 78% of the total underwriting margin. Additionally, investments supporting the reserves for life products produce the majority of excess investment income attributable to the investment segment. The following table presents the summary of results of life insurance. Further discussion of the results by distribution channel is included below. Life Insurance Summary of Results (Dollar amounts in thousands) Nine Months Ended September 30, Change 2024 2023 Amount % of Premium Amount % of Premium Amount % of Premium and policy charges \$2,438,385A 100A \$2,342,429A 100A \$95,956A 4A Policy obligations 1,493,165A 61A 1,536,317A 66A (43,152)(3) Required interest on reserves (605,397)(25) (575,801)(25) (29,596)5A Net policy obligations 887,768A 36A 960,516A 41A (72,748)(8) Commissions, premium taxes, and non-deferred acquisition expenses 270,347A 11A 251,136A 11A 19,211A 8A Amortization of acquisition costs 263,753A 11A 243,285A 10A 20,468A 8A Total expense 1,421,868A 58A 1,454,937A 62A (33,069)(2) Insurance underwriting margin \$1,016,517A 42A \$887,492A 38A \$129,025A 15A Net policy obligations amounted to 36% of premium for the nine months ended September 30, 2024 compared to 41% in the year-ago period. This improvement was primarily due to the assumptions review of lapses, mortality, and morbidity resulting in a remeasurement gain of \$56.8 million compared to a remeasurement loss of \$2.0 million for the nine months ended September 30, 2024 and 2023, respectively. Refer to Note 6a. "Policy Liabilities for further discussion of the Company's annual assumptions review. 66 A A A A A A A A A A GL Q3 2024 FORM 10-Q Table of Contents Globe Life Inc. Management's Discussion & Analysis The table below summarizes life underwriting margin by distribution channel. A Life Insurance Underwriting Margin by Distribution Channel (Dollar amounts in thousands) Nine Months Ended September 30, Change 2024 2023 Change Amount % of Premium Amount % of Premium Amount % of Premium American Income \$600,976A 47A \$536,202A 45A \$64,774A 12A Direct to Consumer 210,712A 28A 175,652A 24A 35,060A 20A Liberty National 106,486A 38A 83,502A 32A 22,984A 28A Other 98,343A 64A 92,136A 59A 6,207A 7A Total \$1,016,517A 42A \$887,492A 38A \$129,025A 15A The following table presents Globe Life's life insurance premium by distribution channel. Life Insurance Premium by Distribution Channel (Dollar amounts in thousands) Nine Months Ended September 30, Change 2024 2023 Amount % of Total Amount % of Total Amount % of Total American Income \$1,265,417A 52A \$1,182,346A 50A \$83,071A 7A Direct to Consumer 743,304A 31A 744,132A 32A (828)Ae " Liberty National 276,599A 11A 260,036A 11A 16,563A 6A Other 153,065A 6A 155,915A 7A (2,850)(2) Total \$2,438,385A 100A \$2,342,429A 100A \$95,956A 4A Annualized life premium in force was \$3.29 billion at September 30, 2024, an increase of 4% over \$3.17 billion a year earlier. 67 A A A A A A A A A A GL Q3 2024 FORM 10-Q Table of Contents Globe Life Inc. Management's Discussion & Analysis An analysis of life net sales, an indicator of new business production, by distribution channel is presented below. A Life Insurance Net Sales by Distribution Channel (Dollar amounts in thousands) Nine Months Ended September 30, Change 2024 2023 Amount % of Total Amount % of Total American Income \$288,602A 64A \$246,335A 59A \$42,267A 17A Direct to Consumer 83,251A 18A 90,593A 22A (7,342)(8) Liberty National 71,846A 16A 69,413A 17A 2,433A 4A Other 6,725A 2A 7,513A 2A (788)(10) Total \$450,424A 100A \$413,854A 100A \$36,570A 9A First-year collected life premium by distribution channel is presented in the table below. A Life Insurance First-Year Collected Premium by Distribution Channel (Dollar amounts in thousands) Nine Months Ended September 30, Change 2024 2023 Amount % of Total Amount % of Total American Income \$227,817A 67A \$197,224A 63A \$30,593A 16A Direct to Consumer 52,080A 15A 59,735A 19A (7,655)(13) Liberty National 56,043A 16A 49,810A 16A 6,233A 13A Other 5,850A 2A 6,513A 2A (663)(10) Total \$341,790A 100A \$313,282A 100A \$28,508A 9A 68 A A A A A A A A A A GL Q3 2024 FORM 10-Q Table of Contents Globe Life Inc. Management's Discussion & Analysis A discussion of life operations by distribution channel follows. The American Income Life Division markets to members of labor unions and other affinity groups and continues to diversify its lead sources, utilizing third-party internet vendor leads and obtaining referrals to facilitate sustainable growth. This Division is Globe Life's largest contributor of life premium of any distribution channel at 52% of the Company's September 30, 2024 total life premium. For the nine months ended September 30, 2024, the average monthly life premium issued per policy was \$56 as compared to \$53 for the same period in the prior year. Net sales were \$289 million for the nine months ended September 30, 2024, up from \$246 million in the year-ago period. The underwriting margin, as a percent of premium, was 47% for the nine months ended September 30, 2024 up from 45% in the year ago period. Below is the average producing agent count for the nine months ended September 30, 2024 for the American Income Life Division. The average producing agent count is based on the actual count at the beginning and end of each week during the year. The average producing agent count increased 12% over the year-ago period, and over 65% of the Division's net sales are driven by agents that have been producing for the Division for 6 months or more. The increase in average producing agent count was driven by an increase in new agent recruiting along with continued improvement in new agent retention. Sales growth in this Division, as well as within our other exclusive agencies, is generally dependent on growth in the size of the agency force. At September 30, Change 2024 2023 Amount % American Income 11,680A 10,395A 1,285A 12A American Income Life continues to focus on growing and strengthening the agency force, specifically through emphasis on agency middle-management growth and additional agency office openings. In addition to offering financial incentives and training opportunities, the Division has made considerable investments in information technology, including a customer relationship management (CRM) tool for the agency force. This tool is designed to drive productivity in lead distribution, conservation of business, manager dashboards and new agent recruiting. Additionally, this Division has invested in and successfully implemented technology that allows the agency force to engage in virtual recruiting, training, and sales activity. The agents have shifted to primarily a virtual experience with the customers and have generated a vast majority of sales through virtual presentations. We find this flexibility to be enticing for new recruits as well as a driver of sustainability for our agency force. The Direct to Consumer Division (DTC) offers adult and juvenile life insurance through a variety of marketing approaches, including direct mailings, insert media, and electronic media. In recent years, production from electronic media, which is comprised of sales through both the internet and inbound phone calls to our call center, continue to be the customer preference when compared to direct mail. The proportion of sales from the internet and inbound phone calls continue to outpace the activity from the direct mailings, but all three channels continue to work in an omnichannel approach. The different media channels support and complement one another in the Division's efforts to reach the consumer. Additionally, this channel provides critical support to our agency business through brand impressions and the generation of sales leads. DTC's long-term growth has been fueled by constant innovation and name recognition. We continually introduce new initiatives in this Division in an attempt to increase response rates and create a seamless customer experience. The juvenile market is an important source of sales, it is also a vehicle to reach the parents and grandparents of juvenile policyholders, who are more likely to respond favorably to a DTC solicitation for life coverage on themselves in comparison to the general adult population. Also, future offerings to juvenile policyholders and their parents are sources of lower acquisition-cost life insurance sales in the future. DTC net sales declined 8% to \$83 million for the nine months ended September 30, 2024 compared with \$91 million for the same period in the prior year. This decline is due primarily to the management of direct mail and mailing insert marketing activity resulting from the impact of inflation on postage, paper and online advertising costs. While total sales have declined, the focus has been on improving profitability and improving the underwriting margin. DTC's underwriting margin, as a percent of premium, was 28% for the nine months ended September 30, 2024 compared with 24% for the same period in 2023. 69 A A A A A A A A A A GL Q3 2024 FORM 10-Q Table of Contents Globe Life Inc. Management's Discussion & Analysis The Liberty National Division markets individual life insurance to middle-income household and worksite customers. Recent investments in new sales technologies as well as recent growth in middle management within the agency are expected to help continue this growth. The underwriting margin as a percent of premium was 38% for the nine months ended September 30, 2024, up from 32% during the same period a year ago. The increase is primarily attributable to increased premiums and lower policy obligations as a percent of premium during the first nine months of 2024 as compared to same period in 2023. For the nine months ended September 30, 2024, the average monthly life premium per policy issued was \$43 down slightly from the prior year period. Net sales rose 4% in the nine months ended September 30, 2024 over the same period in 2023 due primarily to increased agent count. Below is the average producing agent count for the nine months ended September 30, 2024 and 2023 for the Liberty National Division. The average producing agent count is based on the actual count at the beginning and end of each week during the year. At September 30, Change 2024 2023 Amount % Liberty National 3,638A 3,177A 461A 15A The Liberty National Division average producing agent count increased significantly compared with the prior-year comparable period. We continue to execute our long-term plan to grow this agency through expansion from small-town markets in the Southeast to more densely populated areas with larger pools of potential agent recruits and customers. Continued expansion of this agency's presence into more heavily populated, less-penetrated areas will help create long-term agency growth. In addition to the aforementioned geographic expansion, we have also started a campaign of market expansion to increase our agency presence in cities where we currently have offices, but not enough to properly serve the community, region, area and city. These tend to be larger geographic cities which will help create long-term sustainable agency growth. Additionally, the agency continues to help improve the ability of agents to develop new worksite marketing business. Systems that have been put in place, including the addition of a CRM platform and enhanced analytical capabilities, have helped the agents develop additional worksite marketing opportunities as well as improve the productivity of agents selling in the individual life market. As the Division continues to gain momentum in its sales and recruiting initiatives, as well as advances in its technology and CRM platform, the agency anticipates continued growth in recruiting activity and average producing agent count and projects sales growth for the full year. The Other agency distribution channels primarily include non-exclusive independent agencies selling primarily life insurance. The other distribution channels contributed \$153 million of life premium income, or 6% of Globe Life's total life premium income in the nine months ended September 30, 2024, and contributed 2% of net sales for the period. HEALTH INSURANCE Health insurance sold by the Company primarily includes Medicare Supplement insurance including Retiree Health Insurance business, accident coverage, and other limited-benefit supplemental health products including accident, cancer, critical illness, heart, and intensive care products. Health premium accounted for 30% of our total premium in 2024, while the health underwriting margin accounted for 22% of total underwriting margin. Health underwriting margin increased slightly to \$281 million compared to \$280 million in the prior year. While the Company continues to emphasize life insurance sales relative to health due to life's superior long-term profitability and its greater contribution to excess investment income, the health business provides a significant contribution to return on equity as it does not require a substantial amount of up-front capital. 70 A A A A A A A A A A GL Q3 2024 FORM 10-Q Table of Contents Globe Life Inc. Management's Discussion & Analysis The following table presents underwriting margin data for health insurance. Health Insurance Summary of Results (Dollar amounts in thousands) Nine Months Ended September 30, Change 2024 2023 Amount % of Premium Amount % of Premium Amount % of Premium \$1,046,617A 100A \$982,916A 100A \$63,701A 6A Policy obligations 629,676A 60A 580,676A 59A 49,000A 8A Required interest on reserves (82,300)(8) (79,603)(8) (2,697)3A Net policy obligations 547,376A 52A 501,073A 51A 46,303A 9A Commissions, premium taxes, and non-deferred acquisition expenses 177,246A 17A 163,784A 16A 13,462A 8A Amortization of acquisition costs 40,774A 4A 37,608A 4A 3,166A 8A Total expense 765,396A 73A 702,465A 71A 62,931A 9A Insurance underwriting margin \$281,221A 27A \$280,451A 29A \$770A A Net policy obligations amounted to 52% of premium for the nine months ended September 30, 2024 compared to 51% in the year ago period. This increase was primarily due to the assumptions review of lapses and morbidity resulting in a remeasurement loss of \$10.5 million compared to a remeasurement gain of \$5.2 million for the nine months ended September 30, 2024 and 2023, respectively. Refer to Note 6a. "Policy Liabilities for further discussion of the Company's annual assumptions review. The table below summarizes health underwriting margin by distribution channel. A Health Insurance Underwriting Margin by Distribution Channel (Dollar amounts in thousands) Nine Months Ended September 30, Change 2024 2023 Change Amount % of Premium Amount % of Premium Amount % of Premium American \$42,500A 10A \$43,164A 11A (\$664)(2) Family Heritage 106,481A 34A 100,058A 34A 6,423A 6A Liberty National 79,181A 56A 78,160A 56A 1,021A 1A American Income 49,124A 53A 55,588A 62A (6,464)(12) Direct to Consumer 3,935A 7A 3,481A 7A 454A 13A Total \$281,221A 27A \$280,451A 29A \$770A A 71 A A A A A A A A A A GL Q3 2024 FORM 10-Q Table of Contents Globe Life Inc. Management's Discussion & Analysis Globe Life markets supplemental health insurance products through a number of distribution channels. The following table is an analysis of our health premium by distribution channel. Health Insurance Premium by Distribution Channel (Dollar amounts in thousands) Nine Months Ended September 30, Increase (Decrease) A 2024 2023 Amount % of Total Amount % of Total American \$440,375A 42A \$407,137A 42A \$33,238A 8A Family Heritage 317,065A 30A 294,029A 30A 23,036A 8A Liberty National 142,612A 14A 140,518A 14A 2,094A 1A American Income 92,495A 9A 89,656A 9A 2,839A 3A Direct to Consumer 54,070A 5A 51,576A 5A 2,494A 5A Total \$1,046,617A 100A \$982,916A 100A \$63,701A 6A Premium related to limited-benefit supplemental health products comprise \$586 million, or 56%, of the total health premiums for the nine months ended September 30, 2024, compared with \$553 million, or 56%, in the same period in the prior year. Premium from Medicare Supplement products comprises the remaining \$461 million, or 44%, for the nine months ended September 30, 2024, compared with \$430 million, or 44%, in the same period in the prior year. Annualized health premium in force was \$1.45 billion at September 30, 2024, an increase of 7% over \$1.36 billion a year earlier. Presented below is a table of health net sales by distribution channel. A Health Insurance Net Sales by Distribution Channel (Dollar amounts in thousands) Nine Months Ended September 30, Increase (Decrease) A 2024 2023 Amount % of Total Amount % of Total American \$50,180A 29A \$44,053A 29A \$6,127A 14A Family Heritage 78,862A 46A 70,865A 46A 7,997A 11A Liberty National 24,091A 14A 23,806A 15A 285A 1A American Income 15,952A 9A 13,889A 9A 2,063A 15A Direct to Consumer 2,306A 2A 1,773A 1A 533A 30A Total \$171,391A 100A \$154,386A 100A \$17,005A 11A Health net sales related to limited-benefit supplemental health products comprise \$130 million, or 76%, of the total health net sales for the nine months ended September 30, 2024, compared with \$121 million, or 79%, in the same period in the prior year. Medicare Supplement sales make up the remaining \$41 million, or 24%, for 2024 compared with \$33 million, or 21%, in the same period in the prior year. 72 A A A A A A A A A A GL Q3 2024 FORM 10-Q Table of Contents Globe Life Inc. Management's Discussion & Analysis The following table presents health insurance first-year collected premium by

distribution channel. A Health Insurance First-Year Collected Premium by Distribution Channel(Dollar amounts in thousands) Nine Months Ended September 30, Increase(Decrease) % 2024/2023 Amount Total Amount of Total Amount of United American \$66,944 40A \$47,819 35A \$19,125 40A Family Heritage\$58,878 36A \$53,456 39A \$5,422 10A Liberty National\$21,272 13A \$18,877 14A \$2,395 13A American Income\$14,740 9A \$12,857 10A \$1,883 15A Direct to Consumer,\$2,819 2A \$2,538 2A \$253 10A Total \$164,725 100A \$135,647 100A \$29,078 21A A First-year collected premium related to limited-benefit supplemental health products is \$119 million, or 72%, of total first-year collected premium for the nine months ended September 30, 2024 compared with \$98 million, or 72%, in the same period in the prior year. First-year collected premium from Medicare Supplement policies make up the remaining \$46 million, or 28%, for the nine months ended September 30, 2024 compared with \$38 million, or 28%, in the same period in the prior year. A discussion of health operations by distribution channel follows. The United American Division consists of non-exclusive independent agencies who may also sell for other companies. The United American Division was Globe Life's largest health agency in terms of health premium income, with net sales up 14% from the same period in the prior year. This Division includes three different units: a CUA General Agency, which primarily sells individual Medicare Supplement insurance through independent agents; a C Special Markets, which markets retiree health insurance to employer and union groups through brokers; and a C Globe Life Group Benefits, which offers group worksite supplemental health insurance through brokers. The majority of the premium revenue comes from Medicare Supplement. Underwriting margin as a percent of premium for the Division was 10% for the nine months ended September 30, 2024 and 11% for the same period in 2023. The Family Heritage Division primarily markets limited-benefit supplemental health insurance in non-urban areas. Most of its policies include a cash-back feature, such as a return of premium, where any excess of premiums over claims paid is returned to the policyholder at the end of a specified period stated within the insurance policy. Underwriting margin as a percent of premium was 34% for the nine months ended September 30, 2024 and 2023. The Division experienced a 11% rise in health net sales as compared with the nine-month period a year ago, primarily due to improved agent productivity and training. The Division will continue to implement incentive and retention programs to further these increases in the number of producing agents. 73 A A A A A GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc.Management's Discussion & AnalysisBelow is the average producing agent count at the end of the period for the Family Heritage Division. The average producing agent count is based on the actual count at the beginning and end of each week during the year. The average producing agent count was slightly higher than compared with the same period a year ago. The Division has recently increased efforts to grow agent count and middle management. While growth in net sales and earned premium is impacted by agent productivity, growth in the number of average producing agents is what will ultimately be the primary driver of future growth in sales, similar to our other exclusive agencies. At September 30, Change2024/2023AmountFamily Heritage1,362A 1,322A 40A 3A The Liberty National Division represented 14% of all Globe Life health premium income for the nine months ended September 30, 2024. The Liberty National Division markets limited-benefit supplemental health products, consisting primarily of cancer and critical illness insurance. Much of Liberty National's health business is generated through worksite marketing targeting small businesses. Health premium at the Liberty National Division was \$143 million for the nine months ended September 30, 2024 up from \$141 million for the same period in 2023. Liberty National's first-year collected premium rose 13% to \$21 million in the nine months ended September 30, 2024 compared with \$19 million for the same period in 2023. Health net sales for the nine months ended September 30, 2024 rose 1% from the comparable period in 2023. For the nine months ended September 30, 2024 and 2023, underwriting margin as a percent of premium was 56%. While both the American Income Life Division and the Direct to Consumer Division sell life insurance, they also market health products. The American Income Life Division primarily markets accident plans. The Direct to Consumer Division primarily markets Medicare Supplements to employer or union-sponsored groups. On a combined basis, these other channels accounted for 14% of health premium for the nine months ended September 30, 2024 and 2023. ANNUITIESAnnuities represent an insignificant part of our business. We do not currently market stand-alone fixed or deferred annuity products, favoring instead protection-oriented life and supplemental health insurance products. INVESTMENTSWe manage our capital resources, including investments and cash flow, through the investment segment. Excess investment income represents the profit margin attributable to investment operations and is the measure that we use to evaluate the performance of the investment segment as described in Note 12a "Business Segments". It is defined as net investment income less the required interest attributable to policy liabilities. Management also views excess investment income per diluted common share as an important and useful measure to evaluate the performance of the investment segment. It is defined as excess investment income divided by the total diluted weighted average shares outstanding, representing the contribution by the investment segment to the consolidated earnings per share of the Company. As excess investment income per diluted common share incorporates all invested assets and insurance liabilities, we view excess investment income per diluted common share as a useful measure to evaluate the investment segment. 74 A A A A A A GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc.Management's Discussion & AnalysisExcess Investment Income. The following table summarizes Globe Life's investment income, excess investment income, and excess investment income per diluted common share. Analysis of Excess Investment Income(Dollar amounts in thousands, except for per share data)A Nine Months EndedSeptember 30, Change2024/2023AmountNet investment income\$853,178A \$785,275A \$67,903A 9A Interest on policy liabilities(1)(727,099)(690,717)(36,382)5A Excess investment income \$126,079A \$94,558A \$31,521A 33A Excess investment income per diluted share \$1.38A \$0.98A \$0.40A 41A Mean invested assets (at amortized cost)\$21,359,702A \$20,329,079A \$1,030,623A 5A Average insurance policy liabilities17,501,496A 16,677,765A 823,731A 5A (1)Interest on policy liabilities, at original rates, is a component of total policyholder benefits, a GAAP measure. Excess investment income increased \$31.5 million, or 33%, compared with the year-ago period. Excess investment income per diluted common share was \$1.38 for the nine months ended September 30, 2024, an increase of 41% over the prior-year period. Excess investment income per diluted common share generally increases at a faster pace than excess investment income because the number of diluted shares outstanding generally decreases from year to year as a result of our share repurchase program. Net investment income for the nine months ended September 30, 2024 was \$853 million or 9% greater than the year-ago period. Mean invested assets increased 5% during the first nine months of 2024 over the same period last year. Investment income grew in the current period primarily due to the growth in invested assets and higher interest rates compared to the prior year. The effective annual yield rate earned on the fixed maturity portfolio was 5.26% in the first nine months of 2024, compared with 5.18% a year earlier. In addition to fixed maturities, the Company has also invested in commercial mortgage loans and limited partnerships with debt-like characteristics that diversify risk and enhance risk-adjusted, capital-adjusted returns on the portfolio. The earned yield on the Company's commercial mortgage loans for the nine months ended September 30, 2024 was 8.47%. The earned yield on limited partnership investments for the nine months ended September 30, 2024 was 8.64%. See additional information in Note 4a "Investments." Globe Life's net investment income benefits from higher interest rates on new investments. While increasing interest rates have resulted in a net unrealized loss from our available for sale debt securities included in accumulated other comprehensive income (loss) as of September 30, 2024, we are not concerned because we do not generally intend to sell, nor is it likely that we will be required to sell, the fixed maturities prior to their anticipated recovery. Required interest on insurance policy liabilities reduces excess investment income, as it is the amount of net investment income considered by management necessary to a c e f u n d a c y required interest on insurance policy liabilities. As such, it is reclassified from the insurance segment to the investment segment. As discussed in Note 12a "Business Segments," management regards this as a more meaningful analysis of the investment and insurance segments. Required interest is based on the original discount rate assumptions for our insurance policies in force. The vast majority of our life and health insurance policies are fixed interest rate protection policies, not investment products, and are accounted for under current GAAP accounting guidance for long-duration insurance products which mandate that interest rate assumptions for a particular block of business be a c e l o c k e d i n a c y for the life of that block of business. Each calendar year, we set the original discount rate to be used to calculate the benefit reserve liability for all insurance policies issued that year. The liability reported on the balance sheet is updated in subsequent periods using current discount rates as of the end of the relevant reporting period with a corresponding adjustment to Other Comprehensive Income. 75 A A A A A A GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc.Management's Discussion & AnalysisThe discount rate used for policies issued in the current year has no impact on the in-force policies issued in prior years as the rates of all prior issue years are also locked in for purposes of recognizing income. As such, the overall original discount rate for the entire in-force block of 5.5% is a weighted average of the discount rates being used from all issue years. Changes in the overall weighted-average discount rate over time are caused by changes in the mix of the reserves on the entire block of in force business. Business issued in the current year has little impact on the overall weighted-average original discount rate due to the size of our in-force business. In comparison to the year-ago period, required interest on insurance policy liabilities increased \$36 million, or 5%, to \$727 million, consistent with the 5% growth in average interest-bearing insurance policy liabilities. Realized Gains and Losses. Our life and health insurance companies collect premium income from policyholders for the eventual payment of policyholder benefits, sometimes paid for many years or even decades in the future. Since benefits are expected to be paid in future periods, premium receipts in excess of current expenses are invested to provide for these obligations. For this reason, we hold a significant investment portfolio as a part of our core insurance operations. This portfolio consists primarily of high-quality fixed maturities containing an adequate yield to provide for the cost of carrying these long-term insurance product obligations. As a result, fixed maturities are generally held for long periods to support these obligations. Expected yields on these investments are taken into account when setting insurance premium rates and product profitability expectations. Despite our intent to hold fixed maturity investments for a long period of time, investments are occasionally sold, exchanged, called, or experience a credit loss event, resulting in a realized gain or loss. Gains or losses are only secondary to our core insurance operations of providing insurance coverage to policyholders. In a bond exchange offer, bondholders may consent to exchange their existing bonds for another class of debt securities. The Company also has investments in certain limited partnerships, held under the fair value option, with fair value changes recognized in Realized gains (losses) in the Condensed Consolidated Statements of Operations. Realized gains and losses can be significant in relation to the earnings from core insurance operations, and as a result, can have a material positive or negative impact on net income. The significant fluctuations caused by gains and losses can cause period-to-period trends of net income that are not indicative of historical core operating results or predictive of the future trends of core operations. Accordingly, they have no bearing on core insurance operations or segment results as we view operations. For these reasons, and in line with industry practice, we remove the effects of realized gains and losses when evaluating overall insurance operating results. The following table summarizes our tax-effected realized gains (losses) by component. Analysis of Realized Gains (Losses), Net of Tax(Dollar amounts in thousands, except for per share data)A Nine Months Ended September 30, 2024/2023 AmountPer A ShareAmountPer A Share Fixed maturities:\$ales\$(7,693)\$(0.08)\$(61,281)\$(0.64)Matured or other redemptions(1)(171)A \$(125)A \$(13)A \$(5,924)(0.06)Fair value optionA change in fair value(17,994)(0.20)6,284A 0.06A Mortgages(2,788)(0.03)(3,886)(0.03)Other investments\$897A 0.01A 396A A Total realized gains (losses)A investments (27,574)(0.30)(64,536)(0.67)Other gains (losses)(2)6,576A 0.07A 2,156A 0.02A Total realized gains (losses) \$(20,998)\$(0.23)\$(62,380)\$(0.65)(1)During the nine months ended September 30, 2024 and 2023, the Company recorded \$82.2 million and \$39.0 million, respectively, of exchanges of fixed maturity securities (noncash transactions) that resulted in no realized gains (losses), net of tax in either period. (2)Other realized gains (losses) are primarily a result of changes in the fair value for assets held in rabbi trust. 76 A A A A A A GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc.Management's Discussion & AnalysisInvestment Acquisitions. Globe Life's investment policy calls for investing primarily in investment grade fixed maturities that meet our quality and yield objectives. We generally invest in securities with longer-term maturities because they more closely match the long-term nature of our life and health policy liabilities. We believe this strategy is appropriate since our expected future cash flows are generally stable and predictable and the likelihood that we will need to sell invested assets to raise cash is low. The following table summarizes selected information for fixed maturity investments. The effective annual yield shown is based on the acquisition price and call features, if any, of the securities. For non-callable bonds, the yield is calculated to maturity date. For callable bonds acquired at a premium, the yield is calculated to the earliest known call date and call price after acquisition ("first call date"). For all other callable bonds, the yield is calculated to maturity date.Fixed Maturity Acquisitions Selected Information(Dollar amounts in thousands)Nine Months EndedSeptember 30, 2024/2023Cost of acquisitions:Investment-grade corporate securities\$972,998A \$547,330A Investment-grade municipal securities11,231A \$49,528A Other securities20,436A A Total fixed maturity acquisitions(1) \$1,004,665A \$1,096,858A Effective annual yield (one year compounded)(2)5.96A %5.93A %Average life (in years, to next call)29.9A 17.1A Average life (in years, to maturity)32.7A 25.4A Average ratingA-A+(1)Fixed maturity acquisitions included unsettled trades of \$4 million in 2024 and \$20 million in 2023.(2)Tax-equivalent basis, where the yield on tax-exempt securities is adjusted to produce a yield equivalent to the pretax yield on taxable securities.For investments in callable bonds, the actual life of the investment will depend on whether the issuer calls the investment prior to the maturity date. Given our investments in callable bonds, the actual average life of our investments cannot be known at the time of the investment. Absent sales and "make-whole calls," however, the average life will not be less than the average life to next call and will not exceed the average life to maturity. Data for both of these average life measures is provided in the above chart.Acquisitions in 2023 and 2024 consisted primarily of corporate and municipal bonds with securities spanning a diversified range of issuers, industry sectors, and geographical regions. In the first nine months of 2024, we invested primarily in the industrial, financial, and utility sectors.

political divisions æ"À æ"À æ"À æ"À æ"À 3,253,819Å 49,409Å (424,989)2,878,239Å 17Å 16Å Other fixed maturities:Government (U.S. and foreign)æ"À æ"À æ"À æ"À æ"À 439,763Å 55Å (30,911)408,907Å 2Å 2Å Collateralized debt obligations36,685Å 5,798Å æ"À 42,483Å 36,685Å 5,798Å æ"À 42,483Å æ"À æ"À Other asset-backed securities,752Å æ"À (707,682)83,573Å 1Å (1,677)81,897Å 1Å 1Å Total fixed maturities \$555,863Å \$8,341Å \$(71,322)\$492,882Å \$19,077,322Å \$595,188Å (1,337,940)\$18,334,570Å 10010079 Å Å Å Å Å GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc.Management's Discussion & AnalysisFixed Maturities by SectorDecember 31, 2023 (Dollar amounts in thousands)Below Investment GradeTotal Fixed Maturities% of Total Fixed MaturitiesÅ AmortizedCostGrossUnrealizedGainsGrossUnrealizedLossesFairValueAmortizedCostGrossUnrealizedGainsGrossUnrealizedLossesFairValueAt Amortized Cost, netAt Fair ValueCorporates:FinancialInsurance - life, health, P&C\$107,010Å \$æ"À \$(12,472)\$94,538Å \$2,413,685Å \$61,715Å \$(163,455)\$2,311,945Å 13Å 13Å Banks36,906Å æ"À (4,401)32,505Å 1,327,272Å 25,019Å (71,714)1,280,577Å 7Å 7Å Other financial74,965Å æ"À (25,255)49,710Å 1,287,194Å 25,634Å (153,171)1,159,657Å 7Å 7Å Total financial218,881Å æ"À (42,128)176,753Å 5,028,151Å 112,368Å (388,340)4,752,179Å 27Å 27Å IndustrialEnergy44,652Å æ"À (7,481)37,171Å 1,446,480Å 58,637Å (62,324)1,442,793Å 8Å 8Å Basic materialsæ"À æ"À æ"À æ"À æ"À 1,166,385Å 39,248Å (64,501)1,141,132Å 6Å 6Å Consumer, non-cyclicalæ"À æ"À æ"À æ"À æ"À 2,096,651Å 32,071Å 1,160,828Å 1,967,894Å 11Å 11Å Other industrials5,185Å 110Å æ"À 5,295Å 1,101,059Å 32,541Å (78,817)1,054,783Å 6Å 6Å Communicationsæ"À æ"À æ"À æ"À æ"À 868,131Å 21,006Å (73,323)815,814Å 4Å 5Å Transportation8,403Å æ"À 136,343Å æ"À (25,059)111,284Å 515,169Å 4,941Å (57,735)462,375Å 3Å 3Å Technology32,543Å 625Å æ"À 33,168Å 280,668Å 3,521Å (44,670)239,519Å 1Å 1Å Total industrial227,126Å 735Å (32,955)194,906Å 8,009,011Å 213,078Å (566,847)7,655,242Å 42Å 43Å Utilities34,698Å 722Å (1,523)33,897Å 2,017,967Å 73,925Å (94,130)1,997,762Å 11Å 11Å Total corporates480,705Å 1,457Å (76,606)405,556Å 15,055,129Å 399,371Å (1,049,317)17,405,183Å 80Å 81Å States, municipalities, and political divisions:General obligationsæ"À æ"À æ"À æ"À æ"À 887,013Å 8,526Å (135,003)760,536Å 4Å 4Å Revenuesæ"À æ"À æ"À æ"À æ"À 2,409,292Å 38,820Å (268,326)2,179,786Å 13Å 12Å Total states, municipalities, and political divisions æ"À æ"À æ"À æ"À æ"À 3,296,305Å 47,346Å (403,329)2,940,322Å 17Å 16Å Other fixed maturities:Government (U.S., municipal, and foreign)æ"À æ"À æ"À æ"À æ"À 442,903Å 8Å (42,654)400,257Å 2Å 2Å Collateralized debt obligations37,110Å 5,036Å æ"À 42,146Å 37,110Å 5,036Å æ"À 42,146Å æ"À æ"À Other asset-backed securities11,696Å æ"À (409)11,287Å 86,352Å 3Å (4,057)82,298Å 1Å 1Å Total fixed maturities\$529,511Å \$6,493Å \$(77,015)\$458,989Å \$18,917,799Å \$451,764Å \$(1,499,357)\$17,870,206Å 10010080 Å Å Å Å Å GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc.Management's Discussion & AnalysisCorporate securities, which consist of bonds and redeemable preferred stocks, were the largest component of the fixed maturity portfolio as of September 30, 2024, representing 80% of amortized cost, net, and 81% of fair value. The remainder of the portfolio is invested primarily in securities issued by the U.S. government and U.S. municipalities. The Company holds insignificant amounts in foreign government bonds, collateralized debt obligations, asset-backed securities, and mortgage-backed securities. Corporate securities are diversified over a variety of industry sectors and issuers. At September 30, 2024, the total fixed maturity portfolio consisted of 975 issuers.Fixed maturities had a fair value of \$18.3 billion at September 30, 2024, compared with \$17.9 billion at December 31, 2023. The net unrealized loss position in the fixed-maturity portfolio decreased from \$1.0 billion at December 31, 2023 to \$743 million at September 30, 2024 due to an increase in market rates during the period. For more information about our fixed maturity portfolio by sector at September 30, 2024 and December 31, 2023, including a discussion of allowance for credit losses, an analysis of unrealized investment losses, and a schedule of maturities, see Note 4æ"Investments.An analysis of the fixed maturity portfolio by composite quality rating at September 30, 2024 and December 31, 2023, is shown in the following tables. The composite rating for each security, other than private-placement securities managed by third parties, is the average of the securityæ"™s available ratings as assigned by Moodyæ"™s Investor Service, Standard & Pooræ"™s, Fitch Ratings, and Dominion Bond Rating Service, LTD. The ratings assigned by these four nationally recognized statistical rating organizations are evenly weighted when calculating the average. The composite quality rating is created utilizing a methodology developed by Globe Life using ratings from the various rating agencies noted above. The composite quality rating is not a Standard & Poor's credit rating. Standard & Poor's does not sponsor, endorse, or promote the composite quality rating and shall not be liable for any use of the composite quality rating. Included in the following chart are private placement fixed maturity holdings at amortized cost, net of allowance for credit losses, of \$409 million (\$377 million at fair value) for which the ratings were assigned by the third-party managers.Fixed Maturities by RatingAt September 30, 2024 (Dollar amounts in thousands)Amortized Cost, net % of TotalFairValue% of TotalAverage Composite Quality Rating on Amortized Cost, net Investment grade:AAA\$964,999Å 5Å \$902,425Å 5Å AA3,259,652Å 17Å 2,860,220Å 16Å A5,614,869Å 29Å 5,576,664Å 30Å BBB+3,301,623Å 17Å 3,266,781Å 18Å BBB4,312,274Å 23Å 4,192,772Å 23Å BBB-1,068,042Å 6Å 1,042,826Å 5Å Total investment grade 18,521,459Å 97Å 17,841,688Å 97Å A-Below investment grade:BB507,781Å 3Å 439,052Å 3Å B7,517Å æ"À 7,432Å æ"À Below B40,565Å æ"À 46,398Å æ"À Å Total below investment grade 555,863Å 3Å 492,882Å 3Å BB-\$19,077,322Å 100Å 18,334,570Å 100Å Weighted average composite quality rating A-81 Å Å Å Å Å GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc.Management's Discussion & AnalysisFixed Maturities by RatingAt December 31, 2023 (Dollar amounts in thousands)AmortizedCost, net% of TotalFairValue% of TotalAverage Composite Quality Rating on Amortized CostInvestment grade:AAA\$952,822Å 5Å \$880,729Å 5Å AA3,179,618Å 17Å 2,789,626Å 15Å A5,118,085Å 27Å 4,976,280Å 28Å BBB+3,615,102Å 19Å 3,495,898Å 19Å BBB4,278,786Å 23Å 4,056,833Å 23Å BBB-1,243,875Å 6Å 1,211,851Å 7Å Total investment grade 18,388,288Å 97Å 17,411,217Å 97Å A-Below investment grade:BB450,503Å 3Å 376,912Å 3Å B37,896Å æ"À 35,929Å æ"À Below B41,112Å æ"À 46,148Å æ"À Å Total below investment grade 529,511Å 3Å 458,989Å 3Å BB-\$18,917,799Å 100Å 17,870,206Å 100Å Weighted average composite quality rating A-The overall quality rating of the portfolio is A-, the same as of year-end 2023. Fixed maturities rated BBB are 46% of the total portfolio at September 30, 2024, down from 48% at December 31, 2023. While this ratio is high relative to our peers, it is at its lowest level since 2007 and we have limited exposure to higher-risk assets such as derivatives, equities, and asset-backed securities. Additionally, the Company does not participate in securities lending and has no off-balance sheet investments as of September 30, 2024. Of our fixed maturity purchases, BBB securities generally provide the Company with the best risk-adjusted, capital-adjusted returns largely due to our ability to hold securities to maturity regardless of fluctuations in interest rates or equity markets.An analysis of changes in our portfolio of below-investment grade fixed maturities at amortized cost, net of allowance for credit losses is as follows:Below-Investment Grade Fixed Maturities(Dollar amounts in thousands)Nine Months EndedSeptember 30,20242023Balance at beginning of period \$529,511Å \$542,497Å Downgrades by rating agencies35,312Å 56,217Å Upgrades by rating agenciesæ"À (32,540)Net Acquisitions (Dispositions)(12,558)(68,319)Provision for credit losses(17)(7,500)Amortization and other3,615Å 2,797Å Balance at end of period \$555,863Å \$493,152Å Our investment policy calls for investing primarily in fixed maturities that are investment grade and meet our quality and yield objectives. Thus, the balance of below-investment grade issues is primarily the result of ratings 82 Å Å Å Å Å GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc.Management's Discussion & Analysisdowngrades of existing holdings. Below-investment grade bonds at amortized cost, net of allowance for credit losses, were 8% of our shareholdersæ"™ equity excluding accumulated other comprehensive income as of September 30, 2024. Globe Life invests long term and as such, one of our key criterion in our investment process is to select issuers that are anticipated to weather multiple financial cycles. OPERATING EXPENSES Operating expenses are included in the "Corporate and Other" segment and are classified into two categories: insurance administrative expenses and expenses of the Parent Company. Insurance administrative expenses generally include expenses incurred after a policy has been issued. As these expenses relate to premium for a given period, management measures the expenses as a percentage of premium income. The Company also views stock-based compensation expense as a Parent Company expense. Expenses associated with the issuance of our insurance policies are reflected as acquisition expenses and included in the determination of underwriting margin.An analysis of operating expenses is shown below.Operating Expenses Selected Information(Dollar amounts in thousands)Å Nine Months Ended September 30,IncreaseÅ 20242023(Decrease)Amount% of PremiumAmount% of PremiumAmount%Insurance administrative expenses:Salaries\$95,406Å 2.7Å \$89,068Å 2.7Å \$6,338Å 7Å Other employee costs28,531Å 0.8Å 27,850Å 0.8Å 681Å 2Å Information technology costs59,023Å 1.7Å 47,106Å 1.4Å 11,917Å 25Å Legal costs19,771Å 0.6Å 10,614Å 0.3Å 9,157Å 8Å Other administrative costs48,314Å 1.4Å 49,313Å 1.5Å (972)(2)Total insurance administrative expenses151,072Å 4.2Å 124,223,951Å 6.7Å 27,121Å 12Å Parent company expense9,166Å 8,544Å 912Å Stock compensation expense28,590Å 22,732Å 5,858Å Legal costs and proceedings5,764Å æ"À 5,764Å Non-operating expenses2,604Å 1,137Å 1,467Å Total operating expenses, per Condensed Consolidated Statements of Operations \$297,196Å \$256,074Å \$41,122Å 16Å Total operating expenses for September 30, 2024 increased in comparison with the prior year primarily due to increases in insurance administrative expenses as well as stock compensation and legal costs and proceedings. Insurance administrative expenses increased \$27.1 million primarily due to higher information technology costs, legal costs and employee costs, which includes salaries and other. Insurance administrative expenses as a percent of premium were 7.2% for the nine months ended September 30, 2024 compared to 6.7% for the same period in 2023. 83 Å Å Å Å Å GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc.Management's Discussion & AnalysisSHARE REPURCHASESGlobe Life has an ongoing share repurchase program that began in 1986. The share repurchase program is reviewed with the Board of Directors by management quarterly, and continues indefinitely unless and until the Board of Directors decides to suspend, terminate or modify the program. Management generally determines the amount of repurchases based on the amount of the excess cash flows and other available sources after the payment of dividends to the Parent Company shareholders, general market conditions, and other alternative uses. Since implementing our share repurchase program in 1986, we have used \$10.3 billion to repurchase Globe Life Inc. common shares after determining that the repurchases provide a greater risk-adjusted after-tax return than other investment alternatives. Excess cash flow at the Parent Company is primarily comprised of dividends received from the insurance subsidiaries less interest expense paid on its debt and other limited operating activities. Additionally, when stock options are exercised, proceeds from these exercises and the resulting tax benefit are used to repurchase additional shares on the open market to minimize dilution as a result of the option exercises. The following chart summarizes share repurchases for the nine month periods ended September 30, 2024 and 2023.Analysis of Share Repurchases(Amounts in thousands, except per share data)Å Å Nine Months Ended September 30,Å 20242023Å SharesAmountAveragePriceSharesAmountAveragePricePurchases with:Excess cash flow at the Parent Company(1)9,748Å \$910,040Å \$93.36Å 2,708Å \$302,849Å \$111.82Å Option exercise proceeds348Å 31,454Å 90.30Å 526Å 60,216Å 114.58Å Total10,096Å \$941,494Å \$93.25Å 3,234Å \$363,065Å \$112.27Å (1)Excludes excise tax on the repurchase of treasury stock of \$9.0 million and \$2.9 million for the nine months ended September 30, 2024 and 2023, respectively.The amount of share repurchases in the third quarter were higher as we accelerated repurchases given favorable market conditions and the use of additional capital raised during the quarter. Refer to Note 11æ"Debt for further details. Throughout the remainder of this discussion, share repurchases will only refer to those made from excess cash flow at the Parent Company.FINANCIAL CONDITIONÅ Liquidity. Liquidity provides Globe Life with the ability to meet on demand the cash commitments required to support our business operations and meet our financial obligations. Our liquidity is primarily derived from multiple sources: positive cash flow from operations, a portfolio of marketable securities, a revolving credit facility, commercial paper, and advances from the Federal Home Loan Bank.Insurance Subsidiary Liquidity. The operations of our insurance subsidiaries have historically generated substantial cash inflows in excess of immediate cash needs. Cash inflows for the insurance subsidiaries primarily include premium and investment income. In addition to investment income, maturities and scheduled repayments in the investment portfolio are cash inflows. Cash outflows from operations include policy benefit payments, commissions, administrative expenses, and taxes. A portion of the excess cash inflows in the current year will provide for the payment of future policy benefits and are invested primarily in long-term fixed maturities as they better match the long-term nature of these obligations. Excess cash available from the insurance subsidiariesæ"™ operations is generally distributed as a dividend to the Parent Company, subject to regulatory restrictions. The dividends are generally paid in amounts equal to the subsidiariesæ"™ prior year statutory net income excluding realized capital gains. While the leading source of the excess cash is investment income, a significant portion of the excess cash also comes from underwriting income due to our high underwriting margins and effective expense control. 84 Å Å Å Å Å GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc.Management's Discussion & AnalysisWhile the insurance subsidiaries annually generate more operating cash inflows than cash outflows, the companies also have the entire available-for-sale fixed maturity investment portfolio available to create additional cash flows if required.Four of our insurance subsidiaries are members of the FHLB of Dallas. FHLB membership provides the insurance subsidiaries with access to various low-cost collateralized borrowings and funding agreements. While not the only source of liquidity, the FHLB could provide the insurance subsidiaries with an additional source of liquidity, if needed. Refer to Note 11æ"Debt for further details.Parent Company Liquidity. An important source of Parent Company liquidity is the dividends from its insurance subsidiaries. These dividends are received throughout the year and are used by the Parent Company to pay dividends on common and preferred stock, interest and principal repayment requirements on Parent Company debt, and operating expenses of the Parent Company. Nine Months EndedSeptember 30,Twelve Months Ended December 31,20242023Projected 20242023Liquidity Sources:Dividends from Subsidiaries\$451,416Å \$411,661Å \$480,000æ"À \$520,000\$459,535Å Excess Cash Flows(1)412,626Å 387,879Å 430,000æ"À 470,000416,081Å (1)Excess cash flows are reported gross of shareholder dividends. For the nine months ended September 30, 2024 and 2023, shareholder dividends were \$65 million and \$63 million, respectively. For the twelve months ended December 31, 2024, we project approximately \$86 million in shareholder dividends, compared to the \$84 million paid in 2023. Dividends from subsidiaries and excess cash flows are projected to be higher in 2024 than in 2023 primarily due to lower life obligations and the growth in our underwriting margins in 2023, both of which resulted in higher statutory earnings generated by the affiliates. Additional sources of liquidity for the Parent Company are cash, intercompany receivables, intercompany borrowings, debt markets, term loans, and a revolving credit facility. Short-Term Borrowings. An additional source of Parent Company liquidity is a credit facility with a group of lenders. The facility was amended on March 29, 2024, resulting in an increased capacity of \$250 million. The facility allows for unsecured borrowings and stand-by letters of credit up to \$1 billion, which could be increased up to \$1.25 billion. While the Parent Company may request the increase, it is not guaranteed. The updated five-year credit agreement will mature on March 29, 2029. Up to \$250 million in letters of credit can be issued against the facility. The facility serves as a back-up line of credit for a commercial paper program under which commercial paper may be issued at any time, with total commercial paper outstanding not to exceed the facility maximum, less any letters of credit issued. Interest charged on the commercial paper program resembles variable rate debt due to its short term nature. As of September 30, 2024, we had available \$458 million of additional borrowing capacity under this facility, compared to \$384 million a year earlier. As of September 30, 2024, the Parent Company was in full compliance with all covenants related to the aforementioned debt.As a part of the credit facility, Globe Life has stand-by letters of credits. These letters of credit are issued on behalf of our insurance subsidiaries.85 Å Å Å Å Å GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc.Management's Discussion & AnalysisThe following tables present certain information about our commercial paper borrowings.Credit Facilityæ"™Commercial Paper(Dollar amounts in thousands)AtSeptember 30,2024December 31, 2023September 30,2023Balance of commercial paper at end of period (par value)\$426,908Å \$319,000Å \$251,000Å Annualized interest rate5.56Å %5.71Å %5.65Å %Letters of credit outstanding\$115,000Å \$115,000Å \$115,000Å Remaining amount available under credit line458,092Å 316,000Å 384,000Å Credit Facilityæ"™Commercial Paper Activity(Dollar amounts in thousands)Å Nine Months Ended September 30,Å 20242023Average balance of commercial paper outstanding during period (par value)\$375,851Å \$296,816Å Daily-weighted average interest rate (annualized)5.80Å %5.33Å %Maximum daily amount outstanding during period (par value)\$633,425Å \$477,700Å The Company increased the commercial paper borrowings by \$108 million since year-end. The Company was able to issue commercial paper as needed under this facility during the nine months ended September 30, 2024 and 2023. Globe Life expects to have readily available funds for 2024 and the foreseeable future to conduct its operations and to maintain target capital ratios in the insurance subsidiaries through liquid assets currently available, internally-generated cash flow and the credit facility. In the event that more liquidity is needed, the Parent Company could generate additional funds through multiple sources including, but not limited to, the issuance of debt, an additional short-term credit facility or term loan, and intercompany borrowing.Consolidated Liquidity. Consolidated net cash inflows from operations were \$1.07 billion in the first nine months of 2024, compared with \$1.09 billion in the same period of 2023. The decrease is primarily attributable to fluctuations in the settlement of certain amounts included in other liabilities. In addition to cash inflows from operations, our insurance companies received proceeds from dispositions of fixed maturities available for sale, mortgage loans, and other long-term investments in the amount of \$895 million during the

The nine months ended September 30, 2024. As previously noted under the caption Short-Term Borrowings, the Parent Company has in place a revolving credit facility. The insurance companies have no additional outstanding credit facilities. Cash and short-term investments were \$235 million at September 30, 2024, compared with \$185 million at December 31, 2023. In addition to these liquid assets, \$18.3 billion (fair value at September 30, 2024) of fixed income securities are available for sale in the event of an unexpected need. Approximately \$1.4 billion, at fair value, are pledged for outstanding FHLB advances and reinsurance. Further, approximately 97% of our fixed income securities are publicly traded, freely tradable under SEC Rule 144, or qualified for resale under SEC Rule 144A. While our fixed income securities are classified as available for sale, we have the ability and general intent to hold any securities to recovery or maturity. Our strong cash flows from operations, on-going investment maturities, and available liquidity under our credit facility make any need to sell securities for liquidity highly unlikely.

À À À À À À À GL Q3 2024 FORM 10-QTable of ContentsGlobe Life Inc.Management's Discussion & AnalysisCapital Resources. The Parent Company's capital structure consists of short-term debt (the commercial paper facility and current maturities of long-term debt), long-term debt, and shareholders' equity. It does not include short-term FHLB borrowings, which are obligations of the insurance subsidiaries and typically repaid over the course of the year. Long-Term Borrowings. The outstanding long-term debt at book value was \$2.3 billion at September 30, 2024 and \$1.6 billion at December 31, 2023. Selected information about Debt IssuesAs of September 30, 2024 (Dollar amounts in thousands)\Instrument\Issue DateMaturity DateCoupon RateÀ Interest Payment DatesParValueBookValueFairValueSenior notes09/27/201809/15/20284.550%semiannual\$550,000À \$546,820À \$550,088À Senior notes08/21/202008/15/20302.150%semiannual400,000À 397,017À 344,796À Senior notes(1)05/19/202206/15/20324.800%semiannual250,000À 246,172À 248,443À Senior notes08/23/202409/15/20345.850%semiannual450,000À 444,812À 464,881À Junior subordinated debentures11/17/201711/17/20575.275%semiannual125,000À 123,439À 109,657À Junior subordinated debentures06/14/201611/15/20614.250%quarterly325,000À 317,367À 236,730À Term loan(2)05/11/202308/15/20276.593%quarterly250,000À 248,049À 248,049À Total long-term debt 2,350,000À 2,323,676À 2,202,644À FHLB borrowings17,000À 17,000À Commercial paper426,908À 420,418À 420,418À Total short-term debt 443,908À 437,418À 437,418À Total debt \$2,793,908À \$2,761,094À \$2,640,062À (1)An additional \$150 million par value and book value is held by insurance subsidiaries that eliminates in consolidation. (2)Interest calculated quarterly using Secured Overnight Financing Rate (SOFR) plus 135 basis points. The term loan was amended on August 15, 2024 extending the maturity date from November 11, 2024 to August 15, 2027 and increasing the principal amount from \$170 million to \$250 million.On August 23, 2024, Globe Life completed the issuance of \$450 million principal amount of 5.85% Senior notes due September 15, 2034. Total proceeds received by the Parent from the issuance, net of the underwriters' discount, were \$445 million. The proceeds were used for general corporate purposes, which included open market purchases of shares of its common stock under its share repurchase program.

À À À À À À À GL Q3 2024 FORM 10-QTable of ContentsGLOBE LIFE INC.Management's Discussion & AnalysisFinancing costs for the corporate and other segment consist primarily of interest on our various debt instruments. The table below presents the components of financing costs and reconciles interest expense per the Condensed Consolidated Statements of Operations.Analysis of Financing Costs(Dollar amounts in thousands)\Nine Months EndedSeptember 30,\Increase(Decrease)2024\2023\Amount%\Interest on funded debt\$53,633À \$55,732À \$(2,099)(4)\Interest on term loans9,646À 4,605À 5,041À 109À Interest on short-term debt28,115À 16,284À 11,831À 73À Other19À 19À æ"À æ"À Financing costs \$91,413À \$76,640À \$14,773À 19À During the first nine months of 2024, financing costs increased 19% compared with the prior year. The increase in financing costs is primarily due to higher average balances in the current year compared to the prior year. We increased the durations on commercial paper issuances during the quarter ended September 30, 2024 due to market considerations. More information on our debt transactions is disclosed in the Financial Condition section of this report.Subsidiary Capital: The National Association of Insurance Commissioners (NAIC) has established a risk-based factor approach for determining threshold risk-based capital levels for all insurance companies. This approach was designed to assist the regulatory bodies in identifying companies that may require regulatory attention. A Risk-Based Capital (RBC) ratio is typically determined by dividing adjusted total statutory capital by the amount of risk-based capital determined using the NAICæ" factors. If a companyæ" RBC ratio approaches two times the RBC amount, the company must file a plan with the NAIC for improving its capital levels (this level is commonly referred to as æ"Company Action Levelæ" RBC).À Companies typically hold a multiple of the Company Action Level RBC depending on their particular business needs and risk profile.Our goal is to maintain statutory capital within our insurance subsidiaries at levels necessary to support our current ratings.À For 2024, Globe Life has targeted a consolidated Company Action Level RBC ratio of 300% to 320%.À The Company has concluded that this capital level is more than adequate and sufficient to support its current ratings, given the nature of its business and its risk profile. The Parent Company is committed to maintaining the targeted consolidated RBC ratio at its insurance subsidiaries and has sufficient liquidity available to provide additional capital if necessary.Shareholders' Equity: Shareholders'æ" equity was \$4.6 billion at September 30, 2024. This compares with \$4.5 billion at December 31, 2023 and \$4.6 billion at September 30, 2023. During the nine months ending December 31, 2023, shareholders'æ" equity increased as a result of net income of \$816 million during the first nine months of 2024, but was offset by share repurchases of \$910 million and an additional \$31 million in share repurchases to offset the dilution from stock option exercises. Additionally, the balance of AOI increased \$288 million primarily due to increased interest rates and discount rates over the period. On August 8, 2024, the Parent Company announced that it had declared a quarterly dividend of \$0.24 per share. This dividend was paid on November 1, 2024. We plan to use excess cash available at the Parent Company as efficiently as possible in the future. Possible uses of excess cash flow include, but are not limited to, share repurchases, acquisitions, shareholder dividend payments, investments in securities, or repayment of short-term debt. We will determine the best use of excess cash after ensuring that targeted capital levels are maintained in our insurance subsidiaries. If market conditions are favorable, we currently expect that share repurchases will continue to be a primary use of those funds.Future policy benefits are computed using current discount rates with the impact of changes in discount rates included in accumulated other comprehensive income. Additionally, the liability for future policy benefits is calculated 88 À À À À À À À GL Q3 2024 FORM 10-QTable of ContentsGLOBE LIFE INC.Management's Discussion & Analysissuing net premiums rather than gross premiums. Given that gross premiums are considerably higher than net premiums for our business, as seen in Note 6æ"Policies Liabilities, the measurement of the liability is higher than what it would have been computed using gross premiums. This is an important consideration when analyzing shareholders' equity.Globe Life is required under GAAP to revalue its available for sale fixed maturity portfolio to fair market value at the end of each accounting period. These changes, net of their associated impact on income tax, are reflected directly in shareholders'æ" equity. Fluctuations in interest rates cause undue volatility in the period-to-period presentation of our shareholders'æ" equity, capital structure, and financial ratios. Due to the long-term nature of our fixed maturity investments and policy liabilities and the strong cash flows consistently generated by our insurance subsidiaries, we have the ability to hold our securities to maturity. As such, we do not expect to incur losses due to fluctuations in market value of fixed maturities caused by market rate changes and temporarily illiquid markets. Accordingly, our management, credit rating agencies, lenders, many industry analysts, and certain other financial statement users prefer to remove the effect of this accounting rule when analyzing our balance sheet, capital structure, and financial ratios.

89 À À À À À À À GL Q3 2024 FORM 10-QTable of ContentsItem 3. Quantitative and Qualitative Disclosures About Market Risk À There have been no quantitative or qualitative changes with respect to market risk exposure during the nine months ended September 30, 2024.Item 4. Controls and Procedures Evaluation of Disclosure Controls and Procedures: Globe Life Inc., under the direction of the Co-Chairmen and Chief Executive Officers and the Executive Vice President and Chief Financial Officer, has established disclosure controls and procedures that are designed to ensure that information required to be disclosed by Globe Life in the reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SECæ" rules and forms. The disclosure controls and procedures are also intended to ensure that this information is accumulated and communicated to Globe Life's management, including the Co-Chairmen and Chief Executive Officers and the Executive Vice President and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.À As of the end of the fiscal period completed September 30, 2024, an evaluation was performed under the supervision and with the participation of Globe Life management, including the Co-Chairmen and Chief Executive Officers and the Executive Vice President and Chief Financial Officer, of the disclosure controls and procedures (as those terms are defined in Rule 13a-15(e) under the Securities Exchange Act of 1934). Based upon their evaluation, the Co-Chairmen and Chief Executive Officers and the Executive Vice President and Chief Financial Officer have concluded that disclosure controls and procedures are effective as of the date of this Form 10-Q. In compliance with Section 302 of the Sarbanes Oxley Act of 2002 (18 U.S.C. Å§ 1350), each of these officers executed a Certification included as an exhibit to this Form 10-Q.Changes in Internal Control over Financial Reporting: During the period ended September 30, 2024, there were no changes to Globe Life Inc.'s internal control over financial reporting or in other factors that could significantly affect the internal control over financial reporting subsequent to the date of their evaluation which have materially affected, or are reasonably likely to materially affect, internal control over financial reporting. À Part IIæ"Other InformationItem 1. Legal Proceedings Discussion regarding litigation and unclaimed property audits is provided in Note 5æ"Commitments and Contingencies.

90 À À À À À À À GL Q3 2024 FORM 10-QTable of ContentsItem 1A. Risk Factors À The following is an update to the material risks previously disclosed in the Company's December 31, 2023 Form 10-K. There are no other material changes to the Company's risk factors.Our businesses are heavily regulated and changes in regulation or regulatory scrutiny may have a material adverse impact on our business, financial condition or results of operation. Insurance companies, including our insurance subsidiaries, are subject to extensive supervision and regulation in the states in which they conduct business. The primary purpose of this supervision and regulation is the protection of policyholders, not investors. Regulatory agencies have broad administrative power over numerous aspects of our business, including premium rates for our life, Medicare Supplement and other supplement health products, as well as other terms and conditions included in the insurance policies offered by our insurance subsidiaries, marketing practices, advertising, agent licensing, independent agent practices, policy forms, capital adequacy, solvency, reserves and permitted investments. Regulatory authorities also have the power to conduct investigations, and to bring administrative or judicial proceedings against us, which could result in suspension or revocation of our licenses, cease and desist orders, fines, civil penalties, disgorgement, criminal penalties or other disciplinary action that could have a material adverse impact on our business, financial condition or results of operation. Press coverage and other public statements that allege wrongdoing, even if untrue, can lead to increased regulatory inquiries or investigations including any that may arise in connection with the subpoenas from U.S. Attorneyæ"s Office for the Western District of Pennsylvania seeking documents related to sales practices by certain of our independent sales agents contracted to sell American Income Life Insurance Company policies. Additionally, any violation or alleged violation of law or regulations could result in significant legal costs or in legal proceedings that may result in monetary and legal remedies being imposed against the Company, which could have a material adverse effect on our business, financial condition or results of operations. The insurance laws, regulations and policies currently affecting our companies may change at any time, possibly having an adverse effect on our business. Should regulatory changes occur, we may be unable to maintain all required licenses and approvals, or fully comply with the wide variety of applicable laws and regulations or the relevant authorityæ"s interpretation of such laws and regulations. If we do not have the requisite licenses and approvals or do not comply with applicable regulatory requirements, the insurance regulatory authorities could preclude or temporarily suspend some or all of our business activities and/or impose substantial fines.Actual or alleged misclassification of independent contractors at our insurance subsidiaries could result in adverse legal, tax or financial consequences.A significant portion of our sales agents are independent contractors. Although we believe we have properly classified such individuals, a risk nevertheless exists that a court, the Internal Revenue Service or other authority will take the position that our sales agents are employees. From time-to-time, we are subject to civil litigation, including class and collective action litigation, alleging that we have improperly classified certain of our sales agents as independent contractors. In September 2024, the EEOC notified us that it had determined that all sales agents affiliated with State General Agent Simon Arias were employees, not independent contractors, of Globe Life Inc. and/or AIL. Such determination is not binding but we expect any potential civil action brought by the EEOC would include such an allegation. A future adverse judgment in connection with any such civil litigation described above could result in substantial damages. Future changes in rules, regulations or interpretations of existing rules and regulations, or significant adverse judgments in litigation, could require us to reclassify all or a portion of our agents as employees and the impact could significantly increase our operating costs and negatively impact our insurance business.The use of third-party vendors, including independent sales agents, to support the Company's operations makes the Company susceptible to the operational risk of those third parties, which could lower revenues, increase costs, reduce profits, disrupt business, or damage the Companyæ"s reputation. The Company utilizes third-party vendors, including independent sales agents, to provide certain business services and functions, which exposes the Company to risks outside the control of the Company. The reliance on these third-party vendors creates a number of business risks, such as the risk that the Company may not maintain service

91 À À À À À À À GL Q3 2024 FORM 10-QTable of Contentsquality, control or effective management of the outsourced business operations and that the Company cannot control the information systems, facilities or networks of such third-party vendors. We employ controls and procedures designed to facilitate service quality of our third party vendors; however, such controls and procedures cannot be 100% effective in all cases. The Company may be adversely affected by a third-party vendor who operates in a poorly controlled manner or fails to deliver contracted services, which could lower revenues, increase costs, reduce profits, disrupt business, or damage the Companyæ"s reputation.Extensive federal and state laws regulate our business, imposing certain requirements that independent sales agents must follow in dealing with clients. Misconduct of our independent sales agents could result in violations of law by, or claims against, us or our subsidiaries. From time to time, we are subject to private litigation as a result

[illegible]

Benefit, Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Policy Liabilities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Policy Liabilities - Schedule of Liability For Future Policy Benefits To Consolidated Balance Sheets (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Policy Liabilities - Schedule of Weighted Average Interest Rate of Liability For Future Policy Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Policy Liabilities - Schedule of Weighted Average Duration of Liability For Future Policy Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Policy Liabilities - Schedule of Liability For Future Policy Benefits To Consolidated Income Statement (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Policy Liabilities - Schedule of Undiscounted And Discounted Expected Future Gross Premiums And Expected Future Benefits And Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Policy Liabilities - Schedule of Policyholder Account Balance (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Policy Liabilities - Schedule of Policyholder Account Balance, Guaranteed Minimum Crediting Rate (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Deferred Acquisition Costs - Schedule of Analysis of Deferred Acquisition Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Deferred Acquisition Costs - Schedule of Deferred Policy Acquisition Costs to Consolidated Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - Liability for Unpaid Claims - Schedule of Liability for Unpaid Health Claims (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - Liability for Unpaid Claims - Schedule of Reconciliation of Policy Claims and Other Benefits Payable (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - Postretirement Benefits - Schedule of Pension Assets by Component at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - Postretirement Benefits - Schedule of Information Regarding the SERP (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - Postretirement Benefits - Schedule of Pension and SERP Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - Postretirement Benefits - Schedule of Net Periodic Benefit Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - Debt - Schedule of Selected Information about Debt Issues (Details) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - Debt - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954523 - Disclosure - Debt - Short-Term Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 9954524 - Disclosure - Business Segments - Schedule of Segment Premium Income by Distribution Channel (Details) link:presentationLink link:calculationLink link:definitionLink 9954525 - Disclosure - Business Segments - Schedule of Reconciliation of Segment Operating Information to Consolidated Statement of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 9954526 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 gl-20240930 cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 gl-20240930 def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 gl-20240930 lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

Exchanges of fixed maturities, net realized gains Debt Securities, Available-For-Sale, Realized Gain (Loss) On Exchanges Debt Securities, Available-For-Sale, Realized Gain (Loss) On Exchanges Due after ten years through twenty years Debt Securities, Available-For-Sale, Maturity, Allocated And Single Maturity Date, After Ten Through Twenty Years, Amortized Cost, Net Of Allowance For Credit Loss Debt Securities, Available-For-Sale, Maturity, Allocated And Single Maturity Date, After Ten Through Twenty Years, Amortized Cost, Net Of Allowance For Credit Loss U.S. Government and Agency US Government Corporations and Agencies Securities [Member] Debt-to-Value [Axis] Debt-to-Value [Axis] 70% to 80% LTV 70 Percent To 80 Percent [Member] LTV 70 Percent To 80 Percent [Member] Cover page, Cover [Abstract] Net increase (decrease) in cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Term Loan Due November 11 2024 Term Loan Due November 11 2024 [Member] Term Loan Due November 11 2024 Fixed portfolio, number of issuers Entire Portfolio Number Of Issuers Of Fixed Maturities Entire Portfolio Number Of Issuers Of Fixed Maturities Trading Symbol Trading Symbol Pledged Status [Domain] Pledged Status [Domain] Future policy benefit adjustments, net of tax OCI, Liability for Future Policy Benefit, Adjustments, Net Of Tax OCI, Liability for Future Policy Benefit, Adjustments, Net Of Tax Non-NEOs Non-NEOs [Member] Common dividends declared, per share (in dollars per share) Common Stock, Dividends, Per Share, Declared Beginning balance Ending balance PV of expected future net premiums, At original discount rates Liability for Future Policy Benefit, Expected Net Premium, Original Discount Rate, before Cash Flow and Reinsurance Future Policy Benefits Future Policy Benefits [Member] Future Policy Benefits Short-term investments Short-term investments Short-Term Investments [Member] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Annualized interest rate Line of Credit Facility, Interest Rate at Period End Award Timing Disclosures [Line Items] Beginning balance Ending balance PV of expected future policy benefits, At current discount rates Liability for Future Policy Benefit, Expected Future Policy Benefit, before Reinsurance, after Discount Rate Change Interest Sensitive Life Interest Sensitive Life [Member] Investment, Name [Domain] Investment, Name [Domain] Schedule of Commercial Loan Participations, Allowance for Credit Loss Financing Receivable, Allowance for Credit Loss [Table Text Block] Retirement Plan Tax Status [Axis] Retirement Plan Tax Status [Axis] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Non-operating expenses Expenses, Nonoperating Expenses, Nonoperating Policyholder Account Balance, above Guaranteed Minimum Crediting Rate [Axis] Policyholder Account Balance, above Guaranteed Minimum Crediting Rate [Axis] Weighted average dilutive options outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Pledged Status [Axis] Pledged Status [Axis] Operating Segments Operating Segments [Member] Class of Financing Receivable [Domain] Class of Financing Receivable [Domain] Cash provided from (used for) operating activities Net Cash Provided by (Used in) Operating Activities Effect of changes in discount rate assumptions AOCI, Liability for Future Policy Benefit, Expected Future Policy Benefit, before Tax Schedule of Change in Balance by Component of Accumulated Other Comprehensive Income Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Award Timing Method Award Timing Method [Text Block] Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] States, municipalities, and political subdivisions US States and Political Subdivisions Debt Securities [Member] Use of Estimates Use of Estimates, Policy [Policy Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Commercial paper issued during period (par value) Commercial Paper Issued During Period, Par Value Commercial Paper Issued During Period, Par Value Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Payment for debt issuance costs Payments of Debt Issuance Costs Tabular List, Table Tabular List [Table Text Block] Significant Unobservable InputsÂ LevelA 3 Fair Value, Inputs, Level 3 [Member] Antidilutive shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Liability for Future Policy Benefit, Remeasurement Gain (Loss) by Type [Domain] Liability for Future Policy Benefit, Remeasurement Gain (Loss) by Type [Domain] Liability for Future Policy Benefit, Remeasurement Gain (Loss) by Type [Domain] Debt Securities, Available-for-sale, Allowance for Credit Loss [Line Items] Debt Securities, Available-for-Sale, Allowance for Credit Loss [Line Items] PV of expected future gross premiums, At original discount rates Liability for Future Policy Benefit, Expected Future Gross Premiums, Original Discount Rate, before Cash Flow and Reinsurance Liability for Future Policy Benefit, Expected Future Gross Premiums, Original Discount Rate, before Cash Flow and Reinsurance Credit Facility [Domain] Credit Facility [Domain] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Accounts and Financing Receivables [Table] 4.00%-4.99% Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0400 to 0499 [Member] Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0400 to 0499 Policy claims and other benefits payable Beginning balance less reinsurance recoverable Beginning balance plus reinsurance recoverable Liability for Claims and Claims Adjustment Expense Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Goodwill Goodwill Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Long-term debt, par value, gross Long-Term Debt, Face Amount, Gross Long-Term Debt, Face Amount, Gross Schedule of Reconciliation of Policy Claims and Other Benefits Payable Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table Text Block] Employee Stock Option Share-Based Payment Arrangement, Option [Member] Financing Receivable Portfolio Segment [Axis] Financing Receivable Portfolio Segment [Axis] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Reduction of allowance for which the Company intends to sell or more likely than not will be required to sell or sold during the period Debt Securities, Available-for-Sale, Excluding Accrued Interest, Allowance for Credit Loss, Sell before Recovery Comprehensive income (loss) Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Pension Plan Pension Plans Pension Plan [Member] Schedule of Fixed Maturities by Contractual Maturity Investments Classified by Contractual Maturity Date [Table Text Block] Award Type Award Type [Axis] Issuances Liability for Future Policy Benefit, Expected Net Premium, Issuance Corporates Corporate Debt Securities [Member] Due after twenty years Available For Sale Securities Debt Maturities After Twenty Years Fair Value This item represents the fair value of debt securities which are expected to mature after twenty years from the balance sheet date which are categorized neither as held-to-maturity nor trading securities. Schedule of Policyholder Account Balance, Guaranteed Minimum Crediting Rate Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Table Text Block] Infrastructure Infrastructure [Member] Infrastructure Total liabilities Liabilities Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Expiration Date Trading Arrangement Expiration Date Cash provided from (used for) investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Total Shareholder Return Amount Total Shareholder Return Amount Liability for Future Policy Benefit, Expected Net Premium [Roll Forward] Liability for Future Policy Benefit, Expected Net Premium [Roll Forward] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Transfers out of Level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 Gross realized gains Debt Securities, Available-for-Sale, Realized Gain Net liability for future policy benefitsâ€”long duration health Liability for Future Policy Benefit, Current Discount Rate, before Reinsurance and Other Liability for Future Policy Benefit, Current Discount Rate, before Reinsurance and Other Subsequent Event [Line Items] Subsequent Event [Line Items] Average balance of commercial paper outstanding during period (par value) Line of Credit Facility, Average Outstanding Amount Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Alternative Investment [Line Items] Alternative Investment [Line Items] Alternative Investment [Line Items] Alternative Investment Other assets Other Assets Parent expense Parent Expense Parent Expense Issuances Liability for Future Policy Benefit, Expected Future Policy Benefit, Issuance Liability for Future Policy Benefit, Activity [Line Items] Liability for Future Policy Benefit, Activity [Line Items] Policyholder Account Balance, Guaranteed Minimum Crediting Rate Range [Axis] Policyholder Account Balance, Guaranteed Minimum Crediting Rate Range [Axis] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Diluted weighted average shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Mortgage loans Carrying value, net of valuation allowance Financing Receivable, after Allowance for Credit Loss Unrealized gains (losses) on investments, net of tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Net premiums collected Liability for Future Policy Benefit, Expected Net Premium, Net Premium Collected MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Increase (Decrease) in AOCI, Net of Tax AOCI Attributable to Parent, Net of Tax [Roll Forward] Total shareholders' equity Beginning balance Ending balance Equity, Attributable to Parent Proceeds from issuance of debt Proceeds from Issuance of Debt Due in one year or less Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Life premium Life insurance Life Insurance Product Line [Member] Letters of credit facility outstanding Letters of credit outstanding Letters of Credit Outstanding, Amount Other long-term investments Proceeds from Sale and Maturity of Other Investments Long-Term Investment [Table] Long-Term Investment [Table] Long-Term Investment Policyholder Account Balance [Table] Policyholder Account Balance [Table] Effect of change from original to current discount rates AOCI, Liability for Future Policy Benefit, Expected Net Premium, before Tax Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Retirement Plan Tax Status [Domain] Retirement Plan Tax Status [Domain] Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table] Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table] Available forÂ Sale Assets Unrealized Gains (Losses) on Available for Sale Assets AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Assets: Assets [Abstract] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Document Type Document Type Potential maximum borrowing capacity Line Of Credit Facility, Accordion Feature, Increase Limit Line Of Credit Facility, Accordion Feature, Increase Limit Surrenders and withdrawals Policyholder Account Balance, Surrender and Withdrawal Adjusted balance Liability for Future Policy Benefit, Expected Net Premium, Original Discount Rate, before Reinsurance, after Cash Flow Change Mortgage loans Mortgage Loans on Real Estate, Commercial and Consumer, Net Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan [Table] Beginning balance Ending balance Liability for Unpaid Claims and Claims Adjustment Expense, Net Fixed maturities, available for sale, amortized cost Debt Securities, Available-for-Sale, Amortized Cost Total short-term debt, fair value Short-Term Debt, Fair Value Subsequent Event [Table] Subsequent Event [Table] Maximum Maximum [Member] Net amount at risk Policyholder Account Balance, Net Amount at Risk Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Schedule of Liability for Unpaid Health Claims Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block] Investment Type [Axis] Investment Type [Axis] Deferred Acquisition Costs Deferred Policy Acquisition Costs [Text Block] Accrued investment income Accrued Investment Income Receivable Statistical Measurement [Axis] Statistical Measurement [Axis] Interest credited Policyholder Account Balance, Interest Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income before income taxes Total before tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Industrials Industrials [Member] Industrials Name Outstanding Recovery, Individual Name Paid related to: Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract] Expected life of non-redeemable funds General Expected Life of Non-Redeemable Funds General Expected Life of Non-Redeemable Funds Award Timing Predetermined Award Timing Predetermined [Flag] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Investment in Limited Partnerships Investment funds Partnership Interest [Member] Investment, Name [Axis] Investment, Name [Axis] Forecast Forecast [Member] Prior service cost Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Diluted net income per common share (in dollars per share) Earnings Per Share, Diluted Net receipts (payments) from deposit-type products Net Change Annuities and Investment Certificates Liberty National Liberty National Exclusive [Member] Liberty national exclusive [Member] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Unrealized gains (losses) on fixed maturities: OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax [Abstract] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Asset- backed Securities Asset-Backed Securities [Member] Included in realized gains / losses Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Deferred Annuity Deferred Fixed Annuity [Member] Liability for Unpaid Claims Insurance Disclosure [Text Block] Other investments Gain (Loss) on Sale of Other Investments Income tax benefit (expense) Tax Income Tax Expense (Benefit) Interest cost on projected benefit obligation Defined Benefit Plan, Interest Cost Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] At guaranteed minimum Policyholder Account Balance, at Guaranteed Minimum Crediting Rate [Member] Other gains (losses) Other Realized Investment Gains (Losses) Other Realized Investment Gains (Losses) Opportunistic and private credit Opportunistic and Private Credit [Member] Opportunistic and Private Credit Financing Receivable Portfolio Segment [Domain] Financing Receivable Portfolio Segment [Domain] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Cash provided from (used for) investing activities Net Cash Provided by (Used in) Investing Activities Interest expense Interest expense Interest Expense, Operating and Nonoperating All Adjustments to Compensation All Adjustments to Compensation [Member] Additional paid-in-capital Additional Paid in Capital Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract]

Schedule of Liability for Future Policy Benefit, Activity Liability for Future Policy Benefit, Activity [Table Text Block] Scenario [Domain] Scenario [Domain] Equity Exchange Traded Fund Equity Exchange Traded Fund [Member] Equity Exchange Traded Fund Senior Notes Due 2028 Senior Notes Due September 15, 2028 [Member] Senior Notes Due September 15, 2028 [Member] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity Address, State or Province Entity Address, State or Province Expected life of redeemable funds Expected Life of Redeemable Funds Expected Life of Redeemable Funds Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Capitalizations Deferred Policy Acquisition Cost, Capitalization Financial Instruments [Domain] Financial Instruments [Domain] Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Debt Service Coverage Ratio [Domain] Debt Service Coverage Ratio [Domain] [Domain] for Debt Service Coverage Ratio [Axis] Investment funds, Fair Value Alternative Investment Number of claimants Loss Contingency, Number of Plaintiffs Effect of actual variances from expected experience Liability for Future Policy Benefit, Expected Net Premium, Cumulative Increase (Decrease) of Actual Variance from Expected Experience Restatement Determination Date Restatement Determination Date Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Policy charges Policyholder Account Balance, Policy Charge Multi-family Multifamily [Member] Net investment income Net investment income Net investment income Net investment income Net investment income Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Allowance for credit losses, percent Financing Receivable, Allowance For Credit Losses, Percent Financing Receivable, Allowance For Credit Losses, Percent Schedule of Fixed Maturities and Equity Securities Available for Sale by Component Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] California CALIFORNIA Amortization of prior service cost Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member] Earnings Per Share Earnings Per Share [Text Block] Subsequent Event Subsequent Event [Member] Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Mortgage loans Gain (Loss) on Sale of Mortgage Loans Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Other income Other income Other income Other income Segments [Domain] Segments [Domain] Guaranteed annuity contract Guaranteed Annuity Contract [Member] Guaranteed annuity contract [Member]. Schedule Of New Accounting Standards on Previously Reported Results Accounting Standards Update and Change in Accounting Principle [Table Text Block] Fair value optionâ€ change in fair value Fair Value, Option, Changes in Fair Value, Gain (Loss) PEO PEO [Member] Name Trading Arrangement, Individual Name Alabama ALABAMA Family Heritage Family Heritage [Member] Family Heritage [Member] Health Health Segment [Member] Health Segment [Member] Additions (reductions) to allowance for fixed maturities that previously had an allowance Debt Securities, Available-for-Sale, Excluding Accrued Interest, Allowance for Credit Loss, Not to Sell before Recovery, Credit Loss, Previously Recorded, Expense (Reversal) Treasury stock, at cost: (2024â€17,942,902 shares; 2023â€8,426,854 shares) Treasury Stock, Common, Value Benefit obligation Defined Benefit Plan, Benefit Obligation Schedule of Additional Information about Investments in Unrealized Loss Position Schedule Of Additional Information About Investments In Unrealized Loss Position Foreign exchange adjustment Deferred Policy Acquisition Cost, Foreign Currency Translation Adjustment and Other Long-Term Investment [Line Items] Long-Term Investment [Line Items] Long-Term Investment Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Reinsurance recoverables Reinsurance Recoverables, Including Reinsurance Premium Paid Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount At Original Discount Rates Liability for Future Policy Benefit, Original Discount Rate [Abstract] Liability for Future Policy Benefit, Original Discount Rate Local Phone Number Local Phone Number Total debt, book value Debt, Long-Term and Short-Term, Combined Amount Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Activity-based common stock ownership percentage Federal Home Loan Bank, Activity-Based Common Stock Ownership Percentage Federal Home Loan Bank, Activity-Based Common Stock Ownership Percentage Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] Foreign exchange adjustment on fixed maturities recorded at fair value Other Comprehensive Income (Loss), Foreign Exchange Increase (Decrease) On Securities Recorded At Fair Value Before Tax Other Comprehensive Income (Loss), Foreign Exchange Increase (Decrease) On Securities Recorded At Fair Value Before Tax Weighted average current discount rate Liability for Future Policy Benefit, Current Weighted-Average Discount Rate Term Loan Credit Agreement Term Loan Credit Agreement [Member] Term Loan Credit Agreement Movement Analysis of Deferred Policy Acquisition Costs Movement Analysis of Deferred Policy Acquisition Costs [Roll Forward] Fixed maturities, available for sale, allowance for credit losses Allowance for Credit Losses Allowance for credit losses beginning balance Allowance for credit losses ending balance Debt Securities, Available-for-Sale, Allowance for Credit Loss PEO Total Compensation Amount PEO Total Compensation Amount Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Direct to Consumer DTC Direct To Consumer [Member] Direct To Consumer Common Stock, \$1.00 par value per share Common Stock Common Stock [Member] Maximum daily amount outstanding during period (par value) Line of Credit Facility, Maximum Amount Outstanding During Period Greater Than 1.20x Debt Service Coverage Ratio, Greater Than 1.20x [Member] Debt Service Coverage Ratio, Greater Than 1.20x [Member] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Line of Credit [Member] Premiums received Policyholder Account Balance, Premium Received Segment Reporting [Abstract] Segment Reporting [Abstract] Interest expense Liability for Future Policy Benefit, Interest Expense Entity Central Index Key Entity Central Index Key Scenario [Axis] Scenario [Axis] Beginning balance Ending balance PV of expected future net premiums PV of expected future net premiums, At current discount rates Liability for Future Policy Benefit, Expected Net Premium, before Reinsurance, after Discount Rate Change Financing Receivable, Allowance for Credit Loss [Roll Forward] Financing Receivable, Allowance for Credit Loss [Roll Forward] Total incurred Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims Foreign Exchange Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Financial Instrument [Axis] Financial Instrument [Axis] Business Segments Segment Reporting Disclosure [Text Block] Percentage of total plan assets, within plan asset category Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Percentage Fair Value, Inputs, Level 1, 2 and 3 Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member] Amortization of actuarial (gain) loss Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member] Senior Notes Due 2030 Senior Notes Due August 15 2030 [Member] Senior Notes Due August 15 2030 Policyholder Account Balance [Abstract] New Accounting Standards Accounting Standards Update and Change in Accounting Principle [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Measurement Basis [Axis] Measurement Basis [Axis] Fair value of pledged assets Loans Receivable, Fair Value Disclosure Delinquent loans, outstanding interest Financing Receivable, Delinquent, Outstanding Interest Financing Receivable, Delinquent, Outstanding Interest Title Trading Arrangement, Individual Title Junior Subordinated Debentures Due 2061 Junior Subordinated Debentures Due 2061 [Member] Junior Subordinated Debentures Due 2061 Long-term debt, gross, fair value Long-Term Debt, Gross, Fair Value Long-Term Debt, Gross, Fair Value Consolidated Entities [Axis] Consolidated Entities [Axis] Other long-term investments (includes: 2024â€\$979,397; 2023â€\$795,583 under the fair value option) Other long-term investments under fair value option Commercial mortgage loan participations Other Long-Term Investments City Area Code City Area Code Debt Securities, Available-for-sale, Allowance for Credit Loss [Table] Debt Securities, Available-for-Sale, Allowance for Credit Loss [Table] Industrial Industrial Property [Member] Net borrowing (repayment) of commercial paper Proceeds from (Repayments of) Short-Term Debt, Maturing in Three Months or Less Annuity Annuity Segment [Member] Annuity Segment [Member] Unfunded Loan Commitment Unfunded Loan Commitment [Member] Deferred Policy Acquisition Cost [Line Items] Deferred Policy Acquisition Cost [Line Items] Office Office Building [Member] Realized gains (losses) from investments Realized Investment Gains (Losses), Before Redemption Of Debt and Other Gains (Losses) Realized Investment Gains (Losses), Before Redemption Of Debt and Other Gains (Losses) Realized Investment Gains (Losses), Before Redemption Of Debt and Other Gains (Losses) Mortgage-backed and asset-backed securities Debt Securities, Available-For-Sale, Without Single Maturity Date, Net Of Allowance For Credit Loss Debt Securities, Available-For-Sale, Without Single Maturity Date, Net Of Allowance For Credit Loss Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Effect of changes in assumptions on future cash flows Liability for Future Policy Benefit, Expected Future Policy Benefit, Cumulative Increase (Decrease) from Cash Flow Change Unamortized discount & issuance costs, noncurrent Debt Instrument, Unamortized Discount (Premium) And Debt Issuance Costs, Noncurrent, Net Debt Instrument, Unamortized Discount (Premium) And Debt Issuance Costs, Noncurrent, Net Fixed maturities, net of allowance for credit losses Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss Preferred Stock Preferred Stock [Member] Remaining amount available under credit line Line of Credit Facility, Remaining Borrowing Capacity Acquisition of treasury stock Payments for Repurchase of Common Stock Schedule of Analysis of Investment Operations Investment Income [Table Text Block] Long-term debt (estimated fair value: 2024â€\$2,202,644; 2023â€\$1,491,229) Long-term debt Long-Term Debt, Excluding Current Maturities Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Unamortized discount & issuance costs, current Debt Instrument, Unamortized Discount (Premium) And Debt Issuance Costs, Current, Net Debt Instrument, Unamortized Discount (Premium) And Debt Issuance Costs, Current, Net Subsequent Event Type [Axis] Subsequent Event Type [Axis] Mortgage loans Proceeds from Maturities, Prepayments and Calls of Mortgages Proceeds from Maturities, Prepayments and Calls of Mortgages Florida FLORIDA Investments Investment [Text Block] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Equity [Abstract] Equity [Abstract] Benefits and expenses: Benefits, Losses and Expenses [Abstract] Retained earnings Retained Earnings (Accumulated Deficit) Schedule of Reclassifications Out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Class of Stock [Domain] Class of Stock [Domain] Insurance administrative expense General and Administrative Expense Schedule of Selected Information about Debt Issues Schedule of Debt [Table Text Block] Debt Service Coverage Ratio [Axis] Debt Service Coverage Ratio [Axis] Debt Service Coverage Ratio [Axis] External Credit Rating by Grouping [Axis] External Credit Rating by Grouping [Axis] Foreign governments Debt Security, Government, Non-US [Member] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Debt Securities, Available-for-sale, Allowance for Credit Loss [Roll Forward] Debt Securities, Available-for-Sale, Allowance for Credit Loss [Roll Forward] Underlying Securities Award Underlying Securities Amount Daily-weighted average interest rate (annualized) Line of Credit Facility, Interest Rate During Period Carrying value, net, percent Carrying value, net of valuation allowance, percent Financing Receivable, Net, Percentage Financing Receivable, Net, Percentage Amendment Flag Amendment Flag Policy claims and other benefits payable: Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Less than Twelve Months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions Less applicable tax (expense) benefit Other Comprehensive Income Gain Loss On Liability for Future Policy Benefit Period Increase Decrease Tax Other Comprehensive Income Gain Loss On Liability for Future Policy Benefit Period Increase Decrease Tax Subsequent Events [Abstract] Deferred Policy Acquisition Cost [Table] Deferred Policy Acquisition Cost [Table] Interest sensitive life Liability for Future Policy Benefit, Current Discount Rate, Interest Sensitive Life Liability for Future Policy Benefit, Current Discount Rate, Interest Sensitive Life Debt Debt Disclosure [Text Block] Other policyholders' funds Other Policyholder Funds Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Assets held in trust of reserves (as a percent) Coinsurance Agreement, Reinsurer, Percentage Of Assets Held in Trust of Reserves Coinsurance Agreement, Reinsurer, Percentage Of Assets Held in Trust of Reserves Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Balance of commercial paper at end of period (par value) Debt Instrument, Face Amount % of Total Product Premium As Percentage Of Segment Premium Product premium as percentage of segment premium. Entity Address, Postal Zip Code Entity Address, Postal Zip Code Percentage of total fixed maturities (as a percent) Percentage of fixed maturities at fair value Percentage Of Fixed Maturities At Fair Value Percentage of fixed maturities by component at fair value. Range above guaranteed minimum crediting rates (percent) Policyholder Account Balance, above Guaranteed Minimum Crediting Rate Amortization Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Amortization Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, amortization. Annuity reserves ceded Coinsurance Agreement, Annuity Reserves Ceded Coinsurance Agreement, Annuity Reserves Ceded Obligation with Joint and Several Liability Arrangement [Line Items] Obligation with Joint and Several Liability Arrangement [Line Items] Other investing activities Payments for (Proceeds from) Other Investing Activities Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Provision (reversal) for credit losses Financing Receivable, Credit Loss, Expense (Reversal) Investments sold or matured: Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale [Abstract] Other Liability for Future Policy Benefits, Original Discount Rate, Other Contracts Liability for Future Policy Benefits, Original Discount Rate, Other Contracts Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Total investments sold or matured Proceeds from Sale, Maturity and Collection of Investments Fair Value Measurement [Domain] Fair Value Measurement [Domain] Schedule of Short-term Debt [Table] Short-Term Debt [Table] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Class of Financing Receivable [Axis] Class of Financing Receivable [Axis] Change in expected experience, remeasurement gain (loss) Liability for Future Policy Benefit, Change in Expected Experience, Remeasurement Gain (Loss) Liability for Future Policy Benefit, Change in Expected Experience, Remeasurement Gain (Loss) Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Effect of changes in the foreign exchange rate Liability For Future Policy Benefit, Expected Net Premium, Foreign Exchange Effect Liability For Future Policy Benefit, Expected Net Premium, Foreign Exchange Effect Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Total assets Assets Investments in low-income housing interests Investment In Low Income Housing Interests Investment In Low Income Housing Interests Additions to property and equipment Payments to Acquire Property, Plant, and Equipment At original discount rates Liability for Future Policy Benefit, Weighted-Average Duration, Original Discount Liability for Future Policy Benefit, Weighted-Average Duration, Original Discount Entity Listings [Line Items] Entity Listings [Line Items] Schedule of Policyholder Account Balance Policyholder Account Balance [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and Contingencies (Note 5) Commitments and Contingencies Net liability for future policy benefits, after reinsurance recoverable, at current discount rates Liability for Future Policy Benefit, after Reinsurance Short-term Debt Short-Term Debt [Member] Termination Date Trading Arrangement Termination Date Other Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Other Adjustments Increase (Decrease) Other adjustments, including capitalized interest and foreign exchange. Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Benefit payments Liability for Future Policy Benefit, Expected Future Policy Benefit, Benefit Payment Exchange traded fund Exchange Traded Funds [Member] Policy Liabilities Long-Duration Insurance Contracts Disclosure [Text Block] Other liabilities Other Liabilities Required interest on reserves Required Interest on Policy Reserves The interest implied in determining the insurance policy reserve liability, based on the discount rate assumed upon policy issue. Deferred profit liability Liability for Future Policy Benefit, Current Discount Rate, Deferred Profit Liability Liability for Future Policy Benefit, Current Discount Rate, Deferred Profit Liability Due after one year through five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Net commercial paper issued (matured) during period (par value) Net Commercial Paper Issued and Matured During Period Net Commercial Paper Issued and Matured During Period Debt Instrument [Axis] Debt Instrument [Axis] PV of expected future policy benefits, not discounted PV of expected future policy benefits, Not discounted Liability for Future Policy Benefit, Expected Future Policy Benefit, Not Discounted, before Cash Flow and Reinsurance1 Amortized Cost Debt Securities, Available-for-Sale and Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss Net income Net income Total after-tax Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Interest accrual Liability for Future Policy Benefit, Expected Future Policy Benefit, Interest Expense Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Effect of changes in assumptions on future cash flows Liability for Future Policy Benefit, Expected Net Premium, Cumulative Increase (Decrease) from Cash Flow Change Outstanding principal on nonaccrual loan

Financing Receivable, Nonaccrual Schedule of Real Assets by Component at Fair Value Schedule of Allocation of Plan Assets [Table Text Block] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Total benefits and expenses Benefits, Losses and Expenses Entity File Number Entity File Number Schedule of Realized Gains (Losses) on Investments Realized Gain (Loss) on Investments [Table Text Block] Consolidated Entities [Domain] Consolidated Entities [Domain] Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Effect of foreign exchange rate changes on cash of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Common dividends declared Dividends, Common Stock Name Forgone Recovery, Individual Name Schedule of Net Periodic Benefit Cost Schedule of Costs of Retirement Plans [Table Text Block] Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Qualified Plan Qualified Plan [Member] 51-150 basis points above Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0051 to 0150 [Member] New Jersey NEW JERSEY Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Extension options term of non-redeemable funds Extension Options Term of Non-Redeemable Funds Extension Options Term of Non-Redeemable Funds Less than 3.00% Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0200 to 0299 [Member] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Real Estate Investment Trust Real Estate Investment Trust [Member] Real Estate Investment Trust Adjustment to Compensation: Adjustment to Compensation [Axis] Document Quarterly Report Document Quarterly Report Deferred annuity Liability for Future Policy Benefit, Current Discount Rate, Deferred Annuity Liability for Future Policy Benefit, Current Discount Rate, Deferred Annuity Delinquent loans, outstanding par value (in dollars per share) Financing Receivable, Delinquent, Outstanding Par Value Financing Receivable, Delinquent, Outstanding Par Value Policy Loans Policy Loans [Member] Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Extension term Debt Instrument, Extension Term Debt Instrument, Extension Term Acquisitions Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases Percentage change in net investment income Percentage Change In Net Investment Income Percentage Change In Net Investment Income Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Basic weighted average shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Unrealized Loss, Twelve Months or Longer Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] 1.00x-1.20x Debt Service Coverage Ratio, 1.00x-1.20x [Member] Debt Service Coverage Ratio, 1.00x-1.20x [Member] Sales and other Debt Securities, Available-for-Sale, Realized Gain (Loss) Premiums paid for insurance coverage Insurance Premium Paid For Supplemental Pension Plan Insurance premium added to the policy value in the supplemental retirement plan. New York NEW YORK Total revenue Segment Revenues Excluding Realized Investment Gains Losses Segment Revenues Excluding Realized Investment Gains Losses Name Awards Close in Time to MNPI Disclosures, Individual Name Unrealized Loss, Less than Twelve Months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Entity Filer Category Entity Filer Category Statistical Measurement [Domain] Statistical Measurement [Domain] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Hospitality Hospitality [Member] Hospitality [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Additions to allowance for which credit losses were not previously recorded Debt Securities, Available-for-Sale, Excluding Accrued Interest, Allowance for Credit Loss, Not Previously Recorded Mortgage-backed and asset-backed securities Mortgage Backed And Asset Backed Securities At Fair Value Mortgage Backed And Asset Backed Securities At Fair Value Net (increase) decrease in policy loans Payments for (Proceeds from) Policy Loans Investment funds Partnership Interest - Fair Value Option [Member] Partnership Interest - Fair Value Option Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Investment grade securities issued term Defined Benefit Plan, Investment-Grade Securities, Issued Term Defined Benefit Plan, Investment-Grade Securities, Issued Term Due after one year through five years Debt Securities, Available-For-Sale, Maturity, Allocated And Single Maturity Date, After One Through Five Years, Amortized Cost, Net Of Allowance For Credit Losses Debt Securities, Available-For-Sale, Maturity, Allocated And Single Maturity Date, After One Through Five Years, Amortized Cost, Net Of Allowance For Credit Losses Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount SERP Supplemental Employee Retirement Plan [Member] Texas TEXAS Other Performance Measure, Amount Other Performance Measure, Amount Effect of changes in discount rate assumptions Liability for Future Policy Benefit, Effect of Changes in Discount Rate Assumptions Liability for Future Policy Benefit, Effect of Changes in Discount Rate Assumptions Total unrealized investment gains (losses) OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Future policy benefits Net liability for future policy benefitsâ€long duration health liability for Future Policy Benefit, before Reinsurance Letter of credit maximum available amount Letters Of Credit Facility Limit Letters Of Credit Facility Limit Gain Loss From Experience Gain (Loss) From Experience [Member] Gain (Loss) From Experience Collateralized debt obligations Collateralized Debt Obligations [Member] Gross realized losses Debt Securities, Available-for-Sale, Realized Loss Service costâ€benefits earned during the period Defined Benefit Plan, Service Cost Policyholder Account Balance [Line Items] Policyholder Account Balance [Line Items] Entity Tax Identification Number Entity Tax Identification Number Liability for Claims and Claims Adjustment Expense [Table] Liability for Claims and Claims Adjustment Expense [Table] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Total investments: Insurance Cash Value And Investment Fund Supporting Supplemental Pension Plan Liability Deferred acquisition costs Beginning Balance Ending Balance Deferred Policy Acquisition Cost Treasury Stock Treasury Stock, Common [Member] Other operating expense Other Cost and Expense, Operating Total policy liabilities Policyholder Account Balance, Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense Policyholder Account Balance, Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense Equity Components [Axis] Equity Components [Axis] Fixed maturitiesâ€available for sale, at fair value (amortized cost: 2024â€â€\$19,084,454; 2023â€â€\$18,924,914, allowance for credit losses: 2024â€â€\$7,132; 2023â€â€\$7,115) Fair value Fixed maturities, fair value Debt Securities, Available-for-Sale 3.00%-3.99% Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 to 0399 [Member] Other Distribution Channel Other [Member] Distribution channel, other [Member]. Beginning Balance Ending Balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value 1-50 basis points above Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0001 to 0050 [Member] Investments [Domain] Investments [Domain] PV of expected future gross premiums, Not discounted Liability for Future Policy Benefit, Expected Future Gross Premium, Not Discounted, before Cash Flow Reinsurance Liability for Future Policy Benefit, Expected Future Gross Premium, Not Discounted, before Cash Flow Reinsurance Effect of actual variances from expected experience Liability for Future Policy Benefit, Expected Future Policy Benefit, Cumulative Increase (Decrease) of Actual Variance from Expected Experience Geographical [Axis] Geographical [Axis] Fixed maturities available for saleâ€matured or other redemptions Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Other Other [Member] Other [Member] Exchanges of fixed maturities Debt Securities, Available-For-Sale, Noncash Sale, Exchange Of Securities Debt Securities, Available-For-Sale, Noncash Sale, Exchange Of Securities PV of expected future gross premiums PV of expected future gross premiums, At current discount rates Liability for Future Policy Benefit, Expected Future Gross Premiums, before Reinsurance, after Discount Rate Change Liability for Future Policy Benefit, Expected Future Gross Premiums, before Reinsurance, after Discount Rate Change Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Asset Pledged as Collateral Asset Pledged as Collateral [Member] Prior years Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years Liability for Future Policy Benefit, Difference Between Expected Gross Premiums and Expected Future Net Premiums Liability for Future Policy Benefit, Difference Between Expected Gross Premiums and Expected Future Net Premiums Fair Value Debt Securities, Available-for-Sale, Unrealized Loss Position Cash at beginning of year Cash at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Number of loans Financing Receivable, Number Of Loans Financing Receivable, Number Of Loans Consolidation Items [Axis] Consolidation Items [Axis] Reinsurance recoverable Reinsurance recoverable at original discount rates Liability for Future Policy Benefit, Reinsurance Recoverable, after Allowance Common stock, shares held in treasury (in shares) Treasury Stock, Common, Shares Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Percentage change in investment income, gross Percentage Change In Gross Investment Income, Operating Percentage Change In Gross Investment Income, Operating Beginning balance Ending balance PV of expected future policy benefits, At original discount rates Liability for Future Policy Benefit, Expected Future Policy Benefit, Original Discount Rate, before Cash Flow and Reinsurance Product and Service [Domain] Product and Service [Domain] Prior years Prior Year Claims and Claims Adjustment Expense Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Security Exchange Name Security Exchange Name Basis spread Debt Instrument, Basis Spread on Variable Rate Unrealized holding gains (losses) arising during period OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax Capital called from investment funds Payments to Acquire Long-Term Investments Schedule of Fixed Maturities, Allowance for Credit Loss Debt Securities, Available-for-Sale, Allowance for Credit Loss [Table Text Block] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Fixed maturities available for sale Fixed Maturities [Member] Greater than 150 basis points above Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0151 and Greater [Member] Short-term debt Total short-term debt, book value Short-Term Debt Amortized Cost, net Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Investment funds, percentage ownership by pension plan Fair Value, Investments, Entities that Calculate Net Asset Value, Percentage Ownership By Pension Plan Fair Value, Investments, Entities that Calculate Net Asset Value, Percentage Ownership By Pension Plan Schedule of Fair Value of Fixed Maturities Measured on a Recurring Basis Debt Securities, Available-for-Sale [Table Text Block] Net borrowing from FHLB Proceeds from FHLB Borrowings, Financing Activities Realized gains (losses) Realized (gains) losses Realized gains (losses) Total realized gains (losses) Realized Investment Gains (Losses) Sales Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales Unsettled trades Debt Securities, Available-For-Sale, Unsettled Trades Debt Securities, Available-For-Sale, Unsettled Trades Common stock, shares issued (in shares) Common Stock, Shares, Issued Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Change in assumptions of lapse, mortality, and morbidity, remeasurement gain (loss) Liability for Future Policy Benefit, Change in Assumptions of Lapse, Mortality, and Morbidity, Remeasurement Gain (Loss) Liability for Future Policy Benefit, Change in Assumptions of Lapse, Mortality, and Morbidity, Remeasurement Gain (Loss) Carrying value Financing Receivable, before Allowance for Credit Loss Total future policy benefits Liability for Future Policy Benefit, Original Discount Rate, after Reinsurance and Other Liability for Future Policy Benefit, Original Discount Rate, after Reinsurance and Other Unrealized Loss Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash Cash Junior Subordinated Debentures Due 2057 Junior Subordinated Debentures Due 2057 [Member] Junior Subordinated Debentures Due 2057 Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Asset, Gain (Loss), Statement of Other Comprehensive Income or Comprehensive Income [Extensible Enumeration] Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Asset, Gain (Loss), Statement of Other Comprehensive Income or Comprehensive Income [Extensible Enumeration] FHLB borrowings Federal Home Loan Bank Borrowings Federal Home Loan Bank Borrowings [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized At Current Discount Rates Liability for Future Policy Benefit, Current Discount Rate [Abstract] Liability for Future Policy Benefit, Current Discount Rate Consolidation Eliminations Consolidation, Eliminations [Member] Insurance [Abstract] Insurance [Abstract] Transfers into Level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 Net liability for future policy benefits at original discount rates Liability for Future Policy Benefit, Expected Future Policy Benefit, Original Discount Rate Liability for Future Policy Benefit, Expected Future Policy Benefit, Original Discount Rate Total short-term debt, par value Short-term debt, face amount Short-Term Debt, Face Amount Short-term debt, face amount Adjusted balance Liability for Future Policy Benefit, Expected Future Policy Benefit, Original Discount Rate, before Reinsurance, after Cash Flow Change Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Other premium Other Policyholders' Funds Insurance, Other [Member] Fixed maturity, portfolio issues Entire Portfolio Number Of Issues Of Fixed Maturities Total issues of fixed maturities, Actuarial (gain) loss Defined Benefit Plan, Amortization of Gain (Loss) Fair value of plan assets, within plan asset category Defined Benefit Plan, Plan Assets, Investment within Plan Asset Category, Amount Issuances Policyholder Account Balance, Issuance Other bonds Other Bonds [Member] Other bonds [Member]. Gain *Loss) From Unlocking Assumptions Gain (Loss) From Unlocking Assumptions [Member] Gain (Loss) From Unlocking Assumptions Change in discount rate on future policy benefits OCI, Liability for Future Policy Benefit, Change In Discount Rate OCI, Liability for Future Policy Benefit, Change In Discount Rate Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Entity Listings [Table] Entity Listings [Table] Range of guaranteed minimum crediting rates (percent) Policyholder Account Balance, Guaranteed Minimum Credit Rating Fair Value, Twelve Months or Longer Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Long-term debt, net, book value Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Fair value of plan assets Defined Benefit Plan, Plan Assets, Amount Commissions, premium taxes, and non-deferred acquisition costs Commissions, premium taxes, and non-deferred acquisition costs Non Deferred Acquisition Costs And Premium Taxes Non-deferred commissions, non-deferred acquisition costs and premium taxes. Commercial paper Commercial paper Commercial Paper [Member] Investment Income [Table] Investment Income [Table] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Less investment expense Investment Income, Investment Expense Less applicable tax (expense) benefit Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax Utilities Utilities [Member] Utilities [Member] Carrying value, gross, percent Financing Receivable, Gross, Percentage Financing Receivable, Gross, Percentage Net liability for future policy benefitsâ€long duration life liability for Future Policy Benefit, Expected Future Policy Benefit, Original Discount Rate, before Cash Flow and Reinsurance, Net Liability for Future Policy Benefit, Expected Future Policy Benefit, Original Discount Rate, before Cash Flow and Reinsurance, Net Accounting Policies [Abstract] Accounting Policies [Abstract] Liabilities: Liabilities [Abstract] Revenue: Revenue: Revenues [Abstract] Total investments of SERP Insurance Cash Value And Investment Fund Supporting Supplemental Pension Plan Liability Insurance Cash Value And Investment Fund Supporting Supplemental Pension Plan Liability Current Fiscal Year End Date Current Fiscal Year End Date Short-term investments Short-Term Investments PEO Name PEO Name Due after ten years through twenty years Available For Sale Securities Debt Maturities After Ten Through Twenty Years Fair Value This item represents the fair value of debt securities which are expected to mature after ten years and through twenty years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. All Award Types Award Type [Domain] Less than 70% LTV Less than 70 Percent [Member] LTV Less than 70 Percent [Member] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-PEO NEO Non-PEO NEO [Member] Other comprehensive income (loss) before reclassifications, net of tax OCI, before Reclassifications, Net of Tax, Attributable to Parent Additional Paid-In Capital Additional Paid-In Capital [Member] Company owned life insurance Company Owned Life Insurance [Member] Company Owned Life Insurance Schedule of Commercial Mortgage Loan Participations Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] U.S

Operating Segments Total policyholder benefits Policy benefits Policyholder Benefits and Claims Incurred, Net At current discount rates Liability for Future Policy Benefit, Weighted-Average Duration Fair Value Measured at Net Asset Value Per Share Fair Value Measured at Net Asset Value Per Share [Member] Policy loans Loans, Gross, Insurance Policy Pension Adjustments Pension adjustments: Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Coupon Rate Interest rate Debt Instrument, Interest Rate, Stated Percentage Corporate & Other Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Obligation with Joint and Several Liability Arrangement [Table] Obligation with Joint and Several Liability Arrangement [Table] Non-operating items Nonoperating Income (Expense) Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Debt instrument, increase (decrease), net Debt Instrument, Increase (Decrease), Net Measure of segment profitability (pretax) Operating Income (Loss) Schedule of Commercial Loan Participations, Credit Quality Indicators Financing Receivable Credit Quality Indicators [Table Text Block] Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Table] Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Table] Number of reportable segments Number of Reportable Segments Total liabilities and shareholders' equity Liabilities and Equity Subsequent Events Subsequent Events [Text Block] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Health premium Health claims Health insurance Health Insurance Product Line [Member] Mixed use Mixed Use [Member] Mixed Use [Member] Future Policy Benefits: Future Policy Benefits [Abstract] Future Policy Benefits Cash dividends paid to shareholders Payments of Dividends Underlying Security Market Price Change Underlying Security Market Price Change, Percent Expected return on assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Individual: Individual [Axis] PV of expected future net premiums, Not discounted Liability for Future Policy Benefit, Expected Net Premium, Not Discounted, before Cash Flow and Reinsurance Liability for Future Policy Benefit, Expected Net Premium, Not Discounted, before Cash Flow and Reinsurance Accumulated Other Comprehensive Income (Loss) Total AOCI Attributable to Parent [Member] Product and Service [Axis] Product and Service [Axis] Statement [Line items] Statement [Line Items] Less applicable tax (expense) benefit OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax Weighted-average credit rate Policyholder Account Balance, Weighted Average Crediting Rate Increase in allowance for credit losses Financing Receivable, Allowance for Credit Loss, Period Increase (Decrease) Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Schedule of Reconciliation of Segment Operating Information to Consolidated Statement of Operations Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Expenses: Operating Expenses [Abstract] Schedule of Investment Funds Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Table Text Block] Number of loans in non-accrual status Financing Receivable, Number Of Loans in Non-Accrual Status Financing Receivable, Number Of Loans in Non-Accrual Status Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Total debt, unamortized discount & issuance costs, Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Schedule of Fair Value, Assets Measured on Recurring Basis Using Significant Unobservable Inputs Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Repayment of commercial paper with original maturities greater than 90 days Commercial paper matured during period (par value) Commercial Paper Matured During Period Commercial Paper Matured During Period Minimum Minimum [Member] Allowance for credit losses Less allowance for credit losses Allowance for credit losses beginning balance Allowance for credit losses ending balance Financing Receivable, Allowance for Credit Loss Adoption Date Trading Arrangement Adoption Date Other receivables Other Receivables Investment Grade External Credit Rating, Investment Grade [Member] Amortization of deferred acquisition costs Amortization expense Amortization of acquisition costs Deferred Policy Acquisition Costs, Amortization Expense Due after five years through ten years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Less applicable tax (expense) benefit Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Debt Long-Term Debt, Gross Exercise Price Award Exercise Price Due in one year or less Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, Within One Year, Amortized Cost, Net Of Allowance For Credit Losses Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, Within One Year, Amortized Cost, Net Of Allowance For Credit Losses Mortgage loans Mortgage Loans [Member] Mortgage Loans Arrangement Duration Trading Arrangement Duration 5.85% Senior notes due SeptemberÂ 15, 2034 A585 Senior Notes Due September152034 [Member] A585 Senior Notes Due September152034 Pension adjustments Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax Shareholders' equity: Equity, Attributable to Parent [Abstract] Subsidiaries Subsidiaries [Member] Fair Value, Less than Twelve Months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Applicable tax Realized Gains Losses From Investments Applicable Tax Realized gains (losses) from investments, Applicable tax Change in unrealized gains (losses) for the period Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss), OCI Current year Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year Total investments Investments Greater than 5.00% Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0500 and Greater [Member] Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0500 and Greater Policyholder Account Balance, above Guaranteed Minimum Crediting Rate [Domain] Policyholder Account Balance, above Guaranteed Minimum Crediting Rate [Domain] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Proceeds from commercial paper with original maturities greater than 90 days Proceeds from Short-Term Debt, Maturing in More than Three Months All Individuals All Individuals [Member] Financing receivable, number of delinquent loans Financing Receivable, Number Of Delinquent Loans Financing Receivable, Number Of Delinquent Loans Total debt, fair value Debt Instrument, Fair Value Disclosure Net (increase) decrease in short-term investments Payments for (Proceeds from) Short-Term Investments Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Other Policyholder Account Balance, Increase (Decrease) from Other Change Liability for Claims and Claims Adjustment Expense [Line Items] Liability for Claims and Claims Adjustment Expense [Line Items] Unrealized investment (gains) losses on available for sale assets: Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss [Abstract] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Fair value option Fair Value Option, Other Eligible Items [Member] Senior Notes Due June 15 2032 Senior Notes Due June 15 2032 [Member] Senior Notes Due June 15 2032 Due after five years through ten years Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, After Five Through Ten Years, Amortized Cost, Net Of Allowance For Credit Loss Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, After Five Through Ten Years, Amortized Cost, Net Of Allowance For Credit Loss Deferred profit liability Liability for Future Policy Benefit, Original Discount Rate, Deferred Profit Liability Liability for Future Policy Benefit, Original Discount Rate, Deferred Profit Liability Incurred related to: Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract] Less Than 1.00x Debt Service Coverage Ratio, Less Than 1.00x [Member] Debt Service Coverage Ratio, Less Than 1.00x Interest accrual Liability for Future Policy Benefit, Expected Net Premium, Interest Income Policyholder Account Balance [Roll Forward] Policyholder Account Balance [Roll Forward] Total Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions Effect of changes in the foreign exchange rate Liability for Future Policy Benefit, Expected Future Policy Benefit, Foreign Exchange Effect Liability for Future Policy Benefit, Expected Future Policy Benefit, Foreign Exchange Effect Junior Subordinated Debentures Due 2056 Junior Subordinated Debentures Due 2056 [Member] Junior Subordinated Debentures Due 2056 Other asset-backed securities Other Asset Backed Securities [Member] Other Asset Backed Securities [Member] Pension adjustments, net of tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Real Estate [Domain] Real Estate [Domain] 81% to 90% LTV 81 Percent To 90 Percent [Member] LTV 81 Percent To 90 Percent [Member] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Measure: Measure [Axis] Unearned and advance premium Unearned Premiums Investments: Investments [Abstract] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Percentage of total Percent of total fixed maturities Percent Of Available For Sale Securities At Fair Value By Valuation Level Percent Of Available For Sale Securities At Fair Value By Valuation Level Twelve Months or Longer Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions Investment funds, unfunded commitments Investment funds, Unfunded Commitments Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments Entity Emerging Growth Company Entity Emerging Growth Company Gross Premiums Liability for Future Policy Benefit, Gross Premium Income Other Other Investments [Member] Other Other Geographical Location [Member] Other Geographical Location Mortgage loans Payments to Acquire Mortgages Payments to Acquire Mortgages Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Foreign exchange translation: Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent [Abstract] Reclassification, Type [Domain] Reclassification, Type [Domain] Equity Component [Domain] Equity Component [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Realized gains (losses), net of tax Realized Gains Losses From Investments Net Of Tax Realized gains (losses) from investments, Net of tax Debt-to-Value [Domain] Debt-to-Value [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code FHLB stock Federal Home Loan Bank Stock and Federal Reserve Bank Stock Statement [Table] Statement [Table] Significant Accounting Policies Significant Accounting Policies [Text Block] Consolidation Items [Domain] Consolidation Items [Domain] Cash surrender value Policyholder Account Balance, Cash Surrender Value 4.250% Junior Subordinated Debentures Junior Subordinated Debentures [Member] Junior Subordinated Debentures Other Liability for Future Policy Benefit, Current Discount Rate, Other Contracts Liability for Future Policy Benefit, Current Discount Rate, Other Contracts Below Investment Grade External Credit Rating, Noninvestment Grade [Member] QuotedÂ PricesÂ in ActiveÂ Markets forÂ Identical AssetsÂ (LevelÂ 1) QuotedÂ PricesÂ in Active Markets for Identical AssetsÂ (LevelÂ 1) Fair Value, Inputs, Level 1 [Member] Foreign exchange translation adjustments, other than securities, net of tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Senior Notes Senior Notes [Member] Schedule of Pension Liability Schedule of Accumulated and Projected Benefit Obligations [Table Text Block] Direct to Consumer Direct Response [Member] Direct response [Member], Financial Financial [Member] Financial [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward] Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward] Other reclassification adjustments included in net income Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax Benefit payments Policyholder Account Balance, Benefit Payment Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Reclassification, Type [Axis] Reclassification, Type [Axis] Total paid Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid Other long-term investments Other Long-Term Investments [Member] Net Investment Income [Line Items] Net Investment Income [Line Items] Included in other comprehensive income Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) Cash provided from (used for) financing activities Net Cash Provided by (Used in) Financing Activities Accounting Changes and Error Corrections [Abstract] Accounting Changes and Error Corrections [Abstract] Credit Facility [Axis] Credit Facility [Axis] Interest sensitive life Liability for Future Policy Benefit, Original Discount Rate, Interest Sensitive Life Liability for Future Policy Benefit, Original Discount Rate, Interest Sensitive Life Schedule of Analysis of Deferred Acquisition Costs Deferred Policy Acquisition Costs [Table Text Block] Fair Value Long-Term Debt, Fair Value Entity Registrant Name Entity Registrant Name Commercial mortgage loans Commercial Mortgage-Backed Securities [Member] Adjustment to non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Subtotal Gross Profit Less reinsurance recoverables, beginning balance Plus reinsurance recoverables, ending balance Reinsurance Recoverable for Unpaid Claims and Claims Adjustments Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Fair Value as of Grant Date Award Grant Date Fair Value SignificantÂ Other Observable InputsÂ (LevelÂ 2) Significant Observable InputsÂ (LevelÂ 2) Fair Value, Inputs, Level 2 [Member] Geographical [Domain] Geographical [Domain] Schedule of Segment Premium Income by Distribution Channel Disaggregation of Revenue [Table Text Block] Total long-term debt, fair value Long-Term Debt, Fair Value, Excluding Current Maturities Long-Term Debt, Fair Value, Excluding Current Maturities Restatement Determination Date: Restatement Determination Date [Axis] External Credit Rating by Grouping [Domain] External Credit Rating by Grouping [Domain] Title of 12(b) Security Title of 12(b) Security Liability for Future Policy Benefit, Remeasurement Gain (Loss) by Type [Axis] Liability for Future Policy Benefit, Remeasurement Gain (Loss) by Type [Axis] Liability for Future Policy Benefit, Remeasurement Gain (Loss) by Type Common stock, par value \$1 per shareâ€³320,000 shares authorized; outstanding: (2024â€³102,218,183 issued; 2023â€³102,218,183 issued) Common Stock, Value, Issued Policyholder Account Balance, Guaranteed Minimum Crediting Rate Range [Domain] Policyholder Account Balance, Guaranteed Minimum Crediting Rate Range [Domain] Activity in the Liability for Unpaid Health Claims Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward] Expected life of non-redeemable funds Expected Life of Non-Redeemable Funds Expected Life of Non-Redeemable Funds Optional redemption, period from issuance date Debt Instrument, Redemption, Optional Redemption, Period From Issuance Debt Instrument, Redemption, Optional Redemption, Period From Issuance Cash provided from (used for) financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Preferred stock, par value \$1 per shareâ€³5,000 shares authorized; outstanding: 0 in 2024 and 2023 Preferred Stock, Value, Issued Basic net income per common share (in dollars per share) Earnings Per Share, Basic Issuance of common stock Proceeds from Issuance of Common Stock Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Policyholder benefits net of remeasurement gain (losses) Liability for Future Policy Benefit, Remeasurement Gain (Loss) Life Segment [Member] Life Segment [Member] Nonqualified Plan Nonqualified Plan [Member] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Percentage of plan assets Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage Retail Retail Property [Member] Retail Property [Member] Future policy benefits at original rates Liability for Future Policy Benefit, Original Discount Rate, Before Reinsurance and Other Liability for Future Policy Benefit, Original Discount Rate, Before Reinsurance and Other Long-term line of credit Long-Term Line of Credit Repayment of debt Repayments of Notes Payable Exchange traded funds Investment In Investment Fund Investment In Investment Fund Total debt, par value Long-Term And Short-Term Debt, Face Amount Long-Term And Short-Term Debt, Face Amount COLI Insurance Cash Value Of Supplemental Pension Plan Insurance cash value included in the assets of the supplemental pension plan. Total revenue Revenues Beginning Balance Ending Balance Range of guaranteed minimum crediting rates Policyholder Account Balance Weighted average original discount rate Liability for Future Policy Benefit, Weighted-Average Interest Accretion Rate United American United American Independent [Member] United American Independent [Member], Entity Address, City or Town Entity Address, City or Town Schedule of Undiscounted and Discounted Expected Future Gross Premiums and Expected Future Benefits And Expenses Liability for Future Policy Benefit, Undiscounted And Discounted Expected Future Gross Premiums And Expected Future Benefits And Expenses [Table Text Block] Liability for Future Policy Benefit, Undiscounted And Discounted Expected Future Gross Premiums And Expected Future Benefits And Expenses Stock-based compensation expense Share-Based Payment Arrangement, Expense Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Supplemental Information about Changes to Accumulated Other Comprehensive Income Comprehensive Income (Loss) Note [Text Block] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Alternative Investment [Table] Alternative Investment [Table] Alternative Investment Commercial Portfolio Segment Commercial Portfolio Segment [Member] Document Fiscal Year Focus Document Fiscal Year Focus Acquisition of treasury stock Treasury Stock, Value, Acquired, Cost Method Provision for credit losses Debt Securities, Available-for-Sale, Allowance for Credit Loss, Provisions for Credit Losses Debt Securities, Available-for-Sale, Allowance for Credit Loss, Provisions for Credit Losses Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Document Period End Date Document Period End Date Legal proceedings Loss Contingency Accrual, Provision Investment Investment Segment [Member] Investment Segment [Member] Deferred annuity Liability for Future Policy Benefit, Original Discount Rate, Deferred Annuity Liability for Future Policy Benefit, Original Discount Rate, Deferred Annuity Insider Trading Arrangements [Line Items] Adjustments Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member] Proceeds from sale Proceeds from Sale of Debt Securities Excluding Unsettled Trades, Available-for-Sale Proceeds from Sale of Debt Securities Excluding Unsettled Trades, Available-for-Sale Acquisition of investments: Payments to Acquire Investments [Abstract] Liability for Future Policy Benefit Activity [Table] Liability for Future Policy Benefit Activity [Table] Document Transition Report Document Transition Report Current year Current Year Claims and Claims Adjustment Expense Greater than 90% LTV Greater Than 90 Percent [Member] LTV Greater Than 90 Percent [Member] Other

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

W1-27270-17UM0+L+T0VL (C-72-W2-NPV7-1-15-X15-=>[C]6:Q20&+F9J5WS9-E1U-QVGBUVZ74+7JH-MTZV75U/M-#17B-HVCESF2/JW#L5L+<#17Z26;1JU-=>2AJVGS1-
XK0M-TXK-K-X3V-RXOD+T0+LQJ[US6-VQJMF-=>2=>98WV-16H8EATHK#412J0019-1WC5LEUKU[WIKW702NO-M-]>1ZJU[WIKW702NO-M-]>1ZJUHL-660D31-B2
+1#P*66K1L6X-XK-=>5.2W/M-L*SU%GL7V3W6V#W#F-OY+Y&2+YCG0->10VCDD-=>R0S92KBCJ995-1JMYD?=>ZV%#EC56U452%RV1?WH-04W+G-M#-3&1HJLMBTM%
-<LJUI-D9F1640?RQZLNP+5JW5-UQD-1J1USJMD-MOQ-T3D-V103-N-S&N1+QFV1LZJ0-9WEEB13R0U4G1WQM#<1PCJ?HK-M#EILRTUQU%75P%O+QJ?
SNFVJ+X5A-QCG122LSL1-1&L-L-D-M10U1373W9-A-=>GMX<R1P1-N5+LB-J0Q14MU25BH9+LBJR/45,S-7M-<P=98N0J3M+K=57E?J
MCMORQ-66Y-1J14N-HLW0V-3VFKF0566H, MKCZ+TVRLCTRL74PLJEXH1VCM0XSNFVFM, C7K<1W-R-E2T-AU-M-25?7+3#3U-1J-5;[H<1-=>N2VEY,2VLK1D1PDJ+Q4L&
8C0D5&X<1-M.OF->2,YJ->1#20V-8C+XOLCX-P-21T+JF83-D6*KR-S+J97+1JVCMO?>S6K3P42Z5V,2JHBP070D-=>5JNW'SW;=>=>OF12PN84N(*)M,NJ,102,181A5206@<=>E=
[2]->O->=>ZJHUKWOW7NO->=>ZJHUKW7NO-M-P-7+V0-U-XMSL-1WWW|GQ|ONW-1JLTHJA-J->8T+G-Z-LJ-M-N890<1-TZUYU60-1JUL25601-<=>WO<1-1J/F7J-1J2LH-2N-
M/3W-40-HK-M-N-OHK1->=>NEG7VWU9-19-75-16Y-22-OY-Y-C-(W-D|M-G|O+1J2M|K5?7-W%Z->=>SW-1FJ29-MYNO<1-L-PINJ?BQ-P501+<CNW-MO<=>703-TSFZJ-T6&K/KQ1
-PL-CV2-ZBO<1VAYZ1-L-PW5/RG-P#-M(4-PIW4|OWLM-TSEK-EB-T6?KWWW<1G-HV-J001-VFVW6B70-0X+R+Z<22-3ND@610P<QI9-RIL-0HJ1593Q5@&=>MBN<Q)T\$<OIE?
S2/D3V3400/7@/1-K*H\$<L9<1V9C+7YJ+X1-46K-M-=>JF-M,*ZJF-P0XFD7UV7V-CV555212CJ-#1<=>U5-54PEH->=>MML-W\$<L%L-MNZHJ?
1C2J2-2PCADE-ZAD*Q0474231903CJ7L1R1R1A1QIP,*Z4ND-M1+1PHEGBA+3A@<L0D+1J1N#4K+53KJPRB?YNWST<17STZBZ[FW-9-6-M-9<1<1
QN56Q22ZR5V6X6M4V6X1M58175@1F-ENNMM1F-H7C-RGR&R2KT9K?Z@-M/KJDF&K5Y-VJ-=>=VLYVW#D=>ZV7-GMPPMCA966.9PP-0F5EE-0-25Q1M-4JHJ@<XT<S70+
1AI-G#D5&R1WR->=>=>3M8XIG6.27F-WGVCPV6-7DAVE.2&F-M45H1WV-HRR5BJL8W9-BATER1072?1J-7VEU1QJ-GXW1?OY-F-VN>?>5)MPP-255V-M-6)G-K-IX/G-M-1)MJBZ-H?<1
1YF-=>7NOEX?Z<1RIOFU-UMMSVD?2R,SJ1<105Y>P-E5-1J6<1N4N+1P4YJL-ES->1+3+UJ@<M7J-V0J?>10C=>1Y09Q0GGG-E-N16<LRO->=>ZJHUKWOW7NO->=>ZJ
HUKWOW7NDGVCIO-MO.G5NPJ1-F1R1R1MCI<11W5Y>6-6-QR63-(M3&K&K-PBR01-P0D-MAX2B-1J5-GGG9J->B*W5J55C97Y7MGMCGEYKO+BS5(4JH-VJ3M46458@5M)
F0.D6X1A9J3M1-NNX3-96T+1W5IE&3&1-VTJ?OHJH-2+1V7S1-VJ-MJD-SYA-PWCAH1E1VH1G<1J?7BFS.WO2+LUN-KQ>QV8+K3K*=>MYNM-MB-M-IX<N4N1Q41G&C7%+04<=>B.EIHUCCZ-
79?2R7R16DLJ+M-MV459IDCT@B-M4TW4JY-IR-<=>3%BK<=>ML+1,VKAZO-U6.H5CZG+U/Q4,U-M4+300.S5%<HUUO-TW+>KE46-VYMNKB2YD6,*&DNJ.RI5;1%L1TJ-1J6EG-16L32\$%RD2
-M+181818A14<5X<=>A%#HJ-C/KOT-P#<=>Q6Q01GS-P-W17U-W+MSF->=>E57JA-99-Y1EVB1N+YMLH4466%NXU0ZF8E31AB2+1H(%W4C1MRO-6P<10Y960AV&
10F=>B#F-YJ.FXTH@1J?F1V17HJ(BA.S01A.Q1MJE.C4U1-0454DND-=>JAGVW2-CF-VZ+1[2W76+1Y9B-4W?3-M-150&5&5-6L6U(YUSU5J1VFKF7721YMC0-KQ+
+F80&XAB6TEU6U1W4-MT82QJHJL(XT72J105Y>P-E5-1J6<1N4N+1P4YJL-ES->1+3+UJ@<M7J-V0J?>10C=>1Y09Q0GGG-E-N16<LRO->=>ZJHUKWOW7NO->=>ZJ
MKOK74-D2P-W-XL2?50-P#<=>WO<1-1J2LH-2N-P#-61S-ME-1J10K6ZK7W0GK19U0+M-6-1EY-K-6Y-2-1J-20H-P-C1J3-MR01HJT-P#K?<1
7&W%Z->=>SW-TN-MJEZWCWQ?O-JGLX?10->CNWQ?<M&703-PLIYE-ZA-T*6K/KJO-P#T2E+1J-3J.GKWAJK-MU3H<1?>1-M0->RW-3360-HC+19-O?>Z=>S-
-00-1J-7PE-YGM-O-P5&F-M-P-PI0R1JYFX1J-PIW-EKMG-=>RM-L1J-1<1?>272?=>P#NT0L1081ZJ2M150Y17-JCJ3-P#E&X(XJW631+2J-3Y-1J-HC-M&GZ6Z6?>Z=>S-U-M-P#-1J-621
(E1?<K7%K-RM-PI#<1VJHJZ1V0.4-4P446&1JW-M-P#Z-YRE-P17-1J-1?>1?>F0-L0W1J7-6YV-YO00W-GW-O1E-MT-P#E1Y5-U2M1EEOO3-P#3OMG-ES%<VC76HWA-O19-S-2
-14.GP-P>7PFYJZ<MPA1-6Y&P-EK)W-=>PZPW78-P2[B-1J-NL7U1<1?>V7E1)?>M7N?=>M1<39GOW1?<1X2?>JL-K&G7O-K-IX/G-#N+1-MJBZ-H?YF-=>7NOEX?MS?<1RIOFU-XMSID?<1
R-SJ1<105Y>P-E5-1J6<1N4N+1P4YJL-ES-M->1+3+UJ@<M7J-V0J?>10C=>1Y09Q0GGG-E-N16<LRO->=>ZJHUKWOW7NO->=>ZJHUKWOW7NJ-O1A1J
R-D99XIMM=>P5)M1,AGF10QJ4-6HJY19Q0V-MJMF=>GML0F4G050PYTPE8%G11ZE0+QH-O1-Y.OWE=>=>1YAV.RNO<OJVF-M#->=>=>=>
M&5-Q1=>=>6.4J0-N.1UTD578-VWBM6J1-F-Y.FYMW-1CQ-B-MYMF&6-6.FJ7V168-GJGW7R3XJN1+JSM+1D.OJX&ZB-2N3&XRLQ74&FJVSWZ-M1KA<00U45>7.LF5VOB6&TPB=2?<1
*BYD.FWU(X1+BB6&14&1)<C=>=>IWOA-M1F-TJHJHJN<1J-1JGC<=>9/4F&H-N-SJM+1J3-CP-3M705IE&X3O-MOKW1M+R-W-093J10ZRI3J<5<-XBLDM68?>VG-
QJ3->MOW29D-1M-BUYBO&A&IL(PI-MDH@U-H7581JH1MADPUY7W39H&KNL5+NP3&1<=>VE-M-R11<L6%SS13Q-9P&CA1-E6-K-9/F-UMVWF5J3K#1ZJHUKWOW7NO-MO->=>ZJHUKJ?
1P-LW1WJ7-P.6YV-1JHJHJWV-1M-M254C-5VZQ-M1UJ?<1V1-V?>7.2-1J-2JG1B7-MZM61-M-P-CVJYGOW1-P&9IR-MJ0-E0E-8T-1<CNJ727SK5?<1P-L0+YJW?<1-1-M-WF1-
1-D-E2>3+156G-WB/KE#1B+3P>>P#1J-O-G-YG-O-M-#1+1UGUJW-=>=>RE-UT-M-M-<1J-GM?>NJPE?<1-4P#<CNH?709-1YCI-7-41-VBS1->1J-TZFW-1J-13&K1B<601-S-3>?<1
-BHWPF-1<2O/WG#<DDV2-2UVS-1N5U1U+R)R-M61-4V1-1O>BC>QUT%?<1H&K-SV?>RG1?<1-1W4-O-CV6-Z>9RM-U05?>JHL-72S1P-#Z&FV-1J-13&K1B<601-S-3>?<1
->50-P#<=>=>4GO-M3-TJF7-A-1J?#K&amp

[illegible]

[illegible]

[illegible]

[The following text contains extremely dense, non-readable noise or gibberish, likely representing corrupted data or a placeholder.]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[The following block contains extremely dense, repetitive, and largely illegible text, likely representing corrupted or encoded data. It appears to be a mix of random characters and fragments of words, making it impossible to transcribe accurately as meaningful text.]

[illegible]

[illegible]

Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	63-0780404
Entity Address, Address Line One	3700 South Stonebridge Drive
Entity Address, City or Town	McKinney
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75070
City Area Code	972
Local Phone Number	569-4000
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	83,945,064
Entity Central Index Key	0000320335
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Amendment Flag	false

Common Stock, \$1.00 par value per share

Entity Listings [Line Items]

Title of 12(b) Security	Common Stock, \$1.00 par value per share
Trading Symbol	GL
Security Exchange Name	NYSE

4.250% Junior Subordinated Debentures

Entity Listings [Line Items]

Title of 12(b) Security	4.250% Junior Subordinated Debentures
Trading Symbol	GL PRD
Security Exchange Name	NYSE

~~XML 20 R2.htm IDEA XBRL DOCUMENT~~

Condensed Consolidated Balance Sheets - USD (\$) \$ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Investments:		
Fixed maturities—available for sale, at fair value (amortized cost: 2024—\$19,084,454; 2023—\$18,924,914, allowance for credit losses: 2024—\$7,132; 2023—\$7,115)	\$ 18,334,570	\$ 17,870,206
Mortgage loans	381,315	279,199
Policy loans	691,072	657,020
Other long-term investments (includes: 2024—\$979,397; 2023—\$795,583 under the fair value option)	1,221,888	835,878
Short-term investments	100,501	81,740
Total investments	20,729,346	19,724,043
Cash	134,549	103,156
Accrued investment income	284,952	270,396
Other receivables	651,871	630,223
Deferred acquisition costs	6,386,682	6,009,477
Goodwill	490,446	481,791
Other assets	878,974	832,413
Total assets	29,556,820	28,051,499
Liabilities:		
Future policy benefits	19,814,913	19,460,353
Unearned and advance premium	264,644	254,567
Policy claims and other benefits payable	530,399	514,875
Other policyholders' funds	469,288	236,958
Total policy liabilities	21,079,244	20,466,753
Current and deferred income taxes	619,970	494,639
Short-term debt	437,418	486,113
Long-term debt (estimated fair value: 2024—\$2,202,644; 2023—\$1,491,229)	2,323,676	1,629,559
Other liabilities	457,887	487,632
Total liabilities	24,918,195	23,564,696
Commitments and Contingencies (Note 5)		
Shareholders' equity:		
Preferred stock, par value \$1 per share—5,000,000 shares authorized; outstanding: 0 in 2024 and 2023	0	0
Common stock, par value \$1 per share—320,000,000 shares authorized; outstanding: (2024—102,218,183 issued; 2023—102,218,183 issued)	102,218	102,218
Additional paid-in-capital	543,255	532,474
Accumulated other comprehensive income (loss)	(2,484,743)	(2,772,419)
Retained earnings	8,225,030	7,478,813
Treasury stock, at cost: (2024—17,942,902 shares; 2023—8,426,854 shares)	(1,747,135)	(854,283)
Total shareholders' equity	4,638,625	4,486,803
Total liabilities and shareholders' equity	\$ 29,556,820	\$ 28,051,499

~~XML 21 R3.htm IDEA XBRL DOCUMENT~~

Condensed Consolidated Balance Sheets (Parenthetical) - USD (\$) \$ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Assets:		
Fixed maturities, available for sale, amortized cost	\$ 19,084,454	\$ 18,924,914
Fixed maturities, available for sale, allowance for credit losses	7,132	7,115
Other long-term investments under fair value option	1,221,888	835,878
Liabilities:		
Future policy benefits at original rates	17,402,917	16,984,615
Total long-term debt, fair value	\$ 2,202,644	\$ 1,491,229
Shareholders' equity:		
Preferred stock, par value (in dollars per share)	\$ 1	\$ 1
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	\$ 1	\$ 1
Common stock, shares authorized (in shares)	320,000,000	320,000,000
Common stock, shares issued (in shares)	102,218,183	102,218,183
Common stock, shares outstanding (in shares)	102,218,183	102,218,183
Common stock, shares held in treasury (in shares)	17,942,902	8,426,854
Investment funds		

Assets:		
Other long-term investments under fair value option	\$ 979,397	\$ 795,583

~~XML 22 R4.htm IDEA XBRL DOCUMENT~~

Condensed Consolidated	3 Months Ended	9 Months Ended

Statements of Operations - USD (\$) \$ in Thousands	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue:				
Revenue	\$ 1,172,593	\$ 1,119,335	\$ 3,485,002	\$ 3,325,345
Net investment income	284,964	266,926	853,178	785,275
Realized gains (losses)	(2,192)	(2,193)	(26,580)	(78,963)
Other income	42	50	192	185
Total revenue	1,455,407	1,384,118	4,311,792	4,031,842
Benefits and expenses:				
Total policyholder benefits	688,184	719,044	2,155,671	2,144,481
Amortization of deferred acquisition costs	104,310	95,757	305,703	282,159
Commissions, premium taxes, and non-deferred acquisition costs	149,693	138,677	447,605	414,933
Other operating expense	104,874	85,870	297,196	256,074
Interest expense	31,388	25,955	91,413	76,640
Total benefits and expenses	1,078,449	1,065,303	3,297,588	3,174,287
Income before income taxes	376,958	318,815	1,014,204	857,555
Income tax benefit (expense)	(73,964)	(61,732)	(198,638)	(161,602)
Net income	\$ 302,994	\$ 257,083	\$ 815,566	\$ 695,953
Basic net income per common share (in dollars per share)	\$ 3.45	\$ 2.72	\$ 8.96	\$ 7.29
Diluted net income per common share (in dollars per share)	\$ 3.44	\$ 2.68	\$ 8.93	\$ 7.20

Life premium				
Revenue:				
Revenue	\$ 818,638	\$ 788,099	\$ 2,438,385	\$ 2,342,429
Benefits and expenses:				
Total policyholder benefits	[1] 454,502	515,676	1,493,165	1,536,317
Health premium				
Revenue:				
Revenue	353,955	331,236	1,046,617	982,916
Benefits and expenses:				
Total policyholder benefits	[2] 221,926	193,790	629,676	580,676
Other premium				
Revenue:				
Revenue	0	0	0	0
Benefits and expenses:				
Total policyholder benefits	\$ 11,756	\$ 9,578	\$ 32,830	\$ 27,488

[1] Net of total remeasurement including both the impact of assumption changes and the effect of actual to expected experience adjustments, resulting in a gain of \$70.6 million for the three months ended September 30, 2024, and a total remeasurement gain of \$11.3 million for the same period in 2023. Net of a total remeasurement gain of \$87.8 million for the nine months ended September 30, 2024, and a total remeasurement gain of \$16.5 million for the same period in 2023.

[2] Net of total remeasurement including both the impact of assumption changes and the effect of actual to expected experience adjustments, resulting in a loss of \$9.6 million for the three months ended September 30, 2024 and a total remeasurement gain of \$7.8 million for the same period in 2023. Net of a total remeasurement loss of \$3.1 million for the nine months ended September 30, 2024, and a total remeasurement gain of \$8.3 million for the same period in 2023.

~~XML 23 R5.htm IDEA XBRL DOCUMENT~~

Condensed Consolidated Statements of Operations (Parenthetical) - USD (\$) \$ in Millions	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023

Life insurance				
Policyholder benefits net of remeasurement gain (losses)	\$ 70.6	\$ 11.3	\$ 87.8	\$ 16.5
Health premium				
Policyholder benefits net of remeasurement gain (losses)	\$ (9.6)	\$ 7.8	\$ (3.1)	\$ 8.3

~~XML 24 R6.htm IDEA XBRL DOCUMENT~~

Condensed Consolidated Statements of Comprehensive Income (Loss) - USD (\$) \$ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023

Statement of Comprehensive Income [Abstract]

Net income	\$ 302,994	\$ 257,083	\$ 815,566	\$ 695,953
Unrealized gains (losses) on fixed maturities:				
Unrealized holding gains (losses) arising during period	869,743	(1,068,091)	301,715	(932,301)
Other reclassification adjustments included in net income	(2,408)	851	2,580	82,866
Foreign exchange adjustment on fixed maturities recorded at fair value	(954)	1,603	546	603
Total unrealized investment gains (losses)	866,381	(1,065,637)	304,841	(848,832)
Less applicable tax (expense) benefit	(181,941)	223,782	(64,018)	178,250
Unrealized gains (losses) on investments, net of tax	684,440	(841,855)	240,823	(670,582)
Future Policy Benefits:				
Change in discount rate on future policy benefits	(1,247,366)	1,687,310	63,614	1,272,631
Less applicable tax (expense) benefit	261,946	(354,334)	(13,360)	(267,252)
Future policy benefit adjustments, net of tax	(985,420)	1,332,976	50,254	1,005,379
Foreign exchange translation:				
Foreign exchange translation adjustments, other than securities	7,296	(7,881)	(4,660)	(4,039)
Less applicable tax (expense) benefit	(1,532)	1,655	979	847
Foreign exchange translation adjustments, other than securities, net of tax	5,764	(6,226)	(3,681)	(3,192)
Pension:				
Pension adjustments	118	35	354	(336)
Less applicable tax (expense) benefit	(25)	(7)	(74)	70
Pension adjustments, net of tax	93	28	280	(266)
Other comprehensive income (loss)	(295,123)	484,923	287,676	331,339
Comprehensive income (loss)	\$ 7,871	\$ 742,006	\$ 1,103,242	\$ 1,027,292

~~XML 25 R7.htm IDEA XBRL DOCUMENT~~

Condensed Consolidated Statements of Shareholders' Equity - USD (\$) \$ in Thousands	Total	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings	Treasury Stock
Beginning balance at Dec. 31, 2022	\$ 3,949,577	\$ 0	\$ 105,218	\$ 529,661	\$ (2,790,313)	\$ 6,894,535	\$ (789,524)
Increase (Decrease) in Stockholders' Equity							
Comprehensive income (loss)	52,830				(170,780)	223,610	
Common dividends declared	(21,542)					(21,542)	
Acquisition of treasury stock	(179,276)						(179,276)

Stock-based compensation	7,678		(1,022)		8,700
Exercise of stock options	37,024			(4,059)	41,083
Ending balance at Mar. 31, 2023	3,846,291 0	105,218	528,639	(2,961,093)	7,092,544 (919,017)
Beginning balance at Dec. 31, 2022	3,949,577 0	105,218	529,661	(2,790,313)	6,894,535 (789,524)
Increase (Decrease) in Stockholders' Equity					
Comprehensive income (loss)	1,027,292				
Ending balance at Sep. 30, 2023	4,623,131 0	105,218	543,693	(2,458,974)	7,519,893 (1,086,699)
Beginning balance at Mar. 31, 2023	3,846,291 0	105,218	528,639	(2,961,093)	7,092,544 (919,017)
Increase (Decrease) in Stockholders' Equity					
Comprehensive income (loss)	232,456			17,196	215,260
Common dividends declared	(21,330)				(21,330)
Acquisition of treasury stock	(89,755)				(89,755)
Stock-based compensation	7,487		7,487		0
Exercise of stock options	5,157				(665)
Ending balance at Jun. 30, 2023	3,980,306 0	105,218	536,126	(2,943,897)	7,285,809 (1,002,950)
Increase (Decrease) in Stockholders' Equity					
Comprehensive income (loss)	742,006			484,923	257,083
Common dividends declared	(21,181)				(21,181)
Acquisition of treasury stock	(96,898)				
Stock-based compensation	7,567		7,567		(96,898)
Exercise of stock options	11,331				0
Ending balance at Sep. 30, 2023	4,623,131 0	105,218	543,693	(2,458,974)	7,519,893 (1,086,699)
Beginning balance at Dec. 31, 2023	4,486,803 0	102,218	532,474	(2,772,419)	7,478,813 (854,283)
Increase (Decrease) in Stockholders' Equity					
Comprehensive income (loss)	559,400			305,183	254,217
Common dividends declared	(22,603)				(22,603)
Acquisition of treasury stock	(23,469)				
Stock-based compensation	9,267		(5,612)		(23,469)
Exercise of stock options	29,763				(438)
Ending balance at Mar. 31, 2024	5,039,161 0	102,218	526,862	(2,467,236)	7,706,655 (829,338)
Beginning balance at Dec. 31, 2023	4,486,803 0	102,218	532,474	(2,772,419)	7,478,813 (854,283)
Increase (Decrease) in Stockholders' Equity					
Comprehensive income (loss)	1,103,242				
Ending balance at Sep. 30, 2024	4,638,625 0	102,218	543,255	(2,484,743)	8,225,030 (1,747,135)
Beginning balance at Mar. 31, 2024	5,039,161 0	102,218	526,862	(2,467,236)	7,706,655 (829,338)
Increase (Decrease) in Stockholders' Equity					
Comprehensive income (loss)	535,971			277,616	258,355
Common dividends declared	(21,595)				(21,595)
Acquisition of treasury stock	(335,873)				
Stock-based compensation	10,090		7,166		(335,873)
Exercise of stock options	0				2,924
Ending balance at Jun. 30, 2024	5,227,754 0	102,218	534,028	(2,189,620)	7,943,415 (1,162,287)
Increase (Decrease) in Stockholders' Equity					
Comprehensive income (loss)	7,871			(295,123)	302,994
Common dividends declared	(20,215)				(20,215)
Acquisition of treasury stock	(591,106)				
Stock-based compensation	9,233		9,227		(591,106)
Exercise of stock options	5,088				6
Ending balance at Sep. 30, 2024	\$ 4,638,625 \$ 0	\$ 102,218	\$ 543,255	\$ (2,484,743)	\$ 8,225,030 (1,747,135)

~~XML 26 R8.htm IDEA: XBRL DOCUMENT~~

Condensed Consolidated Statements of Shareholders' Equity (Parenthetical) - \$ / shares	3 Months Ended				9 Months Ended	
	Sep. 30, 2024		Jun. 30, 2024		Sep. 30, 2024	
	Jun. 30, 2023		Sep. 30, 2023		Jun. 30, 2023	
Statement of Stockholders' Equity [Abstract]						
Common dividends declared, per share (in dollars per share)	\$ 0.2400	\$ 0.2400	\$ 0.2250	\$ 0.2250	\$ 0.2250	

~~XML 27 R9.htm IDEA: XBRL DOCUMENT~~

Condensed Consolidated Statements of Cash Flows - USD (\$) \$ in Thousands	9 Months Ended	
	Sep. 30, 2024	
	Sep. 30, 2023	
Statement of Cash Flows [Abstract]		
Cash provided from (used for) operating activities	\$ 1,065,513	\$ 1,091,028
Investments sold or matured:		
Fixed maturities available for sale—sold	674,125	192,007
Fixed maturities available for sale—matured or other redemptions	161,275	212,936
Mortgage loans	29,433	32,164
Other long-term investments	29,995	100,999
Total investments sold or matured	894,828	538,106
Acquisition of investments:		
Fixed maturities—available for sale	(1,000,665)	(1,076,699)
Mortgage loans	(134,667)	(95,995)
Other long-term investments	(445,776)	(103,098)
Total investments acquired	(1,581,108)	(1,275,792)
Net (increase) decrease in policy loans	(34,052)	(29,687)
Net (increase) decrease in short-term investments	(18,761)	30,187
Additions to property and equipment	(56,047)	(36,449)
Other investing activities	(96)	0
Investments in low-income housing interests	(27,840)	(54,337)
Cash provided from (used for) investing activities	(822,884)	(827,972)
Cash provided from (used for) financing activities:		
Issuance of common stock	34,851	61,079
Cash dividends paid to shareholders	(65,292)	(62,945)
Repayment of debt	0	(165,612)
Proceeds from issuance of debt	530,000	170,000
Payment for debt issuance costs	(7,138)	(757)
Net borrowing from FHLB	17,000	198,000
Net borrowing (repayment) of commercial paper	31,443	(34,066)
Proceeds from commercial paper with original maturities greater than 90 days	387,247	0
Repayment of commercial paper with original maturities greater than 90 days	(314,836)	0

Acquisition of treasury stock	(950,448)	(365,929)
Net receipts (payments) from deposit-type products	122,291	(69,526)
Cash provided from (used for) financing activities	(214,882)	(269,756)
Effect of foreign exchange rate changes on cash	3,646	(313)
Net increase (decrease) in cash	31,393	(7,013)
Cash at beginning of year	103,156	92,559
Cash at end of period	\$ 134,549	\$ 85,546

[XML 28 R10.htm IDEA: XBRL DOCUMENT](#)

Significant
Accounting Policies
[Accounting Policies](#)
[\[Abstract\]](#)
[Significant Accounting Policies](#)

Note 1—Significant Accounting Policies
Business: (Globe Life), (the Company), refers to Globe Life Inc., an insurance holding company incorporated in Delaware in 1979, and Globe Life Inc. subsidiaries and affiliates. Globe Life Inc.'s direct or indirect primary subsidiaries are Globe Life And Accident Insurance Company, American Income Life Insurance Company, Liberty National Life Insurance Company, Family Heritage Life Insurance Company of America, and United American Insurance Company. The underwriting companies are owned by their ultimate corporate parent, Globe Life Inc. (Parent Company).

Globe Life provides a variety of life and supplemental health insurance products and annuities to a broad base of customers. The Company is organized into four reportable segments: life insurance, supplemental health insurance, annuities, and investments.

Globe Life markets its insurance products through a number of distribution channels, each of which sells the products of one or more of Globe Life's insurance segments. Our distribution channels consist of the following exclusive agencies: American Income Life Division (American Income), Liberty National Division (Liberty National) and Family Heritage Division (Family Heritage); an independent agency, United American Division (United American); and our Direct to Consumer Division (DTC).
Basis of Presentation: The accompanying condensed consolidated financial statements of Globe Life have been prepared in accordance with the instructions to Form 10-Q. Therefore, they do not include all of the disclosures required by accounting principles generally accepted in the United States of America (GAAP) for annual financial statements. However, in the opinion of management, these statements include all adjustments, consisting of normal recurring adjustments, which are necessary for a fair presentation of the condensed consolidated financial position at September 30, 2024, and the condensed consolidated results of operations, comprehensive income, and cash flows for the periods ended September 30, 2024 and 2023. The interim period condensed consolidated financial statements should be read in conjunction with the *Consolidated Financial Statements that are included in the Form 10-K* filed with the Securities Exchange Commission (SEC) on February 28, 2024.

Use of Estimates: The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. See further documentation in the significant accounting policies or the accompanying notes.

[XML 29 R11.htm IDEA: XBRL DOCUMENT](#)

New Accounting
Standards
[Accounting Changes and Error Corrections](#)
[\[Abstract\]](#)
[New Accounting Standards](#)

Note 2—New Accounting Standards

Accounting Pronouncements Adopted in the Current Year			
Standard	Description	Effective Date	Effect on the Condensed Consolidated Financial Statements
ASU No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions	ASU 2022-03 adds disclosure requirements specific to equity securities subject to contractual sale restrictions. The disclosures clarify the nature of the contractual sale as well as the duration of the restriction and the circumstances that could cause a lapse in the restriction.	This standard is effective for the Company for fiscal years beginning on January 1, 2024 and for interim periods within those fiscal years.	The adoption of this standard did not have a material impact on the Condensed Consolidated Financial Statements.
Accounting Pronouncements Yet to be Adopted			
Standard	Description	Effective Date	Effect on the Condensed Consolidated Financial Statements
ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures	ASU 2023-07 adds disclosure requirements to segment expenses, improving the financial reporting of the entity's overall performance and assessment of future cash flows. The disclosures will require more detailed information related to the entity's reportable segments.	This standard is effective for the Company for annual periods beginning on January 1, 2025, and for interim periods beginning on January 1, 2025, and will be implemented on a retrospective basis.	The Company is evaluating the standard, but does not expect the standard will have a material impact on the Condensed Consolidated Financial Statements.
ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures	ASU 2023-09 adds disclosure requirements to disaggregated information related to the effective tax rate reconciliation and information on income taxes paid. The disclosures will enhance the assessment of the entity's operations and related tax risks.	This standard is effective for the Company for annual periods beginning on January 1, 2025, and will be implemented on a prospective basis.	The Company does not expect the standard will have a material impact on the Condensed Consolidated Financial Statements.

[XML 30 R12.htm IDEA: XBRL DOCUMENT](#)

Supplemental
Information about
Changes to
Accumulated Other
Comprehensive
Income
[Equity \[Abstract\]](#)
[Supplemental Information about Changes to Accumulated Other Comprehensive Income](#)

Note 3—Supplemental Information about Changes to Accumulated Other Comprehensive Income
Components of Accumulated Other Comprehensive Income: An analysis of the change in balance by component of Accumulated Other Comprehensive Income is as follows for the three and nine month periods ended September 30, 2024 and 2023:

Three Months Ended September 30, 2024					
	Available for Sale Assets	Future Policy Benefits	Foreign Exchange	Pension Adjustments	Total
Balance at July 1, 2024	\$ (1,271,213)	\$ (911,717)	\$ (4,726)	\$ (1,964)	\$ (2,189,620)
Other comprehensive income (loss) before reclassifications, net of tax	686,343	(985,420)	5,764	—	(293,313)
Reclassifications, net of tax	(1,903)	—	—	93	(1,810)
Other comprehensive income (loss)	684,440	(985,420)	5,764	93	(295,123)
Balance at September 30, 2024	\$ (586,773)	\$ (1,897,137)	\$ 1,038	\$ (1,871)	\$ (2,484,743)
Three Months Ended September 30, 2023					
	Available for Sale Assets	Future Policy Benefits	Foreign Exchange	Pension Adjustments	Total
Balance at July 1, 2023	\$ (1,249,399)	\$ (1,696,801)	\$ 1,353	\$ 950	\$ (2,943,897)
Other comprehensive income (loss) before reclassifications, net of tax	(842,527)	1,332,976	(6,226)	—	484,223
Reclassifications, net of tax	672	—	—	28	700
Other comprehensive income (loss)	(841,855)	1,332,976	(6,226)	28	484,923
Balance at September 30, 2023	\$ (2,091,254)	\$ (363,825)	\$ (4,873)	\$ 978	\$ (2,458,974)
Nine Months Ended September 30, 2024					
	Available for Sale Assets	Future Policy Benefits	Foreign Exchange	Pension Adjustments	Total
Balance at January 1, 2024	\$ (827,596)	\$ (1,947,391)	\$ 4,719	\$ (2,151)	\$ (2,772,419)
Other comprehensive income (loss) before reclassifications, net of tax	238,785	50,254	(3,681)	—	285,358
Reclassifications, net of tax	2,038	—	—	280	2,318
Other comprehensive income (loss)	240,823	50,254	(3,681)	280	287,676
Balance at September 30, 2024	\$ (586,773)	\$ (1,897,137)	\$ 1,038	\$ (1,871)	\$ (2,484,743)
Nine Months Ended September 30, 2023					
	Available for Sale Assets	Future Policy Benefits	Foreign Exchange	Pension Adjustments	Total
Balance at January 1, 2023	\$ (1,420,672)	\$ (1,369,204)	\$ (1,681)	\$ 1,244	\$ (2,790,313)
Other comprehensive income (loss) before reclassifications, net of tax	(736,046)	1,005,379	(3,192)	—	266,141
Reclassifications, net of tax	65,464	—	—	(266)	65,198
Other comprehensive income (loss)	(670,582)	1,005,379	(3,192)	(266)	331,339
Balance at September 30, 2023	\$ (2,091,254)	\$ (363,825)	\$ (4,873)	\$ 978	\$ (2,458,974)

Reclassification Adjustments: Reclassification adjustments out of Accumulated Other Comprehensive Income are presented below for the three and nine month periods ended September 30, 2024 and 2023.

Component Line Item	Three Months Ended September 30,		Nine Months Ended September 30,		Affected line items in the Statements of Operations
	2024	2023	2024	2023	
Unrealized investment (gains) losses on available for sale assets:					
Realized (gains) losses	\$ (257)	\$ 1,759	\$ 9,732	\$ 85,230	Realized (gains) losses
Amortization of (discount) premium	(2,151)	(908)	(7,152)	(2,364)	Net investment income
Total before tax	(2,408)	851	2,580	82,866	
Tax	505	(179)	(542)	(17,402)	Income taxes
Total after-tax	(1,903)	672	2,038	65,464	
Pension adjustments:					
Amortization of prior service cost	265	269	803	807	Other operating expense
Amortization of actuarial (gain) loss	(147)	(234)	(449)	(1,143)	Other operating expense
Total before tax	118	35	354	(336)	
Tax	(25)	(7)	(74)	70	Income taxes
Total after-tax	93	28	280	(266)	
Total reclassification (after-tax)	\$ (1,810)	\$ 700	\$ 2,318	\$ 65,198	

[XML 31-R13.htm IDEA: XBRL DOCUMENT](#)

Investments

Investments, Debt and Equity Securities

[Abstract] Investments

Note 4—Investments

Portfolio Composition: Summaries of fixed maturities available for sale by amortized cost, fair value, and allowance for credit losses at September 30, 2024 and December 31, 2023, and the corresponding amounts of gross unrealized gains and losses recognized in accumulated other comprehensive income (loss) are as follows. Redeemable preferred stock is included within "Corporates, by sector."

	At September 30, 2024					
	Amortized Cost	Allowance for Credit Losses	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value ⁽¹⁾	% of Total Fixed Maturities ⁽²⁾
Fixed maturities available for sale:						
U.S. Government direct, guaranteed, and government-sponsored enterprises	\$ 397,969	\$ —	\$ 38	\$ (21,026)	\$ 376,981	2
States, municipalities, and political subdivisions	3,253,819	—	49,409	(424,989)	2,878,239	16
Foreign governments	41,794	—	17	(9,885)	31,926	—
Corporates, by sector:						
Industrials	8,115,835	(7,132)	258,165	(508,089)	7,858,779	43
Financial	5,014,169	—	171,762	(299,903)	4,886,028	26
Utilities	2,140,610	—	109,998	(72,371)	2,178,237	12
Total corporates	15,270,614	(7,132)	539,925	(880,363)	14,923,044	81
Collateralized debt obligations	36,685	—	5,798	—	42,483	—
Other asset-backed securities	83,573	—	1	(1,677)	81,897	1
Total fixed maturities	\$ 19,084,454	\$ (7,132)	\$ 595,188	\$ (1,337,940)	\$ 18,334,570	100

(1) Amount reported in the balance sheet.
(2) At fair value.

	At December 31, 2023					
	Amortized Cost	Allowance for Credit Losses	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value ⁽¹⁾	% of Total Fixed Maturities ⁽²⁾
Fixed maturities available for sale:						
U.S. Government direct, guaranteed, and government-sponsored enterprises	\$ 398,450	\$ —	\$ 7	\$ (32,306)	\$ 366,151	2
States, municipalities, and political subdivisions	3,296,305	—	47,346	(403,329)	2,940,322	16
Foreign governments	44,453	—	1	(10,348)	34,106	—
Corporates, by sector:						
Industrials	8,016,126	(7,115)	213,078	(566,847)	7,655,242	43
Financial	5,028,151	—	112,368	(388,340)	4,752,179	27
Utilities	2,017,967	—	73,925	(94,130)	1,997,762	11
Total corporates	15,062,244	(7,115)	399,371	(1,049,317)	14,405,183	81
Collateralized debt obligations	37,110	—	5,036	—	42,146	—
Other asset-backed securities	86,352	—	3	(4,057)	82,298	1
Total fixed maturities	\$ 18,924,914	\$ (7,115)	\$ 451,764	\$ (1,499,357)	\$ 17,870,206	100

(1) Amount reported in the balance sheet.
(2) At fair value.

The Company has exposure to real estate investment trusts with an average rating of BBB+, which had a fair value of \$429 million (2% of the total fixed maturity portfolio) and \$425 million (2% of the total fixed maturity portfolio) at September 30, 2024 and December 31, 2023, respectively.

A schedule of fixed maturities available for sale by contractual maturity date at September 30, 2024, is shown below on an amortized cost basis, net of allowance for credit losses, and on a fair value basis. Actual disposition dates could differ from contractual maturities due to call or prepayment provisions.

	At September 30, 2024	
	Amortized Cost, net	Fair Value
Fixed maturities available for sale:		
Due in one year or less	\$ 111,956	\$ 111,456
Due after one year through five years	748,300	771,458
Due after five years through ten years	1,841,477	1,912,103
Due after ten years through twenty years	8,954,048	8,827,993
Due after twenty years	7,301,254	6,587,150
Mortgage-backed and asset-backed securities	120,287	124,410
	\$ 19,077,322	\$ 18,334,570

Analysis of Investment Operations: "Net investment income" for the three and nine month periods ended September 30, 2024 and 2023 is summarized as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,			
	2024	2023	% Change		2024	2023	% Change	
Fixed maturities available for sale	\$ 245,313	\$ 237,609	3	\$	738,626	\$ 704,095	5	
Policy loans	13,296	12,446	7		39,196	36,435	8	
Mortgage loans	7,668	5,363	43		21,337	13,919	53	
Other long-term investments ⁽¹⁾	19,992	14,630	37		58,608	38,753	51	
Short-term investments	3,083	1,396			8,396	4,811		
	289,352	271,444	7		866,163	798,013	9	
Less investment expense	(4,388)	(4,518)	(3)		(12,985)	(12,738)	2	
Net investment income	\$ 284,964	\$ 266,926	7	\$	853,178	\$ 785,275		

(1) For the three months ended September 30, 2024 and 2023, the investment funds, accounted for under the fair value option method, recorded \$19.1 million and \$14.0 million, respectively, in net investment income. For the nine months ended September 30, 2024 and 2023, the investment funds, accounted for under the fair value option method, recorded \$56.1 million and \$37.2 million, respectively, in net investment income. Refer to [Other Long-Term Investments](#) below for further discussion on the investment funds.

Selected information about sales of fixed maturities available for sale is as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Fixed maturities available for sale:				
Proceeds from sales ⁽¹⁾	\$ 163,221	\$ 46,210	\$ 674,125	\$ 192,034
Gross realized gains	2,042	261	6,086	308
Gross realized losses	(1,856)	(67,018)	(15,824)	(77,879)

(1) As of September 30, 2024 and 2023, the Company had \$0 and \$27 thousand of unsettled trades, respectively. An analysis of "Realized gains (losses)" is as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Realized investment gains (losses):				
Fixed maturities available for sale:				
Sales and other ⁽¹⁾	\$ 257	\$ (66,767)	\$ (9,716)	\$ (77,730)
Provision for credit losses	—	65,008	(16)	(7,500)
Fair value option—change in fair value	(3,683)	868	(22,777)	7,954
Mortgage loans	(1,376)	(59)	(3,530)	(4,918)
Other investments	(16)	880	1,135	502
Realized gains (losses) from investments	(4,818)	(70)	(34,904)	(81,692)
Other gains (losses)	2,626	(2,123)	8,324	2,729
Total realized gains (losses)	(2,192)	(2,193)	(26,580)	(78,963)
Applicable tax	460	461	5,582	16,583
Realized gains (losses), net of tax	\$ (1,732)	\$ (1,732)	\$ (20,998)	\$ (62,380)

(1) During the three months ended September 30, 2024 and 2023, the Company recorded \$3.4 million and \$21.1 million of issuer-initiated exchanges of fixed maturities (noncash transactions) that resulted in no realized gains (losses) in either period. During the nine months ended September 30, 2024 and 2023, the Company recorded \$82.2 million and \$39.0 million of issuer-initiated exchanges of fixed maturities (noncash transactions) that resulted in no realized gains (losses) in either period.

Fair Value Measurements: The following tables represent the fair value of fixed maturities measured on a recurring basis at September 30, 2024 and December 31, 2023:

Fair Value Measurement at September 30, 2024:					
	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Total Fair Value	
Fixed maturities available for sale					
U.S. Government direct, guaranteed, and government-sponsored enterprises	\$ —	\$ 376,981	\$ —	\$	376,981
States, municipalities, and political subdivisions	—	2,878,239	—		2,878,239
Foreign governments	—	31,926	—		31,926
Corporates, by sector:					
Industrials	—	7,659,257	199,522		7,858,779
Financial	—	4,754,596	131,432		4,886,028
Utilities	—	2,063,380	114,857		2,178,237
Total corporates	—	14,477,233	445,811		14,923,044
Collateralized debt obligations	—	74,021	42,483		116,504
Other asset-backed securities	—	—	7,876		7,876
Total fixed maturities	\$ —	\$ 17,838,400	\$ 496,170	\$	18,334,570
Percentage of total	— %	97 %	3 %		100 %

Fair Value Measurement at December 31, 2023:					
	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Total Fair Value	
Fixed maturities available for sale					
U.S. Government direct, guaranteed, and government-sponsored enterprises	\$ —	\$ 366,151	\$ —	\$	366,151
States, municipalities, and political subdivisions	—	2,940,322	—		2,940,322
Foreign governments	—	34,106	—		34,106
Corporates, by sector:					
Industrials	—	7,440,493	214,749		7,655,242
Financial	—	4,621,160	131,019		4,752,179
Utilities	—	1,888,797	108,965		1,997,762
Total corporates	—	13,950,450	454,733		14,405,183
Collateralized debt obligations	—	82,298	42,146		124,444
Other asset-backed securities	—	—	—		—
Total fixed maturities	\$ —	\$ 17,373,327	\$ 496,879	\$	17,870,206
Percentage of total	— %	97 %	3 %		100 %

The following tables represent changes in fixed maturities measured at fair value on a recurring basis using significant unobservable inputs (Level 3):

Analysis of Changes in Fair Value Measurements Using Significant Unobservable Inputs (Level 3)					
	Asset-backed Securities	Collateralized Debt Obligations	Corporates	Total	
Balance at January 1, 2024	\$ —	\$ 42,146	\$ 454,733	\$	496,879
Included in realized gains / losses	—	—	—		—
Included in other comprehensive income	—	762	5,448		6,210
Acquisitions	7,876	—	14,800		22,676
Sales	—	—	—		—
Amortization	—	3,414	(38)		3,376
Other ⁽¹⁾	—	(3,839)	(29,132)		(32,971)
Transfers into Level 3 ⁽²⁾	—	—	—		—
Transfers out of Level 3 ⁽²⁾	—	—	—		—
Balance at September 30, 2024	\$ 7,876	\$ 42,483	\$ 445,811	\$	496,170
Percent of total fixed maturities	— %	— %	3 %		3 %

(1) Includes capitalized interest, foreign exchange adjustments, and principal repayments.

(2) Considered to be transferred at the end of the period. Transfers into Level 3 occur when observable inputs are no longer available. Transfers out of Level 3 occur when observable inputs become available.

Analysis of Changes in Fair Value Measurements Using Significant Unobservable Inputs (Level 3)					
	Asset-backed Securities	Collateralized Debt Obligations	Corporates	Total	
Balance at January 1, 2023	\$ —	\$ 50,364	\$ 478,083	\$	528,447
Included in realized gains / losses	—	—	—		—
Included in other comprehensive income	—	(8,424)	(15,968)		(24,392)
Acquisitions	—	—	—		—
Sales	—	—	—		—
Amortization	—	3,429	5		3,434
Other ⁽¹⁾	—	(3,684)	(26,669)		(30,353)
Transfers into Level 3 ⁽²⁾	—	—	—		—
Transfers out of Level 3 ⁽²⁾	—	—	—		—
Balance at September 30, 2023	\$ —	\$ 41,685	\$ 435,451	\$	477,136
Percent of total fixed maturities	— %	— %	3 %		3 %

(1) Includes capitalized interest, foreign exchange adjustments, and principal repayments.

(2) Considered to be transferred at the end of the period. Transfers into Level 3 occur when observable inputs are no longer available. Transfers out of Level 3 occur when observable inputs become available.

The following table presents changes in unrealized gains and losses for the period included in accumulated other comprehensive income for assets held at the end of the reporting period for Level 3 classification:

Changes in Unrealized Gains (Losses) included in Accumulated Other Comprehensive Income for Assets Held at the End of the Period					
	Asset-backed Securities	Collateralized Debt Obligations	Corporates	Total	
At September 30, 2024	\$ —	\$ 762	\$ 5,448	\$	6,210
At September 30, 2023	—	(8,424)	(15,968)		(24,392)

Unrealized Loss Analysis: The following table discloses information about fixed maturities available for sale in an unrealized loss position.

	Less than Twelve Months	Twelve Months or Longer	Total
Number of issues (CUSIPs) held:			
As of September 30, 2024	87	1,553	1,640
As of December 31, 2023	151	1,614	1,765

Globe Life's entire fixed maturity portfolio consisted of 2,532 issues by 975 different issuers at September 30, 2024 and 2,473 issues by 980 different issuers at December 31, 2023. The weighted-average quality rating of all unrealized loss positions at amortized cost was A- as of September 30, 2024 and December 31, 2023.

The following tables disclose unrealized investment losses by class and major sector of fixed maturities available for sale at September 30, 2024 and December 31, 2023.

Analysis of Gross Unrealized Investment Losses					
At September 30, 2024					
	Less than Twelve Months		Twelve Months or Longer		Total
	Fair Value	Unrealized Loss	Fair Value	Unrealized Loss	Unrealized Loss
Fixed maturities available for sale:					
Investment grade securities:					
U.S. Government direct, guaranteed, and government-sponsored enterprises	\$ —	\$ —	\$ 374,361	\$ (21,026)	\$ 374,361
States, municipalities, and political subdivisions	201,640	(4,821)	1,636,467	(420,168)	1,838,107
Foreign governments	—	—	28,493	(9,885)	28,493
Corporates, by sector:					
Industrials	124,717	(11,134)	4,071,839	(464,628)	4,196,556
Financial	19,176	(303)	2,005,383	(261,465)	2,024,559
Utilities	7,012	(92)	667,192	(71,489)	674,204
Total corporates	150,905	(11,529)	6,744,414	(797,582)	6,895,319
Collateralized debt obligations	—	—	—	—	—
Other asset-backed securities	—	—	68,549	(1,607)	68,549
Total investment grade securities	352,545	(16,350)	8,852,284	(1,250,268)	9,204,829
Below investment grade securities:					
Corporates, by sector:					
Industrials	2,670	(169)	143,088	(32,158)	145,758
Financial	4,199	(13)	178,887	(38,122)	183,086
Utilities	—	—	11,945	(790)	11,945
Total corporates	6,869	(182)	333,920	(71,070)	340,789
Collateralized debt obligations	—	—	—	—	—
Other asset-backed securities	—	—	5,432	(70)	5,432
Total below investment grade securities	6,869	(182)	339,352	(71,140)	346,221
Total fixed maturities	\$ 359,414	\$ (16,532)	\$ 9,191,636	\$ (1,321,408)	\$ 9,551,050

Gross unrealized losses may fluctuate quarter over quarter due to factors in the market that affect our holdings, such as changes in interest rates or credit spreads. The Company considers many factors when determining whether an allowance for a credit loss should be recorded. While the Company holds securities that may be in an unrealized loss position from time to time, Globe Life does not generally intend to sell and it is unlikely that the Company will be required to sell the fixed maturities prior to their anticipated recovery or maturity due to the strong cash flows generated by its insurance operations.

Analysis of Gross Unrealized Investment Losses

At December 31, 2023						
	Less than Twelve Months		Twelve Months or Longer		Total	
	Fair Value	Unrealized Loss	Fair Value	Unrealized Loss	Fair Value	Unrealized Loss
Fixed maturities available for sale:						
Investment grade securities:						
U.S. Government direct, guaranteed, and government-sponsored enterprises	\$ —	\$ —	\$ 364,006	\$ (32,306)	\$ 364,006	\$ (32,306)
States, municipalities, and political subdivisions	252,800	(3,520)	1,610,163	(399,809)	1,862,963	(403,329)
Foreign governments	—	—	32,591	(10,348)	32,591	(10,348)
Corporates, by sector:						
Industrials	191,573	(3,881)	4,317,827	(530,011)	4,509,400	(533,892)
Financial	242,099	(6,584)	2,341,424	(339,628)	2,583,523	(346,212)
Utilities	81,194	(648)	686,043	(91,959)	767,237	(92,607)
Total corporates	514,866	(11,113)	7,345,294	(961,598)	7,860,160	(972,711)
Collateralized debt obligations	—	—	—	—	—	—
Other asset-backed securities	—	—	70,956	(3,648)	70,956	(3,648)
Total investment grade securities	767,666	(14,633)	9,423,010	(1,407,709)	10,190,676	(1,422,342)
Below investment grade securities:						
Corporates, by sector:						
Industrials	10,745	(199)	145,697	(32,756)	156,442	(32,955)
Financial	25,563	(2,602)	151,190	(39,526)	176,753	(42,128)
Utilities	—	—	19,654	(1,523)	19,654	(1,523)
Total corporates	36,308	(2,801)	316,541	(73,805)	352,849	(76,606)
Collateralized debt obligations	—	—	—	—	—	—
Other asset-backed securities	—	—	11,288	(409)	11,288	(409)
Total below investment grade securities	36,308	(2,801)	327,829	(74,214)	364,137	(77,015)
Total fixed maturities	\$ 803,974	\$ (17,434)	\$ 9,750,839	\$ (1,481,923)	\$ 10,554,813	\$ (1,499,357)

Fixed Maturities, Allowance for Credit Losses: A summary of the activity in the allowance for credit losses is as follows.

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Allowance for credit losses beginning balance	\$ 7,132	\$ 72,508	\$ 7,115	\$ —
Additions to allowance for which credit losses were not previously recorded	—	—	—	72,508
Additions (reductions) to allowance for fixed maturities that previously had an allowance	—	(65,008)	17	(65,008)
Reduction of allowance for which the Company intends to sell or more likely than not will be required to sell or sold during the period	—	—	—	—
Allowance for credit losses ending balance	\$ 7,132	\$ 7,500	\$ 7,132	\$ 7,500

As of September 30, 2024 and December 31, 2023, the Company did not have any fixed maturities in non-accrual status.

Mortgage Loans (commercial mortgage loans): Summaries of commercial mortgage loans by property type and geographical location at September 30, 2024 and December 31, 2023 are as follows:

	September 30, 2024		December 31, 2023	
	Carrying Value	% of Total	Carrying Value	% of Total
Property type:				
Multi-family	\$ 127,155	33	\$ 116,299	42
Industrial	102,402	27	57,267	20
Retail	73,252	19	23,925	9
Hospitality	43,435	11	43,897	16
Mixed use	35,886	10	34,749	12
Office	6,387	2	6,734	2
Total recorded investment	388,517	102	282,871	101
Less allowance for credit losses	(7,202)	(2)	(3,672)	(1)
Carrying value, net of allowance for credit losses	\$ 381,315	100	\$ 279,199	100

	September 30, 2024		December 31, 2023	
	Carrying Value	% of Total	Carrying Value	% of Total
Geographic location:				
Texas	\$ 75,002	20	\$ 45,111	16
New Jersey	51,454	14	44,574	16
Florida	46,506	12	48,233	17
California	40,715	11	54,721	20
New York	35,865	9	20,284	7
Alabama	35,838	9	11,003	4
Other	103,137	27	58,945	21
Total recorded investment	388,517	102	282,871	101
Less allowance for credit losses	(7,202)	(2)	(3,672)	(1)
Carrying value, net of allowance for credit losses	\$ 381,315	100	\$ 279,199	100

The following tables are reflective of the key factors, debt service coverage ratios, and loan-to-value (LTV) ratios that are utilized by management to monitor the performance of the portfolios. The Company only makes new investments in commercial mortgage loans that have a LTV ratio less than 80%. LTV's that exceed 80% are generally as a result of decreases in the valuation of the underlying property. Generally, a higher LTV ratio and a lower debt service coverage ratio equates to higher risk of loss.

	September 30, 2024				
	Recorded Investment				
	Debt Service Coverage Ratios ⁽¹⁾			Total	% of Gross Total
	<1.00x	1.00x—1.20x	>1.20x		
Loan-to-value ratio⁽²⁾:					
Less than 70%	\$ 22,841	\$ 138,034	\$ 203,226	\$ 364,101	94
70% to 80%	1,058	—	—	1,058	—
81% to 90%	8,569	—	—	8,569	2
Greater than 90%	14,789	—	—	14,789	4
Total	\$ 47,257	\$ 138,034	\$ 203,226	\$ 388,517	100
Less allowance for credit losses				(7,202)	
Total, net of allowance for credit losses				\$ 381,315	

(1) Annual net operating income divided by annual mortgage debt service (principal and interest).

(2) Loan balance divided by stabilized appraised value at origination, including planned renovations and stabilized occupancy. Updated internal valuations are used when a loan is materially underperforming.

	December 31, 2023				
	Recorded Investment				
	Debt Service Coverage Ratios ⁽¹⁾			Total	% of Gross Total
	<1.00x	1.00x—1.20x	>1.20x		
Loan-to-value ratio⁽²⁾:					
Less than 70%	\$ 27,091	\$ 180,761	\$ 58,364	\$ 266,216	94
70% to 80%	—	—	—	—	—
81% to 90%	8,468	—	1,153	9,621	3
Greater than 90%	7,034	—	—	7,034	3
Total	\$ 42,593	\$ 180,761	\$ 59,517	\$ 282,871	100
Less allowance for credit losses				(3,672)	
Total, net of allowance for credit losses				\$ 279,199	

(1) Annual net operating income divided by annual mortgage debt service (principal and interest).

(2) Loan balance divided by stabilized appraised value at origination, including planned renovations and stabilized occupancy. Updated internal valuations are used when a loan is materially underperforming.

As of September 30, 2024, the Company evaluated the commercial mortgage loan portfolio on a pool basis to determine the allowance for credit losses. At the end of the period, the Company had 36 loans in the portfolio. For the nine months ended September 30, 2024, the allowance for credit losses increased by \$3.5 million to \$7.2 million. The provision for credit losses is included in "Realized gains (losses)" in the *Condensed Consolidated Statements of Operations*.

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Allowance for credit losses beginning balance	\$ 5,826	\$ 2,928	\$ 3,672	\$ 1,789
Provision (reversal) for credit losses	1,376	60	3,530	1,199
Allowance for credit losses ending balance	\$ 7,202	\$ 2,988	\$ 7,202	\$ 2,988

There was one delinquent commercial mortgage loan, with an outstanding par value of \$36.0 million and outstanding interest due of \$1.9 million, as of September 30, 2024. The underlying collateral for this loan is in the process of being sold and the Company expects to recover all interest and principal due as of September 30, 2024. There were no delinquent commercial mortgage loans as of December 31, 2023. As of September 30, 2024, the Company had three commercial mortgage loans in non-accrual status with a principal balance of \$8.8 million. As of December 31, 2023, the Company had no commercial mortgage loans in non-accrual status. The Company's unfunded commitment balance to commercial loan borrowers was \$31 million as of September 30, 2024.

Other Long-Term Investments: Other long-term investments consist of the following assets:

	September 30, 2024	December 31, 2023
Investment funds	\$ 979,397	\$ 795,583
Company-owned life insurance	200,114	—
Other	42,377	40,295
Total	\$ 1,221,888	\$ 835,878

During the current quarter ended September 30, 2024, the Company acquired other investments in company-owned life insurance (COLI) in the amount of \$200 million. COLI is reported at cash surrender value.

The following table presents additional information about the Company's investment funds as of September 30, 2024 and December 31, 2023 at fair value:

Investment Category	Fair Value		Unfunded Commitments		Redemption Term/Notice ⁽¹⁾
	September 30, 2024	December 31, 2023	September 30, 2024	December 31, 2023	
Commercial mortgage loans	\$ 567,425	\$ 411,315	\$ 378,892	\$ 166,514	Fully redeemable and non-redeemable with varying terms.
Opportunistic and private credit	195,957	181,410	166,514	166,514	Fully redeemable and non-redeemable with varying terms.
Infrastructure	174,971	165,887	16,318	50,757	Fully redeemable and non-redeemable with varying terms.
Other	41,044	36,971	50,757	50,757	Non-redeemable with varying terms
Total investment funds	\$ 979,397	\$ 795,583	\$ 612,481	\$ 374,542	

(1) Non-redeemable funds generally have an expected life of 7 to 12 years from fund closing with extension options of 1 to 4 years. Redemptions are paid out throughout the life of the funds at the General Partner's discretion. Redeemable funds can generally be redeemed over 6 to 36 months upon request from limited partners.

The Company had \$226 million of capital called during the period from existing investment funds. The Company's unfunded commitments were \$612 million as of September 30, 2024.

[XML 32 R14.htm IDEA: XBRL DOCUMENT](#)

Commitments and Contingencies

[Commitments and Contingencies Disclosure \[Abstract\]](#)

[Commitments and Contingencies](#)

Note 5—Commitments and Contingencies

Guarantees: The Parent Company has guaranteed letters of credit in connection with its credit facility with a group of banks. The letters of credit were issued by TMK Re, Ltd., a wholly-owned subsidiary, to secure TMK Re, Ltd.'s obligation for claims on certain policies reinsured by TMK Re, Ltd. that were sold by other Globe Life insurance subsidiaries. These letters of credit facilitate TMK Re, Ltd.'s ability to reinsure the business of Globe Life's insurance carriers. The credit facility was amended on March 29, 2024 and now expires in 2029. The maximum amount of letters of credit available is \$250 million. The Parent Company would be liable to the extent that TMK Re, Ltd. does not pay the reinsured party. The amount of letters of credit outstanding at September 30, 2024 was \$115 million.

Litigation: Globe Life Inc. and its subsidiaries, in common with the insurance industry in general, are subject to litigation, including: putative class action litigation; alleged breaches of contract; torts, including bad faith and fraud claims based on alleged wrongful or fraudulent acts of agents of the Parent Company's insurance subsidiaries; alleged employment discrimination; alleged worker misclassification; and miscellaneous other causes of action. Based upon information presently available, and in light of legal and other factual defenses available to the Parent Company and its subsidiaries, management does not believe that it is reasonably possible that such litigation will have a material adverse effect on Globe Life's financial condition, future operating results or liquidity; however, assessing the eventual outcome of litigation necessarily involves forward-looking speculation as to judgments to be made by judges, juries and appellate courts in the future. This bespeaks caution, particularly in states with reputations for high punitive damage verdicts.

On July 22, 2022, putative class and collective action litigation was filed against Arias Agencies and American Income Life Insurance Company ("American Income") (collectively, "Defendants") in United States District Court for the Western District of Pennsylvania (*David Burkes v. Arias Agencies and American Income Life Insurance Company*, Case No. 2:22-cv-1054). The complaint alleges that insurance agent trainees should have been classified as employees, and after contracting should have been classified as employees instead of independent contractors. Plaintiff David Burkes is a former Pennsylvania independent sales agent and asserts claims under Pennsylvania law on behalf of a putative class of all individuals who trained to become and/or worked as sales agents for American Income in the three years prior to July 22, 2022 through case conclusion. Burkes makes claims (a) under the Pennsylvania Minimum Wage Act and the Pennsylvania Wage Payment and Collection Law for the alleged failure to pay minimum wage, alleged failure to pay for time spent in training, alleged failure to pay for missed meals and rest breaks, allegedly requiring putative class members to pay for work-related expenses, and allegedly subjecting putative class members to "chargebacks"; (b) for unjust enrichment for allegedly benefiting from the uncompensated labor of putative class members; and (c) for the rescission of putative class members' agent contracts. Burkes also asserts a collective action on behalf of the same group of individuals for minimum wage, overtime, liquidated damages, and attorney's fees and costs under the Fair Labor Standards Act for the three years prior to July 22, 2022 through case conclusion, as well as a claim that American Income allegedly did not keep accurate records of hours worked by sales agents. On January 26, 2023, the court entered an order compelling Burkes to arbitrate his claims on an individual basis and staying the case pending completion of arbitration. Burkes' individual claims, as well as the individual claims of other current and former agents who are members of the putative class, are currently pending in arbitration.

On April 4, 2023, putative class action litigation was filed against National Income Life Insurance Company ("National Income") in New York Supreme Court by plaintiffs Melissa K. Goppert, Sarah Valente, James O'Neill, Jennifer Abe, and Emily Herendeen ("Plaintiffs") (*Goppert, et al. v. National Income Life Insurance Company*, Index No. 153096/2023). Plaintiffs are former National Income independent sales agents who allege they should have been classified as employees and assert claims under New York state law on behalf of a putative class of former independent sales agents and individuals who trained to become independent sales agents since March 2017. Plaintiffs make claims under New York's Minimum Wage Law (NYLL § 633 and 12 NYCRR § 142-2.1); Overtime Compensation Law (NYLL § 633 and 12 NYCRR § 142-2.2); and "Spread of Hours" Law (12 NYCRR § 142-2.4) for the alleged failure to pay minimum wages and overtime pay, including for time spent in training, and attorney's fees and costs. National Income filed a motion to compel arbitration of each Plaintiff's claims on an individual basis, which the Court granted in full on January 11, 2024, and on February 7, 2024, Plaintiffs filed a notice of appeal of the Court's order.

On September 1, 2023, plaintiff Miné Caglar Cost ("Plaintiff") filed a complaint against American Income Life Insurance Company ("American Income") in the Superior Court of the State of California for the County of Los Angeles, asserting a single claim for violation of the Private Attorneys General Act ("PAGA") (*Cost v. American Income Life Insurance Company, et al.*, Case No. 23SMCV04113). Plaintiff is a former California independent insurance sales agent who alleges one cause of action for civil penalties under PAGA arising out of alleged violations of the wage-and-hour provisions of the California Labor Code stemming from American Income's alleged misclassification of Plaintiff and other California-based sales agents as independent contractors. American Income filed a motion to compel arbitration on an individual basis and stay the representative component of Plaintiff's claims, to which Plaintiff stipulated. On December 12, 2023, the Court approved the parties' stipulation to compel the matter to individual arbitration and stayed the case pending the completion of the individual arbitration.

On November 30, 2023, Globe Life Inc. and its subsidiary, American Income Life Insurance Company ("American Income"), received subpoenas from the U.S. Attorney's Office for the Western District of Pennsylvania, seeking documents relating to sales practices by certain of our independent sales agents contracted to sell American Income policies. Globe Life Inc. and American Income continue to fully cooperate in responding to the Department of Justice's requests. The Department of Justice has not asserted any claims or made allegations against Globe Life Inc. and American Income, and Globe Life Inc. currently is not aware that any legal proceedings are contemplated by governmental authorities. While no assurances can be made, at present management does not believe that it is reasonably possible or probable that this matter will result in a material loss.

In April 2024, Globe Life Inc. received an inquiry from the SEC's Fort Worth Regional Office requesting information related to recent short seller reports making allegations about Globe Life Inc. Globe Life Inc. has provided information in response to the SEC's requests and continues to cooperate fully with the SEC. At this time, the SEC has not asserted any claims against Globe Life Inc. or indicated that it intends to do so. While no assurances can be made, at present management does not believe that it is reasonably possible or probable that this matter will result in a material loss.

On April 30, 2024, a putative securities class action was filed against Globe Life Inc. and six of its current/former executives and directors in the United States District Court for the Eastern District of Texas (*City of Miami Gen. Emp. & Sanitation Emp. Ret. Trust, et al. v. Globe Life Inc., et al.*, Case No. 4:24-cv-00376). On July 24, 2024, the Court appointed Lead Plaintiffs and Lead Counsel for the putative class of shareholders. The Lead Plaintiffs filed a Consolidated Complaint on October 4, 2024 that asserts claims under §§ 10(b), 20(a), and 20(A) of the Securities Exchange Act of 1934 and SEC Rules 10b-5(a), 10b-5(b), and 10b-5(c) promulgated thereunder, on behalf of a putative class of purchasers of Globe Life Inc.'s securities from May 8, 2019 through April 10, 2024. The Consolidated Complaint adds four additional executives as defendants and alleges that certain of Globe Life Inc.'s disclosures about financial performance and certain other public statements during the putative class period were materially false or misleading. Defendants' response to the Consolidated Complaint is due December 3, 2024. Globe Life Inc. plans to vigorously defend against the lawsuit. Pursuant to Globe Life Inc.'s Restated Certificate of Incorporation and indemnification agreements with the named defendants, Globe Life Inc. has agreed to indemnify those defendants for all expenses and losses related to the litigation, subject to the terms of those indemnification agreements. The outcome of litigation of this type is inherently uncertain, and there is always the possibility that a Court rules in a manner that is adverse to the interests of Globe Life Inc. and the individual defendants. However, the amount of any such loss in that outcome cannot be reasonably estimated at this time. Further, management cannot reasonably estimate whether an outcome on the putative class action will be resolved in the near term.

On September 26, 2024, Globe Life Inc. and its subsidiary, American Income Life Insurance Company ("American Income"), were notified by the Equal Employment Opportunity Commission ("EEOC") that the EEOC conducted an investigation of charges filed against Globe Life Inc. and/or American Income by five former sales agents and one current sales agent. The EEOC asserts that there is reasonable cause to believe the six complainants were employees, not independent contractors, of Globe Life Inc. and/or American Income and were discriminated against on the basis of sex, and that one complainant was also discriminated against on the basis of race. In addition, the EEOC asserts that there is reasonable cause to believe that a class of female workers were employees, not independent contractors, and were subject to unlawful conduct which also constitutes a pattern-or-practice of discrimination. The EEOC's investigative findings are not binding on Globe Life Inc. The EEOC's procedures provide for a conciliation process that has recently concluded without achieving a resolution. The EEOC may elect to file a lawsuit in federal court on behalf of the workers based on the alleged statutory violations. The EEOC has not filed any legal proceedings at this time. In the event the EEOC elects to pursue any claims in court, Globe Life Inc. intends to defend against any such lawsuit vigorously. The outcome of litigation of this type would be inherently uncertain and cannot be reasonably estimated or determined at this time. There is always the possibility that a Court rules in a manner that is adverse to the interests of Globe Life Inc.

[XML 33 R15.htm IDEA: XBRL DOCUMENT](#)

Policy Liabilities

[Policyholder Account Balance \[Abstract\]](#)

[Policy Liabilities](#)

9 Months Ended Sep. 30, 2024

Note 6—Policy Liabilities

The liability for future policy benefits is determined based on the net level premium method, which requires the liability be calculated as the present value of estimated future policyholder benefits and the related termination expenses, less the present value of estimated future net premiums to be collected from policyholders. The following tables summarize balances and changes in the net liability for future policy benefits, before reinsurance, for traditional life long-duration contracts for the three and nine month periods ended September 30, 2024 and 2023:

	Life				
	Present value of expected future net premiums				
	American Income	DTC	Liberty National	Other	Total
Balance at January 1, 2023	\$ 4,273,156	\$ 5,910,224	\$ 1,094,407	\$ 470,741	\$ 11,748,528
Beginning balance at original discount rates	4,246,723	5,680,864	1,066,123	449,209	11,442,919
Effect of changes in assumptions on future cash flows	14,265	36,170	5,178	8,419	64,032
Effect of actual variances from expected experience	(103,922)	(219,723)	(26,533)	(13,882)	(364,060)
Adjusted balance at January 1, 2023	4,157,066	5,497,311	1,044,768	443,746	11,142,891
Issuances ⁽¹⁾	557,844	450,361	92,894	21,756	1,122,855
Interest accrual ⁽²⁾	147,968	214,988	40,362	17,071	420,389
Net premiums collected ⁽³⁾	(388,288)	(461,367)	(100,093)	(34,542)	(984,290)
Effect of changes in the foreign exchange rate	(631)	—	—	—	(631)
Ending balance at original discount rates	4,473,959	5,701,293	1,077,931	448,031	11,701,214
Effect of change from original to current discount rates	(155,254)	(31,118)	(18,702)	(1,499)	(206,573)
Balance at September 30, 2023	\$ 4,318,705	\$ 5,670,175	\$ 1,059,229	\$ 446,532	\$ 11,494,641
Balance at January 1, 2024	\$ 4,681,888	\$ 6,052,651	\$ 1,129,716	\$ 478,052	\$ 12,342,307
Beginning balance at original discount rates	4,523,329	5,664,259	1,077,831	443,949	11,709,368
Effect of changes in assumptions on future cash flows	(82,348)	(28,366)	(29,292)	(982)	(140,988)
Effect of actual variances from expected experience	(173,180)	(226,062)	(29,381)	(9,292)	(437,915)
Adjusted balance at January 1, 2024	4,267,801	5,409,831	1,019,158	433,675	11,130,465
Issuances ⁽¹⁾	616,527	398,034	90,517	18,126	1,123,204
Interest accrual ⁽²⁾	164,917	220,485	41,610	17,213	444,225
Net premiums collected ⁽³⁾	(412,717)	(455,625)	(101,687)	(33,960)	(1,003,989)
Effect of changes in the foreign exchange rate	(4,101)	—	—	—	(4,101)
Ending balance at original discount rates	4,632,427	5,572,725	1,049,598	435,054	11,689,804
Effect of change from original to current discount rates	204,567	421,888	54,498	35,513	716,466
Balance at September 30, 2024	\$ 4,836,994	\$ 5,994,613	\$ 1,104,096	\$ 470,567	\$ 12,406,270

(1) Issuances represent the present value, using the original discount rate, of the expected net premiums related to new policies issued during each respective period.
(2) The interest accrual is the interest earned on the beginning present value of the expected net premiums, as well as the interest on actual net premiums earned during the period, using the original interest rate.
(3) Net premiums collected represent the product of the current period net premium ratio and the gross premiums collected during the period on the in-force business.

	Life				
	Present value of expected future net premiums				
	American Income	DTC	Liberty National	Other	Total
Balance at July 1, 2023	\$ 4,472,847	\$ 5,988,577	\$ 1,110,017	\$ 471,279	\$ 12,042,720
Beginning balance at original discount rates	4,399,053	5,700,354	1,071,561	445,475	11,616,443
Effect of changes in assumptions on future cash flows	14,265	36,170	5,178	8,419	64,032
Effect of actual variances from expected experience	(34,571)	(91,120)	(10,938)	(7,232)	(143,861)
Adjusted balance at July 1, 2023	4,378,747	5,645,404	1,065,801	446,662	11,536,614
Issuances ⁽¹⁾	181,823	136,611	32,045	7,143	357,622
Interest accrual ⁽²⁾	51,119	72,515	13,707	5,741	143,082
Net premiums collected ⁽³⁾	(131,329)	(153,237)	(33,622)	(11,515)	(329,703)
Effect of changes in the foreign exchange rate	(6,401)	—	—	—	(6,401)
Ending balance at original discount rates	4,473,959	5,701,293	1,077,931	448,031	11,701,214
Effect of change from original to current discount rates	(155,254)	(31,118)	(18,702)	(1,499)	(206,573)
Balance at September 30, 2023	\$ 4,318,705	\$ 5,670,175	\$ 1,059,229	\$ 446,532	\$ 11,494,641
Balance at July 1, 2024	\$ 4,635,903	\$ 5,810,518	\$ 1,085,233	\$ 449,883	\$ 11,981,537
Beginning balance at original discount rates	4,648,111	5,870,288	1,080,642	437,551	11,936,592
Effect of changes in assumptions on future cash flows	(82,348)	(28,366)	(29,292)	(982)	(140,988)
Effect of actual variances from expected experience	(59,483)	(103,089)	(12,113)	(1,970)	(176,655)
Adjusted balance at July 1, 2024	4,506,280	5,538,833	1,039,237	434,599	11,518,949
Issuances ⁽¹⁾	203,828	110,993	30,298	5,969	351,088
Interest accrual ⁽²⁾	55,750	73,134	13,836	5,709	148,429
Net premiums collected ⁽³⁾	(136,552)	(150,235)	(33,773)	(11,223)	(333,783)
Effect of changes in the foreign exchange rate	—	5,121	—	—	5,121
Ending balance at original discount rates	4,632,427	5,572,725	1,049,598	435,054	11,689,804
Effect of change from original to current discount rates	204,567	421,888	54,498	35,513	716,466
Balance at September 30, 2024	\$ 4,836,994	\$ 5,994,613	\$ 1,104,096	\$ 470,567	\$ 12,406,270

- (1) Issuances represent the present value, using the original discount rate, of the expected net premiums related to new policies issued during each respective period.
(2) The interest accrual is the interest earned on the beginning present value of the expected net premiums, as well as the interest on actual net premiums earned during the period, using the original interest rate.
(3) Net premiums collected represent the product of the current period net premium ratio and the gross premiums collected during the period on the in-force business.

	Life				
	Present value of expected future policy benefits				
	American Income	DTC	Liberty National	Other	Total
Balance at January 1, 2023	\$ 9,119,104	\$ 9,225,451	\$ 3,429,256	\$ 3,976,150	\$ 25,749,961
Beginning balance at original discount rates	8,409,761	8,477,892	3,272,980	3,403,704	23,564,337
Effect of changes in assumptions on future cash flows	13,344	34,407	6,156	11,661	65,568
Effect of actual variances from expected experience	(109,386)	(227,639)	(27,482)	(17,962)	(382,469)
Adjusted balance at January 1, 2023	8,313,719	8,284,660	3,251,654	3,397,403	23,247,436
Issuances ⁽¹⁾	557,844	450,362	92,894	21,756	1,122,856
Interest accrual ⁽²⁾	335,349	342,208	130,712	152,378	960,647
Benefit payments ⁽³⁾	(296,133)	(432,393)	(153,294)	(86,008)	(967,828)
Effect of changes in the foreign exchange rate	(819)	—	—	—	(819)
Ending balance at original discount rates	8,909,960	8,644,837	3,321,966	3,485,529	24,362,292
Effect of change from original to current discount rates	80,477	228,607	(46,234)	282,118	544,968
Balance at September 30, 2023	\$ 8,990,437	\$ 8,873,444	\$ 3,275,732	\$ 3,767,647	\$ 24,907,260
Balance at January 1, 2024	\$ 10,163,627	\$ 9,714,516	\$ 3,605,392	\$ 4,239,623	\$ 27,723,158
Beginning balance at original discount rates	9,061,833	8,656,752	3,338,252	3,506,859	24,563,696
Effect of changes in assumptions on future cash flows	(104,498)	(50,106)	(41,836)	(2,027)	(198,467)
Effect of actual variances from expected experience	(187,711)	(241,231)	(34,722)	(12,841)	(476,505)
Adjusted balance at January 1, 2024	8,769,624	8,365,415	3,261,694	3,491,991	23,888,724
Issuances ⁽¹⁾	611,802	398,032	90,518	18,127	1,118,479
Interest accrual ⁽²⁾	367,403	355,850	134,020	157,318	1,014,591
Benefit payments ⁽³⁾	(326,318)	(439,992)	(159,219)	(103,998)	(1,029,527)
Effect of changes in the foreign exchange rate	(8,768)	—	—	—	(8,768)
Ending balance at original discount rates	9,413,743	8,679,305	3,327,013	3,563,438	24,983,499
Effect of change from original to current discount rates	1,091,042	1,082,717	275,358	717,751	3,166,868
Balance at September 30, 2024	\$ 10,504,785	\$ 9,762,022	\$ 3,602,371	\$ 4,281,189	\$ 28,150,367

- (1) Issuances represent the present value, using the original discount rate, of the expected future policy benefits related to new policies issued during each respective period.
(2) The interest accrual is the interest earned on the beginning present value of the expected future policy benefits, as well as the interest on actual benefits and expenses paid during the period, using the original interest rate.
(3) Benefit payments represent the release of the present value, using the original discount rate, of the actual future policy benefits incurred during the period due to death, surrender, and maturity benefit payments based on the revised expected assumptions.

	Life				
	Present value of expected future policy benefits				
	American Income	DTC	Liberty National	Other	Total
Balance at July 1, 2023	\$ 9,668,207	\$ 9,487,233	\$ 3,507,845	\$ 4,109,706	\$ 26,772,991
Beginning balance at original discount rates	8,753,526	8,592,897	3,297,781	3,448,491	24,092,695
Effect of changes in assumptions on future cash flows	13,344	34,407	6,156	11,661	65,568
Effect of actual variances from expected experience	(36,998)	(97,632)	(14,364)	(9,595)	(158,589)
Adjusted balance at July 1, 2023	8,729,872	8,529,672	3,289,572	3,450,557	23,999,674
Issuances ⁽¹⁾	181,822	136,612	32,046	7,145	357,625
Interest accrual ⁽²⁾	114,683	115,547	43,991	51,241	325,470
Benefit payments ⁽³⁾	(101,161)	(136,994)	(43,644)	(23,422)	(305,221)
Effect of changes in the foreign exchange rate	(15,256)	—	—	—	(15,256)
Ending balance at original discount rates	8,909,960	8,644,837	3,321,966	3,485,529	24,362,292
Effect of change from original to current discount rates	80,477	228,607	(46,234)	282,118	544,968
Balance at September 30, 2023	\$ 8,990,437	\$ 8,873,444	\$ 3,275,732	\$ 3,767,647	\$ 24,907,260
Balance at July 1, 2024	\$ 9,811,407	\$ 9,289,834	\$ 3,424,768	\$ 3,981,898	\$ 26,507,907
Beginning balance at original discount rates	9,353,526	8,748,900	3,356,531	3,545,323	25,004,280
Effect of changes in assumptions on future cash flows	(104,498)	(50,106)	(41,836)	(2,027)	(198,467)
Effect of actual variances from expected experience	(65,766)	(111,255)	(15,385)	(2,629)	(195,035)
Adjusted balance at July 1, 2024	9,183,262	8,587,539	3,299,310	3,540,667	24,610,778
Issuances ⁽¹⁾	199,097	110,991	30,298	5,970	346,356
Interest accrual ⁽²⁾	124,308	118,873	44,743	52,747	340,671
Benefit payments ⁽³⁾	(105,757)	(138,098)	(47,338)	(35,946)	(327,139)
Effect of changes in the foreign exchange rate	12,833	—	—	—	12,833
Ending balance at original discount rates	9,413,743	8,679,305	3,327,013	3,563,438	24,983,499
Effect of change from original to current discount rates	1,091,042	1,082,717	275,358	717,751	3,166,868
Balance at September 30, 2024	\$ 10,504,785	\$ 9,762,022	\$ 3,602,371	\$ 4,281,189	\$ 28,150,367

- (1) Issuances represent the present value, using the original discount rate, of the expected future policy benefits related to new policies issued during each respective period.
(2) The interest accrual is the interest earned on the beginning present value of the expected future policy benefits, as well as the interest on actual benefits and expenses paid during the period, using the original interest rate.
(3) Benefit payments represent the release of the present value, using the original discount rate, of the actual future policy benefits incurred during the period due to death, surrender, and maturity benefit payments based on the revised expected assumptions.

	Life ⁽²⁾				
	Net liability for future policy benefits as of September 30, 2023				
	American Income	DTC	Liberty National	Other	Total
Net liability for future policy benefits at original discount rates	\$ 4,436,001	\$ 2,943,544	\$ 2,244,035	\$ 3,037,498	\$ 12,661,078
Effect of changes in discount rate assumptions	235,731	259,725	(27,532)	283,617	751,541
Other adjustments ⁽¹⁾	508	3,982	6,272	466	11,228
Net liability for future policy benefits, after other adjustments, at current discount rates	4,672,240	3,207,251	2,222,775	3,321,581	13,423,847
Reinsurance recoverable	(141)	—	(7,661)	(32,947)	(40,749)
Net liability for future policy benefits, after reinsurance recoverable, at current discount rates	\$ 4,672,099	\$ 3,207,251	\$ 2,215,114	\$ 3,288,634	\$ 13,383,098

- (1) Other adjustments include the Company's effects of capping and flooring the liability (guidance requires an amount not less than zero at the calculation level of the liability for future policy benefits).
(2) Includes the immaterial error correction noted below.

	Life				
	Net liability for future policy benefits as of September 30, 2024				
	American Income	DTC	Liberty National	Other	Total
Net liability for future policy benefits at original discount rates	\$ 4,781,316	\$ 3,106,580	\$ 2,277,415	\$ 3,128,384	\$ 13,293,695
Effect of changes in discount rate assumptions	886,475	660,829	220,860	682,238	2,450,402
Other adjustments ⁽¹⁾	150	—	—	37	187
Net liability for future policy benefits, after other adjustments, at current discount rates	5,667,941	3,767,409	2,498,275	3,810,659	15,744,284
Reinsurance recoverable	(170)	—	(7,885)	(38,506)	(46,561)
Net liability for future policy benefits, after reinsurance recoverable, at current discount rates	\$ 5,667,771	\$ 3,767,409	\$ 2,490,390	\$ 3,772,153	\$ 15,697,723

- (1) Other adjustments include the Company's effects of flooring the liability (guidance requires an amount not less than zero at the calculation level of the liability for future policy benefits).
The following tables summarize balances and changes in the net liability for future policy benefits for long-duration health contracts for the three and nine month periods ended September 30, 2024 and 2023:

	Health					
	Present value of expected future net premiums					
	United American	Family Heritage	Liberty National	American Income	DTC	Total
Balance at January 1, 2023	\$ 2,908,501	\$ 1,594,992	\$ 423,490	\$ 190,296	\$ 90,143	\$ 5,207,422
Beginning balance at original discount rates	2,941,261	1,729,219	415,442	192,631	87,751	5,366,304
Effect of changes in assumptions on future cash flows	466,883	(30,255)	(56,964)	(6,081)	16,553	390,156
Effect of actual variances from expected experience	(6,240)	(50,052)	(30,526)	(7,643)	(1,660)	(96,121)
Adjusted balance at January 1, 2023	3,401,904	1,648,912	327,952	178,927	102,638	5,660,333
Issuances ⁽¹⁾	226,363	202,561	43,373	30,667	6,532	509,496
Interest accrual ⁽²⁾	99,390	50,091	14,047	6,304	3,278	173,110
Net premiums collected ⁽³⁾	(202,669)	(134,009)	(38,322)	(16,611)	(8,028)	(399,639)
Effect of changes in the foreign exchange rate	—	—	—	(165)	—	(165)
Ending balance at original discount rates	3,524,988	1,767,555	347,050	199,122	104,420	5,943,135
Effect of change from original to current discount rates	(183,608)	(192,981)	(30,526)	(9,976)	(1,254)	(396,191)
Balance at September 30, 2023	\$ 3,341,380	\$ 1,574,574	\$ 338,678	\$ 189,146	\$ 103,166	\$ 5,546,944
Balance at January 1, 2024	\$ 3,697,771	\$ 1,711,741	\$ 358,472	\$ 206,381	\$ 115,363	\$ 6,089,728
Beginning balance at original discount rates	3,625,803	1,783,173	348,570	201,869	109,880	6,069,295
Effect of changes in assumptions on future cash flows	9,892	(8,117)	(3,463)	12,207	4,449	14,968
Effect of actual variances from expected experience	(18,894)	(43,359)	(26,123)	(11,168)	(1,818)	(101,362)
Adjusted balance at January 1, 2024	3,616,801	1,731,697	322,984	202,908	112,511	5,982,901
Issuances ⁽¹⁾	287,072	200,220	43,367	34,121	12,325	577,105
Interest accrual ⁽²⁾	128,533	55,733	12,450	7,135	4,221	208,072
Net premiums collected ⁽³⁾	(220,380)	(141,735)	(39,223)	(18,171)	(8,338)	(427,847)
Effect of changes in the foreign exchange rate	—	—	—	(377)	—	(377)
Ending balance at original discount rates	3,812,026	1,845,915	335,578	225,616	120,719	6,339,854
Effect of change from original to current discount rates	130,218	(44,372)	11,529	6,173	7,153	112,701
Balance at September 30, 2024	\$ 3,942,244	\$ 1,801,543	\$ 347,107	\$ 233,789	\$ 127,872	\$ 6,452,555

- (1) Issuances represent the present value, using the original discount rate, of the expected net premiums related to new policies issued during each respective period.
(2) The interest accrual is the interest earned on the beginning present value of the expected net premiums, as well as the interest on actual net premiums earned during the period, using the original interest rate.
(3) Net premiums collected represent the product of the current period net premium ratio and the gross premiums collected during the period on the in-force business.

	Health					
	Present value of expected future net premiums					
	United American	Family Heritage	Liberty National	American Income	DTC	Total
Balance at July 1, 2023	\$ 2,984,534	\$ 1,661,020	\$ 409,551	\$ 201,844	\$ 89,674	\$ 5,346,643
Beginning balance at original discount rates	2,985,660	1,771,206	400,180	201,709	86,840	5,445,595
Effect of changes in assumptions on future cash flows	466,883	(30,255)	(56,964)	(6,061)	16,553	390,156
Effect of actual variances from expected experience	22,683	(15,658)	(2,692)	(2,394)	229	2,168
Adjusted balance at July 1, 2023	3,475,226	1,725,293	340,524	193,254	103,622	5,837,919
Issuances ⁽¹⁾	82,647	70,216	15,183	9,880	2,317	180,243
Interest accrual ⁽²⁾	35,536	17,272	4,380	2,170	1,160	60,518
Net premiums collected ⁽³⁾	(68,421)	(45,226)	(13,037)	(5,630)	(2,679)	(134,993)
Effect of changes in the foreign exchange rate	—	—	—	(552)	—	(552)
Ending balance at original discount rates	3,524,988	1,767,555	347,050	199,122	104,420	5,943,135
Effect of change from original to current discount rates	(183,608)	(192,981)	(8,372)	(9,976)	(1,254)	(396,191)
Balance at September 30, 2023	\$ 3,341,380	\$ 1,574,574	\$ 338,678	\$ 189,146	\$ 103,166	\$ 5,546,944
Balance at July 1, 2024	\$ 3,658,491	\$ 1,690,797	\$ 337,741	\$ 205,889	\$ 114,876	\$ 6,007,794
Beginning balance at original discount rates	3,720,108	1,823,728	338,934	208,867	113,247	6,204,884
Effect of changes in assumptions on future cash flows	9,892	(8,117)	(3,463)	12,207	4,449	14,968
Effect of actual variances from expected experience	18,179	(12,068)	(4,959)	(4,110)	644	(2,314)
Adjusted balance at July 1, 2024	3,748,179	1,803,544	330,512	216,964	118,340	6,217,530
Issuances ⁽¹⁾	95,279	71,345	14,352	11,997	3,823	196,796
Interest accrual ⁽²⁾	43,903	19,016	4,104	2,493	1,460	70,976
Net premiums collected ⁽³⁾	(75,335)	(47,989)	(13,390)	(6,300)	(2,904)	(145,918)
Effect of changes in the foreign exchange rate	—	—	—	462	—	462
Ending balance at original discount rates	3,812,026	1,845,915	335,578	225,616	120,719	6,339,854
Effect of change from original to current discount rates	130,218	(44,372)	11,529	6,173	7,153	112,701
Balance at September 30, 2024	\$ 3,942,244	\$ 1,801,543	\$ 347,107	\$ 233,789	\$ 127,872	\$ 6,452,555

- (1) Issuances represent the present value, using the original discount rate, of the expected net premiums related to new policies issued during each respective period.
(2) The interest accrual is the interest earned on the beginning present value of the expected net premiums, as well as the interest on actual net premiums earned during the period, using the original interest rate.
(3) Net premiums collected represent the product of the current period net premium ratio and the gross premiums collected during the period on the in-force business.

	Health					
	Present value of expected future policy benefits					
	United American	Family Heritage	Liberty National	American Income	DTC	Total
Balance at January 1, 2023	\$ 3,046,829	\$ 3,005,664	\$ 941,574	\$ 912,750	\$ 87,532	\$ 7,394,349
Beginning balance at original discount rates	3,080,633	3,336,344	904,865	303,713	85,212	7,710,767
Effect of changes in assumptions on future cash flows	464,652	(32,428)	(60,437)	(6,407)	15,930	381,310
Effect of actual variances from expected experience	(5,530)	(53,292)	(29,581)	(8,680)	(1,925)	(99,008)
Adjusted balance at January 1, 2023	3,539,755	3,250,624	814,847	288,626	99,217	7,993,069
Issuances ⁽¹⁾	225,915	202,561	42,863	30,667	6,518	508,524
Interest accrual ⁽²⁾	104,932	99,344	34,699	11,199	3,278	253,452
Benefit payments ⁽³⁾	(221,753)	(92,973)	(73,614)	(18,633)	(9,502)	(416,475)
Effect of changes in the foreign exchange rate	—	—	—	(217)	—	(217)
Ending balance at original discount rates	3,648,849	3,459,556	818,795	311,642	99,511	8,338,353
Effect of change from original to current discount rates	(191,041)	(498,312)	(4,792)	(5,601)	(1,111)	(700,857)
Balance at September 30, 2023	\$ 3,457,808	\$ 2,961,244	\$ 814,003	\$ 306,041	\$ 98,400	\$ 7,637,496
Balance at January 1, 2024	\$ 3,814,328	\$ 3,315,880	\$ 865,808	\$ 335,504	\$ 109,482	\$ 8,441,002
Beginning balance at original discount rates	3,741,530	3,506,689	816,819	315,431	104,501	8,484,970
Effect of changes in assumptions on future cash flows	10,680	(5,054)	(2,775)	20,293	7,733	30,877
Effect of actual variances from expected experience	(15,162)	(48,407)	(26,421)	(12,611)	(1,509)	(104,110)
Adjusted balance at January 1, 2024	3,737,048	3,453,228	787,623	323,113	110,725	8,411,737
Issuances ⁽¹⁾	286,358	200,219	42,780	34,123	12,296	575,776
Interest accrual ⁽²⁾	133,143	109,479	32,202	12,145	4,220	291,189
Benefit payments ⁽³⁾	(248,769)	(103,070)	(69,649)	(19,574)	(9,655)	(450,717)
Effect of changes in the foreign exchange rate	—	—	—	(646)	—	(646)
Ending balance at original discount rates	3,907,780	3,659,856	792,956	349,161	117,586	8,827,339
Effect of change from original to current discount rates	131,531	(144,821)	52,819	24,383	6,871	70,783
Balance at September 30, 2024	\$ 4,039,311	\$ 3,515,035	\$ 845,775	\$ 373,544	\$ 124,457	\$ 8,898,122

- (1) Issuances represent the present value, using the original discount rate, of the expected future policy benefits related to new policies issued during each respective period.
(2) The interest accrual is the interest earned on the beginning present value of the expected future policy benefits, as well as the interest on actual benefits and expenses paid during the period, using the original interest rate.
(3) Benefit payments represent the release of the present value, using the original discount rate, of the actual future policy benefits incurred during the period based on the revised expected assumptions.

	Health					
	Present value of expected future policy benefits					
	United American	Family Heritage	Liberty National	American Income	DTC	Total
Balance at July 1, 2023	\$ 3,116,389	\$ 3,167,461	\$ 923,148	\$ 328,579	\$ 85,856	\$ 7,621,433
Beginning balance at original discount rates	3,116,768	3,436,167	880,879	315,087	83,188	7,832,089
Effect of changes in assumptions on future cash flows	464,652	(32,428)	(60,437)	(6,407)	15,930	381,310
Effect of actual variances from expected experience	22,410	(17,000)	(2,563)	(2,662)	(95)	90
Adjusted balance at July 1, 2023	3,603,830	3,386,739	817,879	306,018	99,023	8,213,489
Issuances ⁽¹⁾	82,511	70,215	14,963	9,880	2,310	179,879
Interest accrual ⁽²⁾	37,340	34,024	11,173	3,810	1,160	87,507
Benefit payments ⁽³⁾	(74,832)	(31,422)	(25,220)	(6,973)	(2,982)	(141,429)
Effect of changes in the foreign exchange rate	—	—	—	(1,093)	—	(1,093)
Ending balance at original discount rates	3,648,849	3,459,556	818,795	311,642	99,511	8,338,353
Effect of change from original to current discount rates	(191,041)	(498,312)	(4,792)	(5,601)	(1,111)	(700,857)
Balance at September 30, 2023	\$ 3,457,808	\$ 2,961,244	\$ 814,003	\$ 306,041	\$ 98,400	\$ 7,637,496
Balance at July 1, 2024	\$ 3,758,487	\$ 3,249,466	\$ 815,778	\$ 328,436	\$ 108,617	\$ 8,260,784
Beginning balance at original discount rates	3,823,510	3,605,315	799,316	322,706	107,143	8,657,990
Effect of changes in assumptions on future cash flows	10,680	(5,054)	(2,775)	20,293	7,733	30,877
Effect of actual variances from expected experience	21,522	(13,407)	(4,998)	(4,432)	817	(498)
Adjusted balance at July 1, 2024	3,855,712	3,586,854	791,543	338,567	115,693	8,688,369
Issuances ⁽¹⁾	95,126	71,345	14,177	11,997	3,811	196,456
Interest accrual ⁽²⁾	45,365	37,299	10,653	4,189	1,460	98,966
Benefit payments ⁽³⁾	(88,423)	(35,642)	(23,417)	(6,502)	(3,378)	(157,362)
Effect of changes in the foreign exchange rate	—	—	—	910	—	910
Ending balance at original discount rates	3,907,780	3,659,856	792,956	349,161	117,586	8,827,339
Effect of change from original to current discount rates	131,531	(144,821)	52,819	24,383	6,871	70,783
Balance at September 30, 2024	\$ 4,039,311	\$ 3,515,035	\$ 845,775	\$ 373,544	\$ 124,457	\$ 8,898,122

- (1) Issuances represent the present value, using the original discount rate, of the expected future policy benefits related to new policies issued during each respective period.
(2) The interest accrual is the interest earned on the beginning present value of the expected future policy benefits, as well as the interest on actual benefits and expenses paid during the period, using the original interest rate.
(3) Benefit payments represent the release of the present value, using the original discount rate, of the actual future policy benefits incurred during the period based on the revised expected assumptions.

	Health ⁽²⁾					
	Net liability for future policy benefits as of September 30, 2023					
	United American	Family Heritage	Liberty National	American Income	Direct to Consumer	Total
Net liability for future policy benefits at original discount rates	\$ 123,861	\$ 1,692,001	\$ 471,745	\$ 112,520	\$ (4,909)	\$ 2,395,218
Effect of changes in discount rate assumptions	(7,433)	(305,331)	3,580	4,375	143	(304,666)
Other adjustments ⁽¹⁾	7,729	4,347	8,379	993	5,530	26,978
Net liability for future policy benefits, after other adjustments, at current discount rates	124,157	1,391,017	483,704	117,888	764	2,117,530
Reinsurance recoverable	(3,355)	(9,064)	(1,336)	—	—	(13,755)
Net liability for future policy benefits, after reinsurance recoverable, at current discount rates	\$ 120,802	\$ 1,381,953	\$ 482,368	\$ 117,888	\$ 764	\$ 2,103,775

- (1) Other adjustments include the effects of capping and flooring the liability (guidance requires an amount not less than zero at the calculation level of the liability for future policy benefits).
(2) Includes the immaterial error correction noted below.

	Health					
	Net liability for future policy benefits as of September 30, 2024					
	United American	Family Heritage	Liberty National	American Income	Direct to Consumer	Total
Net liability for future policy benefits at original discount rates	\$ 95,754	\$ 1,813,941	\$ 457,378	\$ 123,545	\$ (3,133)	\$ 2,487,485
Effect of changes in discount rate assumptions	1,313	(100,449)	41,290	16,210	(282)	(41,918)
Other adjustments ⁽¹⁾	17,014	38	9,964	926	4,326	32,268
Net liability for future policy benefits, after other adjustments, at current discount rates	114,081	1,713,530	508,632	140,681	911	2,477,835
Reinsurance recoverable	(2,868)	(11,613)	(1,096)	—	—	(15,577)
Net liability for future policy benefits, after reinsurance recoverable, at current discount rates	\$ 111,213	\$ 1,701,917	\$ 507,536	\$ 140,681	\$ 911	\$ 2,462,258

- (1) Other adjustments include the effects of flooring the liability (guidance requires an amount not less than zero at the calculation level of the liability for future policy benefits).
Immaterial Correction of Previously Issued Financial Statements—The Company previously presented reinsurance recoverable on a net basis as a component of future policy benefits. In the fourth quarter of 2023, the Company corrected its presentation of reinsurance recoverable to a gross basis as a component of other assets, which resulted in the reclassification of \$55 million of reinsurance recoverable at current discount rates from liabilities to assets (\$50 million at original discount rates) as of September 30, 2023, with no change to equity, and the related tables in the footnote have been adjusted to reflect such changes.

In accordance with the accounting guidance, the Company reviews, and updates as necessary, its assumptions utilized in the calculation of the liability for future benefits annually in the third quarter and recalculates the net premium ratio. The revised net premium ratio is used to update the liability for future policy benefits as of the beginning of the current reporting period, and is compared to the liability using the prior cash flow assumptions. The difference is recorded as a component of the remeasurement gain or loss for the current period, along with the effect of the difference between actual and expected experience for the period. The total remeasurement gain or loss is included in the [Condensed Consolidated Statements of Operations](#). The following tables include the total remeasurement gain or loss, bifurcated between the gain or loss due to differences between actual and expected experience and the amount due to assumption updates, for the three and nine month periods ended September 30, 2024 and 2023:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Life Remeasurement Gain (Loss)—Experience:				
American Income	\$ 4,771	\$ 2,388	\$ 12,619	\$ 5,276
Direct to Consumer	6,913	6,293	13,640	7,594
Liberty National	1,537	2,578	2,187	2,115
Other	508	2,082	2,533	3,487
Total Life Remeasurement Gain (Loss)—Experience	13,729	13,341	30,979	18,472
Life Remeasurement Gain (Loss)—Assumption Updates:				
American Income	21,974	308	21,974	308
Direct to Consumer	21,744	1,763	21,744	1,763
Liberty National	12,224	(1,248)	12,224	(1,248)
Other	904	(2,836)	904	(2,836)
Total Life Remeasurement Gain (Loss)—Assumption Updates	56,846	(2,013)	56,846	(2,013)
Total Life Remeasurement Gain (Loss)	70,575	11,328	87,825	16,459
Health Remeasurement Gain (Loss)—Experience:				
United American	(2,100)	239	(1,423)	(651)
Family Heritage	1,420	1,212	4,972	3,009
Liberty National	874	634	2,015	(284)
American Income	729	457	1,769	1,025
Direct to Consumer	28	35	74	10
Total Health Remeasurement Gain (Loss)—Experience	951	2,577	7,407	3,109
Health Remeasurement Gain (Loss)—Assumption Updates:				
United American	1,205	762	1,205	762
Family Heritage	(3,063)	2,173	(3,063)	2,173
Liberty National	(234)	2,171	(234)	2,171
American Income	(8,036)	119	(8,036)	119
Direct to Consumer	(373)	8	(373)	8
Health Remeasurement Gain (Loss)—Assumption Updates	(10,501)	5,233	(10,501)	5,233
Total Health Remeasurement Gain (Loss)	\$ (9,550)	\$ 7,810	\$ (3,094)	\$ 8,342

The Company performs an annual review of its assumptions during the third quarter. This review process resulted in favorable changes to its mortality and lapse assumptions on life and unfavorable changes to morbidity assumptions on health. Generally, in our life segment mortality assumptions were decreased across most channels in line with recent experience consistent with decreasing levels of excess deaths. Also, for the life segment lapse rate assumptions were slightly increased across all channels. For the health segment, morbidity assumptions were increased, causing higher future policy benefit reserves. The assumption review process of the life and health segments resulted in a \$46.3 million net remeasurement gain as compared to a \$3.2 million net remeasurement gain in the year-ago quarter.

Excluding the impact of assumption changes, the Company's results for actual variances from expected experience for both life and health produced a \$14.7 million net remeasurement gain and a \$15.9 million net remeasurement gain for the three months ended September 30, 2024 and 2023, respectively. During the nine months ended September 30, 2024 and 2023, the Company's results for actual variances from expected experience for both life and health produced a \$38.4 million net remeasurement gain and a \$21.6 million net remeasurement gain, respectively.

The following table reconciles the liability for future policy benefits to the [Condensed Consolidated Balance Sheets](#) as of September 30, 2024 and 2023:

	At Original Discount Rates		At Current Discount Rates	
	As of September 30,		As of September 30,	
	2024	2023 ⁽¹⁾	2024	2023 ⁽²⁾
Life ⁽¹⁾ :				
American Income	\$ 4,781,464	\$ 4,436,042	\$ 5,667,941	\$ 4,672,240
Direct to Consumer	3,106,582	2,943,544	3,767,409	3,207,251
Liberty National	2,277,415	2,244,035	2,498,275	2,222,775
Other	3,128,419	3,037,595	3,810,659	3,321,581
Net liability for future policy benefits—long duration life	13,293,880	12,661,216	15,744,284	13,423,847
Health ⁽¹⁾ :				
United American	110,384	129,410	114,081	124,157
Family Heritage	1,813,971	1,692,080	1,713,530	1,391,017
Liberty National	466,474	479,394	508,632	483,704
American Income	124,534	113,340	140,681	117,888
Direct to Consumer	877	752	911	764
Net liability for future policy benefits—long duration health	2,516,240	2,414,976	2,477,835	2,117,530
Deferred profit liability	177,108	173,520	177,108	173,520
Deferred annuity	680,849	813,276	680,849	813,276
Interest sensitive life	725,857	735,025	725,857	735,025
Other	8,983	9,901	8,980	9,904
Total future policy benefits	\$ 17,402,917	\$ 16,807,914	\$ 19,814,913	\$ 17,273,102

(1) Balances are presented net of the effects of capping and flooring the liability (guidance requires an amount not less than zero at the calculation level of the liability for future policy benefits).

(2) Includes the immaterial error correction for reinsurance as noted above.

The following tables provide the weighted-average original and current discount rates for the liability for future policy benefits and the additional insurance liabilities as of September 30, 2024 and 2023:

	As of September 30,			
	2024		2023	
	Original discount rate	Current discount rate	Original discount rate	Current discount rate
Life				
American Income	5.7 %	5.0 %	5.7 %	5.6 %
Direct to Consumer	6.0 %	5.0 %	6.0 %	5.6 %
Liberty National	5.6 %	5.0 %	5.6 %	5.7 %
Other	6.2 %	5.0 %	6.2 %	5.7 %
Health				
United American	5.1 %	4.8 %	5.2 %	5.5 %
Family Heritage	4.2 %	4.9 %	4.3 %	5.7 %
Liberty National	5.8 %	4.8 %	5.8 %	5.7 %
American Income	5.8 %	4.8 %	5.9 %	5.6 %
Direct to Consumer	5.1 %	4.8 %	5.2 %	5.5 %

The following table provides the weighted-average durations of the liability for future policy benefits and the additional insurance liabilities as of September 30, 2024 and 2023:

	As of September 30,			
	2024		2023	
	At original discount rates	At current discount rates	At original discount rates	At current discount rates
Life				
American Income	22.81	23.03	23.08	23.29
Direct to Consumer	19.42	20.81	19.73	21.00
Liberty National	15.31	15.80	15.12	15.20
Other	16.07	17.48	16.34	17.42
Health				
United American	11.73	10.93	11.40	10.34
Family Heritage	15.34	14.60	14.90	13.81
Liberty National	9.26	9.48	9.11	8.97
American Income	12.50	12.89	12.14	12.20
Direct to Consumer	11.73	10.93	11.40	10.34

The following tables summarize the amount of gross premiums and interest related to long duration life and health contracts that are recognized in the [Condensed Consolidated Statements of Operations](#) for the three and nine month periods ended September 30, 2024 and 2023:

	Life			
	Nine Months Ended September 30, 2024		Nine Months Ended September 30, 2023	
	Gross Premiums	Interest expense	Gross Premiums	Interest expense
American Income	\$ 1,264,474	\$ 202,486	\$ 1,181,247	\$ 187,381
Direct to Consumer	734,860	135,249	735,374	127,040
Liberty National	273,746	91,890	256,641	89,765
Other	152,065	138,724	154,836	133,991
Total	\$ 2,425,145	\$ 568,349	\$ 2,328,098	\$ 538,177
	Life			
	Three Months Ended September 30, 2024		Three Months Ended September 30, 2023	
	Gross Premiums	Interest expense	Gross Premiums	Interest expense
American Income	\$ 427,543	\$ 68,558	\$ 399,794	\$ 63,565
Direct to Consumer	243,625	45,708	244,931	42,978
Liberty National	92,636	30,737	87,071	30,095
Other	50,413	46,573	51,493	45,065
Total	\$ 814,217	\$ 191,576	\$ 783,289	\$ 181,703
	Health			
	Nine Months Ended September 30, 2024		Nine Months Ended September 30, 2023	
	Gross Premiums	Interest expense	Gross Premiums	Interest expense
United American	\$ 325,415	\$ 4,449	\$ 298,964	\$ 5,345
Family Heritage	317,065	53,357	294,047	48,904
Liberty National	142,051	19,679	139,875	20,567
American Income	88,017	5,010	84,863	4,896
Direct to Consumer	11,196	—	10,680	—
Total	\$ 883,744	\$ 82,495	\$ 828,429	\$ 79,712

	Health			
	Three Months Ended September 30, 2024		Three Months Ended September 30, 2023	
	Gross Premiums	Interest expense	Gross Premiums	Interest expense
United American	\$ 110,565	\$ 1,408	\$ 100,285	\$ 1,741
Family Heritage	107,819	18,150	99,828	16,632
Liberty National	47,099	6,524	46,441	6,766
American Income	29,628	1,696	28,528	1,640
Direct to Consumer	3,806	—	3,583	—
Total	\$ 298,917	\$ 27,778	\$ 278,665	\$ 26,779

Gross premiums are included within life and health premium on the [Condensed Consolidated Statements of Operations](#), while the related interest expense is included in life and health policyholder benefits. The following tables provide the undiscounted and discounted expected future net premiums, expected future gross premiums, and expected future policy benefits, at both original and current discount rates, for life and health contracts as of September 30, 2024 and 2023:

	Life					
	As of September 30, 2024			As of September 30, 2023		
	Not discounted	At original discount rates	At current discount rates	Not discounted	At original discount rates	At current discount rates
American Income						
PV of expected future gross premiums	\$ 25,300,910	\$ 14,305,914	\$ 15,028,140	\$ 23,974,963	\$ 13,530,015	\$ 13,147,003
PV of expected future net premiums	8,185,825	4,632,427	4,836,994	7,912,903	4,473,959	4,318,705
PV of expected future policy benefits	31,554,905	9,413,743	10,504,785	30,182,319	8,909,960	8,990,437
DTC						
PV of expected future gross premiums	\$ 17,506,090	\$ 9,144,676	\$ 9,825,694	\$ 17,575,618	\$ 9,182,146	\$ 9,112,202
PV of expected future net premiums	10,614,237	5,572,725	5,994,613	10,850,664	5,701,293	5,670,175
PV of expected future policy benefits	25,907,169	8,679,305	9,762,022	25,711,499	8,644,837	8,873,444
Liberty National						
PV of expected future gross premiums	\$ 4,797,146	\$ 2,792,129	\$ 2,886,943	\$ 4,601,176	\$ 2,681,034	\$ 2,577,877
PV of expected future net premiums	1,855,536	1,049,598	1,104,096	1,901,039	1,077,931	1,059,229
PV of expected future policy benefits	9,028,196	3,327,013	3,602,371	8,852,345	3,321,966	3,275,732
Other						
PV of expected future gross premiums	\$ 3,657,885	\$ 1,857,769	\$ 2,063,274	\$ 3,753,093	\$ 1,901,531	\$ 1,953,533
PV of expected future net premiums	894,843	435,054	470,567	919,200	448,031	446,532
PV of expected future policy benefits	12,471,336	3,563,438	4,281,189	12,427,646	3,485,529	3,767,647
Total						
PV of expected future gross premiums	\$ 51,262,031	\$ 28,100,488	\$ 29,804,051	\$ 49,904,850	\$ 27,294,726	\$ 26,790,615
PV of expected future net premiums	21,550,441	11,689,804	12,406,270	21,583,806	11,701,214	11,494,641
PV of expected future policy benefits	78,961,606	24,983,499	28,150,367	77,173,809	24,362,292	24,907,260

As of September 30, 2024, for the life segment using current discount rates, the Company anticipates \$29.8 billion of expected future gross premiums and \$12.4 billion of expected future net premiums. As of September 30, 2023, using current discount rates, the Company anticipated \$26.8 billion of expected future gross premiums and \$11.5 billion in expected future net premiums. For each respective period, only expected future net premiums are included in the determination of the liability for future policy benefits on the balance sheet, while the difference between the expected future gross premiums and the expected future net premiums of \$17.4 billion and \$15.3 billion for September 30, 2024 and 2023, respectively, is not.

	Health					
	As of September 30, 2024			As of September 30, 2023		
	Not discounted	At original discount rates	At current discount rates	Not discounted	At original discount rates	At current discount rates
United American						
PV of expected future gross premiums	\$ 9,068,701	\$ 5,556,347	\$ 5,742,668	\$ 8,442,713	\$ 5,141,771	\$ 4,871,878
PV of expected future net premiums	6,229,763	3,812,026	3,942,244	5,799,017	3,524,988	3,341,380
PV of expected future policy benefits	6,390,307	3,907,780	4,039,311	5,998,770	3,648,849	3,457,808
Family Heritage						
PV of expected future gross premiums	\$ 7,107,124	\$ 4,155,037	\$ 4,074,915	\$ 6,637,472	\$ 3,932,327	\$ 3,523,258
PV of expected future net premiums	3,139,624	1,845,915	1,801,543	2,962,973	1,767,555	1,574,574
PV of expected future policy benefits	7,043,880	3,659,856	3,515,035	6,549,339	3,459,556	2,961,244
Liberty National						
PV of expected future gross premiums	\$ 2,037,319	\$ 1,297,318	\$ 1,370,521	\$ 2,084,428	\$ 1,321,438	\$ 1,308,898
PV of expected future net premiums	495,616	335,578	347,107	515,612	347,050	338,678
PV of expected future policy benefits	1,375,759	792,956	845,775	1,414,512	818,795	814,003
American Income						
PV of expected future gross premiums	\$ 1,781,677	\$ 999,161	\$ 1,063,740	\$ 1,755,682	\$ 984,122	\$ 969,090
PV of expected future net premiums	400,683	225,616	233,789	354,120	199,122	189,146
PV of expected future policy benefits	710,352	349,161	373,544	632,349	311,642	306,041
Direct to Consumer						
PV of expected future gross premiums	\$ 232,805	\$ 147,193	\$ 156,142	\$ 224,522	\$ 141,374	\$ 139,748
PV of expected future net premiums	191,566	120,719	127,872	166,099	104,420	103,166
PV of expected future policy benefits	187,260	117,586	124,457	154,931	99,511	98,400
Total						
PV of expected future gross premiums	\$ 20,227,626	\$ 12,155,056	\$ 12,407,986	\$ 19,144,817	\$ 11,521,032	\$ 10,812,872
PV of expected future net premiums	10,457,252	6,339,854	6,452,555	9,797,821	5,943,135	5,546,944
PV of expected future policy benefits	15,707,558	8,827,339	8,898,122	14,749,901	8,338,353	7,637,496

As of September 30, 2024, for the health segment using current discount rates, the Company anticipates \$12.4 billion of expected future gross premiums and \$6.5 billion of expected future net premiums. As of September 30, 2023, using current discount rates, the Company anticipated \$10.8 billion of expected future gross premiums and \$5.5 billion in expected future net premiums. For each respective period, only expected future net premiums are included in the determination of the liability for future policy benefits on the balance sheet, while the difference between the expected future gross premiums and the expected future net premiums of \$5.9 billion and \$5.3 billion for September 30, 2024 and 2023, respectively, is not.

The following table summarizes the balances of, and changes in, policyholders' account balances as of September 30, 2024 and 2023:

	Policyholders' Account Balances					
	2024			2023		
	Interest Sensitive Life	Deferred Annuity	Other Policy-holders' Funds	Interest Sensitive Life	Deferred Annuity	Other Policy-holders' Funds
Balance at January 1,	\$ 732,948	\$ 773,039	\$ 236,958	\$ 739,105	\$ 954,318	\$ 123,234
Issuances	—	495	—	—	602	—
Premiums received	16,187	8,857	239,114	17,062	10,543	100,113
Policy charges	(9,253)	—	—	(9,729)	—	—
Surrenders and withdrawals	(17,326)	(84,893)	(10,615)	(16,204)	(125,176)	(9,106)
Benefit payments	(23,357)	(34,159)	—	(22,753)	(48,459)	—
Interest credited	20,890	17,990	15,210	21,274	21,608	6,164
Other	5,768	(480)	(11,379)	6,270	(161)	(2,195)
Balance at September 30,	\$ 725,857	\$ 680,849	\$ 469,288	\$ 735,025	\$ 813,275	\$ 218,210

	Policyholders' Account Balances					
	2024			2023		
	Interest Sensitive Life	Deferred Annuity	Other Policy-holders' Funds	Interest Sensitive Life	Deferred Annuity	Other Policy-holders' Funds
Balance at July 1,	\$ 728,097	\$ 706,022	\$ 400,625	\$ 736,920	\$ 853,064	\$ 187,873
Issuances	—	137	—	—	231	—
Premiums received	5,077	2,448	70,644	5,398	2,439	31,704
Policy charges	(3,081)	—	—	(3,213)	—	—
Surrenders and withdrawals	(5,850)	(22,331)	(3,264)	(5,582)	(37,905)	(2,782)
Benefit payments	(6,617)	(10,022)	—	(7,258)	(11,047)	—
Interest credited	6,922	5,777	6,106	7,083	6,863	2,825
Other	1,309	(1,182)	(4,823)	1,677	(370)	(1,410)
Balance at September 30,	\$ 725,857	\$ 680,849	\$ 469,288	\$ 735,025	\$ 813,275	\$ 218,210

Weighted-average credit rate	3.86 %	3.37 %	5.73 %	3.91 %	3.34 %	5.68 %
Net amount at risk	\$ 1,687,182	N/A	N/A	\$ 1,793,787	N/A	N/A
Cash surrender value	\$ 678,556	\$ 680,849	\$ 469,288	\$ 673,814	\$ 813,276	\$ 218,210

The following tables present the policyholders' account balances by range of guaranteed minimum crediting rates and the related range of difference, if any, in basis points between rates being credited to policy holders and the respective guaranteed minimums as of September 30, 2024 and 2023:

Range of guaranteed minimum crediting rates	At September 30, 2024		
	Interest Sensitive Life	Deferred Annuity	Other Policyholders' Funds
At guaranteed minimum			
Less than 3.00%	\$ —	\$ 1,866	\$ 373,729
3.00%-3.99%	29,170	494,585	3,046
4.00%-4.99%	606,425	184,398	6,548
Greater than 5.00%	90,262	—	36,541
Total	725,857	680,849	419,864
1-50 basis points above			
Less than 3.00%	—	—	—
3.00%-3.99%	—	—	—
4.00%-4.99%	—	—	1,678
Greater than 5.00%	—	—	—
Total	—	—	1,678
51-150 basis points above			
Less than 3.00%	—	—	—
3.00%-3.99%	—	—	—
4.00%-4.99%	—	—	47,746
Greater than 5.00%	—	—	—
Total	—	—	47,746
Grand Total	\$ 725,857	\$ 680,849	\$ 469,288

Range of guaranteed minimum crediting rates	At September 30, 2023		
	Interest Sensitive Life	Deferred Annuity	Other Policyholders' Funds
At guaranteed minimum			
Less than 3.00%	\$ —	\$ 2,011	\$ 118,565
3.00%-3.99%	29,018	610,785	4,002
4.00%-4.99%	615,835	199,724	6,851
Greater than 5.00%	90,172	755	38,788
Total	735,025	813,275	168,206
1-50 basis points above			
Less than 3.00%	—	—	—
3.00%-3.99%	—	—	—
4.00%-4.99%	—	—	—
Greater than 5.00%	—	—	—
Total	—	—	—
51-150 basis points above			
Less than 3.00%	—	—	—
3.00%-3.99%	—	—	—
4.00%-4.99%	—	—	50,004
Greater than 5.00%	—	—	—
Total	—	—	50,004
Grand Total	\$ 735,025	\$ 813,275	\$ 218,210

[XML 34-R16.htm-IDEA: XBRL DOCUMENT](#)

Deferred Acquisition Costs	9 Months Ended Sep. 30, 2024
Insurance [Abstract]	
Deferred Acquisition Costs	
Note 7—Deferred Acquisition Costs	
The following tables roll forward the deferred policy acquisition costs for the three and nine month periods ended September 30, 2024 and 2023:	

	Life				
	American Income	DTC	Liberty National	Other	Total
Balance at January 1, 2023	\$ 2,258,291	\$ 1,676,931	\$ 610,723	\$ 298,346	\$ 4,844,291
Capitalizations	351,933	123,774	78,599	9,970	564,276
Amortization expense	(118,207)	(74,496)	(38,192)	(12,390)	(243,285)
Foreign exchange adjustment	(1,297)	—	—	—	(1,297)
Balance at September 30, 2023	\$ 2,490,720	\$ 1,726,209	\$ 651,130	\$ 295,926	\$ 5,163,985

Balance at January 1, 2024	\$ 2,573,370	\$ 1,737,117	\$ 666,419	\$ 294,869	\$ 5,271,775
Capitalizations	391,707	112,198	88,355	9,304	601,564
Amortization expense	(133,410)	(75,898)	(42,041)	(12,404)	(263,753)
Foreign exchange adjustment	(1,857)	—	—	—	(1,857)
Balance at September 30, 2024	\$ 2,829,810	\$ 1,773,417	\$ 712,733	\$ 291,769	\$ 5,607,729

	Life				
	American Income	DTC	Liberty National	Other	Total
Balance at July 1, 2023	\$ 2,417,480	\$ 1,714,715	\$ 636,209	\$ 296,861	\$ 5,065,265
Capitalizations	117,761	36,385	27,950	3,203	185,299
Amortization expense	(40,465)	(24,891)	(13,029)	(4,138)	(82,523)
Foreign exchange adjustment	(4,056)	—	—	—	(4,056)
Balance at September 30, 2023	\$ 2,490,720	\$ 1,726,209	\$ 651,130	\$ 295,926	\$ 5,163,985

Balance at July 1, 2024	\$ 2,740,138	\$ 1,765,673	\$ 696,905	\$ 292,877	\$ 5,495,593
Capitalizations	131,851	33,222	30,255	3,024	198,352
Amortization expense	(46,033)	(25,478)	(14,427)	(4,132)	(90,070)
Foreign exchange adjustment	3,854	—	—	—	3,854
Balance at September 30, 2024	\$ 2,829,810	\$ 1,773,417	\$ 712,733	\$ 291,769	\$ 5,607,729

	Health					
	United American	Family Heritage	Liberty National	American Income	DTC	Total
Balance at January 1, 2023	\$ 77,394	\$ 416,608	\$ 133,096	\$ 57,811	\$ 1,854	\$ 686,763
Capitalizations	1,491	46,977	14,854	9,579	—	72,901
Amortization expense	(4,504)	(20,071)	(9,977)	(2,919)	(137)	(37,608)
Foreign exchange adjustment	—	—	—	(125)	—	(125)
Balance at September 30, 2023	\$ 74,381	\$ 443,514	\$ 137,973	\$ 64,346	\$ 1,717	\$ 721,931

Balance at January 1, 2024	\$ 73,489	\$ 452,843	\$ 139,941	\$ 66,783	\$ 1,679	\$ 734,735
Capitalizations	2,069	52,055	18,033	11,097	2	83,256
Amortization expense	(4,197)	(22,038)	(11,003)	(3,426)	(110)	(40,774)
Foreign exchange adjustment	—	—	—	(55)	—	(55)
Balance at September 30, 2024	\$ 71,361	\$ 482,860	\$ 146,971	\$ 74,399	\$ 1,571	\$ 777,162

	Health					
	United American	Family Heritage	Liberty National	American Income	DTC	Total
Balance at July 1, 2023	\$ 75,349	\$ 433,999	\$ 136,276	\$ 62,285	\$ 1,760	\$ 709,669
Capitalizations	495	16,386	5,120	3,259	—	25,260
Amortization expense	(1,463)	(6,871)	(3,423)	(1,016)	(43)	(12,816)
Foreign exchange adjustment	—	—	—	(182)	—	(182)
Balance at September 30, 2023	\$ 74,381	\$ 443,514	\$ 137,973	\$ 64,346	\$ 1,717	\$ 721,931

Balance at July 1, 2024	\$ 71,975	\$ 472,254	\$ 145,097	\$ 71,589	\$ 1,608	\$ 762,523
Capitalizations	780	18,123	5,589	3,817	—	28,309
Amortization expense	(1,394)	(7,517)	(3,715)	(1,189)	(37)	(13,852)
Foreign exchange adjustment	—	—	—	182	—	182
Balance at September 30, 2024	\$ 71,361	\$ 482,860	\$ 146,971	\$ 74,399	\$ 1,571	\$ 777,162

The following table presents a reconciliation of deferred policy acquisition costs to the [Condensed Consolidated Balance Sheets](#) as of September 30, 2024:

	September 30,	
	2024	2023
Life		
American Income	\$ 2,829,810	\$ 2,490,720
Direct to Consumer	1,773,417	1,726,209
Liberty National	712,733	651,130
Other	291,769	295,926
Total DAC—Life	5,607,729	5,163,985
Health		
United American	71,361	74,381
Family Heritage	482,860	443,514
Liberty National	146,971	137,973
American Income	74,399	64,346
Direct to Consumer	1,571	1,717
Total DAC—Health	777,162	721,931
Annuity	1,791	3,377
Total	\$ 6,386,682	\$ 5,889,293

[XML 35-R17.htm-IDEA: XBRL DOCUMENT](#)

Liability for Unpaid Claims	9 Months Ended Sep. 30, 2024
Insurance [Abstract]	
Liability for Unpaid Claims	
Note 8—Liability for Unpaid Claims	
Activity in the liability for unpaid health claims is summarized as follows:	

	September 30, 2024	December 31, 2023
Balance at beginning of period	\$ 194,809	\$ 184,286
Less reinsurance recoverables	(2,157)	(2,084)
Net balance at beginning of period	192,652	182,202
Incurred related to:		
Current year	560,548	697,521
Prior years	(7,914)	(4,853)
Total incurred	552,634	692,668
Paid related to:		
Current year	399,412	535,971
Prior years	142,020	146,247
Total paid	541,432	682,218
Net balance at end of period	203,854	192,652
Plus reinsurance recoverables	1,623	2,157
Balance at end of period	\$ 205,477	\$ 194,809

Below is the reconciliation of the liability of "Policy claims and other benefits payable" in the [Condensed Consolidated Balance Sheets](#).

	September 30, 2024	December 31, 2023
Policy claims and other benefits payable:		
Life insurance	\$ 324,922	\$ 320,066
Health insurance	205,477	194,809
Total	<u>\$ 530,399</u>	<u>\$ 514,875</u>

[XML 36 R18.htm IDEA: XBRL DOCUMENT](#)

Postretirement Benefits

Retirement Benefits

[Abstract]

Postretirement Benefits

9 Months Ended Sep. 30, 2024

Note 9—Postretirement Benefits

Globe Life has qualified noncontributory defined benefit pension plans (Pension Plans) and contributory savings plans that cover substantially all employees. There is also a nonqualified noncontributory supplemental executive retirement plan (SERP) that covers a limited number of officers. The tables included herein will focus on the Pension Plans and SERP.

Pension Assets: The following table presents the assets of the Company's Pension Plans at September 30, 2024 and December 31, 2023.

Pension Assets by Component at September 30, 2024

	Fair Value Determined by:					Total Amount	% of Total
	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)				
Exchange traded fund ⁽⁴⁾	\$ 38,544	\$ —	\$ —	\$ 38,544	6		
Equity exchange traded fund ⁽¹⁾	318,809	—	—	318,809	49		
U.S. Government and Agency	—	204,990	—	204,990	32		
Other bonds	—	4	—	4	—		
Guaranteed annuity contract ⁽²⁾	—	43,881	—	43,881	7		
Short-term investments	5,122	—	—	5,122	1		
Other	1,858	—	—	1,858	—		
	<u>\$ 364,333</u>	<u>\$ 248,875</u>	<u>\$ —</u>	<u>613,208</u>	<u>95</u>		
Other long-term investments ⁽³⁾				30,356	5		
Total pension assets				<u>\$ 643,564</u>	<u>100</u>		

(1) A fund including marketable securities that mirror the S&P 500 index.

(2) Representing a guaranteed annuity contract issued by Globe Life Inc.'s subsidiary, American Income Life Insurance Company, to fund the obligations of the American Income Life Insurance Company Collective Bargaining Agreement Employees Pension Plan.

(3) Includes non-redeemable investment funds that report the Globe Life Inc. Pension Plan's pro-rata share of the limited partnership's net asset value (NAV) per share, or its equivalent, as a practical expedient for fair value. As of September 30, 2024, the Globe Life Inc. Pension Plan owned less than 1% of two long-term investment funds.

(4) A fund including U.S. dollar-denominated investment-grade securities issued by industrial, utility, and financial companies with maturities greater than 10 years.

Pension Assets by Component at December 31, 2023

	Fair Value Determined by:						Total Amount	% of Total
	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)					
Exchange traded fund ⁽⁴⁾	\$ 18,715	\$ —	\$ —	\$ 18,715			3	
Equity exchange traded fund ⁽¹⁾	315,886	—	—	315,886			55	
U.S. Government and Agency	—	167,450	—	167,450			30	
Other bonds	—	5	—	5			—	
Guaranteed annuity contract ⁽²⁾	—	43,428	—	43,428			8	
Short-term investments	6,506	—	—	6,506			1	
Other	463	—	—	463			—	
	\$ 341,570	\$ 210,883	\$ —	552,453			97	
Other long-term investments ⁽³⁾				18,314			3	
Total pension assets				\$ 570,767			100	

(1) A fund including marketable securities that mirror the S&P 500 index.

(2) Representing a guaranteed annuity contract issued by Globe Life Inc.'s subsidiary, American Income Life Insurance Company, to fund the obligations of the American Income Life Insurance Company Collective Bargaining Agreement Employees Pension Plan.

(3) Includes non-redeemable investment funds that report the Globe Life Inc. Pension Plan's pro-rata share of the limited partnership's net asset value (NAV) per share, or its equivalent, as a practical expedient for fair value. As of December 31, 2023, the Globe Life Inc. Pension Plan owned less than 1% of two long-term investment funds.

(4) A fund including U.S. dollar-denominated investment-grade securities issued by industrial, utility, and financial companies with maturities greater than 10 years.

SERP: The following tables include premiums paid for COLI at September 30, 2024 and 2023 and investments of the Rabbi Trust at September 30, 2024 and December 31, 2023.

	Nine Months Ended September 30,	
	2024	2023
Premiums paid for insurance coverage	\$ 443	\$ 443
	<u>September 30, 2024</u>	<u>December 31, 2023</u>
Total investments:		
COLI	\$ 56,757	\$ 55,185
Exchange traded funds	97,132	86,156
	<u>\$ 153,889</u>	<u>\$ 141,341</u>

Pension Plans and SERP Liabilities: The following table presents liabilities for the defined benefit pension plans and SERP at September 30, 2024 and December 31, 2023.

	September 30, 2024	December 31, 2023
Pension Plans	\$ 615,595	\$ 554,957
SERP	72,654	72,603
Benefit obligation	<u>\$ 688,249</u>	<u>\$ 627,560</u>

Net Periodic Benefit Cost: The following table presents the net periodic benefit costs for the defined benefit pension plans and SERP by expense components for the three and nine month periods ended September 30, 2024 and 2023.

	Components of Net Periodic Benefit Cost			
	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Service cost—benefits earned during the period	\$ 6,224	\$ 5,392	\$ 18,673	\$ 16,174
Interest cost on projected benefit obligation	8,287	7,834	24,862	23,502
Expected return on assets	(10,645)	(9,656)	(31,938)	(28,968)
Amortization:				
Prior service cost	265	269	803	807
Actuarial (gain) loss	6	(48)	18	(152)
Net periodic benefit cost	<u>\$ 4,137</u>	<u>\$ 3,791</u>	<u>\$ 12,418</u>	<u>\$ 11,363</u>

[XML 37 R19.htm IDEA: XBRL DOCUMENT](#)

Earnings Per Share

Earnings Per Share

[Abstract]

Earnings Per Share

9 Months Ended Sep. 30, 2024

Note 10—Earnings Per Share

Earnings per Share: A reconciliation of basic and diluted weighted-average shares outstanding used in the computation of basic and diluted earnings per share is as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Basic weighted average shares outstanding	87,874,488	94,636,867	91,048,853	95,445,416
Weighted average dilutive options outstanding	212,553	1,180,770	273,666	1,211,974
Diluted weighted average shares outstanding	<u>88,087,041</u>	<u>95,817,637</u>	<u>91,322,519</u>	<u>96,657,390</u>
Antidilutive shares	4,234,326	492,970	3,090,848	399,071

Antidilutive shares are excluded from the calculation of diluted earnings per share. All antidilutive shares noted above result from outstanding out of the money employee and Director stock options.

[XML 38 R20.htm IDEA: XBRL DOCUMENT](#)

Debt

Debt Disclosure

[Abstract]

Debt

9 Months Ended Sep. 30, 2024

Note 11—Debt

On August 23, 2024, Globe Life completed the issuance of \$450 million principal amount of 5.85% Senior notes due September 15, 2034. Total proceeds received by the Parent from the issuance, net of the underwriters' discount, were \$445 million. The proceeds were used for general corporate purposes, which included open market purchases of shares of its common stock under its share repurchase program. On August 15, 2024, Globe Life amended its term loan agreement increasing the principal amount from \$170 million to \$250 million, an increase of \$80 million. The amendment extends the maturity date from November 11, 2024 to August 15, 2027.

The following table presents information about the terms and outstanding balances of Globe Life's debt.

Selected Information about Debt Issues

Instrument	Issue Date	Maturity Date	Coupon Rate	As of				December 31, 2023	
				September 30, 2024					
				Par Value	Unamortized Discount & Issuance Costs	Book Value	Fair Value	Book Value	
Senior notes	09/27/2018	09/15/2028	4.550%	\$ 550,000	\$ (3,180)	\$ 546,820	\$ 550,088	\$ 546,283	
Senior notes	08/21/2020	08/15/2030	2.150%	400,000	(2,983)	397,017	344,796	396,670	
Senior notes ⁽¹⁾	05/19/2022	06/15/2032	4.800%	250,000	(3,828)	246,172	248,443	245,873	
Senior notes	08/23/2024	09/15/2034	5.850%	450,000	(5,188)	444,812	464,881	—	
Junior subordinated debentures	11/17/2017	11/17/2057	5.275%	125,000	(1,561)	123,439	109,657	123,427	
Junior subordinated debentures	06/14/2021	06/15/2061	4.250%	325,000	(7,633)	317,367	236,730	317,306	
Term loan ⁽²⁾	05/11/2023	08/15/2027	6.593%	250,000	(1,951)	248,049	248,049	—	
Total long-term debt				2,350,000	(26,324)	2,323,676	2,202,644	1,629,559	
Term loan ⁽²⁾				—	—	—	—	169,549	
FHLB borrowings				17,000	—	17,000	17,000	—	
Commercial paper				426,908	(6,490)	420,418	420,418	316,564	
Total short-term debt				443,908	(6,490)	437,418	437,418	486,113	
Total debt				\$ 2,793,908	\$ (32,814)	\$ 2,761,094	\$ 2,640,062	\$ 2,115,672	

(1) An additional \$150 million par value and book value is held by insurance subsidiaries that eliminates in consolidation.
(2) Interest calculated quarterly using Secured Overnight Financing Rate (SOFR) plus 135 basis points.

The commercial paper has the highest priority of all unsecured debt, followed by senior notes then junior subordinated debentures. The senior notes are callable under a make-whole provision, and the junior subordinated debentures are subject to an optional redemption five years from issuance. Interest on the 4.25% junior subordinated debentures and the term loan are payable quarterly while all other long-term debt is payable semi-annually.

Credit facility: On March 29, 2024, Globe Life amended the credit agreement dated September 30, 2021, which provides for a \$1 billion revolving credit facility that may be increased to \$1.25 billion. The amended credit facility matures March 29, 2029 and may be extended up to two one-year periods upon the Company's request. Pursuant to this agreement, the participating lenders have agreed to make revolving loans to Globe Life and to issue secured or unsecured letters of credit. The Company has not drawn on any of the credit to date. The facility is further designated as a back-up credit line for a commercial paper program under which the Company may either borrow from the credit line or issue commercial paper at any time, with total commercial paper outstanding not to exceed the facility maximum of \$1 billion, less any letters of credit issued. Interest is charged at variable rates. In accordance with the agreement, Globe Life is subject to certain covenants regarding capitalization. As of September 30, 2024, the Company was in full compliance with these covenants.

The following tables present certain information about our commercial paper borrowings.

Credit Facility—Commercial Paper

	As of		
	September 30, 2024	December 31, 2023	September 30, 2023
Balance of commercial paper at end of period (par value)	\$ 426,908	\$ 319,000	\$ 251,000
Annualized interest rate	5.56 %	5.71 %	5.65 %
Letters of credit outstanding	\$ 115,000	\$ 115,000	\$ 115,000
Remaining amount available under credit line	458,092	316,000	384,000

Credit Facility—Commercial Paper Activity

	Nine Months Ended September 30,	
	2024	2023
Average balance of commercial paper outstanding during period (par value)	\$ 375,851	\$ 296,816
Daily-weighted average interest rate (annualized)	5.80 %	5.33 %
Maximum daily amount outstanding during period (par value)	\$ 633,425	\$ 477,700
Commercial paper issued during period (par value)	1,482,556	1,480,000
Commercial paper matured during period (par value)	(1,374,648)	(1,514,000)
Net commercial paper issued (matured) during period (par value)	107,908	(34,000)

Federal Home Loan Bank: FHLB membership provides certain of our insurance subsidiaries with access to various low-cost collateralized borrowings and funding agreements. The membership requires ownership of FHLB common stock, as well as the purchase of activity-based common stock equal to approximately 4.1% of outstanding borrowings.

Globe Life owned \$32.4 million in FHLB common stock as of September 30, 2024 and \$22.3 million as of December 31, 2023. The FHLB stock is restricted for the duration of the membership and recorded at cost (par) as required by applicable guidance. The FHLB stock is included in "Other long-term investments" in the *Condensed Consolidated Balance Sheets*. Borrowings with the FHLB are subject to the availability of pledged assets at the insurance subsidiaries of Globe Life. As of September 30, 2024, Globe Life's insurance subsidiaries maximum borrowing capacity under the FHLB facility was approximately \$781 million, net of outstanding funding agreements and short-term borrowings, on pledged assets with a fair value of \$1.4 billion. As of September 30, 2024, \$372 million in funding agreements were outstanding with the FHLB, compared to \$138 million as of December 31, 2023. This amount is included in "Other policyholders' funds" in the *Condensed Consolidated Balance Sheets*. In addition, the Company had \$17 million in short-term borrowings from the FHLB as of September 30, 2024, compared to \$0 as of December 31, 2023, this amount is recorded in "Short-term debt".

[XML 39 R21.htm IDEA: XBRL DOCUMENT](#)

9 Months Ended Sep. 30, 2024

Business Segments

[Segment Reporting](#)

[\[Abstract\]](#)

[Business Segments](#)

Note 12—Business Segments

Globe Life is organized into four segments: life insurance, supplemental health insurance, annuities, and investments. In addition, other expenses not included in these segments are reported in "Corporate & Other."

Globe Life's reportable insurance segments are based on the insurance product lines it markets and administers: life insurance, supplemental health insurance, and annuities. These major product lines are set out as reportable segments because of the common characteristics of products within these categories, comparability of margins, and the similarity in regulatory environment and management techniques. There is also an investment segment that manages the investment portfolio and cash flow for the insurance segments and the corporate function. The Company's chief operating decision makers evaluate the overall performance of the operations of the Company in accordance with these segments.

Life insurance products marketed by Globe Life include traditional whole life and term life insurance. Health insurance products are generally guaranteed renewable and include Medicare Supplement, cancer, critical illness, accident, and other limited-benefit supplemental hospital and surgical products. Annuities include fixed-benefit contracts.

The following tables present segment premium revenue by each of Globe Life's distribution channels.

Premium Income by Distribution Channel

Distribution Channel	Three Months Ended September 30, 2024							
	Life		Health		Annuity		Total	
	Amount	% of Total	Amount	% of Total	Amount	% of Total	Amount	% of Total
American Income	\$ 427,839	52	\$ 31,277	9	\$ —	—	\$ 459,116	39
Direct to Consumer	246,425	30	18,072	5	—	—	264,497	23
Liberty National	93,625	12	47,277	13	—	—	140,902	12
United American	1,608	—	149,510	42	—	—	151,118	13
Family Heritage	1,684	—	107,819	31	—	—	109,503	9
Other	47,457	6	—	—	—	—	47,457	4
	\$ 818,638	100	\$ 353,955	100	\$ —	—	\$ 1,172,593	100

Distribution Channel	Three Months Ended September 30, 2023							
	Life		Health		Annuity		Total	
	Amount	% of Total	Amount	% of Total	Amount	% of Total	Amount	% of Total
American Income	\$ 400,214	51	\$ 30,535	9	\$ —	—	\$ 430,749	39
Direct to Consumer	247,858	32	17,153	5	—	—	265,011	24
Liberty National	88,199	11	46,643	14	—	—	134,842	12
United American	1,802	—	137,077	42	—	—	138,879	12
Family Heritage	1,561	—	99,828	30	—	—	101,389	9
Other	48,465	6	—	—	—	—	48,465	4
	\$ 788,099	100	\$ 331,236	100	\$ —	—	\$ 1,119,335	100

Distribution Channel	Nine Months Ended September 30, 2024							
	Life		Health		Annuity		Total	
	Amount	% of Total	Amount	% of Total	Amount	% of Total	Amount	% of Total
American Income	\$ 1,265,417	52	\$ 92,495	9	\$ —	—	\$ 1,357,912	39
Direct to Consumer	743,304	31	54,070	5	—	—	797,374	23
Liberty National	276,599	11	142,612	14	—	—	419,211	12
United American	5,009	—	440,375	42	—	—	445,384	13
Family Heritage	4,945	—	317,065	30	—	—	322,010	9
Other	143,111	6	—	—	—	—	143,111	4
	\$ 2,438,385	100	\$ 1,046,617	100	\$ —	—	\$ 3,485,002	100

Distribution Channel	Nine Months Ended September 30, 2023							
	Life		Health		Annuity		Total	
	Amount	% of Total	Amount	% of Total	Amount	% of Total	Amount	% of Total
American Income	\$ 1,182,346	50	\$ 89,656	9	\$ —	—	\$ 1,272,002	38
Direct to Consumer	744,132	32	51,576	5	—	—	795,708	24
Liberty National	260,036	11	140,518	14	—	—	400,554	12
United American	5,533	—	407,137	42	—	—	412,670	13
Family Heritage	4,554	—	294,029	30	—	—	298,583	9
Other	145,828	7	—	—	—	—	145,828	4
	\$ 2,342,429	100	\$ 982,916	100	\$ —	—	\$ 3,325,345	100

Due to the nature of the life insurance industry, Globe Life has no individual or group that would be considered a major customer. Substantially all of Globe Life's business is conducted in the United States.

The measure of profitability established by the chief operating decision makers for the insurance segments is underwriting margin before other income and administrative expenses, in accordance with the manner in which the segments are managed. It essentially represents gross profit margin on insurance products before insurance administrative expenses and consists primarily of premium less net policy benefits, acquisition expenses, and commissions. Required interest on policy liabilities is reflected as a component of the Investment segment (rather than as a component of underwriting margin in the insurance and annuity segments) in order to match this cost with the investment income earned on the assets supporting the policy liabilities.

The measure of profitability for the Investment segment is excess investment income, representing the income earned on the investment portfolio in excess of policy requirements. Other than the required interest on the insurance segments, no other intersegment revenues or expenses are recognized. Expenses directly attributable to corporate operations are included in the "Corporate & Other" category. Stock-based compensation expense is considered a corporate expense by Globe Life management and is included in this category. All other unallocated revenues and expenses on a pretax basis, including insurance administrative expense and interest on debt, are also included in the "Corporate & Other" segment category.

Globe Life holds a sizable investment portfolio to support its insurance liabilities, the yield from which is used to offset policy benefit, acquisition, administrative, and tax expenses. This yield or investment income is taken into account when establishing premium rates and profitability expectations for its insurance products. From time to time, investments are sold or called, or experience a credit loss event, each of which are reflected by the Company as realized gain (loss)—investments. These gains or losses generally occur as a result of disposition due to issuer calls, compliance with Company investment policies, or other reasons often beyond management's control. Unlike investment income, realized gains and losses are incidental to insurance operations, and only overall yields are considered when setting premium rates or insurance product profitability expectations. While these gains and losses are not relevant to segment profitability or core operating results, they can have a material positive or negative result on net income. For these reasons, management removes realized investment gains and losses when it views its segment operations.

Management also removes non-operating items unrelated to the Company's core insurance activities when evaluating those results. Therefore, these items are excluded in its presentation of segment results because accounting guidance requires that operating segment results be presented as management views its business. All of these items are included in "Other operating expense" in the *Condensed Consolidated Statements of Operations* for the appropriate year. See additional detail below in the tables. The following tables set forth a reconciliation of Globe Life's revenues and operations by segment to its major income statement line items. See *Note 1—Significant Accounting Policies* for additional information concerning reconciling items of segment profits to pretax income.

Three Months Ended September 30, 2024							
	Life	Health	Annuity	Investment	Corporate & Other	Adjustments	Consolidated
Revenue:							
Premium	\$ 818,638	\$ 353,955	\$ —	\$ —	\$ —	\$ —	\$ 1,172,593
Net investment income	—	—	—	284,964	—	—	284,964
Other income	—	—	—	—	42	—	42
Total revenue	818,638	353,955	—	284,964	42	—	1,457,599
Expenses:							
Policy benefits	454,502	221,926	5,716	6,040	—	—	688,184
Required interest on reserves	(203,875)	(27,717)	(7,829)	239,421	—	—	104,310
Amortization of acquisition costs	90,070	13,852	388	—	—	—	149,693
Commissions, premium taxes, and non-deferred acquisition costs	90,758	58,931	4	—	—	—	89,195
Insurance administrative expense ⁽¹⁾	—	—	—	—	88,465	730 (3)	6,446
Parent expense	—	—	—	—	3,210	3,236 (2,3)	9,233
Stock-based compensation expense	—	—	—	—	9,233	—	31,388
Interest expense	—	—	—	—	31,388	—	1,078,449
Total expenses	431,455	266,992	(1,721)	245,461	132,296	3,966	379,150
Subtotal	387,183	86,963	1,721	39,503	(132,254)	(3,966)	3,966
Non-operating items	—	—	—	—	—	3,966 (2,3)	—
Measure of segment profitability (pretax)	\$ 387,183	\$ 86,963	\$ 1,721	\$ 39,503	\$ (132,254)	\$ —	\$ 376,958
Realized gains (losses)							(2,192)
Legal costs and proceedings							(3,329)
Non-operating expenses							(637)
Income before income taxes per <i>Condensed Consolidated Statements of Operations</i>							\$ 376,958

- (1) Administrative expense is not allocated to insurance segments.
(2) Non-operating expenses.
(3) Legal costs and proceedings.

Three Months Ended September 30, 2023							
	Life	Health	Annuity	Investment	Corporate & Other	Adjustments	Consolidated
Revenue:							
Premium	\$ 788,099	\$ 331,236	\$ —	\$ —	\$ —	\$ —	\$ 1,119,335
Net investment income	—	—	—	266,926	—	—	266,926
Other income	—	—	—	—	50	—	50
Total revenue	788,099	331,236	—	266,926	50	—	1,386,311
Expenses:							
Policy obligations	515,676	193,790	6,854	2,724	—	—	719,044
Required interest on reserves	(194,199)	(26,732)	(9,353)	230,284	—	—	—
Amortization of acquisition costs	82,523	12,816	418	—	—	—	95,757
Commissions, premium taxes, and non-deferred acquisition costs	84,011	54,662	4	—	—	—	138,677
Insurance administrative expense ⁽¹⁾	—	—	—	—	74,585	—	74,585
Parent expense	—	—	—	—	2,581	1,137 (2)	3,718
Stock-based compensation expense	—	—	—	—	7,567	—	7,567
Interest expense	—	—	—	—	25,955	—	25,955
Total expenses	488,011	234,536	(2,077)	233,008	110,688	1,137	1,065,303
Subtotal	300,088	96,700	2,077	33,918	(110,638)	(1,137)	321,008
Non-operating items	—	—	—	—	—	1,137 (2)	1,137
Measure of segment profitability (pretax)	\$ 300,088	\$ 96,700	\$ 2,077	\$ 33,918	\$ (110,638)	\$ —	\$ 318,815
Realized gains (losses)							(2,193)
Non-operating expenses							(1,137)
Income before income taxes per <i>Condensed Consolidated Statements of Operations</i>							\$ 318,815

- (1) Administrative expense is not allocated to insurance segments.
(2) Non-operating expenses.

Nine Months Ended September 30, 2024							
	Life	Health	Annuity	Investment	Corporate & Other	Adjustments	Consolidated
Revenue:							
Premium	\$ 2,438,385	\$ 1,046,617	\$ —	\$ —	\$ —	\$ —	\$ 3,485,002
Net investment income	—	—	—	853,178	—	—	853,178
Other income	—	—	—	—	192	—	192
Total revenue	2,438,385	1,046,617	—	853,178	192	—	4,338,372
Expenses:							
Policy obligations	1,493,165	629,676	17,786	15,044	—	—	2,155,671
Required interest on reserves	(605,397)	(82,300)	(24,358)	712,055	—	—	—
Amortization of acquisition costs	263,753	40,774	1,176	—	—	—	305,703
Commissions, premium taxes, and non-deferred acquisition costs	270,347	177,246	12	—	—	—	447,605
Insurance administrative expense ⁽¹⁾	—	—	—	—	251,072	1,646 (3)	252,718
Parent expense	—	—	—	—	9,166	6,722 (2,3)	15,888
Stock-based compensation expense	—	—	—	—	28,590	—	28,590
Interest expense	—	—	—	—	91,413	—	91,413
Total expenses	1,421,868	765,396	(5,384)	727,099	380,241	8,368	3,297,588
Subtotal	1,016,517	281,221	5,384	126,079	(380,049)	(8,368)	1,040,784
Non-operating items	—	—	—	—	—	8,368 (2,3)	8,368
Measure of segment profitability (pretax)	\$ 1,016,517	\$ 281,221	\$ 5,384	\$ 126,079	\$ (380,049)	\$ —	\$ 1,049,152
Realized gains (losses)							(26,580)
Legal costs and proceedings							(5,764)
Non-operating expenses							(2,604)
Income before income taxes per <i>Condensed Consolidated Statements of Operations</i>							\$ 1,014,204

- (1) Administrative expense is not allocated to insurance segments.
(2) Non-operating expenses.
(3) Legal costs and proceedings.

Nine Months Ended September 30, 2023							
	Life	Health	Annuity	Investment	Corporate & Other	Adjustments	Consolidated
Revenue:							
Premium	\$ 2,342,429	\$ 982,916	\$ —	\$ —	\$ —	\$ —	\$ 3,325,345
Net investment income	—	—	—	785,275	—	—	785,275
Other income	—	—	—	—	185	—	185
Total revenue	2,342,429	982,916	—	785,275	185	—	4,110,805
Expenses:							
Policy obligations	1,536,317	580,676	21,502	5,986	—	—	2,144,481
Required interest on reserves	(575,801)	(79,603)	(29,327)	684,731	—	—	—
Amortization of acquisition costs	243,285	37,608	1,266	—	—	—	282,159
Commissions, premium taxes, and non-deferred acquisition costs	251,136	163,784	13	—	—	—	414,933
Insurance administrative expense ⁽¹⁾	—	—	—	—	223,951	—	223,951
Parent expense	—	—	—	—	8,254	1,137 (2)	9,391
Stock-based compensation expense	—	—	—	—	22,732	—	22,732
Interest expense	—	—	—	—	76,640	—	76,640
Total expenses	1,454,937	702,465	(6,546)	690,717	331,577	1,137	3,174,287
Subtotal	887,492	280,451	6,546	94,558	(331,392)	(1,137)	936,518
Non-operating items	—	—	—	—	—	1,137 (2)	1,137
Measure of segment profitability (pretax)	\$ 887,492	\$ 280,451	\$ 6,546	\$ 94,558	\$ (331,392)	\$ —	\$ 937,655
Realized gains (losses)							(78,963)
Non-operating expenses							(1,137)
Income before income taxes per <i>Condensed Consolidated Statements of Operations</i>							\$ 857,555

- (1) Administrative expense is not allocated to insurance segments.
(2) Non-operating expenses.

[XML 40 R22.htm IDEA: XBRL DOCUMENT](#)

Subsequent Events

[Subsequent Events](#)

[\[Abstract\]](#)

[Subsequent Events](#)

Note 13—Subsequent Events

In the fourth quarter of 2024, the Company entered into a coinsurance agreement to cede a majority of its annuity business to a third-party insurer. The annuity reserves ceded totaled approximately \$460 million subject to final settlement. The pre-tax ceding commission under the agreement was approximately \$50 million and will be recognized into income over the remaining life of the ceded contracts. Under the terms of the agreement, the reinsurer will be required to maintain assets in trust at 105% of reserves. The Company's annuity business comprises less than 1% of revenue and is not core to the Company's business. We anticipate that we will adjust our segment reporting to reflect the remaining annuity business within the Corporate and Other category of our segment reporting.

[XML 41 R23.htm IDEA: XBRL DOCUMENT](#)

9 Months Ended Sep. 30, 2024

Pay vs Performance Disclosure - USD (\$) \$ in Thousands	3 Months Ended Sep. 30, 2024	9 Months Ended Sep. 30, 2023	3 Months Ended Sep. 30, 2024	9 Months Ended Sep. 30, 2023

Pay vs Performance Disclosure

Net income	\$ 302,994	\$ 257,083	\$ 815,566	\$ 695,953
~~XML 42 R24.htm IDEA: XBRL DOCUMENT~~				

Insider Trading Arrangements	3 Months Ended Sep. 30, 2024

Trading Arrangements, by Individual

Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

~~XML 43 R25.htm IDEA: XBRL DOCUMENT~~

Significant Accounting Policies (Policies)

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation: The accompanying condensed consolidated financial statements of Globe Life have been prepared in accordance with the instructions to Form 10-Q. Therefore, they do not include all of the disclosures required by accounting principles generally accepted in the United States of America (GAAP) for annual financial statements. However, in the opinion of management, these statements include all adjustments, consisting of normal recurring adjustments, which are necessary for a fair presentation of the condensed consolidated financial position at September 30, 2024, and the condensed consolidated results of operations, comprehensive income, and cash flows for the periods ended September 30, 2024 and 2023. The interim period condensed consolidated financial statements should be read in conjunction with the *Consolidated Financial Statements that are included in the Form 10-K* filed with the Securities Exchange Commission (SEC) on February 28, 2024.

Use of Estimates: The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. See further documentation in the significant accounting policies or the accompanying notes.

Use of Estimates

Accounting Pronouncements Yet to be Adopted

Accounting Pronouncements Adopted in the Current Year			
Standard	Description	Effective Date	Effect on the Condensed Consolidated Financial Statements
ASU No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions	ASU 2022-03 adds disclosure requirements specific to equity securities subject to contractual sale restrictions. The disclosures clarify the nature of the contractual sale as well as the duration of the restriction and the circumstances that could cause a lapse in the restriction.	This standard is effective for the Company for fiscal years beginning on January 1, 2024 and interim periods within those fiscal years.	The adoption of this standard did not have a material impact on the Condensed Consolidated Financial Statements.
Accounting Pronouncements Yet to be Adopted			
Standard	Description	Effective Date	Effect on the Condensed Consolidated Financial Statements
ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures	ASU 2023-07 adds disclosure requirements to segment expenses, improving the financial reporting of the entity's overall performance and assessment of future cash flows. The disclosures will require more detailed information related to the entity's reportable segments.	This standard is effective for the Company for annual periods beginning on January 1, 2024 and for interim periods beginning on January 1, 2025, and will be implemented on a retrospective basis.	The Company is evaluating the standard, but does not expect the standard will have a material impact on the Condensed Consolidated Financial Statements.
ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures	ASU 2023-09 adds disclosure requirements to disaggregated information related to the effective tax rate reconciliation and information on income taxes paid. The disclosures will enhance the assessment of the entity's operations and related tax risks.	This standard is effective for the Company for annual periods beginning on January 1, 2025, and will be implemented on a prospective basis.	The Company does not expect the standard will have a material impact on the Condensed Consolidated Financial Statements.

~~XML 44 R26.htm IDEA: XBRL DOCUMENT~~

New Accounting Standards (Tables)

Accounting Changes and Error Corrections [Abstract]

Schedule Of New Accounting Standards on Previously Reported Results

Accounting Pronouncements Adopted in the Current Year			
Standard	Description	Effective Date	Effect on the Condensed Consolidated Financial Statements
ASU No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions	ASU 2022-03 adds disclosure requirements specific to equity securities subject to contractual sale restrictions. The disclosures clarify the nature of the contractual sale as well as the duration of the restriction and the circumstances that could cause a lapse in the restriction.	This standard is effective for the Company for fiscal years beginning on January 1, 2024 and interim periods within those fiscal years.	The adoption of this standard did not have a material impact on the Condensed Consolidated Financial Statements.
Accounting Pronouncements Yet to be Adopted			
Standard	Description	Effective Date	Effect on the Condensed Consolidated Financial Statements
ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures	ASU 2023-07 adds disclosure requirements to segment expenses, improving the financial reporting of the entity's overall performance and assessment of future cash flows. The disclosures will require more detailed information related to the entity's reportable segments.	This standard is effective for the Company for annual periods beginning on January 1, 2024 and for interim periods beginning on January 1, 2025, and will be implemented on a retrospective basis.	The Company is evaluating the standard, but does not expect the standard will have a material impact on the Condensed Consolidated Financial Statements.
ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures	ASU 2023-09 adds disclosure requirements to disaggregated information related to the effective tax rate reconciliation and information on income taxes paid. The disclosures will enhance the assessment of the entity's operations and related tax risks.	This standard is effective for the Company for annual periods beginning on January 1, 2025, and will be implemented on a prospective basis.	The Company does not expect the standard will have a material impact on the Condensed Consolidated Financial Statements.

~~XML 45 R27.htm IDEA: XBRL DOCUMENT~~

Supplemental Information About Changes to Accumulated Other Comprehensive Income (Tables)

Equity [Abstract]

Schedule of Change in Balance by Component of Accumulated Other Comprehensive Income

An analysis of the change in balance by component of Accumulated Other Comprehensive Income is as follows for the three and nine month periods ended September 30, 2024 and 2023:

Three Months Ended September 30, 2024					
	Available for Sale Assets	Future Policy Benefits	Foreign Exchange	Pension Adjustments	Total
Balance at July 1, 2024	\$ (1,271,213)	\$ (911,717)	\$ (4,726)	\$ (1,964)	\$ (2,189,620)
Other comprehensive income (loss) before reclassifications, net of tax	686,343	(985,420)	5,764	—	(293,313)
Reclassifications, net of tax	(1,903)	—	—	93	(1,810)
Other comprehensive income (loss)	684,440	(985,420)	5,764	93	(295,123)
Balance at September 30, 2024	\$ (586,773)	\$ (1,897,137)	\$ 1,038	\$ (1,871)	\$ (2,484,743)
Three Months Ended September 30, 2023					
	Available for Sale Assets	Future Policy Benefits	Foreign Exchange	Pension Adjustments	Total
Balance at July 1, 2023	\$ (1,249,399)	\$ (1,696,801)	\$ 1,353	\$ 950	\$ (2,943,897)
Other comprehensive income (loss) before reclassifications, net of tax	(842,527)	1,332,976	(6,226)	—	484,223
Reclassifications, net of tax	672	—	—	28	700
Other comprehensive income (loss)	(841,855)	1,332,976	(6,226)	28	484,923
Balance at September 30, 2023	\$ (2,091,254)	\$ (363,825)	\$ (4,873)	\$ 978	\$ (2,458,974)
Nine Months Ended September 30, 2024					
	Available for Sale Assets	Future Policy Benefits	Foreign Exchange	Pension Adjustments	Total
Balance at January 1, 2024	\$ (827,596)	\$ (1,947,391)	\$ 4,719	\$ (2,151)	\$ (2,772,419)
Other comprehensive income (loss) before reclassifications, net of tax	238,785	50,254	(3,681)	—	285,358
Reclassifications, net of tax	2,038	—	—	280	2,318
Other comprehensive income (loss)	240,823	50,254	(3,681)	280	287,676
Balance at September 30, 2024	\$ (586,773)	\$ (1,897,137)	\$ 1,038	\$ (1,871)	\$ (2,484,743)
Nine Months Ended September 30, 2023					
	Available for Sale Assets	Future Policy Benefits	Foreign Exchange	Pension Adjustments	Total
Balance at January 1, 2023	\$ (1,420,672)	\$ (1,369,204)	\$ (1,681)	\$ 1,244	\$ (2,790,313)
Other comprehensive income (loss) before reclassifications, net of tax	(736,046)	1,005,379	(3,192)	—	266,141
Reclassifications, net of tax	65,464	—	—	(266)	65,198
Other comprehensive income (loss)	(670,582)	1,005,379	(3,192)	(266)	331,339
Balance at September 30, 2023	\$ (2,091,254)	\$ (363,825)	\$ (4,873)	\$ 978	\$ (2,458,974)

Schedule of Reclassifications Out of Accumulated Other Comprehensive Income

Reclassification adjustments out of Accumulated Other Comprehensive Income are presented below for the three and nine month periods ended September 30, 2024 and 2023.

Component Line Item	Three Months Ended September 30,		Nine Months Ended September 30,		Affected line items in the Statements of Operations
	2024	2023	2024	2023	
Unrealized investment (gains) losses on available for sale assets:					
Realized (gains) losses	\$ (257)	\$ 1,759	\$ 9,732	\$ 85,230	Realized (gains) losses
Amortization of (discount) premium	(2,151)	(908)	(7,152)	(2,364)	Net investment income
Total before tax	(2,408)	851	2,580	82,866	
Tax	505	(179)	(542)	(17,402)	Income taxes
Total after-tax	(1,903)	672	2,038	65,464	
Pension adjustments:					
Amortization of prior service cost	265	269	803	807	Other operating expense
Amortization of actuarial (gain) loss	(147)	(234)	(449)	(1,143)	Other operating expense
Total before tax	118	35	354	(336)	
Tax	(25)	(7)	(74)	70	Income taxes
Total after-tax	93	28	280	(266)	
Total reclassification (after-tax)	\$ (1,810)	\$ 700	\$ 2,318	\$ 65,198	

[XML 46 R28.htm IDEA: XBRL DOCUMENT](#)

Investments (Tables)

[Investments, Debt and Equity Securities \[Abstract\]](#)
[Schedule of Fixed Maturities and Equity Securities Available for Sale by Component](#)

9 Months Ended
 Sep. 30, 2024

Summaries of fixed maturities available for sale by amortized cost, fair value, and allowance for credit losses at September 30, 2024 and December 31, 2023, and the corresponding amounts of gross unrealized gains and losses recognized in accumulated other comprehensive income (loss) are as follows. Redeemable preferred stock is included within "Corporates, by sector."

	At September 30, 2024					
	Amortized Cost	Allowance for Credit Losses	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value ⁽¹⁾	% of Total Fixed Maturities ⁽²⁾
Fixed maturities available for sale:						
U.S. Government direct, guaranteed, and government-sponsored enterprises	\$ 397,969	\$ —	\$ 38	\$ (21,026)	\$ 376,981	2
States, municipalities, and political subdivisions	3,253,819	—	49,409	(424,989)	2,878,239	16
Foreign governments	41,794	—	17	(9,885)	31,926	—
Corporates, by sector:						
Industrials	8,115,835	(7,132)	258,165	(508,089)	7,858,779	43
Financial	5,014,169	—	171,762	(299,903)	4,886,028	26
Utilities	2,140,610	—	109,998	(72,371)	2,178,237	12
Total corporates	15,270,614	(7,132)	539,925	(880,363)	14,923,044	81
Collateralized debt obligations	36,685	—	5,798	—	42,483	—
Other asset-backed securities	83,573	—	1	(1,677)	81,897	1
Total fixed maturities	\$ 19,084,454	\$ (7,132)	\$ 595,188	\$ (1,337,940)	\$ 18,334,570	100

(1) Amount reported in the balance sheet.
 (2) At fair value.

	At December 31, 2023					
	Amortized Cost	Allowance for Credit Losses	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value ⁽¹⁾	% of Total Fixed Maturities ⁽²⁾
Fixed maturities available for sale:						
U.S. Government direct, guaranteed, and government-sponsored enterprises	\$ 398,450	\$ —	\$ 7	\$ (32,306)	\$ 366,151	2
States, municipalities, and political subdivisions	3,296,305	—	47,346	(403,329)	2,940,322	16
Foreign governments	44,453	—	1	(10,348)	34,106	—
Corporates, by sector:						
Industrials	8,016,126	(7,115)	213,078	(566,847)	7,655,242	43
Financial	5,028,151	—	112,368	(388,340)	4,752,179	27
Utilities	2,017,967	—	73,925	(94,130)	1,997,762	11
Total corporates	15,062,244	(7,115)	399,371	(1,049,317)	14,405,183	81
Collateralized debt obligations	37,110	—	5,036	—	42,146	—
Other asset-backed securities	86,352	—	3	(4,057)	82,298	1
Total fixed maturities	\$ 18,924,914	\$ (7,115)	\$ 451,764	\$ (1,499,357)	\$ 17,870,206	100

(1) Amount reported in the balance sheet.
 (2) At fair value.

[Schedule of Fixed Maturities by Contractual Maturity](#)

A schedule of fixed maturities available for sale by contractual maturity date at September 30, 2024, is shown below on an amortized cost basis, net of allowance for credit losses, and on a fair value basis. Actual disposition dates could differ from contractual maturities due to call or prepayment provisions.

	At September 30, 2024	
	Amortized Cost, net	Fair Value
Fixed maturities available for sale:		
Due in one year or less	\$ 111,956	\$ 111,456
Due after one year through five years	748,300	771,458
Due after five years through ten years	1,841,477	1,912,103
Due after ten years through twenty years	8,954,048	8,827,993
Due after twenty years	7,301,254	6,587,150
Mortgage-backed and asset-backed securities	120,287	124,410
	\$ 19,077,322	\$ 18,334,570

[Schedule of Analysis of Investment Operations](#)

"Net investment income" for the three and nine month periods ended September 30, 2024 and 2023 is summarized as follows:

	Three Months Ended September 30,			Nine Months Ended September 30,		
	2024	2023	% Change	2024	2023	% Change
Fixed maturities available for sale	\$ 245,313	\$ 237,609	3	\$ 738,626	\$ 704,095	5
Policy loans	13,296	12,446	7	39,196	36,435	8
Mortgage loans	7,668	5,363	43	21,337	13,919	53
Other long-term investments ⁽¹⁾	19,992	14,630	37	58,608	38,753	51
Short-term investments	3,083	1,396	—	8,396	4,811	—
	289,352	271,444	7	866,163	798,013	9
Less investment expense	(4,388)	(4,518)	(3)	(12,985)	(12,738)	2
Net investment income	\$ 284,964	\$ 266,926	7	\$ 853,178	\$ 785,275	9

(1) For the three months ended September 30, 2024 and 2023, the investment funds, accounted for under the fair value option method, recorded \$19.1 million and \$14.0 million, respectively, in net investment income. For the nine months ended September 30, 2024 and 2023, the investment funds, accounted for under the fair value option method, recorded \$56.1 million and \$37.2 million, respectively, in net investment income. Refer to [Other Long-Term Investments](#) below for further discussion on the investment funds.

Selected information about sales of fixed maturities available for sale is as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Fixed maturities available for sale:				
Proceeds from sales ⁽¹⁾	\$ 163,221	\$ 46,210	\$ 674,125	\$ 192,034
Gross realized gains	2,042	261	6,086	308
Gross realized losses	(1,856)	(67,018)	(15,824)	(77,879)

(1) As of September 30, 2024 and 2023, the Company had \$0 and \$27 thousand of unsettled trades, respectively.
 An analysis of "Realized gains (losses)" is as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Realized investment gains (losses):				
Fixed maturities available for sale:				
Sales and other ⁽¹⁾	\$ 257	\$ (66,767)	\$ (9,716)	\$ (77,730)
Provision for credit losses	—	65,008	(16)	(7,500)
Fair value option—change in fair value	(3,683)	868	(22,777)	7,954
Mortgage loans	(1,376)	(59)	(3,530)	(4,918)
Other investments	(16)	880	1,135	502
Realized gains (losses) from investments	(4,818)	(70)	(34,904)	(81,692)
Other gains (losses)	2,626	(2,123)	8,324	2,729
Total realized gains (losses)	(2,192)	(2,193)	(26,580)	(78,963)
Applicable tax	460	461	5,582	16,583
Realized gains (losses), net of tax	\$ (1,732)	\$ (1,732)	\$ (20,998)	\$ (62,380)

(1) During the three months ended September 30, 2024 and 2023, the Company recorded \$3.4 million and \$21.1 million of issuer-initiated exchanges of fixed maturities (noncash transactions) that resulted in no realized gains (losses) in either period. During the nine months ended September 30, 2024 and 2023, the Company recorded \$82.2 million and \$39.0 million of issuer-initiated exchanges of fixed maturities (noncash transactions) that resulted in no realized gains (losses) in either period.

The following tables represent the fair value of fixed maturities measured on a recurring basis at September 30, 2024 and December 31, 2023:

[Schedule of Fair Value of Fixed Maturities Measured on a Recurring Basis](#)

Fair Value Measurement at September 30, 2024:					
	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Total Fair Value	
Fixed maturities available for sale					
U.S. Government direct, guaranteed, and government-sponsored enterprises \$	—	\$ 376,981	\$ —	\$	376,981
States, municipalities, and political subdivisions	—	2,878,239	—		2,878,239
Foreign governments	—	31,926	—		31,926
Corporates, by sector:					
Industrials	—	7,659,257	199,522		7,858,779
Financial	—	4,754,596	131,432		4,886,028
Utilities	—	2,063,380	114,857		2,178,237
Total corporates	—	14,477,233	445,811		14,923,044
Collateralized debt obligations	—	—	42,483		42,483
Other asset-backed securities	—	74,021	7,876		81,897
Total fixed maturities	\$ —	\$ 17,838,400	\$ 496,170	\$	18,334,570
Percentage of total	— %	97 %	3 %		100 %

Fair Value Measurement at December 31, 2023:					
	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Total Fair Value	
Fixed maturities available for sale					
U.S. Government direct, guaranteed, and government-sponsored enterprises \$	—	\$ 366,151	\$ —	\$	366,151
States, municipalities, and political subdivisions	—	2,940,322	—		2,940,322
Foreign governments	—	34,106	—		34,106
Corporates, by sector:					
Industrials	—	7,440,493	214,749		7,655,242
Financial	—	4,621,160	131,019		4,752,179
Utilities	—	1,888,797	108,855		1,997,652
Total corporates	—	13,950,450	454,733		14,405,183
Collateralized debt obligations	—	—	42,146		42,146
Other asset-backed securities	—	82,298	—		82,298
Total fixed maturities	\$ —	\$ 17,373,327	\$ 496,879	\$	17,870,206
Percentage of total	— %	97 %	3 %		100 %

The following tables disclose unrealized investment losses by class and major sector of fixed maturities available for sale at September 30, 2024 and December 31, 2023.

Analysis of Gross Unrealized Investment Losses						
At September 30, 2024						
	Less than Twelve Months		Twelve Months or Longer		Total	
	Fair Value	Unrealized Loss	Fair Value	Unrealized Loss	Fair Value	Unrealized Loss
Fixed maturities available for sale:						
Investment grade securities:						
U.S. Government direct, guaranteed, and government-sponsored enterprises	\$ —	\$ —	\$ 374,361	\$ (21,026)	\$ 374,361	\$ (21,026)
States, municipalities, and political subdivisions	201,640	(4,821)	1,636,467	(420,168)	1,838,107	(424,989)
Foreign governments	—	—	28,493	(9,885)	28,493	(9,885)
Corporates, by sector:						
Industrials	124,717	(11,134)	4,071,839	(464,628)	4,196,556	(475,762)
Financial	19,176	(303)	2,005,383	(261,465)	2,024,559	(261,768)
Utilities	7,012	(92)	667,192	(71,489)	674,204	(71,581)
Total corporates	150,905	(11,529)	6,744,414	(797,582)	6,895,319	(809,111)
Collateralized debt obligations	—	—	—	—	—	—
Other asset-backed securities	—	—	68,549	(1,607)	68,549	(1,607)
Total investment grade securities	352,545	(16,350)	8,852,284	(1,250,268)	9,204,829	(1,266,618)
Below investment grade securities:						
Corporates, by sector:						
Industrials	2,670	(169)	143,088	(32,158)	145,758	(32,327)
Financial	4,199	(13)	178,887	(38,122)	183,086	(38,135)
Utilities	—	—	11,945	(790)	11,945	(790)
Total corporates	6,869	(182)	333,920	(71,070)	340,789	(71,252)
Collateralized debt obligations	—	—	—	—	—	—
Other asset-backed securities	—	—	5,432	(70)	5,432	(70)
Total below investment grade securities	6,869	(182)	339,352	(71,140)	346,221	(71,322)
Total fixed maturities	\$ 359,414	\$ (16,532)	\$ 9,191,636	\$ (1,321,408)	\$ 9,551,050	\$ (1,337,940)

Analysis of Gross Unrealized Investment Losses						
At December 31, 2023						
	Less than Twelve Months		Twelve Months or Longer		Total	
	Fair Value	Unrealized Loss	Fair Value	Unrealized Loss	Fair Value	Unrealized Loss
Fixed maturities available for sale:						
Investment grade securities:						
U.S. Government direct, guaranteed, and government-sponsored enterprises	\$ —	\$ —	\$ 364,006	\$ (32,306)	\$ 364,006	\$ (32,306)
States, municipalities, and political subdivisions	252,800	(3,520)	1,610,163	(399,809)	1,862,963	(403,329)
Foreign governments	—	—	32,591	(10,348)	32,591	(10,348)
Corporates, by sector:						
Industrials	191,573	(3,881)	4,317,827	(530,011)	4,509,400	(533,892)
Financial	242,099	(6,584)	2,341,424	(339,628)	2,583,523	(346,212)
Utilities	81,194	(648)	686,043	(91,959)	767,237	(92,607)
Total corporates	514,866	(11,113)	7,345,294	(961,598)	7,860,160	(972,711)
Collateralized debt obligations	—	—	—	—	—	—
Other asset-backed securities	—	—	70,956	(3,648)	70,956	(3,648)
Total investment grade securities	767,666	(14,633)	9,423,010	(1,407,709)	10,190,676	(1,422,342)
Below investment grade securities:						
Corporates, by sector:						
Industrials	10,745	(199)	145,697	(32,756)	156,442	(32,955)
Financial	25,563	(2,602)	151,190	(39,526)	176,753	(42,128)
Utilities	—	—	19,654	(1,523)	19,654	(1,523)
Total corporates	36,308	(2,801)	316,541	(73,805)	352,849	(76,606)
Collateralized debt obligations	—	—	—	—	—	—
Other asset-backed securities	—	—	11,288	(409)	11,288	(409)
Total below investment grade securities	36,308	(2,801)	327,829	(74,214)	364,137	(77,015)
Total fixed maturities	\$ 803,974	\$ (17,434)	\$ 9,750,839	\$ (1,481,923)	\$ 10,554,813	\$ (1,499,357)

Schedule of Fair Value Assets Measured on Recurring Basis Using Significant Unobservable Inputs

The following tables represent changes in fixed maturities measured at fair value on a recurring basis using significant unobservable inputs (Level 3):

Analysis of Changes in Fair Value Measurements Using Significant Unobservable Inputs (Level 3)					
	Asset-backed Securities	Collateralized Debt Obligations	Corporates	Total	
Balance at January 1, 2024	\$ —	\$ 42,146	\$ 454,733	\$	496,879
Included in realized gains / losses	—	—	—		—
Included in other comprehensive income	—	762	5,448		6,210
Acquisitions	7,876	—	14,800		22,676
Sales	—	—	—		—
Amortization	—	3,414	(38)		3,376
Other ⁽¹⁾	—	(3,839)	(29,132)		(32,971)
Transfers into Level 3 ⁽²⁾	—	—	—		—
Transfers out of Level 3 ⁽²⁾	—	—	—		—
Balance at September 30, 2024	\$ 7,876	\$ 42,483	\$ 445,811	\$	496,170
Percent of total fixed maturities	— %	— %	3 %		3 %

(1) Includes capitalized interest, foreign exchange adjustments, and principal repayments.

(2) Considered to be transferred at the end of the period. Transfers into Level 3 occur when observable inputs are no longer available. Transfers out of Level 3 occur when observable inputs become available.

Analysis of Changes in Fair Value Measurements Using Significant Unobservable Inputs (Level 3)					
	Asset-backed Securities	Collateralized Debt Obligations	Corporates	Total	
Balance at January 1, 2023	\$ —	\$ 50,364	\$ 478,083	\$	528,447
Included in realized gains / losses	—	—	—		—
Included in other comprehensive income	—	(8,424)	(15,968)		(24,392)
Acquisitions	—	—	—		—
Sales	—	—	—		—
Amortization	—	3,429	5		3,434
Other ⁽¹⁾	—	(3,684)	(26,669)		(30,353)
Transfers into Level 3 ⁽²⁾	—	—	—		—
Transfers out of Level 3 ⁽²⁾	—	—	—		—
Balance at September 30, 2023	\$ —	\$ 41,685	\$ 435,451	\$	477,136
Percent of total fixed maturities	— %	— %	3 %		3 %

(1) Includes capitalized interest, foreign exchange adjustments, and principal repayments.

(2) Considered to be transferred at the end of the period. Transfers into Level 3 occur when observable inputs are no longer available. Transfers out of Level 3 occur when observable inputs become available.

The following table presents changes in unrealized gains and losses for the period included in accumulated other comprehensive income for assets held at the end of the reporting period for Level 3 classification:

Changes in Unrealized Gains (Losses) included in Accumulated Other Comprehensive Income for Assets Held at the End of the Period					
	Asset-backed Securities	Collateralized Debt Obligations	Corporates	Total	
At September 30, 2024	\$ —	\$ 762	\$ 5,448	\$ 6,210	
At September 30, 2023	—	(8,424)	(15,968)	(24,392)	

[Schedule of Additional Information about Investments in Unrealized Loss Position](#)

[Schedule of Fixed Maturities, Allowance for Credit Loss](#)

[Schedule of Commercial Mortgage Loan Participations](#)

[Schedule of Commercial Loan Participations, Credit Quality Indicators](#)

The following table discloses information about fixed maturities available for sale in an unrealized loss position.

	Less than Twelve Months	Twelve Months or Longer	Total
Number of issues (CUSIPs) held:			
As of September 30, 2024	87	1,553	1,640
As of December 31, 2023	151	1,614	1,765

A summary of the activity in the allowance for credit losses is as follows.

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Allowance for credit losses beginning balance	\$ 7,132	\$ 72,508	\$ 7,115	\$ —
Additions to allowance for which credit losses were not previously recorded	—	—	—	72,508
Additions (reductions) to allowance for fixed maturities that previously had an allowance	—	(65,008)	17	(65,008)
Reduction of allowance for which the Company intends to sell or more likely than not will be required to sell or sold during the period	—	—	—	—
Allowance for credit losses ending balance	<u>\$ 7,132</u>	<u>\$ 7,500</u>	<u>\$ 7,132</u>	<u>\$ 7,500</u>

Summaries of commercial mortgage loans by property type and geographical location at September 30, 2024 and December 31, 2023 are as follows:

	September 30, 2024		December 31, 2023	
	Carrying Value	% of Total	Carrying Value	% of Total
Property type:				
Multi-family	\$ 127,155	33	\$ 116,299	42
Industrial	102,402	27	57,267	20
Retail	73,252	19	23,925	9
Hospitality	43,435	11	43,897	16
Mixed use	35,886	10	34,749	12
Office	6,387	2	6,734	2
Total recorded investment	388,517	102	282,871	101
Less allowance for credit losses	(7,202)	(2)	(3,672)	(1)
Carrying value, net of allowance for credit losses	<u>\$ 381,315</u>	<u>100</u>	<u>\$ 279,199</u>	<u>100</u>

	September 30, 2024		December 31, 2023	
	Carrying Value	% of Total	Carrying Value	% of Total
Geographic location:				
Texas	\$ 75,002	20	\$ 45,111	16
New Jersey	51,454	14	44,574	16
Florida	46,506	12	48,233	17
California	40,715	11	54,721	20
New York	35,865	9	20,284	7
Alabama	35,838	9	11,003	4
Other	103,137	27	58,945	21
Total recorded investment	388,517	102	282,871	101
Less allowance for credit losses	(7,202)	(2)	(3,672)	(1)
Carrying value, net of allowance for credit losses	<u>\$ 381,315</u>	<u>100</u>	<u>\$ 279,199</u>	<u>100</u>

The following tables are reflective of the key factors, debt service coverage ratios, and loan-to-value (LTV) ratios that are utilized by management to monitor the performance of the portfolios. The Company only makes new investments in commercial mortgage loans that have a LTV ratio less than 80%. LTV's that exceed 80% are generally as a result of decreases in the valuation of the underlying property. Generally, a higher LTV ratio and a lower debt service coverage ratio equates to higher risk of loss.

	September 30, 2024				
	Recorded Investment				
	Debt Service Coverage Ratios ⁽¹⁾				
	<1.00x	1.00x—1.20x	>1.20x	Total	% of Gross Total
Loan-to-value ratio⁽²⁾:					
Less than 70%	\$ 22,841	\$ 138,034	\$ 203,226	\$ 364,101	94
70% to 80%	1,058	—	—	1,058	—
81% to 90%	8,569	—	—	8,569	2
Greater than 90%	14,789	—	—	14,789	4
Total	<u>\$ 47,257</u>	<u>\$ 138,034</u>	<u>\$ 203,226</u>	<u>388,517</u>	<u>100</u>
Less allowance for credit losses				(7,202)	
Total, net of allowance for credit losses				<u>\$ 381,315</u>	

(1) Annual net operating income divided by annual mortgage debt service (principal and interest).

(2) Loan balance divided by stabilized appraised value at origination, including planned renovations and stabilized occupancy. Updated internal valuations are used when a loan is materially underperforming.

	December 31, 2023				
	Recorded Investment				
	Debt Service Coverage Ratios ⁽¹⁾				
	<1.00x	1.00x—1.20x	>1.20x	Total	% of Gross Total
Loan-to-value ratio⁽²⁾:					
Less than 70%	\$ 27,091	\$ 180,761	\$ 58,364	\$ 266,216	94
70% to 80%	—	—	—	—	—
81% to 90%	8,468	—	1,153	9,621	3
Greater than 90%	7,034	—	—	7,034	3
Total	<u>\$ 42,593</u>	<u>\$ 180,761</u>	<u>\$ 59,517</u>	<u>282,871</u>	<u>100</u>
Less allowance for credit losses				(3,672)	
Total, net of allowance for credit losses				<u>\$ 279,199</u>	

(1) Annual net operating income divided by annual mortgage debt service (principal and interest).

(2) Loan balance divided by stabilized appraised value at origination, including planned renovations and stabilized occupancy. Updated internal valuations are used when a loan is materially underperforming.

[Schedule of Commercial Loan Participations, Allowance for Credit Loss](#)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Allowance for credit losses beginning balance	\$ 5,826	\$ 2,928	\$ 3,672	\$ 1,789
Provision (reversal) for credit losses	1,376	60	3,530	1,199
Allowance for credit losses ending balance	<u>\$ 7,202</u>	<u>\$ 2,988</u>	<u>\$ 7,202</u>	<u>\$ 2,988</u>

Other long-term investments consist of the following assets:

	September 30, 2024	December 31, 2023
Investment funds	\$ 979,397	\$ 795,583
Company-owned life insurance	200,114	—
Other	42,377	40,295
Total	<u>\$ 1,221,888</u>	<u>\$ 835,878</u>

[Schedule of Investment Funds](#)

The following table presents additional information about the Company's investment funds as of September 30, 2024 and December 31, 2023 at fair value:

Investment Category	Fair Value		Unfunded Commitments		Redemption Term/Notice ⁽¹⁾
	September 30, 2024	December 31, 2023	September 30, 2024		
Commercial mortgage loans	\$ 567,425	\$ 411,315	\$ 378,892		Fully redeemable and non-redeemable with varying terms.
Opportunistic and private credit	195,957	181,410	166,514		Fully redeemable and non-redeemable with varying terms.
Infrastructure	174,971	165,887	16,318		Fully redeemable and non-redeemable with varying terms.
Other	41,044	36,971	50,757		Non-redeemable with varying terms
Total investment funds	<u>\$ 979,397</u>	<u>\$ 795,583</u>	<u>\$ 612,481</u>		

(1) Non-redeemable funds generally have an expected life of 7 to 12 years from fund closing with extension options of 1 to 4 years. Redemptions are paid out throughout the life of the funds at the General Partner's discretion. Redeemable funds can generally be redeemed over 6 to 36 months upon request from limited partners.

XML 47-R29.htm IDEA: XBRL DOCUMENT

[Policy Liabilities \(Tables\)](#)

[Policyholder Account Balance \[Abstract\]](#)

[Schedule of Liability for Future Policy Benefit, Activity](#)

**9 Months Ended
Sep. 30, 2024**

Life						
Present value of expected future net premiums						
	American Income	DTC	Liberty National	Other		Total
Balance at January 1, 2023	\$ 4,273,156	\$ 5,910,224	\$ 1,094,407	\$ 470,741	\$	11,748,528
Beginning balance at original discount rates	4,246,723	5,680,864	1,066,123	449,209		11,442,919
Effect of changes in assumptions on future cash flows	14,265	36,170	5,178	8,419		64,032
Effect of actual variances from expected experience	(103,922)	(219,723)	(26,533)	(13,882)		(364,060)
Adjusted balance at January 1, 2023	4,157,066	5,497,311	1,044,768	443,746		11,142,891
Issuances ⁽¹⁾	557,844	450,361	92,894	21,756		1,122,855
Interest accrual ⁽²⁾	147,968	214,988	40,362	17,071		420,389
Net premiums collected ⁽³⁾	(388,288)	(461,367)	(100,093)	(34,542)		(984,290)
Effect of changes in the foreign exchange rate	(631)	—	—	—		(631)
Ending balance at original discount rates	4,473,959	5,701,293	1,077,931	448,031		11,701,214
Effect of change from original to current discount rates	(155,254)	(31,118)	(18,702)	(1,499)		(206,573)
Balance at September 30, 2023	\$ 4,318,705	\$ 5,670,175	\$ 1,059,229	\$ 446,532	\$	11,494,641
Balance at January 1, 2024	\$ 4,681,888	\$ 6,052,651	\$ 1,129,716	\$ 478,052	\$	12,342,307
Beginning balance at original discount rates	4,523,329	5,664,259	1,077,831	443,949		11,709,368
Effect of changes in assumptions on future cash flows	(82,348)	(28,366)	(29,292)	(982)		(140,988)
Effect of actual variances from expected experience	(173,180)	(226,062)	(29,381)	(9,292)		(437,915)
Adjusted balance at January 1, 2024	4,267,801	5,409,831	1,019,158	433,675		11,130,465
Issuances ⁽¹⁾	616,527	398,034	90,517	18,126		1,123,204
Interest accrual ⁽²⁾	164,917	220,485	41,610	17,213		444,225
Net premiums collected ⁽³⁾	(412,717)	(455,625)	(101,687)	(33,960)		(1,003,989)
Effect of changes in the foreign exchange rate	(4,101)	—	—	—		(4,101)
Ending balance at original discount rates	4,632,427	5,572,725	1,049,598	435,054		11,689,804
Effect of change from original to current discount rates	204,567	421,888	54,498	35,513		716,466
Balance at September 30, 2024	\$ 4,836,994	\$ 5,994,613	\$ 1,104,096	\$ 470,567	\$	12,406,270

- (1) Issuances represent the present value, using the original discount rate, of the expected net premiums related to new policies issued during each respective period.
(2) The interest accrual is the interest earned on the beginning present value of the expected net premiums, as well as the interest on actual net premiums earned during the period, using the original interest rate.
(3) Net premiums collected represent the product of the current period net premium ratio and the gross premiums collected during the period on the in-force business.

Life						
Present value of expected future net premiums						
	American Income	DTC	Liberty National	Other		Total
Balance at July 1, 2023	\$ 4,472,847	\$ 5,988,577	\$ 1,110,017	\$ 471,279	\$	12,042,720
Beginning balance at original discount rates	4,399,053	5,700,354	1,071,561	445,475		11,616,443
Effect of changes in assumptions on future cash flows	14,265	36,170	5,178	8,419		64,032
Effect of actual variances from expected experience	(34,571)	(91,120)	(10,938)	(7,232)		(143,861)
Adjusted balance at July 1, 2023	4,378,747	5,645,404	1,065,801	446,662		11,536,614
Issuances ⁽¹⁾	181,823	136,611	32,045	7,143		357,622
Interest accrual ⁽²⁾	51,119	72,515	13,707	5,741		143,082
Net premiums collected ⁽³⁾	(131,329)	(153,237)	(33,622)	(11,515)		(329,703)
Effect of changes in the foreign exchange rate	(6,401)	—	—	—		(6,401)
Ending balance at original discount rates	4,473,959	5,701,293	1,077,931	448,031		11,701,214
Effect of change from original to current discount rates	(155,254)	(31,118)	(18,702)	(1,499)		(206,573)
Balance at September 30, 2023	\$ 4,318,705	\$ 5,670,175	\$ 1,059,229	\$ 446,532	\$	11,494,641
Balance at July 1, 2024	\$ 4,635,903	\$ 5,810,518	\$ 1,085,233	\$ 449,883	\$	11,981,537
Beginning balance at original discount rates	4,648,111	5,670,288	1,080,642	437,551		11,836,592
Effect of changes in assumptions on future cash flows	(82,348)	(28,366)	(29,292)	(982)		(140,988)
Effect of actual variances from expected experience	(59,483)	(109,089)	(12,113)	(1,970)		(176,555)
Adjusted balance at July 1, 2024	4,506,280	5,538,833	1,039,237	434,599		11,518,949
Issuances ⁽¹⁾	203,828	110,993	30,298	5,969		351,088
Interest accrual ⁽²⁾	55,750	73,134	13,836	5,709		148,429
Net premiums collected ⁽³⁾	(138,552)	(150,235)	(33,773)	(11,223)		(333,783)
Effect of changes in the foreign exchange rate	5,121	—	—	—		5,121
Ending balance at original discount rates	4,632,427	5,572,725	1,049,598	435,054		11,689,804
Effect of change from original to current discount rates	204,567	421,888	54,498	35,513		716,466
Balance at September 30, 2024	\$ 4,836,994	\$ 5,994,613	\$ 1,104,096	\$ 470,567	\$	12,406,270

- (1) Issuances represent the present value, using the original discount rate, of the expected net premiums related to new policies issued during each respective period.
(2) The interest accrual is the interest earned on the beginning present value of the expected net premiums, as well as the interest on actual net premiums earned during the period, using the original interest rate.
(3) Net premiums collected represent the product of the current period net premium ratio and the gross premiums collected during the period on the in-force business.

Life						
Present value of expected future policy benefits						
	American Income	DTC	Liberty National	Other		Total
Balance at January 1, 2023	\$ 9,119,104	\$ 9,225,451	\$ 3,429,256	\$ 3,976,150	\$	25,749,961
Beginning balance at original discount rates	8,409,761	8,477,892	3,272,980	3,403,704		23,564,337
Effect of changes in assumptions on future cash flows	13,344	34,407	6,156	11,661		65,568
Effect of actual variances from expected experience	(109,386)	(227,639)	(27,482)	(17,962)		(382,469)
Adjusted balance at January 1, 2023	8,313,719	8,284,660	3,251,654	3,397,403		23,247,436
Issuances ⁽¹⁾	557,844	450,362	92,894	21,756		1,122,856
Interest accrual ⁽²⁾	335,349	342,208	130,712	152,378		960,647
Benefit payments ⁽³⁾	(296,133)	(432,393)	(153,294)	(86,008)		(967,828)
Effect of changes in the foreign exchange rate	(819)	—	—	—		(819)
Ending balance at original discount rates	8,909,960	8,644,837	3,321,966	3,485,529		24,362,292
Effect of change from original to current discount rates	80,477	228,607	(46,234)	282,118		544,968
Balance at September 30, 2023	\$ 8,990,437	\$ 8,873,444	\$ 3,275,732	\$ 3,767,647	\$	24,907,260
Balance at January 1, 2024	\$ 10,163,627	\$ 9,714,516	\$ 3,605,392	\$ 4,239,623	\$	27,723,158
Beginning balance at original discount rates	9,061,833	8,656,752	3,338,252	3,506,859		24,563,696
Effect of changes in assumptions on future cash flows	(104,498)	(50,106)	(41,836)	(2,027)		(198,467)
Effect of actual variances from expected experience	(187,711)	(241,231)	(34,722)	(12,841)		(476,505)
Adjusted balance at January 1, 2024	8,769,624	8,365,415	3,261,694	3,491,991		23,888,724
Issuances ⁽¹⁾	611,802	398,032	90,518	18,127		1,118,479
Interest accrual ⁽²⁾	367,403	355,850	134,020	157,318		1,014,591
Benefit payments ⁽³⁾	(326,318)	(439,992)	(159,219)	(103,998)		(1,029,527)
Effect of changes in the foreign exchange rate	(8,768)	—	—	—		(8,768)
Ending balance at original discount rates	9,413,743	8,679,305	3,327,013	3,563,438		24,983,499
Effect of change from original to current discount rates	1,091,042	1,082,717	275,358	717,751		3,166,868
Balance at September 30, 2024	\$ 10,504,785	\$ 9,762,022	\$ 3,602,371	\$ 4,281,189	\$	28,150,367

- (1) Issuances represent the present value, using the original discount rate, of the expected future policy benefits related to new policies issued during each respective period.
(2) The interest accrual is the interest earned on the beginning present value of the expected future policy benefits, as well as the interest on actual benefits and expenses paid during the period, using the original interest rate.
(3) Benefit payments represent the release of the present value, using the original discount rate, of the actual future policy benefits incurred during the period due to death, surrender, and maturity benefit payments based on the revised expected assumptions.

Life						
Present value of expected future policy benefits						
	American Income	DTC	Liberty National	Other		Total
Balance at July 1, 2023	\$ 9,668,207	\$ 9,487,233	\$ 3,507,845	\$ 4,109,706	\$	26,772,991
Beginning balance at original discount rates	8,753,526	8,592,897	3,297,781	3,448,491		24,092,695
Effect of changes in assumptions on future cash flows	13,344	34,407	6,156	11,661		65,568
Effect of actual variances from expected experience	(36,998)	(97,632)	(14,364)	(9,595)		(158,589)
Adjusted balance at July 1, 2023	8,729,872	8,529,672	3,289,573	3,450,557		23,999,674
Issuances ⁽¹⁾	181,822	136,612	32,046	7,145		357,625
Interest accrual ⁽²⁾	114,683	115,547	43,991	51,249		325,470
Benefit payments ⁽³⁾	(101,161)	(136,994)	(43,644)	(23,422)		(305,221)
Effect of changes in the foreign exchange rate	(15,256)	—	—	—		(15,256)
Ending balance at original discount rates	8,909,960	8,644,837	3,321,966	3,485,529		24,362,292
Effect of change from original to current discount rates	80,477	228,607	(46,234)	282,118		544,968
Balance at September 30, 2023	\$ 8,990,437	\$ 8,873,444	\$ 3,275,732	\$ 3,767,647	\$	24,907,260
Balance at July 1, 2024	\$ 9,811,407	\$ 9,289,834	\$ 3,424,768	\$ 3,981,898	\$	26,507,907
Beginning balance at original discount rates	9,355,526	8,748,900	3,356,531	3,545,323		25,004,280
Effect of changes in assumptions on future cash flows	(104,498)	(50,106)	(41,836)	(2,027)		(198,467)
Effect of actual variances from expected experience	(65,766)	(111,255)	(15,385)	(2,629)		(195,035)
Adjusted balance at July 1, 2024	9,183,262	8,587,539	3,299,310	3,540,667		24,610,778
Issuances ⁽¹⁾	199,097	110,991	30,298	5,970		346,356
Interest accrual ⁽²⁾	124,308	118,873	44,743	52,747		340,671
Benefit payments ⁽³⁾	(105,757)	(138,098)	(47,338)	(35,946)		(327,139)
Effect of changes in the foreign exchange rate	12,833	—	—	—		12,833
Ending balance at original discount rates	9,413,743	8,679,305	3,327,013	3,563,438		24,983,499
Effect of change from original to current discount rates	1,091,042	1,082,717	275,358	717,751		3,166,868
Balance at September 30, 2024	\$ 10,504,785	\$ 9,762,022	\$ 3,602,371	\$ 4,281,189	\$	28,150,367

- (1) Issuances represent the present value, using the original discount rate, of the expected future policy benefits related to new policies issued during each respective period.
(2) The interest accrual is the interest earned on the beginning present value of the expected future policy benefits, as well as the interest on actual benefits and expenses paid during the period, using the original interest rate.
(3) Benefit payments represent the release of the present value, using the original discount rate, of the actual future policy benefits incurred during the period due to death, surrender, and maturity benefit payments based on the revised expected assumptions.

Life ⁽²⁾						
Net liability for future policy benefits as of September 30, 2023						
	American Income	DTC	Liberty National	Other		Total
Net liability for future policy benefits at original discount rates	\$ 4,436,001	\$ 2,943,544	\$ 2,244,035	\$ 3,037,498	\$	12,661,078
Effect of changes in discount rate assumptions	235,731	259,725	(27,532)	283,617		751,541
Other adjustments ⁽¹⁾	508	3,982	6,272	466		11,228
Net liability for future policy benefits, after other adjustments, at current discount rates	4,672,240	3,207,251	2,222,775	3,321,581		13,423,847
Reinsurance recoverable	(141)	—	(7,661)	(32,947)		(40,749)
Net liability for future policy benefits, after reinsurance recoverable, at current discount rates	\$ 4,672,099	\$ 3,207,251	\$ 2,215,114	\$ 3,288,634	\$	13,383,098

- (1) Other adjustments include the Company's effects of capping and flooring the liability (guidance requires an amount not less than zero at the calculation level of the liability for future policy benefits).
(2) Includes the immaterial error correction noted below.

	Life					
	Net liability for future policy benefits as of September 30, 2024					
	American Income	DTC	Liberty National	American Income	Other	Total
Net liability for future policy benefits at original discount rates	\$ 4,781,316	\$ 3,106,580	\$ 2,277,415	\$ 3,128,384	\$ 13,293,695	
Effect of changes in discount rate assumptions	886,475	660,829	220,860	682,238	2,450,402	
Other adjustments ⁽¹⁾	150	—	—	37	187	
Net liability for future policy benefits, after other adjustments, at current discount rates	5,667,941	3,767,409	2,498,275	3,810,659	15,744,284	
Reinsurance recoverable	(170)	—	(7,885)	(38,506)	(46,561)	
Net liability for future policy benefits, after reinsurance recoverable, at current discount rates	\$ 5,667,771	\$ 3,767,409	\$ 2,490,390	\$ 3,772,153	\$ 15,697,723	

(1) Other adjustments include the Company's effects of flooring the liability (guidance requires an amount not less than zero at the calculation level of the liability for future policy benefits).
The following tables summarize balances and changes in the net liability for future policy benefits for long-duration health contracts for the three and nine month periods ended September 30, 2024 and 2023:

	Health					
	Present value of expected future net premiums					
	United American	Family Heritage	Liberty National	American Income	DTC	Total
Balance at January 1, 2023	\$ 2,908,501	\$ 1,594,992	\$ 423,490	\$ 190,296	\$ 90,143	\$ 5,207,422
Beginning balance at original discount rates	2,941,261	1,729,219	415,442	192,631	87,751	5,366,304
Effect of changes in assumptions on future cash flows	466,883	(30,255)	(56,964)	(6,061)	16,553	390,156
Effect of actual variances from expected experience	(6,240)	(192,981)	(30,526)	(9,976)	(1,666)	(96,127)
Adjusted balance at January 1, 2023	3,401,904	1,648,912	327,952	178,927	102,638	5,660,333
Issuances ⁽¹⁾	226,363	202,561	43,373	30,667	6,532	509,496
Interest accrual ⁽²⁾	99,390	50,091	14,047	6,304	3,278	173,110
Net premiums collected ⁽³⁾	(202,669)	(134,009)	(38,322)	(16,611)	(8,028)	(399,639)
Effect of changes in the foreign exchange rate	—	—	—	(165)	—	(165)
Ending balance at original discount rates	3,524,988	1,767,555	347,050	199,122	104,420	5,943,135
Effect of change from original to current discount rates	(183,608)	(192,981)	(30,526)	(9,976)	(1,666)	(396,191)
Balance at September 30, 2023	\$ 3,341,380	\$ 1,574,574	\$ 338,678	\$ 189,146	\$ 103,166	\$ 5,546,944
Balance at January 1, 2024	\$ 3,697,771	\$ 1,711,741	\$ 358,472	\$ 206,381	\$ 115,363	\$ 6,089,728
Beginning balance at original discount rates	3,625,803	1,783,173	348,570	201,869	109,880	6,069,295
Effect of changes in assumptions on future cash flows	9,892	(8,117)	(3,463)	12,207	4,449	14,968
Effect of actual variances from expected experience	(18,894)	(43,359)	(11,123)	(1,111)	(1,818)	(301,362)
Adjusted balance at January 1, 2024	3,616,801	1,731,697	318,984	202,908	112,511	5,982,901
Issuances ⁽¹⁾	287,072	200,220	43,367	34,121	12,325	577,105
Interest accrual ⁽²⁾	128,533	55,733	12,450	7,135	4,221	208,072
Net premiums collected ⁽³⁾	(220,380)	(141,735)	(39,223)	(18,171)	(8,338)	(427,847)
Effect of changes in the foreign exchange rate	—	—	—	(377)	—	(377)
Ending balance at original discount rates	3,812,026	1,845,915	335,578	225,616	120,719	6,339,854
Effect of change from original to current discount rates	(130,218)	(44,372)	(11,529)	(8,173)	(7,153)	(112,701)
Balance at September 30, 2024	\$ 3,942,244	\$ 1,801,543	\$ 347,107	\$ 233,789	\$ 127,872	\$ 6,452,555

- (1) Issuances represent the present value, using the original discount rate, of the expected net premiums related to new policies issued during each respective period.
(2) The interest accrual is the interest earned on the beginning present value of the expected net premiums, as well as the interest on actual net premiums earned during the period, using the original interest rate.
(3) Net premiums collected represent the product of the current period net premium ratio and the gross premiums collected during the period on the in-force business.

	Health					
	Present value of expected future net premiums					
	United American	Family Heritage	Liberty National	American Income	DTC	Total
Balance at July 1, 2023	\$ 2,984,554	\$ 1,661,020	\$ 409,551	\$ 201,844	\$ 89,674	\$ 5,346,643
Beginning balance at original discount rates	2,985,660	1,771,206	400,180	201,709	86,840	5,445,595
Effect of changes in assumptions on future cash flows	466,883	(30,255)	(56,964)	(6,061)	16,553	390,156
Effect of actual variances from expected experience	22,683	(15,658)	(2,692)	(2,394)	229	2,168
Adjusted balance at July 1, 2023	3,475,226	1,725,293	340,524	193,254	103,622	5,837,919
Issuances ⁽¹⁾	82,647	70,216	15,183	9,880	2,317	180,243
Interest accrual ⁽²⁾	35,536	17,272	4,380	2,170	1,160	60,518
Net premiums collected ⁽³⁾	(68,421)	(45,266)	(13,037)	(5,630)	(2,679)	(134,993)
Effect of changes in the foreign exchange rate	—	—	—	(552)	—	(552)
Ending balance at original discount rates	3,524,988	1,767,555	347,050	199,122	104,420	5,943,135
Effect of change from original to current discount rates	(183,608)	(192,981)	(30,526)	(9,976)	(1,666)	(396,191)
Balance at September 30, 2023	\$ 3,341,380	\$ 1,574,574	\$ 338,678	\$ 189,146	\$ 103,166	\$ 5,546,944
Balance at July 1, 2024	\$ 3,658,491	\$ 1,690,797	\$ 337,741	\$ 205,889	\$ 114,876	\$ 6,007,794
Beginning balance at original discount rates	3,720,108	1,823,728	338,934	208,867	113,247	6,204,884
Effect of changes in assumptions on future cash flows	9,892	(8,117)	(3,463)	12,207	4,449	14,968
Effect of actual variances from expected experience	18,179	(12,068)	(4,959)	(4,110)	644	(2,314)
Adjusted balance at July 1, 2024	3,748,179	1,803,543	330,512	216,964	118,340	6,217,538
Issuances ⁽¹⁾	95,279	71,345	14,352	11,997	3,823	196,796
Interest accrual ⁽²⁾	43,903	19,016	4,104	2,493	1,460	70,976
Net premiums collected ⁽³⁾	(75,335)	(47,989)	(13,390)	(6,300)	(2,904)	(145,918)
Effect of changes in the foreign exchange rate	—	—	—	462	—	462
Ending balance at original discount rates	3,812,026	1,845,915	335,578	225,616	120,719	6,339,854
Effect of change from original to current discount rates	(130,218)	(44,372)	(11,529)	(8,173)	(7,153)	(112,701)
Balance at September 30, 2024	\$ 3,942,244	\$ 1,801,543	\$ 347,107	\$ 233,789	\$ 127,872	\$ 6,452,555

- (1) Issuances represent the present value, using the original discount rate, of the expected net premiums related to new policies issued during each respective period.
(2) The interest accrual is the interest earned on the beginning present value of the expected net premiums, as well as the interest on actual net premiums earned during the period, using the original interest rate.
(3) Net premiums collected represent the product of the current period net premium ratio and the gross premiums collected during the period on the in-force business.

	Health					
	Present value of expected future policy benefits					
	United American	Family Heritage	Liberty National	American Income	DTC	Total
Balance at January 1, 2023	\$ 3,046,829	\$ 3,005,664	\$ 941,574	\$ 312,750	\$ 87,532	\$ 7,394,349
Beginning balance at original discount rates	3,080,633	3,336,344	904,865	303,713	85,212	7,710,767
Effect of changes in assumptions on future cash flows	464,652	(32,428)	(60,437)	(6,407)	15,930	381,310
Effect of actual variances from expected experience	(5,530)	(53,292)	(29,581)	(8,680)	(1,925)	(99,008)
Adjusted balance at January 1, 2023	3,539,755	3,250,624	814,847	288,626	99,217	7,993,069
Issuances ⁽¹⁾	225,915	202,561	42,863	30,667	6,518	508,524
Interest accrual ⁽²⁾	104,932	99,344	34,699	11,199	3,278	253,452
Benefit payments ⁽³⁾	(221,753)	(92,973)	(73,614)	(18,633)	(9,502)	(416,475)
Effect of changes in the foreign exchange rate	—	—	—	(217)	—	(217)
Ending balance at original discount rates	3,648,849	3,459,556	818,795	311,642	99,511	8,338,353
Effect of change from original to current discount rates	(191,041)	(498,312)	(4,792)	(5,601)	(1,111)	(700,857)
Balance at September 30, 2023	\$ 3,457,808	\$ 2,961,244	\$ 814,003	\$ 306,041	\$ 98,400	\$ 7,637,496
Balance at January 1, 2024	\$ 3,814,328	\$ 3,315,880	\$ 865,808	\$ 335,504	\$ 109,482	\$ 8,441,002
Beginning balance at original discount rates	3,741,530	3,506,689	816,819	315,431	104,501	8,484,970
Effect of changes in assumptions on future cash flows	10,680	(5,054)	(2,775)	20,293	7,733	30,877
Effect of actual variances from expected experience	(15,162)	(48,407)	(26,421)	(12,611)	(11,509)	(104,110)
Adjusted balance at January 1, 2024	3,737,048	3,453,228	787,623	323,113	110,725	8,411,737
Issuances ⁽¹⁾	286,358	200,219	42,780	34,123	12,296	575,776
Interest accrual ⁽²⁾	133,143	109,479	32,202	12,145	4,220	291,189
Benefit payments ⁽³⁾	(248,769)	(103,070)	(69,649)	(19,574)	(9,655)	(450,717)
Effect of changes in the foreign exchange rate	—	—	—	(646)	—	(646)
Ending balance at original discount rates	3,907,780	3,659,856	792,956	349,161	117,586	8,827,339
Effect of change from original to current discount rates	(131,531)	(144,821)	(52,819)	(24,383)	(6,871)	(70,783)
Balance at September 30, 2024	\$ 4,039,311	\$ 3,515,035	\$ 845,775	\$ 373,544	\$ 124,457	\$ 8,898,122

- (1) Issuances represent the present value, using the original discount rate, of the expected future policy benefits related to new policies issued during each respective period.
(2) The interest accrual is the interest earned on the beginning present value of the expected future policy benefits, as well as the interest on actual benefits and expenses paid during the period, using the original interest rate.
(3) Benefit payments represent the release of the present value, using the original discount rate, of the actual future policy benefits incurred during the period based on the revised expected assumptions.

	Health					
	Present value of expected future policy benefits					
	United American	Family Heritage	Liberty National	American Income	DTC	Total
Balance at July 1, 2023	\$ 3,116,389	\$ 3,167,461	\$ 923,148	\$ 328,579	\$ 85,856	\$ 7,621,433
Beginning balance at original discount rates	3,116,389	3,436,167	880,878	315,087	83,188	7,832,089
Effect of changes in assumptions on future cash flows	464,652	(32,428)	(60,437)	(6,407)	15,930	381,310
Effect of actual variances from expected experience	22,410	(17,000)	(2,563)	(2,662)	(95)	90
Adjusted balance at July 1, 2023	3,603,830	3,386,739	817,879	306,018	99,023	8,213,489
Issuances ⁽¹⁾	82,511	70,215	14,963	9,880	2,310	179,879
Interest accrual ⁽²⁾	37,340	34,024	11,173	3,810	1,160	87,507
Benefit payments ⁽³⁾	(74,832)	(31,422)	(25,220)	(6,973)	(2,982)	(141,429)
Effect of changes in the foreign exchange rate	—	—	—	(1,093)	—	(1,093)
Ending balance at original discount rates	3,648,849	3,459,556	818,795	311,642	99,511	8,338,353
Effect of change from original to current discount rates	(191,041)	(498,312)	(4,792)	(5,601)	(1,111)	(700,857)
Balance at September 30, 2023	\$ 3,457,808	\$ 2,961,244	\$ 814,003	\$ 306,041	\$ 98,400	\$ 7,637,496
Balance at July 1, 2024	\$ 3,758,487	\$ 3,249,466	\$ 815,778	\$ 328,436	\$ 108,617	\$ 8,260,784
Beginning balance at original discount rates	3,823,510	3,605,315	799,316	322,706	107,143	8,657,990
Effect of changes in assumptions on future cash flows	10,680	(5,054)	(2,775)	20,293	7,733	30,877
Effect of actual variances from expected experience	21,522	(13,407)	(4,998)	(4,432)	817	(498)
Adjusted balance at July 1, 2024	3,855,712	3,586,854	791,543	338,567	115,693	8,688,369
Issuances ⁽¹⁾	95,126	71,345	14,177	11,997	3,811	196,456
Interest accrual ⁽²⁾	45,365	37,299	10,653	4,189	1,460	98,966
Benefit payments ⁽³⁾	(88,423)	(35,642)	(23,417)	(6,502)	(3,378)	(157,362)
Effect of changes in the foreign exchange rate	—	—	—	910	—	910
Ending balance at original discount rates	3,907,780	3,659,856	792,956	349,161	117,586	8,827,339
Effect of change from original to current discount rates	(131,531)	(144,821)	(52,819)	(24,383)	(6,871)	(70,783)
Balance at September 30, 2024	\$ 4,039,311	\$ 3,515,035	\$ 845,775	\$ 373,544	\$ 124,457	\$ 8,898,122

- (1) Issuances represent the present value, using the original discount rate, of the expected future policy benefits related to new policies issued during each respective period.
(2) The interest accrual is the interest earned on the beginning present value of the expected future policy benefits, as well as the interest on actual benefits and expenses paid during the period, using the original interest rate.
(3) Benefit payments represent the release of the present value, using the original discount rate, of the actual future policy benefits incurred during the period based on the revised expected assumptions.

	Health ⁽²⁾					
	Net liability for future policy benefits as of September 30, 2023					
	United American	Family Heritage	Liberty National	American Income	Direct to Consumer	Total
Net liability for future policy benefits at original discount rates	\$ 123,861	\$ 1,692,001	\$ 471,745	\$ 112,520	\$ (4,909)	\$ 2,395,218
Effect of changes in discount rate assumptions	(7,433)	(305,331)	3,580	4,375	143	(304,666)
Other adjustments ⁽¹⁾	7,729	4,347	8,379	993	5,530	26,978
Net liability for future policy benefits, after other adjustments, at current discount rates	124,157	1,391,017	483,704	117,888	764	2,117,530
Reinsurance recoverable	(3,355)	(9,064)	(1,336)	—	—	(13,759)
Net liability for future policy benefits, after reinsurance recoverable, at current discount rates	\$ 120,802	\$ 1,381,953	\$ 482,368	\$ 117,888	\$ 764	\$ 2,103,775

- (1) Other adjustments include the effects of capping and flooring the liability (guidance requires an amount not less than zero at the calculation level of the liability for future policy benefits).
(2) Includes the immaterial error correction noted below.

Health						
Net liability for future policy benefits as of September 30, 2024						
	United American	Family Heritage	Liberty National	American Income	Direct to Consumer	Total
Net liability for future policy benefits at original discount rates	95,754	1,813,941	457,378	123,545	(3,133)	2,487,485
Effect of changes in discount rate assumptions	1,313	(100,449)	41,290	16,210	(282)	(41,918)
Other adjustments ⁽¹⁾	17,014	38	9,964	926	4,326	32,268
Net liability for future policy benefits, after other adjustments, at current discount rates	114,081	1,713,530	508,632	140,681	911	2,477,835
Reinsurance recoverable	(2,868)	(11,613)	(1,096)	—	—	(15,577)
Net liability for future policy benefits, after reinsurance recoverable, at current discount rates	\$ 111,213	\$ 1,701,917	\$ 507,536	\$ 140,681	\$ 911	\$ 2,462,258

(1) Other adjustments include the effects of flooring the liability (guidance requires an amount not less than zero at the calculation level of the liability for future policy benefits).

The following tables include the total remeasurement gain or loss, bifurcated between the gain or loss due to differences between actual and expected experience and the amount due to assumption updates, for the three and nine month periods ended September 30, 2024 and 2023:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Life Remeasurement Gain (Loss)—Experience:				
American Income	\$	4,771	\$	2,388
Direct to Consumer		6,913		6,293
Liberty National		1,537		2,578
Other		508		2,082
Total Life Remeasurement Gain (Loss)—Experience		13,729		13,341
Life Remeasurement Gain (Loss)—Assumption Updates:				
American Income		21,974		308
Direct to Consumer		21,744		1,763
Liberty National		12,224		(1,248)
Other		(2,836)		904
Total Life Remeasurement Gain (Loss)—Assumption Updates		56,846		(2,013)
Total Life Remeasurement Gain (Loss)		70,575		11,328
Health Remeasurement Gain (Loss)—Experience:				
United American		(2,100)		239
Family Heritage		1,420		1,212
Liberty National		874		634
American Income		729		457
Direct to Consumer		28		35
Total Health Remeasurement Gain (Loss)—Experience		951		2,577
Health Remeasurement Gain (Loss)—Assumption Updates:				
United American		1,205		762
Family Heritage		(3,063)		2,173
Liberty National		(234)		2,171
American Income		(8,036)		119
Direct to Consumer		(373)		8
Health Remeasurement Gain (Loss)—Assumption Updates		(10,501)		5,233
Total Health Remeasurement Gain (Loss)	\$	(9,550)	\$	7,810
			\$	(3,094)
			\$	8,342

The Company performs an annual review of its assumptions during the third quarter. This review process resulted in favorable changes to its mortality and lapse assumptions on life and unfavorable changes to morbidity assumptions on health. Generally, in our life segment mortality assumptions were decreased across most channels in line with recent experience consistent with decreasing levels of excess deaths. Also, for the life segment lapse rate assumptions were slightly increased across all channels. For the health segment, morbidity assumptions were increased, causing higher future policy benefit reserves. The assumption review process of the life and health segments resulted in a \$46.3 million net remeasurement gain as compared to a \$3.2 million net remeasurement gain in the year-ago quarter.

Excluding the impact of assumption changes, the Company's results for actual variances from expected experience for both life and health produced a \$14.7 million net remeasurement gain and a \$15.9 million net remeasurement gain for the three months ended September 30, 2024 and 2023, respectively. During the nine months ended September 30, 2024 and 2023, the Company's results for actual variances from expected experience for both life and health produced a \$38.4 million net remeasurement gain and a \$21.6 million net remeasurement gain, respectively.

The following table reconciles the liability for future policy benefits to the [Condensed Consolidated Balance Sheets](#) as of September 30, 2024 and 2023:

	At Original Discount Rates		At Current Discount Rates	
	As of September 30,		As of September 30,	
	2024	2023 ⁽²⁾	2024	2023 ⁽²⁾
Life ⁽¹⁾ :				
American Income	\$ 4,781,464	\$ 4,436,042	\$ 5,667,941	\$ 4,672,240
Direct to Consumer	3,106,582	2,943,544	3,767,409	3,207,251
Liberty National	2,277,415	2,244,035	2,498,275	2,222,775
Other	3,128,419	3,037,595	3,810,659	3,321,581
Net liability for future policy benefits—long duration life	13,293,880	12,661,216	15,744,284	13,423,847
Health ⁽¹⁾ :				
United American	110,384	129,410	114,081	124,157
Family Heritage	1,813,971	1,692,080	1,713,530	1,391,017
Liberty National	466,474	479,394	508,632	483,704
American Income	124,534	113,340	140,681	117,888
Direct to Consumer	877	752	911	764
Net liability for future policy benefits—long duration health	2,516,240	2,414,976	2,477,835	2,117,530
Deferred profit liability	177,108	173,520	177,108	173,520
Deferred annuity	680,849	813,276	680,849	813,276
Interest sensitive life	725,857	735,025	725,857	735,025
Other	8,983	9,901	8,980	9,904
Total future policy benefits	\$ 17,402,917	\$ 16,807,914	\$ 19,814,913	\$ 17,273,102

(1) Balances are presented net of the effects of capping and flooring the liability (guidance requires an amount not less than zero at the calculation level of the liability for future policy benefits).

(2) Includes the immaterial error correction for reinsurance as noted above.

The following tables provide the weighted-average original and current discount rates for the liability for future policy benefits and the additional insurance liabilities as of September 30, 2024 and 2023:

	As of September 30,			
	2024		2023	
	Original discount rate	Current discount rate	Original discount rate	Current discount rate
Life				
American Income	5.7 %	5.0 %	5.7 %	5.6 %
Direct to Consumer	6.0 %	5.0 %	6.0 %	5.6 %
Liberty National	5.6 %	5.0 %	5.6 %	5.7 %
Other	6.2 %	5.0 %	6.2 %	5.7 %
Health				
United American	5.1 %	4.8 %	5.2 %	5.5 %
Family Heritage	4.2 %	4.9 %	4.3 %	5.7 %
Liberty National	5.8 %	4.8 %	5.8 %	5.7 %
American Income	5.8 %	4.8 %	5.9 %	5.6 %
Direct to Consumer	5.1 %	4.8 %	5.2 %	5.5 %

The following table provides the weighted-average durations of the liability for future policy benefits and the additional insurance liabilities as of September 30, 2024 and 2023:

	As of September 30,			
	2024		2023	
	At original discount rates	At current discount rates	At original discount rates	At current discount rates
Life				
American Income	22.81	23.03	23.08	23.29
Direct to Consumer	19.42	20.81	19.73	21.00
Liberty National	15.31	15.80	15.12	15.20
Other	16.07	17.48	16.34	17.42
Health				
United American	11.73	10.93	11.40	10.34
Family Heritage	15.34	14.60	14.90	13.81
Liberty National	9.26	9.48	9.11	8.97
American Income	12.50	12.89	12.14	12.20
Direct to Consumer	11.73	10.93	11.40	10.34

The following tables summarize the amount of gross premiums and interest related to long duration life and health contracts that are recognized in the [Condensed Consolidated Statements of Operations](#) for the three and nine month periods ended September 30, 2024 and 2023:

	Life			
	Nine Months Ended September 30, 2024		Nine Months Ended September 30, 2023	
	Gross Premiums	Interest expense	Gross Premiums	Interest expense
American Income	\$ 1,264,474	\$ 202,486	\$ 1,181,247	\$ 187,381
Direct to Consumer	734,860	135,249	735,374	127,040
Liberty National	273,746	91,890	256,641	89,765
Other	152,065	138,724	154,836	133,991
Total	\$ 2,425,145	\$ 568,349	\$ 2,328,098	\$ 538,177
	Life			
	Three Months Ended September 30, 2024		Three Months Ended September 30, 2023	
	Gross Premiums	Interest expense	Gross Premiums	Interest expense
American Income	\$ 427,543	\$ 68,558	\$ 399,794	\$ 63,565
Direct to Consumer	243,625	45,708	244,931	42,978
Liberty National	92,636	30,737	87,071	30,095
Other	50,413	46,573	51,493	45,065
Total	\$ 814,217	\$ 191,576	\$ 783,289	\$ 181,703

	Health			
	Nine Months Ended September 30, 2024		Nine Months Ended September 30, 2023	
	Gross Premiums	Interest expense	Gross Premiums	Interest expense
United American	\$ 325,415	\$ 4,449	\$ 298,964	\$ 5,345
Family Heritage	317,065	53,357	294,047	48,904
Liberty National	142,051	19,679	139,875	20,567
American Income	88,017	5,010	84,863	4,896
Direct to Consumer	11,196	—	10,680	—
Total	\$ 883,744	\$ 82,495	\$ 828,429	\$ 79,712

	Health			
	Three Months Ended September 30, 2024		Three Months Ended September 30, 2023	
	Gross Premiums	Interest expense	Gross Premiums	Interest expense
United American	\$ 110,565	\$ 1,408	\$ 100,285	\$ 1,741
Family Heritage	107,819	18,150	99,828	16,632
Liberty National	47,099	6,524	46,441	6,766
American Income	29,628	1,696	28,528	1,640
Direct to Consumer	3,806	—	3,583	—
Total	\$ 298,917	\$ 27,778	\$ 278,665	\$ 26,779

[Schedule of Undiscounted and Discounted Expected Future Gross Premiums and Expected Future Benefits And Expenses](#)

The following tables provide the undiscounted and discounted expected future net premiums, expected future gross premiums, and expected future policy benefits, at both original and current discount rates, for life and health contracts as of September 30, 2024 and 2023:

	Life					
	As of September 30, 2024			As of September 30, 2023		
	Not discounted	At original discount rates	At current discount rates	Not discounted	At original discount rates	At current discount rates
American Income						
PV of expected future gross premiums	\$ 25,300,910	\$ 14,305,914	\$ 15,028,140	\$ 23,974,963	\$ 13,530,015	\$ 13,147,003
PV of expected future net premiums	8,185,825	4,632,427	4,836,994	7,912,903	4,473,959	4,318,705
PV of expected future policy benefits	31,554,905	9,413,743	10,504,785	30,182,319	8,909,960	8,990,437
DTC						
PV of expected future gross premiums	\$ 17,506,090	\$ 9,144,676	\$ 9,825,694	\$ 17,575,618	\$ 9,182,146	\$ 9,112,202
PV of expected future net premiums	10,614,237	5,572,725	5,994,613	10,850,664	5,701,293	5,670,175
PV of expected future policy benefits	25,907,169	8,679,305	9,762,022	25,711,499	8,644,837	8,873,444
Liberty National						
PV of expected future gross premiums	\$ 4,797,146	\$ 2,792,129	\$ 2,886,943	\$ 4,601,176	\$ 2,681,034	\$ 2,577,877
PV of expected future net premiums	1,855,536	1,049,598	1,104,096	1,901,039	1,077,931	1,059,229
PV of expected future policy benefits	9,028,196	3,327,013	3,602,371	8,852,345	3,321,966	3,275,732
Other						
PV of expected future gross premiums	\$ 3,657,885	\$ 1,857,769	\$ 2,063,274	\$ 3,753,093	\$ 1,901,531	\$ 1,953,533
PV of expected future net premiums	894,843	435,054	470,567	919,200	448,031	446,532
PV of expected future policy benefits	12,471,336	3,563,438	4,281,189	12,427,646	3,485,529	3,767,647
Total						
PV of expected future gross premiums	\$ 51,262,031	\$ 28,100,488	\$ 29,804,051	\$ 49,904,850	\$ 27,294,726	\$ 26,790,615
PV of expected future net premiums	21,550,441	11,689,804	12,406,270	21,583,806	11,701,214	11,494,641
PV of expected future policy benefits	78,961,606	24,983,499	28,150,367	77,173,809	24,362,292	24,907,260

	Health					
	As of September 30, 2024			As of September 30, 2023		
	Not discounted	At original discount rates	At current discount rates	Not discounted	At original discount rates	At current discount rates
United American						
PV of expected future gross premiums	\$ 9,068,701	\$ 5,556,347	\$ 5,742,668	\$ 8,442,713	\$ 5,141,771	\$ 4,871,878
PV of expected future net premiums	6,229,763	3,812,026	3,942,244	5,799,017	3,524,988	3,341,380
PV of expected future policy benefits	6,390,307	3,907,780	4,039,311	5,998,770	3,648,849	3,457,808
Family Heritage						
PV of expected future gross premiums	\$ 7,107,124	\$ 4,155,037	\$ 4,074,915	\$ 6,637,472	\$ 3,932,327	\$ 3,523,258
PV of expected future net premiums	3,139,624	1,845,915	1,801,543	2,962,973	1,767,555	1,574,574
PV of expected future policy benefits	7,043,880	3,659,856	3,515,035	6,549,339	3,459,556	2,961,244
Liberty National						
PV of expected future gross premiums	\$ 2,037,319	\$ 1,297,318	\$ 1,370,521	\$ 2,084,428	\$ 1,321,438	\$ 1,308,898
PV of expected future net premiums	495,616	335,578	347,107	515,612	347,050	338,678
PV of expected future policy benefits	1,375,759	792,956	845,775	1,414,512	818,795	814,003
American Income						
PV of expected future gross premiums	\$ 1,781,677	\$ 999,161	\$ 1,063,740	\$ 1,755,682	\$ 984,122	\$ 969,090
PV of expected future net premiums	400,683	225,616	233,789	354,120	199,122	189,146
PV of expected future policy benefits	710,352	349,161	373,544	632,349	311,642	306,041
Direct to Consumer						
PV of expected future gross premiums	\$ 232,805	\$ 147,193	\$ 156,142	\$ 224,522	\$ 141,374	\$ 139,748
PV of expected future net premiums	191,566	120,719	127,872	166,099	104,420	103,166
PV of expected future policy benefits	187,260	117,586	124,457	154,931	99,511	98,400
Total						
PV of expected future gross premiums	\$ 20,227,626	\$ 12,155,056	\$ 12,407,986	\$ 19,144,817	\$ 11,521,032	\$ 10,812,872
PV of expected future net premiums	10,457,252	6,339,854	6,452,555	9,797,821	5,943,135	5,546,944
PV of expected future policy benefits	15,707,558	8,827,339	8,898,122	14,749,901	8,338,353	7,637,496

[Schedule of Policyholder Account Balance](#)

The following table summarizes the balances of, and changes in, policyholders' account balances as of September 30, 2024 and 2023:

	Policyholders' Account Balances					
	2024			2023		
	Interest Sensitive Life	Deferred Annuity	Other Policy-holders' Funds	Interest Sensitive Life	Deferred Annuity	Other Policy-holders' Funds
Balance at January 1,	\$ 732,948	\$ 773,039	\$ 236,958	\$ 739,105	\$ 954,318	\$ 123,234
Issuances	—	495	—	—	602	—
Premiums received	16,187	8,857	239,114	17,062	10,543	100,113
Policy charges	(9,253)	—	—	(9,729)	—	—
Surrenders and withdrawals	(17,326)	(84,893)	(10,615)	(16,204)	(125,176)	(9,106)
Benefit payments	(23,357)	(34,159)	—	(22,753)	(48,459)	—
Interest credited	20,890	17,990	15,210	21,274	21,608	6,164
Other	5,768	(480)	(11,379)	6,270	(161)	(2,195)
Balance at September 30,	\$ 725,857	\$ 680,849	\$ 469,288	\$ 735,025	\$ 813,275	\$ 218,210

	Policyholders' Account Balances					
	2024			2023		
	Interest Sensitive Life	Deferred Annuity	Other Policy-holders' Funds	Interest Sensitive Life	Deferred Annuity	Other Policy-holders' Funds
Balance at July 1,	\$ 728,097	\$ 706,022	\$ 400,625	\$ 736,920	\$ 853,064	\$ 187,873
Issuances	—	137	—	—	231	—
Premiums received	5,077	2,448	70,644	5,398	2,439	31,704
Policy charges	(3,081)	—	—	(3,213)	—	—
Surrenders and withdrawals	(5,850)	(22,331)	(3,264)	(5,582)	(37,905)	(2,782)
Benefit payments	(6,617)	(10,022)	—	(7,258)	(11,047)	—
Interest credited	6,922	5,777	6,106	7,083	6,863	2,825
Other	1,309	(1,182)	(4,823)	1,677	(370)	(1,410)
Balance at September 30,	\$ 725,857	\$ 680,849	\$ 469,288	\$ 735,025	\$ 813,275	\$ 218,210

Weighted-average credit rate	3.86 %	3.37 %	5.73 %	3.91 %	3.34 %	5.68 %
Net amount at risk	\$ 1,687,182	N/A	N/A	\$ 1,793,787	N/A	N/A
Cash surrender value	\$ 678,556	\$ 680,849	\$ 469,288	\$ 673,814	\$ 813,276	\$ 218,210

[Schedule of Policyholder Account Balance, Guaranteed Minimum Crediting Rate](#)

The following tables present the policyholders' account balances by range of guaranteed minimum crediting rates and the related range of difference, if any, in basis points between rates being credited to policy holders and the respective guaranteed minimums as of September 30, 2024 and 2023:

Range of guaranteed minimum crediting rates	At September 30, 2024		
	Interest Sensitive Life	Deferred Annuity	Other Policyholders' Funds
At guaranteed minimum			
Less than 3.00%	\$ —	\$ 1,866	\$ 373,729
3.00%-3.99%	29,170	494,585	3,046
4.00%-4.99%	606,425	184,398	6,548
Greater than 5.00%	90,262	—	36,541
Total	725,857	680,849	419,864
1-50 basis points above			
Less than 3.00%	—	—	—
3.00%-3.99%	—	—	—
4.00%-4.99%	—	—	1,678
Greater than 5.00%	—	—	—
Total	—	—	1,678
51-150 basis points above			
Less than 3.00%	—	—	—
3.00%-3.99%	—	—	—
4.00%-4.99%	—	—	47,746
Greater than 5.00%	—	—	—
Total	—	—	47,746
Grand Total	\$ 725,857	\$ 680,849	\$ 469,288

Range of guaranteed minimum crediting rates	At September 30, 2023		
	Interest Sensitive Life	Deferred Annuity	Other Policyholders' Funds
At guaranteed minimum			
Less than 3.00%	\$ —	\$ 2,011	\$ 118,565
3.00%-3.99%	29,018	610,785	4,002
4.00%-4.99%	615,835	199,724	6,851
Greater than 5.00%	90,172	755	38,788
Total	735,025	813,275	168,206
1-50 basis points above			
Less than 3.00%	—	—	—
3.00%-3.99%	—	—	—
4.00%-4.99%	—	—	—
Greater than 5.00%	—	—	—
Total	—	—	—
51-150 basis points above			
Less than 3.00%	—	—	—
3.00%-3.99%	—	—	—
4.00%-4.99%	—	—	50,004
Greater than 5.00%	—	—	—
Total	—	—	50,004
Grand Total	\$ 735,025	\$ 813,275	\$ 218,210

[XML 48 R30.htm IDEA: XBRL DOCUMENT](#)

Deferred Acquisition Costs (Tables)

[Insurance \[Abstract\]](#)

[Schedule of Analysis of Deferred Acquisition Costs](#)

9 Months Ended Sep. 30, 2024

The following tables roll forward the deferred policy acquisition costs for the three and nine month periods ended September 30, 2024 and 2023:

	Life				
	American Income	DTC	Liberty National	Other	Total
Balance at January 1, 2023	\$ 2,258,291	\$ 1,676,931	\$ 610,723	\$ 298,346	\$ 4,844,291
Capitalizations	351,933	123,774	78,599	9,970	564,276
Amortization expense	(118,207)	(74,496)	(38,192)	(12,390)	(243,285)
Foreign exchange adjustment	(1,297)	—	—	—	(1,297)
Balance at September 30, 2023	\$ 2,490,720	\$ 1,726,209	\$ 651,130	\$ 295,926	\$ 5,163,985
Balance at January 1, 2024	\$ 2,573,370	\$ 1,737,117	\$ 666,419	\$ 294,869	\$ 5,271,775
Capitalizations	391,707	112,198	88,355	9,304	601,564
Amortization expense	(133,410)	(75,898)	(42,041)	(12,404)	(263,753)
Foreign exchange adjustment	(1,857)	—	—	—	(1,857)
Balance at September 30, 2024	\$ 2,829,810	\$ 1,773,417	\$ 712,733	\$ 291,769	\$ 5,607,729

	Life				
	American Income	DTC	Liberty National	Other	Total
Balance at July 1, 2023	\$ 2,417,480	\$ 1,714,715	\$ 636,209	\$ 296,861	\$ 5,065,265
Capitalizations	117,761	36,385	27,950	3,203	185,299
Amortization expense	(40,465)	(24,891)	(13,029)	(4,138)	(82,523)
Foreign exchange adjustment	(4,056)	—	—	—	(4,056)
Balance at September 30, 2023	\$ 2,490,720	\$ 1,726,209	\$ 651,130	\$ 295,926	\$ 5,163,985
Balance at July 1, 2024	\$ 2,740,138	\$ 1,765,673	\$ 696,905	\$ 292,877	\$ 5,495,593
Capitalizations	131,851	33,222	30,255	3,024	198,352
Amortization expense	(46,033)	(25,478)	(14,427)	(4,132)	(90,070)
Foreign exchange adjustment	3,854	—	—	—	3,854
Balance at September 30, 2024	\$ 2,829,810	\$ 1,773,417	\$ 712,733	\$ 291,769	\$ 5,607,729

	Health					
	United American	Family Heritage	Liberty National	American Income	DTC	Total
Balance at January 1, 2023	\$ 77,394	\$ 416,608	\$ 133,096	\$ 57,811	\$ 1,854	\$ 686,763
Capitalizations	1,491	46,977	14,854	9,579	—	72,901
Amortization expense	(4,504)	(20,071)	(9,977)	(2,919)	(137)	(37,608)
Foreign exchange adjustment	—	—	—	(125)	—	(125)
Balance at September 30, 2023	\$ 74,381	\$ 443,514	\$ 137,973	\$ 64,346	\$ 1,717	\$ 721,931
Balance at January 1, 2024	\$ 73,489	\$ 452,843	\$ 139,941	\$ 66,783	\$ 1,679	\$ 734,735
Capitalizations	2,069	52,055	18,033	11,097	2	83,256
Amortization expense	(4,197)	(22,038)	(11,003)	(3,426)	(110)	(40,774)
Foreign exchange adjustment	—	—	—	(55)	—	(55)
Balance at September 30, 2024	\$ 71,361	\$ 482,860	\$ 146,971	\$ 74,399	\$ 1,571	\$ 777,162

	Health					
	United American	Family Heritage	Liberty National	American Income	DTC	Total
Balance at July 1, 2023	\$ 75,349	\$ 433,999	\$ 136,276	\$ 62,285	\$ 1,760	\$ 709,669
Capitalizations	495	16,386	5,120	3,259	—	25,260
Amortization expense	(1,463)	(6,871)	(3,423)	(1,016)	(43)	(12,816)
Foreign exchange adjustment	—	—	—	(182)	—	(182)
Balance at September 30, 2023	\$ 74,381	\$ 443,514	\$ 137,973	\$ 64,346	\$ 1,717	\$ 721,931
Balance at July 1, 2024	\$ 71,975	\$ 472,254	\$ 145,097	\$ 71,589	\$ 1,608	\$ 762,523
Capitalizations	780	18,123	5,589	3,817	—	28,309
Amortization expense	(1,394)	(7,517)	(3,715)	(1,189)	(37)	(13,852)
Foreign exchange adjustment	—	—	—	182	—	182
Balance at September 30, 2024	\$ 71,361	\$ 482,860	\$ 146,971	\$ 74,399	\$ 1,571	\$ 777,162

The following table presents a reconciliation of deferred policy acquisition costs to the [Condensed Consolidated Balance Sheets](#) as of September 30, 2024:

	September 30,	
	2024	2023
Life		
American Income	\$ 2,829,810	\$ 2,490,720
Direct to Consumer	1,773,417	1,726,209
Liberty National	712,733	651,130
Other	291,769	295,926
Total DAC—Life	5,607,729	5,163,985
Health		
United American	71,361	74,381
Family Heritage	482,860	443,514
Liberty National	146,971	137,973
American Income	74,399	64,346
Direct to Consumer	1,571	1,717
Total DAC—Health	777,162	721,931
Annuity	1,791	3,377
Total	\$ 6,386,682	\$ 5,889,293

[XML 49 R31.htm IDEA: XBRL DOCUMENT](#)

Liability for Unpaid Claims (Tables)

[Insurance \[Abstract\]](#)

[Schedule of Liability for Unpaid Health Claims](#)

9 Months Ended Sep. 30, 2024

Activity in the liability for unpaid health claims is summarized as follows:

	September 30, 2024	December 31, 2023
Balance at beginning of period	\$ 194,809	\$ 184,286
Less reinsurance recoverables	(2,157)	(2,084)
Net balance at beginning of period	192,652	182,202
Incurred related to:		
Current year	560,548	697,521
Prior years	(7,914)	(4,853)
Total incurred	552,634	692,668
Paid related to:		
Current year	399,412	535,971
Prior years	142,020	146,247
Total paid	541,432	682,218
Net balance at end of period	203,854	192,652
Plus reinsurance recoverables	1,623	2,157
Balance at end of period	\$ 205,477	\$ 194,809

[Schedule of Reconciliation of Policy Claims and Other Benefits Payable](#) Below is the reconciliation of the liability of "Policy claims and other benefits payable" in the [Condensed Consolidated Balance Sheets](#).

	September 30, 2024	December 31, 2023
Policy claims and other benefits payable:		
Life insurance	\$ 324,922	\$ 320,066
Health insurance	205,477	194,809
Total	\$ 530,399	\$ 514,875

[XML 50-R32.htm IDEA: XBRL DOCUMENT](#)

Postretirement
Benefits (Tables)

[Retirement Benefits \[Abstract\]](#)

[Schedule of Pension Assets by
Component at Fair Value](#)

9 Months Ended Sep. 30, 2024	
<i>Pension Assets:</i> The following table presents the assets of the Company's Pension Plans at September 30, 2024 and December 31, 2023.	
Pension Assets by Component at September 30, 2024	

Fair Value Determined by:					
	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Total Amount	% of Total
Exchange traded fund ⁽⁴⁾	\$ 38,544	\$ —	\$ —	\$ 38,544	6
Equity exchange traded fund ⁽¹⁾	318,809	—	—	318,809	49
U.S. Government and Agency	—	204,990	—	204,990	32
Other bonds	—	4	—	4	—
Guaranteed annuity contract ⁽²⁾	—	43,881	—	43,881	7
Short-term investments	5,122	—	—	5,122	1
Other	1,858	—	—	1,858	—
	\$ 364,333	\$ 248,875	\$ —	613,208	95
Other long-term investments ⁽³⁾				30,356	5
Total pension assets				\$ 643,564	100

- (1) A fund including marketable securities that mirror the S&P 500 index.
(2) Representing a guaranteed annuity contract issued by Globe Life Inc.'s subsidiary, American Income Life Insurance Company, to fund the obligations of the American Income Life Insurance Company Collective Bargaining Agreement Employees Pension Plan.
(3) Includes non-redeemable investment funds that report the Globe Life Inc. Pension Plan's pro-rata share of the limited partnership's net asset value (NAV) per share, or its equivalent, as a practical expedient for fair value. As of September 30, 2024, the Globe Life Inc. Pension Plan owned less than 1% of two long-term investment funds.
(4) A fund including U.S. dollar-denominated investment-grade securities issued by industrial, utility, and financial companies with maturities greater than 10 years.

Fair Value Determined by:					
	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Total Amount	% of Total
Exchange traded fund ⁽⁴⁾	\$ 18,715	\$ —	\$ —	\$ 18,715	3
Equity exchange traded fund ⁽¹⁾	315,886	—	—	315,886	55
U.S. Government and Agency	—	167,450	—	167,450	30
Other bonds	—	5	—	5	—
Guaranteed annuity contract ⁽²⁾	—	43,428	—	43,428	8
Short-term investments	6,506	—	—	6,506	1
Other	463	—	—	463	—
	\$ 341,570	\$ 210,883	\$ —	552,453	97
Other long-term investments ⁽³⁾				18,314	3
Total pension assets				\$ 570,767	100

- (1) A fund including marketable securities that mirror the S&P 500 index.
(2) Representing a guaranteed annuity contract issued by Globe Life Inc.'s subsidiary, American Income Life Insurance Company, to fund the obligations of the American Income Life Insurance Company Collective Bargaining Agreement Employees Pension Plan.
(3) Includes non-redeemable investment funds that report the Globe Life Inc. Pension Plan's pro-rata share of the limited partnership's net asset value (NAV) per share, or its equivalent, as a practical expedient for fair value. As of December 31, 2023, the Globe Life Inc. Pension Plan owned less than 1% of two long-term investment funds.
(4) A fund including U.S. dollar-denominated investment-grade securities issued by industrial, utility, and financial companies with maturities greater than 10 years.

[Schedule of Information Regarding
the SERP](#)

The following tables include premiums paid for COLI at September 30, 2024 and 2023 and investments of the Rabbi Trust at September 30, 2024 and December 31, 2023.

Nine Months Ended September 30,			
	2024	2023	
Premiums paid for insurance coverage	\$ 443	\$ 443	
	September 30, 2024	December 31, 2023	
Total investments:			
COLI	\$ 56,757	\$ 55,185	
Exchange traded funds	97,132	86,156	
	\$ 153,889	\$ 141,341	

[Schedule of Pension Liability](#)

The following table presents liabilities for the defined benefit pension plans and SERP at September 30, 2024 and December 31, 2023.

	September 30, 2024	December 31, 2023
Pension Plans	\$ 615,595	\$ 554,957
SERP	72,654	72,603
Benefit obligation	\$ 688,249	\$ 627,560

The following table presents the net periodic benefit costs for the defined benefit pension plans and SERP by expense components for the three and nine month periods ended September 30, 2024 and 2023.

Components of Net Periodic Benefit Cost					
Three Months Ended September 30,			Nine Months Ended September 30,		
	2024	2023	2024	2023	
Service cost—benefits earned during the period	\$ 6,224	\$ 5,392	\$ 18,673	\$ 16,174	
Interest cost on projected benefit obligation	8,287	7,834	24,862	23,502	
Expected return on assets	(10,645)	(9,656)	(31,938)	(28,968)	
Amortization:					
Prior service cost	265	269	803	807	
Actuarial (gain) loss	6	(48)	18	(152)	
Net periodic benefit cost	\$ 4,137	\$ 3,791	\$ 12,418	\$ 11,363	

[XML 51-R33.htm IDEA: XBRL DOCUMENT](#)

Earnings Per Share
(Tables)

[Earnings Per Share \[Abstract\]](#)

[Schedule of Reconciliation of Basic and Diluted Weighted-Average Shares
Outstanding](#)

9 Months Ended
Sep. 30, 2024

A reconciliation of basic and diluted weighted-average shares outstanding used in the computation of basic and diluted earnings per share is as follows:

Three Months Ended September 30,				Nine Months Ended September 30,			
	2024	2023		2024	2023		
Basic weighted average shares outstanding	87,874,488	94,636,867		91,048,853	95,445,416		
Weighted average dilutive options outstanding	212,553	1,180,770		273,666	1,211,974		
Diluted weighted average shares outstanding	88,087,041	95,817,637		91,322,519	96,657,390		
Antidilutive shares	4,234,326	492,970		3,090,848	399,071		

[XML 52-R34.htm IDEA: XBRL DOCUMENT](#)

Debt (Tables)

[Debt Disclosure \[Abstract\]](#)

[Schedule of Selected Information about Debt
Issues](#) The following table presents information about the terms and outstanding balances of Globe Life's debt.

Selected Information about Debt Issues

9 Months Ended
Sep. 30, 2024

				As of						
				September 30, 2024				December 31, 2023		
Instrument	Issue Date	Maturity Date	Coupon Rate	Par Value	Unamortized Discount & Issuance Costs	Book Value	Fair Value	Book Value		
Senior notes	09/27/2018	09/15/2028	4.550%	\$ 550,000	\$(3,180)	\$ 546,820	\$ 550,088	\$ 546,283		
Senior notes	08/21/2020	08/15/2030	2.150%	400,000	(2,983)	397,017	344,796	396,670		
Senior notes ⁽¹⁾	05/19/2022	06/15/2032	4.800%	250,000	(3,828)	246,172	248,443	245,873		
Senior notes	08/23/2024	09/15/2034	5.850%	450,000	(5,188)	444,812	464,881	—		
Junior subordinated debentures	11/17/2017	11/17/2057	5.275%	125,000	(1,561)	123,439	109,657	123,427		
Junior subordinated debentures	06/14/2021	06/15/2061	4.250%	325,000	(7,633)	317,367	236,730	317,306		
Term loan ⁽²⁾	05/11/2023	08/15/2027	6.593%	250,000	(1,951)	248,049	248,049	—		
Total long-term debt				2,350,000	(26,324)	2,323,676	2,202,644	1,629,559		
Term loan ⁽²⁾				—	—	—	—	169,549		
FHLB borrowings				17,000	—	17,000	17,000	—		
Commercial paper				426,908	(6,490)	420,418	420,418	316,564		
Total short-term debt				443,908	(6,490)	437,418	437,418	486,113		
Total debt				\$ 2,793,908	\$ (32,814)	\$ 2,761,094	\$ 2,640,062	\$ 2,115,672		

(1) An additional \$150 million par value and book value is held by insurance subsidiaries that eliminates in consolidation.
(2) Interest calculated quarterly using Secured Overnight Financing Rate (SOFR) plus 135 basis points.
The following tables present certain information about our commercial paper borrowings.

Credit Facility—Commercial Paper

	As of		
	September 30, 2024	December 31, 2023	September 30, 2023
Balance of commercial paper at end of period (par value)	\$ 426,908	\$ 319,000	\$ 251,000
Annualized interest rate	5.56 %	5.71 %	5.65 %
Letters of credit outstanding	\$ 115,000	\$ 115,000	\$ 115,000
Remaining amount available under credit line	458,092	316,000	384,000

Credit Facility—Commercial Paper Activity

	Nine Months Ended September 30,	
	2024	2023
Average balance of commercial paper outstanding during period (par value)	\$ 375,851	\$ 296,816
Daily-weighted average interest rate (annualized)	5.80 %	5.33 %
Maximum daily amount outstanding during period (par value)	\$ 633,425	\$ 477,700
Commercial paper issued during period (par value)	1,482,556	1,480,000
Commercial paper matured during period (par value)	(1,374,648)	(1,514,000)
Net commercial paper issued (matured) during period (par value)	107,908	(34,000)

[XML 53-R35.htm-IDEA: XBRL DOCUMENT](#)

Business Segments (Tables)

Segment Reporting [Abstract]

[Schedule of Segment Premium Income by Distribution Channel](#)

9 Months Ended Sep. 30, 2024

The following tables present segment premium revenue by each of Globe Life's distribution channels.

Premium Income by Distribution Channel

Distribution Channel	Three Months Ended September 30, 2024							
	Life		Health		Annuity		Total	
	Amount	% of Total	Amount	% of Total	Amount	% of Total	Amount	% of Total
American Income	\$ 427,839	52	\$ 31,277	9	\$ —	—	\$ 459,116	39
Direct to Consumer	246,425	30	18,072	5	—	—	264,497	23
Liberty National	93,625	12	47,277	13	—	—	140,902	12
United American	1,608	—	149,510	42	—	—	151,118	13
Family Heritage	1,684	—	107,819	31	—	—	109,503	9
Other	47,457	6	—	—	—	—	47,457	4
	\$ 818,638	100	\$ 353,955	100	\$ —	—	\$ 1,172,593	100

Distribution Channel	Three Months Ended September 30, 2023							
	Life		Health		Annuity		Total	
	Amount	% of Total	Amount	% of Total	Amount	% of Total	Amount	% of Total
American Income	\$ 400,214	51	\$ 30,535	9	\$ —	—	\$ 430,749	39
Direct to Consumer	247,858	32	17,153	5	—	—	265,011	24
Liberty National	88,199	11	46,643	14	—	—	134,842	12
United American	1,802	—	137,077	42	—	—	138,879	12
Family Heritage	1,561	—	99,828	30	—	—	101,389	9
Other	48,465	6	—	—	—	—	48,465	4
	\$ 788,099	100	\$ 331,236	100	\$ —	—	\$ 1,119,335	100

Distribution Channel	Nine Months Ended September 30, 2024							
	Life		Health		Annuity		Total	
	Amount	% of Total	Amount	% of Total	Amount	% of Total	Amount	% of Total
American Income	\$ 1,265,417	52	\$ 92,495	9	\$ —	—	\$ 1,357,912	39
Direct to Consumer	743,304	31	54,070	5	—	—	797,374	23
Liberty National	276,599	11	142,612	14	—	—	419,211	12
United American	5,009	—	440,375	42	—	—	445,384	13
Family Heritage	4,945	—	317,065	30	—	—	322,010	9
Other	143,111	6	—	—	—	—	143,111	4
	\$ 2,438,385	100	\$ 1,046,617	100	\$ —	—	\$ 3,485,002	100

Distribution Channel	Nine Months Ended September 30, 2023							
	Life		Health		Annuity		Total	
	Amount	% of Total	Amount	% of Total	Amount	% of Total	Amount	% of Total
American Income	\$ 1,182,346	50	\$ 89,656	9	\$ —	—	\$ 1,272,002	38
Direct to Consumer	744,132	32	51,576	5	—	—	795,708	24
Liberty National	260,036	11	140,518	14	—	—	400,554	12
United American	5,533	—	407,137	42	—	—	412,670	13
Family Heritage	4,554	—	294,029	30	—	—	298,583	9
Other	145,828	7	—	—	—	—	145,828	4
	\$ 2,342,429	100	\$ 982,916	100	\$ —	—	\$ 3,325,345	100

[Schedule of Reconciliation of Segment Operating Information to Consolidated Statement of Operations](#)

The following tables set forth a reconciliation of Globe Life's revenues and operations by segment to its major income statement line items. See [Note 1—Significant Accounting Policies](#) for additional information concerning reconciling items of segment profits to pretax income.

	Three Months Ended September 30, 2024					
	Life	Health	Annuity	Investment	Corporate & Other	Consolidated
Revenue:						
Premium	\$ 818,638	\$ 353,955	\$ —	\$ —	\$ —	\$ 1,172,593
Net investment income	—	—	—	284,964	—	284,964
Other income	—	—	—	—	42	42
Total revenue	818,638	353,955	—	284,964	42	1,457,599
Expenses:						
Policy benefits	454,502	221,926	5,716	6,040	—	688,184
Required interest on reserves	(203,875)	(27,717)	(7,829)	239,421	—	6,446
Amortization of acquisition costs	90,070	13,852	388	—	—	104,310
Commissions, premium taxes, and non-deferred acquisition costs	90,758	58,931	4	—	—	149,693
Insurance administrative expense ⁽¹⁾	—	—	—	—	88,465	89,195
Parent expense	—	—	—	—	3,210	3,210
Stock-based compensation expense	—	—	—	—	9,233	9,233
Interest expense	—	—	—	—	31,388	31,388
Total expenses	431,455	266,992	(1,721)	245,461	132,296	1,078,449
Subtotal	387,183	86,963	1,721	39,503	(132,254)	379,150
Non-operating items	—	—	—	—	3,966	3,966
Measure of segment profitability (pretax)	\$ 387,183	\$ 86,963	\$ 1,721	\$ 39,503	\$ (132,254)	\$ 383,116
Realized gains (losses)						(2,192)
Legal costs and proceedings						(3,329)
Non-operating expenses						(637)
Income before income taxes per Condensed Consolidated Statements of Operations						\$ 376,958

(1) Administrative expense is not allocated to insurance segments.
(2) Non-operating expenses.
(3) Legal costs and proceedings.

Three Months Ended September 30, 2023							
	Life	Health	Annuity	Investment	Corporate & Other	Adjustments	Consolidated
Revenue:							
Premium	\$ 788,099	\$ 331,236	\$ —	\$ —	\$ —	\$ —	\$ 1,119,335
Net investment income	—	—	—	266,926	—	—	266,926
Other income	—	—	—	—	50	—	50
Total revenue	788,099	331,236	—	266,926	50	—	1,386,311
Expenses:							
Policy obligations	515,676	193,790	6,854	2,724	—	—	719,044
Required interest on reserves	(194,199)	(26,732)	(9,353)	230,284	—	—	—
Amortization of acquisition costs	82,523	12,816	418	—	—	—	95,757
Commissions, premium taxes, and non-deferred acquisition costs	84,011	54,662	4	—	—	—	138,677
Insurance administrative expense ⁽¹⁾	—	—	—	—	74,585	—	74,585
Parent expense	—	—	—	—	2,581	1,137	(2) 3,718
Stock-based compensation expense	—	—	—	—	7,567	—	7,567
Interest expense	—	—	—	—	25,955	—	25,955
Total expenses	488,011	234,536	(2,077)	233,008	110,688	1,137	1,065,303
Subtotal	300,088	96,700	2,077	33,918	(110,638)	(1,137)	321,008
Non-operating items	—	—	—	—	—	1,137	(2) 1,137
Measure of segment profitability (pretax)	\$ 300,088	\$ 96,700	\$ 2,077	\$ 33,918	\$ (110,638)	\$ —	322,145
Realized gains (losses)							(2,193)
Non-operating expenses							(1,137)
Income before income taxes per Condensed Consolidated Statements of Operations							\$ 318,815

(1) Administrative expense is not allocated to insurance segments.
(2) Non-operating expenses.

Nine Months Ended September 30, 2024							
	Life	Health	Annuity	Investment	Corporate & Other	Adjustments	Consolidated
Revenue:							
Premium	\$ 2,438,385	\$ 1,046,617	\$ —	\$ —	\$ —	\$ —	\$ 3,485,002
Net investment income	—	—	—	853,178	—	—	853,178
Other income	—	—	—	—	192	—	192
Total revenue	2,438,385	1,046,617	—	853,178	192	—	4,338,372
Expenses:							
Policy obligations	1,493,165	629,676	17,786	15,044	—	—	2,155,671
Required interest on reserves	(605,397)	(82,300)	(24,358)	712,055	—	—	—
Amortization of acquisition costs	263,753	40,774	1,176	—	—	—	305,703
Commissions, premium taxes, and non-deferred acquisition costs	270,347	177,246	12	—	—	—	447,605
Insurance administrative expense ⁽¹⁾	—	—	—	—	251,072	1,646	(3) 252,718
Parent expense	—	—	—	—	9,166	6,722	(2,3) 15,888
Stock-based compensation expense	—	—	—	—	28,590	—	28,590
Interest expense	—	—	—	—	91,413	—	91,413
Total expenses	1,421,868	765,396	(5,384)	727,099	380,241	8,368	3,297,588
Subtotal	1,016,517	281,221	5,384	126,079	(380,049)	(8,368)	1,040,784
Non-operating items	—	—	—	—	—	8,368	(2,3) 8,368
Measure of segment profitability (pretax)	\$ 1,016,517	\$ 281,221	\$ 5,384	\$ 126,079	\$ (380,049)	\$ —	1,049,152
Realized gains (losses)							(26,580)
Legal costs and proceedings							(5,764)
Non-operating expenses							(2,604)
Income before income taxes per Condensed Consolidated Statements of Operations							\$ 1,014,204

(1) Administrative expense is not allocated to insurance segments.
(2) Non-operating expenses.
(3) Legal costs and proceedings.

Nine Months Ended September 30, 2023							
	Life	Health	Annuity	Investment	Corporate & Other	Adjustments	Consolidated
Revenue:							
Premium	\$ 2,342,429	\$ 982,916	\$ —	\$ —	\$ —	\$ —	\$ 3,325,345
Net investment income	—	—	—	785,275	—	—	785,275
Other income	—	—	—	—	185	—	185
Total revenue	2,342,429	982,916	—	785,275	185	—	4,110,805
Expenses:							
Policy obligations	1,536,317	580,676	21,502	5,986	—	—	2,144,481
Required interest on reserves	(575,801)	(79,603)	(29,327)	684,731	—	—	—
Amortization of acquisition costs	243,285	37,608	1,266	—	—	—	282,159
Commissions, premium taxes, and non-deferred acquisition costs	251,136	163,784	13	—	—	—	414,933
Insurance administrative expense ⁽¹⁾	—	—	—	—	223,951	—	223,951
Parent expense	—	—	—	—	8,254	1,137	(2) 9,391
Stock-based compensation expense	—	—	—	—	22,732	—	22,732
Interest expense	—	—	—	—	76,640	—	76,640
Total expenses	1,454,937	702,465	(6,546)	690,717	331,577	1,137	3,174,287
Subtotal	887,492	280,451	6,546	94,558	(331,392)	(1,137)	936,518
Non-operating items	—	—	—	—	—	1,137	(2) 1,137
Measure of segment profitability (pretax)	\$ 887,492	\$ 280,451	\$ 6,546	\$ 94,558	\$ (331,392)	\$ —	937,655
Realized gains (losses)							(78,963)
Non-operating expenses							(1,137)
Income before income taxes per Condensed Consolidated Statements of Operations							\$ 857,555

(1) Administrative expense is not allocated to insurance segments.
(2) Non-operating expenses.

[XML 54 R36.htm IDEA: XBRL DOCUMENT](#)

Significant Accounting Policies - Additional Information (Details) 9 Months Ended Sep. 30, 2024 segment

[Accounting Policies \[Abstract\]](#)

[Number of reportable segments](#) 4

[XML 55 R37.htm IDEA: XBRL DOCUMENT](#)

	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Increase (Decrease) in AOCL, Net of Tax				
Beginning balance	\$ 5,227,754	\$ 3,980,306	\$ 4,486,803	\$ 3,949,577
Other comprehensive income (loss) before reclassifications, net of tax	(293,313)	484,223	285,358	266,141
Reclassifications, net of tax	(1,810)	700	2,318	65,198
Other comprehensive income (loss)	(295,123)	484,923	287,676	331,339
Ending balance	4,638,625	4,623,131	4,638,625	4,623,131
Total				
Increase (Decrease) in AOCL, Net of Tax				
Beginning balance	(2,189,620)	(2,943,897)	(2,772,419)	(2,790,313)
Ending balance	(2,484,743)	(2,458,974)	(2,484,743)	(2,458,974)
Available for Sale Assets				
Increase (Decrease) in AOCL, Net of Tax				
Beginning balance	(1,271,213)	(1,249,399)	(827,596)	(1,420,672)
Other comprehensive income (loss) before reclassifications, net of tax	686,343	(842,527)	238,785	(736,046)
Reclassifications, net of tax	(1,903)	672	2,038	65,464
Other comprehensive income (loss)	684,440	(841,855)	240,823	(670,582)

Ending balance	(586,773)	(2,091,254)	(586,773)	(2,091,254)
Future Policy Benefits				
Increase (Decrease) in AOCL, Net of Tax				
Beginning balance	(911,717)	(1,696,801)	(1,947,391)	(1,369,204)
Other comprehensive income (loss) before reclassifications, net of tax	(985,420)	1,332,976	50,254	1,005,379
Reclassifications, net of tax	0	0	0	0
Other comprehensive income (loss)	(985,420)	1,332,976	50,254	1,005,379
Ending balance	(1,897,137)	(363,825)	(1,897,137)	(363,825)
Foreign Exchange				
Increase (Decrease) in AOCL, Net of Tax				
Beginning balance	(4,726)	1,353	4,719	(1,681)
Other comprehensive income (loss) before reclassifications, net of tax	5,764	(6,226)	(3,681)	(3,192)
Reclassifications, net of tax	0	0	0	0
Other comprehensive income (loss)	5,764	(6,226)	(3,681)	(3,192)
Ending balance	1,038	(4,873)	1,038	(4,873)
Pension Adjustments				
Increase (Decrease) in AOCL, Net of Tax				
Beginning balance	(1,964)	950	(2,151)	1,244
Other comprehensive income (loss) before reclassifications, net of tax	0	0	0	0
Reclassifications, net of tax	93	28	280	(266)
Other comprehensive income (loss)	93	28	280	(266)
Ending balance	\$ (1,871)	\$ 978	\$ (1,871)	\$ 978

~~XML 56 R38.htm IDEA: XBRL DOCUMENT~~

Supplemental Information about Changes to Accumulated Other Comprehensive Income - Schedule of Reclassifications (Details) - USD (\$) \$ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023

Unrealized investment (gains) losses on available for sale assets:				
Realized (gains) losses		\$ 2,192	\$ 2,193	\$ 26,580
Net investment income		(284,964)	(266,926)	(853,178)
Other operating expense		104,874	85,870	297,196
Total before tax		(376,958)	(318,815)	(1,014,204)
Tax		73,964	61,732	198,638
Total after-tax		(302,994)	(257,083)	(815,566)
Reclassification out of Accumulated Other Comprehensive Income				(695,953)
Unrealized investment (gains) losses on available for sale assets:				
Total after-tax	(1,810)	700	2,318	65,198
Reclassification out of Accumulated Other Comprehensive Income Unrealized Gains (Losses) on Available for Sale Assets				
Unrealized investment (gains) losses on available for sale assets:				
Realized (gains) losses	(257)	1,759	9,732	85,230
Net investment income	(2,151)	(908)	(7,152)	(2,364)
Total before tax	(2,408)	851	2,580	82,866
Tax	505	(179)	(542)	(17,402)
Total after-tax	(1,903)	672	2,038	65,464
Reclassification out of Accumulated Other Comprehensive Income Pension adjustments:				
Unrealized investment (gains) losses on available for sale assets:				
Total before tax	118	35	354	(336)
Tax	(25)	(7)	(74)	70
Total after-tax	93	28	280	(266)
Reclassification out of Accumulated Other Comprehensive Income Amortization of prior service cost				
Unrealized investment (gains) losses on available for sale assets:				
Other operating expense	265	269	803	807
Reclassification out of Accumulated Other Comprehensive Income Amortization of actuarial (gain) loss				
Unrealized investment (gains) losses on available for sale assets:				
Other operating expense	\$ (147)	\$ (234)	\$ (449)	\$ (1,143)

~~XML 57 R39.htm IDEA: XBRL DOCUMENT~~

Investments - Schedule of Fixed Maturities Available for Sale by Component (Details) - USD (\$) \$ in Thousands	Sep. 30, 2024		Jun. 30, 2024		Dec. 31, 2023		Sep. 30, 2023		Jun. 30, 2023		Dec. 31, 2022	

Debt Securities, Available-for-sale [Line Items]		
Amortized Cost	\$ 19,084,454	\$ 18,924,914
Allowance for Credit Losses	(7,132)	(7,115)
Gross Unrealized Gains	595,188	451,764
Gross Unrealized Losses	(1,337,940)	(1,499,357)
Fair value	\$ 18,334,570	\$ 17,870,206
Percentage of total fixed maturities (as a percent)	100.00%	100.00%
U.S. Government direct, guaranteed, and government-sponsored enterprises		
Debt Securities, Available-for-sale [Line Items]		
Amortized Cost	\$ 397,969	\$ 398,450
Allowance for Credit Losses	0	0
Gross Unrealized Gains	38	7
Gross Unrealized Losses	(21,026)	(32,306)
Fair value	\$ 376,981	\$ 366,151
Percentage of total fixed maturities (as a percent)	2.00%	2.00%
States, municipalities, and political subdivisions		
Debt Securities, Available-for-sale [Line Items]		
Amortized Cost	\$ 3,253,819	\$ 3,296,305
Allowance for Credit Losses	0	0
Gross Unrealized Gains	49,409	47,346
Gross Unrealized Losses	(424,989)	(403,329)
Fair value	\$ 2,878,239	\$ 2,940,322
Percentage of total fixed maturities (as a percent)	16.00%	16.00%
Foreign governments		
Debt Securities, Available-for-sale [Line Items]		
Amortized Cost	\$ 41,794	\$ 44,453
Allowance for Credit Losses	0	0
Gross Unrealized Gains	17	1
Gross Unrealized Losses	(9,885)	(10,348)
Fair value	\$ 31,926	\$ 34,106
Percentage of total fixed maturities (as a percent)	0.00%	0.00%
Corporates		

Debt Securities, Available-for-sale [Line Items]

Amortized Cost	\$ 15,270,614		\$ 15,062,244			
Allowance for Credit Losses	(7,132)	\$ (7,132)	(7,115)	\$ (7,500)	\$ (72,508)	\$ 0
Gross Unrealized Gains	539,925		399,371			
Gross Unrealized Losses	(880,363)		(1,049,317)			
Fair value	\$ 14,923,044		\$ 14,405,183			
Percentage of total fixed maturities (as a percent)	81.00%		81.00%			

Corporates | Industrials

Debt Securities, Available-for-sale [Line Items]

Amortized Cost	\$ 8,115,835		\$ 8,016,126			
Allowance for Credit Losses	(7,132)		(7,115)			
Gross Unrealized Gains	258,165		213,078			
Gross Unrealized Losses	(508,089)		(566,847)			
Fair value	\$ 7,858,779		\$ 7,655,242			
Percentage of total fixed maturities (as a percent)	43.00%		43.00%			

Corporates | Financial

Debt Securities, Available-for-sale [Line Items]

Amortized Cost	\$ 5,014,169		\$ 5,028,151			
Allowance for Credit Losses	0		0			
Gross Unrealized Gains	171,762		112,368			
Gross Unrealized Losses	(299,903)		(388,340)			
Fair value	\$ 4,886,028		\$ 4,752,179			
Percentage of total fixed maturities (as a percent)	26.00%		27.00%			

Corporates | Utilities

Debt Securities, Available-for-sale [Line Items]

Amortized Cost	\$ 2,140,610		\$ 2,017,967			
Allowance for Credit Losses	0		0			
Gross Unrealized Gains	109,998		73,925			
Gross Unrealized Losses	(72,371)		(94,130)			
Fair value	\$ 2,178,237		\$ 1,997,762			
Percentage of total fixed maturities (as a percent)	12.00%		11.00%			

Collateralized debt obligations

Debt Securities, Available-for-sale [Line Items]

Amortized Cost	\$ 36,685		\$ 37,110			
Allowance for Credit Losses	0		0			
Gross Unrealized Gains	5,798		5,036			
Gross Unrealized Losses	0		0			
Fair value	\$ 42,483		\$ 42,146			
Percentage of total fixed maturities (as a percent)	0.00%		0.00%			

Other asset-backed securities

Debt Securities, Available-for-sale [Line Items]

Amortized Cost	\$ 83,573		\$ 86,352			
Allowance for Credit Losses	0		0			
Gross Unrealized Gains	1		3			
Gross Unrealized Losses	(1,677)		(4,057)			
Fair value	\$ 81,897		\$ 82,298			
Percentage of total fixed maturities (as a percent)	1.00%		1.00%			

~~XMLE 58 R40.htm IDEA: XBRL DOCUMENT~~

Investments - Additional Information (Details) \$ in Thousands	3 Months Ended		9 Months Ended				Dec. 31, 2023		Jun. 30, 2023	
	Sep. 30, 2024		Sep. 30, 2024		Sep. 30, 2023		Jun. 30, 2024		Dec. 31, 2023	
	USD (\$)		USD (\$)		USD (\$)		USD (\$)		USD (\$)	
	commercial_mortgage_loan	Sep. 30, 2023	commercial_mortgage_loan	Sep. 30, 2023	commercial_mortgage_loan	Jun. 30, 2024	commercial_mortgage_loan	Jun. 30, 2024	commercial_mortgage_loan	Dec. 31, 2023
	loan	USD (\$)	loan	USD (\$)	loan	USD (\$)	loan	USD (\$)	loan	USD (\$)
	issuer		issuer		issuer		issuer		issuer	
	Issue		Issue		Issue		Issue		Issue	
Debt Securities, Available-for-sale [Line Items]										
Fair value		\$ 18,334,570		\$ 18,334,570				\$ 17,870,206		
Percentage of fixed maturities at fair value		100.00%		100.00%				100.00%		
Fixed maturity, portfolio issues Issue		2,532		2,532				2,473		
Fixed portfolio, number of issuers issuer		975		975				980		
Number of loans loan		36		36						
Increase in allowance for credit losses				\$ 3,500						
Allowance for credit losses		\$ 7,202		\$ 2,988		\$ 2,988	\$ 5,826	\$ 3,672		\$ 2,928
Realized gains (losses)		\$ (2,192)		\$ (2,193)		\$ (26,580)		\$ (78,963)		\$ 1,789
Number of loans in non-accrual status commercial_mortgage_loan		0		0				0		
Mortgage loans		\$ 381,315		\$ 381,315				\$ 279,199		
Other long-term investments under fair value option		1,221,888		1,221,888				835,878		
Investment funds, unfunded commitments		612,000		612,000						
Unfunded Loan Commitment										
Debt Securities, Available-for-sale [Line Items]										
Mortgage loans		\$ 31,000		\$ 31,000						
Commercial Portfolio Segment										
Debt Securities, Available-for-sale [Line Items]										
Financing receivable, number of delinquent loans commercial_mortgage_loan		1		1						
Delinquent loans, outstanding par value (in dollars per share)		\$ 36,000		\$ 36,000						
Delinquent loans, outstanding interest		\$ 1,900		\$ 1,900						
Number of loans in non-accrual status commercial_mortgage_loan		3,000		3,000						
Outstanding principal on nonaccrual loan		\$ 8,800		\$ 8,800						
Corporates										
Debt Securities, Available-for-sale [Line Items]										
Fair value		\$ 14,923,044		\$ 14,923,044				\$ 14,405,183		
Percentage of fixed maturities at fair value		81.00%		81.00%				81.00%		
Company owned life insurance										
Debt Securities, Available-for-sale [Line Items]										
Other long-term investments under fair value option		\$ 200,114		\$ 200,114				\$ 0		
Investment in Limited Partnerships										
Debt Securities, Available-for-sale [Line Items]										
Capital called from investment funds				226,000						
Investment funds, unfunded commitments		612,481		612,481						
Real Estate Investment Trust Fixed maturities available for sale Corporates										
Debt Securities, Available-for-sale [Line Items]										
Fair value		\$ 429,000		\$ 429,000				\$ 425,000		
Percentage of fixed maturities at fair value		2.00%		2.00%				2.00%		

[XML 59 R41.htm IDEA: XBRL DOCUMENT](#)

Investments - Schedule of Fixed Maturities by Contractual Maturity (Details) - USD (\$) \$ in Thousands		Sep. 30, 2024	Dec. 31, 2023
Amortized Cost, net			
Due in one year or less		\$ 111,956	
Due after one year through five years		748,300	
Due after five years through ten years		1,841,477	
Due after ten years through twenty years		8,954,048	
Due after twenty years		7,301,254	
Mortgage-backed and asset-backed securities		120,287	
Fixed maturities, net of allowance for credit losses		19,077,322	
Fair Value			
Due in one year or less		111,456	
Due after one year through five years		771,458	
Due after five years through ten years		1,912,103	
Due after ten years through twenty years		8,827,993	
Due after twenty years		6,587,150	
Mortgage-backed and asset-backed securities		124,410	
Fixed maturities, fair value		\$ 18,334,570	\$ 17,870,206

[XML 60 R42.htm IDEA: XBRL DOCUMENT](#)

Investments - Schedule of Analysis of Investment Operations (Details) - USD (\$) \$ in Thousands		3 Months Ended		9 Months Ended	
		Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Net Investment Income [Line Items]					
Investment income, gross		\$ 289,352	\$ 271,444	\$ 866,163	\$ 798,013
Percentage change in investment income, gross		7.00%		9.00%	
Less investment expense		\$ (4,388)	(4,518)	\$ (12,985)	(12,738)
Percentage change in investment expense		(3.00%)		2.00%	
Net investment income		\$ 284,964	266,926	\$ 853,178	785,275
Percentage change in net investment income		7.00%		9.00%	
Fixed maturities available for sale					
Net Investment Income [Line Items]					
Investment income, gross		\$ 245,313	237,609	\$ 738,626	704,095
Percentage change in investment income, gross		3.00%		5.00%	
Policy loans					
Net Investment Income [Line Items]					
Investment income, gross		\$ 13,296	12,446	\$ 39,196	36,435
Percentage change in investment income, gross		7.00%		8.00%	
Mortgage loans					
Net Investment Income [Line Items]					
Investment income, gross		\$ 7,668	5,363	\$ 21,337	13,919
Percentage change in investment income, gross		43.00%		53.00%	
Other long-term investments					
Net Investment Income [Line Items]					
Investment income, gross		\$ 19,992	14,630	\$ 58,608	38,753
Percentage change in investment income, gross		37.00%		51.00%	
Short-term investments					
Net Investment Income [Line Items]					
Investment income, gross		\$ 3,083	1,396	\$ 8,396	4,811
Percentage change in investment income, gross					
Fair value option					
Net Investment Income [Line Items]					
Net investment income		\$ 19,100	\$ 14,000	\$ 56,100	\$ 37,200

[XML 61 R43.htm IDEA: XBRL DOCUMENT](#)

Investments - Schedule of Selected Information about Sales of Fixed Maturities (Details) - USD (\$) \$ in Thousands		3 Months Ended		9 Months Ended	
		Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]					
Proceeds from sale		\$ 163,221	\$ 46,210	\$ 674,125	\$ 192,034
Gross realized gains		2,042	261	6,086	308
Gross realized losses		(1,856)	(67,018)	(15,824)	(77,879)
Unsettled trades		\$ 0	\$ 27	\$ 0	\$ 27

[XML 62 R44.htm IDEA: XBRL DOCUMENT](#)

Investments - Schedule of Realized Gain (Loss) on Investments (Details) - USD (\$)		3 Months Ended		9 Months Ended	
		Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]					
Sales and other		\$ 257,000	\$ (66,767,000)	\$ (9,716,000)	\$ (77,730,000)
Provision for credit losses		0	65,008,000	(16,000)	(7,500,000)
Fair value option—change in fair value		(3,683,000)	868,000	(22,777,000)	7,954,000
Mortgage loans		(1,376,000)	(59,000)	(3,530,000)	(4,918,000)
Other investments		(16,000)	880,000	1,135,000	502,000
Realized gains (losses) from investments		(4,818,000)	(70,000)	(34,904,000)	(81,692,000)
Other gains (losses)		2,626,000	(2,123,000)	8,324,000	2,729,000
Total realized gains (losses)		(2,192,000)	(2,193,000)	(26,580,000)	(78,963,000)
Applicable tax		460,000	461,000	5,582,000	16,583,000
Realized gains (losses), net of tax		(1,732,000)	(1,732,000)	(20,998,000)	(62,380,000)
Exchanges of fixed maturities		3,400,000	21,100,000	\$ 82,200,000	\$ 39,000,000.0
Exchanges of fixed maturities, net realized gains		\$ 0	\$ 0		

[XML 63 R45.htm IDEA: XBRL DOCUMENT](#)

Investments - Schedule of Assets Measured at Fair Value on Recurring Basis (Details) - USD (\$) \$ in Thousands		3 Months Ended		9 Months Ended	
		Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]					
Fair value				\$ 18,334,570	\$ 17,870,206

Percentage of total	100.00%	100.00%	
U.S. Government direct, guaranteed, and government-sponsored enterprises			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	\$ 376,981	\$ 366,151	
States, municipalities, and political subdivisions			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	2,878,239	2,940,322	
Foreign governments			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	31,926	34,106	
Corporates			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	14,923,044	14,405,183	
Corporates Industrials			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	7,858,779	7,655,242	
Corporates Financial			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	4,886,028	4,752,179	
Corporates Utilities			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	2,178,237	1,997,762	
Collateralized debt obligations			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	42,483	42,146	
Other asset-backed securities			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	81,897	82,298	
Quoted Prices in Active Markets for Identical Assets (Level 1)			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	\$ 0	\$ 0	
Percentage of total	0.00%	0.00%	
Quoted Prices in Active Markets for Identical Assets (Level 1) U.S. Government direct, guaranteed, and government-sponsored enterprises			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	\$ 0	\$ 0	
Quoted Prices in Active Markets for Identical Assets (Level 1) States, municipalities, and political subdivisions			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	0	0	
Quoted Prices in Active Markets for Identical Assets (Level 1) Foreign governments			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	0	0	
Quoted Prices in Active Markets for Identical Assets (Level 1) Corporates			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	0	0	
Quoted Prices in Active Markets for Identical Assets (Level 1) Corporates Industrials			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	0	0	
Quoted Prices in Active Markets for Identical Assets (Level 1) Corporates Financial			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	0	0	
Quoted Prices in Active Markets for Identical Assets (Level 1) Corporates Utilities			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	0	0	
Quoted Prices in Active Markets for Identical Assets (Level 1) Collateralized debt obligations			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	0	0	
Quoted Prices in Active Markets for Identical Assets (Level 1) Other asset-backed securities			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	0	0	
Significant Other Observable Inputs (Level 2)			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	\$ 17,838,400	\$ 17,373,327	
Percentage of total	97.00%	97.00%	
Significant Other Observable Inputs (Level 2) U.S. Government direct, guaranteed, and government-sponsored enterprises			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	\$ 376,981	\$ 366,151	
Significant Other Observable Inputs (Level 2) States, municipalities, and political subdivisions			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	2,878,239	2,940,322	
Significant Other Observable Inputs (Level 2) Foreign governments			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	31,926	34,106	
Significant Other Observable Inputs (Level 2) Corporates			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	14,477,233	13,950,450	
Significant Other Observable Inputs (Level 2) Corporates Industrials			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	7,659,257	7,440,493	
Significant Other Observable Inputs (Level 2) Corporates Financial			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	4,754,596	4,621,160	
Significant Other Observable Inputs (Level 2) Corporates Utilities			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	2,063,380	1,888,797	
Significant Other Observable Inputs (Level 2) Collateralized debt obligations			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	0	0	
Significant Other Observable Inputs (Level 2) Other asset-backed securities			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	74,021	82,298	
Significant Unobservable Inputs (Level 3)			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	\$ 496,170	\$ 496,879	
Percentage of total	3.00%	3.00%	3.00%
Significant Unobservable Inputs (Level 3) U.S. Government direct, guaranteed, and government-sponsored enterprises			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value	\$ 0	\$ 0	

Significant Unobservable Inputs (Level 3) States, municipalities, and political subdivisions				
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]				
Fair value	0	0		
Significant Unobservable Inputs (Level 3) Foreign governments				
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]				
Fair value	0	0		
Significant Unobservable Inputs (Level 3) Corporates				
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]				
Fair value	\$ 445,811	454,733		
Percentage of total	3.00%		3.00%	
Significant Unobservable Inputs (Level 3) Corporates Industrials				
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]				
Fair value	\$ 199,522	214,749		
Significant Unobservable Inputs (Level 3) Corporates Financial				
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]				
Fair value	131,432	131,019		
Significant Unobservable Inputs (Level 3) Corporates Utilities				
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]				
Fair value	114,857	108,965		
Significant Unobservable Inputs (Level 3) Collateralized debt obligations				
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]				
Fair value	\$ 42,483	42,146		
Percentage of total	0.00%		0.00%	
Significant Unobservable Inputs (Level 3) Other asset-backed securities				
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]				
Fair value	\$ 7,876	\$ 0		
~~XML 64 R46.htm IDEA: XBRL DOCUMENT~~				
Investments -				
Schedule of Changes				
in Assets Measured at				
Fair Value on a				
Recurring Basis				
Using Significant				
Unobservable Inputs				
(Level 3) (Details) -				
USD (\$)				
\$ in Thousands				
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation				
Percent of total fixed maturities	100.00%			100.00%
Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Realized gains (losses)	Realized gains (losses)		
Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Asset, Gain (Loss), Statement of Other Comprehensive Income or Comprehensive Income [Extensible Enumeration]	Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent		
Significant Unobservable Inputs (Level 3)				
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation				
Beginning Balance	\$ 496,879	\$ 528,447		
Included in realized gains / losses	0	0		
Included in other comprehensive income	6,210	(24,392)		
Acquisitions	22,676	0		
Sales	0	0		
Amortization	3,376	3,434		
Other	(32,971)	(30,353)		
Transfers into Level 3	0	0		
Transfers out of Level 3	0	0		
Ending Balance	\$ 496,170	\$ 477,136		
Percent of total fixed maturities	3.00%	3.00%		3.00%
Significant Unobservable Inputs (Level 3) Asset- backed Securities				
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation				
Beginning Balance	\$ 0	\$ 0		
Included in realized gains / losses	0	0		
Included in other comprehensive income	0	0		
Acquisitions	7,876	0		
Sales	0	0		
Amortization	0	0		
Other	0	0		
Transfers into Level 3	0	0		
Transfers out of Level 3	0	0		
Ending Balance	\$ 7,876	\$ 0		
Percent of total fixed maturities	0.00%	0.00%		
Significant Unobservable Inputs (Level 3) Collateralized debt obligations				
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation				
Beginning Balance	\$ 42,146	\$ 50,364		
Included in realized gains / losses	0	0		
Included in other comprehensive income	762	(8,424)		
Acquisitions	0	0		
Sales	0	0		
Amortization	3,414	3,429		
Other	(3,839)	(3,684)		
Transfers into Level 3	0	0		
Transfers out of Level 3	0	0		
Ending Balance	\$ 42,483	\$ 41,685		
Percent of total fixed maturities	0.00%	0.00%		
Significant Unobservable Inputs (Level 3) Corporates				
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation				
Beginning Balance	\$ 454,733	\$ 478,083		
Included in realized gains / losses	0	0		
Included in other comprehensive income	5,448	(15,968)		
Acquisitions	14,800	0		
Sales	0	0		
Amortization	(38)	5		
Other	(29,132)	(26,669)		
Transfers into Level 3	0	0		
Transfers out of Level 3	0	0		
Ending Balance	\$ 445,811	\$ 435,451		
Percent of total fixed maturities	3.00%	3.00%		

~~XML 65 R47.htm IDEA: XBRL DOCUMENT~~

Investments - Schedule of Unrealized Gains or (Losses) Included in Other Comprehensive Income (Details) - USD (\$) \$ in Thousands	9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023

[Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation \[Line Items\]](#)

Change in unrealized gains (losses) for the period	\$ 6,210	\$ (24,392)

[Asset- backed Securities](#)

[Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation \[Line Items\]](#)

Change in unrealized gains (losses) for the period	0	0

[Collateralized debt obligations](#)

[Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation \[Line Items\]](#)

Change in unrealized gains (losses) for the period	762	(8,424)

[Corporates](#)

[Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation \[Line Items\]](#)

Change in unrealized gains (losses) for the period	\$ 5,448	\$ (15,968)

~~XML 66 R48.htm IDEA: XBRL DOCUMENT~~

Investments - Schedule of Information about Investments in Unrealized Loss Position (Details) - Issue	Sep. 30, 2024 Dec. 31, 2023	

[Investments, Debt and Equity Securities \[Abstract\]](#)

Less than Twelve Months	87	151
Twelve Months or Longer	1,553	1,614
Total	1,640	1,765

~~XML 67 R49.htm IDEA: XBRL DOCUMENT~~

Investments - Schedule of Unrealized Investment Losses by Class of Investment (Details) - USD (\$) \$ in Thousands	Sep. 30, 2024 Dec. 31, 2023	

[Debt Securities, Available-for-sale \[Line Items\]](#)

Fair Value, Less than Twelve Months	\$ 359,414	\$ 803,974
Unrealized Loss, Less than Twelve Months	(16,532)	(17,434)
Fair Value, Twelve Months or Longer	9,191,636	9,750,839
Unrealized Loss, Twelve Months or Longer	(1,321,408)	(1,481,923)
Fair Value	9,551,050	10,554,813
Unrealized Loss	(1,337,940)	(1,499,357)
Investment Grade		

[Debt Securities, Available-for-sale \[Line Items\]](#)

Fair Value, Less than Twelve Months	352,545	767,666
Unrealized Loss, Less than Twelve Months	(16,350)	(14,633)
Fair Value, Twelve Months or Longer	8,852,284	9,423,010
Unrealized Loss, Twelve Months or Longer	(1,250,268)	(1,407,709)
Fair Value	9,204,829	10,190,676
Unrealized Loss	(1,266,618)	(1,422,342)
Investment Grade U.S. Government direct, guaranteed, and government-sponsored enterprises		

[Debt Securities, Available-for-sale \[Line Items\]](#)

Fair Value, Less than Twelve Months	0	0
Unrealized Loss, Less than Twelve Months	0	0
Fair Value, Twelve Months or Longer	374,361	364,006
Unrealized Loss, Twelve Months or Longer	(21,026)	(32,306)
Fair Value	374,361	364,006
Unrealized Loss	(21,026)	(32,306)
Investment Grade States, municipalities, and political subdivisions		

[Debt Securities, Available-for-sale \[Line Items\]](#)

Fair Value, Less than Twelve Months	201,640	252,800
Unrealized Loss, Less than Twelve Months	(4,821)	(3,520)
Fair Value, Twelve Months or Longer	1,636,467	1,610,163
Unrealized Loss, Twelve Months or Longer	(420,168)	(399,809)
Fair Value	1,838,107	1,862,963
Unrealized Loss	(424,989)	(403,329)
Investment Grade Foreign governments		

[Debt Securities, Available-for-sale \[Line Items\]](#)

Fair Value, Less than Twelve Months	0	0
Unrealized Loss, Less than Twelve Months	0	0
Fair Value, Twelve Months or Longer	28,493	32,591
Unrealized Loss, Twelve Months or Longer	(9,885)	(10,348)
Fair Value	28,493	32,591
Unrealized Loss	(9,885)	(10,348)
Investment Grade Corporates		

[Debt Securities, Available-for-sale \[Line Items\]](#)

Fair Value, Less than Twelve Months	150,905	514,866
Unrealized Loss, Less than Twelve Months	(11,529)	(11,113)
Fair Value, Twelve Months or Longer	6,744,414	7,345,294
Unrealized Loss, Twelve Months or Longer	(797,582)	(961,598)
Fair Value	6,895,319	7,860,160
Unrealized Loss	(809,111)	(972,711)
Investment Grade Corporates Industrials		

[Debt Securities, Available-for-sale \[Line Items\]](#)

Fair Value, Less than Twelve Months	124,717	191,573
Unrealized Loss, Less than Twelve Months	(11,134)	(3,881)
Fair Value, Twelve Months or Longer	4,071,839	4,317,827
Unrealized Loss, Twelve Months or Longer	(464,628)	(530,011)
Fair Value	4,196,556	4,509,400
Unrealized Loss	(475,762)	(533,892)
Investment Grade Corporates Financial		

[Debt Securities, Available-for-sale \[Line Items\]](#)

Fair Value, Less than Twelve Months	19,176	242,099
Unrealized Loss, Less than Twelve Months	(303)	(6,584)
Fair Value, Twelve Months or Longer	2,005,383	2,341,424
Unrealized Loss, Twelve Months or Longer	(261,465)	(339,628)

Fair Value	2,024,559	2,583,523
Unrealized Loss	(261,768)	(346,212)
Investment Grade Corporates Utilities		
Debt Securities, Available-for-sale [Line Items]		
Fair Value, Less than Twelve Months	7,012	81,194
Unrealized Loss, Less than Twelve Months	(92)	(648)
Fair Value, Twelve Months or Longer	667,192	686,043
Unrealized Loss, Twelve Months or Longer	(71,489)	(91,959)
Fair Value	674,204	767,237
Unrealized Loss	(71,581)	(92,607)
Investment Grade Collateralized debt obligations		
Debt Securities, Available-for-sale [Line Items]		
Fair Value, Less than Twelve Months	0	0
Unrealized Loss, Less than Twelve Months	0	0
Fair Value, Twelve Months or Longer	0	0
Unrealized Loss, Twelve Months or Longer	0	0
Fair Value	0	0
Unrealized Loss	0	0
Investment Grade Other asset-backed securities		
Debt Securities, Available-for-sale [Line Items]		
Fair Value, Less than Twelve Months	0	0
Unrealized Loss, Less than Twelve Months	0	0
Fair Value, Twelve Months or Longer	68,549	70,956
Unrealized Loss, Twelve Months or Longer	(1,607)	(3,648)
Fair Value	68,549	70,956
Unrealized Loss	(1,607)	(3,648)
Below Investment Grade		
Debt Securities, Available-for-sale [Line Items]		
Fair Value, Less than Twelve Months	6,869	36,308
Unrealized Loss, Less than Twelve Months	(182)	(2,801)
Fair Value, Twelve Months or Longer	339,352	327,829
Unrealized Loss, Twelve Months or Longer	(71,140)	(74,214)
Fair Value	346,221	364,137
Unrealized Loss	(71,322)	(77,015)
Below Investment Grade Corporates		
Debt Securities, Available-for-sale [Line Items]		
Fair Value, Less than Twelve Months	6,869	36,308
Unrealized Loss, Less than Twelve Months	(182)	(2,801)
Fair Value, Twelve Months or Longer	333,920	316,541
Unrealized Loss, Twelve Months or Longer	(71,070)	(73,805)
Fair Value	340,789	352,849
Unrealized Loss	(71,252)	(76,606)
Below Investment Grade Corporates Industrials		
Debt Securities, Available-for-sale [Line Items]		
Fair Value, Less than Twelve Months	2,670	10,745
Unrealized Loss, Less than Twelve Months	(169)	(199)
Fair Value, Twelve Months or Longer	143,088	145,697
Unrealized Loss, Twelve Months or Longer	(32,158)	(32,756)
Fair Value	145,758	156,442
Unrealized Loss	(32,327)	(32,955)
Below Investment Grade Corporates Financial		
Debt Securities, Available-for-sale [Line Items]		
Fair Value, Less than Twelve Months	4,199	25,563
Unrealized Loss, Less than Twelve Months	(13)	(2,602)
Fair Value, Twelve Months or Longer	178,887	151,190
Unrealized Loss, Twelve Months or Longer	(38,122)	(39,526)
Fair Value	183,086	176,753
Unrealized Loss	(38,135)	(42,128)
Below Investment Grade Corporates Utilities		
Debt Securities, Available-for-sale [Line Items]		
Fair Value, Less than Twelve Months	0	0
Unrealized Loss, Less than Twelve Months	0	0
Fair Value, Twelve Months or Longer	11,945	19,654
Unrealized Loss, Twelve Months or Longer	(790)	(1,523)
Fair Value	11,945	19,654
Unrealized Loss	(790)	(1,523)
Below Investment Grade Collateralized debt obligations		
Debt Securities, Available-for-sale [Line Items]		
Fair Value, Less than Twelve Months	0	0
Unrealized Loss, Less than Twelve Months	0	0
Fair Value, Twelve Months or Longer	0	0
Unrealized Loss, Twelve Months or Longer	0	0
Fair Value	0	0
Unrealized Loss	0	0
Below Investment Grade Other asset-backed securities		
Debt Securities, Available-for-sale [Line Items]		
Fair Value, Less than Twelve Months	0	0
Unrealized Loss, Less than Twelve Months	0	0
Fair Value, Twelve Months or Longer	5,432	11,288
Unrealized Loss, Twelve Months or Longer	(70)	(409)
Fair Value	5,432	11,288
Unrealized Loss	\$ (70)	\$ (409)

~~[XML-68-R50.htm-IDEA- XBRL DOCUMENT](#)~~

Investments - Schedule of Fixed Maturities, Allowance for Credit Loss (Details) - USD (\$) \$ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Debt Securities, Available-for-sale, Allowance for Credit Loss [Roll Forward]				
Allowance for credit losses beginning balance			\$ 7,115	
Allowance for credit losses ending balance	\$ 7,132		7,132	
Corporates				
Debt Securities, Available-for-sale, Allowance for Credit Loss [Roll Forward]				
Allowance for credit losses beginning balance	7,132	\$ 72,508	7,115	\$ 0
Additions to allowance for which credit losses were not previously recorded	0	0	0	72,508
Additions (reductions) to allowance for fixed maturities that previously had an allowance	0	(65,008)	17	(65,008)
Reduction of allowance for which the Company intends to sell or more likely than not will be required to sell or sold during the period	0	0	0	0

Allowance for credit losses ending balance\$ 7,132\$ 7,500\$ 7,132\$ 7,500

~~XML 69-R51.htm IDEA: XBRL DOCUMENT~~

Investments - Schedule of Commercial Mortgage Loan Participations (Details) - USD (\$) \$ in Thousands	Sep. 30, 2024	Jun. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2022

Accounts, Notes, Loans and Financing Receivable [Line Items]

Carrying value	\$ 388,517			\$ 282,871		
Carrying value, gross, percent	102.00%			101.00%		
Less allowance for credit losses	\$ (7,202)	\$ (5,826)		\$ (3,672)	\$ (2,988)	\$ (1,789)
Allowance for credit losses, percent	(2.00%)			(1.00%)		
Carrying value, net of valuation allowance	\$ 381,315			\$ 279,199		
Carrying value, net, percent	100.00%			100.00%		

Texas

Accounts, Notes, Loans and Financing Receivable [Line Items]

Carrying value	\$ 75,002			\$ 45,111		
Carrying value, gross, percent	20.00%			16.00%		

New Jersey

Accounts, Notes, Loans and Financing Receivable [Line Items]

Carrying value	\$ 51,454			\$ 44,574		
Carrying value, gross, percent	14.00%			16.00%		

Florida

Accounts, Notes, Loans and Financing Receivable [Line Items]

Carrying value	\$ 46,506			\$ 48,233		
Carrying value, gross, percent	12.00%			17.00%		

California

Accounts, Notes, Loans and Financing Receivable [Line Items]

Carrying value	\$ 40,715			\$ 54,721		
Carrying value, gross, percent	11.00%			20.00%		

New York

Accounts, Notes, Loans and Financing Receivable [Line Items]

Carrying value	\$ 35,865			\$ 20,284		
Carrying value, gross, percent	9.00%			7.00%		

Alabama

Accounts, Notes, Loans and Financing Receivable [Line Items]

Carrying value	\$ 35,838			\$ 11,003		
Carrying value, gross, percent	9.00%			4.00%		

Other

Accounts, Notes, Loans and Financing Receivable [Line Items]

Carrying value	\$ 103,137			\$ 58,945		
Carrying value, gross, percent	27.00%			21.00%		

Multi-family

Accounts, Notes, Loans and Financing Receivable [Line Items]

Carrying value	\$ 127,155			\$ 116,299		
Carrying value, gross, percent	33.00%			42.00%		

Industrial

Accounts, Notes, Loans and Financing Receivable [Line Items]

Carrying value	\$ 102,402			\$ 57,267		
Carrying value, gross, percent	27.00%			20.00%		

Retail

Accounts, Notes, Loans and Financing Receivable [Line Items]

Carrying value	\$ 73,252			\$ 23,925		
Carrying value, gross, percent	19.00%			9.00%		

Hospitality

Accounts, Notes, Loans and Financing Receivable [Line Items]

Carrying value	\$ 43,435			\$ 43,897		
Carrying value, gross, percent	11.00%			16.00%		

Mixed use

Accounts, Notes, Loans and Financing Receivable [Line Items]

Carrying value	\$ 35,886			\$ 34,749		
Carrying value, gross, percent	10.00%			12.00%		

Office

Accounts, Notes, Loans and Financing Receivable [Line Items]

Carrying value	\$ 6,387			\$ 6,734		
Carrying value, gross, percent	2.00%			2.00%		

~~XML 70-R52.htm IDEA: XBRL DOCUMENT~~

Investments - Schedule of Commercial Mortgage Loan Participations Recorded Investment (Details) - USD (\$) \$ in Thousands	Sep. 30, 2024	Jun. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2022

Accounts, Notes, Loans and Financing Receivable [Line Items]

Carrying value, net of valuation allowance	\$ 381,315			\$ 279,199		
Carrying value	388,517			282,871		
Less allowance for credit losses	\$ (7,202)	\$ (5,826)		\$ (3,672)	\$ (2,988)	\$ (1,789)
Carrying value, net of valuation allowance, percent	100.00%			100.00%		

Less than 70%

Accounts, Notes, Loans and Financing Receivable [Line Items]

Carrying value	\$ 364,101			\$ 266,216		
Carrying value, net of valuation allowance, percent	94.00%			94.00%		

70% to 80%

Accounts, Notes, Loans and Financing Receivable [Line Items]

Carrying value	\$ 1,058			\$ 0		
Carrying value, net of valuation allowance, percent	0.00%			0.00%		

81% to 90%

Accounts, Notes, Loans and Financing Receivable [Line Items]

Carrying value	\$ 8,569			\$ 9,621		
Carrying value, net of valuation allowance, percent	2.00%			3.00%		

Greater than 90%

Accounts, Notes, Loans and Financing Receivable [Line Items]

Carrying value	\$ 14,789			\$ 7,034		
Carrying value, net of valuation allowance, percent	4.00%			3.00%		

Less Than 1.00x

Accounts, Notes, Loans and Financing Receivable [Line Items]

Carrying value, net of valuation allowance	\$ 47,257	\$ 42,593
Less Than 1.00x Less than 70%		
Accounts, Notes, Loans and Financing Receivable [Line Items]		
Carrying value, net of valuation allowance	22,841	27,091
Less Than 1.00x 70% to 80%		
Accounts, Notes, Loans and Financing Receivable [Line Items]		
Carrying value, net of valuation allowance	1,058	0
Less Than 1.00x 81% to 90%		
Accounts, Notes, Loans and Financing Receivable [Line Items]		
Carrying value, net of valuation allowance	8,569	8,468
Less Than 1.00x Greater than 90%		
Accounts, Notes, Loans and Financing Receivable [Line Items]		
Carrying value, net of valuation allowance	14,789	7,034
1.00x-1.20x		
Accounts, Notes, Loans and Financing Receivable [Line Items]		
Carrying value, net of valuation allowance	138,034	180,761
1.00x-1.20x Less than 70%		
Accounts, Notes, Loans and Financing Receivable [Line Items]		
Carrying value, net of valuation allowance	138,034	180,761
1.00x-1.20x 70% to 80%		
Accounts, Notes, Loans and Financing Receivable [Line Items]		
Carrying value, net of valuation allowance	0	0
1.00x-1.20x 81% to 90%		
Accounts, Notes, Loans and Financing Receivable [Line Items]		
Carrying value, net of valuation allowance	0	0
1.00x-1.20x Greater than 90%		
Accounts, Notes, Loans and Financing Receivable [Line Items]		
Carrying value, net of valuation allowance	0	0
Greater Than 1.20x		
Accounts, Notes, Loans and Financing Receivable [Line Items]		
Carrying value, net of valuation allowance	203,226	59,517
Greater Than 1.20x Less than 70%		
Accounts, Notes, Loans and Financing Receivable [Line Items]		
Carrying value, net of valuation allowance	203,226	58,364
Greater Than 1.20x 70% to 80%		
Accounts, Notes, Loans and Financing Receivable [Line Items]		
Carrying value, net of valuation allowance	0	0
Greater Than 1.20x 81% to 90%		
Accounts, Notes, Loans and Financing Receivable [Line Items]		
Carrying value, net of valuation allowance	0	1,153
Greater Than 1.20x Greater than 90%		
Accounts, Notes, Loans and Financing Receivable [Line Items]		
Carrying value, net of valuation allowance	\$ 0	\$ 0

XML 71 R53.htm IDEA: XBRL DOCUMENT				
Investments -	3 Months Ended	9 Months Ended		
Schedule of				
Commercial Loan				
Participations,				
Allowance for Credit	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Loss (Details) - USD				
(\$)				
\$ in Thousands				
Financing Receivable, Allowance for Credit Loss [Roll Forward]				
Allowance for credit losses beginning balance	\$ 5,826	\$ 2,928	\$ 3,672	\$ 1,789
Provision (reversal) for credit losses	1,376	60	3,530	1,199
Allowance for credit losses ending balance	\$ 7,202	\$ 2,988	\$ 7,202	\$ 2,988

XML 72 R54.htm IDEA: XBRL DOCUMENT				
Investments -	Sep. 30, 2024	Dec. 31, 2023		
Schedule of Other				
Long-Term				
Investments (Details)				
- USD (\$)				
\$ in Thousands				
Long-Term Investment [Line Items]				
Commercial mortgage loan participations	\$ 1,221,888	\$ 835,878		
Other				
Long-Term Investment [Line Items]				
Commercial mortgage loan participations	42,377	40,295		
Investment funds				
Long-Term Investment [Line Items]				
Commercial mortgage loan participations	\$ 979,397	\$ 795,583		

XML 73 R55.htm IDEA: XBRL DOCUMENT				
Investments -	9 Months Ended			
Schedule of				
Investment Funds	Sep. 30, 2024	Dec. 31, 2023		
(Details) - USD (\$)				
\$ in Thousands				
Alternative Investment [Line Items]				
Investment funds, Unfunded Commitments	\$ 612,000			
Minimum				
Alternative Investment [Line Items]				
Expected life of non-redeemable funds	7 years			
Extension options term of non-redeemable funds	1 year			
Expected life of redeemable funds	6 months			
Maximum				
Alternative Investment [Line Items]				
Expected life of non-redeemable funds	12 years			
Extension options term of non-redeemable funds	4 years			
Expected life of redeemable funds	36 months			
Commercial mortgage loans				
Alternative Investment [Line Items]				
Investment funds, Fair Value	\$ 567,425	\$ 411,315		
Investment funds, Unfunded Commitments	378,892			
Opportunistic and private credit				
Alternative Investment [Line Items]				
Investment funds, Fair Value	195,957	181,410		
Investment funds, Unfunded Commitments	166,514			
Infrastructure				
Alternative Investment [Line Items]				
Investment funds, Fair Value	174,971	165,887		

Investment funds, Unfunded Commitments	16,318								
Other									
Alternative Investment [Line Items]									
Investment funds, Fair Value	41,044	36,971							
Investment funds, Unfunded Commitments	50,757								
Investment funds									
Alternative Investment [Line Items]									
Investment funds, Fair Value	979,397	\$ 795,583							
Investment funds, Unfunded Commitments	\$ 612,481								
~~XML 74-R56.htm-IDEA: XBRL DOCUMENT~~									
Commitments and Contingencies - Additional Information (Details)			Sep. 26, 2024 complainant	Sep. 30, 2024 USD (\$)	Dec. 31, 2023 USD (\$)	Sep. 30, 2023 USD (\$)			
\$ in Thousands									
Obligation with Joint and Several Liability Arrangement [Line Items]									
Letters of credit facility outstanding				\$ 115,000	\$ 115,000	\$ 115,000			
Number of complainants complainant	6								
Letter of Credit									
Obligation with Joint and Several Liability Arrangement [Line Items]									
Letter of credit maximum available amount				\$ 250,000					
~~XML 75-R57.htm-IDEA: XBRL DOCUMENT~~									
Policy Liabilities - Schedule of Liability for Future Policy Benefit, Activity (Details) - USD (\$)									
\$ in Thousands									
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]									
Net liability for future policy benefits—long duration health			\$ 19,814,913	\$ 17,273,102	\$ 19,814,913	\$ 17,273,102		\$ 19,460,353	
Life									
Liability for Future Policy Benefit, Expected Net Premium [Roll Forward]									
Beginning balance			11,981,537	12,042,720	12,342,307	11,748,528			
Beginning balance			11,836,592	11,616,443	11,709,368	11,442,919			
Effect of changes in assumptions on future cash flows							\$ (140,988)	(140,988)	\$ 64,032
Effect of actual variances from expected experience							(176,655)	(437,915)	(143,861)
Adjusted balance							11,518,949	11,130,465	11,536,614
Issuances			351,088	357,622	1,123,204	1,122,855			
Interest accrual			148,429	143,082	444,225	420,389			
Net premiums collected			(333,783)	(329,703)	(1,003,989)	(984,290)			
Effect of changes in the foreign exchange rate			5,121	(6,401)	(4,101)	(631)			
Ending balance			11,689,804	11,701,214	11,689,804	11,701,214			
Effect of change from original to current discount rates			716,466	(206,573)	716,466	(206,573)			
Ending balance			12,406,270	11,494,641	12,406,270	11,494,641			
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]									
Beginning balance			26,507,907	26,772,991	27,723,158	25,749,961			
Beginning balance			25,004,280	24,092,695	24,563,696	23,564,337			
Effect of changes in assumptions on future cash flows							(198,467)	(198,467)	65,568
Effect of actual variances from expected experience							(195,035)	(476,505)	(158,589)
Adjusted balance							24,610,778	23,888,724	23,999,674
Issuances			346,356	357,625	1,118,479	1,122,856			
Interest accrual			340,671	325,470	1,014,591	960,647			
Benefit payments			(327,139)	(305,221)	(1,029,527)	(967,828)			
Effect of changes in the foreign exchange rate			12,833	(15,256)	(8,768)	(819)			
Ending balance			24,983,499	24,362,292	24,983,499	24,362,292			
Effect of changes in discount rate assumptions			3,166,868	544,968	3,166,868	544,968			
Ending balance			28,150,367	24,907,260	28,150,367	24,907,260			
Net liability for future policy benefits at original discount rates			13,293,695	12,661,078	13,293,695	12,661,078			
Effect of changes in discount rate assumptions			2,450,402	751,541	2,450,402	751,541			
Other Adjustments			187	11,228	187	11,228			
Net liability for future policy benefits—long duration health			15,744,284	13,423,847	15,744,284	13,423,847			
Reinsurance recoverable			(46,561)	(40,749)	(46,561)	(40,749)			
Net liability for future policy benefits, after reinsurance recoverable, at current discount rates			15,697,723	13,383,098	15,697,723	13,383,098			
Policyholder benefits net of remeasurement gain (losses)			70,575	11,328	87,825	16,459			
Life Gain Loss From Expreinece									
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]									
Policyholder benefits net of remeasurement gain (losses)			13,729	13,341	30,979	18,472			
Life Gain *Loss) From Unlocking Assumptions									
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]									
Policyholder benefits net of remeasurement gain (losses)			56,846	(2,013)	56,846	(2,013)			
Health									
Liability for Future Policy Benefit, Expected Net Premium [Roll Forward]									
Beginning balance			6,007,794	5,346,643	6,089,728	5,207,422			
Beginning balance			6,204,884	5,445,595	6,069,295	5,366,304			
Effect of changes in assumptions on future cash flows							14,968	14,968	390,156
Effect of actual variances from expected experience							(2,314)	(101,362)	2,168
Adjusted balance							6,217,538	5,982,901	5,837,919
Issuances			196,796	180,243	577,105	509,496			
Interest accrual			70,976	60,518	208,072	173,110			
Net premiums collected			(145,918)	(134,993)	(427,847)	(399,639)			
Effect of changes in the foreign exchange rate			462	(552)	(377)	(165)			
Ending balance			6,339,854	5,943,135	6,339,854	5,943,135			
Effect of change from original to current discount rates			112,701	(396,191)	112,701	(396,191)			
Ending balance			6,452,555	5,546,944	6,452,555	5,546,944			
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]									
Beginning balance			8,260,784	7,621,433	8,441,002	7,394,349			
Beginning balance			8,657,990	7,832,089	8,484,970	7,710,767			
Effect of changes in assumptions on future cash flows							30,877	30,877	381,310
Effect of actual variances from expected experience							(498)	(104,110)	90
Adjusted balance							8,688,369	8,411,737	8,213,489
Issuances			196,456	179,879	575,776	508,524			
Interest accrual			98,966	87,507	291,189	253,452			
Benefit payments			(157,362)	(141,429)	(450,717)	(416,475)			
Effect of changes in the foreign exchange rate			910	(1,093)	(646)	(217)			

Ending balance	8,827,339	8,338,353	8,827,339	8,338,353				
Effect of changes in discount rate assumptions	70,783	(700,857)	70,783	(700,857)				
Ending balance	8,898,122	7,637,496	8,898,122	7,637,496				
Net liability for future policy benefits at original discount rates	2,487,485	2,395,218	2,487,485	2,395,218				
Effect of changes in discount rate assumptions	(41,918)	(304,666)	(41,918)	(304,666)				
Other Adjustments	32,268	26,978	32,268	26,978				
Net liability for future policy benefits—long duration health	2,477,835	2,117,530	2,477,835	2,117,530				
Reinsurance recoverable	(15,577)	(13,755)	(15,577)	(13,755)				
Net liability for future policy benefits, after reinsurance recoverable, at current discount rates	2,462,258	2,103,775	2,462,258	2,103,775				
Policyholder benefits net of remeasurement gain (losses)	(9,550)	7,810	(3,094)	8,342				
Health Gain Loss From Expereince								
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]								
Policyholder benefits net of remeasurement gain (losses)	951	2,577	7,407	3,109				
Health Gain *Loss) From Unlocking Assumptions								
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]								
Policyholder benefits net of remeasurement gain (losses)	(10,501)	5,233	(10,501)	5,233				
American Income Life								
Liability for Future Policy Benefit, Expected Net Premium [Roll Forward]								
Beginning balance	4,635,903	4,472,847	4,681,888	4,273,156				
Beginning balance	4,648,111	4,399,053	4,523,329	4,246,723	(82,348)	(82,348)	14,265	14,265
Effect of changes in assumptions on future cash flows					(59,483)	(173,180)	(34,571)	(103,922)
Effect of actual variances from expected experience								
Adjusted balance					4,506,280	4,267,801	4,378,747	4,157,066
Issuances	203,828	181,823	616,527	557,844				
Interest accrual	55,750	51,119	164,917	147,968				
Net premiums collected	(138,552)	(131,329)	(412,717)	(388,288)				
Effect of changes in the foreign exchange rate	5,121	(6,401)	(4,101)	(631)				
Ending balance	4,632,427	4,473,959	4,632,427	4,473,959				
Effect of change from original to current discount rates	204,567	(155,254)	204,567	(155,254)				
Ending balance	4,836,994	4,318,705	4,836,994	4,318,705				
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]								
Beginning balance	9,811,407	9,668,207	10,163,627	9,119,104				
Beginning balance	9,353,526	8,753,526	9,061,833	8,409,761	(104,498)	(104,498)	13,344	13,344
Effect of changes in assumptions on future cash flows					(65,766)	(187,711)	(36,998)	(109,386)
Effect of actual variances from expected experience					9,183,262	8,769,624	8,729,872	8,313,719
Adjusted balance								
Issuances	199,097	181,822	611,802	557,844				
Interest accrual	124,308	114,683	367,403	335,349				
Benefit payments	(105,757)	(101,161)	(326,318)	(296,133)				
Effect of changes in the foreign exchange rate	12,833	(15,256)	(8,768)	(819)				
Ending balance	9,413,743	8,909,960	9,413,743	8,909,960				
Effect of changes in discount rate assumptions	1,091,042	80,477	1,091,042	80,477				
Ending balance	10,504,785	8,990,437	10,504,785	8,990,437				
Net liability for future policy benefits at original discount rates	4,781,316	4,436,001	4,781,316	4,436,001				
Effect of changes in discount rate assumptions	886,475	235,731	886,475	235,731				
Other Adjustments	150	508	150	508				
Net liability for future policy benefits—long duration health	5,667,941	4,672,240	5,667,941	4,672,240				
Reinsurance recoverable	(170)	(141)	(170)	(141)				
Net liability for future policy benefits, after reinsurance recoverable, at current discount rates	5,667,771	4,672,099	5,667,771	4,672,099				
American Income Life Gain Loss From Expereince								
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]								
Policyholder benefits net of remeasurement gain (losses)	4,771	2,388	12,619	5,276				
American Income Life Gain *Loss) From Unlocking Assumptions								
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]								
Policyholder benefits net of remeasurement gain (losses)	21,974	308	21,974	308				
American Income Health								
Liability for Future Policy Benefit, Expected Net Premium [Roll Forward]								
Beginning balance	205,889	201,844	206,381	190,296				
Beginning balance	208,867	201,709	201,869	192,631				
Effect of changes in assumptions on future cash flows					12,207	12,207	(6,061)	(6,061)
Effect of actual variances from expected experience					(4,110)	(11,168)	(2,394)	(7,643)
Adjusted balance					216,964	202,908	193,254	178,927
Issuances	11,997	9,880	34,121	30,667				
Interest accrual	2,493	2,170	7,135	6,304				
Net premiums collected	(6,300)	(5,630)	(18,171)	(16,611)				
Effect of changes in the foreign exchange rate	462	(552)	(377)	(165)				
Ending balance	225,616	199,122	225,616	199,122				
Effect of change from original to current discount rates	8,173	(9,976)	8,173	(9,976)				
Ending balance	233,789	189,146	233,789	189,146				
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]								
Beginning balance	328,436	328,579	335,504	312,750				
Beginning balance	322,706	315,087	315,431	303,713				
Effect of changes in assumptions on future cash flows					20,293	20,293	(6,407)	(6,407)
Effect of actual variances from expected experience					(4,432)	(12,611)	(2,662)	(8,680)
Adjusted balance					338,567	323,113	306,018	288,626
Issuances	11,997	9,880	34,123	30,667				
Interest accrual	4,189	3,810	12,145	11,199				
Benefit payments	(6,502)	(6,973)	(19,574)	(18,633)				
Effect of changes in the foreign exchange rate	910	(1,093)	(646)	(217)				
Ending balance	349,161	311,642	349,161	311,642				
Effect of changes in discount rate assumptions	24,383	(5,601)	24,383	(5,601)				
Ending balance	373,544	306,041	373,544	306,041				
Net liability for future policy benefits at original discount rates	123,545	112,520	123,545	112,520				
Effect of changes in discount rate assumptions	16,210	4,375	16,210	4,375				
Other Adjustments	926	993	926	993				
Net liability for future policy benefits—long duration health	140,681	117,888	140,681	117,888				
Reinsurance recoverable	0	0	0	0				
Net liability for future policy benefits, after reinsurance recoverable, at current discount rates	140,681	117,888	140,681	117,888				
American Income Health Gain Loss From Expereince								
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll								

Forward]									
Policyholder benefits net of remeasurement gain (losses)	729	457	1,769	1,025					
American Income Health Gain *Loss) From Unlocking Assumptions									
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]									
Policyholder benefits net of remeasurement gain (losses)	(8,036)	119	(8,036)	119					
Direct to Consumer Life									
Liability for Future Policy Benefit, Expected Net Premium [Roll Forward]									
Beginning balance	5,810,518	5,988,577	6,052,651	5,910,224					
Beginning balance	5,670,288	5,700,354	5,664,259	5,680,864					
Effect of changes in assumptions on future cash flows					(28,366)	(28,366)	36,170	36,170	
Effect of actual variances from expected experience					(103,089)	(226,062)	(91,120)	(219,723)	
Adjusted balance					5,538,833	5,409,831	5,645,404	5,497,311	
Issuances	110,993	136,611	398,034	450,361					
Interest accrual	73,134	72,515	220,485	214,988					
Net premiums collected	(150,235)	(153,237)	(455,625)	(461,367)					
Effect of changes in the foreign exchange rate	0	0	0	0					
Ending balance	5,572,725	5,701,293	5,572,725	5,701,293					
Effect of change from original to current discount rates	421,888	(31,118)	421,888	(31,118)					
Ending balance	5,994,613	5,670,175	5,994,613	5,670,175					
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]									
Beginning balance	9,289,834	9,487,233	9,714,516	9,225,451					
Beginning balance	8,748,900	8,592,897	8,656,752	8,477,892					
Effect of changes in assumptions on future cash flows					(50,106)	(50,106)	34,407	34,407	
Effect of actual variances from expected experience					(111,255)	(241,231)	(97,632)	(227,639)	
Adjusted balance					8,587,539	8,365,415	8,529,672	8,284,660	
Issuances	110,991	136,612	398,032	450,362					
Interest accrual	118,873	115,547	355,850	342,208					
Benefit payments	(138,098)	(136,994)	(439,992)	(432,393)					
Effect of changes in the foreign exchange rate	0	0	0	0					
Ending balance	8,679,305	8,644,837	8,679,305	8,644,837					
Effect of changes in discount rate assumptions	1,082,717	228,607	1,082,717	228,607					
Ending balance	9,762,022	8,873,444	9,762,022	8,873,444					
Net liability for future policy benefits at original discount rates	3,106,580	2,943,544	3,106,580	2,943,544					
Effect of changes in discount rate assumptions	660,829	259,725	660,829	259,725					
Other Adjustments	0	3,982	0	3,982					
Net liability for future policy benefits—long duration health	3,767,409	3,207,251	3,767,409	3,207,251					
Reinsurance recoverable	0	0	0	0					
Net liability for future policy benefits, after reinsurance recoverable, at current discount rates	3,767,409	3,207,251	3,767,409	3,207,251					
Direct to Consumer Life Gain Loss From Expereince									
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]									
Policyholder benefits net of remeasurement gain (losses)	6,913	6,293	13,640	7,594					
Direct to Consumer Life Gain *Loss) From Unlocking Assumptions									
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]									
Policyholder benefits net of remeasurement gain (losses)	21,744	1,763	21,744	1,763					
Direct to Consumer Health									
Liability for Future Policy Benefit, Expected Net Premium [Roll Forward]									
Beginning balance	114,876	89,674	115,363	90,143					
Beginning balance	113,247	86,840	109,880	87,751					
Effect of changes in assumptions on future cash flows					4,449	4,449	16,553	16,553	
Effect of actual variances from expected experience					644	(1,818)	229	(1,666)	
Adjusted balance					118,340	112,511	103,622	102,638	
Issuances	3,823	2,317	12,325	6,532					
Interest accrual	1,460	1,160	4,221	3,278					
Net premiums collected	(2,904)	(2,679)	(8,338)	(8,028)					
Effect of changes in the foreign exchange rate	0	0	0	0					
Ending balance	120,719	104,420	120,719	104,420					
Effect of change from original to current discount rates	7,153	(1,254)	7,153	(1,254)					
Ending balance	127,872	103,166	127,872	103,166					
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]									
Beginning balance	108,617	85,856	109,482	87,532					
Beginning balance	107,143	83,188	104,501	85,212					
Effect of changes in assumptions on future cash flows					7,733	7,733	15,930	15,930	
Effect of actual variances from expected experience					817	(1,509)	(95)	(1,925)	
Adjusted balance					115,693	110,725	99,023	99,217	
Issuances	3,811	2,310	12,296	6,518					
Interest accrual	1,460	1,160	4,220	3,278					
Benefit payments	(3,378)	(2,982)	(9,655)	(9,502)					
Effect of changes in the foreign exchange rate	0	0	0	0					
Ending balance	117,586	99,511	117,586	99,511					
Effect of changes in discount rate assumptions	6,871	(1,111)	6,871	(1,111)					
Ending balance	124,457	98,400	124,457	98,400					
Net liability for future policy benefits at original discount rates	(3,133)	(4,909)	(3,133)	(4,909)					
Effect of changes in discount rate assumptions	(282)	143	(282)	143					
Other Adjustments	4,326	5,530	4,326	5,530					
Net liability for future policy benefits—long duration health	911	764	911	764					
Reinsurance recoverable	0	0	0	0					
Net liability for future policy benefits, after reinsurance recoverable, at current discount rates	911	764	911	764					
Direct to Consumer Health Gain Loss From Expereince									
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]									
Policyholder benefits net of remeasurement gain (losses)	28	35	74	10					
Direct to Consumer Health Gain *Loss) From Unlocking Assumptions									
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]									
Policyholder benefits net of remeasurement gain (losses)	(373)	8	(373)	8					
Liberty National Life									
Liability for Future Policy Benefit, Expected Net Premium [Roll Forward]									
Beginning balance	1,085,233	1,110,017	1,129,716	1,094,407					
Beginning balance	1,080,642	1,071,561	1,077,831	1,066,123					
Effect of changes in assumptions on future cash flows					(29,292)	(29,292)	5,178	5,178	
Effect of actual variances from expected experience					(12,113)	(29,381)	(10,938)	(26,533)	
Adjusted balance					1,039,237	1,019,158	1,065,801	1,044,768	

Issuances	30,298	32,045	90,517	92,894				
Interest accrual	13,836	13,707	41,610	40,362				
Net premiums collected	(33,773)	(33,622)	(101,687)	(100,093)				
Effect of changes in the foreign exchange rate	0	0	0	0				
Ending balance	1,049,598	1,077,931	1,049,598	1,077,931				
Effect of change from original to current discount rates	54,498	(18,702)	54,498	(18,702)				
Ending balance	1,104,096	1,059,229	1,104,096	1,059,229				
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]								
Beginning balance	3,424,768	3,507,845	3,605,392	3,429,256				
Beginning balance	3,356,531	3,297,781	3,338,252	3,272,980				
Effect of changes in assumptions on future cash flows					(41,836)	(41,836)	6,156	6,156
Effect of actual variances from expected experience					(15,385)	(34,722)	(14,364)	(27,482)
Adjusted balance					3,299,310	3,261,694	3,289,573	3,251,654
Issuances	30,298	32,046	90,518	92,894				
Interest accrual	44,743	43,991	134,020	130,712				
Benefit payments	(47,338)	(43,644)	(159,219)	(153,294)				
Effect of changes in the foreign exchange rate	0	0	0	0				
Ending balance	3,327,013	3,321,966	3,327,013	3,321,966				
Effect of changes in discount rate assumptions	275,358	(46,234)	275,358	(46,234)				
Ending balance	3,602,371	3,275,732	3,602,371	3,275,732				
Net liability for future policy benefits at original discount rates	2,277,415	2,244,035	2,277,415	2,244,035				
Effect of changes in discount rate assumptions	220,860	(27,532)	220,860	(27,532)				
Other Adjustments	0	6,272	0	6,272				
Net liability for future policy benefits—long duration health	2,498,275	2,222,775	2,498,275	2,222,775				
Reinsurance recoverable	(7,885)	(7,661)	(7,885)	(7,661)				
Net liability for future policy benefits, after reinsurance recoverable, at current discount rates	2,490,390	2,215,114	2,490,390	2,215,114				
Liberty National Life Gain Loss From Expereince								
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]								
Policyholder benefits net of remeasurement gain (losses)	1,537	2,578	2,187	2,115				
Liberty National Life Gain *Loss) From Unlocking Assumptions								
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]								
Policyholder benefits net of remeasurement gain (losses)	12,224	(1,248)	12,224	(1,248)				
Liberty National Health								
Liability for Future Policy Benefit, Expected Net Premium [Roll Forward]								
Beginning balance	337,741	409,551	358,472	423,490				
Beginning balance	338,934	400,180	348,570	415,442				
Effect of changes in assumptions on future cash flows					(3,463)	(3,463)	(56,964)	(56,964)
Effect of actual variances from expected experience					(4,959)	(26,123)	(2,692)	(30,526)
Adjusted balance					330,512	318,984	340,524	327,952
Issuances	14,352	15,183	43,367	43,373				
Interest accrual	4,104	4,380	12,450	14,047				
Net premiums collected	(13,390)	(13,037)	(39,223)	(38,322)				
Effect of changes in the foreign exchange rate	0	0	0	0				
Ending balance	335,578	347,050	335,578	347,050				
Effect of change from original to current discount rates	11,529	(8,372)	11,529	(8,372)				
Ending balance	347,107	338,678	347,107	338,678				
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]								
Beginning balance	815,778	923,148	865,808	941,574				
Beginning balance	799,316	880,879	816,819	904,865				
Effect of changes in assumptions on future cash flows					(2,775)	(2,775)	(60,437)	(60,437)
Effect of actual variances from expected experience					(4,998)	(26,421)	(2,563)	(29,581)
Adjusted balance					791,543	787,623	817,879	814,847
Issuances	14,177	14,963	42,780	42,863				
Interest accrual	10,653	11,173	32,202	34,699				
Benefit payments	(23,417)	(25,220)	(69,649)	(73,614)				
Effect of changes in the foreign exchange rate	0	0	0	0				
Ending balance	792,956	818,795	792,956	818,795				
Effect of changes in discount rate assumptions	52,819	(4,792)	52,819	(4,792)				
Ending balance	845,775	814,003	845,775	814,003				
Net liability for future policy benefits at original discount rates	457,378	471,745	457,378	471,745				
Effect of changes in discount rate assumptions	41,290	3,580	41,290	3,580				
Other Adjustments	9,964	8,379	9,964	8,379				
Net liability for future policy benefits—long duration health	508,632	483,704	508,632	483,704				
Reinsurance recoverable	(1,096)	(1,336)	(1,096)	(1,336)				
Net liability for future policy benefits, after reinsurance recoverable, at current discount rates	507,536	482,368	507,536	482,368				
Liberty National Health Gain Loss From Expereince								
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]								
Policyholder benefits net of remeasurement gain (losses)	874	634	2,015	(284)				
Liberty National Health Gain *Loss) From Unlocking Assumptions								
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]								
Policyholder benefits net of remeasurement gain (losses)	(234)	2,171	(234)	2,171				
Other premium Life								
Liability for Future Policy Benefit, Expected Net Premium [Roll Forward]								
Beginning balance	449,883	471,279	478,052	470,741				
Beginning balance	437,551	445,475	443,949	449,209				
Effect of changes in assumptions on future cash flows					(982)	(982)	8,419	8,419
Effect of actual variances from expected experience					(1,970)	(9,292)	(7,232)	(13,882)
Adjusted balance					434,599	433,675	446,662	443,746
Issuances	5,969	7,143	18,126	21,756				
Interest accrual	5,709	5,741	17,213	17,071				
Net premiums collected	(11,223)	(11,515)	(33,960)	(34,542)				
Effect of changes in the foreign exchange rate	0	0	0	0				
Ending balance	435,054	448,031	435,054	448,031				
Effect of change from original to current discount rates	35,513	(1,499)	35,513	(1,499)				
Ending balance	470,567	446,532	470,567	446,532				
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]								
Beginning balance	3,981,898	4,109,706	4,239,623	3,976,150				
Beginning balance	3,545,323	3,448,491	3,506,859	3,403,704				
Effect of changes in assumptions on future cash flows					(2,027)	(2,027)	11,661	11,661
Effect of actual variances from expected experience					(2,629)	(12,841)	(9,595)	(17,962)

Adjusted balance					3,540,667	3,491,991	3,450,557	3,397,403
Issuances	5,970	7,145	18,127	21,756				
Interest accrual	52,747	51,249	157,318	152,378				
Benefit payments	(35,946)	(23,422)	(103,998)	(86,008)				
Effect of changes in the foreign exchange rate	0	0	0	0				
Ending balance	3,563,438	3,485,529	3,563,438	3,485,529				
Effect of changes in discount rate assumptions	717,751	282,118	717,751	282,118				
Ending balance	4,281,189	3,767,647	4,281,189	3,767,647				
Net liability for future policy benefits at original discount rates	3,128,384	3,037,498	3,128,384	3,037,498				
Effect of changes in discount rate assumptions	682,238	283,617	682,238	283,617				
Other Adjustments	37	466	37	466				
Net liability for future policy benefits—long duration health	3,810,659	3,321,581	3,810,659	3,321,581				
Reinsurance recoverable	(38,506)	(32,947)	(38,506)	(32,947)				
Net liability for future policy benefits, after reinsurance recoverable, at current discount rates	3,772,153	3,288,634	3,772,153	3,288,634				
Other premium Life Gain Loss From Expeirence								
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]								
Policyholder benefits net of remeasurement gain (losses)	508	2,082	2,533	3,487				
Other premium Life Gain *Loss) From Unlocking Assumptions								
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]								
Policyholder benefits net of remeasurement gain (losses)	904	(2,836)	904	(2,836)				
United American Health								
Liability for Future Policy Benefit, Expected Net Premium [Roll Forward]								
Beginning balance	3,658,491	2,984,554	3,697,771	2,908,501				
Beginning balance	3,720,108	2,985,660	3,625,803	2,941,261				
Effect of changes in assumptions on future cash flows					9,892	9,892	466,883	466,883
Effect of actual variances from expected experience					18,179	(18,894)	22,683	(6,240)
Adjusted balance					3,748,179	3,616,801	3,475,226	3,401,904
Issuances	95,279	82,647	287,072	226,363				
Interest accrual	43,903	35,536	128,533	99,390				
Net premiums collected	(75,335)	(68,421)	(220,380)	(202,669)				
Effect of changes in the foreign exchange rate	0	0	0	0				
Ending balance	3,812,026	3,524,988	3,812,026	3,524,988				
Effect of change from original to current discount rates	130,218	(183,608)	130,218	(183,608)				
Ending balance	3,942,244	3,341,380	3,942,244	3,341,380				
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]								
Beginning balance	3,758,487	3,116,389	3,814,328	3,046,829				
Beginning balance	3,823,510	3,116,768	3,741,530	3,080,633				
Effect of changes in assumptions on future cash flows					10,680	10,680	464,652	464,652
Effect of actual variances from expected experience					21,522	(15,162)	22,410	(5,530)
Adjusted balance					3,855,712	3,737,048	3,603,830	3,539,755
Issuances	95,126	82,511	286,358	225,915				
Interest accrual	45,365	37,340	133,143	104,932				
Benefit payments	(88,423)	(74,832)	(248,769)	(221,753)				
Effect of changes in the foreign exchange rate	0	0	0	0				
Ending balance	3,907,780	3,648,849	3,907,780	3,648,849				
Effect of changes in discount rate assumptions	131,531	(191,041)	131,531	(191,041)				
Ending balance	4,039,311	3,457,808	4,039,311	3,457,808				
Net liability for future policy benefits at original discount rates	95,754	123,861	95,754	123,861				
Effect of changes in discount rate assumptions	1,313	(7,433)	1,313	(7,433)				
Other Adjustments	17,014	7,729	17,014	7,729				
Net liability for future policy benefits—long duration health	114,081	124,157	114,081	124,157				
Reinsurance recoverable	(2,868)	(3,355)	(2,868)	(3,355)				
Net liability for future policy benefits, after reinsurance recoverable, at current discount rates	111,213	120,802	111,213	120,802				
United American Health Gain Loss From Expeirence								
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]								
Policyholder benefits net of remeasurement gain (losses)	(2,100)	239	(1,423)	(651)				
United American Health Gain *Loss) From Unlocking Assumptions								
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]								
Policyholder benefits net of remeasurement gain (losses)	1,205	762	1,205	762				
Family Heritage Health								
Liability for Future Policy Benefit, Expected Net Premium [Roll Forward]								
Beginning balance	1,690,797	1,661,020	1,711,741	1,594,992				
Beginning balance	1,823,728	1,771,206	1,783,173	1,729,219				
Effect of changes in assumptions on future cash flows					(8,117)	(8,117)	(30,255)	(30,255)
Effect of actual variances from expected experience					(12,068)	(43,359)	(15,658)	(50,052)
Adjusted balance					1,803,543	1,731,697	1,725,293	1,648,912
Issuances	71,345	70,216	200,220	202,561				
Interest accrual	19,016	17,272	55,733	50,091				
Net premiums collected	(47,989)	(45,226)	(141,735)	(134,009)				
Effect of changes in the foreign exchange rate	0	0	0	0				
Ending balance	1,845,915	1,767,555	1,845,915	1,767,555				
Effect of change from original to current discount rates	(44,372)	(192,981)	(44,372)	(192,981)				
Ending balance	1,801,543	1,574,574	1,801,543	1,574,574				
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]								
Beginning balance	3,249,466	3,167,461	3,315,880	3,005,664				
Beginning balance	3,605,315	3,436,167	3,506,689	3,336,344				
Effect of changes in assumptions on future cash flows					(5,054)	(5,054)	(32,428)	(32,428)
Effect of actual variances from expected experience					(13,407)	(48,407)	(17,000)	(53,292)
Adjusted balance					\$ 3,586,854	\$ 3,453,228	\$ 3,386,739	\$ 3,250,624
Issuances	71,345	70,215	200,219	202,561				
Interest accrual	37,299	34,024	109,479	99,344				
Benefit payments	(35,642)	(31,422)	(103,070)	(92,973)				
Effect of changes in the foreign exchange rate	0	0	0	0				
Ending balance	3,659,856	3,459,556	3,659,856	3,459,556				
Effect of changes in discount rate assumptions	(144,821)	(498,312)	(144,821)	(498,312)				
Ending balance	3,515,035	2,961,244	3,515,035	2,961,244				
Net liability for future policy benefits at original discount rates	1,813,941	1,692,001	1,813,941	1,692,001				
Effect of changes in discount rate assumptions	(100,449)	(305,331)	(100,449)	(305,331)				
Other Adjustments	38	4,347	38	4,347				
Net liability for future policy benefits—long duration health	1,713,530	1,391,017	1,713,530	1,391,017				
Reinsurance recoverable	(11,613)	(9,064)	(11,613)	(9,064)				
Net liability for future policy benefits, after reinsurance recoverable, at current								

discount rates	1,701,917	1,381,953	1,701,917	1,381,953				
Family Heritage Health Gain Loss From Expereince								
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]								
Policyholder benefits net of remeasurement gain (losses)	1,420	1,212	4,972	3,009				
Family Heritage Health Gain *Loss) From Unlocking Assumptions								
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]								
Policyholder benefits net of remeasurement gain (losses)	\$ (3,063)	\$ 2,173	\$ (3,063)	\$ 2,173				
~~XML 76 R58.htm IDEA: XBRL DOCUMENT~~								
Policy Liabilities - Additional	3 Months Ended				9 Months Ended			
Information (Details)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2022
- USD (\$)								
\$ in Thousands								
Liability for Future Policy Benefit, Activity [Line Items]								
Change in assumptions of lapse, mortality, and morbidity, remeasurement gain (loss)	\$ 46,300	\$ 3,200						
Change in expected experience, remeasurement gain (loss)	14,700	15,900	\$ 38,400	\$ 21,600				
Reclassification, Other								
Liability for Future Policy Benefit, Activity [Line Items]								
Reinsurance recoverables						\$ 55,000		
Reinsurance recoverable at original discount rates						50,000		
Life								
Liability for Future Policy Benefit, Activity [Line Items]								
Reinsurance recoverable at original discount rates	46,561	40,749	46,561	40,749				
PV of expected future gross premiums	29,804,051	26,790,615	29,804,051	26,790,615				
PV of expected future net premiums	12,406,270	11,494,641	12,406,270	11,494,641	\$ 11,981,537	12,342,307	\$ 12,042,720	\$ 11,748,528
PV of expected future policy benefits, not discounted	78,961,606	77,173,809	78,961,606	77,173,809				
Liability for Future Policy Benefit, Difference Between Expected Gross Premiums and Expected Future Net Premiums	17,400,000	15,300,000	17,400,000	15,300,000				
Health								
Liability for Future Policy Benefit, Activity [Line Items]								
Reinsurance recoverable at original discount rates	15,577	13,755	15,577	13,755				
PV of expected future gross premiums	12,407,986	10,812,872	12,407,986	10,812,872				
PV of expected future net premiums	6,452,555	5,546,944	6,452,555	5,546,944	\$ 6,007,794	\$ 6,089,728	\$ 5,346,643	\$ 5,207,422
PV of expected future policy benefits, not discounted	15,707,558	14,749,901	15,707,558	14,749,901				
Liability for Future Policy Benefit, Difference Between Expected Gross Premiums and Expected Future Net Premiums	\$ 5,900,000	\$ 5,300,000	\$ 5,900,000	\$ 5,300,000				
~~XML 77 R59.htm IDEA: XBRL DOCUMENT~~								
Policy Liabilities - Schedule of Liability								
For Future Policy Benefits To Consolidated Balance Sheets (Details) - USD (\$)	Sep. 30, 2024		Dec. 31, 2023	Sep. 30, 2023				
\$ in Thousands								
At Original Discount Rates								
Deferred profit liability	\$ 177,108			\$ 173,520				
Deferred annuity	680,849			813,276				
Interest sensitive life	725,857			735,025				
Other	8,983			9,901				
Total future policy benefits	17,402,917			16,807,914				
At Current Discount Rates								
Deferred profit liability	177,108			173,520				
Deferred annuity	680,849			813,276				
Interest sensitive life	725,857			735,025				
Other	8,980			9,904				
Net liability for future policy benefits—long duration health	19,814,913	\$ 19,460,353	17,273,102					
Life								
At Original Discount Rates								
Net liability for future policy benefits—long duration life	13,293,880			12,661,216				
At Current Discount Rates								
Net liability for future policy benefits—long duration health	15,744,284			13,423,847				
Net liability for future policy benefits—long duration health	15,744,284			13,423,847				
Health								
At Original Discount Rates								
Net liability for future policy benefits—long duration life	2,516,240			2,414,976				
At Current Discount Rates								
Net liability for future policy benefits—long duration health	2,477,835			2,117,530				
Net liability for future policy benefits—long duration health	2,477,835			2,117,530				
American Income Life								
At Original Discount Rates								
Net liability for future policy benefits—long duration life	4,781,464			4,436,042				
At Current Discount Rates								
Net liability for future policy benefits—long duration health	5,667,941			4,672,240				
Net liability for future policy benefits—long duration health	5,667,941			4,672,240				
American Income Health								
At Original Discount Rates								
Net liability for future policy benefits—long duration life	124,534			113,340				
At Current Discount Rates								
Net liability for future policy benefits—long duration health	140,681			117,888				
Net liability for future policy benefits—long duration health	140,681			117,888				
Direct to Consumer Life								
At Original Discount Rates								
Net liability for future policy benefits—long duration life	3,106,582			2,943,544				
At Current Discount Rates								
Net liability for future policy benefits—long duration health	3,767,409			3,207,251				
Net liability for future policy benefits—long duration health	3,767,409			3,207,251				
Direct to Consumer Health								
At Original Discount Rates								
Net liability for future policy benefits—long duration life	877			752				
At Current Discount Rates								
Net liability for future policy benefits—long duration health	911			764				
Net liability for future policy benefits—long duration health	911			764				
Liberty National Life								
At Original Discount Rates								
Net liability for future policy benefits—long duration life	2,277,415			2,244,035				

At Current Discount Rates		
Net liability for future policy benefits—long duration health	2,498,275	2,222,775
Net liability for future policy benefits—long duration health	2,498,275	2,222,775
Liberty National Health		
At Original Discount Rates		
Net liability for future policy benefits—long duration life	466,474	479,394
At Current Discount Rates		
Net liability for future policy benefits—long duration health	508,632	483,704
Net liability for future policy benefits—long duration health	508,632	483,704
Other premium Life		
At Original Discount Rates		
Net liability for future policy benefits—long duration life	3,128,419	3,037,595
At Current Discount Rates		
Net liability for future policy benefits—long duration health	3,810,659	3,321,581
Net liability for future policy benefits—long duration health	3,810,659	3,321,581
United American Health		
At Original Discount Rates		
Net liability for future policy benefits—long duration life	110,384	129,410
At Current Discount Rates		
Net liability for future policy benefits—long duration health	114,081	124,157
Net liability for future policy benefits—long duration health	114,081	124,157
Family Heritage Health		
At Original Discount Rates		
Net liability for future policy benefits—long duration life	1,813,971	1,692,080
At Current Discount Rates		
Net liability for future policy benefits—long duration health	1,713,530	1,391,017
Net liability for future policy benefits—long duration health	\$ 1,713,530	\$ 1,391,017

~~XML 78-R60.htm IDEA: XBRL DOCUMENT~~

Policy Liabilities -
Schedule of Weighted
Average Interest Rate
of Liability For Future
Policy Benefits
(Details)

Sep. 30, 2024Sep. 30, 2023

[American Income | Life](#)

[Liability for Future Policy Benefit, Activity \[Line Items\]](#)

Weighted average original discount rate	5.70%	5.70%
Weighted average current discount rate	5.00%	5.60%

[American Income | Health](#)

[Liability for Future Policy Benefit, Activity \[Line Items\]](#)

Weighted average original discount rate	5.80%	5.90%
Weighted average current discount rate	4.80%	5.60%

[DTC | Life](#)

[Liability for Future Policy Benefit, Activity \[Line Items\]](#)

Weighted average original discount rate	6.00%	6.00%
Weighted average current discount rate	5.00%	5.60%

[DTC | Health](#)

[Liability for Future Policy Benefit, Activity \[Line Items\]](#)

Weighted average original discount rate	5.10%	5.20%
Weighted average current discount rate	4.80%	5.50%

[Liberty National | Life](#)

[Liability for Future Policy Benefit, Activity \[Line Items\]](#)

Weighted average original discount rate	5.60%	5.60%
Weighted average current discount rate	5.00%	5.70%

[Liberty National | Health](#)

[Liability for Future Policy Benefit, Activity \[Line Items\]](#)

Weighted average original discount rate	5.80%	5.80%
Weighted average current discount rate	4.80%	5.70%

[Other premium | Life](#)

[Liability for Future Policy Benefit, Activity \[Line Items\]](#)

Weighted average original discount rate	6.20%	6.20%
Weighted average current discount rate	5.00%	5.70%

[United American | Health](#)

[Liability for Future Policy Benefit, Activity \[Line Items\]](#)

Weighted average original discount rate	5.10%	5.20%
Weighted average current discount rate	4.80%	5.50%

[Family Heritage | Health](#)

[Liability for Future Policy Benefit, Activity \[Line Items\]](#)

Weighted average original discount rate	4.20%	4.30%
Weighted average current discount rate	4.90%	5.70%

~~XML 79-R61.htm IDEA: XBRL DOCUMENT~~

Policy Liabilities -
Schedule of Weighted
Average Duration of
Liability For Future
Policy Benefits
(Details)

Sep. 30, 2024Sep. 30, 2023

[American Income | Life](#)

[Liability for Future Policy Benefit, Activity \[Line Items\]](#)

At original discount rates	22 years 9 months 21 days	23 years 29 days
At current discount rates	23 years 10 days	23 years 3 months 14 days

[American Income | Health](#)

[Liability for Future Policy Benefit, Activity \[Line Items\]](#)

At original discount rates	12 years 6 months	12 years 1 month 20 days
At current discount rates	12 years 10 months 20 days	12 years 2 months 12 days

[DTC | Life](#)

[Liability for Future Policy Benefit, Activity \[Line Items\]](#)

At original discount rates	19 years 5 months 1 day	19 years 8 months 23 days
At current discount rates	20 years 9 months 21 days	21 years

[DTC | Health](#)

[Liability for Future Policy Benefit, Activity \[Line Items\]](#)

At original discount rates	11 years 8 months 23 days	11 years 4 months 24 days
At current discount rates	10 years 11 months 4 days	10 years 4 months 2 days

[Liberty National | Life](#)

[Liability for Future Policy Benefit, Activity \[Line Items\]](#)

At original discount rates	15 years 3 months 21 days	15 years 1 month 13 days
At current discount rates	15 years 9 months 18 days	15 years 2 months 12 days

[Liberty National | Health](#)

[Liability for Future Policy Benefit, Activity \[Line Items\]](#)

At original discount rates	9 years 3 months 3 days	9 years 1 month 9 days
At current discount rates	9 years 5 months 23 days	8 years 11 months 19 days
Other premium Life		

[Liability for Future Policy Benefit, Activity |Line Items|](#)

At original discount rates	16 years 25 days	16 years 4 months 2 days
At current discount rates	17 years 5 months 23 days	17 years 5 months 1 day
United American Health		

[Liability for Future Policy Benefit, Activity |Line Items|](#)

At original discount rates	11 years 8 months 23 days	11 years 4 months 24 days
At current discount rates	10 years 11 months 4 days	10 years 4 months 2 days
Family Heritage Health		

[Liability for Future Policy Benefit, Activity |Line Items|](#)

At original discount rates	15 years 4 months 2 days	14 years 10 months 24 days
At current discount rates	14 years 7 months 6 days	13 years 9 months 21 days
XML-80-R62.htm IDEA: XBRL DOCUMENT		

Policy Liabilities - Schedule of Liability For Future Policy Benefits To	3 Months Ended	9 Months Ended		
Consolidated Income Statement (Details) - USD (\$) \$ in Thousands	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023

[Life](#)

[Liability for Future Policy Benefit, Activity |Line Items|](#)

Gross Premiums	\$ 814,217	\$ 783,289	\$ 2,425,145	\$ 2,328,098
Interest expense	191,576	181,703	568,349	538,177
Health				

[Liability for Future Policy Benefit, Activity |Line Items|](#)

Gross Premiums	298,917	278,665	883,744	828,429
Interest expense	27,778	26,779	82,495	79,712
American Income Life				

[Liability for Future Policy Benefit, Activity |Line Items|](#)

Gross Premiums	427,543	399,794	1,264,474	1,181,247
Interest expense	68,558	63,565	202,486	187,381
American Income Health				

[Liability for Future Policy Benefit, Activity |Line Items|](#)

Gross Premiums	29,628	28,528	88,017	84,863
Interest expense	1,696	1,640	5,010	4,896
Direct to Consumer Life				

[Liability for Future Policy Benefit, Activity |Line Items|](#)

Gross Premiums	243,625	244,931	734,860	735,374
Interest expense	45,708	42,978	135,249	127,040
Direct to Consumer Health				

[Liability for Future Policy Benefit, Activity |Line Items|](#)

Gross Premiums	3,806	3,583	11,196	10,680
Interest expense	0	0	0	0
Liberty National Life				

[Liability for Future Policy Benefit, Activity |Line Items|](#)

Gross Premiums	92,636	87,071	273,746	256,641
Interest expense	30,737	30,095	91,890	89,765
Liberty National Health				

[Liability for Future Policy Benefit, Activity |Line Items|](#)

Gross Premiums	47,099	46,441	142,051	139,875
Interest expense	6,524	6,766	19,679	20,567
Other premium Life				

[Liability for Future Policy Benefit, Activity |Line Items|](#)

Gross Premiums	50,413	51,493	152,065	154,836
Interest expense	46,573	45,065	138,724	133,991
United American Health				

[Liability for Future Policy Benefit, Activity |Line Items|](#)

Gross Premiums	110,565	100,285	325,415	298,964
Interest expense	1,408	1,741	4,449	5,345
Family Heritage Health				

[Liability for Future Policy Benefit, Activity |Line Items|](#)

Gross Premiums	107,819	99,828	317,065	294,047
Interest expense	\$ 18,150	\$ 16,632	\$ 53,357	\$ 48,904
XML-81-R63.htm IDEA: XBRL DOCUMENT				

Policy Liabilities - Schedule of Undiscounted And Discounted Expected Future Gross Premiums And Expected Future Benefits And Expenses (Details) - USD (\$) \$ in Thousands	Sep. 30, 2024	Jun. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2022

[Life](#)

[Liability for Future Policy Benefit, Activity |Line Items|](#)

PV of expected future gross premiums, Not discounted	\$ 51,262,031			\$ 49,904,850		
PV of expected future gross premiums, At original discount rates	28,100,488			27,294,726		
PV of expected future gross premiums, At current discount rates	29,804,051			26,790,615		
PV of expected future net premiums, Not discounted	21,550,441			21,583,806		
PV of expected future net premiums, At original discount rates	11,689,804	\$ 11,836,592	\$ 11,709,368	11,701,214	\$ 11,616,443	\$ 11,442,919
PV of expected future net premiums, At current discount rates	12,406,270	11,981,537	12,342,307	11,494,641	12,042,720	11,748,528
PV of expected future policy benefits, Not discounted	78,961,606			77,173,809		
PV of expected future policy benefits, At original discount rates	24,983,499	25,004,280	24,563,696	24,362,292	24,092,695	23,564,337
PV of expected future policy benefits, At current discount rates	28,150,367	26,507,907	27,723,158	24,907,260	26,772,991	25,749,961
Health						

[Liability for Future Policy Benefit, Activity |Line Items|](#)

PV of expected future gross premiums, Not discounted	20,227,626			19,144,817		
PV of expected future gross premiums, At original discount rates	12,155,056			11,521,032		
PV of expected future gross premiums, At current discount rates	12,407,986			10,812,872		
PV of expected future net premiums, Not discounted	10,457,252			9,797,821		
PV of expected future net premiums, At original discount rates	6,339,854	6,204,884	6,069,295	5,943,135	5,445,595	5,366,304
PV of expected future net premiums, At current discount rates	6,452,555	6,007,794	6,089,728	5,546,944	5,346,643	5,207,422
PV of expected future policy benefits, Not discounted	15,707,558			14,749,901		
PV of expected future policy benefits, At original discount rates	8,827,339	8,657,990	8,484,970	8,338,353	7,832,089	7,710,767
PV of expected future policy benefits, At current discount rates	8,898,122	8,260,784	8,441,002	7,637,496	7,621,433	7,394,349

American Income | Life

Liability for Future Policy Benefit, Activity [Line Items]

PV of expected future gross premiums, Not discounted	25,300,910			23,974,963		
PV of expected future gross premiums, At original discount rates	14,305,914			13,530,015		
PV of expected future gross premiums, At current discount rates	15,028,140			13,147,003		
PV of expected future net premiums, Not discounted	8,185,825			7,912,903		
PV of expected future net premiums, At original discount rates	4,632,427	4,648,111	4,523,329	4,473,959	4,399,053	4,246,723
PV of expected future net premiums, At current discount rates	4,836,994	4,635,903	4,681,888	4,318,705	4,472,847	4,273,156
PV of expected future policy benefits, Not discounted	31,554,905			30,182,319		
PV of expected future policy benefits, At original discount rates	9,413,743	9,353,526	9,061,833	8,909,960	8,753,526	8,409,761
PV of expected future policy benefits, At current discount rates	10,504,785	9,811,407	10,163,627	8,990,437	9,668,207	9,119,104

American Income | Health

Liability for Future Policy Benefit, Activity [Line Items]

PV of expected future gross premiums, Not discounted	1,781,677			1,755,682		
PV of expected future gross premiums, At original discount rates	999,161			984,122		
PV of expected future gross premiums, At current discount rates	1,063,740			969,090		
PV of expected future net premiums, Not discounted	400,683			354,120		
PV of expected future net premiums, At original discount rates	225,616	208,867	201,869	199,122	201,709	192,631
PV of expected future net premiums, At current discount rates	233,789	205,889	206,381	189,146	201,844	190,296
PV of expected future policy benefits, Not discounted	710,352			632,349		
PV of expected future policy benefits, At original discount rates	349,161	322,706	315,431	311,642	315,087	303,713
PV of expected future policy benefits, At current discount rates	373,544	328,436	335,504	306,041	328,579	312,750

Direct to Consumer | Life

Liability for Future Policy Benefit, Activity [Line Items]

PV of expected future gross premiums, Not discounted	17,506,090			17,575,618		
PV of expected future gross premiums, At original discount rates	9,144,676			9,182,146		
PV of expected future gross premiums, At current discount rates	9,825,694			9,112,202		
PV of expected future net premiums, Not discounted	10,614,237			10,850,664		
PV of expected future net premiums, At original discount rates	5,572,725	5,670,288	5,664,259	5,701,293	5,700,354	5,680,864
PV of expected future net premiums, At current discount rates	5,994,613	5,810,518	6,052,651	5,670,175	5,988,577	5,910,224
PV of expected future policy benefits, Not discounted	25,907,169			25,711,499		
PV of expected future policy benefits, At original discount rates	8,679,305	8,748,900	8,656,752	8,644,837	8,592,897	8,477,892
PV of expected future policy benefits, At current discount rates	9,762,022	9,289,834	9,714,516	8,873,444	9,487,233	9,225,451

Direct to Consumer | Health

Liability for Future Policy Benefit, Activity [Line Items]

PV of expected future gross premiums, Not discounted	232,805			224,522		
PV of expected future gross premiums, At original discount rates	147,193			141,374		
PV of expected future gross premiums, At current discount rates	156,142			139,748		
PV of expected future net premiums, Not discounted	191,566			166,099		
PV of expected future net premiums, At original discount rates	120,719	113,247	109,880	104,420	86,840	87,751
PV of expected future net premiums, At current discount rates	127,872	114,876	115,363	103,166	89,674	90,143
PV of expected future policy benefits, Not discounted	187,260			154,931		
PV of expected future policy benefits, At original discount rates	117,586	107,143	104,501	99,511	83,188	85,212
PV of expected future policy benefits, At current discount rates	124,457	108,617	109,482	98,400	85,856	87,532

Liberty National | Life

Liability for Future Policy Benefit, Activity [Line Items]

PV of expected future gross premiums, Not discounted	4,797,146			4,601,176		
PV of expected future gross premiums, At original discount rates	2,792,129			2,681,034		
PV of expected future gross premiums, At current discount rates	2,886,943			2,577,877		
PV of expected future net premiums, Not discounted	1,855,536			1,901,039		
PV of expected future net premiums, At original discount rates	1,049,598	1,080,642	1,077,831	1,077,931	1,071,561	1,066,123
PV of expected future net premiums, At current discount rates	1,104,096	1,085,233	1,129,716	1,059,229	1,110,017	1,094,407
PV of expected future policy benefits, Not discounted	9,028,196			8,852,345		
PV of expected future policy benefits, At original discount rates	3,327,013	3,356,531	3,338,252	3,321,966	3,297,781	3,272,980
PV of expected future policy benefits, At current discount rates	3,602,371	3,424,768	3,605,392	3,275,732	3,507,845	3,429,256

Liberty National | Health

Liability for Future Policy Benefit, Activity [Line Items]

PV of expected future gross premiums, Not discounted	2,037,319			2,084,428		
PV of expected future gross premiums, At original discount rates	1,297,318			1,321,438		
PV of expected future gross premiums, At current discount rates	1,370,521			1,308,898		
PV of expected future net premiums, Not discounted	495,616			515,612		
PV of expected future net premiums, At original discount rates	335,578	338,934	348,570	347,050	400,180	415,442
PV of expected future net premiums, At current discount rates	347,107	337,741	358,472	338,678	409,551	423,490
PV of expected future policy benefits, Not discounted	1,375,759			1,414,512		
PV of expected future policy benefits, At original discount rates	792,956	799,316	816,819	818,795	880,879	904,865
PV of expected future policy benefits, At current discount rates	845,775	815,778	865,808	814,003	923,148	941,574

Other premium | Life

Liability for Future Policy Benefit, Activity [Line Items]

PV of expected future gross premiums, Not discounted	3,657,885			3,753,093		
PV of expected future gross premiums, At original discount rates	1,857,769			1,901,531		
PV of expected future gross premiums, At current discount rates	2,063,274			1,953,533		
PV of expected future net premiums, Not discounted	894,843			919,200		
PV of expected future net premiums, At original discount rates	435,054	437,551	443,949	448,031	445,475	449,209
PV of expected future net premiums, At current discount rates	470,567	449,883	478,052	446,532	471,279	470,741
PV of expected future policy benefits, Not discounted	12,471,336			12,427,646		
PV of expected future policy benefits, At original discount rates	3,563,438	3,545,323	3,506,859	3,485,529	3,448,491	3,403,704
PV of expected future policy benefits, At current discount rates	4,281,189	3,981,898	4,239,623	3,767,647	4,109,706	3,976,150

United American | Health

Liability for Future Policy Benefit, Activity [Line Items]

PV of expected future gross premiums, Not discounted	9,068,701			8,442,713		
PV of expected future gross premiums, At original discount rates	5,556,347			5,141,771		
PV of expected future gross premiums, At current discount rates	5,742,668			4,871,878		
PV of expected future net premiums, Not discounted	6,229,763			5,799,017		
PV of expected future net premiums, At original discount rates	3,812,026	3,720,108	3,625,803	3,524,988	2,985,660	2,941,261
PV of expected future net premiums, At current discount rates	3,942,244	3,658,491	3,697,771	3,341,380	2,984,554	2,908,501
PV of expected future policy benefits, Not discounted	6,390,307			5,998,770		
PV of expected future policy benefits, At original discount rates	3,907,780	3,823,510	3,741,530	3,648,849	3,116,768	3,080,633
PV of expected future policy benefits, At current discount rates	4,039,311	3,758,487	3,814,328	3,457,808	3,116,389	3,046,829

Family Heritage | Health

Liability for Future Policy Benefit, Activity [Line Items]

PV of expected future gross premiums, Not discounted	7,107,124			6,637,472		
PV of expected future gross premiums, At original discount rates	4,155,037			3,932,327		
PV of expected future gross premiums, At current discount rates	4,074,915			3,523,258		
PV of expected future net premiums, Not discounted	3,139,624			2,962,973		
PV of expected future net premiums, At original discount rates	1,845,915	1,823,728	1,783,173	1,767,555	1,771,206	1,729,219
PV of expected future net premiums, At current discount rates	1,801,543	1,690,797	1,711,741	1,574,574	1,661,020	1,594,992
PV of expected future policy benefits, Not discounted	7,043,880			6,549,339		
PV of expected future policy benefits, At original discount rates	3,659,856	3,605,315	3,506,689	3,459,556	3,436,167	3,336,344

PV of expected future policy benefits, At current discount rates \$ 3,515,035 \$ 3,249,466 \$ 3,315,880 \$ 2,961,244 \$ 3,167,461 \$ 3,005,664

~~XML-82-R64.htm-IDEA: XBRL DOCUMENT~~

Policy Liabilities - Schedule of	3 Months Ended		9 Months Ended	
Policyholder Account Balance (Details) - USD (\$)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
\$ in Thousands				

Interest Sensitive Life

Policyholder Account Balance [Roll Forward]

Beginning Balance	\$ 728,097	\$ 736,920	\$ 732,948	\$ 739,105
Issuances	0	0	0	0
Premiums received	5,077	5,398	16,187	17,062
Policy charges	(3,081)	(3,213)	(9,253)	(9,729)
Surrenders and withdrawals	(5,850)	(5,582)	(17,326)	(16,204)
Benefit payments	(6,617)	(7,258)	(23,357)	(22,753)
Interest credited	6,922	7,083	20,890	21,274
Other	1,309	1,677	5,768	6,270
Ending Balance	\$ 725,857	\$ 735,025	\$ 725,857	\$ 735,025
Weighted-average credit rate	3.86%	3.91%	3.86%	3.91%
Net amount at risk	\$ 1,687,182	\$ 1,793,787	\$ 1,687,182	\$ 1,793,787
Cash surrender value	678,556	673,814	678,556	673,814

Deferred Annuity

Policyholder Account Balance [Roll Forward]

Beginning Balance	706,022	853,064	773,039	954,318
Issuances	137	231	495	602
Premiums received	2,448	2,439	8,857	10,543
Policy charges	0	0	0	0
Surrenders and withdrawals	(22,331)	(37,905)	(84,893)	(125,176)
Benefit payments	(10,022)	(11,047)	(34,159)	(48,459)
Interest credited	5,777	6,863	17,990	21,608
Other	(1,182)	(370)	(480)	(161)
Ending Balance	\$ 680,849	\$ 813,275	\$ 680,849	\$ 813,275
Weighted-average credit rate	3.37%	3.34%	3.37%	3.34%
Cash surrender value	\$ 680,849	\$ 813,276	\$ 680,849	\$ 813,276

Other Policy-holders' Funds

Policyholder Account Balance [Roll Forward]

Beginning Balance	400,625	187,873	236,958	123,234
Issuances	0	0	0	0
Premiums received	70,644	31,704	239,114	100,113
Policy charges	0	0	0	0
Surrenders and withdrawals	(3,264)	(2,782)	(10,615)	(9,106)
Benefit payments	0	0	0	0
Interest credited	6,106	2,825	15,210	6,164
Other	(4,823)	(1,410)	(11,379)	(2,195)
Ending Balance	\$ 469,288	\$ 218,210	\$ 469,288	\$ 218,210
Weighted-average credit rate	5.73%	5.68%	5.73%	5.68%
Cash surrender value	\$ 469,288	\$ 218,210	\$ 469,288	\$ 218,210

~~XML-83-R65.htm-IDEA: XBRL DOCUMENT~~

Policy Liabilities - Schedule of	Sep. 30, 2024 Jun. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Jun. 30, 2023 Dec. 31, 2022					
Policyholder Account Balance, Guaranteed Minimum Crediting Rate (Details) - USD (\$)						
\$ in Thousands						

1-50 basis points above | Minimum

Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]

Range above guaranteed minimum crediting rates (percent)	0.0001	0.0001

1-50 basis points above | Maximum

Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]

Range above guaranteed minimum crediting rates (percent)	0.0050	0.0050

51-150 basis points above | Minimum

Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]

Range above guaranteed minimum crediting rates (percent)	0.0051	0.0051

Greater than 150 basis points above | Maximum

Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]

Range above guaranteed minimum crediting rates (percent)	0.0150	0.0150

Interest Sensitive Life

Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]

Range of guaranteed minimum crediting rates	\$ 725,857	\$ 728,097	\$ 732,948	\$ 735,025	\$ 736,920	\$ 739,105

Interest Sensitive Life | At guaranteed minimum

Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]

Range of guaranteed minimum crediting rates	725,857	735,025

Interest Sensitive Life | 1-50 basis points above

Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]

Range of guaranteed minimum crediting rates	0	0

Interest Sensitive Life | 51-150 basis points above

Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]

Range of guaranteed minimum crediting rates	\$ 0	\$ 0

Interest Sensitive Life | Less than 3.00% | At guaranteed minimum

Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]

Range of guaranteed minimum crediting rates (percent)	3.00%	3.00%

Range of guaranteed minimum crediting rates

	\$ 0	\$ 0

Interest Sensitive Life | Less than 3.00% | 1-50 basis points above

Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]

Range of guaranteed minimum crediting rates (percent)	3.00%	3.00%

Range of guaranteed minimum crediting rates

	\$ 0	\$ 0

Interest Sensitive Life | Less than 3.00% | 51-150 basis points above

Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]

Range of guaranteed minimum crediting rates (percent)	3.00%	3.00%

Range of guaranteed minimum crediting rates

	\$ 0	\$ 0

Interest Sensitive Life | 3.00%-3.99% | At guaranteed minimum

Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]

Range of guaranteed minimum crediting rates	\$ 29,170	\$ 29,018

Interest Sensitive Life | 3.00%-3.99% | At guaranteed minimum | Minimum

Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]

Range of guaranteed minimum crediting rates (percent)	3.00%	3.00%

Interest Sensitive Life | 3.00%-3.99% | At guaranteed minimum | Maximum

[illegible]

Range of guaranteed minimum crediting rates	0			0		
Deferred Annuity Greater than 5.00% At guaranteed minimum						
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]						
Range of guaranteed minimum crediting rates	0			755		
Deferred Annuity Greater than 5.00% 1-50 basis points above						
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]						
Range of guaranteed minimum crediting rates	0			0		
Deferred Annuity Greater than 5.00% 51-150 basis points above						
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]						
Range of guaranteed minimum crediting rates	0			0		
Other premium						
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]						
Range of guaranteed minimum crediting rates	469,288	\$ 400,625	\$ 236,958	218,210	\$ 187,873	\$ 123,234
Other premium At guaranteed minimum						
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]						
Range of guaranteed minimum crediting rates	419,864			168,206		
Other premium 1-50 basis points above						
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]						
Range of guaranteed minimum crediting rates	1,678			0		
Other premium 51-150 basis points above						
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]						
Range of guaranteed minimum crediting rates	47,746			50,004		
Other premium Less than 3.00% At guaranteed minimum						
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]						
Range of guaranteed minimum crediting rates	373,729			118,565		
Other premium Less than 3.00% 1-50 basis points above						
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]						
Range of guaranteed minimum crediting rates	0			0		
Other premium Less than 3.00% 51-150 basis points above						
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]						
Range of guaranteed minimum crediting rates	0			0		
Other premium 3.00%-3.99% At guaranteed minimum						
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]						
Range of guaranteed minimum crediting rates	3,046			4,002		
Other premium 3.00%-3.99% 1-50 basis points above						
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]						
Range of guaranteed minimum crediting rates	0			0		
Other premium 3.00%-3.99% 51-150 basis points above						
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]						
Range of guaranteed minimum crediting rates	0			0		
Other premium 4.00%-4.99% At guaranteed minimum						
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]						
Range of guaranteed minimum crediting rates	6,548			6,851		
Other premium 4.00%-4.99% 1-50 basis points above						
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]						
Range of guaranteed minimum crediting rates	1,678			0		
Other premium 4.00%-4.99% 51-150 basis points above						
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]						
Range of guaranteed minimum crediting rates	47,746			50,004		
Other premium Greater than 5.00% At guaranteed minimum						
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]						
Range of guaranteed minimum crediting rates	36,541			38,788		
Other premium Greater than 5.00% 1-50 basis points above						
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]						
Range of guaranteed minimum crediting rates	0			0		
Other premium Greater than 5.00% 51-150 basis points above						
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]						
Range of guaranteed minimum crediting rates	\$ 0			\$ 0		
~~XML 84 R66.htm IDEA: XBRL DOCUMENT~~						
Deferred Acquisition	3 Months Ended		9 Months Ended			
Costs - Schedule of						
Analysis of Deferred						
Acquisition Costs	Sep. 30, 2024		Sep. 30, 2023		Sep. 30, 2024	
(Details) - USD (\$)					Sep. 30, 2023	
\$ in Thousands						
Movement Analysis of Deferred Policy Acquisition Costs						
Beginning Balance			\$ 6,009,477			
Amortization expense	\$ (104,310)	\$ (95,757)	(305,703)	\$ (282,159)		
Ending Balance	6,386,682	5,889,293	6,386,682	5,889,293		
Life						
Movement Analysis of Deferred Policy Acquisition Costs						
Beginning Balance	5,495,593	5,065,265	5,271,775	4,844,291		
Capitalizations	198,352	185,299	601,564	564,276		
Amortization expense	(90,070)	(82,523)	(263,753)	(243,285)		
Foreign exchange adjustment	3,854	(4,056)	(1,857)	(1,297)		
Ending Balance	5,607,729	5,163,985	5,607,729	5,163,985		
Health						
Movement Analysis of Deferred Policy Acquisition Costs						
Beginning Balance	762,523	709,669	734,735	686,763		
Capitalizations	28,309	25,260	83,256	72,901		
Amortization expense	(13,852)	(12,816)	(40,774)	(37,608)		
Foreign exchange adjustment	182	(182)	(55)	(125)		
Ending Balance	777,162	721,931	777,162	721,931		
American Income Life						
Movement Analysis of Deferred Policy Acquisition Costs						
Beginning Balance	2,740,138	2,417,480	2,573,370	2,258,291		
Capitalizations	131,851	117,761	391,707	351,933		
Amortization expense	(46,033)	(40,465)	(133,410)	(118,207)		
Foreign exchange adjustment	3,854	(4,056)	(1,857)	(1,297)		
Ending Balance	2,829,810	2,490,720	2,829,810	2,490,720		
American Income Health						
Movement Analysis of Deferred Policy Acquisition Costs						
Beginning Balance	71,589	62,285	66,783	57,811		
Capitalizations	3,817	3,259	11,097	9,579		
Amortization expense	(1,189)	(1,016)	(3,426)	(2,919)		
Foreign exchange adjustment	182	(182)	(55)	(125)		
Ending Balance	74,399	64,346	74,399	64,346		
DTC Life						

<u>Beginning Balance</u>	1,765,673	1,714,715	1,737,117	1,676,931
<u>Capitalizations</u>	33,222	36,385	112,198	123,774
<u>Amortization expense</u>	(25,478)	(24,891)	(75,898)	(74,496)
<u>Foreign exchange adjustment</u>	0	0	0	0
<u>Ending Balance</u>	1,773,417	1,726,209	1,773,417	1,726,209

<u>Beginning Balance</u>	1,608	1,760	1,679	1,854
<u>Capitalizations</u>	0	0	2	0
<u>Amortization expense</u>	(37)	(43)	(110)	(137)
<u>Foreign exchange adjustment</u>	0	0	0	0
<u>Ending Balance</u>	1,571	1,717	1,571	1,717

<u>Beginning Balance</u>	696,905	636,209	666,419	610,723
<u>Capitalizations</u>	30,255	27,950	88,355	78,599
<u>Amortization expense</u>	(14,427)	(13,029)	(42,041)	(38,192)
<u>Foreign exchange adjustment</u>	0	0	0	0
<u>Ending Balance</u>	712,733	651,130	712,733	651,130

<u>Beginning Balance</u>	145,097	136,276	139,941	133,096
<u>Capitalizations</u>	5,589	5,120	18,033	14,854
<u>Amortization expense</u>	(3,715)	(3,423)	(11,003)	(9,977)
<u>Foreign exchange adjustment</u>	0	0	0	0
<u>Ending Balance</u>	146,971	137,973	146,971	137,973

<u>Beginning Balance</u>	292,877	296,861	294,869	298,346
<u>Capitalizations</u>	3,024	3,203	9,304	9,970
<u>Amortization expense</u>	(4,132)	(4,138)	(12,404)	(12,390)
<u>Foreign exchange adjustment</u>	0	0	0	0
<u>Ending Balance</u>	291,769	295,926	291,769	295,926

Beginning Balance	71,975	75,349	73,489	77,394
Capitalizations	780	495	2,069	1,491
Amortization expense	(1,394)	(1,463)	(4,197)	(4,504)
Foreign exchange adjustment	0	0	0	0
Ending Balance	71,361	74,381	71,361	74,381

<u>Beginning Balance</u>	472,254	433,999	452,843	416,608
<u>Capitalizations</u>	18,123	16,386	52,055	46,977
<u>Amortization expense</u>	(7,517)	(6,871)	(22,038)	(20,071)
<u>Foreign exchange adjustment</u>	0	0	0	0
<u>Ending Balance</u>	\$ 482,860	\$ 443,514	\$ 482,860	\$ 443,514

Deferred Acquisition Costs - Schedule of Deferred Policy Acquisition Costs to Consolidated Balance Sheet (Details) - USD (\$) \$ in Thousands	Sep. 30, 2024	Jun. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2022

Deferred acquisition costs Life	\$ 6,386,682		\$ 6,009,477	\$ 5,889,293		
Deferred Policy Acquisition Cost [Line Items]						
Deferred acquisition costs Health	5,607,729	\$ 5,495,593	5,271,775	5,163,985	\$ 5,065,265	\$ 4,844,291
Deferred Policy Acquisition Cost [Line Items]						
Deferred acquisition costs Annuity	777,162	762,523	734,735	721,931	709,669	686,763
Deferred Policy Acquisition Cost [Line Items]						
Deferred acquisition costs American Income Life	1,791			3,377		
Deferred Policy Acquisition Cost [Line Items]						
Deferred acquisition costs American Income Health	2,829,810	2,740,138	2,573,370	2,490,720	2,417,480	2,258,291
Deferred Policy Acquisition Cost [Line Items]						
Deferred acquisition costs DTC Life	74,399	71,589	66,783	64,346	62,285	57,811
Deferred Policy Acquisition Cost [Line Items]						
Deferred acquisition costs DTC Health	1,773,417	1,765,673	1,737,117	1,726,209	1,714,715	1,676,931
Deferred Policy Acquisition Cost [Line Items]						
Deferred acquisition costs Liberty National Life	1,571	1,608	1,679	1,717	1,760	1,854
Deferred Policy Acquisition Cost [Line Items]						
Deferred acquisition costs Liberty National Health	712,733	696,905	666,419	651,130	636,209	610,723
Deferred Policy Acquisition Cost [Line Items]						
Deferred acquisition costs Other premium Life	146,971	145,097	139,941	137,973	136,276	133,096
Deferred Policy Acquisition Cost [Line Items]						
Deferred acquisition costs United American Health	291,769	292,877	294,869	295,926	296,861	298,346
Deferred Policy Acquisition Cost [Line Items]						
Deferred acquisition costs Family Heritage Health	71,361	71,975	73,489	74,381	75,349	77,394
Deferred Policy Acquisition Cost [Line Items]						
Deferred acquisition costs	\$ 482,860	\$ 472,254	\$ 452,843	\$ 443,514	\$ 433,999	\$ 416,608

Liability for Unpaid Claims - Schedule of Liability for Unpaid	9 Months Ended	12 Months Ended

Health Claims (Details) - USD (\$) \$ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Activity in the Liability for Unpaid Health Claims		
Beginning balance less reinsurance recoverable	\$ 514,875	
Paid related to:		
Beginning balance plus reinsurance recoverable	530,399	\$ 514,875
Health claims		
Activity in the Liability for Unpaid Health Claims		
Beginning balance	192,652	182,202
Less reinsurance recoverables, beginning balance	2,157	2,084
Beginning balance less reinsurance recoverable	194,809	184,286
Incurred related to:		
Current year	560,548	697,521
Prior years	(7,914)	(4,853)
Total incurred	552,634	692,668
Paid related to:		
Current year	399,412	535,971
Prior years	142,020	146,247
Total paid	541,432	682,218
Ending balance	203,854	192,652
Plus reinsurance recoverables, ending balance	1,623	2,157
Beginning balance plus reinsurance recoverable	\$ 205,477	\$ 194,809

[XML 87 R69.htm IDEA: XBRL DOCUMENT](#)

Liability for Unpaid Claims - Schedule of Reconciliation of Policy Claims and Other Benefits Payable (Details) - USD (\$) \$ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022

Policy claims and other benefits payable:			
Policy claims and other benefits payable	\$ 530,399	\$ 514,875	
Life insurance			
Policy claims and other benefits payable:			
Policy claims and other benefits payable	324,922	320,066	
Health insurance			
Policy claims and other benefits payable:			
Policy claims and other benefits payable	\$ 205,477	\$ 194,809	\$ 184,286

[XML 88 R70.htm IDEA: XBRL DOCUMENT](#)

Postretirement Benefits - Schedule of Pension Assets by Component at Fair Value (Details) - Pension Plan - USD (\$) \$ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets	\$ 643,564	\$ 570,767
Percentage of plan assets	100.00%	100.00%
Investment funds, percentage ownership by pension plan	1.00%	
Fair Value, Inputs, Level 1, 2 and 3		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets	\$ 613,208	\$ 552,453
Percentage of plan assets	95.00%	97.00%
Quoted Prices in Active Markets for Identical Assets (Level 1)		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets	\$ 364,333	\$ 341,570
Significant Observable Inputs (Level 2)		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets	248,875	210,883
Significant Unobservable Inputs (Level 3)		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets	0	0
Fair Value Measured at Net Asset Value Per Share		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets	\$ 30,356	\$ 18,314
Percentage of plan assets	5.00%	3.00%
Exchange traded fund		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	\$ 38,544	\$ 18,715
Percentage of total plan assets, within plan asset category	6.00%	3.00%
Investment grade securities issued term	10 years	
Exchange traded fund Quoted Prices in Active Markets for Identical Assets (Level 1)		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	\$ 38,544	\$ 18,715
Exchange traded fund Significant Observable Inputs (Level 2)		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	0	0
Exchange traded fund Significant Unobservable Inputs (Level 3)		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	0	0
Equity Exchange Traded Fund		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	\$ 318,809	\$ 315,886
Percentage of total plan assets, within plan asset category	49.00%	55.00%
Equity Exchange Traded Fund Quoted Prices in Active Markets for Identical Assets (Level 1)		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	\$ 318,809	\$ 315,886
Equity Exchange Traded Fund Significant Observable Inputs (Level 2)		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	0	0
Equity Exchange Traded Fund Significant Unobservable Inputs (Level 3)		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	0	0
U.S. Government and Agency		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	\$ 204,990	\$ 167,450

Percentage of total plan assets, within plan asset category	32.00%	30.00%
U.S. Government and Agency Quoted Prices in Active Markets for Identical Assets (Level 1)		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	\$ 0	\$ 0
U.S. Government and Agency Significant Observable Inputs (Level 2)		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	204,990	167,450
U.S. Government and Agency Significant Unobservable Inputs (Level 3)		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	0	0
Other bonds		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	\$ 4	\$ 5
Percentage of total plan assets, within plan asset category	0.00%	0.00%
Other bonds Quoted Prices in Active Markets for Identical Assets (Level 1)		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	\$ 0	\$ 0
Other bonds Significant Observable Inputs (Level 2)		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	4	5
Other bonds Significant Unobservable Inputs (Level 3)		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	0	0
Guaranteed annuity contract		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	\$ 43,881	\$ 43,428
Percentage of total plan assets, within plan asset category	7.00%	8.00%
Guaranteed annuity contract Quoted Prices in Active Markets for Identical Assets (Level 1)		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	\$ 0	\$ 0
Guaranteed annuity contract Significant Observable Inputs (Level 2)		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	43,881	43,428
Guaranteed annuity contract Significant Unobservable Inputs (Level 3)		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	0	0
Short-term investments		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	\$ 5,122	\$ 6,506
Percentage of total plan assets, within plan asset category	1.00%	1.00%
Short-term investments Quoted Prices in Active Markets for Identical Assets (Level 1)		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	\$ 5,122	\$ 6,506
Short-term investments Significant Observable Inputs (Level 2)		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	0	0
Short-term investments Significant Unobservable Inputs (Level 3)		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	0	0
Other		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	\$ 1,858	\$ 463
Percentage of total plan assets, within plan asset category	0.00%	0.00%
Other Quoted Prices in Active Markets for Identical Assets (Level 1)		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	\$ 1,858	\$ 463
Other Significant Observable Inputs (Level 2)		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	0	0
Other Significant Unobservable Inputs (Level 3)		
Defined Benefit Plan Disclosure [Line Items]		
Fair value of plan assets, within plan asset category	\$ 0	\$ 0

XML 89-R71.htm-IDEA- XBRL DOCUMENT

Postretirement	9 Months Ended	
Benefits - Schedule of		
Information		
Regarding the SERP	Sep. 30, 2024	Sep. 30, 2023
(Details) - USD (\$)	Dec. 31, 2023	
\$ in Thousands		

Retirement Benefits [Abstract]

Premiums paid for insurance coverage	\$ 443	\$ 443
Total investments:		
COLI	56,757	\$ 55,185
Exchange traded funds	97,132	86,156
Total investments of SERP	\$ 153,889	\$ 141,341

XML 90-R72.htm-IDEA- XBRL DOCUMENT

Postretirement	3 Months Ended		9 Months Ended	
Benefits - Schedule of				
Pension and SERP				
Liabilities (Details) -	Sep. 30, 2024	Dec. 31, 2023		
USD (\$)				
\$ in Thousands				

Defined Benefit Plan Disclosure [Line Items]

Benefit obligation	\$ 688,249	\$ 627,560

Qualified Plan | Pension Plans

Defined Benefit Plan Disclosure [Line Items]

Benefit obligation	615,595	554,957

Nonqualified Plan | SERP

Defined Benefit Plan Disclosure [Line Items]

Benefit obligation	\$ 72,654	\$ 72,603

XML 91-R73.htm-IDEA- XBRL DOCUMENT

Postretirement	3 Months Ended		9 Months Ended	
Benefits - Schedule of				
Net Periodic Benefit				
Cost (Details) - USD	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
(\$)				
\$ in Thousands				

Retirement Benefits [Abstract]

Service cost—benefits earned during the period	\$ 6,224	\$ 5,392	\$ 18,673	\$ 16,174

Interest cost on projected benefit obligation	8,287	7,834	24,862	23,502

Expected return on assets	(10,645)	(9,656)	(31,938)	(28,968)
Prior service cost	265	269	803	807
Actuarial (gain) loss	6	(48)	18	(152)
Net periodic benefit cost	\$ 4,137	\$ 3,791	\$ 12,418	\$ 11,363

~~[XML 92-R74.htm-IDEA: XBRL DOCUMENT](#)~~

Earnings Per Share (Details) - shares	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023

Earnings Per Share [Abstract]

Basic weighted average shares outstanding (in shares)	87,874,488	94,636,867	91,048,853	95,445,416
Weighted average dilutive options outstanding (in shares)	212,553	1,180,770	273,666	1,211,974
Diluted weighted average shares outstanding (in shares)	88,087,041	95,817,637	91,322,519	96,657,390
Antidilutive shares (in shares)	4,234,326	492,970	3,090,848	399,071

~~[XML 93-R75.htm-IDEA: XBRL DOCUMENT](#)~~

Debt - Schedule of Selected Information about Debt Issues (Details) - USD (\$)	9 Months Ended	
	Sep. 30, 2024	Dec. 31, 2023

Debt Instrument [Line Items]

Long-term debt, par value, gross	\$ 2,350,000,000	
Total short-term debt, par value	443,908,000	
Total debt, par value	2,793,908,000	
Unamortized discount & issuance costs, noncurrent	(26,324,000)	
Unamortized discount & issuance costs, current	(6,490,000)	
Total debt, unamortized discount & issuance costs,	(32,814,000)	
Long-term debt	2,323,676,000	\$ 1,629,559,000
Total short-term debt, book value	437,418,000	486,113,000
Total debt, book value	2,761,094,000	2,115,672,000
Fair Value	2,202,644,000	
Total short-term debt, fair value	437,418,000	
Total debt, fair value	2,640,062,000	
FHLB borrowings		

Debt Instrument [Line Items]

Total short-term debt, par value	17,000,000	0
Unamortized discount & issuance costs, current	0	
Total short-term debt, book value	17,000,000	0
Total short-term debt, fair value	17,000,000	
Commercial paper		

Debt Instrument [Line Items]

Total short-term debt, par value	426,908,000	
Unamortized discount & issuance costs, current	(6,490,000)	
Total short-term debt, book value	420,418,000	316,564,000
Total short-term debt, fair value	420,418,000	
Term Loan Due November 11 2024		

Debt Instrument [Line Items]

Total short-term debt, par value	0	
Unamortized discount & issuance costs, current	0	
Total short-term debt, book value	0	169,549,000
Total short-term debt, fair value	\$ 0	
Senior Notes Due 2028		

Debt Instrument [Line Items]

Coupon Rate	4.55%	
Long-term debt, par value, gross	\$ 550,000,000	
Unamortized discount & issuance costs, noncurrent	(3,180,000)	
Debt	546,820,000	546,283,000
Long-term debt, gross, fair value	\$ 550,088,000	
Senior Notes Due 2030		

Debt Instrument [Line Items]

Coupon Rate	2.15%	
Long-term debt, par value, gross	\$ 400,000,000	
Unamortized discount & issuance costs, noncurrent	(2,983,000)	
Debt	397,017,000	396,670,000
Long-term debt, gross, fair value	\$ 344,796,000	
Senior Notes Due June 15 2032		

Debt Instrument [Line Items]

Coupon Rate	4.80%	
Long-term debt, par value, gross	\$ 250,000,000	
Unamortized discount & issuance costs, noncurrent	(3,828,000)	
Debt	246,172,000	245,873,000
Long-term debt, gross, fair value	248,443,000	
Senior Notes Due June 15 2032 Consolidation Eliminations Subsidiaries		

Debt Instrument [Line Items]

Long-term debt, net, book value	\$ 150,000,000	
5.85% Senior notes due September 15, 2034		

Debt Instrument [Line Items]

Coupon Rate	5.85%	
Long-term debt, par value, gross	\$ 450,000,000	
Unamortized discount & issuance costs, noncurrent	(5,188,000)	
Debt	444,812,000	0
Long-term debt, gross, fair value	\$ 464,881,000	
Junior Subordinated Debentures Due 2057		

Debt Instrument [Line Items]

Coupon Rate	5.275%	
Long-term debt, par value, gross	\$ 125,000,000	
Unamortized discount & issuance costs, noncurrent	(1,561,000)	
Debt	123,439,000	123,427,000
Long-term debt, gross, fair value	\$ 109,657,000	
Junior Subordinated Debentures Due 2061		

Debt Instrument [Line Items]

Coupon Rate	4.25%	
Long-term debt, par value, gross	\$ 325,000,000	
Unamortized discount & issuance costs, noncurrent	(7,633,000)	
Debt	317,367,000	317,306,000
Long-term debt, gross, fair value	\$ 236,730,000	
Term Loan Due November 11 2024		

Debt Instrument [Line Items]

Coupon Rate	6.593%	
Long-term debt, par value, gross	\$ 250,000,000	
Unamortized discount & issuance costs, noncurrent	(1,951,000)	

Debt	248,049,000	\$ 0
Long-term debt, gross, fair value	\$ 248,049,000	
Basis spread	1.35%	
XML 94 R76.htm IDEA: XBRL DOCUMENT		

Debt - Additional Information (Details)	9 Months Ended						
	Aug. 23, 2024 USD (\$)	Aug. 15, 2024 USD (\$)	Mar. 29, 2024 USD (\$) extension_option	Sep. 30, 2024 USD (\$)	Sep. 30, 2023 USD (\$)	Aug. 14, 2024 USD (\$)	Dec. 31, 2023 USD (\$)
Debt Instrument [Line Items]							
Proceeds from issuance of debt				\$ 530,000,000	\$ 170,000,000		
Activity-based common stock ownership percentage				0.041			
FHLB stock				\$ 32,400,000			\$ 22,300,000
Short-term debt, face amount				443,908,000			
Estimate of Fair Value Measurement Asset Pledged as Collateral							
Debt Instrument [Line Items]							
Fair value of pledged assets				1,400,000,000			
Federal Home Loan Bank Borrowings							
Debt Instrument [Line Items]							
Short-term debt, face amount				\$ 17,000,000			0
Line of Credit							
Debt Instrument [Line Items]							
Maximum borrowing capacity			\$ 1,000,000,000				
Potential maximum borrowing capacity			\$ 1,250,000,000				
Number of extension options extension_option			2				
Extension term			1 year				
Junior Subordinated Debentures Due 2056							
Debt Instrument [Line Items]							
Interest rate				4.25%			
Senior Notes							
Debt Instrument [Line Items]							
Optional redemption, period from issuance date				5 years			
Senior Notes 5.85% Senior notes due September 15, 2034							
Debt Instrument [Line Items]							
Balance of commercial paper at end of period (par value)	\$ 450,000,000						
Interest rate	5.85%						
Proceeds from issuance of debt	\$ 445,000,000						
Term Loan Credit Agreement							
Debt Instrument [Line Items]							
Balance of commercial paper at end of period (par value)		\$ 250,000,000			\$ 170,000,000		
Debt instrument, increase (decrease), net		\$ 80,000,000					
Federal Home Loan Bank Borrowings							
Debt Instrument [Line Items]							
Maximum borrowing capacity				\$ 781,000,000			
Long-term line of credit				\$ 372,000,000			\$ 138,000,000
XML 95 R77.htm IDEA: XBRL DOCUMENT							

Debt - Short-Term Borrowings (Details) - USD (\$)	9 Months Ended		
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
\$ in Thousands			
Short-term Debt [Line Items]			
Annualized interest rate	5.56%	5.65%	5.71%
Letters of credit outstanding	\$ 115,000	\$ 115,000	\$ 115,000
Remaining amount available under credit line	\$ 458,092	\$ 384,000	316,000
Daily-weighted average interest rate (annualized)	5.80%	5.33%	
Maximum daily amount outstanding during period (par value)	\$ 633,425	\$ 477,700	
Commercial paper matured during period (par value)	314,836	0	
Short-term Debt			
Short-term Debt [Line Items]			
Balance of commercial paper at end of period (par value)	426,908	251,000	\$ 319,000
Commercial paper			
Short-term Debt [Line Items]			
Average balance of commercial paper outstanding during period (par value)	375,851	296,816	
Commercial paper issued during period (par value)	1,482,556	1,480,000	
Commercial paper matured during period (par value)	(1,374,648)	(1,514,000)	
Net commercial paper issued (matured) during period (par value)	\$ 107,908	\$ (34,000)	
XML 96 R78.htm IDEA: XBRL DOCUMENT			

Business Segments - Schedule of Segment Premium Income by Distribution Channel (Details)	3 Months Ended		9 Months Ended	
	Sep. 30, 2024 USD (\$)	Sep. 30, 2023 USD (\$)	Sep. 30, 2024 USD (\$) segment	Sep. 30, 2023 USD (\$)
\$ in Thousands				
Segment Reporting [Abstract]				
Number of segments segment		4		
Segment Reporting Information [Line Items]				
Premium	\$ 1,172,593	\$ 1,119,335	\$ 3,485,002	\$ 3,325,345
% of Total	100.00%	100.00%	100.00%	100.00%
Life				
Segment Reporting Information [Line Items]				
Premium	\$ 818,638	\$ 788,099	\$ 2,438,385	\$ 2,342,429
% of Total	100.00%	100.00%	100.00%	100.00%
Health				
Segment Reporting Information [Line Items]				
Premium	\$ 353,955	\$ 331,236	\$ 1,046,617	\$ 982,916
% of Total	100.00%	100.00%	100.00%	100.00%
Annuity				
Segment Reporting Information [Line Items]				
Premium	\$ 0	\$ 0	\$ 0	\$ 0
% of Total	0.00%	0.00%	0.00%	0.00%
American Income				
Segment Reporting Information [Line Items]				
Premium	\$ 459,116	\$ 430,749	\$ 1,357,912	\$ 1,272,002
% of Total	39.00%	39.00%	39.00%	38.00%
American Income Life				
Segment Reporting Information [Line Items]				
Premium	\$ 427,839	\$ 400,214	\$ 1,265,417	\$ 1,182,346
% of Total	52.00%	51.00%	52.00%	50.00%
American Income Health				
Segment Reporting Information [Line Items]				

Premium	\$ 31,277	\$ 30,535	\$ 92,495	\$ 89,656
% of Total	9.00%	9.00%	9.00%	9.00%
American Income Annuity				
Segment Reporting Information [Line Items]				
Premium	\$ 0	\$ 0	\$ 0	\$ 0
% of Total	0.00%	0.00%	0.00%	0.00%
Direct to Consumer				
Segment Reporting Information [Line Items]				
Premium	\$ 264,497	\$ 265,011	\$ 797,374	\$ 795,708
% of Total	23.00%	24.00%	23.00%	24.00%
Direct to Consumer Life				
Segment Reporting Information [Line Items]				
Premium	\$ 246,425	\$ 247,858	\$ 743,304	\$ 744,132
% of Total	30.00%	32.00%	31.00%	32.00%
Direct to Consumer Health				
Segment Reporting Information [Line Items]				
Premium	\$ 18,072	\$ 17,153	\$ 54,070	\$ 51,576
% of Total	5.00%	5.00%	5.00%	5.00%
Direct to Consumer Annuity				
Segment Reporting Information [Line Items]				
Premium	\$ 0	\$ 0	\$ 0	\$ 0
% of Total	0.00%	0.00%	0.00%	0.00%
Liberty National				
Segment Reporting Information [Line Items]				
Premium	\$ 140,902	\$ 134,842	\$ 419,211	\$ 400,554
% of Total	12.00%	12.00%	12.00%	12.00%
Liberty National Life				
Segment Reporting Information [Line Items]				
Premium	\$ 93,625	\$ 88,199	\$ 276,599	\$ 260,036
% of Total	12.00%	11.00%	11.00%	11.00%
Liberty National Health				
Segment Reporting Information [Line Items]				
Premium	\$ 47,277	\$ 46,643	\$ 142,612	\$ 140,518
% of Total	13.00%	14.00%	14.00%	14.00%
Liberty National Annuity				
Segment Reporting Information [Line Items]				
Premium	\$ 0	\$ 0	\$ 0	\$ 0
% of Total	0.00%	0.00%	0.00%	0.00%
United American				
Segment Reporting Information [Line Items]				
Premium	\$ 151,118	\$ 138,879	\$ 445,384	\$ 412,670
% of Total	13.00%	12.00%	13.00%	13.00%
United American Life				
Segment Reporting Information [Line Items]				
Premium	\$ 1,608	\$ 1,802	\$ 5,009	\$ 5,533
% of Total	0.00%	0.00%	0.00%	0.00%
United American Health				
Segment Reporting Information [Line Items]				
Premium	\$ 149,510	\$ 137,077	\$ 440,375	\$ 407,137
% of Total	42.00%	42.00%	42.00%	42.00%
United American Annuity				
Segment Reporting Information [Line Items]				
Premium	\$ 0	\$ 0	\$ 0	\$ 0
% of Total	0.00%	0.00%	0.00%	0.00%
Family Heritage				
Segment Reporting Information [Line Items]				
Premium	\$ 109,503	\$ 101,389	\$ 322,010	\$ 298,583
% of Total	9.00%	9.00%	9.00%	9.00%
Family Heritage Life				
Segment Reporting Information [Line Items]				
Premium	\$ 1,684	\$ 1,561	\$ 4,945	\$ 4,554
% of Total	0.00%	0.00%	0.00%	0.00%
Family Heritage Health				
Segment Reporting Information [Line Items]				
Premium	\$ 107,819	\$ 99,828	\$ 317,065	\$ 294,029
% of Total	31.00%	30.00%	30.00%	30.00%
Family Heritage Annuity				
Segment Reporting Information [Line Items]				
Premium	\$ 0	\$ 0	\$ 0	\$ 0
% of Total	0.00%	0.00%	0.00%	0.00%
Other				
Segment Reporting Information [Line Items]				
Premium	\$ 47,457	\$ 48,465	\$ 143,111	\$ 145,828
% of Total	4.00%	4.00%	4.00%	4.00%
Other Life				
Segment Reporting Information [Line Items]				
Premium	\$ 47,457	\$ 48,465	\$ 143,111	\$ 145,828
% of Total	6.00%	6.00%	6.00%	7.00%
Other Health				
Segment Reporting Information [Line Items]				
Premium	\$ 0	\$ 0	\$ 0	\$ 0
% of Total	0.00%	0.00%	0.00%	0.00%
Other Annuity				
Segment Reporting Information [Line Items]				
Premium	\$ 0	\$ 0	\$ 0	\$ 0
% of Total	0.00%	0.00%	0.00%	0.00%
XML 97-R79.htm IDEA: XBRL DOCUMENT				
Business Segments -				
Schedule of				
Reconciliation of				
Segment Operating				
Information to				
Consolidated				
Statement of				
Operations (Details) -				
USD (\$)				
\$ in Thousands				
Revenue:				
Premium		\$ 1,172,593	\$ 1,119,335	\$ 3,485,002
				\$ 3,325,345

Net investment income	284,964	266,926	853,178	785,275
Other income	42	50	192	185
Total revenue	1,457,599	1,386,311	4,338,372	4,110,805
Expenses:				
Policy benefits	688,184	719,044	2,155,671	2,144,481
Required interest on reserves	0	0	0	0
Amortization of acquisition costs	104,310	95,757	305,703	282,159
Commissions, premium taxes, and non-deferred acquisition costs	149,693	138,677	447,605	414,933
Insurance administrative expense	89,195	74,585	252,718	223,951
Parent expense	6,446	3,718	15,888	9,391
Stock-based compensation expense	9,233	7,567	28,590	22,732
Interest expense	31,388	25,955	91,413	76,640
Total benefits and expenses	1,078,449	1,065,303	3,297,588	3,174,287
Subtotal	379,150	321,008	1,040,784	936,518
Non-operating items	3,966	1,137	8,368	1,137
Measure of segment profitability (pretax)	383,116	322,145	1,049,152	937,655
Realized gains (losses)	(2,192)	(2,193)	(26,580)	(78,963)
Legal proceedings	3,329		5,764	1,137
Non-operating expenses	(637)	(1,137)	(2,604)	
Income before income taxes	376,958	318,815	1,014,204	857,555
Life				
Revenue:				
Premium	818,638	788,099	2,438,385	2,342,429
Expenses:				
Amortization of acquisition costs	90,070	82,523	263,753	243,285
Health				
Revenue:				
Premium	353,955	331,236	1,046,617	982,916
Expenses:				
Amortization of acquisition costs	13,852	12,816	40,774	37,608
Annuity				
Revenue:				
Premium	0	0	0	0
Operating Segments				
Expenses:				
Non-operating items	0	0	0	0
Operating Segments Life				
Revenue:				
Premium	818,638	788,099	2,438,385	2,342,429
Net investment income	0	0	0	0
Other income	0	0	0	0
Total revenue	818,638	788,099	2,438,385	2,342,429
Expenses:				
Policy benefits	454,502	515,676	1,493,165	1,536,317
Required interest on reserves	(203,875)	(194,199)	(605,397)	(575,801)
Amortization of acquisition costs	90,070	82,523	263,753	243,285
Commissions, premium taxes, and non-deferred acquisition costs	90,758	84,011	270,347	251,136
Insurance administrative expense	0	0	0	0
Parent expense	0	0	0	0
Stock-based compensation expense	0	0	0	0
Interest expense	0	0	0	0
Total benefits and expenses	431,455	488,011	1,421,868	1,454,937
Subtotal	387,183	300,088	1,016,517	887,492
Measure of segment profitability (pretax)	387,183	300,088	1,016,517	887,492
Operating Segments Health				
Revenue:				
Premium	353,955	331,236	1,046,617	982,916
Net investment income	0	0	0	0
Other income	0	0	0	0
Total revenue	353,955	331,236	1,046,617	982,916
Expenses:				
Policy benefits	221,926	193,790	629,676	580,676
Required interest on reserves	(27,717)	(26,732)	(82,300)	(79,603)
Amortization of acquisition costs	13,852	12,816	40,774	37,608
Commissions, premium taxes, and non-deferred acquisition costs	58,931	54,662	177,246	163,784
Insurance administrative expense	0	0	0	0
Parent expense	0	0	0	0
Stock-based compensation expense	0	0	0	0
Interest expense	0	0	0	0
Total benefits and expenses	266,992	234,536	765,396	702,465
Subtotal	86,963	96,700	281,221	280,451
Measure of segment profitability (pretax)	86,963	96,700	281,221	280,451
Operating Segments Annuity				
Revenue:				
Premium	0	0	0	0
Net investment income	0	0	0	0
Other income	0	0	0	0
Total revenue	0	0	0	0
Expenses:				
Policy benefits	5,716	6,854	17,786	21,502
Required interest on reserves	(7,829)	(9,353)	(24,358)	(29,327)
Amortization of acquisition costs	388	418	1,176	1,266
Commissions, premium taxes, and non-deferred acquisition costs	4	4	12	13
Insurance administrative expense	0	0	0	0
Parent expense	0	0	0	0
Stock-based compensation expense	0	0	0	0
Interest expense	0	0	0	0
Total benefits and expenses	(1,721)	(2,077)	(5,384)	(6,546)
Subtotal	1,721	2,077	5,384	6,546
Measure of segment profitability (pretax)	1,721	2,077	5,384	6,546
Operating Segments Investment				
Revenue:				
Premium	0	0	0	0
Net investment income	284,964	266,926	853,178	785,275
Other income	0	0	0	0
Total revenue	284,964	266,926	853,178	785,275
Expenses:				
Policy benefits	6,040	2,724	15,044	5,986

Premium

Expenses:

Expenses:

Insurance administrative expense

Parent expense

<u>Non-operating items</u>	0	0	0	0

Measure of segment

Premium

Net invest

Required inte

Amortization of acquisition co

Interest expense

Total benefits are

Subsequent Events

(Details) -

Assets held in trust of y

[Coinsurance Agreement](#) [Coding Commission](#)

Cominsurance Agreement, Ceding Commission, Before Tax \$ 50

[illegible]

[illegible]

[illegible]


```

@CAX3,B,RMFJJ^TN0,^&8,Q16> M4JL$742+TK",.F0R9TB'71>GLLG%FHK690!$ZSIN>|HKM M" 1V13.4; SIOA3V7
B@5YF#^0+=*OZNXJ!HDMYX6U2Z^JL^KIC 6U^M^ECG MO/3Q+=+5C9J)S!^>FLBJVOH\AXS/(FLY9+U;GEI8-DLH\Q1ZL/Q149 M1
<K35IK/B^Y^ 1-6IX-AIKILO0XIGJN^>XH5^>^CFE^"6">^&K5-G;KP^D>^FLBJVOH\AXS/(FLY9+U;GEI8-DLH\Q1ZL/Q149 M1
MHC_Y@&$Y^ZPVY+/+Q3-<$04REIHM$2R/LI= 3V6 KEJ8(EB_K^1DQU-H M*7 W2|KU>65VW7W(W6UfG0VZAVP"W^M^+IGA<
|N15FJNIMJ9S5! 1^HS MYR,ZK1(31FICG<.#P9<?C14$^>+>Q?6X#^JG<+>7)BP1S:T.ID0#=>MHOT3U!+P04^Z4IDH$>.$@&0
^AL+W=OBQ^0E;HHT6H8/WY6QNI(//A&PA9O)^F@+>RQ9W M@S7^?QEHT05D9.SWNCZ/2^V %NP1^E0-4.6(M&2OUT=ZIF9SW0DM(5K(P
M%P^@IK$DM.19A0.5#<+Y,K&N7^M.M.<|KY+127A92,J|HFS= M1HCA.3E7#05J8E19Y#04RW19"2,GYY9RY:5#4286XC#>..QN5^U/U^K;ZD
M/CX;&^"SBPP^3^6BHT^0B4G;U5CYH|B9RIN71_2EJ6Y|W^QMJT2^>=IG80<2H(6RG)G>|%*1Y M#Z13LK7V10>^S9U$2QMA#.#%XC>A#Z10L-
E8F<^LB1LB7$HA)-(EJHN V12K.F.^|4WT^&%)HE.E45Q.1>6P=O MYJV46^1^G AM4TCL|MJ2..2)M1+E0#9T&|BHAW^|TV^FY>O.WLV 7^&-
M^N^W.3UTBQ:22Y511.WY$V3A MGD@ "FB"7^2.15T>14$;LX=|RE KCL^1^%|@VB+ 12&AYH|Q52>^?CTI5=MKCF$75ET$..DBX.X#K?
(6|^R"B6$&F3LB M1^=QF2F$+LNRI@8LZE41^RS#1<^0&&NE 482D@L3. 0R&X#EN2><MY$F0A5%F$)DN=A1S;/F37HR:~?SV<^<1+6
GRDGP34)MXJ@M9!%3W MQS|L5;L.42;#R *V@#1)SOH@S0RR^@WV19YV^PASNY%VOL 3.HMP7419E
1YV|NXP|PSH8^05B^A1$6S0%GL 8SF@8R71=XG^(+7-R1D5^NZYVOCS- M03K^GRSVE&5FG~0^LQN^M(LNAX(W@V^X>MHT$X.B;D.2
MH)^D8<SNHM/|68E8;QVC GG.77Y^|^-GKBV/D7?+_WC#&#AS;U|@G.GB=|IVO067H^D4+W1X;U 201H M>ZZT;$X;.$F3LDI|V
1>#CV.F8G0<&CHHG+FX26AP;OM57Y$>AEE^M2R<L M.77^977?Z<^J @|V>1YVM#@3.9$E^KM^0PYM2K^PELL;4H|P.0(M.4TPQ=3(|P
8Z$1G1A1>..E51N).7EJ$+9&TR6T4|_G.C223C>X1LC^0Q.ZIK^OPL^N19JXW.MGH|W|GKR^WIRO.
W25I@XUO!+5L9^Y+B"8NE;K/|>NGZXMH^X;PVP|DO- M6I^D*^DDE..#412^%3;2?WH;HQ:N^1.8V6.JEUS+L5$MG8^J=F=6-76#1^M^6KX+U|+ P04
1^..S1WCGC9R@>^0^Z^W.W23 ZZZNR^EC2^M9QFHCJ@612W-RAW3K.^2^QG-IDJK< *5>@EZNRR6|4-7JOK9-6ZRM*%=%HM MGQG?#9^MTKPX>?
ZUM+VIGG1>..HE7F1E^E505|N7OL6Y.WYXSHDZ|A-7Y1M|AV7.OU^EUIBYK|J25^A|UH^RR=94>=EH:KLZIN3^WW^K0I90;|X6Y|= MUJ
GQ:5.FLY7|UVWIK MGJCY|F|^5=L9$^SRPOY-/|<^4P^TW8P K>=2*#1+FW2YU|7Y.VJ^#5&XX.L
M57H#N+S@JQK^QR;HU_ S^7Q^L;^3JHG|H^9U>=2^VLP.G|_F|^<..M8NX9)5&ORZ^YJ=62BD6VY.|#1#U8)D.K$-P0?
9>LSY.F.HQ^XSG|U.YIDW|R.O.JL^Q22?_W|1^+| "OU<1^VCTY^|CXO.E/EE^H^X M.YPMU.NTZ<?>7LS$IS1?D@5J?>12_%P>:=>E^MU66-GIE;X
Q^NAP:0^P M$^L1$%03>^UTZ|JLFOQ^|FKM|^7.5YI3ZERTWT^CI$HPA1>^VUIS*%GFC MEF5=<40RUDWVY>HRJWLD^P?
92.V5ANK9P=K.C)4V^WL<1%7EQS^@UQ&P? M5QA5:0HPK4>=VF9?>NG..^YN5U6.E9|CSS6J53|NIEA@9T&KJNR&E3
MAD_PGJ9.Y|J|J.M196.F17$HIMYFBPP.E-N/E<90^HHD/HAKJIEUN0^J@-MIN8&W?^|MK^QR?L^V^_M^Y|C=NN9O14?<4>5VZ7(?
F6;FM$T>1^CGZL9NS/UO-DJHP2EEKEDV$< M^24FK=*BR;*%97K.L.G>Z>ZY%@.1.O654Y GR@OB9PD3^T^1^1HL LBW&M?
S.C^>=8WR/0B>)M3+J76.W.K4UGF^QGS21CO9NN3^NK_Y>+ %>5$K MSS&|Y0Z22P$|=W$S7SC8IADU-
EG#B^>..E2H<*+^1.O1C|7BM?^U|BP/H M2.T2)XZ#4V)A8L+^E|G#%|06GRUK^CM;|SWN|FD6|K#E|D|B? MC1V7
$5.C+8H213OX40^M^ZJL|QOM8|DQSD@PTV^PD<1+7.U4^X JQ<5^% M6|L.W.X0E|A|UPFU.W|UT2| 85Q0AS^|3L0J2T.3%DWB| 683<Q2 _ASOP M.
((W^L.EZ(R0%=> HIT?5 _AN^ Q24-52W0!_M.R.MQ|A<<?>Q?|UR^%#C=|+U.XQ|D4@_BSTGB(|_3#=";|H%#X<8(%M>O9 MXUQ/E$ZPY;
|C|SYQKEW$8Q4D@-CP4M|9P^|YPU^79K!_1^9C Q0>20$7PFC MOKI5C64@Y$;Z75$H4R3TF= 621^|@F=|W>+F Q|U|>NNE|S^G%?>^="<DI
M^ST>T>OZ>DQ C#8CD1XG|AZ|UW| (2.T.CN9>BO#>^/Q 1CT#7ISOY^_ M78WE@|J(31H|PEB01 1^#1^V(|WV$>+>^GV;6^BAT1C|DT|T|6@^E^O
M=Z^E)HH$VW1MZO)2^>^19XDRP @|=P.C^L|DLM^XD;S$<1$=R1P3N>N&8P+4?^DO@-^|H|F$S^4C@@^!E<MXQ^|Q|@^1^7=53C7JD3Y
3FG;PGI>^W^X^S^3^N^N^JD^3^ZGSS42PM^7J05P9J|CGUQ79|1K|P^7^1^H6^%#H0^X4D8F (CVG&W4=ONM|W|F)3|MI& MD^M|
805C4L^&K9ZCS<^%S;U5^72?4D00Q2A=XC7V|3^|C^SBCFQY|E|F& MAIM32P&T&EKKW-(6^|6Y^FF^FN^1^E|H|18|F2X^3.0&Q16.$63 MX?>?
H|F3T$#^3^! 41.L&?DG 629;5&XM.)IK@!$7BYJB&6.^?>85;| MD|BMH4=$6R<^>5>|AZ.^NT$K#5(H|00^P^S=|<9U-1V!^C@KXP>0.1Z?
M($51^MCK$S8^0WQ/GQ^4TF@ O4&L1#AP@A<31H@T1P2LB6^#^TWT^I M^E^XXQZ.VL|O.H1K0.65DMB|JL=|S|@+4 BL4%|6Q2536.MJM/6U2-9-
%>=I0 M^H>^"W$G+6^@P#E+4Q#D|VXPXWGC^00H9@.P.7R|1VR&43)R+H^D4 MLCB^Y(R ?^@&T$>R11K@-#1DB0?
5H+^LTH$|S$EQ|OH/D?7OD.^0^3N M^M=@^B)K$(6XTU;|S)^+|G+|J|^%#^Y@>W#+8YH 2^@TK 20K$5Q8.4.162P-
HR_J(C9=KX=FKK+DIH7W28|XV.O=GG&FURI=+ M^245;^W^Z%7L^K3R RSN^+68VH^S2D4^3Z?Q&^PK^W05YT9GY@6H?2!
M$|NBL2NB17MBXMCU9^7W8X|2PP.H?ONT<+3^<HV5FK93BN.1W%-|8$Y MQ$D14$@A6!7 M1E.^#1TC BN^HY^?;?
H@DIO^_VIM^ZPD^PDRH(2G=^P.3&2GPI|S|^TV M^#FES<(|_CL=^X^X^AHJ|G^H15=^N042G^S$MIM1^|QT+7+^#>@&$&VK1 MO;Z
ZQ#S1(00(=4^D^XROT^|+T^Y^WFOZ&A^CWYU0ZIGV|S^MMSGLHW MD_DZ&290E^V$>T@UBQ89A2^33%+G$B+7GTPPE79V23A#^|<@HS
M=H69$KCH| TNYM^ GEM1^M@Q19.9YX0?>Y>J& W4=B+4|VA5|^&E$G^@ MZ7M0|AGM^&Y99;SLZ?10+2N5AA0^7^N.32+XEM|^>=
(=1&G@S$N$21 M6#MA8KK)=@8Q(1N-GT^EPM^22H^9|C.SJGLG9@X^7PH 0562T900NF2 MNEBOH2$|3;19U=BW^D^0TS>
/Y12^OM#W84HS&RG|+1$13/)(G$S;T M)U.#11X#4A77CY.6^9-73O RBQ<|_VQ19H# MSHJRF^2U#2FVJ%JFE$ FYN45F^|6;96;U>N_2X
3Z>12.DZOZB M85/(P^8)D|H
```

M>U\$#SWI#W#OE0#<@06RJH>3/X<@UO.BJ:QV105CRX#A+-BN=2T8F8N\$JAIQ05 M?Z:IQJ3306;2^0#\$E&^/5S00UXI+5N\$J. KU2/*3AE*P-
*=-T-0L:1C\$0H MIU<1%%9W4I4Y E2U?2?1>B81FE 1.7\$?WP4NT>>JFR4ZPT1X)P37C01 M+ "B0\$HL I UB\$+06<^P2?>G
I3W2@.1%"X2/L,*I+DP>%%9%-V=4 I@G2 M\$2SR:*PXV\$YB> B000N* B51P)(DPUN@%2-71%O)"I\$1.P1E>D^825T.Y8fE
M1C10*HBK09J;Z12G6C7.10/>WW8 X\$F@E08M&VK0:6K&8E1N<=IRU MU9&N3I@.@23FE85@.(I3^>FZFB7? A9"U'O'W)O Y87IP5BfP
M\$1"YP:9YD0M.MXDVIAP3@7LXA\$5^"/UX*P\$J@N"6R".DN?/B12+&:KD@.MI0J=3<3>B1.P08UYM;3@1A^IK1&I2MR^%?
G6@HMP6;0>*.8(\$I9\$1*LOYK M"/9?>#9P59N&9RFM=>#9V(I(ZT?I\$1^B\$^>0BT3W(I00&I'NIO,QZ'0Y/H) MMC>98U W@I%'^@-0MIEJ?
(5"RLR7@IC0A\$#4#Y#=-HXLFEW8=0@="0A:J6I'Q MU:OFLMBJ'.PGI+@>H#ENI. 9' 0#3Y83.ZO?C>.:0)49Z\$CTWP0#KWM5(80# M=)
(I^M"EV+V9)*\$ (K1SP"N%75-23D RIJ#6?#(C)I W-5>=D:IIB &BXG" M@'XN1X\$P(P) " @O"P"+(2R8CO"W>&I@89SLY?
DLFDUD>0T0I\$>71%1HL"/C M(3P%)#8 I#Z2:0L)(I%N17VRYE?IWF:NFL.Y:HIS.8ASU32.U7WHYJ;N9J- M00Q"XJL15"W(IJF 135'K7'W3I-
W-&Y+GX148#F\$E(0&)-G\$ " " " " "D:2KO(T MG9A@.YK'WB OD= WW7\$F8;/- FW.E)>L. I> \$C8B=RV654V%SIG^<=>I> MN&+JYHSUR8I&G?5T Y/-
00*P#*OSIIRXF 18F\$0Q\$44MZVF I\$7%#H<5L4- MH6P09 S\$N @S0 G1+C@I'Q"SWF81@*"85D(9&)Q + (9>- MBBL\$SW>H4I4'
MQ<6LJRY6.*S%K/L+Y W-Y4T.51MZIA@H;I'P(Y2>I.JY8OCON@KE;TSI&TZI\$ MX1+&K&KPT5GO@@I'BBYI'f18IC0@HFWT ZJ&V6;129" M
#AJ\$N\$X)3EMIP9JR.Y8Z'CC89D?2H125V:R*L \$0.Q@I?K9I #43N-O*9/ M%&*>>M04W(DO%=-Y9I'H&1%3M#XP4="3AW; MDPI&^I. ^&5I/KF1'DPI-
JUH6E25ZB1' #3F4W>H.UVRZVJLYVIOI-F M/ ^V4%@X.EJ<^TIGTO'EGL'8>_UO@IAR@L.XQA>W8V2\$/&N'K>BXQ@J M/BY" ^I^E^XWAQ(O9X
#^"8-K9#>#^I F\$1^85#W2 88AY)(P ^EOG=I2I.%#1 MTHJ 6#.^@JFRF(45Z7R> @O:JIR\$AM>_ M.O'("E\$P. 9.U'U-5X.GG6I
M%9J)Z>E5/1@OKB1.)I+@4OYAFXNK65W+RX IZ^J.Z4I-B@\$1F<6T2VKP>6* MKZL E89/BV#1^V3\$KY.RYIOH0AFW9_P<3&N; E@9)J2-
YHJ>%=IYB:2W MVY72L>=**CA59:3K3XJ.4P@6CZ+AJ9<#(63K2I4JLW=%KRI)GBCBU+X+XO2C\$Q%K%K@"/U'Y1 MN\$>I3NA17 *%R<4G1
2I0A1:LL.G@I@H8I90Y2L.W^X^I. IQQJZG:7JZDTJND181#U4BH.%SXTI%633TIGD&I M&K&YMMN:IX@20M) MV.XG^14&C.O.Q.TO%164Q-
R0Z>64I=WIDG1* T.C@IW M1P.J'G.T=%2(R9 P%I?5%2IN V%O#WV786HO\$(CJBI-F)RO+< Z40 M85"G324'SIMZE 2>1I0CQ(UM;IXS)CA@1&DTES-
S.J+^J I^P^00I TO.P5C) MX0QYOQ^I O/TN"13M+IJBXPXP#D15>^YK.V"D+&MSR4O3YLE M+U26EJ7BA)7I. _E2?#*UQP5#9" ^DLD5* M2JWNW>J+?
T1\$9I+4OR2G<.(D_ABN*83O.)D M'L M56MYT9850 " .B09J@#@D18I5HOY"\$23>G/G QE
M1@N\$AH8HP1^5IA@6D\$J1(F0Q\$43&P6T98G<50Q"/V" I LR=5-\$1^K0I8EO:RC8 VR*L8)2+^UOV.I@=IHVV7>&T"19 ^VLY>D
M34A>ZS0?9KTD2F\$J9(D0BRVN.I'9@+@S9<4Y O3I+YZ; &CA>@.(2)X1'0' M2@ANVPJR976+DDK%_0E8MFI(B&R)R%<.&07#^CV=T^H-O/
MBFXW7=*?R^5K&:0G&SURIK.3<^=V13KUR2HRW-MJ.V565E6TW=SWE#6"@N7JODU# +2OD\$LH?@K>EF^C'N'NBJ#F.)>OAYR.7K(I
M0" H9"HO-T.JRRRPMIF^DPIYXE4^2#>I0C6T3QTN-K0.2NQY>Q@3 UFWVE5C M ME2D-N8UD#27U%I'Q)D2:SR11LR
I25* @> \$44)YFPD2XI5SPY01*70"W>W9J- MIAP_>(UNANQD4^GZ#0ZVA-#43% FGHJ\$10 I@1AQ\$ZH0I=9^)R8KCAQP!> MB> 2TR
S^TT@I>98AHBH75EJCA"(LP.I+I+N:L#KFI)FF4C%Q@VX4>=1DMQV MJP)2I9UG8J 2M@X2/I+NON\$8 J64.Z#821NH<^MZ^JM'D#P7HXT3')@
%7^U8EX^90DK&F&E.O.Q3OQF^BEO+JBLQ M+R1PA'GE8G&A6" ^QBG&^ IZ879^CB+CS^F#Z.LM5B&#=:729;I2^D^A(C S
M149.G")YMU*\$J.U.4=I+^#/'MD6030;SL (?AOR I<.)&Q0?+W0O M^2D?P10M5I)\$YB2W_\$/SY\$QY_#/'M\$Z(XOS TO>XNHP-
4G1CA15FT2 4@I(H80<#9J24.F+@I'"^Z3D(GXN0(N MYDQ8"0O#VZK\$1J2QJ\$65I)FU Z (>HFL>F^")4D "Y0V;Lk2>7C:O#IUN<
MHJ(RF=V4U3.T.XR.(7+1+I.M+0'L'D^D? (EVI<J .0T3FEIQL9WXBGUQ M.50BJR.M MBA.HP&@Z14VS">K.IXR0%5/S/_=I
N=-1W&DHSC%\$JF+1.#\$R9P8D!A. MZ< *\$T3-2>*LJ6-H X V5%J1"7IIZI8%"#7 IV"\$=\$JX"6E#AIK I". M \$)1.X.VI6+8I.C.D@F2I?8"C"W+("C.2)
<0A;AJP.IT44\$4W.N(D-82T MQ\$1\$51+^ FP*A^RE4NG^3ZQCI(B)604YTT>XST_RI'=(6%#H3S.D56HIIHPX MBK&FF: X6SHD;B+9D004IS(Q-
T\$<7%#E&9HEVR>L(P I>A\$K?2* MEY)*WHI0D8R2"X%JAKMN_B IJ 60C5"X.SH;YL@9&9-I I^2M9 81YK.P.M&N6(AI0XMZ6"FI&B(RPI?
Z\$H.%KRI\$ICDY^9C0 2&M&82>672YIV6S;2D^M%"/@4UAEDJ@G<_I FBAI_HB@F9-DAAA;44(<%LH6%Q.O&S -UDSBU+J
MI0+ZH41W\$;*6@Y..5:25=XI(Q@<#&^7C&#>.:5.OE*6+1QA5K"KABZ5\$#/'1 M#%.2JEB"PO^3.2GIRIGHGA'#\$KKX%N;OD'W7DIP\$*7.
*@Y2YF="DINO@4 MD.#0%#X71<#BG06S9N9LCT"62T MWVY93PM4MLTZ=H-IH8234.KOJIN:X.LROI#;W-MS_4\$IOI+58CP2)YFIP)DI8T=(Z2E0.2
@VIEE0I#>#2&.18'0QJUR256'05\$&A.O)D(0_&\$/ADJPAI)SIXI'F.XENTE'1FJC MDSR\$8'FU2:QSAF@(\$S.O^/W33@/Y2I\$FYK2I76I2D9ER7*VH
I08.OYV. MXI3I>^_ARUD.GHI54@F.X^_0PT3KC+YAI5@IW2.'Q*B."R#1."9EKHIQJR>OI#..BYJ5"&0INYO6F5W1.N-WMV.=MS:)Z.A-
^@PY)GW^<^A J>#<C#SUV97H^TW.ZI="ODX7.KI #IU;#>N+ M62W@&L%#I'Q=3^<+>?D^@MAY8EJU70I@OZ>=
I64<4Z;K&K^Y=6;U I9B+&#DZ6CIS/NP12 (LIQKCC'G:X7WU M- RD8#=-I.04)I>MM@#>^I^f2N2N.K#XDJKF6.5YP4H=X+Q@.XJYG=I2ZM
M+YH.I.GP\$ILW=VH=A^J>SKP90IZLU.M>TOI'7M@A^AW<:IOAI2LPH&_G^I>LEK UX9SR??@.#8XLD)<24UHTJX?
MIR3#1#SJI^FN1I@NEY(NAG= M#W<I'NDF'5:IV%&3BJ&XI1I<96JCI1^@&(3.C.5%)X9BK70.M1A'WS9_XZ# M%3I L.C^UMKOWI3VVT^B;?
#5JL-RV.OFHNIHVJ^TEYXJ?12@HKSX@/7%# MIFP?2.#E9ZIG2HCGSKUAG;HW+9(B^G4:EJ5IUB5I=G2_ZN^+JO3JLZ)JMZ
M1@6YEIHO+/I.EYB5MBJULFJYM&QUG:C^ED.HUH6PYI'VU24X2YX4UFJR-IJ
MJZETRBJ3UFDAI9BTDI\$U"XINXIY+UT0C=&R&WJ^R&JUNE:5,==L2M;E&2 M>6X.I+Q'^I'LI:ST3H V>=?^T6.^+5T#K2.QIVSS\$XO.5E6GIXI>QH8B
M2E+ MBHG6.O.ZI=0R4L&3*G>Y>E7>:BVH?2EY7L^411X. Q" ^FL4>:<X B
M2X@FSYK(4M"BP.4J8N81'6.>>KBLI%4=B.VR4YE@C47IPII9S JINVA ME M/9C9FR5)HJZ+^W_EVV5+7/0:I6JRI@S?
3= 4>AQ:6SS.M1XQZ+T>1U.O.M'Q2IO>WL\$E5G=W>M14 /9+YIHAD;PA3U7 6U;X'IE1KCH^% VTYG%*1 MK-IJZ6%1&)M"PP/K_/_*F_7?
I0INMTSS\$ JMK/KHEN.IMWFFDM%58*0 O MKIHORV;H:LLGU(X?TO73.)@>=5C TTQZ^0I'ISS&_ ^VRV1Y2YT&T +I/;=JY68_J)UKT
MY4R/OUL.#IV.@UTIGM6_N/6* M5 M8Z5"_.F^2IRF>HUL>JHU9IOJH/UZ?N4PLK_F@+M'AIRO69.(I#R_SV-M
MWN4^L7XJMQG%W^D QQY^I@JDM9 F.WJ7_/(I1*+G0I^4:6LX^W&XMA(+/- M604GK^
(W=H"PCN6P2DT&Y.;0=4.)^XOIEOYUF9V.Y8V@06/L<L20XYH<^L212%#SRL M206>\$5J.B->CJR3;
L6B^RXLH1.6@<(ZTQ'GXD'IH3GR%Q2TYEYI)P>C M QVY+K5I'QI(X)WIREN. " R3=1^2XK JMES.W.V.D%+UIX MLVK^LR=58MG9Z.)24FO%\$-
IRXIMGK^<N\$^MY.)D2GH15 BV'2Z. _HM MC>+OB@0N^YVORP%:CIQ" B2G9VT_AI MSH?B8AN+22^7BH.\$EOZJMU9N^M;XKMW2)
<%^2I\$3BL>.^IY2X@SQ M.JFP2MNSQ@+65687EJX(U(I1^TW)E^Y^Y5JH.HCT+ QG2.X5X=;TK0Q4D)@ M=13OZG#;W%(TM\$^912T ME(1DW0RZ0JOH)
5ARK^3R\$(<@.4AKAMJVI2DHR>#IU7;HH&EJX-M<ZE>0LKTJN7T\$2ISAFI S+8.B0.R7I5_70>=ZB'IV<.R=XK\$1%V+G1Q1
MH>JO(8EAV'I/FZ(26(WNW*^<=>IY)I\$IQ)/PRVO3^RZIN_#224L&U@PI.P-^AYHZ-H.W.78D_8@D:)%
MGZ29E5CUE.H5SPG7W\$2D'I@DVY@/7>32M0^I=P8+GFL2YV.&F\$+>VRP.Q MVR-FLP9=^@.(I;PZ6/HQ/+WT4)GNN<I\$Z4\$&+5
2ZOX+LSIF12)(RG% MPW2X2F7HIGJR&K@G/9%S23J16&^*T8.VI-SIDWFF7KM(4N9S+>BI;H13Z&
I^BG1.YCZ.@*YIR@#XTTSD_HW..15U=D>J9.U"G M%#J+39G M?B0LVQ33.4LA4'1(+./J.RJU@I>O_0K'3N%I5;5F8Y;I(%E<2"D8R>W8I6I M3^6
@4.U8J816GHV#(L.;I>I7^@_I0KK.R\$E; G+2>N68F\$4*F5E/BUH18F\$;FOF1Y-M=*M.BJ.(9 +I>906X.HI+>#X I1^ILG*)3N&=ZG?
HB0UR9AL7B"JOI'6(GARRX+^G^24 MU.9KZS.U98ZL9V=JFY 2.0CEQ6W=7BL)/2TR;R&\$O*(<= F"/K?#CIV M.;%I0<^I+HH<I(T) #9IB+
(R2A+*QG6:062+L+^#5?+^P*EK55GIB&4I* M4K9J;NV2MRI'R@5Y=/E.6Y0G06\$^ U69%-0N%)BIYY=@0
HK19.X&RR3.3+N<0\$=;MH9L7I=SI\$H&97.WK9VSCIH'20KW2QI'S&(S)M2IJZ.M.A.CI=ZSS2IL<L\$SCQEZZF% XO-P3%B;X
<67S1I'PVZ%&X_ EK9IG>WD<^1 MTS2RNUC%+&4/I@67HY1X6KA81DKUK=1&5M.V>QOAG M#N-F>?UT8S&^L.8E56<^S.B&L&IP?
CN2336RDU'BV1ROGP.NA+07U3 M2@G2^2E=7.YP7 IJ0P.4=J0I+YK&YA)=4>8)I^XWRZFJP#P*8R&KWT M=8IYAI.0HHQD^<L154F&-
Z^44ML IJ24V19&58\$N2E\$&I(G.M8\$V)OI M^6BY&_UHN9I.O.9I"4H-FC?M3L>4^@OIUR MAA IIBPC&T8&4XO8.I+&Y3E
_5E=BI&5I#ZV0(ELGI\$Y.SCIV1LF=I3R M#>MRTY7I7>I@.@BEFV>Q"IV.C@3I.M0:LI+(RK^N") DG2^83>LEO53 MT7M=?
5**B\$ISL U78#AX.MYKWHB@ORZIM+I#F I^4227I25Y7PY3>#^0@=EHHDC8FYZ@TI:9FT06 /O MT% 3VAGE&#7NQXTU^604.VKI0?L&I^I2%<
M32D.O@.*F1+RQ?>M/P^NY8=9P^T^OIRXI>0DPI\$QBIRLSNABEL^AIDBO:<0Y3IYIOS.(@8I%F@E2.MLC@%7K*1%2SGMRK
M(=R=Z)Q"W/I.W%*R;ICL'L.ZP.9WP3B6L47HWN\$ ABIZ M#Y=HV.12?S6AL=1R1.Y6VI0Y)3&GYKKFC_700ZQ^@IIS!@;#^#I2I.MV MUCCG
+I1>=>S1G+ LU@.7C^I+H&1GU5C12.HK1?27.FSSIWH;4N@22TUR. MV1A.M5+I\$3U4_C@I(V^N1L-B>L.FN2F_F%I+Y54I M_2P70_9TNV@HP?
OHI_20>?_IUI+ P04 "AYQ@H' #W M\$P &0 ^AL+W=O@'Q:9C=67)*&F?I ZGDM)SL_/(F0V)2 MXKVJYHSI(7VT+2=LVJU7I?KT^5?P.M/I&3I<\$OY?
TRTHIQ=^FZN _W(CZZZ_M1B-MUJF9>K4^=E4I.YI.XGE+TRM&Z MM.#097CHGHP9>7+7+1.YA2^+I(H%#620-17I%)>AJD@15/AT#G9;DF"
M3I>CIA^3I_#EKNC=&5/HYSY?2DDGHY6I2^0I2^P@S^6I.Y.JDQ V4_ MUF+I+V;S6H0QGQ5UOUO167_X8E+X^I(\$%):0IC9^5_T4L+IYI;YH&UMH;
M.);<3=(PKJRIE-08XFT)N7AQ\$Q:A;<.<?7BIJ=^=G MTXB-/ET-BBIZI6J TH^I^FIX)C?ZIG8?YO10\$K.4#&T?BG;(E.;15/6357.OB*!JV9I?C!
M2K0R+ML06%/68WMY8I@ZU#66S.C@6\$ 9^8UC=A79+^=BTHC=LUI+/3<3XJH@2P45D/Q7UI@E' MR:I^LSIQ097-N?
(28IDSEW&O:9O)P5V_PN=IUI7XPFT(93'I>.@PL7%-NI'=28G0A3M@I9IC M&08ZYI(K^3BV/LI E.%E@D2ITB2^R7F8^MX=1-DEF M=9IK-
ZC4CDOI2&66<2-I4@ET.YI4^H9I+ M 1)IAD#N8XW0>G>@09.^I?I R(I-I3SIL2LW^6%#/BS1(P>65<^ S\$R M62\$RD)M\$@.R8:ED\$-(I>6XMX(A9
52(H<@- PMN3I_A.CU+I.T3X90/7)GT(I>2 M/@/=UNM=>#7%#.%HDJ100IA3S@9)JDZ674(WHP+K0E>:>#)A@VR@WP4HV!
MOI^X_IJ&I@MN_29MX O*^CWBUIJ.U.^P@P@Q64^@.F\$0?&W>C?ER+ _M0S=P#@67K#4R@PV)I N2^+OL'D9.#@>@O-3JLI^J#?
MN84Z>2..V+T2\$*4\$M1&B\$+2IQ24&8HH+^Q.W.\$BI>S)BIJEN8V'R MWZ 966D2-LCT/I#^T.IB'I:EAR=I&A#H@
(B7C\$1Y6)Y7PUJ0.#'IS;1E.MGU.C.NG=ZH.ZCJBI;H&E0#<5U@E2^_L1PY8P_U7N2_3I'"M4.\$A4+S1_M9>DIJ0SD_IKZ-
T)MGR)M7P\$5ZH2^Y3@77H/3E64J8\$QOR0_I(A(KM'RIF9>N.M.%>=PWT4&T2.T@.WYM#<^1I2^CBI#P2/CG?^I.T.O>4.Y8Y(Z1D:U5\$6&
M8I151&I&0&8Z2^H&I83>E%#<^Y^)>I\$F1I8I7YD9DJN3I.WSY#GW0^I MXITA:1P=4Y_8U@IYY3?>HI=FI5M5.7)^
WR8WIMQC6+KEU+B<%P-MLZ>E579>X^U>M7FMBD&IUU@UL+HJX3J./B>4^I-HQ2I=Q.)&N;IL.G>YS.M.@.73WG>IR;Z>%Y*>%)I)/(B
VDGG38QV1.3NJ/K7<I'W2I'OK\$-CR>=>OAC<M7%#X/I^73COTX\$H0_4^I2NXV4I&GD<4Y;R'>.>9>@C^0J377B@H&JL M+^G+8(8)V-
*7M.UHHR4B@Z-G^XNO2BK^&I8O\$.P4H'E3SW_YJMN@.AWR M.0.6W#^3AT^I^' KO.INGVJI9E_S'G<7G_2>SGHKTODI(L
MI&3^1UC7IR+.&?W#W9_ /5;A=?&NELM-HXIOVG^2VWF#+I8W>HJ(O^YU; MINAHUHG=&N1-\$&IEPM^T2EHN5#2;A+N%F4WTSDEFA<&'
IMJ6F<I>WNR MI9I^4NNO G#23^4\$T9M2H(G8G0\$.I/I#1+<O^CXJO>#L H#^2I'="^ER MBW=._B\$;MYE&PP@/7&I=&=I2_P%I>P+I6DL2F?
O1V0OGIGG6YI83JW0G4K M.I.IX4I@F+XAP'H%GAWB@+I+HSQV<3H/LC.FM#I@I@H<4^XHCMI05T'R M;OPI1^60PCT#1IB^J^T7#>Q+I^EH+
ISIS14I/4D<?+ODIH^G7>HI W4\$7S2 MRFTL_*P;%(I+I)3P2).=.I9I&J M1OCS=FF=H>3XZYR9^4IO^L47S-AN>8W3B^K"HGG"/;C#UF5_G2I8W'D6%Q"
MGSU2 38IB:7^29.YI+M^FC=8H1I2SSI&HE7@10H;G^A7BG=>XDYGN.I2 MI-B^I^4_V"WI%2K=LQ4-0X/60Q5+HIN8.EKH520PIVH5LT
M0C=P=FBH(2IR_<I&1PYV_4@Z>D1LHJ50NBR^AHTP<^ MI@P6A&I)R(PB<9^7Y.O.OI&CYKOR6YL<6Q\$LKKOKH0(j5J2DD>NCK=
M+I04I2.A7\$BIMEKHS\$YEPJ9G5SIZ Y"@F\$>+I P S/S:OBX8N MHY?<^/WI+I MJORZU R=HJZ1.4%I2Q)R@)EY I.W>PLVEIOI>G6/J
M1"N\$EYA20.18V\$5Q6E6'/ORZI^D0XBI#^RB;UCREUR R^C^H#P_.1D M6K5HUF\$F6ZCU3KENIONH\$8X9JRNASP<18YK3T4@7^U93/90_ \$ @R
MDZJFIE.U^E&5JZ0W4U'GT_?=64B1%F5N;J(1SN305YVRBB%I6-56I5ZR2 M#^>8+I;N.'SA;\$+HXNSALJ9>3^FXG^-.13^7G-A.92\$5.FYX/+XOJL_O=
MAB^B_&237I:B72Y2G-MPROBA7&4J#XN6=065590F#CIXI^H+2^MP< MKZC_ZF2+%.JY5M9_9.79G\$J^R>D9#ZK-R-

```

@Z(1)+U"5MKD)P_MWB0>MD&X:RIP"@YI+H=Z/6P+ZW(*O)^>#9M3W="G0%0YH>S:X>/U3 MD/IO#G;JHS&AZA?W"
(CRV7?B)R121<E,HS,#UJ&JEW4AA1&& $JY(EJH MM63IA#AIS3,I4W*W8&OF*0L%W-BK#.#)YW Q082> S2/5GZ:6
MDX#U2)9K0>%V_ONI+&D:KG;Y&>KF72?B/45XE M#8S;ZY_R_C2:(VZCREYI_N2FT2?JM(CF#N0>ID_IH(N?E?K19A'MX.R7MY_MSY1P+FIU?
SEGHGCL=X=>I(W_LX)LDG&L>P)T6I<_QGM(D)570_0_S5_C_M_ $4L1%VCJ?G_D3D7GP_30CMPNIS(IH&QUS)2IG_E7A>_&_J_UJT"7.#E
M2:ZS9WL5$DUC+XHBG.(8NLF2#86G0>2%2DI&24>RDF^RQ1=&PJ+T12DG3&
M:CJ/I8+A4DA49+&)/I92+U+UE9<6-6RM)4_ JSSJ19L53<&8#>OY= 32U_N(KCVB&M)8L_WXG_JDVL2_+IC@ MMW+I&
(CX)X1<4-8.5Y*N6(O_I^JEDH<_34@L@_BWJO(UTY200(C^9HIG7E5D1AT0I#NKPHH2=J#H: M:DI_*K6*6L_F5LAVG32M;#65&S*$XKCRP-K^3GH
<SL+IM@# M_PL$A%F1@10(M6)X)_H7^85K8223_7UGALY/I813ORAG_2S^DB9W02_MHY?DG
2@/F+D>>UZDCPG9(IHYL6)OS_+I^T(DS>D^_B_A^Y^G^5_YLO<3? ME;Y=7>6_.(UV=FRN($#@9=DOLT7@0^H1O*3H(OLD9DG/TP7_I41#*#D_D
M^USA96GV5HFXU_U_P7RQ_WL_9KHXT_D23<3/N2N1,MJXJEC_I7J(NIOSZ MW>DT_I/3A<L#:#8M+>#246Y>^<^--MG4XYN5/(("IK?
#Y"CJVNN=WMHKL<_C/L^DL1%- "L2QU"W2_O:K=M:$_K@_M_+05%SB4>EF2V0&#ZSS9FX4T_+T13DJ1>@("$_.26S1/K8CP"4@DQOPD+1W
MD/3#%>13J>NF-CG$P2)=L6GUM05U#F@7:6_6S)9D1FT13X8I$>#M^TNS&HJ_MJF56V^HJ28:>05RS+(O3^T)DK# M^*V)2A$66^B^I
DF<@APFP>9#MD(S5Z2Z^G_Q^"R0=QF8<UMN:70P=U^I^#&ZZ5Y0_U:N7W_M^"L^("Q8CVZA_Y009N5I)FNWK=0251%F^@<_H1M:=^X86A?
8A(O&@WS^%H2>9>F3I&8JZPPRI3I5S.W$R_8JZTZE,)VPP4*6"N^=IG M$KU_-I$7I_1%_#4$1#1!0_(_R(ED B)&1#0_/_@&9>&PO M=VJR-W
H965T_KLL<6ZQ08RT_0#E#UW%#1P=14*252VH/PJ^U^&Y2+U MTHW=J252#I81=XIT$SY$7=H_NKO#/7L M64+72>R_X4E>2JES>)C>1?
PM^02M<#ZV40XU7^<K>9>8(6P^)=8J4W/_MWR#36_#_I.G_4IK$0^VS^GOGG:SLN<8WLODB$E_QO_R#^@L_RI/VI_MDY^>U2MEHT=3E-
LX$S$Y_/_#9D(6M&-3_YI^@I/28BFA_AOCQ_YRK?<V52_MRI_H&TUIJMN&LNR^$YU=E)U^H^90GEF_XZH3W5^#2K8U5PA_/_9IQO4KY^
MH0ELF1^1.8MM1+J^7#6_&29&=1#>^Z^JNG^3ZIS731F6X_717<87#<<^@_J+D_MBXINXV_7QOQM_ILIMHHVAS_7Q(RB67Y>R^N=4I+W^ET8G0J!
I06H$>_!MIU=@DQDVN:<_WM$K(K&801H^@D9E^&_I.W.U&E&MER+4K@705013.8K_+VX%8 MO=XIH^#_IK4I^DPVE
/@&I)D1K$98L_HX_+|QGGGFK_9UY_2C1QIY@P<M_T3B6+U_CE+I_MW_$<_KUJL3$30&KB&@VRHN_A_#<P^KO>_#Z2H:V?19JS@&B#)+1
M>9@1K2_(YHH+I^#(6_K(6%P$E.F.E_FK81%<4+1%21%1+>_#>_#>YI_7_M10NR$^YM<_J1_6L1^5W_U2I0V7&PC2(SF5I_U$^<^C^<#5T=IGZG^Z4&
M_JG^"S76V%#C9_IJVUX_IJ2N6=.O"94"H<^8?W_K_P20P.$ M @_("AF620(6LAWULC5=>_<I^LV_OXXK0U0G^VP$>_#JLSMK>_I^T^C^OM/NSL
T11%J8DH1^M^>_>QWPI@I64MI26M3M^9LLK9VAVZQ_5_-L+I_MJ4_Y+I/272_LIMWVPEPZ^2K/U_0+H:HA&JG9R2^K6:IOQ4I96K:SR/L
M(JG2UGKQI^EYPT7_M7HVK6^Q2GLMS+VE_VIQT^UY^>5J9&N4JF3JH_M7MW&:OJ^L/O2CZ:/9J<JDNM_W^3CJ79)^0^R5J6UB$(#_R2M:U_X(8?
XZ8_MDIIV1CG&2W)>_IVARU(8>7K?ZO*KL1F^80N1)^L6_UNTIRU^>D9>6NC?2 MXI
WP8EE_ZQN1F&_I4_H@_ZVFS@<_O_PB2_26KY_P+B+M^3AY_U^>_>P9DY1&I>_7P$+IKI%WFI^Z)A^Y0I_M_YWZ3M)_L&=HB%_OY2=L^"K^#V_Y_`AG
J^49Q_D@)^=YR^I(Y+&_M.TGC8^CG=|BWJHEZ17=<B5%7ULAISS_Q$4I%7Z^_OQ32^_#A^QI>UD6N_MD8FJO2?K0$Y>E=8:4J_!LMAN9=
<8$FU%#6$6A=<BEJF13I_V^>5>BGIDUB^M^QO@DQ+<_OU^NC^#PLAKL7FZLO_I_R^ZL^A=<X1?7^C?BE$SWE_XL<#CH/E_#5="I4_UUL
ME>ZHU1_BA<6^9RAM+8<+>SAQ>Z$B^87Y_M2QAQ^&_75D4Q^&5_0GRIC^<MDA_5=<8DKFN9=SBYA_2R&D^IG.#%#F%#Z^T^I_7H//<?T?
1+W2%TA(L^M^!E3MG.S+)<_<DC?>#<(*$0T^M:U>=<B=<#Z^&C7&USETCQJDRM)8UEIY0_M(=<#?%J^I$5^=$IQ)=="TNR5HT//5=
(f=2MT6I6P2>_>|H$&Y^9>49=I_M8T$SYBT6^V2I#>NK(D$A2;T^L3FO=28^N@=<F6I8O<_<I72I9QI2I>I@I
M2MR%J1)MM$(GI^H^FZV19U^V5E_UW$B^<_#C3E=028%642I_MFO= M_1SVHN^L1_QM_2^Y2OS_Y=I<_C_K9Q57=>I9$69*553=<_U@-
K:O7.&3.9)2FIP9_P4+ADJ38XZ4O^U7W>JTN1_!%J3_MMJ)=?<T^M^W7_L2#4+70K^WN1_T6T:5B%$U4@(+I@#_41H7L_I^ZPKO^I
MXL#Y^UXOK_IKMK2VI2Q^E^MMP$YHYWUE^W16#<_<F5H$@ES983REF^UJ$MIQ?>=470HCOL_X3>1%&$X_XJHH>Y<#A: WXO$*>7*ZRX2
MLBS(GYE?_J:3IAWZXQ<_MP_OJ^E^H:8CLR8>@$Y5_AH^#QTS5SL7?YQI+U_XACRIV^A^>:W_VB+H^MPU_!AR?
89I^=H9I+5=<#>#>9%N>=>8.$ZLW_BFOU^R^Z^N^I^4G=N_RN_MBLX<0?W:L_G_P=02P.$% @_("AF613@*3R^P<2L^D^IX;"HW M:W)K&ULS5K;_N
&OV5AE^>M8_N^LYE3&G^&2_M:9O@_JLONPV=>..MM;)_AZ_GDZ=<4R)9HF0K=C8I#(N7H)5I:IDZ54V^
M^<A60I37(33LTV>U^V^KIOFYOG0<3VI#HNL?E>A)_W+LMJD34XK_Z_ZYL^M9+X:3$5_D(DQXLL+PY_7L1KIJ3J^<5M_+^+^YBI>UBD56?
ZX5Y^2^E@<35H_M+YSE51<-73@<^>73787STQTIZ^V2$@99800E^G9<J_&5ER49:TE_FY9+V)^#SX2P_L5G)AJ_K)/@>21-7_MCWOWT;8IW_LX=
M^G^_IK=U4RZZR=<I@D12M:_JH_#JIAN@HIZMP^6GZ=<_G)BZKIR^H_#6ET_M$S_Y_LZ<7M^BG#<5IN:8UYRNUQI^I9>_B^KYN^:I^+N:A/GIQW$
<C3J>M=K)>M+4%EDI^Z$LFNN:25_PNSN_&H_2BG>N5>J9T^SV_Z8292THHLT>_M^HS49I>#B_>R_I^35DU>7%_G_Z43<5H^7_7-
^69<&H7+I_HFFX:7XB_M_E02P1%>W^<23BAJAYZT^7LDGYRCQ^;W2=UI=<_I_M5(4H:B^H5L^DU^M_W>7@3V?
ZX9_E&SV;J>TU>@MD#&6<XKZL0IH^+KELMPN(B5_<XJ/8=RS=<_I^LM^AN^8S>U^VY7Q_B$E)OS=<_&M^0H&013D32PX&^A^Y(GP^P-3:J6
<9LRK(05GLI^FRWR^6=KNH_Y&Z2X^MY_FUW_MMNEI^Z_P4MZI_(QX^?)2T8+7?2N^5#8@>I^P94TS$JRS^>K13:C_X:XSZ5:(846L_M9QH(<#Q_0HORX64+
<2L2I2YS)&>X^JXFI+WFFTFK@O=D^2_4RD_E+M1_MBG&G/O4MOB$>+>4YIRKRSQ$S")<^<72+JAJ/H+I2U$A=R$REI$&V
```



```

C00@>T$+QX38<82$*$S4H>+|04 MN5IL>#86 #+>07Q:~NSLNS?GC HX5@/LP!PC!A(OHP P X)5>5LQU(0&0D4L M^M#
<(8E/LN H77$O^>XHKG>KHI^>+V 4Z5<9THMMW19|L28W00.$>@#&/S39S01Z:6$P"(M4+MK/2*>YMJ4XM">HU^MLO8DY)84++
QJ^I7|N<@S0A(GCLT59@)>|>E|RO M(OLN$>W>9.GI<0%?U?J2UT=OIMDL^M^?..8%$/>K^!1$..62*780@>1 M3@>D&SLH|^>X:XOS/L%:(ID..5
03^>(S9D5D01^>FW&6_EK=5/C@I^M^A8UH6^T92)"^2+SA7SS251-WQYN^?^M4$!L#10 (<R|E9G$F>#0X+>G 9>S0=VIR-W:
H965TBV^US=960GZ^G.<^H^D>^>^L_B +7/L$JWY51N#E<+|R| MLX53O7H.XV1U:KJ2^J
MPN:/ 70#|Z7WMR>72;0L1XJG=RM 96RBAW">+7Y 7 12U1XYE=XZW>+^M_OJO=5MS9:SW>9$<UQ>7%CS^R?^ X6HU3S0N/PS%UCU!:=0^"SZ
GOH:/R 70#|H2YNC^H1H5H4UWUGZ^F15ZU^M^N^9F8^K2 2C1K179&5 Q17UQ4WYF:7 M^* 21.Y1:5Q5XZK57X;>F#16V>1^42?
XS^")1%&R.LC.#.#<^?2LFD^B_M_IRMUJUD6)X<=V$>Y1:7(BK">|M_50HO/&EUA|97QAQ(GQIZ=TGX2)K<^M^DJ3JQM?
K605OCN:9WW&O/MHH|PS3>+95|X>|^<G(1K^RN^<R?SN MVN5793^?^ILZ=|9UT+>_HR?|HVI>|MN:7Z(P_MX&Q=QU.AN|8.K5G|DTSK_M|7_<4-I
>%|S F_NOKV: WOMJ:4KD)=<Z>K:9FNVE^0)DUTP)=<Z>K:YJ3^?Z|L729.8|7>5VD1.CMW=V^>Z&|R M=^Y+PSRM$J|+>>QN804$R
QHLR1T|RTIR)SOIG9WW2V^LB+^+C?&|3^>U_MO_N/P^R8V^NT^>FT=;LLOLO>|^<6NOHVIC-
YCI$#>2DF0&^*WP:GO@T6E/2>|/N9L726Q8P|D|E|J:@|N^F#>+P@L&Y0NHFD^H:&0B.%F:T.M
MT_Q+FP66JZ=Q1$1:6GQV$V57TD8C$;YS3:15GUP=SP^&@*ZAYJ@F4EMIQ^DEB8LZRN9<@
M|R:1@=<L(#/7^<^Q/MGLR^+PVUW^H_>|=A%03^*6U&R64_|9>0P%&B: M0^FIH9_P|@OYX/R.&AE|^<|ON>UOCQW^0=Q^*M+|^<7 9+H_%
X_2Q=<^M29BLX^ZG2+30Z2^2^614E|41^*(Q1:5PQ849:|J|6FA|>QHH312CXDAVN^M.M9EIRW=^
R|<RN^NAYUA_3W9|YS359D.^LT 2@Y_|HAU^DZZM^W^J|B<8%2 M4SM1@HC%EX^7^4+2|J@F4FAH^B386_39F2_XH|6=3K^J^>DYW&|@L#S7|US
MF+9H|<2(2R:(6|3|..X^SU_R2:6MZQDAO<5$V@U_102+ZQ+Z.Z M^R^"HB^B|^<|RHRP&G1?WX^K3^4(RZO1|/G/9.B|^#B:0^*FV1823FQS46EL
M0Q$JB90.FHH|>+8/2|9|M2^L^9^<L^P4$ DKE:6%2AZW1 GOYS@OQCUL^Y 3^/E7^|B&M^<^2)D|<^Y^>_XURI MB%ZB|2%GHE5GYT%2B4#5|L
^46GZL|>UBP A22HFH^H_&0D&33^VN&S *|M50G2JGWK:2)H:Z:Z^0G$1@E8..K:4M:6<16|C:&NF>B09PZ:9XY)S75%$ MXH+%=1GHW_5RD H-
36JDH^L93&0#64@|D|J^FAD QDSV:>6H&< <GN^>^J_M|7Y^|K^&HKGPI(|IX^&#U_H|7R^4E.K025067Q^H2R^E|H_344$C>XK_Y
MB|>2G^R^IL(VH3ZDPK_XQ|_SJK>^>ZK#^2^?T0H?2%4E.#).F+|XN^>J2^ MH&H^T:|HK$;9S9IU0KDG_#1^IV3/53TA>GZ>0^O<4&H
M7>0G|F6MV>%0N(|^92:&@H)=WSVP|U:>9P^>|L(VH3Z|DIRXC0Y_6Y307|^M^C^VWZ$<+9Q#J^E1DMS^J7ZAT_|1JHF4&KJ.E)<|L|4!>UV^/C^T^O&T
M5|E^SDT^>TX.9%DD>2H|W06CR4FAHCRZ:|L85.5^*>Z|D|E^H|^DEQ MSNQE14Y|O5|K6N&M(F@HOH$SGW|>2(DO:SM&C$K>AU)38138:Y%9
M^Y<=<L_X^V^T8+D%TCB0Z9_>)>^JDU+20V$;0=4_Y4N:30N^3Q:6%T129M_M|A|^7U:AE|3@R69SUG6BB@<^G90-8%24T.AP9)<50|YQ-
/|H6MPOMM.7R2 MW:XK^Z6D_Z^J^%05%T|L6K):RY25G9^<0VDE|J:B@DIKFS5V^5^MHN MAK:/S5:2=|6T^>NV^/W7+|<(K76-
|H(GE9<UBHJ>2.25JWL&^<MFFJ$Z^ M7|J.YLQO^<T^T^G9103$HJ5&3F.ON^Y^<^<9IU01^30V%Q^1W:B^5^KW|
M^*:UZH(D:9HH|>>|^/J:94P.FDI.V<=>R(A^*HDE)H:TE)WK(HR8-2$E1_MH_344$A^E|F93DM=<H.XM&L:|=FD2-LTU6=)>3|EB&EXU29MQA!!<4HE)H:
M_E1WK(XRH-R^%|H_344$B.^F9SE^?>|^>K|>N9ATL^M+V3/57$H^|3_MW>^K<^E|CQYGT^E)K:<|XVMO>UWLW^HAE43:~4U|G^<|FK^?
RVM19_X|MS|U_2^2Z6M|8W^?TQ^6S75^TE^DU|L30K66D+1DH|^>@U=>8H26<^MLM9P^<5@<HDE)H:<^EA_NPU^Y|H@>9.G.H^EZ$2NOHR:O)
WO66MFFJ$Y)V_M2)IVD).67=>|VS$ZW$&+^5|J:@PD?2G+6K+E0SD|JB90.FHH)(2Y=<#WBD^F.MMS^>PYW_OWK^U=<#UV^EN^X%7^X?_D|^<TR^F
K+&D|H|^H|^?2@U_082 MPQOE+>7RH5P&5|L_H_344DLOV4NU_/8Z+MT:=O77Z-V^<2^<IWNM_XJT35+|M^IRTU/4TMP|016W0Z &
/9C|SESF2R|SE|42RXZ^>5$1_H_340H(DG_6S_M5V<=>^NS<L^H(VH3ZDPKR^6CRF9G_H^L^E:7&S^CFHF2^J:00|8L^Q^6_4R^M|H)
J:FAD^P6S$Z$%;176^GVL<0^R=<8XN2_MT^+^1.G6G^4K=F_Z<2_J^E.G_HZQ>>L|S0L>2>FXT<E(%@%02=|8^ GH:DM^BT3@/UYQ_<^
I9OZ<^<BQX3)SC:3P4^KXZD2D|M|E|H|31Q|P_P+G|Y|DM^QO|EK+<FOMTD>6#RPQ<BY+1X_>2G^<NV559Q^M|OA_2|9Y|JCA:3CVEN-
M#&^?2^*|J:3%HS.^B<@<E|S6C^#EL8|H^J^E|S0.BT<#<#MAY^DEE$7P_M0>#HB|=N3PV^TTFYQ_4P^#U&37|@3WL^M|SOJ_SJY_ICAQV6?
%|R6O|WR(QJX^_Q|@<QRS|07Z5G_MS_W^SLL^#2DM^YQ|L:&^|Q+|JY0L3HM^<X?8^YB:6#RP_MM<2T^+^1H#5K|AXO)PGE^4C^>BG=GW^H>8-
GU4)9<L^23|2R^>G|<M_R<L<IN=S<L>2^2ZW+7^C^|A|J4BE)P6A@8560NC(@M+15_Y_9J3XM&@M^<FL^%5GMHC2/1_0U<^W
6J$&:&O&^GN5^T51<(<B0+G>E99CV^Y>^>Y|8T>
2MGGS^?>=1A8_/U^>=<=V3TKX$XMB03Y1_3%&ZBK&I0_0M^FA:G7ZY^*=O:XH^H^V$&V5M867)1)5)>|>L^?H1#3>O#0(91VWVS|S:2T^F?D>)_V4 MI
<SK1 2/>^<B_+L9:7^D3M2>^>|+N_G^*MXH|Q|K^Y^AY+2|P_K>C0|>UN^Q^F8Q^@5#S>C6<^#|X)B0&GQ2RB>|J|7
M|J^R3+>OQ9M^ZYN14TOD(K&2A0N^CR^N8BBP^*X|Z>@P9S^P^/6+|Y|+M4K,DF=BGD3_~M=R>S^1F^M^G@>R2_)T|H$+
<@K_~V2^*Q_14^UK3^|ISR3 MR:X>K^+8A7^UES_7B3@>_E.#_#U^_SN^%/(^*T|+CTQ@8^>F92D|9|18E MGUVGR1-
^*VOEK74|K_2<5^W44S5MZ$;^>2XD>1255(E:SKM^""U3|_M|H>T^S+XXW(4|BCVRP3ZOO@<F=Y^M:(2_QS#U^T^XIR9:NJA|Z(59ZF8:Q!
M=SP+>0M^U^XOPDT<C=78|EDIO$25X56N|HJ3A
```


(N#6Z2\$Z=\$/EM>IQ08Y>>EIQ&/8ZU^9K>L2 M6^L>IN+CF ECIUI(ZV:72/NP/Q_3&@f>GZ@P=V7#>OOA7K8*>T)@!."OZP M*
f#3f@=>IRL5?>#=>SSFD!~!>#3(fH A lPT&SPO(MEUY^MM9P M,S M=>#L0K/Q2I8=>3f0f"VB)G:20^<=>WT.S:JWTFDCA^F7T&P^WKLN,2E+
MA9LDQ:E 9G>K2QNA@>?9TWGT>Q4P8, 5!6ONZ1 K^DH%>X:9T^9JS=>J.CI# MP.,8^6^P>.=W(CX3%#I#P.,8^6U^P6&JZ M^#-
AYPCP@>90Q>E(WA11X&S18Y26Y0!..SE, X3V^/^>E)R=>@WNE9AVA_6B>f-!-I\$J>A0SH>THI(N=EUJ, Q77Z^ZHIZ" M8-A4^*%#>3ORRTD@/H/-A^<-
N1C.2WDI.P>5D90V@%>OZY:7j7%>fZ, Z_B?A_U+ P04 M^ L^2^0L>@>UE05%>Y^AB<:6T"(@+A.F:FT>Y.O)0%+V4+Y!>5HD6f@Z%>G6 MVLBX
^8B,R2^I<=>#0YVZ@%<O=S- IPU IPTSO70+0#>=9IG:2+!B:10YD^A788X_DJ^I_9MYHH:GPSMUx2PWL7J2EXH!U6 M32?
CZIS^Y^/D#D\$K16QP0@>PZ76fR7FG)H^IB_ R7G!_U+57A/W?%D:OO MUKM/M!G=>QA:NGQK4JJS)Kf^X?>>WNLRT2>=W239KB:R2PVZ9PVX3^Z2:
MGB!/#1@>8+6\$#AF%CA LQ3FIH<=>T=MDODY63fC21^5fIG=7LC>f.O M?4L>#^fKW2NUf/ZPIB"/\$!+V:1#f>_OIXP>+>VA.UFOT.&O)8T70?
BEHOU_QM52>5-1-1.NF\$20>2FV35<?>3-826241@S@!>_ WC3H,X=MDOEMDLU(fOD M<^%CF,16&K2UPO5L 0DHZV06G^T^2^9G0
M/56XP6O"98FNG^LHDQEOERSYP,@D.T=82&-DG^U&0\$>0J0>?7TH=H/407G8 M-2D74\$!#^!0 (<R(9ED-X"A.80H^\$Y!9>>PO=VJR-W:H965T
MEMF>R(H-3K^?B7?_ MZ73Z>99@FQ^5\$G^30Yf04D1!!!&Q.A4^!1-0\$>6N>@> ZOR.NGfO! M.E6Y^Y&CVTI>K>->
S.O@B:RZfJ5^>^WfQ512f)0QY.S5R=VY^<=>G^OJR6C=EL>0?>Z>+O9Y_?5G7E9/5R-O!T.GXKfAHf MP2CZ_KGZ6M^X34UE7BSXLBfHf5/SNZO16^!<-
BfQNP&+?Q3VfJ3GX MWNG^E.NJ^MPf>#>_&KG=>O&2SfH.D8LOCWS^Rf(CB?WxfPXZVfMV P^_T:G MF5f)>_#&W><G.5?
G/8MX^?f(2V2D3/G=>FZ,?f153f^ PW14=KQ953, YVGVG(N.MR)FMf9f1+!>5@4R^W7_ ONB3@8X 7#^"f!>38^?YN@_!<@>W(W#AV0+@_ M\$;Xf(H-
B(X=>#&QfNSMf NOHfT, /KRfHf MM+7X,2^&M=20EH^!>45MM8WfSVKfD1E3Y?EJRfHfQfM5CP>E.Df2.AJMMHf49G,
M^Rf?A_SNBfUfQ2K0.fEQ7fJ2fS8NR>2G&_WF3.Bf^>NGfVf1+YX^>MfWDRWES M.6f!GG9ZXFfENKfWf>
fA5YfQfN^K^!>U7^Gf0)8f@>Mf0=>_VT#D.MP^U^X^f!_ M57^2^>P!f2N=>P^GQ.Vf.SHPf>?>C.O.Vf<CfV1<CfV2^!>9WAO9f1f+>KCE2>
MU7f0fJNfOQ&^Kf18YfML9fQWfQ5f+QfS6UfY^XfO_ZfEB^>YB.WZH^9K7N.MP/Nf6>4S?
C42fH&UXf!>VfWOWB1^W=3&2!A*1^6(6\$4^6.@f%)_ KZ8?fO! M>fK7f!>N8fHS85P6;WF>>_!>Qf\$87f4fQ9Q<&>_V+UZfQfBf!fQ1.<^f/I
MfO9>4f1JCTKf8f!68DfC^>C5fLY4>QQLH.6YfQ)DfA,4>-6f1N^&S;RfXF2RWfTY M&fJfTQ49Gf;WSS^#UE>+GJ?^fCN7U^>YD.KP^SOH, fA22<7F3(O!<-
(f^f ME&^f(40^5fH+15f3K^DfAIEVW=HWKZ%5f!Q88fT?>_ 47Ef67fA: _U^_SD^>M4RfHf2(fU1+!&0#%fFfO=S+4;NMK/C%,5YfY5L&AYGf?>
+Tf/422,^6^fL9-1f MLf1.KL7_P+!fEQ K0.&_ HNf!PE+D,^>_&f/E^KP7fFJN&=fHR3f14Ef9f M.f1f4fJ\$TAJ^Hf760U^DfGOGG>
0YGZ3AT>^MNNfY@_ NB0>AY^<@0%>50&Df1 M5&-EPN99.Y Nf1RHSfMGOfHfQD:CYDUO4CW&9R06D,15-fJEN&79T^?N/fMSf^!>OA7HZ?
(2&@f1.506@>E42B_H6Afb>@PS0O.NWf! QFf13^V%TC(HC4)f M#553BTH&f)XfP3MBX=>fO\$<O^>-f0KfJ^#f_+OH\$8f1SHfPI2E\$)H\$553C96f1
MHf2fW7f(Xf1 9) <?>T=fP#fGf1WLHfEA5^>0Q%4XY6<7%GSPMf6=7%#fYfS+f!f1^X724BfM@>MfHE,90+6H9f+RfV34^2fHD+>
MW+>C7PF#7&>Q_750.8f?J8^*4BB_H6BfJL3^>).AfVf)H0f1.3N.fL8<=>+f1 M5&f9@Vf2^>(VfA:*KfC.SfDfL2P.U/QKZK^>04F: fH.042fLN@_fJf, f1+f1^9
Mf1+HfO.fL&9fQfHWA=12^*VfTBB4QfE TM.ADRDF&=>\$4R.30^>Af46_9^fTO#f+>f\$ M8E^<G(fJ2f\$TAJ^fQfLXNDfSK?>SOQBf6fH2700Wf(EN-#f19?
>8T=15_0>4B^&\$& MTABfJOHN^fTfB3Qf2fEOEMOC^f!_22&MA=(R^<fU^>00%45f);H<_fIQMDGZT M3f1^2Z&T^>f\$JfCAHfT=2BDJfG2VfJfL
_06f2K^"f-f&#4KfCf8_fZHfYfEN?MH" M^DfJA_<fBfJ<^>fJ^>MTGZQfL^>WBK^KCO8f+>.HOER\$BE(HC:~fHJM\$^>Q^VOX>_ MMP^!<-
OHf);9&fTE(Hf+8/2^f3&2fU.F0&Z0G730f0@>fHfE9f).f4f1f\$TAJ^fM124^#3_4^fDF.WZWHNf;fGfZY_fTf^fA, @E^23f!fD50&Df15&=E4NFC>Rf1
MHfLBZfD_>f1f?>U=>P^>Df!fH^f53C9f;fH6f!#S^>LRf9X296Cf;5^fE4fJ^fYfTAB^fA:3^>fH59^>Mf!&22&MA=(R^<fU^>00%4XfM^QfIS^fJ8V2 M?>
KfJGT2.Q^>HfG+>NfQ^>PO_H.fI^f?1fJ@>JA=(8BfJ9>VfT@fFE &Z53(P=BWfJfE3 MN^Y0fRVB@=>fQ_16E4f!fT52C96H8V%#>=fOYNfFGK(B^<-
fDf);&fNf\$Kf+>#0^>Mf3\$432fTfE3f+YVfV5^*MDEf;fJ5E4fJ^fTAB^fA:5S^f1^f4UfE@>Wf7Hn>2H^! M&B<f;5_8Q+fIS?>040fJE.f11-
=>2^>NfHfC6R.fE@fEMD4f+>fK^>G;+>fKf!<fT.MH32&fHfD^<R^<@>PL\$>fG:7fS;Z>fY4A^>2^*VfTBB4QfE TM3QD_ABS^<X^>N?_>O&_>%MDA^>2f4
MED^>1%>f1C^>fL(3)Z#>(S+AR0>=T42DNAM^>CfHU:0f4HCfJX#P_P.f1CfT52Qf040fJE.f11-58fE^>Z0S(f7f1fHQf+>3ZCVfL/M?>#0fTA-
(8BfJZf+>f\$TfX- GYfW5YAO^&?>CfX#f1f4Hf;0_2f-O&Df4U^>0f76^>MfMWM,(<fH-^>6E4fH&fI5fHC;~fHfE^>fE#_M34Rf!>fO7W05f)0-O-
OJf.MfM^fMO^>fU^>YfW6^>?Cf1 M727fBMVfJG;4^>UNH7_V4\$L^>#f!0 (<R(9EEf)2^>Y0H_fJf1 9 M>+>PO=VfR-W:H965TfZOfX
M^O.RQ5f1_5R4GZfH^>6OGWfJfU6Y&#>W6f123>5XfL N05fV?>=>fS.fLUH=KfWfWOMR=ETfUfJM(f^>7306Xf7F2F\$) M52^f!>_&7fHQ6fJf-MOC&?>
7V^>Q>WfLKZf^>WfLKDWfE^>6^>5fNfJKS8.^>6fNfQfJf MZ+>TfL:0_Y%>WQ5UP^>5T>WfG?97^>5@4GfHf;YfXfP<=>?>7Y@<=>W0f!YH=02fHf627GQ>f?>
^>fNfDECVZ^>MfJZAJ.f4MBE6U^>fHfVfYUf1BfJ+>=12^>fY 5SfY^>74^>fL^>DfA5f)Qf=>fE2, ZfZfUVf7Q_3ME5=(Hf9UfZfL
MfD+>C50A^>fSfZf+Y^>KfJ^>Rf1.YYKfISASO_W^>BfV_ MZV2^>45f&S^>f);fQf0^>BfN@fHfL\$GfVfSfLORC%fH^>VfI MUKfIEXYHf\$XZ>W^>8f=MfJVD6^>f!<@1=?>
CfV1&f(=>@XfIA3GfRf;93fE.fA1>B4UfK\$M23^>GG_CfQ.N5^>f)F3fV\$^>f!>_E MCOXEC8P^>2?>K2CU+G69fJ^>Q^>N^>fJOfT6\$QSE3f!>fGH5UfUfEJZX2fJNf2:f(f
(fPOH>f_09^>A^>?>fR;9Q: MND=VGlISCP^>7D_<f;fHfHf?R9C^>A@0CfJfXfYfP^>Uf+K42X^>M^>#>NfU328DfGf!>9B^>9B^>S^>fA^>T^>Af
(\$BD<5>3>49fE^>f1fRZ<1+f^>fL_2^>MM@>(Hf+872&f)3&H32fHE&f?>P^>NZRfYfT\$^>f!>MA=(8E;A_<fB45^>fD^>fSL2^>T.M.AfEZ9YX^>f)2WN_K7K_#G=?>
B^>f!>G50FD^>f1.\$>V57>?9^>f5_2f4f1.ERO^>Q02^>^>_MfC.R:D4-fD6C=5>>Gf>7E^>T^>f)A^>f)C-Q;fD_>7%>fD^>fH3^>fJMOC^>?>f9 MN-fL^>f5NfH^>fN7>fSMK^>
(fYX.fL50&H2fJ0F4^>2fJ\$V5@>fN^>EEQf1(fVf;f50 M&H2f)0f4^>0fJ^>N6_>f9WfL5^>fV2^>0^>8fAQ^>Z.US_8f!6AB^>fT^>02f=^>fH M66Cf15=>fV>+fH.GK.fL^>G^>
<_Q\$>DfD^>fFE_0^>Q^>XU^>0_>H&fJ2fN4fNYX&@> M&T.AMf1^>8U^>fAfBD9%>f0Q5^>f6H.B6TAYfWfA^>V_NQZ^>Mf38T22fNM^>fB M0Y^>R\$Y@>+f3HRD?>
US3fJL_9MWfJ9<=>8S^>f13A=(8E;A_<fB^>T^>7?>4UN^>RG M&D_f52@>MA=(8E;A_<fB45^>f3S6P^>f52MWf7f1^>3fJ^>9AN0>0C6TACfFf!>fB.D M4f) fT6BfE= <-
<f+>fW69^>f=W<G_5S.MHf042fP_0&H2f1^>fS4f+7W.fHf7UMfYP^>74^>S<@>f!>fMf;f&=<=>O^>fE^>W^>fW^>4H3
M^>fHMN7f)>fS>8Z\$SfD;2fLQ0ZfDf;L9^>0Q^>XU^>0_>H^>f)1G^>fUQVCVH_72A.MMf1^>8U^>fA^>f\$BD9^>f0S=P&f;fJG4^>fE@>S_>fL-
C&P^>5HfP22^>S2^>0GfQ^>6R@>_MK;GR6P.SWfKK^>f^>fU^>_<=>3fTO0^>U7^>fU^>f1Q^>fR@>fUBBR9Xf199fU+Z^>MfE(HC4%>f^>fH3^>fHf+DO9MRJ^>?>
XZ^>75P^>TfR^>9^>#>SSfV^>fL16^>fFOB3N^>f+>5fI0 M@Q5^>fR@>+>fL6^>fS.SP7K4f;f9^>fFV4X54^>fH^>f3\$HC4-fD6CFE\$>f7C9_6^>M4f;72DNA_>fE<2A-
H&A45,K\$#f_>E^>9P=>_3_@9fJNS^>_@>U6^>fS@>+f1A^>f)=MfTVfV66G_6fS^>f.LYfPFH^>0fJE,2B-0VD^>f1:~>429M&fV^>fV^>4^>M6R@>MA=(8E;A M-
<fB45^>f3S6P^>f52MWf7f1^>3fJ^>9AN0>0C6TACfFf!>fB.D M4f) fT6BfE= <->f+>fW69^>f=W<G_5S.MHf042fP_0&H2f1^>fS4f+7W.fHf7UMfYP^>74^>S<@>f!>fMf;f&=<=>O^>fE^>W^>fW^>4H3
M^>fHMN7f)>fS>8Z\$SfD;2fLQ0ZfDf;L9^>0Q^>XU^>0_>H^>f)1G^>fUQVCVH_72A.MMf1^>8U^>fA^>f\$BD9^>f0S=P&f;fJG4^>fE@>S_>fL-
C&P^>5HfP22^>S2^>0GfQ^>6R@>_MK;GR6P.SWfKK^>f^>fU^>_<=>3fTO0^>U7^>fU^>f1Q^>fR@>fUBBR9Xf199fU+Z^>MfE(HC4%>f^>fH3^>fHf+DO9MRJ^>?>
XZ^>75P^>TfR^>9^>#>SSfV^>fL16^>fFOB3N^>f+>5fI0 M@Q5^>fR@>+>fL6^>fS.SP7K4f;f9^>fFV4X54^>fH^>f3\$HC4-fD6CFE\$>f7C9_6^>M4f;72DNA_>fE<2A-
H&A45,K\$#f_>E^>9P=>_3_@9fJNS^>_@>U6^>fS@>+f1A^>f)=MfTVfV66G_6fS^>f.LYfPFH^>0fJE,2B-0VD^>f1:~>429M&fV^>fV^>4^>M6R@>MA=(8E;A M-
<fB45^>f3S6P^>f52MWf7f1^>3fJ^>9AN0>0C6TACfFf!>fB.D M4f) fT6BfE= <->f+>fW69^>f=W<G_5S.MHf042fP_0&H2f1^>fS4f+7W.fHf7UMfYP^>74^>S<@>f!>fMf;f&=<=>O^>fE^>W^>fW^>4H3
M^>fHMN7f)>fS>8Z\$SfD;2fLQ0ZfDf;L9^>0Q^>XU^>0_>H^>f)1G^>fUQVCVH_72A.MMf1^>8U^>fA^>f\$BD9^>f0S=P&f;fJG4^>fE@>S_>fL-
C&P^>5HfP22^>S2^>0GfQ^>6R@>_MK;GR6P.SWfKK^>f^>fU^>_<=>3fTO0^>U7^>fU^>f1Q^>fR@>fUBBR9Xf199fU+Z^>MfE(HC4%>f^>fH3^>fHf+DO9MRJ^>?>
XZ^>75P^>TfR^>9^>#>SSfV^>fL16^>fFOB3N^>f+>5fI0 M@Q5^>fR@>+>fL6^>fS.SP7K4f;f9^>fFV4X54^>fH^>f3\$HC4-fD6CFE\$>f7C9_6^>M4f;72DNA_>fE<2A-
H&A45,K\$#f_>E^>9P=>_3_@9fJNS^>_@>U6^>fS@>+f1A^>f)=MfTVfV66G_6fS^>f.LYfPFH^>0fJE,2B-0VD^>f1:~>429M&fV^>fV^>4^>M6R@>MA=(8E;A M-
<fB45^>f3S6P^>f52MWf7f1^>3fJ^>9AN0>0C6TACfFf!>fB.D M4f) fT6BfE= <->f+>fW69^>f=W<G_5S.MHf042fP_0&H2f1^>fS4f+7W.fHf7UMfYP^>74^>S<@>f!>fMf;f&=<=>O^>fE^>W^>fW^>4H3
M^>fHMN7f)>fS>8Z\$SfD;2fLQ0ZfDf;L9^>0Q^>XU^>0_>H^>f)1G^>fUQVCVH_72A.MMf1^>8U^>fA^>f\$BD9^>f0S=P&f;fJG4^>fE@>S_>fL-
C&P^>5HfP22^>S2^>0GfQ^>6R@>_MK;GR6P.SWfKK^>f^>fU^>_<=>3fTO0^>U7^>fU^>f1Q^>fR@>fUBBR9Xf199fU+Z^>MfE(HC4%>f^>fH3^>fHf+DO9MRJ^>?>
XZ^>75P^>TfR^>9^>#>SSfV^>fL16^>fFOB3N^>f+>5fI0 M@Q5^>fR@>+>fL6^>fS.SP7K4f;f9^>fFV4X54^>fH^>f3\$HC4-fD6CFE\$>f7C9_6^>M4f;72DNA_>fE<2A-
H&A45,K\$#f_>E^>9P=>_3_@9fJNS^>_@>U6^>fS@>+f1A^>f)=MfTVfV66G_6fS^>f.LYfPFH^>0fJE,2B-0VD^>f1:~>429M&fV^>fV^>4^>M6R@>MA=(8E;A M-
<fB45^>f3S6P^>f52MWf7f1^>3fJ^>9AN0>0C6TACfFf!>fB.D M4f) fT6BfE= <->f+>fW69^>f=W<G_5S.MHf042fP_0&H2f1^>fS4f+7W.fHf7UMfYP^>74^>S<@>f!>fMf;f&=<=>O^>fE^>W^>fW^>4H3
M^>fHMN7f)>fS>8Z\$SfD;2fLQ0ZfDf;L9^>0Q^>XU^>0_>H^>f)1G^>fUQVCVH_72A.MMf1^>8U^>fA^>f\$BD9^>f0S=P&f;fJG4^>fE@>S_>fL-
C&P^>5HfP22^>S2^>0GfQ^>6R@>_MK;GR6P.SWfKK^>f^>fU^>_<=>3fTO0^>U7^>fU^>f1Q^>fR@>fUBBR9Xf199fU+Z^>MfE(HC4%>f^>fH3^>fHf+DO9MRJ^>?>
XZ^>75P^>TfR^>9^>#>SSfV^>fL16^>fFOB3N^>f+>5fI0 M@Q5^>fR@>+>fL6^>fS.SP7K4f;f9^>fFV4X54^>fH^>f3\$HC4-fD6CFE\$>f7C9_6^>M4f;72DNA_>fE<2A-
H&A45,K\$#f_>E^>9P=>_3_@9fJNS^>_@>U6^>fS@>+f1A^>f)=MfTVfV66G_6fS^>f.LYfPFH^>0fJE,2B-0VD^>f1:~>429M&fV^>fV^>4^>M6R@>MA=(8E;A M-
<fB45^>f3S6P^>f52MWf7f1^>3fJ^>9AN0>0C6TACfFf!>fB.D M4f) fT6BfE= <->f+>fW69^>f=W<G_5S.MHf042fP_0&H2f1^>fS4f+7W.fHf7UMfYP^>74^>S<@>f!>fMf;f&=<=>O^>fE^>W^>fW^>4H3
M^>fHMN7f)>fS>8Z\$SfD;2fLQ0ZfDf;L9^>0Q^>XU^>0_>H^>f)1G^>fUQVCVH_72A.MMf1^>8U^>fA^>f\$BD9^>f0S=P&f;fJG4^>fE@>S_>fL-
C&P^>5HfP22^>S2^>0GfQ^>6R@>_MK;GR6P.SWfKK^>f^>fU^>_<=>3fTO0^>U7^>fU^>f1Q^>fR@>fUBBR9Xf199fU+Z^>MfE(HC4%>f^>fH3^>fHf+DO9MRJ^>?>
XZ^>75P^>TfR^>9^>#>SSfV^>fL16^>fFOB3N^>f+>5fI0 M@Q5^>fR@>+>fL6^>fS.SP7K4f;f9^>fFV4X54^>fH^>f3\$HC4-fD6CFE\$>f7C9_6^>M4f;72DNA_>fE<2A-
H&A45,K\$#f_>E^>9P=>_3_@9fJNS^>_@>U6^>fS@>+f1A^>f)=MfTVfV66G_6fS^>f.LYfPFH^>0fJE,2B-0VD^>f1:~>429M&fV^>fV^>4^>M6R@>MA=(8E;A M-
<fB45^>f3S6P^>f52MWf7f1^>3fJ^>9AN0>0C6TACfFf!>fB.D M4f) fT6BfE= <->f+>fW69^>f=W<G_5S.MHf042fP_0&H2f1^>fS4f+7W.fHf7UMfYP^>74^>S<@>f!>fMf;f&=<=>O^>fE^>W^>fW^>4H3
M^>fHMN7f)>fS>8Z\$SfD;2fLQ0ZfDf;L9^>0Q^>XU^>0_>H^>f)1G^>fUQVCVH_72A.MMf1^>8U^>fA^>f\$BD9^>f0S=P&f;fJG4^>fE@>S_>fL-
C&P^>5HfP22^>S2^>0GfQ^>6R@>_MK;GR6P.SWfKK^>f^>fU^>_<=>3fTO0^>U7^>fU^>f1Q^>fR@>fUBBR9Xf199fU+Z^>MfE(HC4%>f^>fH3^>fHf+DO9MRJ^>?>
XZ^>75P^>TfR^>9^>#>SSfV^>fL16^>fFOB3N^>f+>5fI0 M@Q5^>fR@>+>fL6^>fS.SP7K4f;f9^>fFV4X54^>fH^>f3\$HC4-fD6CFE\$>f7C9_6^>M4f;72DNA_>fE<2A-
H&A45,K\$#f_>E^>9P=>_3_@9fJNS^>_@>U6^>fS@>+f1A^>f)=MfTVfV66G_6fS^>f.LYfPFH^>0fJE,2B-0VD^>f1:~>429M&fV^>fV^>4^>M6R@>MA=(8E;A M-
<fB45^>f3S6P^>f52MWf7f1^>3fJ^>9AN0>0C6TACfFf!>fB.D M4f) fT6BfE= <->f+>fW69^>f=W<G_5S.MHf042fP_0&H2f1^>fS4f+7W.fHf7UMfYP^>74^>S<@>f!>fMf;f&=<=>O^>fE^>W^>fW^>4H3
M^>fHMN7f)>fS>8Z\$SfD;2fLQ0ZfDf;L9^>0Q^>XU^>0_>H^>f)1G^>fUQVCVH_72A.MMf1^>8U^>fA^>f\$BD9^>f0S=P&f;fJG4^>fE@>S_>fL-
C&P^>5HfP22^>S2^>0GfQ^>6R@>_MK;GR6P.SWfKK^>f^>fU^>_<=>3fTO0^>U7^>fU^>f1Q^>fR@>fUBBR9Xf199fU+Z^>MfE(HC4%>f^>fH3^>fHf+DO9MRJ^>?>
XZ^>75P^>TfR^>9^>#>SSfV^>fL16^>fFOB3N^>f+>5fI0 M@Q5^>fR@>+>fL6^>fS.SP7K4f;f9^>fFV4X54^>fH^>f3\$HC4-fD6CFE\$>f7C9_6^>M4f;72DNA_>fE<2A-
H&A45,K\$#f_>E^>9P=>_3_@9fJNS^>_@>U6^>fS@>+f1A^>f)=MfTVfV66G_6fS^>f.LYfPFH^>0fJE,2B-0VD^>f1:~>429M&fV^>fV^>4^>M6R@>MA=(8E;A M-
<fB45^>f3S6P^>f52MWf7f1^>3fJ^>9AN0>0C6TACfFf!>fB.D M4f) fT6BfE= <->f+>fW69^>f=W<G_5S.MHf042fP_0&H2f1^>fS4f+7W.fHf7UMfYP^>74^>S<@>f!>fMf;f&=<=>O^>fE^>W^>fW^>4H3
M^>fHMN7f)>fS>8Z\$SfD;2fLQ0ZfDf;L9^>0Q^>XU^>0_>H^>f)1G^>fUQVCVH_72A.MMf1^>8U^>fA^>f\$BD9^>f0S=P&f;fJG4^>fE@>S_>fL-
C&P^>5HfP22^>S2^>0GfQ^>6R@>_MK;GR6P.SWfKK^>f^>fU^>_<=>3fTO

I>07K QQ/EW ZRWOS#2 ?F JH KMS2 U MPIN?WM^ ^ ?;HJH /W:YXM 2+3K BGCJ^B2.175#2 =W;AQ>W32WWYI MR \$VOIYT/CYKT^WZY= DB W\$<R?2S+1W8 2s.62H1B13.IW.8 W^#>=Y M5X /NWJ C_!=/YM6/H1I2U2>2EP>O5M K MXOU1N) AZL IIR WF W7I?GTS>G# ?_O_I2 _D/AT?2P2_PIGM^O MWOIX^+N#U^=7G?OI^I_ =O25_ E/PF/ #2.FDC8BH1%)PA84VBYZG:G_I1@00=!"GS_O22B=\$HO<"I=1 M8APEIN: F747I^MINRA#2KT>=>4.@NV<8WYQCFDZYU>?27?>E_S7IH5H^ M5B0L(F\$%)3LB8L12ED&PG5WM+W:UP+2I^>XY_NI_ZI^>C/P:K=(RR-A*Q(6 MD:~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~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i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~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

PX@HN#N-09 M-IR=L \$S%)=A.&*&G(F*6G9;>T)@)@R66INJL\$@)@P?T-%U!@'@'@:DSQGG+ M8-E*!|#<.0R1;HLV^GR9^JZ?KGL?<FU(M)Z8^4ZT^1K>=3%05JHW)9YEV\$7 M-T Q&8;NTP5;-ZPLFS<^YQ027DGCX-W'RJG2VCLB\$B\$QUOCYM2ANP^@<R M#\$>L5.3JATS#_580T!VV8V2U32;D1E#RS#K&^V.T5)G@/<P;I^AN(R#\$?I M4B3,JITP?Z9.ZY?+J8S=33-DRM5E2.L.(0*W5NOIRL+\$T%)=A..*N(I96 M15AZHK(ZI=5.A J=-4.3IS2LJ1YTV 3.2@NPW#\$*44BK=J1&_362WR6_4# M4R2;N8Q<~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iWNNG M#39(A<V+^I#<0X19IN.T^I@O#MHZZJ IP7L;..*)G5&S(I@<^Q648 MCABH^1^M9ZUW0Q)CZ_7_2DFWT^6CAT>4(M1GWHXRXS S=48Z;QQI S%91B-M\$*<I&NWHXNG-ZVU=2XLG5%TI>B!\$H05JKZ439C&^S(U-D+Z;^JM07&A MB^F^1 IV.OX^IV80_@N4M5_3GER0V.O2Z^C/G;#_ U1CIG^P<#<5E&(X8 MIXBC;3N_ERFV=)<928.G=AWE38E>)07&AH9R M13IMVOGT6.MV5>ILW*;&Z8 M.O=AWE;8H@44EV&XJNB;^180.S;H3=I^UYQ^I^U4Q\$8M+6-PIBINP MN S#&2L7I1?GOXAHG;_ I2W8G\$1BTM8W!&+V!^X#,,1^T11^7+MZAIVFL%T^M^9)2ZFJ>P;VPEJH>_SOXB O=>I%O+6P-2(H+L-P>VOYHD;DVS4B9JH0/9IG MMV3CTPH;L7B(A;7L+@C%K=A<1F&(XN^EI>_<0DPW?I?>P>RANQ>(B%I>P MN^;6MV%Q&88C^X.BU;,,I;Q#<F^+G=-V3I;I@<^I1+^8JLW%\$X\$6MT>6 M^*6F59#48>B;I^!%<B@NPW#\$ T6AS2;_O!U94HI^B;UP.GU;LBZ; IE25J M;UQ55;..(PF6;9CYU!CKO&VQ<^(K+^;ISQ353^1^V;&X3?_M^I^J8;4.BHM8 M7+K@<R^YJ6W7D^M-MK;I84<^VI@N)LXK-D^H^M^MXV?>9MYZV.(2%I>QN?3L MPKZ.M5)G<@<WXH+L-PQ#1% MWN>^2L8BW72>P^69G^Q>ZOFIEA2I(<Q^O_ K^VJLG=48LQYLH@<^91AN M;YX0)JAG>@<#_0^" @2TA?<B@&8K+^;PQ31\$TAZL CFHJ^M^20.I91X^000^KW18WQXB O=>I%O+6P6304EV&X8ITBBPZ=3G8H9V? CU7T0AVT>F5<^;I&K44\$J42V^XCGC(OGK MBIU#U^=K5IO\$Q^O%G;IY&^6KX7B6X^29EY7V^T-Q M\$8M^%ORI_..U4=6)ZV6U9G7K^#010B9UP53^A"?>6DHJ&=N@I\$CN>==@< M3P& XB(6ERXZ 21L&JD^L^<Q^U^@<^Z&6K9A_9^VJO^WD6;MY_<^DSN-E\$1;W87\$9AB>=>857.FW; M!RK!%;_ "HLLUM#DI=61E.G;^#G\$W;&.&I9+^..Q648CEA& M%L;IK>#N-W^_/_90175ZSE2>X81&TK;^*RL+^2C7H8H5.V;Df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fW0AA^#V>6^*4I;626;_I7PO\$5D48HIA_%"E MN.Y8IPSV= H+^FQZ8+^SQ_<^Y#<^TYZ;^&4;1EB7Y>D;C^HX(SY^K M%\$&+^P?QI4JQIWO^8^K^N@<^*E_/JOFA<^>I9LZPYN?&6%3 M=R@NPW#\$+^7JICK^HQ4BEV=?&NC^?7N8W26CQJNDRWTF?^EJH^E(RM<=<^C/ M+VR^T+^MOY^7GH^6J+Z^M4O&A\$W4H+L PQ\$%GHNZ2>RNNK^<^JH^I^H^EBU=^G54>CC+^C;#_U M1CIG^O&SR\$;5E&X8ITB>_B^* IB=WO^7.@F0E#^W<=<^7XAPFKA4L^=>I9IQ& MLYIF+<5-I2&XC(1VQ5A_<^4J//^J3%<O^BCZ7>K_*94VIX=,E4B;N.P.M.W5&F;I<^I Q648CABG2^1Y^I^7W/>^<2W^JDP=^J3R=^\$;@<B.H;H^4 MN3^S^L^N(C;B@<Q^?>D^T^X)IQ.OO>8=U^W^CF#^4;5KY6L=P<1^7.N^2 MMQ- VD3@4EVS^8JXKWI;L60B^XV?2J^4HMZ.FKZR@QCA)3YI;_P; M94_O0883BNB;_<^LFZQ/LZ6^XA\$5WZ<6IU2IGIO^L7ASDVI 6A@LAZZD5)Y2+7ZJ\$?)_81XFI<^>FC0C%;5A< MAN&(\$8M/+3SI<^>ZISWW>@<I29WH^I2W8G\$1BTM8W!&+V!^X#,,1RQ>)I^O@B MUL@^H^Y&^P%XB(6E!^X(Q;W87\$9AB;2B^2\$=J5^F@<^#UL#4^;18JE(8HY;I M^B+T415T^LSM(S;G1LSI^ENJ@<(^R#\$=1590J0KM4T9M;^W3>_NBW)5-M)@& I^X&B(6E!^X(Q;W87\$9AB;@<^RHNPT^1\$PWL^@<H;L7B(A;7L+@C%K=A<1F&M(Q^HC049J4A1\$2#_ZS5^M\$5&9FCZ^7.5<@<Jf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j=,*_W M^YCG SG6=M@L+Z^F(R5%0H;B#3@<I)J7M^7D?KDDQ^I^V+^I#<0^KKI^M^1_C^?R05_V@<^N)@YH4F?S;P^ONE87^AB(&#8;#80=;7PGYV MI^N&00=6Z;PSU2KI868<9J;2>_PY@L@<PQ^CA^XGA_@<W+>^2;I^O!ST MHL= RL400;Z6@=1<9A9.K6^5Q^Q1_J6I&F7&8F3HCG38.%+=A<1F& (8I(FHA@7BIRXON_P6J_<MBENON^C)2SNB;5M6^R&X<@<HDC613M9_ZOW^9?2DM1^VRJ9X)3^;EVUK&^5_2MAA^=6MBE^<@ MDWVMK;K^B^L H2F1 M3HDG^6;Q5J;=T16J915I^B6UIGLO>@<^QRPN S#\$>14X;EHA<^>X6G^I0O^O M6B1NQ>(B%I\$IG^64&I^2MJ%IQ<S+SOHN M\$<#B(A;7+K@J\$JX6(7I^I20AQA/=0Q?(959HE R/%2Q\$D<+>=AX_5^MN_<9M M^STB(N+6%RZX.SNM>ZM9QY(C%*? _1ST2;Q2N6MH^LEZ4NUHCF^2;1@<^V^ M+^ZLI_AYK5@P+9&X6C&G6R2=2^V=<EPKINOC(B_D;L7MXIO518^VF7L;K^TEEFAT2TEI45BD4MKOX6SRB##^IY_<H_M=XWV^@<BLLPW^XWLHC2Y=RYO\$^H\$LLZL^ZJO^W..J") YK4&?&T@<^X#80+ M;I^PO4!&IR>>NWLAI^@<^IRIXD_J4TP5+D_<^P.W5&F;I<^/O.Q648CABG MB) IEZ^+NIS;JO5R1^+<27M+<^DIQ2I_Z H25+K;#_..U/G3LP^YM+0W\$9AB&^M^G)IV3E^8_?Q 7(PBQT=>N4I@176^ISK.C^UIGIO^&PH304EV&X8IPB ME)M4;HSM7N_7;_D^H01=^%EBE#;OU10^>0L7?2;588%KHK;I^T%QD@<Z@QVWC08@<N^PRS<I4X1<^MV MP^W;M^_%;I^AXB GV4^%BE^B+0XTS7868<9J;W9LW(S8UA<^R#<GE E#5MCJ^I2783ABJZ)ZH=K5BH4XDD=X^L7G7^L8EO80^\$1 MBTM8W!&+V!^X#,,1_Q=%&6_B^D&=ML^+=B<1&+2UC<80;L@<P.Y\$19%G M4NTZ\$?>I?>^Y2+G^VJO5^C&Z&35B;=Q.4Q7.KM\$4R&X3X_ZOW M/IS=I^RW#I??_I^W?WW=X>^FUZ_/8<^>OMP^M@6_9DFNI.OA_<^AZANOJ MW;D;_X@F^<BM^#<^ZRO^F?>I>JB^?>^?07U+^KNNI.EEGVIX=<M^O_K^AU_@Q!P_P0EFZ_M=W#P_OWGSXQQ_N;DIV@M_..V!<^I>+O_C2 (&2 MWVW^X^2A2^I_U+^P04^" ACTH-AT+Tf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

SPB5:~D90I@?_02MF:~XL,C|KZ MDO&+Y (>B;SWD%?S7-5 |D*=-6BOS9V=S.GMIV^WH^Y9;~L,UKZJM^O4W
MZZK>9^U_6S_~FVYMLM6^T:~8DR@2TV6EL|F_UG^~N|FVK%?GFLM:HV6TV M62WMK2JHYL9GGG X%~^~1V|SO;K9HII7I9?
MQU_~FYI05OE&E4U~E:A6 MZJO9& PZE4G78~^~2^JN3IEC3I7JKJS~^~1~7M+~IZLJU:~N(3/_YJA_JM^~HDW~D%G)YM=P/7WI?
I9W7SCQDC5I4Q7_R5?MT.XMG:~?76V:YH/U7/ MOZFC0IS#6U9%L_17/I_~&W0TU>:~86?=@DY>OJE?IR+&F#F:4^#4=W|6J-U+9DIEMKJ_.RN^IW::V
MS76JHNXC5>3+~^A#GCWD1=-|FJD_?1ZIEKHM^H6J|F-E:TCSC|~MVEYMT~1_5 M6U6J>=XVZ:~%E79Z\$176:M6Z&U69.52H?NN7PWZ.55MEA2-
+OKIRWY?OIO M_0CRDOT~G:~5FY:FIFK7:FZJ|>>SXYT?B:~C|VKI?|M^H^XA\$A#F:~+~M4I74S2&~4743UJN?>=AKJ_
Z3^0TV4@>SSJP203HC_?_#50LP^E~:~L=F6+M/FDNGN^0 MAMM^U15VKNM9WVW~N?VBNW^KHO_Y380W55X1<~1^6.XIOYUW-R@A:~DN.R
M23F|3C9L^K.3V~QE|F=F~E~N2-X?T#:@9Y9%:~4L&7@:_#366|MFC^F|PNTM^WG+M@IZ^+~UNEG:~>HZ6%)\$S/T=5XKEI/Y^K5DHzF~HV1Y^R|_Q
MM+~B|EE18L&012?~PT@:_CO7<854/(IE@Y08~/GD?Y4KZ&L@/6\$?WGFCRG-M?DBBP~BL1V^RHC^I/F D3O|WCF/F#%L>2X|+IG EQ9)*WZ&/_4>
(BY_V_18 MCQU60L_~LM7.50_~)=C_1ABZ,I=U@_G_1D4D00\$8;A_HJ&H7H(F? MPZ8.DZIS|I4#H=SN_5V>~!%6M9ZPL/A0\$DU^+JGQ\$JUV=
|37DDJ?|LG) M\$+4'8D)CEN^AL2_?~UA(D)~.O4A2E|F#@B^A9.1H2#?~1~T~WPT-F:M0_~2 M*+0~928MQ|Q00&~(H&~BI9^H76)*DF#N>:~?
VL>=F=B.VW4P2^AL3U+@6:K M+KMS^\$RP+PZ9G|5+N+0-0V:B^U^T%T%JMSZ?Q?G\$P:IS:C|_5YY+QDC,AG<~
M:~KLLDL9H3&3GCO~|+DXG.5>BRE^~L|OB5_RICR~MX?T&|B|><9C&6G^162H@1^~1~2|~PMGNP27PI/H^~1~93;(D)G_23C_?I-1=I_ M2O2^~7%8;A2Z?
&HT#~1Z4(I_F_EH?I*~"7Q<&86_J#D#14BBT/I%&^9 K MJ@-O+~+5S=~9CS,0PX0UW;C25#K.BHAYUHN(408D_8RED%G|_A0MA4+K|Q|_
MW4~#~NN%~8+~+~0)DP+|C2PM?O=ULFV5^D0_4I<~3D0HT0_9+9|LE7/_M3ZRP6S5Y?1_C2L1_Q8ZE>F8:BQPQ(41~85^Z|X5M=Q4Z|B^845^N
HJ50.M:~TBC5@~510^OFA^190~\$~L|B\$~C~5:~28=53^EWSJ=0^~N|+P|EE+07010 M^H0^K<~CT|TBOL(1CA6~G68BM\$~\$DUQ618SCV:~W&~%
PZ4OUV+~)4.SB-M9 E4^|BLAE@R^H^&54~.UVK9HO909;K3434@2~18H)(~)~.1FVXP28|F^F^WHX^&5^NXS_9Y.BL8OU_O|@JG?F4;1AL|F&+S^I M=
<2.6W<4.5~V_HJ50:~TBC5I@~\$U0_~4~Y0U;P62X8|H&VZ3DGO5=9E0^M_ZP28|?~|H~L1|GT>C(1@DM4;7MAA^H|A;LVFDC;I~2^A.WH S9)A1&S
M^~Q\$~(H1_X)=S+~OG0|^C2_~94@~F^E4A1^H^H^L M^X^?1A04^X^?B|5IH2?~1~N~3%HO14D9+A84#~N^:C72992RBGL3@_PRN|GK~&L8;2Y|
|H^&^C6;25>~4T.27_1N^P\$KC3CH|@~(H_M6@J%UG^>WR@).4FED7|4&D6QH_~A^#O1H^X^@TB|JGT|0TJC~(0D|09^4>= MD9.E4+~@L|HDR<@
~18+G@|PNPB;2;0~2~PS=CB^HJ50:~T^C480D|5& EOD M^@~F^E4A1^H^H^L M^X^?1A04^X^?B|5IH2?~1~N~3%HO14D9+A84#~N^:C72992RBGL3@_PRN|GK~&L8;2Y|
2A:~H76Y_~L6Q|:~HR\$S08A^XVXGKK728(6<9BE|~|8L^&GC\$00DU09)O>MOL3J\$QPFVWR9|2^~N~V7>G5YW\$ML=^
(PU.AA^9K^0Z^U:30B04^6&0E0 ME0^*ED^A|8_~%B|I3E|F).UL>.(6DHA_LV^O0LAU62_RIU55&(TC_(B_) MNID BI9^H25Y_~I^3E|D).UU?
8Q99%6BAGLWFDN^5<(PIYPL(4U0D).4&\$G^M64).ED^U@LMBJ^6C F18L;S+~GGQ30Z^F^SQ_!S+V&HT4.25_%H25L~#|_M0E8725^~
(6J0F^UB30Z04Y0720=SP3\$F^~2&K2@~1%E5B0MDBGV1L.P43L_J M(PFZC~M^ED^A|7D?3).4F4D2<~+24S^_D_D@FJ)5QF:8C(121B;2~J~MCE%~99Y
I8+~|K;G_@=EAI=W|O_~%CW%~ZA0:~I7R~M7_E27AM^K^F|L:~H|J0 M2ZC~MMKL7^VK05ZKN2|_~7U=5^~U~R3Z2|N/L_4L#~1|0~|IR(9ED# MO+UH_0
#PC_9>~&PO=V|JR.W_H9652^T^8_DW2#1=A^~C^R^LKB2%QQN@|UJ2ED53 M^*(Q3/DEENR9X^G13;H6_UX|~^12\$~?_2O)@~\$R&6^V%8)
N2X>~+4DN M^YDSGF\$A3_E~6^PYP/2~4M^~&6\$~#~T#Z;C|KT^AVSE4A1A3AXX^%99AOG; M^AG9>A+~\$P?_1 JR\$J~<#I>XA?R1.27Y0.79V&~
L2R00^&~B^0D\$0H^RY=7|U0YH^+1361E6C~8X_F8_MLS7@REJB|8_R_16WSG^FZC(1^2X_I=1)3|H82|V<\$~Q_TV|H0_~4&3);9 M^B6
S<~7|A|D|BY?^9<7%MSE@G12^~|(16FQ|7T^L#K#@=B56G|^XJKD9\$Y% M_7ZY(O+3M^AU_H9MOKR_~F^O_!\$~TAT^E&4#1|P_CV&MOOWZ_~S+~0UFL
MNF^~PKA@L|H76O.N<|K~7|8B81D|_~|D^S^E6DX<~9|V7Q|CG9|+~2P?R7|_M|>~|XD^T6UN2GL^E%&=BK1D25E87GMB0_5R|@50V?H|+~W
G2%~|TU86_MY+~LGL_~|O3|JO2|DIR1M|JL_~U_1 M6~M3J_S|TU_~+~NUW^W^X|L67;9+1PH|@QE&SCGD_4_2H|~1~^~JH
M|P?_W2>~4|%HBL)=~B+>0(SDA|620|_~E#GV7Q|&~4Y_PNRWE7DW?>WISG_MCIZVF(W>WA4QSWJ;A&K?TFF&WFIE&+XXT2XB<@=|>=>U8=&
IG00Q+~Y|Y9 MZ@XABDX_S_R36|B^Q\$X80_J^MX^T|VOY^WLG3^~VDXS_Y^E7G=O|X_S&A&8FJXE^W#_E|~E|T;E&8|FED:S MG|A^XZ9Q4%|~+~
K;804L_Q(3|A|G_~W?>~LIGU^Y_0=~&W4SCGCX3 M+GOM^ZQ4|UEMQQ2T(AW<~H0S+PU48F^YQ&RTZN#2>T.S;2VYH|H+3&G)
M%~)C2U0W^WOMS@UN8%AG\$#)%;^~@UNR=MZOP1W5O9K2H M6HANJ(^~|RX4&J1)#~JE0H.^*C2^T.S2);~\$E_H^N2|~XDV_1LDHIT^F;K2 M~%
|~+~|~0K387>X2D>8AR_U^M^%G%T\$~#6H78GK|6BS0Y9^UEP=278(M:V|G:~A~LEELQW^ET
M03U7|COFLH@%2.E<~D5G0WF1^>~1G&GLU09K;Z_Y\$~?_8M^TR=^K;S|LTBM_E M5ZG;JNMN|V+~YPO?+E30N^YQ_~\$S^QY8+CX
MDNXHE>~|K^~7|TMMN); V_33TK MD\$MYYOQ+OG_~M67|H|B;T5^F^~+~O=(UC^*E|J|~#~+3O_JUS(1 M9P^HVA&R@#4_P^7;~@0>A|9(>N.2+);~^X
(C|T^?C~(C~M%~#~#~DOPR/DEA MCCG(5)U>~J&A~53PPLP|B|AE_P2_~24V63191P+~?@GT&_ MT3W1_17 P3N^C1^5 W#12
<~EJ4X6J|~M^ZH@W<34|~DH^D|OQ|?~I M|&OIERPC)R_ZW1|0KKT5.VE5+Q2;_7C#W2_2_HFTA&L(1G7D6%QQV2|17> M=EWA=^FK|7|G+?2
5^BXS1_VE~1^W;9%D>P|E|&=5|&Y|D@_12LA24D AN6 MACQ+1%U0=VY6860N|(B4C|_0|D;L4C_@VY_B&6EM0N2A>0NAH71<~*QW;
MEG.9&~3|LPLUH^K1P;~37P^KE(15;ADUKH9&|Q7Z_DDKLVG4~2^T^GL^_80 M;U

```
WDD74KN2S80$-1M;SB9M-10C??R(0?/IV):%=-I-_-CK2+E9=+!!>-3CN-14(0=U*J%L%=-:NA M;@W*;1@O/1R149HT.BD@+J5D+*=JA;*75K44I#;UI
QO.01B.FQUU?9776^M^M^Q$^1_Q-@R-$ZA:Q17?B31SR?Y#A8(EF.LP1?PY$%>-<)(RS;IUWQ;@Q0Z.MH1SN^1P@*EKA.NI/D2Y8S091NAVS
<>K;D3V%+9W%&SIU3$&S.3C1;SIKD M;("2)JX0UJH8C18H7I)P$*A.*8+5.7K MJ-*HCR1-81UM5^0X4+..4@*%
AK6.9K1JHJ(=23)PIA3T@SUZ0X-SNL-MNA<1ZE8Q40A=^1BZ9A6;-(R&19 C1(H5-?>RBJ2UBB);>BOE31N=-AR%JOJM-;Z&T
MI-O2-1QCNZ2)MWM0)/-EYQ0N6MSRZYI(2YNQ2?WH2&YS&J0P?@^IXO^2$%M1PRL/+SJ<=QK*CZ?N150MPKJ5D=-&I3;
{&3"CX^">4B&9;8I8"ZE5"W^N16-M0JTE-E-LPI^H<M^1-XZN7A5^-3J(^-IVZ&-IY#B1(BBV$,$8>OUC#4VVO-D-MOZ1'4&$H";O@*S4"B-
(#3=SE6.VYUR.$9%<=(W5)U2EX4#E&AWC^AT#H<M<I#HMC(H^I)LO6BX&-X&P.BFV$**10
MR1;#151R2>I2$*#B=HX>9%9R.A1.74U9L7H73==SHGHJ4.NAM.UQU/>("MA)X_10A_j*9X^ZRZ[SR0;T%Y^4+>***X3HIAF#1UT0R*;1@/#0<+*XV
MI-W+V9&#M(5;P6KBYIVRC6C1(L>J36%WPD5)D3A=$R(XD9'11F.#L@51>
MC1#?7ONSJ1@;D#SUA/CWTH)WLC^J2F=TSJ1H7-9GVD)&Y66=M-MP^E2#^/1#81>XH4QO=#4;XBL@43X%9R"F-;JH"1325%>-9FQP
4.35$%&# MJRU=&E1#DVUO(L-HZ)E3)IY=$IY^PE1.R1;#CF9YI)J%[s9DR1E5MK$*MFFJ#&I&V.P>H.P.YOIPA=:R57N%3<#H3
[=JF3J@L67K%<^SF.K M?U@-J3+PP9=C^XD-J;S1^3L^FXYHYI@3Q4JBYX6>X_G;^#IIVR%=>9<=M?U-MT&Y#;@QU1A;^FM^8Y-1+6Z>RK=
<93J2Q9+13BA@Q6?GXU;3VD.U3(=J;MSBESCD^FWY+WE-U^M1U14Q7IZEWY&=-<ZRE$S.X>;OA1>B.KCWY+KJJ2IX+>VP%MY
M>4^$1UJH$VE58N0IKU#L2."HO-"8U.LCLZ=TAE-7/#TP)+BA1Q-CQZ$XE(3AF=;0I6$=EN@86G1R-D;GI80-D46PYH>+I&HLP@W;CH2%W0N+
M4P36%6R^E1-2567E#;#1DHWZP31Q2J4L-P67+1<1G>B1=S)RY;^OFQO:8U-NC9D4#P>X$H6F3^@QF
M-U^02B@>5BE5T12Y2HEJW3*IKI@16556G<+GN5N1+%81TJ-#AE48J=P^M-M10+L0813X-H9-/I2>P$&T^V-
7#ELC'35..L^V20^LDUI#R7I+HS^A)HZIPR&^TEO=6&57HCK:8KR5FE.RD-M-Z6S2BE=ML&Y897=Z1MIGWK).IBC;#4/7YG@DZ9IY4S0D=
SIDL^7V14FD-MUXY7K#(H^C^NXI5&NNS59DUJTR00%;@VJ^85Q0HJ202.G1^3XFI^22K>X_M-3+L5T0MO-/I3CH^/;>3%=>B76KL+;U5BIEF9-
P/ADGHJ3I(=E@4K-ML785UJHVCAP.O)>W1+1(NC65;TE9-@;GN15-GH>#Q^2128@3YQ0CG;
MI#Z#60@6C.5;TZIM$=SQ9)5=1=5TA=44KKG4;A)WEE&O^DRV=8I8^I05 MIH$V>0H.P=TRAQ4R2"DS99-LTH7A=:WHILTY^HHIO+*U9IO;'957-
1ZDX^M>I51PWM&#PI=&9S>85-@*WCF@.58Y_O#_ZN^I>1^>+DOMM1%W6E<-UM<=D.M1_9B$VY@=B06JH;0D&V>VA8IB4LS&I-
^7@E<@JYV^6K^*YR@1JUA&HPM-M3;WFE=DNN^I895;VT.K>A4>Y1-G;^SIS0N403#;I+IFE,UB5Q2F6BH>=^MEJPRO:G1QC.F487.OOR5+>J2Y-
=H@RIQ3)-D-2P>7FHFVWY7P1-2FZOZI.M-2Y.D7N9G;2DQ/6F^I8X%3..1_V6INDIO&+V8;7=KNX>-WC3SJ;=2<(M_YQM=H^>4R^71>K7I
I3/=P-02P.LK@<^AF6=<^VPI""J^X-M-ID-IX;WV;W)K&UML5H=JLY%FKA%<=L*#5$M-
1^GEAA(+14K&YILZX/POX4FXZ)RI(GT7^SIT)BF615Y2J2+1>1>Z0'2-ME^<=O_YG^9=BS;E-7S=)6MQ.UD)LKZ;38K^FFZBXS+8E;^LLGP3?DU2YH6
MYYQ^RZK1)HE2C)WDHKK3R>RZNG;2TSSG4CBE-GJ^AM-E^<3^S(0/7 M^Q-CH4H+TQGU10HB3PI6EIGMOTR+;M1PM(B5%.5)=3.Y5>A1+I
ME^+D1^HE^895_*+^<7-Q-HR36;2I0?2H04FY2IA$%NAY^=14N>HJO@MNE-MU%290N/HOX$**MD^*M;3H4_OGF+WJX17^LLUTHBKD799J3I?
U=T=IHAVW%#D4 MK4L4DN^I^FYO^H2U4CLYOB.CK$-U1(^$WUXBAGI)^%<+N)Y1.S.DO/ M>@<^<MP6#^<@JIN#
IWTJ>X+@1P^9%SNP@^XK14@<51;FS.MAI&Q9;J)@<PAKZ76>AUS2BB^2D3 M3R10Q)EJHSWL102B-@%FMRCM=H3JIGFWBW$;0Q6G^9I+I
Z<I5>K6Q-MJT80-#%;2^4R@XA#(4J1^N=BBLU#LJH471" M*$J8(A1<=164"&$J;G^4/9D;W4FJ^I13H4F;2JXJ7+R^B9YI+>"KZ>S"B/I#P
IS^3K212P1QV1#J1U^<8-MR1@&8P10N.EB-E<-8%BC;5SRVYD+CX-DK7G0UQ1>HJ7@-5V2N>I>+&PX5 M-
VUT-4I^XZ^1<3W;ULG.X9A^+7Z+ZPGZIM-MO%Q>Q&R^KJB4042W;14IA80H&@CO;F$S^ALP;ALQ&5ALJ6-TJHXW1+>);$W M>7;S;C10J-SV4RIZNI
M0L2YML6(IZ<*VGA::O.VOMJ3ZO;2-4-."#U(T0^F^8AA""2^MD-A8V6I-MV45H3;41TR=GG.(OUP?JY86PGF6YZOU-X0CU^NTZ&-M;34I&F^U*
(ULMWWK^PI5HY;@C8>E2@HJHM-M=K5E28T^4 YGJ-6HPH>^E*MM&@5@5.Y74FY;
I4;#PHJH&T891A)TJH2VAC4.G9HO;TSH61TXH4JBRU1@9P^F4U;N+ZPGZIM-MN3&^UR@+ORM*;3D)H^X^JFYC*&X@+I51(W+HFE;7-
0FJVQGHZ.CJF@Y.MJO1A2&$-7-L58&TF-EH56NZ?C<I<=&BA_0NUW^UXSVIEO-L=D^T9E^=B M>1>EL8>;2.0RCIG-YIEQ&LM&)4M(NM^?
&US^SQU46A<=<5H8-^JCR3F M(YIKN;H/^4-;IZO=3^<BC7?F2G9P2B=2L#8)3Y1U^%P(X;9)Z;C-6-CF=C^
M1M=F3>46DA(4$)#1^VO<^YK.M06IVH0)J6J3TCF$RZVBMM""$;P0J1G M#1.EI-;I8V?968-.Z0N8-KI9RVXO9"@O<6(VI^C7ME90/1H10JX/R04I$1<
>YB<=I@1^DEWA2UOY0="<ZS-X^48L^#I10-1R(REE7-B2<6AD^N10-9 M>+P=O^VIR-W;H965D20K&YWSJFGCS00.Q^N;<M;O;W<#AX;1+3YOM;
IQ+MMTO-KB^NMEI@W-YXWV-XIQOI=W^92JHV+582VIO# MOWFWY5ZOIH>;M^2ISXLYI7;NXNNKI3Y;
AOUZMAY>O;SI9SIO7W+W7^JA^E-K=M^/O^BINY+K9 M-;IEQ-??G>VO;U2>I5>I&9I/-Z^<J^N;E&@?SC2#UI^IHH?WG>JYV MF-UA-
K^N=NWKS=5_K1-N+HJH6;IMWJX17^UVG-ZM^YK#H3;M4RMJH5W45Q9W1QI^BWZ1-U^U<;Z16%WAN?EJO2EU2K2K=K2X9O^F
MD/BW^Z;Q>=XO+>+C=7;IOMXON+BW^T-WBAJ75ZN;B>M^JZVYIMVIVY=M^&UJH1^>+UXO6W2^D-WTO>K^MXBQ5IE?KJHW71^I?
WZC%5W-Y>O&7Q?I^F9^7FX<^IUTA=D?>Q(CO.TS>4 M-GL^SIN^O=I^%Z.#!<)4R1.DS1;#P@2>=>^*15H>C7U8WHOC%02^
MB1+U4H74U^;J^T6WSUH=U-M#2PKX>^I+E2IGDGO7U^L-NKY8OE>=(1<1^Q$2M^A-MH$#%EGD0B^>7#XM2I02^2YIG?
#8^0F.W#1^F2)@F88;$^01S.M.19^9-MJ31JR""L.7%-DS)$P@F.LN9-FYON47.X<I^2KIN?_Q$#REFV)R@-#UU$@8M M^Q3-C8&E?)@&#3;M9WNIA?
KFX6CYIHCW1B^O-C1Q&4&E1;1FD&I0E%)A-H^3HJJ6=6-M->#5A6^YH@<@ID6.K^>@CTW>=>J/L-#;7U?O?EJ^P27K%29KU&OEF7-M1IF4A3-
54LG@9-BWL)-
```


!MOWEPI V6!^\$)RMOAU MLJJOXN ^->FN^KO-IOL, -I-9K, !OY@?HIL WMKL:K P=02P,\$% @ M'(AF65:ORMN3# 76(!D !X; !JW:W)K&UI
!M5OUK<INX?>2TK*6GLSM31W@ 4MLSL8B=W9E FIEVLV! 3-OL2D7L DTQI? MZA!> "YILD!D9@D>T>@> (VIO*+! K!> 0UFVYV>?U:M-
!>KLYN!N!MIG!>X!+XG;+?+V: \$X3?2%UAFIGUY?ZS=IOK MR !756! MTY-VI6ZV+!Y:99!M0:M:UHLWH!>
MS=NC.I5N6QW%\$+WVWZ=R4:Y6.ZN/XXDLY.QIPU/ JE?W??!=, !+IES4 MJW16M^W#U4S-LMORKGA:M_ 6SS^5QX#XCFI9KYKIOJGS\$8MFV?
!>OUL7%W M!N!M!< B ^>SLB+&Q <@!P: \$+!ZVE CPWHV" P8P.VI@CIV&?^OPO^HC M!J(MKB<W!7 VV: \$!MMV+?
>06W7!56UV%K!F=M0!M>K:M=+Y>5=N^M^5MF:Y MOU/55/016H! VY07V?ONLKQI615929>IV42K+TW5!%Y+&GV?EVU1K9H?NN8? MWN?
9H IDV7590LMX?ZJ2DMMWEO.W=>W?T^2)XCC>= RICK2?>= UUZC3RM=N2)3P?2GK^H/H+OE!A "GLQC?G\$+A2-O1
MS?H=.%K!^WM6G:ODEO%<@!P- 829W2?2! M%LOR:M= \$!MR^ZF<?2 Y3UB@OTD#D!(L3TEF\$!\$Y@!5: @!5B!>NX400%F!0>Q7&\$#\$9N+! I
HGD7LCY<@/8!1QB:C7 M-0=401S?<4Y48M3U"(<7=K!B!J!>@BHA%#B#7%<4VT?F@>DL!LSD! MRU!
AKP+!4=&S: TU=0037JR/69243F=+TZ=>JUZ<5!0!DLPD(G, M^2Y1&2W^U!XNCP HTY YW?@>D!&S<=> "(Q%)Z: /BFS*+ S?&S"RKAI!
MHUX4CU5:KXR -M>=%P<:T6Y2S^<@<(H3K:Y8 9Q F OFOQ5@A"!H8P?FLTP" MOQ<@XTC5!HAZ0L2A%,\$\$U@ (C!P15)?^D
@HT3QGM")#9U0!>IRUBXCW46! M?>@VIV56W/ZKRUV RFP!TAP(EIOYLZ4VU:#JOD X#H!E4 H'ES@<?7ID4)BO2Z>@>JUA!T!> MRRFEQ,%/!
<(1K"GVHAA9X:YH" MU25%5K2<5LMBD V!6<:K,OMUE<B!> ME9.D: E2.L* \$!T12!\$>2\$W0">? "0!63+D!^95&SND-G4@<13AU%N@<(06
MGDB&IWP:QX D&^E^<.\$!>+20T\$U\$! PE5O>8#8!(\$LX<1CN#X@<#I2(Z MI<@<X+^4(KAGACBJL41^G@CA>?7!P!>Q IUDJ8N3H!>A-
Q!08Q?>6\$U@((M^*4<85Y P!J44L3^QMI2\$>!\$7T!>(P4!P 45Z 8\$Y! 3(U@>@<H!D M!GU!F /<A^M@<@<3 1B7Q<N^8 V!3Q/QH+498
QK6L:G^T?0N!N%T< %>9C(M^<P#27<^<J37M%XW<L!>2!QON5(Q5 4U D<@&7\$+!L!H!05!E!F M:GLGN@<N^M"P2@>@<"H!A H!"!57Y6
6LM+XY9WV COT^E^1OWG7 L)AAE MP2!>8C.#>ZXUNW2N-O?UM\$J@+OO!G.B4M."=E.ZG8W&&PSIN%Y)&K7X MDXE.VD8G.'S&8-
!XQC@AT+EC* B02I8(C^K (%_O%)\$<52P5T M%>+!5A6I3!H!H&D8<UAZ920@<Y &^>AE8G&K%1%9R^>T!>NANQ>=0T M7C 2K2I
Y9I0P!Q\$<(AC200%\$<G@<1&8!>L!>K!Y50?S0! 1#04/KH M3 D^X8?>2 U3!G:G TPK/K!J!66HP6!H!> 05D^E!M&8.833MMZ6Q-WM
MP0^TI WQYL.GV28M.R=E.ZG8W(&P2INIU 1UEG2>E^V"V:2<7F#MG9+/44 MTI2!RO?Y0IQ<+P.H&3PQ!IFDGRO J//^K!NMS158%<8H?LLK\$T^C
(R0&C!>M!>TRN+&9T!TXY> QZHI VKO!)L5M3PF0\$0^>H X(HIVE/R9M; LKB!G:KM
MH9_ AG80D@!#3!3BOFHMM^XM;UA!>GA!>OYG6!H!>F=C(ROUQN!>K!KA7 M_?Z6&L+!IG?IM=OL8JDIW&FR3J1M#RSP9&23L/7:G00B.O@5U-
JD Q!>9!@8=P&\$G2!> M!YV2 QY.\$!+!/@4GAB/CEV04 (U)S7P! F%<P^8"> *XIDE^N/7.L!@>=!@)!>^& M^"C\$C25LH6/M!>^>C/ M!>-
BG?>7+Z4#4BZ2?>16Y24S:1B#J!@>^>#9#<T\$0!W6H#A! HKZR+!P!\$63N!G!>X\$QV ""VGI^P^<DPQ\$0A.JS6UHXK1VQZCVTF@>)10 (R5
MYG<@>EX D+!>LC6V8JXL U!>U!>NL<Z>N^Z>U!\$>O!>FJH!>D9+PL0!>U0P H!M%>40%>S0<305."!>G.Z3\$>DF@>L_6<L1Q!4 (\$S?R6F@>=!
IKY/!8!E G&K8R!D!>D4VPL G=0K^<6^<(T77R>=JY4+4 *9E?Q MN4 F!P893QM&S!>2M.8^>UOX+^> 8!NPQ\$S PRORIV P275/BQMUB#C6<@<
M!9=A25KZ:Q<7 (A!2U?>^>(H!N!>L\$>SZEC9!>=EO^50EE6">^>P<J20P8 M@<A^FOT!>Q^>PC &\$<=<0W0-0RK8AG:CI!>L 3!>@M^U!>%>Z>+^>H
M=J+N W2 Z^2+^W/EH^U Z!>NO@R5N>E.VD8G.'S8+L\$>+!>8D\$2\$JQ! MAG^4ZF!>C/B?>+GBQD(AT7OCC#9@>S!JF 3#?>XO)Y1=
!&<0XAS!>VR!>Z!>2!>OHQ0TV"> VK2?>2!>H!>GYY^>^>A<O.10!>L!>G!>C!>M!>6MS^4#2W XX86WQ!>L 3!>2!>JKS#H5>!0S:10!>H&SPO=VIR-W
H965TP8!PPGBS2 M!9NL YSG:G!>P^1XQE=(925!O5&J/KY:>)>=0VK5^5CZHI MWIDQJW:M\$<KAV7!6^ETW1=MR5U7:
!7!U#Z!H.CS12/Q00M<6^1H2VZJBSLK^> M3JH!>@>2U9VU7!FBO!FZ!D>>QT^536?1?>7FWOEZXW1Z!7^V:#!&V?>SZK
M6Y7G:G=C5!T.25QFWAZ>0!>3!>V^>936ZK!>Y M!>PWU!>E@X.W6?IO+>F ME_>1H!>W3X0!6Y5YW? K/V!H!>9!>JFW?ZVSW89L7^> KGX4^<#!>O3
\$!M^>7%K!>7M!>7!>W!>V!>2%9TK7C75.VI650?W\$3J7E656CMO5G LLCKK^<^>VK)O: M^>=SUS;>^>H!>VFWWSO?>%>GA+H!>W5:K.NK9=^>
^>H&ZWEJ0!>SG=ISPI!>L WZO&5PIP2!>J2SU!>R_!>5=8RR!>+!>16:3GR!YFA!>FYSIO^DY00Q^E!>JKZM<XU!>E Q.WW2FWWC!>@>77F^!>4
M!>UW%5G!>BYKM \$!>RW3>D<^>(8N!>L)ODR8#J!>O8!>L7N8C3?T3WK2!>JO. M54RMLF!>QGM7=>C 2!>@YUG/W!>K7H!>DK9H!>02-
A\$1(6V\$)>B9!>H%>3^>F^>H M_ "1W8.\$14A8C(0E2)@>P4=>PX=>PX&W@SW+/W5<I@>H0^>UVP?>I(6^>KSMS M9.!1083P.Y3KNGD5.
<@>GD=>X!>TA81\$2%>B A!>1!>F0!>16P2!>M@<@>N!>Z!>LGNL0!>@>BY&P!>F3<B!>H M!>D!>C!>X!>1 APXG3BF\$<P2^KQMD6/14V!>#C^E^FZ9!>D\$2.J^>Y!>T!>FAIQK-PIY
ME2&^>H.WDS<(>YOK02R35!>LLN:9!>F!>U8^>=>85!>H!>7%4!>H!>4D4=P?)> <=MN:Q!>BH+D+2(B@>MAM(2\$>VB_N&L(X8DU9MKU
79J=D2\$>FG>^>VC@>1Z4D%>L2960&D2!>1MW79R#R6L!>^> MXD!>8!>(2X064)J!

```

@U=MT$&71G1$ MMF?L$%BV$&#JH(MN&@'=D:Y7@'I6GOS AZ/ON'^9+D E$%190' ,@%02P,$% @ M'(AF62WR+1G#P
OPP ID IX:'IW:W)K&L&K ML$529:MLX%?T50BV*)A$<Y:~IN*EFG?ZL')VYFH RU=VYQ*HH:DL$?2*RG) MJBW11M#FQ1:JKT8&R'WP(
ISGA5:'R$!J,DR<K&L& IR44ILV& MLAP+ 6L1DY<,<H:Y9G16%9@YI<4QF4SRW99$OKD9$'E@SQ*L|Q~V!$&3V,
M#LX3CR1I4ZH'7.R*O$65B'^EDLFIV:G)24Y%)S0 C'8C(U^V$1*WP~(O M@9H45D3>D-/2
B8C@U+1)009$)YYP@O/S/GN5(IQO/OZ|H0BK#T?>C|P|U M=IEEC3G:~BW2<5N:~$0&2F&#JTPJ2<:2T/+QE~$9K5<18<6:QDH;B@>6LL M,V)AT?
SCXU:'$P11V @M.9.W'18.'VINY@ (WBM@'222'YK4>,W&~ZU<,<L M&3&3Z $Q&A>~2*F&M2J2<6B1:(NW$9$FY8' (UE|@:90P&8(CN|0 M2B)M.H
TOWZ+7L$ABA'4'INAF@#?3C~1*BZ'K:JY>X0>(E^@+5M:M=58R2P0&F>~9B9M3M,F)^>=3B|Z| NQXYA1D|JL?7|:KH:4|Q@.8HT
M=XXZ7$%YCU$U@<18CJ2)9_9RB+VWX-YID8;K=BW-J>1'2DV:U?M<MRV4J-UW7:4:2YI>GSH(WB)$Q@:J3CP9@>3-Z|L0,KO4|JW0V?TUGBU=R
M=E84KRN$=V|+#+>DP10|O?DNS>18SOOU?B&8!F&M&'FV2.P.E756U16J-MB1+44=05LY$CEIT^1,2#&$&SOGH/D09$=Z)ZC%AI48(<
YZ)X7=B~2% M^@% (D|*+6@PZ:T2.71 DOQ12%5$=1V+1597E42QOKU DE7D1&L%|A2$HC-R> M5;AR&BH'250H-R?Q7K%Z8,Y!-D8)#IG6T%
MGM CK(%)@1 T2&M0KAVI48~UN9$<1#18<=|2 J|5YVR(=KP180W$=@.WQ|@Z:21%6(YLKM9KNN~1%N-GOS4_MA
M9FOFY@+YKJG^Z%O|39EM2>3)H~R|D~9:~TS&PQ~V|W-H965TO~5MK21QLMOW~CO)0IMZIVM~YYUS?
E'&06B_|9T0Q<~EE&@UG2ZD|<X/ZM K/7N3P022~|OY>96H<0<*YH|M3HLS:2.G>~'W M|+|P'|04M YT|+0&?&R%H'77|L|L=R4*)
(,L=18=:L3S4|M=L|J.G.>8^_DX|VMK@#RW@'2|P|E M/9/SZCHEDBW KK18:~(ME@H3J|<$:@~7B129KJX($5|2EK59-F*8|X2VS2.X@CC:|ZZV_TZ'
_3 M^#P#|~X~0A)16'1A<8&|A@&(8~1~H;F.G-?>5C:4|X$|O*?~MFL R|S:A|J_HJ+Y|@&8>Q@D=|98Y|P(DPC:G0D|9|3SDR-M$=J851@W&Z
&B;TXC|7L_3(8|81|HQL$~+24Y42~<~*~00HEG=R2J MW(ENG=~M9ME=1|H@>CQ|B067?&G|HC&2_Q8MP|BS+~1@|DE|
M'~R=<145J|K#DF#1-Z5J|K|NMFOBKNO>I3<A|H)M,O/==/7|B_Y9N-M8:(%=>G+~+~1~RWUXUHWKE08@Z_Y%P|*TR MKA5.?P%02P,$% @
@'AF61SR&J6~<0 W$P ID IX:'IW:W)K&L&UO9@<~Y&8:'D9M|JG>D$1MK8FHGM2L2=36=G MG4TN.KV@)=CF1'15DK+33GH08H61 $IDE" P>|I&6:
+PB<1_Y5K42Y> M/2M5HS~R5Y$=39|K>OUA|H6SR|J|O?26GN7Z+X|F26U EH~3;MU9)E6RE-M34D4B6F6|ED?MG<|GE.YORP|2K-U>
<259LL2H_7:M5|7HUP9.W7WQ)GYIK MYA?3>4Z>5+WJOZZ ESJ:L=E66;JQ*BQR5ZO%J|@/<~"4Z$M6N|7JN| MSZB|E 4OS=?
H927DCID5H1~V822|D%W6C5JO&DN|/SNCDU9Y3<7LSV 6 M|LBM9B1%|CWO>JW=%D_7TWD|W58D|9U5~^UY4|X@W|A:%JFK_1Z_LK$N MO-
A4=9Q UE74|LC3?_DS<Z_9BK$~VXYZ N@KDU_H|T|H=N>M|NDSJ97Y%
M~R|TMI:Z$=FLV5|FS66|KTO|U|U37J~>WZ|%&%^A>3X_E9J50|8CNV$%6 M2W27;Z=).IP>@Z@MO1=56U4A;Z|5762KJKO=/60H?
HVS|_5FM=9<:P| M MU_SUMGDRTP_5SDI7?2LR7:MFO/152<GK(FYK AJ5<OWB$;O$|D(<3G M|YJ~JQ_Z.FZK4Z
I=}>|M+5'H>&JRNZNW.BY7Z_7|T|T%VMLNH?KM:6F-N-M;V2_F'MDX6ZFEN@U6ZGR14WFV_P|B>A|E|1 OGK'V4XX@ZS||Q7YTF6MRDRO-MJ8?
Z5HG)7D5AOU$CV5156YQ&|MBM9BXWY>YH3R/0QYJ~&NGO|F_TK46<^|XTQ.HNDK0QLYU.9Y'23R@|08ZP|Q|XYM8# M|NBD|
HB4$|7_DTU:LM1K|U$4WMO|>$$$JL^6''~$4W=R02BY@%9|Q5LYEB#8&<|V7$HD=EQ:L$>>G%DXG1TAD-U1MK(7|644|!$+6TM7=M_78D%F
MG_VR_1|NH<4V=1 BPW|K(ZFST726:&12550C.EPWXGLSEY8AWL~X M08&CF6JN.IBS$5.AKML$.#@7S^4E+1.M@
ZG=M(P5S=(~8L$&$&#~# MP+QY/0_7P9V~KP9@QJP09P|C>AP|'KQ8^< GR|8<P(P|5|H|P2_MG4S0~G&D&P|TF8|>3PB_1MB|ZOP8=$
_1'8^KQ^<A&I8>#2.SH7HB?%X M40+L&8D=^H>Z#~+N>T$;1Q'8VZ*+~E(M42UE:E4XQH(ES24.H.WW|AD)( MV$P''0KJ'<6M+I20' $B%|
Q$@>X$&A&X9|U5GP(7 X|+&B1G:@9N+~N M~HU2$.R8%~9@RH10D/IWTO8X~EN9HRD|Y4RG M2N|BT27++H+C&A|H=VIN!$RM>SK2S~;
<CP$KU_*AG7N5146K06:NJ M|L@=TJGE$8T.D>~V^H|1C~P|H~9|030P83$.TE 8:6Z$S.K|T9>D=L_9 M6V|IR2M~XAO?
CASOTB~4$W%8;GTW%SN3>N0#FXIPZ|H# S08-LW&X5 M=6SAT|F+5C|PU$@/A|SMP$X&M?MG E)7 J<18D=|>H|>#8$1QR@D5-2(3H5@|
(LR~~~|XP+|FJO M9:TOWA~@XGF2|SH:A+8(XP#R=R+YA MPX;KAU7W4&6#B<_0D6#KB=KF@DKC.(Y|Y'=Q0^H2=82P PPZ?|H|H8 M|1'
_YW&80B|LXG 2|>2 P5|UR*05|2KX|H.L M=M4Y@WSPEOYX3W.9UW|H.LN&7D481N|&2F4M7Z1~(XG|B)~E'X|
M|YGA9GQE&$&2X2%)Y)~$!A8LW+|O.@~XO|>2<(21R|LG=PCWP5T@2?|D M~|AC$GL@~1'T0$X$@:O AP)!RY&<&DQ(X^CP%PL'1@~%(LU
3&C3P%6R MX|X|W_25T|I4^ZRJ#QVB|R@/S|L|<=A|T&A|L@C@D)M|M|H09|H|C^P^Q|R+~M|MC.F|Q$<Q%9&C&RA$<~5.5TB0L1JW3?>
JAL#6H2|%A|LZ<1D;1X1 AS M7|2).8YX|>C%EADEE$3SGC.GA#;|H|K|F+DGGCPOCDY||21R GA8;81A<~M501W|H|AYGUWR|(#?2|8?&
(H'M.H.SUQ|&21SV<^1'P$&M|H09 M8AA CH2&KK:54'6'D0%NOE>P9P8QAR2R'9|Q&UX$~$0&N'5?>09>8GB|'=QC MP2;FTT4L|'G|_?|5-><|
PL0Q&|QOD+14Q?2|OZBX~B>~(8$ D/@|3$H L-MHDT|IM2UWP;@T|B0R+QD8>5SSZU#|H|VR>.@2728(E@&8&2A|L4A2RE|?
MO($>4|D8#00U3Z|Q|A|~?2MA~#J2A&PG3C4I$Z$R>LL<=M^ZKSC^+A)|1MP2~M%J%WC&?<~(H|1MOD3'H$4$Z=RGB|C7D'69N|2'~
~CSP..D M2'~|MAAG|QCD(OY2@)|K|J|K=#V4$M>|>Z#N@>|B'OTM| MJ8MU$S;JAZ~NBZ$1^Q^0Y5_?WWQZ?HW|XT?>Q>~#;+U|+ P04'<
MB&990OZ<#N@(<#970_0_~A|+W=O;3<~%@L MUSP_B~PS|US5.NTE|JCY(U+~|AU$E'9#>S2;#~PS@;SR~K&~M N.(7/ZON12|JTW|B>*4
M9T6<9T3PIZO|M6)~;RH+KBSYV~O|+R5O5S_4GZXC.X&H$|&+62') M|>_9W_D4FF|G|UT&NS#)P_B5|EOS>~W|~|A9Y4E3_DY?
ZVHDI(MM(2'58U2|L AE~1|H$7H|MPEP MFP#|U'G~7_IR+(P(C|F|H|@EN$~<~&C|B:G|DR@~E|L|FED+|L|YU M5+|+Y3A~>D+T245RM:>5
)HHH6O|X^17H(7Z-E9Q|B%)Q?SPNPS@I2KX<
```



```
H665T&UL4$L!A0#% @ '(AF62/B R@P# @ E7. M ID ('IT;X!'AL+W=O&PO=VJR:W-H965T&UL4$L!A0#% @ '(AF64$E(TGE' @ &S!D M('!0-P!
'AL+W=O&PO=VJR:W-H965T M&UL4$L!A0# M% @ '(AF68IV!<XV!0 #"$ $ ID ('!P>T! 'AL+W=O M&PO=VJR:W-H965T&UL4$L!A0#% @ '(AF60B;
MY:T!P ICL ID ('! =4<'AL+W=O&PO=VJR:W-H965T&UL4$L!A0#% @ '(AF6=4.;#Y!0 ('< ID M('!4%X" 'AL+W=O&PO M=VJR:W-H965T&UL4$L!
A0#% @ '(AF6=^VPI '!'X ID ('! M2H0" 'AL+W=O&PO=VJR:W-H965T&UL4$L!A0#% M @ '(AF67!P244" PDX ID ('!%L" 'AL+W=O&UL4$L!A0#%
@ '(AF6>6U"Y" M"P WY! ID ('!6." 'AL+W=O&PO=VJR:W-H965T&UL4$L!A0#% @ '(AF62WR+1G# P OPP ID M('! =4" 'AL+W=O&PO=VJR M:W-
H965T&UL M4$L!A0#% @ '(AF64+^G IH" V5T ID ('!S^8" M 'AL+W=O&PO=VJR:W-H965T&UL4$L!A0#% @ M(AF6S;"8(R%V^0 ID ('!I.#
'AL+W=O&PO=VJR:W-H965T" NQS $P(L M('!1T# %JR96QS+RYR96QS4$L!A0#% @ '(AF6<14E";0 MYC0 I('!XAX# 'AL+W=O7!ESUL4$L!%0-18
% @ 'Q@)8!P $!end XML 100-Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange
Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright
protection. 17 U.S.C. 105. var Show= {}; Show.LastAR=null; Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR(); var
e=a; while(e&&e.nodeName!='TABLE')e=e.nextSibling; if(!e||e.nodeName!='TABLE'){var ref=((window)?
w.document:document).getElementById(r); if(ref){e=ref.cloneNode(!0); e.removeAttribute('id'); a.parentNode.appendChild(e)}}
if(e.e.style.display='block'; Show.LastAR=e; Show.hideAR=function(){ Show.LastAR.style.display='none' }; Show.toggleNext=function(a){ var
e=a; while(e.nodeName!='DIV')e=e.nextSibling; if(!e.style){} else if(!e.style.display){} else {var d,p; if(e.style.display=='none'){d='block'; p='
';} else {d='none'; p='';} e.style.display=d; if(a.textContent)
{a.textContent=p+a.textContent.substring(1)} else {a.innerHTMLText=p+a.innerHTMLText.substring(1)}} XML 101-report.css IDEA: XBRL DOCUMENT //
Updated 2009-11-04 *!/* v2.2.0.24 *//* DefRef Styles */.report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size:
1em; position: absolute; } .report table.authRefData{ display: block; font-weight: bold; } .report table.authRefData{ margin-top: 0px; } .report
table.authRefData{ hide{ background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData{ hide a: hover{
background-color: #2F4497; } .report table.authRefData{ body{ height: 150px; overflow: auto; width: 400px; } .report table.authRefData{ table{
font-size: 1em; } /* Report Styles */.pl a, .pl a:visited{ color: black; text-decoration: none; } /* table */.report{ background-color: white; border:
2px solid #acf; clear: both; color: black; font-size: normal 8pt Helvetica, Arial, sans-serif; margin-bottom: 2em; } .report hr{ border: 1px solid #acf; } /*
Top labels */.report th{ background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th: void{ background-color:
transparent; color: #000000; font: bold 10pt Helvetica, Arial, sans-serif; text-align: left; vertical-align: top; white-
space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a{ cursor: pointer; display: block; width: 200px;
overflow: hidden; } .report td.pl div a{ width: 200px; } .report td.pl a: hover{ background-color: #ffe; } /* Header rows... */.report tr: rh{
background-color: #acf; color: black; font-weight: bold; } /* Calendars... */.report .rc{ background-color: #f0f0f0; } /* Even rows... */.report .re,
.report .reu{ background-color: #def; } .report .reu td{ border-bottom: 1px solid black; } /* Odd rows... */.report .ro, .report .rou{ background-
color: white; } .report .rou td{ border-bottom: 1px solid black; } .report .rou table td, .report .reu table td{ border-bottom: 0px solid black; } /*
styles for footnote marker */.report .fn{ white-space: nowrap; } /* styles for numeric types */.report .num, .report .nump{ text-align: right; white-
space: nowrap; } .report .nump{ padding-left: 2em; } .report .nump{ padding: 0px 0.4em 0px 2em; } /* styles for text types */.report .text{ text-
align: left; white-space: normal; } .report .text .big{ margin-bottom: 1em; width: 17em; } .report .text .more{ display: none; } .report .text .note{
font-style: italic; font-weight: bold; } .report .text .small{ width: 10em; } .report .sup{ font-style: italic; } .report .outerFootnotes{ font-size: 1em;
} XML 103-FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3.html9884281true1360false11 falsefalseR1.htm0000001- Document-
CoverSheethttp://www.globelifeinsurance.com/role/CoverCoverCover1 falsefalseR2.htm9952151- Statement- Condensed Consolidated Balance
SheetsSheethttp://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheetsCondensed Consolidated Balance SheetsStatements2
falsefalseR3.htm9952152- Statement- Condensed Consolidated Balance Sheets
(Parenthetical)Sheethttp://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheetsParentheticalCondensed Consolidated Balance
Sheets (Parenthetical)Statements3 falsefalseR4.htm9952153- Statement- Condensed Consolidated Statements of
OperationsSheethttp://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfOperationsCondensed Consolidated Statements of
OperationsStatements4 falsefalseR5.htm9952154- Statement- Condensed Consolidated Statements of Operations
(Parenthetical)Sheethttp://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfOperationsParentheticalCondensed Consolidated
Statements of Operations (Parenthetical)Statements5 falsefalseR6.htm9952155- Statement- Condensed Consolidated Statements of
Comprehensive Income
(Loss)Sheethttp://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossCondensed Consolidated
Statements of Comprehensive Income (Loss)Statements6 falsefalseR7.htm9952156- Statement- Condensed Consolidated Statements of
Shareholders' EquitySheethttp://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityCondensed
Consolidated Statements of Shareholders' EquityStatements7 falsefalseR8.htm9952157- Statement- Condensed Consolidated Statements of
Shareholders' Equity
(Parenthetical)Sheethttp://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityParentheticalCondensed
Consolidated Statements of Shareholders' Equity (Parenthetical)Statements8 falsefalseR9.htm9952158- Statement- Condensed Consolidated
Statements of Cash FlowsSheethttp://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfCashFlowsCondensed Consolidated
Statements of Cash FlowsStatements9 falsefalseR10.htm9952159- Disclosure- Significant Accounting
PoliciesSheethttp://www.globelifeinsurance.com/role/SignificantAccountingPoliciesSignificant Accounting PoliciesNotes10
falsefalseR11.htm9952160- Disclosure- New Accounting StandardsSheethttp://www.globelifeinsurance.com/role/NewAccountingStandardsNew
Accounting StandardsNotes11 falsefalseR12.htm9952161- Disclosure- Supplemental Information about Changes to Accumulated Other
Comprehensive
IncomeSheethttp://www.globelifeinsurance.com/role/SupplementalInformationAboutChangesToAccumulatedOtherComprehensiveIncomeSupplement
Information about Changes to Accumulated Other Comprehensive IncomeNotes12 falsefalseR13.htm9952162- Disclosure-
InvestmentsSheethttp://www.globelifeinsurance.com/role/InvestmentsInvestmentsNotes13 falsefalseR14.htm9952163- Disclosure- Commitments
and ContingenciesSheethttp://www.globelifeinsurance.com/role/CommitmentsandContingenciesCommitments and ContingenciesNotes14
falsefalseR15.htm9952164- Disclosure- Policy LiabilitiesSheethttp://www.globelifeinsurance.com/role/PolicyLiabilitiesPolicy LiabilitiesNotes15
falsefalseR16.htm9952165- Disclosure- Deferred Acquisition
CostsSheethttp://www.globelifeinsurance.com/role/DeferredAcquisitionCostsDeferred Acquisition CostsNotes16 falsefalseR17.htm9952166-
Disclosure- Liability for Unpaid ClaimsSheethttp://www.globelifeinsurance.com/role/LiabilityforUnpaidClaimsLiability for Unpaid ClaimsNotes17
falsefalseR18.htm9952167- Disclosure- Postretirement
BenefitsSheethttp://www.globelifeinsurance.com/role/PostretirementBenefitsPostretirement BenefitsNotes18 falsefalseR19.htm9952168-
Disclosure- Earnings Per ShareSheethttp://www.globelifeinsurance.com/role/EarningsPerShareEarnings Per ShareNotes19
falsefalseR20.htm9952169- Disclosure- DebtSheethttp://www.globelifeinsurance.com/role/DebtDebtNotes20 falsefalseR21.htm9952170-
Disclosure- Business SegmentsSheethttp://www.globelifeinsurance.com/role/BusinessSegmentsBusiness SegmentsNotes21
falsefalseR22.htm9952171- Disclosure- Subsequent EventsSheethttp://www.globelifeinsurance.com/role/SubsequentEventsSubsequent
EventsNotes22 falsefalseR23.htm995410- Disclosure- Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PyvDisclosurePay vs
Performance DisclosureNotes23 falsefalseR24.htm995445- Disclosure- Insider Trading
ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes24 falsefalseR25.htm9954471-
Disclosure- Significant Accounting Policies
(Policies)Sheethttp://www.globelifeinsurance.com/role/SignificantAccountingPoliciesPoliciesSignificant Accounting Policies
(Policies)Policieshthttp://www.globelifeinsurance.com/role/SignificantAccountingPolicies25 falsefalseR26.htm9954472- Disclosure- New Accounting
Standards (Tables)Sheethttp://www.globelifeinsurance.com/role/NewAccountingStandardsTablesNew Accounting Standards
(Tables)Tableshthttp://www.globelifeinsurance.com/role/NewAccountingStandards26 falsefalseR27.htm9954473- Disclosure- Supplemental
Information About Changes to Accumulated Other Comprehensive Income
(Tables)Sheethttp://www.globelifeinsurance.com/role/SupplementalInformationAboutChangesToAccumulatedOtherComprehensiveIncomeTablesSup
Information About Changes to Accumulated Other Comprehensive Income (Tables)Tables27 falsefalseR28.htm9954474- Disclosure- Investments
(Tables)Sheethttp://www.globelifeinsurance.com/role/InvestmentsTablesInvestments
(Tables)Tableshthttp://www.globelifeinsurance.com/role/Investments28 falsefalseR29.htm9954475- Disclosure- Policy Liabilities
(Tables)Sheethttp://www.globelifeinsurance.com/role/PolicyLiabilitiesTablesPolicy Liabilities
(Tables)Tableshthttp://www.globelifeinsurance.com/role/PolicyLiabilities29 falsefalseR30.htm9954476- Disclosure- Deferred Acquisition Costs
(Tables)Sheethttp://www.globelifeinsurance.com/role/DeferredAcquisitionCostsTablesDeferred Acquisition Costs
(Tables)Tableshthttp://www.globelifeinsurance.com/role/DeferredAcquisitionCosts30 falsefalseR31.htm9954477- Disclosure- Liability for Unpaid
Claims (Tables)Sheethttp://www.globelifeinsurance.com/role/LiabilityforUnpaidClaimsTablesLiability for Unpaid Claims
(Tables)Tableshthttp://www.globelifeinsurance.com/role/LiabilityforUnpaidClaims31 falsefalseR32.htm9954478- Disclosure- Postretirement
Benefits (Tables)Sheethttp://www.globelifeinsurance.com/role/PostretirementBenefitsTablesPostretirement Benefits
(Tables)Tableshthttp://www.globelifeinsurance.com/role/PostretirementBenefits32 falsefalseR33.htm9954479- Disclosure- Earnings Per Share
(Tables)Sheethttp://www.globelifeinsurance.com/role/EarningsPerShareTablesEarnings Per Share
(Tables)Tableshthttp://www.globelifeinsurance.com/role/EarningsPerShare33 falsefalseR34.htm9954480- Disclosure- Debt
(Tables)Sheethttp://www.globelifeinsurance.com/role/DebtTablesDebt (Tables)Tableshthttp://www.globelifeinsurance.com/role/Debt34
falsefalseR35.htm9954481- Disclosure- Business Segments
(Tables)Sheethttp://www.globelifeinsurance.com/role/BusinessSegmentsTablesBusiness Segments
(Tables)Tableshthttp://www.globelifeinsurance.com/role/BusinessSegments35 falsefalseR36.htm9954482- Disclosure- Significant Accounting
Policies- Additional Information
```


[\(Details\)Sheethttp://www.globellifeinsurance.com/role/SignificantAccountingPoliciesAdditionalInformationDetailsSignificantAccountingPolicies-AdditionalInformation\(Details\)Details36 falsefalseR37.htm9954483-Disclosure-SupplementalInformationaboutChanges to Accumulated Other Comprehensive Income-Schedule of Change in Balance by Component \(Details\)Details37 falsefalseR38.htm9954484-Disclosure-SupplementalInformationaboutChanges to Accumulated Other Comprehensive Income-Schedule of Reclassifications \(Details\)Sheethttp://www.globellifeinsurance.com/role/SupplementalInformationaboutChanges to Accumulated Other Comprehensive IncomeScheduleofInformationaboutChanges to Accumulated Other Comprehensive Income-Schedule of Reclassifications \(Details\)Details38 falsefalseR39.htm9954485-Disclosure-Investments-Schedule of Fixed Maturities Available for Sale by Component \(Details\)Sheethttp://www.globellifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAvailableforSalebyComponentDetailsInvestments-Schedule of Fixed Maturities Available for Sale by Component \(Details\)Details39 falsefalseR40.htm9954486-Disclosure-Investments-Additional Information \(Details\)Sheethttp://www.globellifeinsurance.com/role/InvestmentsAdditionalInformationDetailsInvestments-Additional Information \(Details\)Details40 falsefalseR41.htm9954487-Disclosure-Investments-Schedule of Fixed Maturities by Contractual Maturity \(Details\)Sheethttp://www.globellifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetailsInvestments-Schedule of Fixed Maturities by Contractual Maturity \(Details\)Details41 falsefalseR42.htm9954488-Disclosure-Investments-Schedule of Analysis of Investment Operations \(Details\)Sheethttp://www.globellifeinsurance.com/role/InvestmentsScheduleofAnalysisofInvestmentOperationsDetailsInvestments-Schedule of Analysis of Investment Operations \(Details\)Details42 falsefalseR43.htm9954489-Disclosure-Investments-Schedule of Selected Information about Sales of Fixed Maturities \(Details\)Sheethttp://www.globellifeinsurance.com/role/InvestmentsScheduleofSelectedInformationaboutSalesofFixedMaturitiesDetailsInvestments-Schedule of Selected Information about Sales of Fixed Maturities \(Details\)Details43 falsefalseR44.htm9954490-Disclosure-Investments-Schedule of Realized Gain \(Loss\) on Investments \(Details\)Sheethttp://www.globellifeinsurance.com/role/InvestmentsScheduleofRealizedGainLossonInvestmentsDetailsInvestments-Schedule of Realized Gain \(Loss\) on Investments \(Details\)Details44 falsefalseR45.htm9954491-Disclosure-Investments-Schedule of Assets Measured at Fair Value on Recurring Basis \(Details\)Sheethttp://www.globellifeinsurance.com/role/InvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetailsInvestments-Schedule of Assets Measured at Fair Value on Recurring Basis \(Details\)Details45 falsefalseR46.htm9954492-Disclosure-Investments-Schedule of Changes in Assets Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs \(Level 3\) \(Details\)Sheethttp://www.globellifeinsurance.com/role/InvestmentsScheduleofChangesinAssetsMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputs \(Level 3\) \(Details\)Details46 falsefalseR47.htm9954493-Disclosure-Investments-Schedule of Unrealized Gains or \(Losses\) Included in Other Comprehensive Income \(Details\)Sheethttp://www.globellifeinsurance.com/role/InvestmentsScheduleofUnrealizedGainsorLossesIncludedinOtherComprehensiveIncomeDetailsInvestments-Schedule of Unrealized Gains or \(Losses\) Included in Other Comprehensive Income \(Details\)Details47 falsefalseR48.htm9954494-Disclosure-Investments-Schedule of Information about Investments in Unrealized Loss Position \(Details\)Sheethttp://www.globellifeinsurance.com/role/InvestmentsScheduleofInformationaboutInvestmentsinUnrealizedLossPositionDetailsInvestments-Schedule of Information about Investments in Unrealized Loss Position \(Details\)Details48 falsefalseR49.htm9954495-Disclosure-Investments-Schedule of Unrealized Investment Losses by Class of Investment \(Details\)Sheethttp://www.globellifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetailsInvestments-Schedule of Unrealized Investment Losses by Class of Investment \(Details\)Details49 falsefalseR50.htm9954496-Disclosure-Investments-Schedule of Fixed Maturities, Allowance for Credit Loss \(Details\)Sheethttp://www.globellifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAllowanceforCreditLossDetailsInvestments-Schedule of Fixed Maturities, Allowance for Credit Loss \(Details\)Details50 falsefalseR51.htm9954497-Disclosure-Investments-Schedule of Commercial Mortgage Loan Participations \(Details\)Sheethttp://www.globellifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetailsInvestments-Schedule of Commercial Mortgage Loan Participations \(Details\)Details51 falsefalseR52.htm9954498-Disclosure-Investments-Schedule of Commercial Mortgage Loan Participations Recorded Investment \(Details\)Sheethttp://www.globellifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsRecordedInvestmentDetailsInvestments-Schedule of Commercial Mortgage Loan Participations Recorded Investment \(Details\)Details52 falsefalseR53.htm9954499-Disclosure-Investments-Schedule of Commercial Loan Participations, Allowance for Credit Loss \(Details\)Sheethttp://www.globellifeinsurance.com/role/InvestmentsScheduleofCommercialLoanParticipationsAllowanceforCreditLossDetailsInvestments-Schedule of Commercial Loan Participations, Allowance for Credit Loss \(Details\)Details53 falsefalseR54.htm9954500-Disclosure-Investments-Schedule of Other Long-Term Investments \(Details\)Sheethttp://www.globellifeinsurance.com/role/InvestmentsScheduleofOtherLongTermInvestmentsDetailsInvestments-Schedule of Other Long-Term Investments \(Details\)Details54 falsefalseR55.htm9954501-Disclosure-Investments-Schedule of Investment Funds \(Details\)Sheethttp://www.globellifeinsurance.com/role/InvestmentsScheduleofInvestmentFundsDetailsInvestments-Schedule of Investment Funds \(Details\)Details55 falsefalseR56.htm9954502-Disclosure-Commitments and Contingencies-Additional Information \(Details\)Sheethttp://www.globellifeinsurance.com/role/CommitmentsandContingenciesAdditionalInformationDetailsCommitments and Contingencies-Additional Information \(Details\)Details56 falsefalseR57.htm9954503-Disclosure-Policy Liabilities-Schedule of Liability for Future Policy Benefit Activity \(Details\)Sheethttp://www.globellifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetailsPolicy Liabilities-Schedule of Liability for Future Policy Benefit Activity \(Details\)Details57 falsefalseR58.htm9954504-Disclosure-Policy Liabilities-Additional Information \(Details\)Sheethttp://www.globellifeinsurance.com/role/PolicyLiabilitiesAdditionalInformationDetailsPolicy Liabilities-Additional Information \(Details\)Details58 falsefalseR59.htm9954505-Disclosure-Policy Liabilities-Schedule of Liability For Future Policy Benefits To Consolidated Balance Sheets \(Details\)Sheethttp://www.globellifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetailsPolicy Liabilities-Schedule of Liability For Future Policy Benefits To Consolidated Balance Sheets \(Details\)Details59 falsefalseR60.htm9954506-Disclosure-Policy Liabilities-Schedule of Weighted Average Interest Rate of Liability For Future Policy Benefits \(Details\)Sheethttp://www.globellifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageInterestRateofLiabilityForFuturePolicyBenefitsDetailsPolicy Liabilities-Schedule of Weighted Average Interest Rate of Liability For Future Policy Benefits \(Details\)Details60 falsefalseR61.htm9954507-Disclosure-Policy Liabilities-Schedule of Weighted Average Duration of Liability For Future Policy Benefits \(Details\)Sheethttp://www.globellifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageDurationofLiabilityForFuturePolicyBenefitsDetailsPolicy Liabilities-Schedule of Weighted Average Duration of Liability For Future Policy Benefits \(Details\)Details61 falsefalseR62.htm9954508-Disclosure-Policy Liabilities-Schedule of Liability For Future Policy Benefits To Consolidated Income Statement \(Details\)Sheethttp://www.globellifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedIncomeStatementDetailsPolicy Liabilities-Schedule of Liability For Future Policy Benefits To Consolidated Income Statement \(Details\)Details62 falsefalseR63.htm9954509-Disclosure-Policy Liabilities-Schedule of Undiscounted And Discounted Expected Future Gross Premiums And Expected Future Benefits And Expenses \(Details\)Sheethttp://www.globellifeinsurance.com/role/PolicyLiabilitiesScheduleofUndiscountedAndDiscountedExpectedFutureGrossPremiumsAndExpected Future Benefits And Expenses \(Details\)Details63 falsefalseR64.htm9954510-Disclosure-Policy Liabilities-Schedule of Policyholder Account Balance \(Details\)Sheethttp://www.globellifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceDetailsPolicy Liabilities-Schedule of Policyholder Account Balance \(Details\)Details64 falsefalseR65.htm9954511-Disclosure-Policy Liabilities-Schedule of Policyholder Account Balance, Guaranteed Minimum Crediting Rate \(Details\)Sheethttp://www.globellifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetailsPolicy Liabilities-Schedule of Policyholder Account Balance, Guaranteed Minimum Crediting Rate \(Details\)Details65 falsefalseR66.htm9954512-Disclosure-Deferred Acquisition Costs-Schedule of Analysis of Deferred Acquisition Costs \(Details\)Sheethttp://www.globellifeinsurance.com/role/DeferredAcquisitionCostsScheduleofAnalysisofDeferredAcquisitionCostsDetailsDeferred Acquisition Costs-Schedule of Analysis of Deferred Acquisition Costs \(Details\)Details66 falsefalseR67.htm9954513-Disclosure-Deferred Acquisition Costs-Schedule of Deferred Policy Acquisition Costs to Consolidated Balance Sheet \(Details\)Sheethttp://www.globellifeinsurance.com/role/DeferredAcquisitionCostsScheduleofDeferredPolicyAcquisitionCoststoConsolidatedBalanceSheetDetailsDeferred Acquisition Costs-Schedule of Deferred Policy Acquisition Costs to Consolidated Balance Sheet \(Details\)Details67 falsefalseR68.htm9954514-Disclosure-Liability for Unpaid Claims-Schedule of Liability for Unpaid Health Claims \(Details\)Sheethttp://www.globellifeinsurance.com/role/LiabilityforUnpaidClaimsScheduleofLiabilityforUnpaidHealthClaimsDetailsLiability for Unpaid Claims-Schedule of Liability for Unpaid Health Claims \(Details\)Details68 falsefalseR69.htm9954515-Disclosure-Liability for Unpaid Claims-Schedule of Reconciliation of Policy Claims and Other Benefits Payable \(Details\)Sheethttp://www.globellifeinsurance.com/role/LiabilityforUnpaidClaimsScheduleofReconciliationofPolicyClaimsandOtherBenefitsPayableDetailsLiability for Unpaid Claims-Schedule of Reconciliation of Policy Claims and Other Benefits Payable \(Details\)Details69 falsefalseR70.htm9954516-Disclosure-Postretirement Benefits-Schedule of Pension Assets by Component at Fair Value](#)

(Details)Sheethttp://www.globellifeinsurance.com/role/PostretirementBenefitsScheduleofPensionAssetsbyComponentatFairValueDetailsPostretirementBenefits - Schedule of Pension Assets by Component at Fair Value (Details)Details70 falsefalseR71.htm9954517 - Disclosure - Postretirement Benefits - Schedule of Information Regarding the SERP

(Details)Sheethttp://www.globellifeinsurance.com/role/PostretirementBenefitsScheduleofInformationRegardingtheSERPDetailsPostretirementBenefits - Schedule of Information Regarding the SERP (Details)Details71 falsefalseR72.htm9954518 - Disclosure - Postretirement Benefits - Schedule of Pension and SERP Liabilities

(Details)Sheethttp://www.globellifeinsurance.com/role/PostretirementBenefitsScheduleofPensionandSERPLiabilitiesDetailsPostretirementBenefits - Schedule of Pension and SERP Liabilities (Details)Details72 falsefalseR73.htm9954519 - Disclosure - Postretirement Benefits - Schedule of Net Periodic Benefit Cost

(Details)Sheethttp://www.globellifeinsurance.com/role/PostretirementBenefitsScheduleofNetPeriodicBenefitCostDetailsPostretirementBenefits - Schedule of Net Periodic Benefit Cost (Details)Details73 falsefalseR74.htm9954520 - Disclosure - Earnings Per Share

(Details)Sheethttp://www.globellifeinsurance.com/role/Details74 falsefalseR75.htm9954521 - Disclosure - Debt - Schedule of Selected Information about Debt Issues

(Details)Detailshttp://www.globellifeinsurance.com/role/EarningsPerShareTables74 falsefalseR75.htm9954521 - Disclosure - Debt - Schedule of Selected Information about Debt Issues

(Details)Sheethttp://www.globellifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetailsDebt - Schedule of Selected Information about Debt Issues (Details)Details75 falsefalseR76.htm9954522 - Disclosure - Debt - Additional Information

(Details)Sheethttp://www.globellifeinsurance.com/role/DebtAdditionalInformationDetailsDebt - Additional Information (Details)Details76 falsefalseR77.htm9954523 - Disclosure - Debt - Short-Term Borrowings

(Details)Sheethttp://www.globellifeinsurance.com/role/DebtShortTermBorrowingsDetailsDebt - Short-Term Borrowings (Details)Details77 falsefalseR78.htm9954524 - Disclosure - Business Segments - Schedule of Segment Premium Income by Distribution Channel

(Details)Sheethttp://www.globellifeinsurance.com/role/BusinessSegmentsScheduleofSegmentPremiumIncomebyDistributionChannelDetailsBusinessSegments - Schedule of Segment Premium Income by Distribution Channel (Details)Details78 falsefalseR79.htm9954525 - Disclosure - Business Segments - Schedule of Reconciliation of Segment Operating Information to Consolidated Statement of Operations

(Details)Sheethttp://www.globellifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedSt Segments - Schedule of Reconciliation of Segment Operating Information to Consolidated Statement of Operations (Details)Details79 falsefalseR80.htm9954526 - Disclosure - Subsequent Events

(Details)Sheethttp://www.globellifeinsurance.com/role/SubsequentEventsDetailsSubsequent Events

(Details)Detailshttp://www.globellifeinsurance.com/role/SubsequentEvents80 falsefalseAll ReportsBookAll Reports gl-20240930.htmgl-20240930.xsdgl-20240930_cal.xmlgl-20240930_def.xmlgl-20240930_lab.xmlgl-20240930_pre.xmlgl-20240930_g1.jpggl-20240930_g2.jpggl-20240930_g3.jpggl-20240930_g4.jpggl-20240930_g5.jpggl-20240930_g6.jpggl-20240930_g7.jpg http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024truetrue JSON-105 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "gl-20240930.htm": { "nsprefix": "gl", "nsuri": "http://www.globellifeinsurance.com/20240930", "dts": { "inline": { "local": { "gl-20240930.htm" } }, "schema": { "local": { "gl-20240930.xsd" }, "remote": { "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrl-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/rrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/rrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/rrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" } }, "calculationLink": { "local": { "gl-20240930_cal.xml" } }, "definitionLink": { "local": { "gl-20240930_def.xml" } }, "labelLink": { "local": { "gl-20240930_lab.xml" } }, "presentationLink": { "local": { "gl-20240930_pre.xml" } } }, "keyStandard": 321, "keyCustom": 107, "axisStandard": 32, "axisCustom": 2, "memberStandard": 78, "memberCustom": 52, "hidden": { "total": 9, "http://fasb.org/us-gaap/2024": 4, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 988, "entityCount": 1, "segmentCount": 136, "elementCount": 831, "unitCount": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 3889, "http://xbrl.sec.gov/dei/2024": 32, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.globellifeinsurance.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "R2": { "role": "http://www.globellifeinsurance.com/role/CondensedConsolidatedBalanceSheets", "longName": "9952151 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:MortgageLoansOnRealEstateCommercialAndConsumerNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "div", "td": "tr", "table": "div", "body": "html", "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "div", "td": "tr", "table": "div", "body": "html", "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "R4": { "role": "http://www.globellifeinsurance.com/role/CondensedConsolidatedStatementsofOperations", "longName": "9952153 - Statement - Condensed Consolidated Statements of Operations", "shortName": "Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:PremiumsEarnedNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "R5": { "role": "http://www.globellifeinsurance.com/role/CondensedConsolidatedStatementsofOperationsParenthetical", "longName": "9952154 - Statement - Condensed Consolidated Statements of Operations (Parenthetical)", "shortName": "Condensed Consolidated Statements of Operations (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:LiabilityForFuturePolicyBenefitRemeasurementGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "link:footnote": "span", "div": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:LiabilityForFuturePolicyBenefitRemeasurementGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "link:footnote": "span", "div": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "R6": { "role": "http://www.globellifeinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss", "longName": "9952155 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "R7": { "role": "http://www.globellifeinsurance.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "longName": "9952156 - Statement - Condensed Consolidated Statements of Shareholders' Equity", "shortName": "Condensed Consolidated Statements of Shareholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-70", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-73", "name": "us-gaap:ComprehensiveIncomeNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "R8": { "role": "http://www.globellifeinsurance.com/role/CondensedConsolidatedStatementsofShareholdersEquityParenthetical", "longName": "9952157 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Parenthetical)", "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements"

"order": "8", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "div", "td": "tr", "table": "div", "body": "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "div", "td": "tr", "table": "div", "body": "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "R9": { "role": "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfCashFlows", "longName": "9952158 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.globelifeinsurance.com/role/SignificantAccountingPolicies", "longName": "9952159 - Disclosure - Significant Accounting Policies", "shortName": "Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "R11": { "role": "http://www.globelifeinsurance.com/role/NewAccountingStandards", "longName": "9952160 - Disclosure - New Accounting Standards", "shortName": "New Accounting Standards", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "R12": { "role": "http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncome", "longName": "9952161 - Disclosure - Supplemental Information about Changes to Accumulated Other Comprehensive Income", "shortName": "Supplemental Information about Changes to Accumulated Other Comprehensive Income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "R13": { "role": "http://www.globelifeinsurance.com/role/Investments", "longName": "9952162 - Disclosure - Investments", "shortName": "Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "R14": { "role": "http://www.globelifeinsurance.com/role/CommitmentsandContingencies", "longName": "9952163 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "R15": { "role": "http://www.globelifeinsurance.com/role/PolicyLiabilities", "longName": "9952164 - Disclosure - Policy Liabilities", "shortName": "Policy Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LongDurationInsuranceContractsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "R16": { "role": "http://www.globelifeinsurance.com/role/DeferredAcquisitionCosts", "longName": "9952165 - Disclosure - Deferred Acquisition Costs", "shortName": "Deferred Acquisition Costs", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredPolicyAcquisitionCostsTextBlock1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "R17": { "role": "http://www.globelifeinsurance.com/role/LiabilityforUnpaidClaims", "longName": "9952166 - Disclosure - Liability for Unpaid Claims", "shortName": "Liability for Unpaid Claims", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InsuranceDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "R18": { "role": "http://www.globelifeinsurance.com/role/PostretirementBenefits", "longName": "9952167 - Disclosure - Postretirement Benefits", "shortName": "Postretirement Benefits", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "R19": { "role": "http://www.globelifeinsurance.com/role/EarningsPerShare", "longName": "9952168 - Disclosure - Earnings Per Share", "shortName": "Earnings Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "R20": { "role": "http://www.globelifeinsurance.com/role/Debt", "longName": "9952169 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "R21": { "role": "http://www.globelifeinsurance.com/role/BusinessSegments", "longName": "9952170 - Disclosure - Business Segments", "shortName": "Business Segments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "R22": { "role": "http://www.globelifeinsurance.com/role/SubsequentEvents", "longName": "9952171 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "R24": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-21", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ecd:NonRule10b51ArrAdoptedFlag", "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true,

"unique": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ecd:NonRule10b51ArrAdoptedFlag", "span": "div", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.globelifeinsurance.com/role/SignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap: BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap: BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.globelifeinsurance.com/role/NewAccountingStandardsTables", "longName": "9954472 - Disclosure - New Accounting Standards (Tables)", "shortName": "New Accounting Standards (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap: ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "contextRef": "c-1", "name": "us-gaap: ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.globelifeinsurance.com/role/SupplementalInformationAboutChangesToAccumulatedOtherComprehensiveIncomeTables", "longName": "9954473 - Disclosure - Supplemental Information About Changes to Accumulated Other Comprehensive Income (Tables)", "shortName": "Supplemental Information About Changes to Accumulated Other Comprehensive Income (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap: ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap: ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.globelifeinsurance.com/role/InvestmentsTables", "longName": "9954474 - Disclosure - Investments (Tables)", "shortName": "Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap: ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap: ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.globelifeinsurance.com/role/PolicyLiabilitiesTables", "longName": "9954475 - Disclosure - Policy Liabilities (Tables)", "shortName": "Policy Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap: LiabilityForFuturePolicyBenefitActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap: LiabilityForFuturePolicyBenefitActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsTables", "longName": "9954476 - Disclosure - Deferred Acquisition Costs (Tables)", "shortName": "Deferred Acquisition Costs (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap: DeferredPolicyAcquisitionCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap: DeferredPolicyAcquisitionCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.globelifeinsurance.com/role/LiabilityForUnpaidClaimsTables", "longName": "9954477 - Disclosure - Liability for Unpaid Claims (Tables)", "shortName": "Liability for Unpaid Claims (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap: ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap: ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.globelifeinsurance.com/role/PostretirementBenefitsTables", "longName": "9954478 - Disclosure - Postretirement Benefits (Tables)", "shortName": "Postretirement Benefits (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap: ScheduleOfAllocationOfPlanAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap: ScheduleOfAllocationOfPlanAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.globelifeinsurance.com/role/EarningsPerShareTables", "longName": "9954479 - Disclosure - Earnings Per Share (Tables)", "shortName": "Earnings Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap: ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap: ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.globelifeinsurance.com/role/DebtTables", "longName": "9954480 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap: ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap: ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.globelifeinsurance.com/role/BusinessSegmentsTables", "longName": "9954481 - Disclosure - Business Segments (Tables)", "shortName": "Business Segments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap: DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap: DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.globelifeinsurance.com/role/SignificantAccountingPolicies - Additional Information (Details)", "longName": "9954482 - Disclosure - Significant Accounting Policies - Additional Information (Details)", "shortName": "Significant Accounting Policies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap: NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap: NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span", "div", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.globelifeinsurance.com/role/SupplementalInformationAboutChangesToAccumulatedOtherComprehensiveIncomeScheduleofChangeinBal", "longName": "9954483 - Disclosure - Supplemental Information about Changes to Accumulated Other Comprehensive Income - Schedule of Change in Balance by Component (Details)", "shortName": "Supplemental Information about Changes to Accumulated Other Comprehensive Income - Schedule of Change in Balance by Component (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-53", "name": "us-gaap: StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap: OCIBeforeReclassificationsNetOfTaxAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.globelifeinsurance.com/role/SupplementalInformationAboutChangesToAccumulatedOtherComprehensiveIncomeScheduleofReclassifications", "longName": "9954484 - Disclosure - Supplemental Information about Changes to Accumulated Other Comprehensive Income - Schedule of Reclassifications (Details)", "shortName": "Supplemental Information about Changes to Accumulated Other Comprehensive Income - Schedule of Reclassifications (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap: RealizedInvestmentGainsLosses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US",

"decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-162", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "gl-20240930.htm", "unique": true } }, "R39": { "role": "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAvailableforSalebyComponentDetails", "longName": "9954485 - Disclosure - Investments - Schedule of Fixed Maturities Available for Sale by Component (Details)", "shortName": "Investments - Schedule of Fixed Maturities Available for Sale by Component (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails", "longName": "9954486 - Disclosure - Investments - Additional Information (Details)", "shortName": "Investments - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "gl:EntirePortfolioNumberOfIssuesOfFixedMaturities", "unitRef": "issue", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "gl-20240930.htm", "unique": true } }, "R41": { "role": "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails", "longName": "9954487 - Disclosure - Investments - Schedule of Fixed Maturities by Contractual Maturity (Details)", "shortName": "Investments - Schedule of Fixed Maturities by Contractual Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-5", "name": "gl:DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateWithinOneYearAmortizedCostNetOfAllowanceForCreditLosses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "gl:DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateWithinOneYearAmortizedCostNetOfAllowanceForCreditLosses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAnalysisofInvestmentOperationsDetails", "longName": "9954488 - Disclosure - Investments - Schedule of Analysis of Investment Operations (Details)", "shortName": "Investments - Schedule of Analysis of Investment Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:GrossInvestmentIncomeOperating", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:GrossInvestmentIncomeOperating", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.globelifeinsurance.com/role/InvestmentsScheduleofSelectedInformationaboutSalesofFixedMaturitiesDetails", "longName": "9954489 - Disclosure - Investments - Schedule of Selected Information about Sales of Fixed Maturities (Details)", "shortName": "Investments - Schedule of Selected Information about Sales of Fixed Maturities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-21", "name": "gl:ProceedsFromSaleOfDebtSecuritiesExcludingUnsettledTradesAvailableForSale", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "gl:ProceedsFromSaleOfDebtSecuritiesExcludingUnsettledTradesAvailableForSale", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.globelifeinsurance.com/role/InvestmentsScheduleofRealizedGainLossOnInvestmentsDetails", "longName": "9954490 - Disclosure - Investments - Schedule of Realized Gain (Loss) on Investments (Details)", "shortName": "Investments - Schedule of Realized Gain (Loss) on Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails", "longName": "9954491 - Disclosure - Investments - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)", "shortName": "Investments - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-237", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "gl-20240930.htm", "unique": true } }, "R46": { "role": "http://www.globelifeinsurance.com/role/InvestmentsScheduleofChangesinAssetsMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputs", "longName": "9954492 - Disclosure - Investments - Schedule of Changes in Assets Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level 3) (Details)", "shortName": "Investments - Schedule of Changes in Assets Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level 3) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-5", "name": "gl:PercentOfAvailableForSaleSecuritiesAtFairValueByValuationLevel", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-269", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "gl-20240930.htm", "unique": true } }, "R47": { "role": "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedGainsorLossesIncludedinOtherComprehensiveIncomeDetails", "longName": "9954493 - Disclosure - Investments - Schedule of Unrealized Gains or (Losses) Included in Other Comprehensive Income (Details)", "shortName": "Investments - Schedule of Unrealized Gains or (Losses) Included in Other Comprehensive Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.globelifeinsurance.com/role/InvestmentsScheduleofInformationaboutInvestmentsinUnrealizedLossPositionDetails", "longName": "9954494 - Disclosure - Investments - Schedule of Information about Investments in Unrealized Loss Position (Details)", "shortName": "Investments - Schedule of Information about Investments in Unrealized Loss Position (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "unitRef": "issue", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "unitRef": "issue", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R49": { "role":

http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails", "longName": "9954495 - Disclosure - Investments - Schedule of Unrealized Investment Losses by Class of Investment (Details)", "shortName": "Investments - Schedule of Unrealized Investment Losses by Class of Investment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "R50": { "role": "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAllowanceforCreditLossDetails", "longName": "9954496 - Disclosure - Investments - Schedule of Fixed Maturities, Allowance for Credit Loss (Details)", "shortName": "Investments - Schedule of Fixed Maturities, Allowance for Credit Loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-331", "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "unique": true }, "R51": { "role": "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails", "longName": "9954497 - Disclosure - Investments - Schedule of Commercial Mortgage Loan Participations (Details)", "shortName": "Investments - Schedule of Commercial Mortgage Loan Participations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NotesReceivableGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "gl:FinancingReceivableGrossPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "unique": true }, "R52": { "role": "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsRecordedInvestmentDetails", "longName": "9954498 - Disclosure - Investments - Schedule of Commercial Mortgage Loan Participations Recorded Investment (Details)", "shortName": "Investments - Schedule of Commercial Mortgage Loan Participations Recorded Investment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NotesReceivableNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-363", "name": "us-gaap:NotesReceivableGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "unique": true }, "R53": { "role": "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialLoanParticipationsAllowanceforCreditLossDetails", "longName": "9954499 - Disclosure - Investments - Schedule of Commercial Loan Participations, Allowance for Credit Loss (Details)", "shortName": "Investments - Schedule of Commercial Loan Participations, Allowance for Credit Loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-53", "name": "us-gaap:FinancingReceivableAllowanceForCreditLosses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:ProvisionForLoanLossesExpensed", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "unique": true }, "R54": { "role": "http://www.globelifeinsurance.com/role/InvestmentsScheduleofOtherLongTermInvestmentsDetails", "longName": "9954500 - Disclosure - Investments - Schedule of Other Long Term Investments (Details)", "shortName": "Investments - Schedule of Other Long Term Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:OtherLongTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-402", "name": "us-gaap:OtherLongTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-412", "name": "gl:GeneralExpectedLifeOfNonRedeemableFunds", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "unique": true }, "R55": { "role": "http://www.globelifeinsurance.com/role/InvestmentsScheduleofInvestmentFundsDetails", "longName": "9954501 - Disclosure - Investments - Schedule of Investment Funds (Details)", "shortName": "Investments - Schedule of Investment Funds (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "div", "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-412", "name": "gl:GeneralExpectedLifeOfNonRedeemableFunds", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "unique": true }, "R56": { "role": "http://www.globelifeinsurance.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "longName": "9954502 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "shortName": "Commitments and Contingencies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:LettersOfCreditOutstandingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-416", "name": "us-gaap:LossContingencyNumberOfPlaintiffs", "unitRef": "complainant", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "unique": true }, "R57": { "role": "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails", "longName": "9954503 - Disclosure - Policy Liabilities - Schedule of Liability for Future Policy Benefit Activity (Details)", "shortName": "Policy Liabilities - Schedule of Liability for Future Policy Benefit Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:LiabilityForFuturePolicyBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-461", "name": "us-gaap:LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChange", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "unique": true }, "R58": { "role": "http://www.globelifeinsurance.com/role/PolicyLiabilitiesAdditionalInformationDetails", "longName": "9954504 - Disclosure - Policy Liabilities - Additional Information (Details)", "shortName": "Policy Liabilities - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-21", "name": "gl:LiabilityForFuturePolicyBenefitChangeInAssumptionsOfLapseMortalityAndMorbidityRemeasurementGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "div", "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "gl:LiabilityForFuturePolicyBenefitChangeInAssumptionsOfLapseMortalityAndMorbidityRemeasurementGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "div", "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "R59": { "role": "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails", "longName": "9954505 - Disclosure - Policy Liabilities - Schedule of Liability For Future Policy Benefits To Consolidated Balance Sheets (Details)", "shortName": "Policy Liabilities - Schedule of Liability For Future Policy Benefits To Consolidated Balance Sheets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType":

"longName": "9954506 - Disclosure - Policy Liabilities - Schedule of Weighted Average Interest Rate of Liability For Future Policy Benefits (Details)", "shortName": "Policy Liabilities - Schedule of Weighted Average Interest Rate of Liability For Future Policy Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-442", "name": "us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-442", "name": "us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageDurationofLiabilityForFuturePolicyBenefitsDetails", "longName": "9954507 - Disclosure - Policy Liabilities - Schedule of Weighted Average Duration of Liability For Future Policy Benefits (Details)", "shortName": "Policy Liabilities - Schedule of Weighted Average Duration of Liability For Future Policy Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-442", "name": "gl:LiabilityForFuturePolicyBenefitWeightedAverageDurationOriginalDiscount", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-442", "name": "gl:LiabilityForFuturePolicyBenefitWeightedAverageDurationOriginalDiscount", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedIncomeStatementDetails", "longName": "9954508 - Disclosure - Policy Liabilities - Schedule of Liability For Future Policy Benefits To Consolidated Income Statement (Details)", "shortName": "Policy Liabilities - Schedule of Liability For Future Policy Benefits To Consolidated Income Statement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-446", "name": "us-gaap:LiabilityForFuturePolicyBenefitGrossPremiumIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-446", "name": "us-gaap:LiabilityForFuturePolicyBenefitGrossPremiumIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofUndiscountedAndDiscountedExpectedFutureGrossPremiumsAndExpectedFuture", "longName": "9954509 - Disclosure - Policy Liabilities - Schedule of Undiscounted And Discounted Expected Future Gross Premiums And Expected Future Benefits And Expenses (Details)", "shortName": "Policy Liabilities - Schedule of Undiscounted And Discounted Expected Future Gross Premiums And Expected Future Benefits And Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-446", "name": "gl:LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumNotDiscountedBeforeCashFlowReinsurance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "gl:LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumsAndExpectedFutureBenefitsAndExpensesTableTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-446", "name": "gl:LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumNotDiscountedBeforeCashFlowReinsurance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "gl:LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumsAndExpectedFutureBenefitsAndExpensesTableTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalance", "longName": "9954510 - Disclosure - Policy Liabilities - Schedule of Policyholder Account Balance (Details)", "shortName": "Policy Liabilities - Schedule of Policyholder Account Balance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-632", "name": "us-gaap:PolicyholderFunds", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "us-gaap:PolicyholderAccountBalanceTableTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-638", "name": "us-gaap:PolicyholderAccountBalanceIssuance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "us-gaap:PolicyholderAccountBalanceTableTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true }, "unique": true } }, "R65": { "role": "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetails", "longName": "9954511 - Disclosure - Policy Liabilities - Schedule of Policyholder Account Balance, Guaranteed Minimum Crediting Rate (Details)", "shortName": "Policy Liabilities - Schedule of Policyholder Account Balance, Guaranteed Minimum Crediting Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-661", "name": "us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": { "span": "div", "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-661", "name": "us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": { "span": "div", "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofAnalysisofDeferredAcquisitionCostsDetails", "longName": "9954512 - Disclosure - Deferred Acquisition Costs - Schedule of Analysis of Deferred Acquisition Costs (Details)", "shortName": "Deferred Acquisition Costs - Schedule of Analysis of Deferred Acquisition Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:DeferredPolicyAcquisitionCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-466", "name": "us-gaap:DeferredPolicyAcquisitionCostsAdditions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "unique": true } }, "R67": { "role": "http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofDeferredPolicyAcquisitionCoststoConsolidatedBalanceSheetDetails", "longName": "9954513 - Disclosure - Deferred Acquisition Costs - Schedule of Deferred Policy Acquisition Costs to Consolidated Balance Sheet (Details)", "shortName": "Deferred Acquisition Costs - Schedule of Deferred Policy Acquisition Costs to Consolidated Balance Sheet (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:DeferredPolicyAcquisitionCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-764", "name": "us-gaap:DeferredPolicyAcquisitionCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "unique": true } }, "R68": { "role": "http://www.globelifeinsurance.com/role/LiabilityforUnpaidClaimsScheduleofLiabilityforUnpaidHealthClaimsDetails", "longName": "9954514 - Disclosure - Liability for Unpaid Claims - Schedule of Liability for Unpaid Health Claims (Details)", "shortName": "Liability for Unpaid Claims - Schedule of Liability for Unpaid Health Claims (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-767", "name": "us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "unique": true } }, "R69": { "role": "http://www.globelifeinsurance.com/role/LiabilityforUnpaidClaimsScheduleofReconciliationofPolicyClaimsandOtherBenefitsPayableDetails", "longName": "9954515 - Disclosure - Liability for Unpaid Claims - Schedule of Reconciliation of Policy Claims and Other Benefits Payable (Details)", "shortName": "Liability for Unpaid Claims - Schedule of Reconciliation of Policy Claims and Other Benefits Payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-770", "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "gl-20240930.htm", "unique": true } }, "R70": { "role": "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionAssetsbyComponentatFairValueDetails", "longName": "9954516

Disclosure - Postretirement Benefits - Schedule of Pension Assets by Component at Fair Value (Details)", "shortName": "Postretirement Benefits - Schedule of Pension Assets by Component at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-805", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-805", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofInformationRegardingtheSERPDetails", "longName": "9954517 - Disclosure - Postretirement Benefits - Schedule of Information Regarding the SERP (Details)", "shortName": "Postretirement Benefits - Schedule of Information Regarding the SERP (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-1", "name": "gl:InsurancePremiumPaidForSupplementalPensionPlan", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "gl:InsurancePremiumPaidForSupplementalPensionPlan", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionandSERPLiabilitiesDetails", "longName": "9954518 - Disclosure - Postretirement Benefits - Schedule of Pension and SERP Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:DefinedBenefitPlanBenefitObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:DefinedBenefitPlanBenefitObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofNetPeriodicBenefitCostDetails", "longName": "9954519 - Disclosure - Postretirement Benefits - Schedule of Net Periodic Benefit Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:DefinedBenefitPlanServiceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:DefinedBenefitPlanServiceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.globelifeinsurance.com/role/EarningsPerShareDetails", "longName": "9954520 - Disclosure - Earnings Per Share (Details)", "shortName": "Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails", "longName": "9954521 - Disclosure - Debt - Schedule of Selected Information about Debt Issues (Details)", "shortName": "Debt - Schedule of Selected Information about Debt Issues (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-5", "name": "gl:LongTermDebtFaceAmountGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "gl:LongTermDebtFaceAmountGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails", "longName": "9954522 - Disclosure - Debt - Additional Information (Details)", "shortName": "Debt - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromIssuanceOfDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromIssuanceOfDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.globelifeinsurance.com/role/DebtShortTermBorrowingsDetails", "longName": "9954523 - Disclosure - Debt - Short-Term Borrowings (Details)", "shortName": "Debt - Short-Term Borrowings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofSegmentPremiumIncomebyDistributionChannelDetails", "longName": "9954524 - Disclosure - Business Segments - Schedule of Segment Premium Income by Distribution Channel (Details)", "shortName": "Business Segments - Schedule of Segment Premium Income by Distribution Channel (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "ix:continuation", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "ix:continuation", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOperations", "longName": "9954525 - Disclosure - Business Segments - Schedule of Reconciliation of Segment Operating Information to Consolidated Statement of Operations (Details)", "shortName": "Business Segments - Schedule of Reconciliation of Segment Operating Information to Consolidated Statement of Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:PremiumsEarnedNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:PremiumsEarnedNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.globelifeinsurance.com/role/SubsequentEventsDetails", "longName": "9954526 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-987", "name": "gl:CoinsuranceAgreementAnnuityReservesCeded", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "div", "ix:continuation", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "gl-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-987", "name": "gl:CoinsuranceAgreementAnnuityReservesCeded", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "div", "ix:continuation", "ix:continuation": "body", "html": "reportCount": 1, "baseRef": "gl-20

"auth_ref": [1], "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingChangesAndErrorCorrectionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Changes and Error Corrections [Abstract]", "label": "Accounting Changes and Error Corrections [Abstract]" } } }, "auth_ref": [1], "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [1], "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesAndLoansReceivableLineItems", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsRecordedInvestmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [r286, "r1159"] }, "us-gaap_AccruedIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxes", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "terseLabel": "Current and deferred income taxes", "label": "Accrued Income Taxes", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes." } } }, "auth_ref": [r57, "r62", "r116", "r706"] }, "us-gaap_AccruedInvestmentIncomeReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedInvestmentIncomeReceivable", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "terseLabel": "Accrued investment income", "label": "Accrued Investment Income Receivable", "documentation": "Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments." } } }, "auth_ref": [r113, "r715", "r1126"] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": { "http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofChangeinBal": { "parentTag": "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofReclassificat": { "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments", "verboseLabel": "Pension adjustments", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [r3, "r4", "r13", "r19", "r77", "r1128", "r1129", "r1130"] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember", "presentation": { "http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofReclassificat": { "lang": { "en-us": { "role": { "terseLabel": "Amortization of prior service cost", "label": "Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to prior service cost (credit) component of defined benefit plans attributable to the parent." } } }, "auth_ref": [r3, "r13", "r19", "r198", "r199", "r1128"] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember", "presentation": { "http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofReclassificat": { "lang": { "en-us": { "role": { "terseLabel": "Amortization of actuarial (gain) loss", "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit plans attributable to the parent." } } }, "auth_ref": [r13, "r19", "r77", "r198", "r199", "r1128"] }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "presentation": { "http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofChangeinBal": { "lang": { "en-us": { "role": { "terseLabel": "Available foru00a0Sale Assets", "verboseLabel": "Unrealized Gains (Losses) on Available for Sale Assets", "label": "AOCI Accumulated Gain (Loss), Debt Securities, Available for Sale, Parent [Member]", "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale), attributable to parent." } } }, "auth_ref": [r185, "r186", "r187", "r190", "r198", "r199", "r1128"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": { "http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofChangeinBal": { "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [r197, "r198", "r597", "r598", "r599", "r600", "r601", "r603"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "verboseLabel": "Accumulated other comprehensive income (loss)", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [r18, "r19", "r78", "r183", "r712", "r785", "r788"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": { "http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofChangeinBal": { "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [r197, "r198", "r597", "r598", "r599", "r600", "r601", "r603"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofChangeinBal": { "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "verboseLabel": "Total", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [r1, "r13", "r19", "r561", "r564", "r612", "r780", "r781", "r1128", "r1129", "r1130", "r1143", "r1144", "r1145", "r1147"] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": { "http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofChangeinBal": { "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature, attributable to the parent." } } }, "auth_ref": [r2, "r13", "r19", "r75", "r76", "r198", "r199", "r598", "r599", "r600", "r601", "r603", "r1128"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PyvDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [r1052"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [r68, "r974", "r1358"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofShareholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the

entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": { "r798",
"r1143", "r1144", "r1145", "r1147", "r1274", "r1360" } }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": {
"role": { "terseLabel": "Adjustment to Compensation Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": { "r1065" } },
"ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation", "label": "Adjustment to
Compensation [Axis]" } } }, "auth_ref": { "r1065" } }, "ecd_AdjToNonPcoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPcoNeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" },
"lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO
Compensation Footnote [Text Block]" } } }, "auth_ref": { "r1065" } }, "ecd_AdjToPcoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPcoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": {
"en-us": { "role": { "terseLabel": "Adjustment to PEO Compensation, Footnote", "label": "Adjustment to PEO Compensation, Footnote [Text Block]"
} } }, "auth_ref": { "r1065" } }, "us-
gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": {
"http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofShareholdersEquity" }, "lang": { "en-us": { "role": { "terseLabel":
"Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of
increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": { "r49",
"r50", "r510" } }, "ecd_AggtChngPnsnValInSummaryCompstnTblForApblYrMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummaryCompstnTblForApblYrMember", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated
Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for
All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": { "r1098" } }, "ecd_AggtErrCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": {
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount",
"label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": { "r1024", "r1034", "r1044", "r1076" } },
"ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AggtErrCompNotYetDeterminedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": {
"terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text
Block]" } } }, "auth_ref": { "r1027", "r1037", "r1047", "r1079" } }, "ecd_AggtPnsnAdjSvcCstMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang":
{ "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]"
} } }, "auth_ref": { "r1099" } }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AllAdjToCompMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "All Adjustments
to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": { "r1065" } }, "ecd_AllExecutiveCategoriesMember": {
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive
Categories [Member]" } } }, "auth_ref": { "r1072" } }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } },
"auth_ref": { "r1028", "r1038", "r1048", "r1072", "r1080", "r1084", "r1092" } }, "ecd_AllTradingArrangementsMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All
Trading Arrangements [Member]" } } }, "auth_ref": { "r1090" } }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit",
"calculation": {
"http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps
{ "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0, "order": 6.0 } }, "presentation": {
"http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps
{ "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense",
"documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": {
"r537", "r538" } }, "us-gaap-AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Commercial Loan
Participations, Allowance for Credit Loss", "label": "Financing Receivable, Allowance for Credit Loss [Table Text Block]", "documentation":
"Tabular disclosure of allowance for credit loss on financing receivable." } } }, "auth_ref": { "r130", "r1184" } }, "us-gaap_AlternativeInvestment": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AlternativeInvestment", "crdr": "debit", "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofInvestmentFundsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Investment
funds, Fair Value", "label": "Alternative Investment", "documentation": "Fair value of investment other than investment in equity security,
investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset
value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate
partnership or fund." } } }, "auth_ref": { "r572", "r588", "r959", "r963", "r964", "r1276", "r1278", "r1279", "r1280" } },
"gl_AlternativeInvestmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname":
"AlternativeInvestmentLineItems", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofInvestmentFundsDetails" },
"lang": { "en-us": { "role": { "terseLabel": "Alternative Investment [Line Items]", "label": "Alternative Investment [Line Items]", "documentation":
"Alternative Investment" } } }, "auth_ref": { } }, "gl_AlternativeInvestmentTable": { "xbrltype": "stringItemType", "nsuri":
"http://www.globelifeinsurance.com/20240930", "localname": "AlternativeInvestmentTable", "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofInvestmentFundsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Alternative
Investment [Table]", "label": "Alternative Investment [Table]", "documentation": "Alternative Investment" } } }, "auth_ref": { } },
"dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": {
"http://www.globelifeinsurance.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag",
"documentation": "Boolean flag that is true when the XBRL content amends previously filed or accepted submission." } } }, "auth_ref": { } },
"gl_AmericanIncomeExclusiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname":
"AmericanIncomeExclusiveMember", "presentation": {
"http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofSegmentPremiumIncomebyDistributionChannelDetails",
"http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofAnalysisofDeferredAcquisitionCostsDetails",
"http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofDeferredPolicyAcquisitionCoststoConsolidatedBalanceSheetDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedIncomeStatementDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitActivityDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofUndiscountedAndDiscountedExpectedFutureGrossPremiumsAndExpectedFuture",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageDurationofLiabilityForFuturePolicyBenefitsDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageInterestRateofLiabilityForFuturePolicyBenefitsDetails" },
"lang": { "en-us": { "role": { "terseLabel": "American Income", "label": "American Income Exclusive [Member]", "documentation": "American
income exclusive [Member]" } } }, "auth_ref": { } }, "gl_AnnuitySegmentMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.globelifeinsurance.com/20240930", "localname": "AnnuitySegmentMember", "presentation": {
"http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps
"http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofSegmentPremiumIncomebyDistributionChannelDetails",
"http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofDeferredPolicyAcquisitionCoststoConsolidatedBalanceSheetDetails" },
"lang": { "en-us": { "role": { "terseLabel": "Annuity", "label": "Annuity Segment [Member]", "documentation": "Annuity Segment [Member]" } } },
"auth_ref": { } }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": {
"http://www.globelifeinsurance.com/role/EarningsPerShareDetails" }, "lang": { "en-us": { "role": { "verboseLabel": "Antidilutive shares (in shares)",
"label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those
issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the
future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per
share or unit amounts for the period presented." } } }, "auth_ref": { "r241" } }, "us-

gaap_AOCIliabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AOCIliabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Effect of changes in discount rate assumptions", "label": "AOCI Liability for Future Policy Benefit, Expected Future Policy Benefit, before Tax", "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) (AOCI) from (increase) decrease in expected future policy benefit component of liability for future policy benefit from change in discount rate." } } }, "auth_ref": { "r988", "r995", "r1335", "r1352" } }, "us-gaap_AOCIliabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AOCIliabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Effect of change from original to current discount rates", "label": "AOCI Liability for Future Policy Benefit, Expected Net Premium, before Tax", "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) (AOCI) from increase (decrease) in expected net premium component of liability for future policy benefit from change in discount rate." } } }, "auth_ref": { "r988", "r995", "r1335", "r1352" } }, "us-gaap_AssetBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetBackedSecuritiesMember", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofChangesinAssetsMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservable": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedGainsorLossesIncludedinOtherComprehensiveIncomeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Asset-backed Securities", "label": "Asset-Backed Securities [Member]", "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans." } } }, "auth_ref": { "r946", "r972", "r1169", "r1176", "r1177" } }, "us-gaap_AssetPledgedAsCollateralMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetPledgedAsCollateralMember", "presentation": { "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Asset Pledged as Collateral", "label": "Asset Pledged as Collateral [Member]", "documentation": "Asset pledged as collateral." } } }, "auth_ref": { "r555", "r822", "r958", "r1301" } }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": { "r114", "r129", "r176", "r210", "r245", "r253", "r272", "r276", "r327", "r387", "r388", "r390", "r391", "r392", "r393", "r394", "r396", "r397", "r555", "r557", "r594", "r704", "r845", "r924", "r925", "r971", "r1015", "r1203", "r1204", "r1293" } }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheetsParenthetical": { "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]", "auth_ref": { "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAvailableforSalebyComponentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Gains", "label": "Debt Securities, Available for Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r296" } }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAvailableforSalebyComponentDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Gross Unrealized Losses", "label": "Debt Securities, Available for Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r297" } }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheetsParenthetical": { "lang": { "en-us": { "role": { "verboseLabel": "Fixed maturities, available for sale, amortized cost", "label": "Debt Securities, Available for Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r293", "r343", "r702" } }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Due after five years through ten years", "label": "Debt Securities, Available for Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r302", "r694" } }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Due after one year through five years", "label": "Debt Securities, Available for Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r301", "r693" } }, "gl_AvailableForSaleSecuritiesDebtMaturitiesAfterTenThroughTwentyYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenThroughTwentyYearsFairValue", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Due after ten years through twenty years", "label": "Available For Sale Securities Debt Maturities After Ten Through Twenty Years Fair Value", "documentation": "This item represents the fair value of debt securities which are expected to mature after ten years and through twenty years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities." } } }, "auth_ref": { "gl_AvailableForSaleSecuritiesDebtMaturitiesAfterTwentyYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTwentyYearsFairValue", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Due after twenty years", "label": "Available For Sale Securities Debt Maturities After Twenty Years Fair Value", "documentation": "This item represents the fair value of debt securities which are expected to mature after twenty years from the balance sheet date which are categorized neither as held-to-maturity nor trading securities." } } }, "auth_ref": { "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Debt Securities, Available for Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]", "auth_ref": { "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Amortized Cost, net", "label": "Debt Securities, Available for Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]", "auth_ref": { "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails": { "parentTag": "us-

gaap-AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 1.0 }, "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails"}, "lang": { "en-us": { "role": {
 "terseLabel": "Due in one year or less", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year
 One", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other
 comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year
 following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position
 date (rolling approach)."} } }, "auth_ref": { "r300", "r692" } }, "us-gaap-AvailableForSaleSecuritiesDebtSecurities": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit",
 "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap-Investments", "weight":
 1.0, "order": 1.0 }, "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails": { "parentTag":
 null, "weight": null, "order": null, "root": true } }, "presentation": {
 "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets",
 "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails",
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails",
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAvailableforSalebyComponentDetails",
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails"}, "lang": { "en-us": { "role": {
 "terseLabel": "Fixed maturities available for sale, at fair value (amortized cost: 2024u2014\$19,084,454; 2023u2014\$18,924,914; allowance
 for credit losses: 2024u2014\$7,132; 2023u2014\$7,115)", "verboseLabel": "Fairu00a0value", "totalLabel": "Fixed maturities, fair value", "label":
 "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value
 recognized in other comprehensive income (available-for-sale)."} } }, "auth_ref": { "r294", "r343", "r573", "r686", "r959", "r963", "r1160", "r1279",
 "r1279", "r1280" } }, "ecd-AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
 "AwardExrcPrice", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}, "lang": { "en-us": { "role": { "terseLabel": "Exercise
 Price", "label": "Award Exercise Price"} } }, "auth_ref": { "r1087" } }, "ecd-AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},
 "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value"} } }, "auth_ref": { "r1088" } },
 "ecd-AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems",
 "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": { "r1083" } },
 "ecd-AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
 "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}, "lang": { "en-us": { "role": {
 "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": { "r1083" } },
 "ecd-AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
 "AwardTmgMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}, "lang": { "en-us": { "role": { "terseLabel":
 "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": { "r1083" } }, "ecd-AwardTmgMnpiCnsdrdFlag": {
 "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": {
 "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}, "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label":
 "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": { "r1083" } }, "ecd-AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType",
 "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": {
 "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}, "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award
 Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": { "r1083" } }, "ecd-AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},
 "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": { "r1083"
 } }, "us-gaap-AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis",
 "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}, "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award
 Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": { "r511", "r512", "r513",
 "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532",
 "r533", "r534", "r535", "r536" } }, "ecd-AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
 "localname": "AwardUndrlygSecuritiesAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}, "lang": { "en-us": { "role": {
 "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount"} } }, "auth_ref": { "r1086" } },
 "ecd-AwardsCloseToMnpiDiscName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
 "AwardsCloseToMnpiDiscName", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}, "lang": { "en-us": { "role": {
 "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name"} } }, "auth_ref": { "r1085" } },
 "ecd-AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
 "AwardsCloseToMnpiDiscTable", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}, "lang": { "en-us": { "role": { "terseLabel":
 "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": { "r1084" } },
 "ecd-AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
 "AwardsCloseToMnpiDiscTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"}, "lang": { "en-us": { "role": {
 "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } },
 "auth_ref": { "r1084" } }, "us-gaap-BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": {
 "http://www.globelifeinsurance.com/role/SignificantAccountingPoliciesPolicies"}, "lang": { "en-us": { "role": { "terseLabel": "Basis of
 Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting,
 or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other
 Comprehensive Basis of Accounting, IFRS)."} } }, "auth_ref": { "r1084" } }, "us-gaap-BenefitsLossesAndExpenses": { "xbrltype": "monetaryItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BenefitsLossesAndExpenses", "crdr": "debit", "calculation": {
 "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-
 gaap-IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 },
 "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps":
 { "parentTag": "us-gaap-GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": {
 "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps":
 "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofOperations"}, "lang": { "en-us": { "role": { "totalLabel": "Total
 benefits and expenses", "label": "Benefits, Losses and Expenses", "documentation": "The total amount of expense recognized during the period for
 future policy benefits, claims and claims adjustment costs, and for selling, general and administrative costs." } } }, "auth_ref": { "r729" } }, "us-
 gaap-BenefitsLossesAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "BenefitsLossesAndExpensesAbstract", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofOperations"},
 "lang": { "en-us": { "role": { "terseLabel": "Benefits and expenses", "label": "Benefits, Losses and Expenses [Abstract]" } } }, "auth_ref": { "r1084"
 } }, "stpr-CA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "CA", "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails"}, "lang": { "en-us": { "role": {
 "terseLabel": "California", "label": "CALIFORNIA"} } }, "auth_ref": { "r1084" } }, "us-gaap-Cash": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "calculation": {
 "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 2.0 } },
 "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets"}, "lang": { "en-us": { "role": { "terseLabel":
 "Cash", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes
 other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and
 discontinued operation." } } }, "auth_ref": { "r150", "r709", "r809", "r838", "r971", "r1015", "r1124" } }, "us-
 gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": {
 "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows"}, "lang": { "en-us": { "role": { "periodStartLabel": "Cash
 at beginning of year", "periodEndLabel": "Cash at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash
 Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes
 amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or
 financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-
 term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present
 insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r26", "r94", "r207" } }, "us-
 gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit",
 "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null,
 "order": null, "root": true } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows"}, "lang":
 { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash

Equivalents, Period Increase (Decrease), Including Exchange Rate Effect": "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r0", "r94" } }, "us-gaap_CashSurrenderValueDuePolicyholdersAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashSurrenderValueDuePolicyholdersAmount", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Cash surrender value", "label": "Policyholder Account Balance, Cash Surrender Value", "documentation": "Amount of cash to be paid to policyholder upon termination and surrender of long-duration contract issued by insurance entity." } } }, "auth_ref": { "r777", "r996" } }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": { "r1063" } }, "ecd_ChngInFrValAsOfVstngDtOffPrYrEqtyAwrdsVstDnInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOffPrYrEqtyAwrdsVstDnInCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": { "r1060" } }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": { "r1058" } }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": { "http://www.globelifeinsurance.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": { "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": { "http://www.globelifeinsurance.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Class of Stock {Domain}", "label": "Class of Stock {Domain}", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": { "r162", "r178", "r179", "r180", "r210", "r235", "r236", "r238", "r240", "r247", "r248", "r327", "r387", "r390", "r391", "r392", "r396", "r397", "r428", "r429", "r430", "r431", "r433", "r594", "r793", "r794", "r795", "r796", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r810", "r830", "r854", "r873", "r895", "r896", "r897", "r898", "r899", "r1102", "r1140", "r1148" } }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": { "r1064" } }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": { "r1064" } }, "gl_CoinsuranceAgreementAnnuityReservesCeded": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "CoinsuranceAgreementAnnuityReservesCeded", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Annuity reserves ceded", "label": "Coinsurance Agreement, Annuity Reserves Ceded", "documentation": "Coinsurance Agreement, Annuity Reserves Ceded" } } }, "auth_ref": { "gl_CoinsuranceAgreementCedingCommissionBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "CoinsuranceAgreementCedingCommissionBeforeTax", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Coinsurance Agreement, Ceding Commission, Before Tax", "label": "Coinsurance Agreement, Ceding Commission, Before Tax", "documentation": "Coinsurance Agreement, Ceding Commission, Before Tax" } } }, "auth_ref": { "gl_CoinsuranceAgreementReinsurerPercentageOfAssetsHeldInTrustOfReserves": { "xbrltype": "percentItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "CoinsuranceAgreementReinsurerPercentageOfAssetsHeldInTrustOfReserves", "presentation": { "http://www.globelifeinsurance.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Assets held in trust of reserves (as a percent)", "label": "Coinsurance Agreement, Reinsurer, Percentage Of Assets Held in Trust of Reserves", "documentation": "Coinsurance Agreement, Reinsurer, Percentage Of Assets Held in Trust of Reserves" } } }, "auth_ref": { "us-gaap_CollateralizedDebtObligationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollateralizedDebtObligationsMember", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofChangesinAssetsMeasuredatFairValueonRecurringBasisUsingSignificantUnobservableInputs", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAvailableforSalebyComponentDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedGainsorLossesIncludedinOtherComprehensiveIncomeDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Collateralized debt obligations", "label": "Collateralized Debt Obligations [Member]", "documentation": "Securities collateralized by a pool of assets." } } }, "auth_ref": { "r959", "r961", "r963", "r1162", "r1174", "r1231" } }, "us-gaap_CommercialMortgageBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialMortgageBackedSecuritiesMember", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofInvestmentFundsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Commercial mortgage loans", "label": "Commercial Mortgage-Backed Securities [Member]", "documentation": "Securities collateralized by commercial real estate mortgage loans." } } }, "auth_ref": { "r959", "r961", "r963", "r1169", "r1176", "r1177", "r1231" } }, "gl_CommercialPaperIssuedDuringPeriodParValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "CommercialPaperIssuedDuringPeriodParValue", "crdr": "debit", "presentation": { "http://www.globelifeinsurance.com/role/DebtShortTermBorrowingsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Commercial paper issued during period (par value)", "label": "Commercial Paper Issued During Period, Par Value", "documentation": "Commercial Paper Issued During Period, Par Value" } } }, "auth_ref": { "gl_CommercialPaperMaturedDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "CommercialPaperMaturedDuringPeriod", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.globelifeinsurance.com/role/DebtShortTermBorrowingsDetails" }, "lang": { "en-us": { "role": { "negatedLabel": "Repayment of commercial paper with original maturities greater than 90 days", "terseLabel": "Commercial paper matured during period (par value)", "label": "Commercial Paper Matured During Period", "documentation": "Commercial Paper Matured During Period" } } }, "auth_ref": { "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": { "http://www.globelifeinsurance.com/role/DebtShortTermBorrowingsDetails", "http://www.globelifeinsurance.com/role/DebtShortTermBorrowingsDetails" }, "lang": { "en-us": { "role": { "verboseLabel": "Commercial paper", "terseLabel": "Commercial paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": { "r101", "r386", "r1010", "r1011", "r1012", "r1013" } }, "us-gaap_CommercialPortfolioSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPortfolioSegmentMember", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Commercial Portfolio Segment", "label": "Commercial Portfolio Segment [Member]", "documentation": "Portfolio segment of the company's total financing receivables related to commercial receivables." } } }, "auth_ref": { "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies (Note 5)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": { "r63", "r119", "r708", "r829" } }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": { "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-

```

"gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": f
"http://www.globelifeinsurance.com/role/CommitmentsAndContingencies", "lang": f "en-us", f "role": f "terseLabel": "Commitments and
Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and
contingencies." } } }, "auth_ref": f "r99", "r379", "r380", "r901", "r1189", "r1194" } }, "us-gaap-CommonStockDividendsPerShareDeclared": f
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareDeclared", "presentation":
f "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityParenthetical", "lang": f "en-us", f "role": f
"terseLabel": "Common dividends declared, per share (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared",
"documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": f "r104" } },
"us-gaap-CommonStockMember": f "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember",
"presentation": f "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfShareholdersEquity",
"http://www.globelifeinsurance.com/role/Cover", "lang": f "en-us", f "role": f "netLabel": "Common Stock, $1.00 par value per share",
"terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." }
} }, "auth_ref": f "r1006", "r1007", "r1008", "r1010", "r1011", "r1012", "r1013", "r1143", "r1144", "r1147", "r1274", "r1356", "r1360" } }, "us-
gaap-CommonStockParOrStatedValuePerShare": f "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockParOrStatedValuePerShare", "presentation": f
"http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "lang": f "en-us", f "role": f "terseLabel":
"Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or
stated value per share of common stock." } } }, "auth_ref": f "r66" } }, "us-gaap-CommonStockSharesAuthorized": f "xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": f
"http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "lang": f "en-us", f "role": f "terseLabel":
"Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common
shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": f "r66", "r830" } }, "us-gaap-CommonStockSharesIssued": f
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": f
"http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "lang": f "en-us", f "role": f "terseLabel":
"Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an
entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These
shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized.
Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": f "r66" } }, "us-
gaap-CommonStockSharesOutstanding": f "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockSharesOutstanding", "presentation": f
"http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "lang": f "en-us", f "role": f "terseLabel":
"Common stock, shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common
stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": f "r14", "r66", "r830", "r851", "r1360",
"r1361" } }, "us-gaap-CommonStockValue": f "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockValue", "crdr": "credit", "calculation": f "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": f
"parentTag": "us-gaap-StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": f
"http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets", "lang": f "en-us", f "role": f "verboseLabel": "Common stock,
par value $1 per share,u2014320,000,000 shares authorized; outstanding: (2024u2014102,218,183 issued; 2023u2014102,218,183 issued)",
"label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common
stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of
nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": f
"r66", "r711", "r971" } }, "ecd-CompActuallyPaidVsCoSelectedMeasureTextBlock": f "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": f
"http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": f "en-us", f "role": f "terseLabel": "Compensation Actually Paid vs. Company Selected
Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "auth_ref": f "r1069" } },
"ecd-CompActuallyPaidVsNetIncomeTextBlock": f "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsNetIncomeTextBlock", "presentation": f "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": f "en-us", f "role": f
"terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]", "auth_ref": f
"r1068" } }, "ecd-CompActuallyPaidVsOtherMeasureTextBlock": f "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": f "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": f "en-us", f
"role": f "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "auth_ref": f
"r1070" } }, "ecd-CompActuallyPaidVsTotalShareholderRtnTextBlock": f "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": f
"http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": f "en-us", f "role": f "terseLabel": "Compensation Actually Paid vs. Total Shareholder
Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "auth_ref": f "r1067" } },
"gl-CompanyOwnedLifeInsuranceMember": f "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname":
"CompanyOwnedLifeInsuranceMember", "presentation": f "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails",
"http://www.globelifeinsurance.com/role/InvestmentsScheduleOfOtherLongTermInvestmentsDetails", "lang": f "en-us", f "role": f "terseLabel":
"Company owned life insurance", "label": "Company Owned Life Insurance [Member]", "documentation": "Company Owned Life Insurance" } } },
"auth_ref": f "us-gaap-CompensationAndRetirementDisclosureAbstract": f "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CompensationAndRetirementDisclosureAbstract", "lang": f "en-us", f "role": f "terseLabel": "Retirement Benefits [Abstract]",
"label": "Retirement Benefits [Abstract]" } } }, "auth_ref": f "us-gaap-ComprehensiveIncomeNetOfTax": f "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": f
"http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": f "parentTag": null, "weight": null,
"order": null, "root": true } }, "presentation": f
"http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss",
"http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfShareholdersEquity", "lang": f "en-us", f "role": f "totalLabel":
"Comprehensive income (loss)", "terseLabel": "Comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to
Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net
income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and
distributions to owners." } } }, "auth_ref": f "r20", "r194", "r196", "r202", "r689", "r724", "r725" } }, "us-
gaap-ComprehensiveIncomeNoteTextBlock": f "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ComprehensiveIncomeNoteTextBlock", "presentation": f
"http://www.globelifeinsurance.com/role/SupplementalInformationAboutChangesToAccumulatedOtherComprehensiveIncome", "lang": f "en-us", f
"role": f "terseLabel": "Supplemental Information about Changes to Accumulated Other Comprehensive Income", "label": "Comprehensive Income
(Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount
of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the
reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of
comprehensive income." } } }, "auth_ref": f "r74", "r201", "r688", "r719" } }, "srt-ConsolidatedEntitiesAxis": f "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": f
"http://www.globelifeinsurance.com/role/DebtScheduleOfSelectedInformationAboutDebtIssuesDetails", "lang": f "en-us", f "role": f "terseLabel":
"Consolidated Entities [Axis]", "label": "Consolidated Entities [Axis]" } } }, "auth_ref": f "r211", "r555", "r556", "r557", "r558", "r615", "r906",
"r1202", "r1205", "r1206" } }, "srt-ConsolidatedEntitiesDomain": f "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"ConsolidatedEntitiesDomain", "presentation": f
"http://www.globelifeinsurance.com/role/DebtScheduleOfSelectedInformationAboutDebtIssuesDetails", "lang": f "en-us", f "role": f "terseLabel":
"Consolidated Entities [Domain]", "label": "Consolidated Entities [Domain]" } } }, "auth_ref": f "r211", "r555", "r556", "r557", "r558", "r615",
"r906", "r1202", "r1205", "r1206" } }, "srt-ConsolidationEliminationsMember": f "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024",
"localname": "ConsolidationEliminationsMember", "presentation": f
"http://www.globelifeinsurance.com/role/DebtScheduleOfSelectedInformationAboutDebtIssuesDetails", "lang": f "en-us", f "role": f "terseLabel":
"Consolidation Eliminations", "label": "Consolidation, Eliminations [Member]" } } }, "auth_ref": f "srt-ConsolidationItemsAxis": f "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": f
"http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleOfReconciliationOfSegmentOperatingInformationToConsolidatedStatementOfOps",
"http://www.globelifeinsurance.com/role/DebtScheduleOfSelectedInformationAboutDebtIssuesDetails", "lang": f "en-us", f "role": f "terseLabel":
"Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } } }, "auth_ref": f "r127", "r211", "r245", "r255", "r270", "r271", "r272", "r273",
"r274", "r276", "r277", "r278", "r387", "r388", "r389", "r390", "r392", "r393", "r394", "r395", "r396", "r924", "r925", "r1203", "r1204" } },
"srt-ConsolidationItemsDomain": f "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain",
"presentation": f
"http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleOfReconciliationOfSegmentOperatingInformationToConsolidatedStatementOfOps",
"http://www.globelifeinsurance.com/role/DebtScheduleOfSelectedInformationAboutDebtIssuesDetails", "lang": f "en-us", f "role": f "terseLabel":

```

"Consolidation Items [Domain]", "label": "Consolidation Items [Domain]", "auth_ref": "r127", "r211", "r245", "r255", "r270", "r271", "r272", "r273", "r274", "r276", "r277", "r278", "r387", "r388", "r389", "r390", "r392", "r393", "r394", "r395", "r396", "r924", "r925", "r1203", "r1204", "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofChangesinAssetsMeasuredatFairValueonRecurringBasisUsingSignificantUnobservableInputsDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAllowanceforCreditLossDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAvailableforSalebyComponentDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedGainsorLossesIncludedinOtherComprehensiveIncomeDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails", "lang": { "en-us": { "role": { "terseLabel": "Corporates", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } }, "auth_ref": "r946", "r948", "r959", "r972", "r1003", "r1353", "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateNonSegmentMember", "presentation": "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOperations", "lang": { "en-us": { "role": { "terseLabel": "Corporate & Other", "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } }, "auth_ref": "r15", "r271", "r272", "r273", "r274", "r277", "r1153", "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page", "label": "Cover [Abstract]", "documentation": "Cover page." } }, "auth_ref": "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } }, "auth_ref": "r386", "r1200", "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } }, "auth_ref": "r386", "r1200", "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": "http://www.globelifeinsurance.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD--", "auth_ref": "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]", "auth_ref": "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": "http://www.globelifeinsurance.com/role/Debt", "lang": { "en-us": { "role": { "terseLabel": "Debt", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } }, "auth_ref": "r100", "r209", "r369", "r370", "r371", "r372", "r375", "r385", "r386", "r398", "r404", "r405", "r406", "r407", "r408", "r409", "r414", "r421", "r422", "r424", "r607", "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails", "http://www.globelifeinsurance.com/role/DebtShortTermBorrowingsDetails", "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } }, "auth_ref": "r17", "r56", "r57", "r115", "r118", "r211", "r399", "r400", "r401", "r402", "r403", "r405", "r410", "r411", "r412", "r413", "r415", "r416", "r417", "r418", "r419", "r420", "r938", "r939", "r940", "r941", "r942", "r970", "r1141", "r1190", "r1191", "r1192", "r1288", "r1289", "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails", "lang": { "en-us": { "role": { "terseLabel": "Basis spread", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } }, "auth_ref": "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails", "parentTag": null, "weight": null, "order": null, "root": true, "presentation": "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails", "lang": { "en-us": { "role": { "totalLabel": "Debt", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } }, "auth_ref": "r17", "r118", "r425", "gl_DebtInstrumentExtensionTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "DebtInstrumentExtensionTerm", "presentation": "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Extension term", "label": "Debt Instrument, Extension Term", "documentation": "Debt Instrument, Extension Term" } }, "auth_ref": "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails", "http://www.globelifeinsurance.com/role/DebtShortTermBorrowingsDetails", "lang": { "en-us": { "role": { "terseLabel": "Balance of commercial paper at end of period (par value)", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } }, "auth_ref": "r399", "r607", "r608", "r939", "r940", "r970", "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFairValue", "crdr": "credit", "calculation": "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails", "parentTag": null, "weight": null, "order": null, "root": true, "presentation": "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails", "lang": { "en-us": { "role": { "totalLabel": "Total debt, fair value", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } }, "auth_ref": "r412", "r593", "r939", "r940", "r1277", "r1278", "r1279", "r1280", "r1281", "us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentIncreaseDecreaseForPeriodNet", "crdr": "credit", "presentation": "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, increase (decrease), net", "label": "Debt Instrument, Increase (Decrease), Net", "documentation": "Net increase or decrease in the carrying amount of the debt instrument for the period." } }, "auth_ref": "r1141", "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails", "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails", "lang": { "en-us": { "role": { "terseLabel": "Coupon Rate", "verboseLabel": "Interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } }, "auth_ref": "r59", "r400", "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails", "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails", "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } }, "auth_ref": "r211", "r399", "r400", "r401", "r402", "r403", "r405", "r410", "r411", "r412", "r413", "r415", "r416", "r417", "r418", "r419", "r420", "r423", "r938", "r939", "r940", "r941", "r942", "r970", "r1141", "r1288", "r1289", "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails", "http://www.globelifeinsurance.com/role/DebtShortTermBorrowingsDetails", "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } }, "auth_ref": "r17", "r211", "r399", "r400", "r401", "r402", "r403", "r405", "r410", "r411", "r412", "r413", "r415", "r416", "r417", "r418", "r419", "r420", "r423", "r938", "r939", "r940", "r941", "r942", "r970", "r1141", "r1190", "r1191", "r1192", "r1288", "r1289", "gl_DebtInstrumentRedemptionOptionalRedemptionPeriodFromIssuance": { "xbrltype": "durationItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "DebtInstrumentRedemptionOptionalRedemptionPeriodFromIssuance", "presentation": "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Optional redemption,

period from issuance date", "label": "Debt Instrument, Redemption, Optional Redemption, Period From Issuance", "documentation": "Debt Instrument, Redemption, Optional Redemption, Period From Issuance" } } }, "auth_ref": [] }, "us-gaap-DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": { "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails": { "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement" } } }, "auth_ref": ["r17", "r41", "r42", "r53", "r102", "r103", "r211", "r399", "r400", "r401", "r402", "r403", "r405", "r410", "r411", "r412", "r413", "r415", "r416", "r417", "r418", "r419", "r420", "r423", "r938", "r939", "r940", "r941", "r942", "r970", "r1141", "r1288", "r1289"] }, "gl-DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsCurrentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsCurrentNet", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails": { "parentTag": "us-gaap-DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Unamortized discount & issuance costs, current", "label": "Debt Instrument, Unamortized Discount (Premium) And Debt Issuance Costs, Current, Net", "documentation": "Debt Instrument, Unamortized Discount (Premium) And Debt Issuance Costs, Current, Net" } } }, "auth_ref": [] }, "us-gaap-DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails": { "parentTag": "us-gaap-DebtLongtermAndShorttermCombinedAmount", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails": { "lang": { "en-us": { "role": { "negatedTotalLabel": "Total debt, unamortized discount & issuance costs", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": ["r410", "r426", "r606", "r607", "r608", "r939", "r940", "r970"] }, "gl-DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNoncurrentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNoncurrentNet", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails": { "parentTag": "us-gaap-DebtInstrumentCarryingAmount", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Unamortized discount & issuance costs, noncurrent", "label": "Debt Instrument, Unamortized Discount (Premium) And Debt Issuance Costs, Noncurrent, Net", "documentation": "Debt Instrument, Unamortized Discount (Premium) And Debt Issuance Costs, Noncurrent, Net" } } }, "auth_ref": [] }, "us-gaap-DebtLongtermAndShorttermCombinedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtLongtermAndShorttermCombinedAmount", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total debt, book value", "label": "Debt, Long-Term and Short-Term, Combined Amount", "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt." } } }, "auth_ref": [] }, "us-gaap-DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheetsParenthetical": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAllowanceforCreditLossDetails": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAvailableforSalebyComponentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fixed maturities, available for sale, allowance for credit losses", "negatedLabel": "Allowance for Credit Losses", "periodStartLabel": "Allowance for credit losses beginning balance", "periodEndLabel": "Allowance for credit losses ending balance", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": ["r295", "r343", "r351", "r355"] }, "gl-DebtSecuritiesAvailableForSaleAllowanceForCreditLossProvisionsForCreditLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossProvisionsForCreditLosses", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofRealizedGainLossonInvestmentsDetails": { "parentTag": "gl-RealizedInvestmentGainsLossesBeforeRedemptionOfDebtAndOtherGainsLosses", "weight": -1.0, "order": 5.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofRealizedGainLossonInvestmentsDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Provision for credit losses", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Provisions for Credit Losses", "documentation": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Provisions for Credit Losses" } } }, "auth_ref": [] }, "us-gaap-DebtSecuritiesAvailableForSaleAllowanceForCreditLossRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossRollForward", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAllowanceforCreditLossDetails": { "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available for sale, Allowance for Credit Loss [Roll Forward]", "label": "Debt Securities, Available for Sale, Allowance for Credit Loss [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap-DebtSecuritiesAvailableForSaleAllowanceForCreditLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossTable", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAllowanceforCreditLossDetails": { "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available for sale, Allowance for Credit Loss [Table]", "label": "Debt Securities, Available for Sale, Allowance for Credit Loss [Table]", "documentation": "Disclosure of information about allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": ["r350"] }, "us-gaap-DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails": { "lang": { "en-us": { "role": { "totalLabel": "Fixed maturities, net of allowance for credit losses", "label": "Debt Securities, Available for Sale, Amortized Cost, after Allowance for Credit Loss", "documentation": "Amortized cost, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": ["r1162"] }, "us-gaap-DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss", "crdr": "debit", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAvailableforSalebyComponentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Amortized Cost", "label": "Debt Securities, Available for Sale and Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss", "documentation": "Amortized cost, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": ["r1163", "r1175"] }, "us-gaap-DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails": { "parentTag": "us-gaap-DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails": { "lang": { "en-us": { "role": { "role": { "terseLabel": "Fair Value, Twelve Months or Longer", "label": "Debt Securities, Available for Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": ["r144", "r348", "r936"] }, "us-gaap-DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails": { "parentTag": "us-


```

gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails" }, "lang": { "en-us": {
"role": { "negatedTerseLabel": "Unrealized Loss, Twelve Months or Longer", "label": "Debt Securities, Available for Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": {
"r144", "r348" } }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
"xbrltype": "IntegerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions", "calculation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofInformationaboutInvestmentsinUnrealizedLossPositionDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofInformationaboutInvestmentsinUnrealizedLossPositionDetails" }, "lang": { "en-us": {
"role": { "terseLabel": "Twelve Months or Longer", "label": "Debt Securities, Available for Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions", "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": { "r1186" } }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
"xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "crdr":
"debit", "calculation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails" }, "lang": { "en-us": {
"role": { "terseLabel": "Fair Value, Less than Twelve Months", "label": "Debt Securities, Available for Sale, Continuous Unrealized Loss Position, Less than 12 Months", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": { "r144", "r348", "r936" } }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "crdr": "debit", "calculation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails" }, "lang": { "en-us": {
"role": { "negatedTerseLabel": "Unrealized Loss, Less than Twelve Months", "label": "Debt Securities, Available for Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": {
"r144", "r348" } }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": {
"xbrltype": "IntegerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "calculation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofInformationaboutInvestmentsinUnrealizedLossPositionDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofInformationaboutInvestmentsinUnrealizedLossPositionDetails" }, "lang": { "en-us": {
"role": { "terseLabel": "Less than Twelve Months", "label": "Debt Securities, Available for Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions", "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": { "r1186" } }, "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded", "crdr": "debit", "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAllowanceforCreditLossDetails" }, "lang": { "en-us": { "role": {
"terseLabel": "Additions to allowance for which credit losses were not previously recorded", "label": "Debt Securities, Available for Sale, Excluding Accrued Interest, Allowance for Credit Loss, Not Previously Recorded", "documentation": "Amount, excluding accrued interest, of credit loss expense on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) with no credit loss previously recorded." } } }, "auth_ref": { "r352" } }, "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpense": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpense", "crdr": "debit", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAllowanceforCreditLossDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Additions (reductions) to allowance for fixed maturities that previously had an allowance", "label": "Debt Securities, Available for Sale, Excluding Accrued Interest, Allowance for Credit Loss, Not to Sell before Recovery, Credit Loss, Previously Recorded, Expense (Reversal)", "documentation": "Amount, excluding accrued interest, of credit loss expense (reversal of expense) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) with previously recorded allowance and not intended to be sold and not more likely than not will be required to sell before recovery of amortized cost basis." } } }, "auth_ref": { "r354" } }, "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossSellBeforeRecovery": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossSellBeforeRecovery", "crdr": "debit", "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAllowanceforCreditLossDetails" }, "lang": { "en-us": { "role": { "negatedLabel": "Reduction of allowance for which the Company intends to sell or more likely than not will be required to sell or sold during the period", "label": "Debt Securities, Available for Sale, Excluding Accrued Interest, Allowance for Credit Loss, Sell before Recovery", "documentation": "Amount, excluding accrued interest, of decrease in allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) from intent to sell or more likely than not will be required to sell before recovery of amortized cost basis." } } }, "auth_ref": { "r353" } }, "gl_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAmortizedCostNetOfAllowanceForCreditLoss": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname":
"DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAmortizedCostNetOfAllowanceForCreditLoss", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0, "order": 3.0 } }, "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Due after five years through ten years", "label": "Debt Securities, Available For Sale, Maturity, Allocated And Single Maturity Date, After Five Through Ten Years, Amortized Cost, Net Of Allowance For Credit Loss", "documentation": "Debt Securities, Available For Sale, Maturity, Allocated And Single Maturity Date, After Five Through Ten Years, Amortized Cost, Net Of Allowance For Credit Loss" } } }, "auth_ref": { H1 }, "gl_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAmortizedCostNetOfAllowanceForCreditLoss": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname":
"DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAmortizedCostNetOfAllowanceForCreditLosses", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Due after one year through five years", "label": "Debt Securities, Available For Sale, Maturity, Allocated And Single Maturity Date, After One Through Five Years, Amortized Cost, Net Of Allowance For Credit Losses", "documentation": "Debt Securities, Available For Sale, Maturity, Allocated And Single Maturity Date, After One Through Five Years, Amortized Cost, Net Of Allowance For Credit Losses" } } }, "auth_ref": { H1 }, "gl_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterTenThroughTwentyYearsAmortizedCostNetOfAllowanceForCreditLoss": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname":
"DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterTenThroughTwentyYearsAmortizedCostNetOfAllowanceForCreditLoss", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0, "order": 4.0 } }, "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Due after ten years through twenty years", "label": "Debt Securities, Available For Sale, Maturity, Allocated And Single Maturity Date, After Ten Through Twenty Years, Amortized Cost, Net Of Allowance For Credit Loss", "documentation": "Debt Securities, Available For Sale, Maturity, Allocated And Single Maturity Date, After Ten Through Twenty Years, Amortized Cost, Net Of Allowance For Credit Loss" } } }, "auth_ref": { H1 }

```

"auth_ref": [] },
"gl_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterTwentyYearsAmortizedCostNetOfAllowanceForCreditLoss": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname":
"DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterTwentyYearsAmortizedCostNetOfAllowanceForCreditLoss", "crdr":
"debit", "calculation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails": {
"parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0, "order": 5.0 } }, "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails": { "lang": { "en-us": { "role": {
"terseLabel": "Due after twenty years", "label": "Debt Securities, Available For Sale, Maturity, Allocated And Single Maturity Date, After Twenty
Years, Amortized Cost, Net Of Allowance For Credit Loss", "documentation": "Debt Securities, Available For Sale, Maturity, Allocated And Single
Maturity Date, After Twenty Years, Amortized Cost, Net Of Allowance For Credit Loss" } } }, "auth_ref": [] },
"gl_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateWithinOneYearAmortizedCostNetOfAllowanceForCreditLosses": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname":
"DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateWithinOneYearAmortizedCostNetOfAllowanceForCreditLosses", "crdr":
"debit", "calculation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails": {
"parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails": { "lang": { "en-us": { "role": {
"terseLabel": "Due in one year or less", "label": "Debt Securities, Available For Sale, Maturity, Allocated And Single Maturity Date, Within One
Year, Amortized Cost, Net Of Allowance For Credit Losses", "documentation": "Debt Securities, Available For Sale, Maturity, Allocated And Single
Maturity Date, Within One Year, Amortized Cost, Net Of Allowance For Credit Losses" } } }, "auth_ref": [] },
"gl_DebtSecuritiesAvailableForSaleNoncashSaleExchangeOfSecurities": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.globelifeinsurance.com/20240930", "localname": "DebtSecuritiesAvailableForSaleNoncashSaleExchangeOfSecurities", "crdr": "debit",
"presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofRealizedGainLossOnInvestmentsDetails": { "lang": { "en-us": {
"role": { "terseLabel": "Exchanges of fixed maturities", "label": "Debt Securities, Available For Sale, Noncash Sale, Exchange Of Securities",
"documentation": "Debt Securities, Available For Sale, Noncash Sale, Exchange Of Securities" } } }, "auth_ref": [] }, "us-
gaap_DebtSecuritiesAvailableForSaleRealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtSecuritiesAvailableForSaleRealizedGain", "crdr": "credit", "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofSelectedInformationaboutSalesofFixedMaturitiesDetails": { "lang": { "en-us": {
"role": { "terseLabel": "Gross realized gains", "label": "Debt Securities, Available for Sale, Realized Gain", "documentation": "Amount of realized
gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for
sale)." } } }, "auth_ref": ["r322"] }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "crdr": "credit", "calculation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofRealizedGainLossOnInvestmentsDetails": { "parentTag":
"gl_RealizedInvestmentGainsLossesBeforeRedemptionOfDebtAndOtherGainsLosses", "weight": 1.0, "order": 3.0 } }, "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofRealizedGainLossOnInvestmentsDetails": { "lang": { "en-us": { "role": {
"terseLabel": "Sales and other", "label": "Debt Securities, Available for Sale, Realized Gain (Loss)", "documentation": "Amount of realized gain
(loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for
sale)." } } }, "auth_ref": ["r1178"] }, "gl_DebtSecuritiesAvailableForSaleRealizedGainLossOnExchanges": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "DebtSecuritiesAvailableForSaleRealizedGainLossOnExchanges", "crdr":
"credit", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofRealizedGainLossOnInvestmentsDetails": { "lang": { "en-
us": { "role": { "terseLabel": "Exchanges of fixed maturities, net realized gains", "label": "Debt Securities, Available For Sale, Realized Gain (Loss)
On Exchanges", "documentation": "Debt Securities, Available For Sale, Realized Gain (Loss) On Exchanges" } } }, "auth_ref": [] }, "us-
gaap_DebtSecuritiesAvailableForSaleRealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtSecuritiesAvailableForSaleRealizedLoss", "crdr": "debit", "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofSelectedInformationaboutSalesofFixedMaturitiesDetails": { "lang": { "en-us": {
"role": { "negatedLabel": "Gross realized losses", "label": "Debt Securities, Available for Sale, Realized Loss", "documentation": "Amount of realized
loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for
sale)." } } }, "auth_ref": ["r322"] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails":
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAvailableForSalebyComponentDetails",
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails": { "lang": { "en-us": {
"role": { "terseLabel": "Debt Securities, Available for sale [Table]", "label": "Debt Securities, Available for Sale [Table]", "documentation":
"Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive
income (available for sale)." } } }, "auth_ref": ["r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303"] }, "us-
gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsTables": { "lang": { "en-us":
{ "role": { "terseLabel": "Schedule of Fair Value of Fixed Maturities Measured on a Recurring Basis", "label": "Debt Securities, Available for Sale
[Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value
recognized in other comprehensive income (available for sale)." } } }, "auth_ref": ["r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169",
"r1170", "r1171", "r1172", "r1173", "r1178"] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "crdr":
"debit", "calculation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails":
{ "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails": { "lang": { "en-us": {
"role": { "totalLabel": "Fair Value", "label": "Debt Securities, Available for Sale, Unrealized Loss Position", "documentation": "Amount of
investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale), in
unrealized loss position without allowance for credit loss." } } }, "auth_ref": ["r141", "r345", "r346"] }, "us-
gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "crdr": "debit", "calculation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails": { "parentTag": null,
"weight": null, "order": null, "root": true } }, "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails": { "lang": { "en-us": {
"role": { "negatedTotalLabel": "Unrealized Loss", "label": "Debt Securities, Available for Sale, Unrealized Loss Position, Accumulated Loss",
"documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value
recognized in other comprehensive income (available for sale), in unrealized loss position, without allowance for credit loss. Includes beneficial
interest in securitized financial asset." } } }, "auth_ref": ["r142", "r346"] }, "us-
gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "calculation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofInformationaboutInvestmentsinUnrealizedLossPositionDetails": { "parentTag":
null, "weight": null, "order": null, "root": true } }, "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofInformationaboutInvestmentsinUnrealizedLossPositionDetails": { "lang": { "en-us":
{ "role": { "totalLabel": "Total", "label": "Debt Securities, Available for Sale, Unrealized Loss Position, Number of Positions", "documentation":
"Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available
for sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref":
["r143", "r347"] }, "gl_DebtSecuritiesAvailableForSaleUnsettledTrades": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.globelifeinsurance.com/20240930", "localname": "DebtSecuritiesAvailableForSaleUnsettledTrades", "crdr": "debit", "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofSelectedInformationaboutSalesofFixedMaturitiesDetails": { "lang": { "en-us": {
"role": { "terseLabel": "Unsettled trades", "label": "Debt Securities, Available For Sale, Unsettled Trades", "documentation": "Debt Securities,
Available For Sale, Unsettled Trades" } } }, "auth_ref": [] },
"gl_DebtSecuritiesAvailableForSaleWithoutSingleMaturityDateNetOfAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.globelifeinsurance.com/20240930", "localname":
"DebtSecuritiesAvailableForSaleWithoutSingleMaturityDateNetOfAllowanceForCreditLoss", "crdr": "debit", "calculation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails": { "parentTag": "us-
gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0, "order": 6.0 } }, "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails": { "lang": { "en-us": { "role": {
"terseLabel": "Mortgage-backed and asset-backed securities", "label": "Debt Securities, Available For Sale, Without Single Maturity Date, Net Of
Allowance For Credit Loss", "documentation": "Debt Securities, Available For Sale, Without Single Maturity Date, Net Of Allowance For Credit
Loss" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableforsaleAllowanceForCreditLossLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableforsaleAllowanceForCreditLossLineItems", "presentation": {

```

http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAllowanceforCreditLossDetails },"lang":{ "en-us": { "role": { "terseLabel": "Debt Securities, Available for sale, Allowance for Credit Loss [Line Items]", "label": "Debt Securities, Available for Sale, Allowance for Credit Loss [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r350" } },
"gl_DebtServiceCoverageRatio1.00x1.20xMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "DebtServiceCoverageRatio1.00x1.20xMember", "presentation": {
http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsRecordedInvestmentDetails },"lang":{ "en-us": { "role": { "terseLabel": "1.00x-1.20x", "label": "Debt Service Coverage Ratio, 1.00x-1.20x [Member]", "documentation": "Debt Service Coverage Ratio, 1.00x-1.20x [Member]" } } }, "auth_ref": { } }, "gl_DebtServiceCoverageRatioAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "DebtServiceCoverageRatioAxis", "presentation": {
http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsRecordedInvestmentDetails },"lang":{ "en-us": { "role": { "terseLabel": "Debt Service Coverage Ratio [Axis]", "label": "Debt Service Coverage Ratio [Axis]", "documentation": "Debt Service Coverage Ratio [Axis]" } } }, "auth_ref": { } }, "gl_DebtServiceCoverageRatioDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "DebtServiceCoverageRatioDomain", "presentation": {
http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsRecordedInvestmentDetails },"lang":{ "en-us": { "role": { "terseLabel": "Debt Service Coverage Ratio [Domain]", "label": "Debt Service Coverage Ratio [Domain]", "documentation": "Domain for Debt Service Coverage Ratio [Axis]" } } }, "auth_ref": { } }, "gl_DebtServiceCoverageRatioGreaterThan1.20xMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "DebtServiceCoverageRatioGreaterThan1.20xMember", "presentation": {
http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsRecordedInvestmentDetails },"lang":{ "en-us": { "role": { "terseLabel": "Greater Than 1.20x", "label": "Debt Service Coverage Ratio, Greater Than 1.20x [Member]", "documentation": "Debt Service Coverage Ratio, Greater Than 1.20x [Member]" } } }, "auth_ref": { } }, "gl_DebtServiceCoverageRatioLessThan1.00xMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "DebtServiceCoverageRatioLessThan1.00xMember", "presentation": {
http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsRecordedInvestmentDetails },"lang":{ "en-us": { "role": { "terseLabel": "Less Than 1.00x", "label": "Debt Service Coverage Ratio, Less Than 1.00x [Member]", "documentation": "Debt Service Coverage Ratio, Less Than 1.00x" } } }, "auth_ref": { } }, "us-gaap_DeferredFixedAnnuityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFixedAnnuityMember", "presentation": {
http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceDetails,
http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetails },"lang":{ "en-us": { "role": { "terseLabel": "Deferred Annuity", "label": "Deferred Fixed Annuity [Member]", "documentation": "Contract that provides a guaranteed stream of fixed payments beginning at a future date." } } }, "auth_ref": { } }, "us-gaap_DeferredPolicyAcquisitionCostAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredPolicyAcquisitionCostAmortizationExpense", "crdr": "debit", "calculation": {
http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps },"parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0, "order": 1.0 },
http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfOperations },"parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": {
http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps,
http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfOperations },
http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofAnalysisofDeferredAcquisitionCostsDetails },"lang":{ "en-us": { "role": { "netLabel": "Amortization of deferred acquisition costs", "negatedLabel": "Amortization expense", "verboseLabel": "Amortization of acquisition costs", "label": "Deferred Policy Acquisition Costs, Amortization Expense", "documentation": "Amount of amortization expense (reversal of expense) for deferred policy acquisition costs." } } }, "auth_ref": { "r145", "r730", "r750", "r751", "r783", "r981", "r1137", "r1305" } }, "us-gaap_DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredPolicyAcquisitionCostForeignCurrencyTranslationAdjustmentAndOther", "crdr": "debit", "presentation": {
http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofAnalysisofDeferredAcquisitionCostsDetails },"lang":{ "en-us": { "role": { "terseLabel": "Foreign exchange adjustment", "label": "Deferred Policy Acquisition Cost, Foreign Currency Translation Adjustment and Other", "documentation": "Amount of increase (decrease) in deferred policy acquisition cost due to the effect of foreign currency translation gain (loss) and increase (decrease) classified as other." } } }, "auth_ref": { "r1318", "r1352" } }, "us-gaap_DeferredPolicyAcquisitionCostLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredPolicyAcquisitionCostLineItems", "presentation": {
http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofAnalysisofDeferredAcquisitionCostsDetails,
http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofDeferredPolicyAcquisitionCoststoConsolidatedBalanceSheetDetails },"lang":{ "en-us": { "role": { "terseLabel": "Deferred Policy Acquisition Cost [Line Items]", "label": "Deferred Policy Acquisition Cost [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r751", "r783", "r981" } }, "us-gaap_DeferredPolicyAcquisitionCostTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredPolicyAcquisitionCostTable", "presentation": {
http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofAnalysisofDeferredAcquisitionCostsDetails,
http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofDeferredPolicyAcquisitionCoststoConsolidatedBalanceSheetDetails },"lang":{ "en-us": { "role": { "terseLabel": "Deferred Policy Acquisition Cost [Table]", "label": "Deferred Policy Acquisition Cost [Table]", "documentation": "Disclosure of information about deferred policy acquisition cost." } } }, "auth_ref": { "r751", "r783", "r981" } }, "us-gaap_DeferredPolicyAcquisitionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredPolicyAcquisitionCosts", "crdr": "debit", "calculation": {
http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets },"parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": {
http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofAnalysisofDeferredAcquisitionCostsDetails,
http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofDeferredPolicyAcquisitionCoststoConsolidatedBalanceSheetDetails },"lang":{ "en-us": { "role": { "terseLabel": "Deferred acquisition costs", "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Deferred Policy Acquisition Cost", "documentation": "Amount of deferred policy acquisition cost capitalized on contract remaining in force." } } }, "auth_ref": { "r147", "r716", "r751", "r752", "r783", "r981" } }, "us-gaap_DeferredPolicyAcquisitionCostsAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredPolicyAcquisitionCostsAdditions", "crdr": "debit", "presentation": {
http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofAnalysisofDeferredAcquisitionCostsDetails },"lang":{ "en-us": { "role": { "terseLabel": "Capitalizations", "label": "Deferred Policy Acquisition Cost, Capitalization", "documentation": "Amount of deferred policy acquisition cost capitalized." } } }, "auth_ref": { "r981", "r1318", "r1352" } }, "us-gaap_DeferredPolicyAcquisitionCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredPolicyAcquisitionCostsTableTextBlock", "presentation": {
http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsTables },"lang":{ "en-us": { "role": { "verboseLabel": "Schedule of Analysis of Deferred Acquisition Costs", "label": "Deferred Policy Acquisition Costs [Table Text Block]", "documentation": "Tabular disclosure of the movement in deferred policy acquisition costs." } } }, "auth_ref": { "r751", "r783", "r981", "r1319" } }, "us-gaap_DeferredPolicyAcquisitionCostsTextBlock1": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredPolicyAcquisitionCostsTextBlock1", "presentation": {
http://www.globelifeinsurance.com/role/DeferredAcquisitionCosts },"lang":{ "en-us": { "role": { "terseLabel": "Deferred Acquisition Costs", "label": "Deferred Policy Acquisition Costs [Text Block]", "documentation": "The entire disclosure for deferred policy acquisition costs." } } }, "auth_ref": { "r125" } }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "crdr": "credit", "calculation": {
http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofNetPeriodicBenefitCostDetails },"parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 5.0 } }, "presentation": {
http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofNetPeriodicBenefitCostDetails },"lang":{ "en-us": { "role": { "negatedTerseLabel": "Actuarial (gain) loss", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "documentation": "Amount of gain
```

"DefinedBenefitPlanBenefitObligation", "crdr": "credit", "presentation": {
 "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionandSERPLiabilitiesDetails", "lang": { "en-us": { "role": {
 "terseLabel": "Benefit obligation", "label": "Defined Benefit Plan, Benefit Obligation", "documentation": "Amount of actuarial present value of
 benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": { "r438" } }, "us-
 gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DefinedBenefitPlanByPlanAssetCategoriesAxis", "presentation": {
 "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionAssetsbyComponentatFairValueDetails", "lang": { "en-us": {
 "role": { "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]",
 "documentation": "Information by defined benefit plan asset investment." } } }, "auth_ref": { "r459", "r460", "r462", "r463", "r464", "r465", "r466",
 "r467", "r485", "r946", "r947", "r948" } }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": {
 "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionAssetsbyComponentatFairValueDetails",
 "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionandSERPLiabilitiesDetails", "lang": { "en-us": { "role": {
 "terseLabel": "Defined Benefit Plan Disclosure [Line Items]", "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items
 represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members
 defined in one or many axes to the table." } } }, "auth_ref": { } }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "crdr": "credit",
 "calculation": { "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofNetPeriodicBenefitCostDetails": { "parentTag": "us-
 gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 4.0 } }, "presentation": {
 "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofNetPeriodicBenefitCostDetails", "lang": { "en-us": { "role": {
 "negatedTerseLabel": "Expected return on assets", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "documentation":
 "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and
 market-related value of plan assets of defined benefit plan." } } }, "auth_ref": { "r437", "r474", "r495", "r948", "r949" } }, "us-
 gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DefinedBenefitPlanFairValueOfPlanAssets", "crdr": "debit", "presentation": {
 "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionAssetsbyComponentatFairValueDetails", "lang": { "en-us": {
 "role": { "terseLabel": "Fair value of plan assets", "label": "Defined Benefit Plan, Plan Assets, Amount", "documentation": "Amount of asset
 segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment,
 earning from investment, and contribution by employer and employee." } } }, "auth_ref": { "r449", "r460", "r462", "r463", "r946", "r947", "r948" } }, "us-
 gaap_DefinedBenefitPlanInterestCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DefinedBenefitPlanInterestCost", "crdr": "debit", "calculation": {
 "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofNetPeriodicBenefitCostDetails": { "parentTag": "us-
 gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 1.0 } }, "presentation": {
 "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofNetPeriodicBenefitCostDetails", "lang": { "en-us": { "role": {
 "verboseLabel": "Interest cost on projected benefit obligation", "label": "Defined Benefit Plan, Interest Cost", "documentation": "Amount of cost
 recognized for passage of time related to defined benefit plan." } } }, "auth_ref": { "r437", "r441", "r473", "r494", "r948", "r949" } },
 "gl_DefinedBenefitPlanInvestmentGradeSecuritiesIssuedTerm": { "xbrltype": "durationItemType", "nsuri":
 "http://www.globelifeinsurance.com/20240930", "localname": "DefinedBenefitPlanInvestmentGradeSecuritiesIssuedTerm", "presentation": {
 "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionAssetsbyComponentatFairValueDetails", "lang": { "en-us": {
 "role": { "terseLabel": "Investment grade securities issued term", "label": "Defined Benefit Plan, Investment-Grade Securities, Issued Term",
 "documentation": "Defined Benefit Plan, Investment-Grade Securities, Issued Term" } } }, "auth_ref": { } }, "us-
 gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DefinedBenefitPlanNetPeriodicBenefitCost", "crdr": "debit", "calculation": {
 "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofNetPeriodicBenefitCostDetails": { "parentTag": null, "weight": null,
 "order": null, "root": true } }, "presentation": {
 "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofNetPeriodicBenefitCostDetails", "lang": { "en-us": { "role": {
 "totalLabel": "Net periodic benefit cost", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "documentation": "Amount of net
 periodic benefit cost (credit) for defined benefit plan." } } }, "auth_ref": { "r471", "r492", "r948", "r949" } }, "us-
 gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryAmount", "crdr": "debit", "presentation": {
 "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionAssetsbyComponentatFairValueDetails", "lang": { "en-us": {
 "role": { "terseLabel": "Fair value of plan assets, within plan asset category", "label": "Defined Benefit Plan, Plan Assets, Investment within Plan
 Asset Category, Amount", "documentation": "Amount of investment within defined benefit plan asset category." } } }, "auth_ref": { "r1231" } }, "us-
 gaap_DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsInvestmentWithinPlanAssetCategoryPercentage", "presentation": {
 "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionAssetsbyComponentatFairValueDetails", "lang": { "en-us": {
 "role": { "terseLabel": "Percentage of total plan assets, within plan asset category", "label": "Defined Benefit Plan, Plan Assets, Investment within
 Plan Asset Category, Percentage", "documentation": "Percentage of investment to total investment within defined benefit plan asset category." } } }
 }, "auth_ref": { "r948", "r1231" } }, "us-gaap_DefinedBenefitPlanServiceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "DefinedBenefitPlanServiceCost", "crdr": "debit", "calculation": {
 "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofNetPeriodicBenefitCostDetails": { "parentTag": "us-
 gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 3.0 } }, "presentation": {
 "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofNetPeriodicBenefitCostDetails", "lang": { "en-us": { "role": {
 "terseLabel": "Service cost", "label": "Defined Benefit Plan, Service Cost", "documentation": "Amount of
 cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": { "r439", "r472",
 "r493", "r948", "r949" } }, "us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations": { "xbrltype": "percentItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanWeightedAverageAssetAllocations", "presentation": {
 "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionAssetsbyComponentatFairValueDetails", "lang": { "en-us": {
 "role": { "terseLabel": "Percentage of plan assets", "label": "Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage", "documentation":
 "Percentage of actual investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted average basis if more than
 one plan." } } }, "auth_ref": { "r1230" } }, "gl_DirectResponseMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.globelifeinsurance.com/20240930", "localname": "DirectResponseMember", "presentation": {
 "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofSegmentPremiumIncomebyDistributionChannelDetails", "lang": { "en-us":
 { "role": { "terseLabel": "Direct to Consumer", "label": "Direct Response [Member]", "documentation": "Direct response [Member]." } } } },
 "auth_ref": { } }, "gl_DirectToConsumerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930",
 "localname": "DirectToConsumerMember", "presentation": {
 "http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofAnalysisofDeferredAcquisitionCostsDetails",
 "http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofDeferredPolicyAcquisitionCoststoConsolidatedBalanceSheetDetails",
 "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails",
 "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedIncomeStatementDetails",
 "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitActivityDetails",
 "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofUndiscountedAndDiscountedExpectedFutureGrossPremiumsAndExpectedFuture
 Income by Distribution Channel", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation
 of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } } },
 "auth_ref": { "r1208" } }, "gl_DistributionChannelOtherMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.globelifeinsurance.com/20240930", "localname": "DistributionChannelOtherMember", "presentation": {
 "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofSegmentPremiumIncomebyDistributionChannelDetails", "lang": { "en-us":
 { "role": { "terseLabel": "Other", "label": "Distribution Channel Other [Member]", "documentation": "Distribution channel, other [Member]." } } } },
 "auth_ref": { } }, "us-gaap_DividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DividendsCommonStock", "crdr": "debit", "presentation": {
 "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfShareholdersEquity", "lang": { "en-us": { "role": { "negatedLabel":
 Common dividends declared", "label": "Dividends, Common Stock", "documentation": "Amount of paid and unpaid common stock dividends
 declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": { "r8", "r104" } },

"dei DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": { "http://www.globelifeinsurance.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } } }, "auth_ref": { } }, "dei DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": { "http://www.globelifeinsurance.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } } }, "auth_ref": { } }, "dei DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": { "http://www.globelifeinsurance.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } } }, "auth_ref": { } }, "dei DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": { "http://www.globelifeinsurance.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } } }, "auth_ref": { "r1019": { } }, "dei DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": { "http://www.globelifeinsurance.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } } }, "auth_ref": { "r1051": { } }, "dei DocumentType": { "xbrltype": "submissionItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": { "http://www.globelifeinsurance.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } } }, "auth_ref": { } }, "ecd DvddsOrOthrErngsPdOnEqtyAwrdNtOthrRfctdInTHCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdNtOthrRfctdInTHCompForCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } } }, "auth_ref": { "r203", "r221", "r222", "r223", "r224", "r225", "r226", "r233", "r235", "r238", "r239", "r240", "r244", "r551", "r554", "r570", "r571", "r690", "r726", "r917": { } }, "us-gaap EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } } }, "auth_ref": { "r203", "r221", "r222", "r223", "r224", "r225", "r226", "r233", "r235", "r238", "r239", "r240", "r244", "r551", "r554", "r570", "r571", "r690", "r726", "r917": { } }, "us-gaap EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofOperations": { "lang": { "en-us": { "role": { "verboseLabel": "Basic net income per common share (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } } }, "auth_ref": { "r203", "r221", "r222", "r223", "r224", "r225", "r226", "r233", "r235", "r238", "r239", "r240", "r244", "r551", "r554", "r570", "r571", "r690", "r726", "r917": { } }, "us-gaap EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofOperations": { "lang": { "en-us": { "role": { "verboseLabel": "Diluted net income per common share (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } } }, "auth_ref": { "r203", "r221", "r222", "r223", "r224", "r225", "r226", "r233", "r235", "r238", "r239", "r240", "r244", "r551", "r554", "r570", "r571", "r690", "r726", "r917": { } }, "us-gaap EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": { "http://www.globelifeinsurance.com/role/EarningsPerShare": { "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } } }, "auth_ref": { "r232", "r241", "r242", "r243": { } }, "us-gaap EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Effect of foreign exchange rate changes on cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } } }, "auth_ref": { "r596": { } }, "us-gaap EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } } }, "auth_ref": { } }, "gl EntirePortfolioNumberOfIssuersOffixedMaturities": { "xbrltype": "integerItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "EntirePortfolioNumberOfIssuersOffixedMaturities", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fixed portfolio number of issuers", "label": "Entire Portfolio Number Of Issuers Of Fixed Maturities", "documentation": "Entire Portfolio Number Of Issuers Of Fixed Maturities" } } } }, "auth_ref": { } }, "gl EntirePortfolioNumberOfIssuesOffixedMaturities": { "xbrltype": "integerItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "EntirePortfolioNumberOfIssuesOffixedMaturities", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fixed maturity portfolio issues", "label": "Entire Portfolio Number Of Issues Of Fixed Maturities", "documentation": "Total issues of fixed maturities." } } } }, "auth_ref": { } }, "dei EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": { "http://www.globelifeinsurance.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } } }, "auth_ref": { } }, "dei EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": { "http://www.globelifeinsurance.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } } }, "auth_ref": { } }, "dei EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": { "http://www.globelifeinsurance.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } } }, "auth_ref": { } }, "dei EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": { "http://www.globelifeinsurance.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } } }, "auth_ref": { } }, "dei EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": { "http://www.globelifeinsurance.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } } }, "auth_ref": { "r1017": { } }, "dei EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": { "http://www.globelifeinsurance.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/instrument by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } } }, "auth_ref": { } }, "dei EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": { "http://www.globelifeinsurance.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports); and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } } }, "auth_ref": { } }, "dei EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": {

"http://www.globelifeinsurance.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": { "r1017" }], "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": { "http://www.globelifeinsurance.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": { "r1017" } }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": { "http://www.globelifeinsurance.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { "r1017" } }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": { "http://www.globelifeinsurance.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": { "r1017" } }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": { "http://www.globelifeinsurance.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": { "r1101" } }, "dei_EntityListingsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsLineItems", "presentation": { "http://www.globelifeinsurance.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Listings [Line Items]", "label": "Entity Listings [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r1017" } }, "dei_EntityListingsTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsTable", "presentation": { "http://www.globelifeinsurance.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Listings [Table]", "label": "Entity Listings [Table]", "documentation": "Container for exchange listing information for an entity." } } }, "auth_ref": { "r1017" } }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": { "http://www.globelifeinsurance.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": { "r1017" } }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": { "http://www.globelifeinsurance.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": { "r1017" } }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": { "http://www.globelifeinsurance.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": { "r1017" } }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": { "http://www.globelifeinsurance.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": { "r1017" } }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": { "r1056" } }, "ecd_EqtyAwrdsAdjExclgValRprtddInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValRprtddInSummryCompstnTblMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "documentation": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": { "r1097" } }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityAbstract", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": { "r1097" } }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityComponentDomain", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": { "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1260", "r1261", "r1262", "r1263", "r1264", "r1265", "r1266", "r1267", "r1268", "r1269", "r1270", "r1271", "r1272", "r1273", "r1274", "r1275", "r1276", "r1277", "r1278", "r1279", "r1280", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1360", "r1361", "r1362", "r1363", "r1364", "r1365", "r1366", "r1367", "r1368", "r1369", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402", "r1403", "r1404", "r1405", "r1406", "r1407", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413", "r1414", "r1415", "r1416", "r1417", "r1418", "r1419", "r1420", "r1421", "r1422", "r1423", "r1424", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440", "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451", "r1452", "r1453", "r1454", "r1455", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480", "r1481", "r1482", "r1483", "r1484", "r1485", "r1486", "r1487", "r1488", "r1489", "r1490", "r1491", "r1492", "r1493", "r1494", "r1495", "r1496", "r1497", "r1498", "r1499", "r1500", "r1501", "r1502", "r1503", "r1504", "r1505", "r1506", "r1507", "r1508", "r1509", "r1510", "r1511", "r1512", "r1513", "r1514", "r1515", "r1516", "r1517", "r1518", "r1519", "r1520", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526", "r1527", "r1528", "r1529", "r1530", "r1531", "r1532", "r1533", "r1534", "r1535", "r1536", "r1537", "r1538", "r1539", "r1540", "r1541", "r1542", "r1543", "r1544", "r1545", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1572", "r1573", "r1574", "r1575", "r1576", "r1577", "r1578", "r1579", "r1580", "r1581", "r1582", "r1583", "r1584", "r1585", "r1586", "r1587", "r1588", "r1589", "r1590", "r1591", "r1592", "r1593", "r1594", "r1595", "r1596", "r1597", "r1598", "r1599", "r1600", "r1601", "r1602", "r1603", "r1604", "r1605", "r1606", "r1607", "r1608", "r1609", "r1610", "r1611", "r1612", "r1613", "r1614", "r1615", "r1616", "r1617", "r1618", "r1619", "r1620", "r1621", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1628", "r1629", "r1630", "r1631", "r1632", "r1633", "r1634", "r1635", "r1636", "r1637", "r1638", "r1639", "r1640", "r1641", "r1642", "r1643", "r1644", "r1645", "r1646", "r1647", "r1648", "r1649", "r1650", "r1651", "r1652", "r1653", "r1654", "r1655", "r1656", "r1657", "r1658", "r1659", "r1660", "r1661", "r1662", "r1663", "r1664", "r1665", "r1666", "r1667", "r1668", "r1669", "r1670", "r1671", "r1672", "r1673", "r1674", "r1675", "r1676", "r1677", "r1678", "r1679", "r1680", "r1681", "r1682", "r1683", "r1684", "r1685", "r1686", "r1687", "r1688", "r1689", "r1690", "r1691", "r1692", "r1693", "r1694", "r1695", "r1696", "r1697", "r1698", "r1699", "r1700", "r1701", "r1702", "r1703", "r1704", "r1705", "r1706", "r1707", "r1708", "r1709", "r1710", "r1711", "r1712", "r1713", "r1714", "r1715", "r1716", "r1717", "r1718", "r1719", "r1720", "r1721", "r1722", "r1723", "r1724", "r1725", "r1726", "r1727", "r1728", "r1729", "r1730", "r1731", "r1732", "r1733", "r1734", "r1735", "r1736", "r1737", "r1738", "r1739", "r1740", "r1741", "r1742", "r1743", "r1744", "r1745", "r1746", "r1747", "r1748", "r1749", "r1750", "r1751", "r1752", "r1753", "r1754", "r1755", "r1756", "r1757", "r1758", "r1759", "r1760", "r1761", "r1762", "r1763", "r1764", "r1765", "r1766", "r1767", "r1768", "r1769", "r1770", "r1771", "r1772", "r1773", "r1774", "r1775", "r1776", "r1777", "r1778", "r1779", "r1780", "r1781", "r1782", "r1783", "r1784", "r1785", "r1786", "r1787", "r1788", "r1789", "r1790", "r1791", "r1792", "r1793", "r1794", "r1795", "r1796", "r1797", "r1798", "r1799", "r1800", "r1801", "r1802", "r1803", "r1804", "r1805", "r1806", "r1807", "r1808", "r1809", "r1810", "r1811", "r1812", "r1813", "r1814", "r1815", "r1816", "r1817", "r1818", "r1819", "r1820", "r1821", "r1822", "r1823", "r1824", "r1825", "r1826", "r1827", "r1828", "r1829", "r1830", "r1831", "r1832", "r1833", "r1834", "r1835", "r1836", "r1837", "r1838", "r1839", "r1840", "r1841", "r1842", "r1843", "r1844", "r1845", "r1846", "r1847", "r1848", "r1849", "r1850", "r1851", "r1852", "r1853", "r1854", "r1855", "r1856", "r1857", "r1858", "r1859", "r1860", "r1861", "r1862", "r1863", "r1864", "r1865", "r1866", "r1867", "r1868", "r1869", "r1870", "r1871", "r1872", "r1873", "r1874", "r1875", "r1876", "r1877", "r1878", "r1879", "r1880", "r1881", "r1882", "r1883", "r1884", "r1885", "r1886", "r1887", "r1888", "r1889", "r1890", "r1891", "r1892", "r1893", "r1894", "r1895", "r1896", "r1897", "r1898", "r1899", "r1900", "r1901", "r1902", "r1903", "r1904", "r1905", "r1906", "r1907", "r1908", "r1909", "r1910", "r1911", "r1912", "r1913", "r1914", "r1915", "r1916", "r1917", "r1918", "r1919", "r1920", "r1921", "r1922", "r1923", "r1924", "r1925", "r1926", "r1927", "r1928", "r1929", "r1930", "r1931", "r1932", "r1933", "r1934", "r1935", "r1936", "r1937", "r1938", "r1939", "r1940", "r1941", "r1942", "r1943", "r1944", "r1945", "r1946", "r1947", "r1948", "r1949", "r1950", "r1951", "r1952", "r1953", "r1954", "r1955", "r1956", "r1957", "r1958", "r1959", "r1960", "r1961", "r1962", "r1963", "r1964", "r1965", "r1966", "r1967", "r1968", "r1969", "r1970", "r1971", "r1972", "r1973", "r1974", "r1975", "r1976", "r1977", "r1978", "r1979", "r1980", "r1981", "r1982", "r1983", "r1984", "r1985", "r1986", "r1987", "r1988", "r1989", "r1990", "r1991", "r1992", "r1993", "r1994", "r1995", "r1996", "r1997", "r1998", "r1999", "r2000", "r2001", "r2002", "r2003", "r2004", "r2005", "r2006", "r2007", "r2008", "r2009", "r2010", "r2011", "r2012", "r2013", "r2014", "r2015", "r2016", "r2017", "r2018", "r2019", "r2020", "r2021", "r2022", "r2023", "r2024", "r2025", "r2026", "r2027", "r2028", "r2029", "r2030", "r2031", "r2032", "r2033", "r2034", "r2035", "r2036", "r2037", "r2038", "r2039", "r2040", "r2041", "r2042", "r2043", "r2044", "r2045", "r2046", "r2047", "r2048", "r2049", "r2050", "r2051", "r2052", "r2053", "r2054", "r2055", "r2056", "r2057", "r2058", "r2059", "r2060", "r2061", "r2062", "r2063", "r2064", "r2065", "r2066", "r2067", "r2068", "r2069", "r2070", "r2071", "r2072", "r2073", "r2074", "r2075", "r2076", "r2077", "r2078", "r2079", "r2080", "r2081", "r2082", "r2083", "r2084", "r2085", "r2086", "r2087", "r2088", "r2089", "r2090", "r2091", "r2092", "r2093", "r2094", "r2095", "r2096", "r2097", "r2098", "r2099", "r2100", "r2101", "r2102", "r2103", "r2104", "r2105", "r2106", "r2107", "r2108", "r2109", "r2110", "r2111", "r2112", "r2113", "r2114", "r2115", "r2116", "r2117", "r2118", "r2119", "r2120", "r2121", "r2122", "r2123", "r2124", "r2125", "r2126", "r2127", "r2128", "r2129", "r2130", "r2131", "r2132", "r2133", "r2134", "r2135", "r2136", "r2137", "r2138", "r2139", "r2140", "r2141", "r2142", "r2143", "r2144", "r2145", "r2146", "r2147", "r2148", "r2149", "r2150", "r2151", "r2152", "r2153", "r2154", "r2155", "r2156", "r2157", "r2158", "r2159", "r2160", "r2161", "r2162", "r2163", "r2164", "r2165", "r2166", "r2167", "r2168", "r2169", "r2170", "r2171", "r2172", "r2173", "r2174", "r2175", "r2176", "r2177", "r2178", "r2179", "r2180", "r2181", "r2182", "r2183", "r2184", "r2185", "r2186", "r2187", "r2188", "r2189", "r2190", "r2191", "r2192", "r2193", "r2194", "r2195", "r2196", "r2197", "r2198", "r2199", "r2200", "r2201", "r2202", "r2203", "r2204", "r2205", "r2206", "r2207", "r2208", "r2209", "r2210", "r2211", "r2212", "r2213", "r2214", "r2215", "r2216", "r2217", "r2218", "r2219", "r2220", "r2221", "r2222", "r2223", "r2224", "r2225", "r2226", "r2227", "r2228", "r2229", "r2230", "r2231", "r2232", "r2233", "r2234", "r2235", "r2236", "r2237", "r2238", "r2239", "r2240", "r2241", "r2242", "r2243", "r2244", "r2245", "r2246", "r2247", "r2248", "r2249", "r2250", "r2251", "r2252", "r2253", "r2254", "r2255", "r2256", "r2257", "r2258", "r2259", "r2260", "r2261", "r2262", "r2263", "r2264", "r2265", "r2266", "r2267", "r2268", "r2269", "r2270", "r2271", "r2272", "r2273", "r2274", "r2275", "r2276", "r2277", "r2278", "r2279", "r2280", "r2281", "r2282", "r2283", "r2284", "r2285", "r2286", "r2287", "r2288", "r2289", "r2290", "r2291", "r2292", "r2293", "r2294", "r2295", "r2296", "r2297", "r2298", "r2299", "r2300", "r2301", "r2302", "r2303", "r2304", "r2305", "r2306", "r2307", "r2308", "r2309", "r2310", "r2311", "r2312", "r2313", "r2314", "r2315", "r2316", "r2317", "r2318", "r2319", "r2320", "r2321", "r2322", "r2323", "r2324", "r2325", "r2326", "r2327", "r2328", "r2329", "r2330", "r2331", "r2332", "r2333", "r2334", "r2335", "r2336", "r2337", "r2338", "r2339", "r2340", "r2341", "r2342", "r2343", "r2344", "r2345", "r2346", "r2347", "r2348", "r2349", "r2350", "r2351", "r2352", "r2353", "r2354", "r2355", "r2356", "r2357", "r2358", "r2359", "r2360", "r2361", "r2362", "r2363", "r2364", "r2365", "r2366", "r2367", "r2368", "r2369", "r2370", "r2371", "r2372", "r2373", "r2374", "r2375", "r2376", "r2377", "r2378", "r2379", "r2380", "r2381", "r2382", "r2383", "r2384", "r2385", "r2386", "r2387", "r2388", "r2389", "r2390", "r2391", "r2392", "r2393", "r2394", "r2395", "r2396", "r2397", "r2398", "r2399", "r2400", "r2401", "r2402", "r2403", "r2404", "r2405", "r2406", "r2407", "r2408", "r2409", "r2410", "r2411", "r2412", "r2413", "r2414", "r2415", "r2416", "r2417", "r2418", "r2419", "r2420", "r2421", "r2422", "r2423", "r2424", "r2425", "r2426", "r2427", "r2428", "r2429", "r2430", "r2431", "r2432", "r2433", "r2434", "r2435", "r2436", "r2437", "r2438", "r2439", "r2440", "r2441", "r2442", "r2443", "r2444", "r2445", "r2446", "r2447", "r2448", "r2449", "r2450", "r2451", "r2452", "r2453", "r2454", "r2455", "r2456", "r2457", "r2458", "r2459", "r2460", "r2461", "r2462", "r2463", "r2464", "r2465", "r2466", "r2467", "r2468", "r2469", "r2470", "r2471", "r2472", "r2473", "r2474", "r2475", "r2476", "r2477", "r2478", "r2479", "r2480", "r2481", "r2482", "r2483", "r2484", "r2485", "r2486", "r2487", "r2488", "r2489", "r2490", "r2491", "r2492", "r2493", "r2494", "r2495", "r2496", "r2497", "r2498", "r2499", "r2500", "r2501", "r2502", "r2503", "r2504", "r2505", "r2506", "r2507", "r2508", "r2509", "r2510", "r2511", "r2512", "r2513", "r2514", "r2515", "r2516", "r2517", "r2518", "r2519", "r2520", "r2521", "r2522", "r2523", "r2524", "r2525", "r2526", "r2527", "r2528", "r2529", "r2530", "r2531", "r2532", "r2533", "r2534", "r2535", "r2536", "r2537", "r2538", "r2539", "r2540", "r2541", "r2542", "r2543", "r2544", "r2545", "r2546", "r2547",

Life of non-redeemable funds, "label": "Expected Life of Non-Redeemable Funds", "documentation": "Expected Life of Non-Redeemable Funds" } }
 }, "auth_ref": [] }, { "gl_ExpectedLifeOfRedeemableFunds": { "xbrltype": "durationItemType", "nsuri":
 "http://www.globelifeinsurance.com/20240930", "localname": "ExpectedLifeOfRedeemableFunds", "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofInvestmentFundsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Expected
 life of redeemable funds", "label": "Expected Life of Redeemable Funds", "documentation": "Expected Life of Redeemable Funds" } } }, "auth_ref":
 [] }, { "gl_ExpensesNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "ExpensesNonoperating",
 "crdr": "debit", "calculation": {
 "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps
 ", "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0,
 "order": 2.0 } }, "presentation": {
 "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps
 ", "lang": { "en-us": { "role": { "negatedTerseLabel": "Non-operating expenses", "label": "Expenses, Nonoperating", "documentation": "Expenses,
 Nonoperating" } } }, "auth_ref": [] }, { "gl_ExtensionOptionsTermOfNonRedeemableFunds": { "xbrltype": "durationItemType", "nsuri":
 "http://www.globelifeinsurance.com/20240930", "localname": "ExtensionOptionsTermOfNonRedeemableFunds", "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofInvestmentFundsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Extension
 options term of non-redeemable funds", "label": "Extension Options Term of Non-Redeemable Funds", "documentation": "Extension Options Term
 of Non-Redeemable Funds" } } }, "auth_ref": [] }, { "us-gaap_ExternalCreditRatingByGroupingAxis": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "ExternalCreditRatingByGroupingAxis", "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "External Credit Rating by Grouping [Axis]", "label": "External Credit Rating by Grouping [Axis]", "documentation":
 "Information by external rating classified as investment grade or non-investment grade." } } }, "auth_ref": ["r134", "r135", "r136", "r559", "r1185"
] }, { "us-gaap_ExternalCreditRatingByGroupingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ExternalCreditRatingByGroupingDomain", "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "External Credit Rating by Grouping [Domain]", "label": "External Credit Rating by Grouping [Domain]", "documentation":
 "External credit rating classified as investment grade or non-investment grade." } } }, "auth_ref": ["r51"] }, { "us-
 gaap_ExternalCreditRatingInvestmentGradeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ExternalCreditRatingInvestmentGradeMember", "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Investment Grade", "label": "External Credit Rating, Investment Grade [Member]", "documentation": "External credit rating
 that could be used to describe the current status of the payment and performance risk of credit derivatives and guarantee obligations that connote
 investment grade." } } }, "auth_ref": ["r51"] }, { "us-gaap_ExternalCreditRatingNonInvestmentGradeMember": { "xbrltype": "domainItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ExternalCreditRatingNonInvestmentGradeMember", "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Below Investment Grade", "label": "External Credit Rating, Noninvestment Grade [Member]", "documentation": "External
 credit rating used to describe current status of payment and performance risk of credit derivative and guarantee obligation that connote
 noninvestment grade." } } }, "auth_ref": ["r51"] }, { "stpr_FL": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname":
 "FL", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails" }, "lang": {
 "en-us": { "role": { "terseLabel": "Florida", "label": "FLORIDA" } } }, "auth_ref": [] }, { "us-
 gaap_FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci", "crdr": "credit", "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedGainsorLossesIncludedinOtherComprehensiveIncomeDetails" }, "lang": {
 "en-us": { "role": { "terseLabel": "Change in unrealized gains (losses) for the period", "label": "Fair Value, Asset, Recurring Basis, Still Held,
 Unrealized Gain (Loss), OCI", "documentation": "Amount of unrealized gain (loss) recognized in other comprehensive income (OCI) from asset
 measured at fair value on recurring basis using unobservable input (level 3) and still held." } } }, "auth_ref": ["r583", "r586", "r961"] }, { "us-
 gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
 "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails" }, "lang": {
 "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair
 Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial
 concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many
 axes to the table." } } }, "auth_ref": ["r573", "r574", "r585", "r959"] }, { "us-
 gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails" }, "lang": { "en-us": { "role":
 { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation":
 "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r573", "r574",
 "r585", "r959"] }, { "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype":
 "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofChangesinAssetsMeasuredatFairValueonaRecurringBasisUsingSignificantUnobserva
 ", "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation",
 "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll
 forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, { "us-
 gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
 "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofChangesinAssetsMeasuredatFairValueonaRecurringBasisUsingSignificantUnobserva
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedGainsorLossesIncludedinOtherComprehensiveIncomeDetails" }, "lang": {
 "en-us": { "role": { "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "label": "Fair
 Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial
 concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many
 axes to the table." } } }, "auth_ref": ["r578", "r579", "r580", "r581", "r582", "r583", "r586", "r961"] }, { "us-
 gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofChangesinAssetsMeasuredatFairValueonaRecurringBasisUsingSignificantUnobserva
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedGainsorLossesIncludedinOtherComprehensiveIncomeDetails" }, "lang": {
 "en-us": { "role": { "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "label": "Fair Value,
 Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial
 instrument asset measured at fair value on recurring basis using unobservable input." } } }, "auth_ref": ["r578", "r579", "r580", "r581", "r582",
 "r583", "r586", "r961"] }, { "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype":
 "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value, Assets Measured
 on Recurring Basis Using Significant Unobservable Inputs", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input
 Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable
 inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the
 following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in
 net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in
 earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type
 disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant
 inputs), by class of asset." } } }, "auth_ref": ["r578", "r583", "r586", "r961"] }, { "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype":
 "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails",
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofChangesinAssetsMeasuredatFairValueonaRecurringBasisUsingSignificantUnobserva
 "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionAssetsbyComponentatFairValueDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by
 level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r412", "r462",
 "r463", "r464", "r465", "r466", "r467", "r572", "r574", "r575", "r576", "r577", "r584", "r585", "r588", "r622", "r623", "r624", "r939", "r940", "r946",

"r947", "r948", "r959", "r963" }], "us-gaap-FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementBasisAxis", "presentation": {
 "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": { "r412", "r939", "r940" } },
 "us-gaap-FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": { "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": { "r412", "r939", "r940" } }, "us-gaap-FairValueInputsLevel12And3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel12And3Member", "presentation": {
 "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionAssetsbyComponentatFairValueDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 1, 2 and 3", "label": "Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member]", "documentation": "Fair value measurement input including quoted price in active market for identical asset or liability reporting entity can access at measurement date (level 1), input other than quoted price included within level 1 either directly or indirectly observable for asset or liability (level 2) and unobservable input reflecting entity's own assumption (level 3)." } } }, "auth_ref": { "r959", "r1232", "r1277", "r1282" } }, "us-gaap-FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "Quoted u00a0Prices u00a0in Active u00a0Markets for u00a0Identical Assets u00a0(L Level u00a001)", "verboseLabel": "Quoted u00a0Prices u00a0in Active Markets for Identical Assets u00a0(L Level u00a001)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": { "r412", "r462", "r467", "r574", "r585", "r622", "r946", "r947", "r948", "r959" } }, "us-gaap-FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "Significant u00a0Other Observable Inputs u00a0(L Level u00a002)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": { "r412", "r462", "r467", "r574", "r575", "r585", "r623", "r939", "r940", "r946", "r947", "r948", "r959" } }, "us-gaap-FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "Significant Unobservable Inputs u00a0(L Level u00a003)", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": { "r412", "r462", "r463", "r464", "r465", "r466", "r467", "r574", "r575", "r576", "r585", "r624", "r939", "r940", "r947", "r948", "r959" } }, "us-gaap-FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investment Funds", "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Table Text Block]", "documentation": "Tabular disclosure of investments in certain entities that calculate net asset value per share or equivalent measured at fair value on a recurring or nonrecurring basis." } } }, "auth_ref": { "r572", "r587", "r591", "r964" } }, "us-gaap-FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommitments", "credit": "credit", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Investment funds, unfunded commitments", "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments", "documentation": "The amount of unfunded commitments for which the entity is obligated, to those certain investments for which net asset value per share is calculated (including by unit, membership interest, or other equity ownership interest) (unit measure) (alternative investments)." } } }, "auth_ref": { "r589", "r964" } }, "gl-FairValueInvestmentsEntitiesThatCalculateNetAssetValuePercentageOwnershipByPensionPlan": { "xbrltype": "percentItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePercentageOwnershipByPensionPlan", "presentation": {
 "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionAssetsbyComponentatFairValueDetails": { "lang": { "en-us": { "role": { "terseLabel": "Investment funds, percentage ownership by pension plan", "label": "Fair Value, Investments, Entities that Calculate Net Asset Value, Percentage Ownership By Pension Plan", "documentation": "Fair Value, Investments, Entities that Calculate Net Asset Value, Percentage Ownership By Pension Plan" } } }, "auth_ref": { "r572", "r587", "r591", "r964" } }, "us-gaap-FairValueMeasuredAtNetAssetValuePerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasuredAtNetAssetValuePerShareMember", "presentation": { "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionAssetsbyComponentatFairValueDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measured at Net Asset Value Per Share", "label": "Fair Value Measured at Net Asset Value Per Share [Member]", "documentation": "Fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": { "r462", "r572", "r588", "r959" } }, "gl-FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetAmortization", "credit": "debit", "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofChangesinAssetsMeasuredatFairValueonRecurringBasisUsingSignificantUnobservable": { "lang": { "en-us": { "role": { "terseLabel": "Amortization", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Amortization", "documentation": "Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, amortization." } } }, "auth_ref": { "r572", "r588", "r959" } }, "us-gaap-FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "credit": "credit", "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofChangesinAssetsMeasuredatFairValueonRecurringBasisUsingSignificantUnobservable": { "lang": { "en-us": { "role": { "terseLabel": "Included in realized gains / losses", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": { "r579", "r586", "r961", "r962" } }, "us-gaap-FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss", "credit": "debit", "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofChangesinAssetsMeasuredatFairValueonRecurringBasisUsingSignificantUnobservable": { "lang": { "en-us": { "role": { "terseLabel": "Included in other comprehensive income", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Other Adjustments Increase (Decrease)", "documentation": "Other adjustments, including capitalized interest and foreign exchange." } } }, "auth_ref": { "r580", "r586", "r961" } }, "gl-FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherAdjustmentsIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetOtherAdjustmentsIncreaseDecrease", "credit": "debit", "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofChangesinAssetsMeasuredatFairValueonRecurringBasisUsingSignificantUnobservable": { "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Other Adjustments Increase (Decrease)", "documentation": "Other adjustments, including capitalized interest and foreign exchange." } } }, "auth_ref": { "r580", "r586", "r961" } }, "us-gaap-FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases", "credit": "debit", "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofChangesinAssetsMeasuredatFairValueonRecurringBasisUsingSignificantUnobservable": { "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Other Adjustments Increase (Decrease)", "documentation": "Other adjustments, including capitalized interest and foreign exchange." } } }, "auth_ref": { "r580", "r586", "r961" } }, "us-gaap-FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases", "credit": "debit", "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofChangesinAssetsMeasuredatFairValueonRecurringBasisUsingSignificantUnobservable": { "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Other Adjustments Increase (Decrease)", "documentation": "Other adjustments, including capitalized interest and foreign exchange." } } }, "auth_ref": { "r580", "r586", "r961" } }, "us-gaap-FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases", "credit": "debit", "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofChangesinAssetsMeasuredatFairValueonRecurringBasisUsingSignificantUnobservable": { "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Other Adjustments Increase (Decrease)", "documentation": "Other adjustments, including capitalized interest and foreign exchange." } } }, "auth_ref": { "r580", "r586", "r961" } }, "us-gaap-FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases", "credit": "debit", "presentation": {
 "http://www.globelifeinsurance.com/role/

Basis, Asset, Purchases", "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": { "r581", "r586", "r961" } }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofChangesinAssetsMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputs", "lang": { "en-us": { "role": { "negatedTerseLabel": "Sales", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales", "documentation": "Amount of sale of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": { "r581", "r586", "r961" } }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "crdr": "debit", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofChangesinAssetsMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputs", "lang": { "en-us": { "role": { "terseLabel": "Transfers into Level 3", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3", "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy." } } }, "auth_ref": { "r582", "r586", "r961" } }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofChangesinAssetsMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputs", "lang": { "en-us": { "role": { "negatedLabel": "Transfers out of Level 3", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3", "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy." } } }, "auth_ref": { "r582", "r586", "r961" } }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "crdr": "debit", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofChangesinAssetsMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputs", "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": { "r578", "r586", "r961" } }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofChangesinAssetsMeasuredatFairValueonRecurringBasisUsingSignificantUnobservableInputs", "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionAssetsbyComponentatFairValueDetails", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": { "r412", "r462", "r463", "r464", "r465", "r466", "r467", "r572", "r574", "r575", "r576", "r577", "r584", "r585", "r588", "r622", "r623", "r624", "r939", "r940", "r946", "r947", "r948", "r959", "r963" } }, "us-gaap_FairValueOptionChangesInFairValueGainLoss1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOptionChangesInFairValueGainLoss1", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofRealizedGainLossonInvestmentsDetails", "parentTag": "gl_RealizedInvestmentGainsLossesBeforeRedemptionOfDebtAndOtherGainsLosses", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofRealizedGainLossonInvestmentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Fair value optionu2014change in fair value", "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)", "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings." } } }, "auth_ref": { "r52" } }, "us-gaap_FairValueOptionOtherEligibleItemsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOptionOtherEligibleItemsMember", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAnalysisofInvestmentOperationsDetails", "lang": { "en-us": { "role": { "terseLabel": "Fair value option", "label": "Fair Value Option, Other Eligible Items [Member]", "documentation": "This element embodies certain items identified as eligible for the fair value option that are not within the definition of financial assets and liabilities. Such items may consist of: (a) a firm commitment that would otherwise not be recognized at inception and that involves only financial instruments (for example, a forward purchase contract for a loan that is not readily convertible to cash. That commitment involves only financial instruments-a loan and cash-and would not otherwise be recognized because it is not a derivative instrument; (b) a written loan commitment; (c) the rights and obligations under an insurance contract that is not a financial instrument (because it requires or permits the insurer to provide goods or services rather than a cash settlement), but whose terms permit the insurer to settle by paying a third party to provide those goods or services; (d) the rights and obligations under a warranty that is not a financial instrument (because it requires or permits the warrantor to provide goods or services rather than a cash settlement) but whose terms permit the warrantor to settle by paying a third party to provide those goods or services; and (e) a host financial instrument resulting from the separation of an embedded nonfinancial derivative instrument from a nonfinancial hybrid instrument (for example, an instrument in which the value of the bifurcated embedded derivative is payable in cash, services, or merchandise but the debt host is payable only in cash)." } } }, "auth_ref": { "r108", "r109", "r110", "r111", "r112" } }, "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofChangesinAssetsMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputs", "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from asset measured at fair value using unobservable input (level 3)." } } }, "auth_ref": { "r579", "r586" } }, "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfOtherComprehensiveIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfOtherComprehensiveIncomeExtensibleList", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofChangesinAssetsMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputs", "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Asset, Gain (Loss), Statement of Other Comprehensive Income or Comprehensive Income [Extensible Enumeration]", "label": "Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Asset, Gain (Loss), Statement of Other Comprehensive Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement in which other comprehensive income (OCI) is reported that includes gain (loss) from asset measured at fair value using unobservable input (level 3)." } } }, "auth_ref": { "r580", "r586" } }, "gl_FamilyHeritageMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "FamilyHeritageMember", "presentation": { "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofSegmentPremiumIncomebyDistributionChannelDetails", "http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofAnalysisofDeferredAcquisitionCostsDetails", "http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofDeferredPolicyAcquisitionCoststoConsolidatedBalanceSheetDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedIncomeStatementDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitActivityDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofUndiscountedAndDiscountedExpectedFutureGrossPremiumsAndExpectedFuture", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageDurationofLiabilityForFuturePolicyBenefitsDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageInterestRateofLiabilityForFuturePolicyBenefitsDetails", "lang": { "en-us": { "role": { "terseLabel": "Family Heritage", "label": "Family Heritage [Member]", "documentation": "Family Heritage [Member]" } } }, "auth_ref": { } }, "gl_FederalHomeLoanBankActivityBasedCommonStockOwnershipPercentage": { "xbrltype": "pureItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "FederalHomeLoanBankActivityBasedCommonStockOwnershipPercentage", "presentation": { "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Activity-based common stock ownership percentage", "label": "Federal Home Loan Bank, Activity-Based Common Stock Ownership Percentage", "documentation": "Federal Home Loan Bank, Activity-Based Common Stock Ownership Percentage" } } }, "auth_ref": { } }, "us-gaap_FederalHomeLoanBankBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FederalHomeLoanBankBorrowingsMember", "presentation": { "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails", "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails", "lang": { "en-us": { "role": { "verboseLabel": "FHLB borrowings", "terseLabel": "Federal Home Loan Bank Borrowings", "label": "Federal Home Loan Bank Borrowings" } } } }

[Member]": "documentation": "This item represents the amount that a bank with insufficient reserves borrows, from the Federal Home Loan Bank [system], to meet its reserve requirements." } } }, "auth_ref": [] }, "us-gaap_FederalHomeLoanBankStockAndFederalReserveBankStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FederalHomeLoanBankStockAndFederalReserveBankStock", "crdr": "debit", "presentation": { "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "FHLB stock", "label": "Federal Home Loan Bank Stock and Federal Reserve Bank Stock", "documentation": "Amount of Federal Home Loan Bank (FHLB) and Federal Reserve Bank stock." } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofChangesinAssetsMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAllowanceforCreditLossDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAvailableforSalebyComponentDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofOtherLongTermInvestmentsDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedGainsorLossesIncludedinOtherComprehensiveIncomeDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r333", "r334", "r338", "r339", "r341", "r344", "r349", "r350", "r423", "r432", "r567", "r590", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r720", "r936", "r959", "r961", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r972", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1178", "r1179", "r1180", "r1181", "r1275", "r1278", "r1279", "r1280", "r1281", "r1283"] }, "gl_FinancialMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "FinancialMember", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAvailableforSalebyComponentDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Financial", "label": "Financial [Member]", "documentation": "Financial [Member]" } } }, "auth_ref": [] }, "us-gaap_FinancingReceivableAllowanceForCreditLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableAllowanceForCreditLosses", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails": { "parentTag": "us-gaap_NotesReceivableNet", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialLoanParticipationsAllowanceforCreditLossDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsRecordedInvestmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Allowance for credit losses", "negatedTerseLabel": "Less allowance for credit losses", "periodStartLabel": "Allowance for credit losses beginning balance", "periodEndLabel": "Allowance for credit losses ending balance", "label": "Financing Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement." } } }, "auth_ref": ["r132", "r165", "r167", "r169", "r184", "r332", "r335", "r337", "r1302"] }, "gl_FinancingReceivableAllowanceForCreditLossesPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "FinancingReceivableAllowanceForCreditLossesPercent", "calculation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails": { "parentTag": "gl_FinancingReceivableNetPercentage", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails" }, "lang": { "en-us": { "role": { "negatedLabel": "Allowance for credit losses, percent", "label": "Financing Receivable, Allowance For Credit Losses, Percent", "documentation": "Financing Receivable, Allowance For Credit Losses, Percent" } } }, "auth_ref": [] }, "us-gaap_FinancingReceivableAllowanceForCreditLossesPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableAllowanceForCreditLossesPeriodIncreaseDecrease", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Increase in allowance for credit losses", "label": "Financing Receivable, Allowance for Credit Loss, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in allowance for credit loss on financing receivable." } } }, "auth_ref": ["r131", "r1184"] }, "us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableAllowanceForCreditLossesRollForward", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialLoanParticipationsAllowanceforCreditLossDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Financing Receivable, Allowance for Credit Loss [Roll Forward]", "label": "Financing Receivable, Allowance for Credit Loss [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableCreditQualityIndicatorsTableTextBlock", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Commercial Loan Participations, Credit Quality Indicators", "label": "Financing Receivable Credit Quality Indicators [Table Text Block]", "documentation": "Tabular disclosure of financing receivables by credit quality indicator. The credit quality indicator is a statistic about the credit quality of financing receivables. Examples include, but not limited to, consumer credit risk scores, credit-rating-agency ratings, an entity's internal credit risk grades, loan-to-value ratios, collateral, collection experience and other internal metrics." } } }, "auth_ref": ["r133", "r1185"] }, "gl_FinancingReceivableDelinquentOutstandingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "FinancingReceivableDelinquentOutstandingInterest", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Delinquent loans, outstanding interest", "label": "Financing Receivable, Delinquent, Outstanding Interest", "documentation": "Financing Receivable, Delinquent, Outstanding Interest" } } }, "auth_ref": [] }, "gl_FinancingReceivableDelinquentOutstandingParValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "FinancingReceivableDelinquentOutstandingParValue", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Delinquent loans, outstanding par value (in dollars per share)", "label": "Financing Receivable, Delinquent, Outstanding Par Value", "documentation": "Financing Receivable, Delinquent, Outstanding Par Value" } } }, "auth_ref": [] }, "gl_FinancingReceivableGrossPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "FinancingReceivableGrossPercentage", "calculation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails": { "parentTag": "gl_FinancingReceivableNetPercentage", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Carrying value, gross, percent", "label": "Financing Receivable, Gross, Percentage", "documentation": "Financing Receivable, Gross, Percentage" } } }, "auth_ref": [] }, "gl_FinancingReceivableNetPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "FinancingReceivableNetPercentage", "calculation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsRecordedInvestmentDetails" }, "lang": { "en-us": { "role": { "totalLabel": "Carrying value, net, percent", "terseLabel": "Carrying value, net of valuation allowance, percent", "label": "Financing Receivable, Net, Percentage", "documentation": "Financing Receivable, Net, Percentage" } } }, "auth_ref": [] }, "gl_FinancingReceivableNumberOfDelinquentLoans": { "xbrltype": "integerItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "FinancingReceivableNumberOfDelinquentLoans", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Financing receivable, number of delinquent loans", "label": "Financing Receivable, Number Of Delinquent Loans", "documentation": "Financing Receivable, Number Of Delinquent Loans" } } }, "auth_ref": [] }, "gl_FinancingReceivableNumberOfLoans": { "xbrltype": "integerItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "FinancingReceivableNumberOfLoans", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Number of loans", "label": "Financing Receivable, Number Of Loans", "documentation": "Financing Receivable, Number Of Loans" } } }, "auth_ref": [] }, "gl_FinancingReceivableNumberOfLoansInNonAccrualStatus": { "xbrltype": "integerItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "FinancingReceivableNumberOfLoansInNonAccrualStatus", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Number of loans in non-accrual status", "label": "Financing Receivable, Number Of Loans in Non-Accrual Status", "documentation": "Financing Receivable, Number


```

Of Loans in Non-Accrual Status" } } }, "auth_ref": [ ] }, "us-gaap_FinancingReceivablePortfolioSegmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivablePortfolioSegmentAxis", "presentation": [ "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Receivable Portfolio Segment [Axis]", "label": "Financing Receivable Portfolio Segment [Axis]", "documentation": "Information by the level at which an entity develops and documents a systematic methodology to determine its allowance for credit losses." } } }, "auth_ref": { "r163", "r164", "r168", "r169", "r333", "r334", "r930", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1120", "r1121", "r1122" } }, "us-gaap_FinancingReceivablePortfolioSegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivablePortfolioSegmentDomain", "presentation": [ "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Receivable Portfolio Segment [Domain]", "label": "Financing Receivable Portfolio Segment [Domain]", "documentation": "Level at which an entity develops and documents a systematic methodology to determine its allowance for credit losses." } } }, "auth_ref": { "r163", "r164", "r168", "r169", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1120", "r1121", "r1122" } }, "us-gaap_FinancingReceivableRecordedInvestmentByClassOffFinancingReceivableAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableRecordedInvestmentByClassOffFinancingReceivableAxis", "presentation": [ "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Financing Receivable [Axis]", "label": "Class of Financing Receivable [Axis]", "documentation": "Information by class of financing receivable determined on the basis of initial measurement attribute, risk characteristics and method of monitoring and assessing credit risk." } } }, "auth_ref": { "r135", "r137", "r139", "r140", "r163", "r164", "r168", "r169", "r286", "r287", "r288", "r289", "r290", "r338", "r339", "r341", "r929", "r931", "r932", "r934", "r935", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1120", "r1121", "r1122", "r1158" } }, "us-gaap_FinancingReceivableRecordedInvestmentClassOffFinancingReceivableDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableRecordedInvestmentClassOffFinancingReceivableDomain", "presentation": [ "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Financing Receivable [Domain]", "label": "Class of Financing Receivable [Domain]", "documentation": "Financing receivables determined on the basis of initial measurement attribute, risk characteristics and method of monitoring and assessing credit risk." } } }, "auth_ref": { "r140", "r163", "r164", "r168", "r169", "r286", "r287", "r288", "r289", "r290", "r929", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1120", "r1121", "r1122", "r1158" } }, "us-gaap_FinancingReceivableRecordedInvestmentNonaccrualStatus": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableRecordedInvestmentNonaccrualStatus", "crdr": "debit", "presentation": [ "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding principal on nonaccrual loan", "label": "Financing Receivable, Nonaccrual", "documentation": "Amortized cost of financing receivable on nonaccrual status. Excludes net investment in lease." } } }, "auth_ref": { "r138", "r166", "r167", "r340" } }, "us-gaap_FixedMaturitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FixedMaturitiesMember", "presentation": [ "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAnalysisofInvestmentOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed maturities available for sale", "label": "Fixed Maturities [Member]", "documentation": "This element provides types of investments that may be contained within the fixed maturity category which are securities having a stated final repayment date. Examples of items within this category may include bonds, including convertibles and bonds with warrants, and redeemable preferred stocks." } } }, "auth_ref": { "r1353" } }, "us-gaap_ForeignGovernmentDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignGovernmentDebtSecuritiesMember", "presentation": [ "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAvailableforSalebyComponentDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign governments", "label": "Debt Security, Government, Non-US [Member]", "documentation": "Debt security issued by government not domiciled in United States of America (US)." } } }, "auth_ref": { "r972", "r1231", "r1353" } }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": { "r1028", "r1038", "r1048", "r1080" } }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": { "r1028", "r1038", "r1048", "r1080" } }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": { "r1028", "r1038", "r1048", "r1080" } }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": { "r1028", "r1038", "r1048", "r1080" } }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": { "r1028", "r1038", "r1048", "r1080" } }, "ecd_FrValAsOfPrYrEndOfEqtyAwrdsGrntdInPrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrYrEndOfEqtyAwrdsGrntdInPrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": { "r1061" } }, "gl_FuturePolicyBenefitsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "FuturePolicyBenefitsAbstract", "presentation": [ "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Future Policy Benefits", "label": "Future Policy Benefits [Abstract]", "documentation": "Future Policy Benefits" } } }, "auth_ref": [ ] }, "gl_FuturePolicyBenefitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "FuturePolicyBenefitsMember", "presentation": [ "http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofChangeinBal", "lang": { "en-us": { "role": { "terseLabel": "Future Policy Benefits", "label": "Future Policy Benefits [Member]", "documentation": "Future Policy Benefits" } } }, "auth_ref": [ ] }, "gl_GainLossFromExperienceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "GainLossFromExperienceMember", "presentation": [ "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (Loss) From Experience", "label": "Gain (Loss) From Experience [Member]", "documentation": "Gain (Loss) From Experience" } } }, "auth_ref": [ ] }, "gl_GainLossFromUnlockingAssumptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "GainLossFromUnlockingAssumptionsMember", "presentation": [ "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (Loss) From Unlocking Assumptions", "label": "Gain (Loss) From Unlocking Assumptions [Member]", "documentation": "Gain (Loss) From Unlocking Assumptions" } } }, "auth_ref": [ ] }, "us-gaap_GainLossOnSaleOfMortgageLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfMortgageLoans", "crdr": "credit", "calculation": [ "http://www.globelifeinsurance.com/role/InvestmentsScheduleofRealizedGainLossonInvestmentsDetails" ], "parentFag": "gl_RealizedInvestmentGainsLossesBeforeRedemptionOfDebtAndOtherGainsLosses", "weight": 1.0, "order": 2.0 }, "presentation": [ "http://www.globelifeinsurance.com/role/InvestmentsScheduleofRealizedGainLossonInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgage loans", "label": "Gain (Loss) on Sale of Mortgage Loans", "documentation": "The gains (losses) included in earnings that represent the difference between the sale price and the carrying value of loans made to finance real estate acquisitions. This element refers to the gain (loss) and not to the cash proceeds of the sale. This element is a noncash adjustment to net income when calculating net cash generated by operating activities using the indirect method." } } }, "auth_ref": { "r11", "r146", "r148", "r152" } }, "us-gaap_GainLossOnSaleOfOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfOtherInvestments", "crdr": "credit", "calculation": [ "http://www.globelifeinsurance.com/role/InvestmentsScheduleofRealizedGainLossonInvestmentsDetails" ], "parentFag": "gl_RealizedInvestmentGainsLossesBeforeRedemptionOfDebtAndOtherGainsLosses", "weight": 1.0, "order": 4.0 }, "presentation": [ "http://www.globelifeinsurance.com/role/InvestmentsScheduleofRealizedGainLossonInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other investments", "label": "Gain (Loss) on Sale of Other Investments", "documentation": "Amount of gain (loss) included in
```

{ "parentTag": "us-gaap-BenefitsLossesAndExpenses", "weight": 1.0, "order": 5.0 }, "presentation": {
 "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps",
 "lang": { "en-us": { "role": { "terseLabel": "Insurance administrative expense", "label": "General and Administrative Expense", "documentation":
 "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not
 directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": { "r84", "r857" } },
 "gl-GeneralExpectedLifeOfNonRedeemableFunds": { "xbrltype": "durationItemType", "nsuri": "http://www.globelifeinsurance.com/20240930",
 "localname": "GeneralExpectedLifeOfNonRedeemableFunds", "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofInvestmentFundsDetails", "lang": { "en-us": { "role": { "terseLabel": "Expected
 life of non-redeemable funds", "label": "General Expected Life of Non-Redeemable Funds", "documentation": "General Expected Life of Non-
 Redeemable Funds" } } }, "auth_ref": { } }, "us-gaap-Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": {
 "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 6.0 }, "presentation": {
 "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label":
 "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset
 acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } },
 "auth_ref": { "r174", "r356", "r685", "r925", "r937", "r960", "r971", "r1187", "r1188" } }, "us-gaap-GrossInvestmentIncomeOperating": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossInvestmentIncomeOperating", "crdr": "credit", "calculation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAnalysisofInvestmentOperationsDetails": { "parentTag": "us-
 gaap-NetInvestmentIncome", "weight": 1.0, "order": 1.0 }, "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAnalysisofInvestmentOperationsDetails", "lang": { "en-us": { "role": {
 "terseLabel": "Investment income, gross", "label": "Gross Investment Income, Operating", "documentation": "Amount, before investment expense,
 of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and
 interest. Excludes realized gain (loss) on investments." } } }, "auth_ref": { "r721", "r1014", "r1359" } }, "us-gaap-GrossProfit": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": {
 "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps",
 "parentTag": "us-gaap-OperatingIncomeLoss", "weight": 1.0, "order": 1.0 }, "presentation": {
 "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps",
 "lang": { "en-us": { "role": { "totalLabel": "Subtotal", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services
 sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": { "r79", "r81", "r128", "r210", "r327", "r387",
 "r388", "r390", "r391", "r392", "r393", "r394", "r396", "r397", "r594", "r919", "r924", "r1150", "r1152", "r1154", "r1155", "r1156", "r1203" } },
 "gl-GuaranteedAnnuityContractMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname":
 "GuaranteedAnnuityContractMember", "presentation": {
 "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionAssetsbyComponentatFairValueDetails", "lang": { "en-us": {
 "role": { "terseLabel": "Guaranteed annuity contract", "label": "Guaranteed Annuity Contract [Member]", "documentation": "Guaranteed annuity
 contract [Member]." } } }, "auth_ref": { } }, "us-gaap-HealthInsuranceProductLineMember": { "xbrltype": "domainItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "HealthInsuranceProductLineMember", "presentation": {
 "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfOperations",
 "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical",
 "http://www.globelifeinsurance.com/role/LiabilityforUnpaidClaimsScheduleofLiabilityforUnpaidHealthClaimsDetails",
 "http://www.globelifeinsurance.com/role/LiabilityforUnpaidClaimsScheduleofReconciliationofPolicyClaimsandOtherBenefitsPayableDetails",
 "lang": { "en-us": { "role": { "terseLabel": "Health premium", "netLabel": "Health claims", "verboseLabel": "Health insurance", "label": "Health
 Insurance Product Line [Member]", "documentation": "Product line consisting of insurance against loss by illness or injury." } } }, "auth_ref": {
 "r764" } }, "gl-HealthSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname":
 "HealthSegmentMember", "presentation": {
 "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps",
 "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofSegmentPremiumIncomebyDistributionChannelDetails",
 "http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofAnalysisofDeferredAcquisitionCostsDetails",
 "http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofDeferredPolicyAcquisitionCoststoConsolidatedBalanceSheetDetails",
 "http://www.globelifeinsurance.com/role/PolicyLiabilitiesAdditionalInformationDetails",
 "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails",
 "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedIncomeStatementDetails",
 "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails",
 "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofUndiscountedAndDiscountedExpectedFutureGrossPremiumsAndExpectedFuture",
 "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageDurationofLiabilityForFuturePolicyBenefitsDetails",
 "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageInterestRateofLiabilityForFuturePolicyBenefitsDetails",
 "lang": { "en-us": { "role": { "terseLabel": "Health", "label": "Health Segment [Member]", "documentation": "Health Segment [Member]" } } },
 "auth_ref": { } }, "gl-HospitalityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname":
 "HospitalityMember", "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails", "lang": { "en-us": { "role": {
 "terseLabel": "Hospitality", "label": "Hospitality [Member]", "documentation": "Hospitality [Member]" } } }, "auth_ref": { } }, "us-
 gaap-IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": {
 "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap-NetIncomeLoss", "weight": 1.0,
 "order": 2.0 },
 "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps",
 "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": {
 "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps",
 "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfOperations",
 "http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofReclassificati",
 "lang": { "en-us": { "role": { "totalLabel": "Income before income taxes", "negatedLabel": "Total before tax", "label": "Income (Loss) from
 Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations,
 including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to
 noncontrolling interest." } } }, "auth_ref": { "r80", "r123", "r128", "r691", "r717", "r919", "r924", "r1150", "r1152", "r1154", "r1155", "r1156" } },
 "us-gaap-IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } },
 "auth_ref": { } }, "us-gaap-IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": {
 "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap-NetIncomeLoss", "weight":
 1.0, "order": 1.0 }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfOperations",
 "http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofReclassificati",
 "lang": { "en-us": { "role": { "negatedLabel": "Income tax benefit (expense)", "terseLabel": "Tax", "label": "Income Tax Expense (Benefit)",
 "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing
 operations." } } }, "auth_ref": { "r149", "r157", "r228", "r229", "r245", "r261", "r276", "r540", "r541", "r544", "r732", "r957" } }, "us-
 gaap-IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": {
 "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfShareholdersEquity", "lang": { "en-us": { "role": { "terseLabel":
 "Increase (Decrease) in Stockholders' Equity", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll
 forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { } }, "ecd-IndividualAxis": {
 "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": {
 "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
 "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel":
 "Individual", "label": "Individual [Axis]" } } }, "auth_ref": { "r1028", "r1038", "r1048", "r1072", "r1080", "r1084", "r1092" } },
 "srt-IndustrialPropertyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "IndustrialPropertyMember",
 "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails", "lang": { "en-
 us": { "role": { "terseLabel": "Industrial", "label": "Industrial Property [Member]" } } }, "auth_ref": { "r1362", "r1363" } }, "gl-IndustrialsMember":
 { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "IndustrialsMember", "presentation": {
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails",
 "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAvailableforSalebyComponentDetails",

```

    "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Industrials", "label": "Industrials [Member]", "documentation": "Industrials" } } }, "auth_ref": { "gl-InfrastructureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "InfrastructureMember", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofInvestmentFundsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Infrastructure", "label": "Infrastructure [Member]", "documentation": "Infrastructure" } } }, "auth_ref": { "ecd-InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbnl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": { "r1090": { "ecd-InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbnl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": { "r1020", "r1096": { "ecd-InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbnl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": { "http://xbnl.sec.gov/ecd/role/InsiderTradingPoliciesProc": { "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": { "r1020", "r1096": { "ecd-InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbnl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": { "http://xbnl.sec.gov/ecd/role/InsiderTradingPoliciesProc": { "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": { "r1020", "r1096": { "us-gaap_InsuranceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InsuranceAbstract", "lang": { "en-us": { "role": { "terseLabel": "Insurance [Abstract]", "label": "Insurance [Abstract]" } } }, "auth_ref": { "gl-InsuranceCashValueAndInvestmentFundSupportingSupplementalPensionPlanLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "InsuranceCashValueAndInvestmentFundSupportingSupplementalPensionPlanLiability", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofInformationRegardingtheSERPDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofInformationRegardingtheSERPDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total investments of SERP", "label": "Insurance Cash Value And Investment Fund Supporting Supplemental Pension Plan Liability", "documentation": "Insurance Cash Value And Investment Fund Supporting Supplemental Pension Plan Liability" } } }, "auth_ref": { "gl-InsuranceCashValueAndInvestmentFundSupportingSupplementalPensionPlanLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "InsuranceCashValueAndInvestmentFundSupportingSupplementalPensionPlanLiabilityAbstract", "presentation": { "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofInformationRegardingtheSERPDetails": { "lang": { "en-us": { "role": { "terseLabel": "Total investments:", "label": "Insurance Cash Value And Investment Fund Supporting Supplemental Pension Plan Liability [Abstract]", "documentation": "Insurance Cash Value And Investment Fund Supporting Supplemental Pension Plan Liability" } } }, "auth_ref": { "gl-InsuranceCashValueOfSupplementalPensionPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "InsuranceCashValueOfSupplementalPensionPlan", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofInformationRegardingtheSERPDetails": { "parentTag": "gl-InsuranceCashValueAndInvestmentFundSupportingSupplementalPensionPlanLiability", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofInformationRegardingtheSERPDetails": { "lang": { "en-us": { "role": { "terseLabel": "COLI", "label": "Insurance Cash Value Of Supplemental Pension Plan", "documentation": "Insurance cash value included in the assets of the supplemental pension plan." } } }, "auth_ref": { "us-gaap_InsuranceDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InsuranceDisclosureTextBlock", "presentation": { "http://www.globelifeinsurance.com/role/LiabilityforUnpaidClaims": { "lang": { "en-us": { "role": { "terseLabel": "Liability for Unpaid Claims", "label": "Insurance Disclosure [Text Block]", "documentation": "The entire disclosure for the types of coverages and products sold, and the assets, obligations, recorded liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items." } } }, "auth_ref": { "r695", "r696", "r753", "r754": { "gl-InsurancePremiumPaidForSupplementalPensionPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "InsurancePremiumPaidForSupplementalPensionPlan", "crdr": "debit", "presentation": { "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofInformationRegardingtheSERPDetails": { "lang": { "en-us": { "role": { "terseLabel": "Interest Credited To Policyholders Account Balances", "label": "Insurance Premium Paid For Supplemental Pension Plan", "documentation": "Insurance premium added to the policy value in the supplemental retirement plan." } } }, "auth_ref": { "us-gaap-InterestCreditedToPolicyholdersAccountBalances": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestCreditedToPolicyholdersAccountBalances", "crdr": "debit", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceDetails": { "lang": { "en-us": { "role": { "terseLabel": "Interest credited", "label": "Policyholder Account Balance, Interest Expense", "documentation": "Amount of interest expense for allocation to policyholder account balance." } } }, "auth_ref": { "r994", "r996", "r1304", "r1317", "r1343": { "us-gaap-InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementOfOps": { "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0, "order": 8.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementOfOps": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfOperations": { "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "verboseLabel": "Interest expense", "label": "Interest Expense, Operating and Nonoperating", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": { "r245", "r253", "r257", "r263", "r276", "r605", "r924", "r925": { "us-gaap-InterestSensitiveLifeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestSensitiveLifeMember", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceDetails": { "lang": { "en-us": { "role": { "terseLabel": "Interest Sensitive Life", "label": "Interest Sensitive Life [Member]", "documentation": "Contract providing death benefits in which the rate credited by the insurer is adjusted periodically." } } }, "auth_ref": { "gl-InvestmentInInvestmentFund": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "InvestmentInInvestmentFund", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofInformationRegardingtheSERPDetails": { "parentTag": "gl-InsuranceCashValueAndInvestmentFundSupportingSupplementalPensionPlanLiability", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofInformationRegardingtheSERPDetails": { "lang": { "en-us": { "role": { "terseLabel": "Exchange traded funds", "label": "Investment In Investment Fund", "documentation": "Investment In Investment Fund" } } }, "auth_ref": { "gl-InvestmentInLowIncomeHousingInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "InvestmentInLowIncomeHousingInterests", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Investments in low income housing interests", "label": "Investment In Low Income Housing Interests", "documentation": "Investment In Low Income Housing Interests" } } }, "auth_ref": { "us-gaap-InvestmentIncomeInvestmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInvestmentExpense", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAnalysisofInvestmentOperationsDetails": { "parentTag": "us-gaap_NetInvestmentIncome", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAnalysisofInvestmentOperationsDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Less investment expense", "label": "Investment Income, Investment Expense", "documentation": "Amount of expenses related to the generation of investment income." } } }, "auth_ref": { "r89", "r1014", "r1314": { "us-gaap-InvestmentIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeTextBlock", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Analysis of Investment Operations", "label": "Investment Income [Table Text Block]", "documentation": "Tabular disclosure of investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments." } } }, "auth_ref": { "r85", "r86", "r88", "r89", "r1315": { "gl-InvestmentSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "InvestmentSegmentMember", "presentation": { "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementOfOps": { "lang": { "en-us": { "role": { "terseLabel": "Investment", "label": "Investment Segment [Member]", "documentation": "Investment Segment [Member]" } } }, "auth_ref": { "us-gaap-InvestmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTextBlock", "presentation": { "http://www.globelifeinsurance.com/role/Investments": { "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investment [Text Block]", "documentation": "The entire disclosure for investment." } } }, "auth_ref": {

```

"r1110", "r1111", "r1159" | }, "us-gaap-InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeAxis", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAnalysisofInvestmentOperationsDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofInvestmentFundsDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofOtherLongTermInvestmentsDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Investment Type [Axis]", "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": { "r811", "r813", "r814", "r816", "r818", "r876", "r878", "r880", "r883", "r884", "r885", "r890", "r891", "r892", "r893", "r894", "r1008" | }, "us-gaap-InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeCategorizationMember", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAnalysisofInvestmentOperationsDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofInvestmentFundsDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofOtherLongTermInvestmentsDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Investments [Domain]", "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": { "r811", "r813", "r814", "r816", "r818", "r876", "r878", "r880", "r883", "r884", "r885", "r890", "r891", "r892", "r893", "r894", "r1008" | }, "us-gaap-Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Investments", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "totalLabel": "Total investments", "label": "Investments", "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments." } } }, "auth_ref": { "r697", "r701", "r1002", "r1005" | }, "us-gaap-InvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsAbstract", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets", "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" }, "lang": { "en-us": { "role": { "verboseLabel": "Investments", "terseLabel": "Investments", "label": "Investments [Abstract]" } } }, "auth_ref": { } }, "us-gaap-InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fixed Maturities by Contractual Maturity", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments." } } }, "auth_ref": { } }, "us-gaap-InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Investments, Debt and Equity Securities [Abstract]", "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": { } }, "gl-JuniorSubordinatedDebenturesDue2056Member": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "JuniorSubordinatedDebenturesDue2056Member", "presentation": { "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Junior Subordinated Debentures Due 2056", "label": "Junior Subordinated Debentures Due 2056" } } }, "auth_ref": { } }, "gl-JuniorSubordinatedDebenturesDue2057Member": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "JuniorSubordinatedDebenturesDue2057Member", "presentation": { "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Junior Subordinated Debentures Due 2057", "label": "Junior Subordinated Debentures Due 2057 [Member]", "documentation": "Junior Subordinated Debentures Due 2057" } } }, "auth_ref": { } }, "gl-JuniorSubordinatedDebenturesDue2061Member": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "JuniorSubordinatedDebenturesDue2061Member", "presentation": { "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Junior Subordinated Debentures Due 2061", "label": "Junior Subordinated Debentures Due 2061 [Member]", "documentation": "Junior Subordinated Debentures Due 2061" } } }, "auth_ref": { } }, "gl-JuniorSubordinatedDebenturesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "JuniorSubordinatedDebenturesMember", "presentation": { "http://www.globelifeinsurance.com/role/Cover", "http://www.globelifeinsurance.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "4.250% Junior Subordinated Debentures", "label": "Junior Subordinated Debentures [Member]", "documentation": "Junior Subordinated Debentures" } } }, "auth_ref": { } }, "gl-LTV70PercentTo80PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LTV70PercentTo80PercentMember", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsRecordedInvestmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "70% to 80%", "label": "LTV 70 Percent To 80 Percent [Member]", "documentation": "LTV 70 Percent To 80 Percent [Member]" } } }, "auth_ref": { } }, "gl-LTV81PercentTo90PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LTV81PercentTo90PercentMember", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsRecordedInvestmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "81% to 90%", "label": "LTV 81 Percent To 90 Percent [Member]", "documentation": "LTV 81 Percent To 90 Percent [Member]" } } }, "auth_ref": { } }, "gl-LTVGreaterThan90PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LTVGreaterThan90PercentMember", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsRecordedInvestmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Greater than 90%", "label": "LTV Greater Than 90 Percent [Member]", "documentation": "LTV Greater Than 90 Percent [Member]" } } }, "auth_ref": { } }, "gl-LTVLessThan70PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LTVLessThan70PercentMember", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsRecordedInvestmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Less than 70%", "label": "LTV Less Than 70 Percent [Member]", "documentation": "LTV Less Than 70 Percent [Member]" } } }, "auth_ref": { } }, "us-gaap-LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LetterOfCreditMember", "presentation": { "http://www.globelifeinsurance.com/role/CommitmentsandContingenciesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Letter of Credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": { } }, "gl-LettersOfCreditFacilityLimit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LettersOfCreditFacilityLimit", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/CommitmentsandContingenciesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Letter of credit maximum available amount", "label": "Letters Of Credit Facility Limit", "documentation": "Letters Of Credit Facility Limit" } } }, "auth_ref": { } }, "us-gaap-LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "http://www.globelifeinsurance.com/role/DebtShortTermBorrowingsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Letters of credit outstanding", "verboseLabel": "Letters of credit outstanding", "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": { } }, "us-gaap-Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap-LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": { "r17", "r56", "r57", "r58", "r61", "r62", "r63", "r64", "r210", "r327", "r387", "r388", "r390", "r391", "r392", "r393", "r394", "r396", "r397", "r556", "r557", "r558", "r594", "r828", "r918", "r1015", "r1203", "r1293", "r1294" | }, "us-gaap-LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAbstract", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets", "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheetsParenthetical" }, "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities [Abstract]" } } }, "auth_ref": { } }, "us-gaap-LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and shareholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": { "r72", "r120", "r714", "r971", "r1142", "r1182", "r1285" | }, "us-gaap-LiabilityForClaimsAndClaimsAdjustmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "gl-PolicyholderAccountBalanceLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets", "http://www.globelifeinsurance.com/role/LiabilityforUnpaidClaimsScheduleofLiabilityforUnpaidHealthClaimsDetails" },

"http://www.globelifeinsurance.com/role/LiabilityForUnpaidClaimsScheduleofReconciliationofPolicyClaimsandOtherBenefitsPayableDetails" },
"lang": { "en-us": { "role": { "terseLabel": "Policy claims and other benefits payable", "periodStartLabel": "Beginning balance less reinsurance recoverable", "periodEndLabel": "Beginning balance plus reinsurance recoverable", "label": "Liability for Claims and Claims Adjustment Expense", "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date." } } }, "auth_ref": { "r997", "r1001", "r1307", "r1325" } }, "us-gaap-LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems", "presentation": -1
"http://www.globelifeinsurance.com/role/LiabilityForUnpaidClaimsScheduleofLiabilityForUnpaidHealthClaimsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Liability for Claims and Claims Adjustment Expense [Line Items]", "label": "Liability for Claims and Claims Adjustment Expense [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { } }, "us-gaap-LiabilityForClaimsAndClaimsAdjustmentExpenseTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseTable", "presentation": -1
"http://www.globelifeinsurance.com/role/LiabilityForUnpaidClaimsScheduleofLiabilityForUnpaidHealthClaimsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Liability for Claims and Claims Adjustment Expense [Table]", "label": "Liability for Claims and Claims Adjustment Expense [Table]", "documentation": "Disclosure of information about the liability for claims and claims adjustment expense." } } }, "auth_ref": { } }, "us-gaap-LiabilityForFuturePolicyBenefitActivityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForFuturePolicyBenefitActivityLineItems", "presentation": -1
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesAdditionalInformationDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedIncomeStatementDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofUndiscountedAndDiscountedExpectedFutureGrossPremiumsAndExpectedFuture",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageDurationofLiabilityForFuturePolicyBenefitsDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageInterestRateofLiabilityForFuturePolicyBenefitsDetails" },
"lang": { "en-us": { "role": { "terseLabel": "Liability for Future Policy Benefit, Activity [Line Items]", "label": "Liability for Future Policy Benefit, Activity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r783", "r995" } }, "us-gaap-LiabilityForFuturePolicyBenefitActivityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForFuturePolicyBenefitActivityTable", "presentation": -1
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesAdditionalInformationDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedIncomeStatementDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofUndiscountedAndDiscountedExpectedFutureGrossPremiumsAndExpectedFuture",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageDurationofLiabilityForFuturePolicyBenefitsDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageInterestRateofLiabilityForFuturePolicyBenefitsDetails" },
"lang": { "en-us": { "role": { "terseLabel": "Liability for Future Policy Benefit, Activity [Table]", "label": "Liability for Future Policy Benefit, Activity [Table]", "documentation": "Disclosure of information about activity for liability for future policy benefit. Includes, but is not limited to, beginning and ending balance, issuance, interest income (expense), net premium collected, benefit payment, derecognition, experience adjustment, change in cash flow assumption, and change in discount rate assumption." } } }, "auth_ref": { "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r783", "r995" } }, "us-gaap-LiabilityForFuturePolicyBenefitActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForFuturePolicyBenefitActivityTableTextBlock", "presentation": -1
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Liability for Future Policy Benefit, Activity", "label": "Liability for Future Policy Benefit, Activity [Table Text Block]", "documentation": "Tabular disclosure of beginning balance to ending balance for liability for future policy benefit, with separate presentation of expected future net premium and expected future benefit." } } }, "auth_ref": { "r766", "r783", "r995" } }, "us-gaap-LiabilityForFuturePolicyBenefitAfterReinsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForFuturePolicyBenefitAfterReinsurance", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": -1
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails" }, "lang": { "en-us": { "role": { "totalLabel": "Net liability for future policy benefits, after reinsurance recoverable, at current discount rates", "label": "Liability for Future Policy Benefit, after Reinsurance", "documentation": "Amount, after effect of reinsurance, of liability for future policy benefit." } } }, "auth_ref": { "r995", "r1335", "r1352" } }, "gl-LiabilityForFuturePolicyBenefitChangeInAssumptionsOfLapseMortalityAndMorbidityRemeasurementGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LiabilityForFuturePolicyBenefitChangeInAssumptionsOfLapseMortalityAndMorbidityRemeasurementGainLoss", "crdr": "credit", "presentation": -1
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Change in assumptions of lapse, mortality, and morbidity, remeasurement gain (loss)", "label": "Liability for Future Policy Benefit, Change in Assumptions of Lapse, Mortality, and Morbidity, Remeasurement Gain (Loss)", "documentation": "Liability for Future Policy Benefit, Change in Assumptions of Lapse, Mortality, and Morbidity, Remeasurement Gain (Loss)" } } }, "auth_ref": { } },
"gl-LiabilityForFuturePolicyBenefitChangeInExpectedExperienceRemeasurementGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LiabilityForFuturePolicyBenefitChangeInExpectedExperienceRemeasurementGainLoss", "crdr": "credit", "presentation": -1
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Change in expected experience, remeasurement gain (loss)", "label": "Liability for Future Policy Benefit, Change in Expected Experience, Remeasurement Gain (Loss)", "documentation": "Liability for Future Policy Benefit, Change in Expected Experience, Remeasurement Gain (Loss)" } } }, "auth_ref": { } },
"gl-LiabilityForFuturePolicyBenefitCurrentDiscountRateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LiabilityForFuturePolicyBenefitCurrentDiscountRateAbstract", "presentation": -1
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "At Current Discount Rates", "label": "Liability for Future Policy Benefit, Current Discount Rate [Abstract]", "documentation": "Liability for Future Policy Benefit, Current Discount Rate" } } }, "auth_ref": { } },
"gl-LiabilityForFuturePolicyBenefitCurrentDiscountRateBeforeReinsuranceAndOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LiabilityForFuturePolicyBenefitCurrentDiscountRateBeforeReinsuranceAndOther", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails": { "parentTag": "us-gaap-LiabilityForFuturePolicyBenefits", "weight": 1.0, "order": 1.0 } }, "presentation": -1
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Net liability for future policy benefits, 2014 long duration health", "label": "Liability for Future Policy Benefit, Current Discount Rate, before Reinsurance and Other", "documentation": "Liability for Future Policy Benefit, Current Discount Rate, before Reinsurance and Other" } } }, "auth_ref": { } },
"gl-LiabilityForFuturePolicyBenefitCurrentDiscountRateDeferredAnnuity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LiabilityForFuturePolicyBenefitCurrentDiscountRateDeferredAnnuity", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails": { "parentTag": "us-gaap-LiabilityForFuturePolicyBenefits", "weight": 1.0, "order": 3.0 } }, "presentation": -1
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Deferred annuity", "label": "Liability for Future Policy Benefit, Current Discount Rate, Deferred Annuity", "documentation": "Liability for Future Policy Benefit, Current Discount Rate, Deferred Annuity" } } }, "auth_ref": { } },
"gl-LiabilityForFuturePolicyBenefitCurrentDiscountRateDeferredProfitLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LiabilityForFuturePolicyBenefitCurrentDiscountRateDeferredProfitLiability", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails": { "parentTag": "us-gaap-LiabilityForFuturePolicyBenefits", "weight": 1.0, "order": 2.0 } }, "presentation": -1
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Deferred profit liability", "label": "Liability for Future Policy Benefit, Current Discount Rate, Deferred Profit Liability", "documentation": "Liability for Future Policy Benefit, Current Discount Rate, Deferred Profit Liability" } } }, "auth_ref": { } },
"gl-LiabilityForFuturePolicyBenefitCurrentDiscountRateInterestSensitiveLife": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LiabilityForFuturePolicyBenefitCurrentDiscountRateInterestSensitiveLife", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails": {

"parentTag": "us-gaap_LiabilityForFuturePolicyBenefits", "weight": 1.0, "order": 4.0 } }, "presentation": {
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails"},
"lang": { "en-us": { "role": { "terseLabel": "Interest sensitive life", "label": "Liability for Future Policy Benefit, Current Discount Rate, Interest Sensitive Life", "documentation": "Liability for Future Policy Benefit, Current Discount Rate, Interest Sensitive Life" } } }, "auth_ref": { } },
"gl_LiabilityForFuturePolicyBenefitCurrentDiscountRateOtherContracts": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.globelifeinsurance.com/20240930", "localname": "LiabilityForFuturePolicyBenefitCurrentDiscountRateOtherContracts", "crdr":
"credit", "calculation": {
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails": {
"parentTag": "us-gaap_LiabilityForFuturePolicyBenefits", "weight": 1.0, "order": 5.0 } }, "presentation": {
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails"},
"lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Liability for Future Policy Benefit, Current Discount Rate, Other Contracts",
"documentation": "Liability for Future Policy Benefit, Current Discount Rate, Other Contracts" } } }, "auth_ref": { } }, "us-
gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate", "presentation": {
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageInterestRateofLiabilityForFuturePolicyBenefitsDetails"},
"lang": { "en-us": { "role": { "terseLabel": "Weighted average current discount rate", "label": "Liability for Future Policy Benefit, Current Weighted Average Discount Rate", "documentation": "Current weighted average discount rate used to measure liability for future policy benefit." } } },
"auth_ref": { "r772", "r905" } }, "gl_LiabilityForFuturePolicyBenefitDifferenceBetweenExpectedGrossPremiumsAndExpectedFutureNetPremiums": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname":
"LiabilityForFuturePolicyBenefitDifferenceBetweenExpectedGrossPremiumsAndExpectedFutureNetPremiums", "crdr": "credit", "presentation": {
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesAdditionalInformationDetails"}, "lang": { "en-us": { "role": { "terseLabel": "Liability for Future Policy Benefit, Difference Between Expected Gross Premiums and Expected Future Net Premiums", "label": "Liability for Future Policy Benefit, Difference Between Expected Gross Premiums and Expected Future Net Premiums", "documentation": "Liability for Future Policy Benefit, Difference Between Expected Gross Premiums and Expected Future Net Premiums" } } }, "auth_ref": { } },
"gl_LiabilityForFuturePolicyBenefitEffectOfChangesInDiscountRateAssumptions": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.globelifeinsurance.com/20240930", "localname": "LiabilityForFuturePolicyBenefitEffectOfChangesInDiscountRateAssumptions",
"crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails": {
"parentTag": "us-gaap_LiabilityForFuturePolicyBenefits", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails"}, "lang": { "en-us": { "role": {
"terseLabel": "Effect of changes in discount rate assumptions", "label": "Liability for Future Policy Benefit, Effect of Changes in Discount Rate Assumptions", "documentation": "Liability for Future Policy Benefit, Effect of Changes in Discount Rate Assumptions" } } }, "auth_ref": { } },
"gl_LiabilityForFuturePolicyBenefitEffectOfOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.globelifeinsurance.com/20240930", "localname": "LiabilityForFuturePolicyBenefitEffectOfOtherAdjustments", "crdr": "credit",
"calculation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails": { "parentTag":
"us-gaap_LiabilityForFuturePolicyBenefits", "weight": 1.0, "order": 3.0 } }, "presentation": {
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails"}, "lang": { "en-us": { "role": {
"terseLabel": "Other Adjustments", "label": "Liability for Future Policy Benefit, Effect of Other Adjustments", "documentation": "Liability for Future Policy Benefit, Effect of Other Adjustments" } } }, "auth_ref": { } },
"gl_LiabilityForFuturePolicyBenefitExpectedFutureBenefitOriginalDiscountRate": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.globelifeinsurance.com/20240930", "localname": "LiabilityForFuturePolicyBenefitExpectedFutureBenefitOriginalDiscountRate",
"crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails": {
"parentTag": "us-gaap_LiabilityForFuturePolicyBenefits", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails"}, "lang": { "en-us": { "role": {
"terseLabel": "Net liability for future policy benefits at original discount rates", "label": "Liability for Future Policy Benefit, Expected Future Benefit, Original Discount Rate", "documentation": "Liability for Future Policy Benefit, Expected Future Benefit, Original Discount Rate" } } },
"auth_ref": { } }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureBenefitOriginalDiscountRateBeforeReinsuranceAfterCashFlowChange": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilityForFuturePolicyBenefitExpectedFutureBenefitOriginalDiscountRateBeforeReinsuranceAfterCashFlowChange", "crdr": "credit",
"calculation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails": { "parentTag":
null, "weight": null, "order": null, "root": true } }, "presentation": {
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails"}, "lang": { "en-us": { "role": {
"totalLabel": "Adjusted balance", "label": "Liability for Future Policy Benefit, Expected Future Benefit, Original Discount Rate, before Reinsurance, after Cash Flow Change", "documentation": "Amount, before effect of reinsurance and after current period update of cash flow assumption, of expected future benefit and expense component for liability for future policy benefit, discounted at original rate." } } }, "auth_ref": { "r995",
"r1335", "r1352" } }, "gl_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumNotDiscountedBeforeCashFlowReinsurance": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname":
"LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumNotDiscountedBeforeCashFlowReinsurance", "crdr": "credit", "presentation": {
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofUndiscountedAndDiscountedExpectedFutureGrossPremiumsAndExpectedFuture",
"lang": { "en-us": { "role": { "terseLabel": "PV of expected future gross premiums, Not discounted", "label": "Liability for Future Policy Benefit, Expected Future Gross Premium, Not Discounted, before Cash Flow Reinsurance", "documentation": "Liability for Future Policy Benefit, Expected Future Gross Premium, Not Discounted, before Cash Flow Reinsurance" } } }, "auth_ref": { } },
"gl_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumsBeforeReinsuranceAfterDiscountRateChange": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname":
"LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumsBeforeReinsuranceAfterDiscountRateChange", "crdr": "credit", "presentation": {
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesAdditionalInformationDetails"},
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofUndiscountedAndDiscountedExpectedFutureGrossPremiumsAndExpectedFuture",
"lang": { "en-us": { "role": { "verboseLabel": "PV of expected future gross premiums", "terseLabel": "PV of expected future gross premiums, At current discount rates", "label": "Liability for Future Policy Benefit, Expected Future Gross Premiums, before Reinsurance, after Discount Rate Change", "documentation": "Liability for Future Policy Benefit, Expected Future Gross Premiums, before Reinsurance, after Discount Rate Change" } } }, "auth_ref": { } }, "gl_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumsOriginalDiscountRateBeforeCashFlowAndReinsurance": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname":
"LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumsOriginalDiscountRateBeforeCashFlowAndReinsurance", "crdr": "credit",
"presentation": {
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofUndiscountedAndDiscountedExpectedFutureGrossPremiumsAndExpectedFuture",
"lang": { "en-us": { "role": { "terseLabel": "PV of expected future gross premiums, At original discount rates", "label": "Liability for Future Policy Benefit, Expected Future Gross Premiums, Original Discount Rate, before Cash Flow and Reinsurance", "documentation": "Liability for Future Policy Benefit, Expected Future Gross Premiums, Original Discount Rate, before Cash Flow and Reinsurance" } } }, "auth_ref": { } }, "us-
gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange", "crdr": "credit", "presentation": {
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails"},
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofUndiscountedAndDiscountedExpectedFutureGrossPremiumsAndExpectedFuture",
"lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "terseLabel": "PV of expected future policy benefits, At current discount rates", "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit, before Reinsurance, after Discount Rate Change", "documentation": "Amount, before effect of reinsurance and after current period update of cash flow assumption and discount rate change, of expected future policy benefit and expense component for liability for future policy benefit." } } }, "auth_ref": { "r766",
"r767", "r783", "r995" } }, "us-
gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChange": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChange", "crdr": "credit", "calculation": {
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails": { "parentTag": "us-
gaap_LiabilityForFuturePolicyBenefitExpectedFutureBenefitOriginalDiscountRateBeforeReinsuranceAfterCashFlowChange", "weight": 1.0, "order":
2.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails"},
"lang": { "en-us": { "role": { "terseLabel": "Effect of changes in assumptions on future cash flows", "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit, Cumulative Increase (Decrease) from Cash Flow Change", "documentation": "Amount of cumulative increase (decrease) in expected future policy benefit and expense component for liability of future policy benefit from cash flow assumption change for future cash flows." } } }, "auth_ref": { "r987", "r995", "r1335", "r1352" } }, "us-
gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience": { "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails": { "parentTag": "us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeReinsuranceAfterCashFlowChange", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Effect of actual variances from expected experience", "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit, Cumulative Increase (Decrease) of Actual Variance from Expected Experience", "documentation": "Amount of cumulative increase (decrease) in expected future policy benefit and expense component for liability of future policy benefit from effect of variance from cash flow assumption change for actual experience." } } }, "auth_ref": { "r768", "r986", "r995", "r1335", "r1352" } }, "gl_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitForeignExchangeEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitForeignExchangeEffect", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Effect of changes in the foreign exchange rate", "label": "Liability For Future Policy Benefit, Expected Future Policy Benefit, Foreign Exchange Effect", "documentation": "Liability For Future Policy Benefit, Expected Future Policy Benefit, Foreign Exchange Effect" } } }, "auth_ref": { "r982", "r995", "r1335", "r1352" } }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpense", "crdr": "debit", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Interest accrual", "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit, Interest Expense", "documentation": "Amount of interest expense for expected future policy benefit and expense component of liability for future policy benefit." } } }, "auth_ref": { "r983", "r995", "r1335", "r1352" } }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuance", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Issuances", "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit, Issuance", "documentation": "Amount of increase in expected future policy benefit and expense component of liability for future policy benefit from contract issuance." } } }, "auth_ref": { "r982", "r995", "r1335", "r1352" } }, "gl_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitNotDiscountedBeforeCashFlowAndReinsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitNotDiscountedBeforeCashFlowAndReinsurance", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesAdditionalInformationDetails": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofUndiscountedAndDiscountedExpectedFutureGrossPremiumsAndExpectedFuture": { "lang": { "en-us": { "role": { "verboseLabel": "PV of expected future policy benefits, not discounted", "terseLabel": "PV of expected future policy benefits, Not discounted", "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit, Not Discounted, before Cash Flow and Reinsurance", "documentation": "Liability for Future Policy Benefit, Expected Future Policy Benefit, Not Discounted, before Cash Flow and Reinsurance1" } } }, "auth_ref": { "r983", "r995", "r1335", "r1352" } }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails": { "parentTag": "us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeReinsuranceAfterCashFlowChange", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofUndiscountedAndDiscountedExpectedFutureGrossPremiumsAndExpectedFuture": { "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "verboseLabel": "PV of expected future policy benefits, At original discount rates", "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit, Original Discount Rate, before Cash Flow and Reinsurance", "documentation": "Amount, before effect of reinsurance and current period update of cash flow assumption, of expected future policy benefit and expense component of liability for future policy benefit, discounted at original rate." } } }, "auth_ref": { "r995", "r1335", "r1352" } }, "gl_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsuranceNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsuranceNet", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails": { "parentTag": "gl_LiabilityForFuturePolicyBenefitOriginalDiscountRateAfterReinsuranceAndOther", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net liability for future policy benefits at 2014 long duration life", "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit, Original Discount Rate, before Cash Flow and Reinsurance, Net", "documentation": "Liability for Future Policy Benefit, Expected Future Policy Benefit, Original Discount Rate, before Cash Flow and Reinsurance, Net" } } }, "auth_ref": { "r983", "r995", "r1335", "r1352" } }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]", "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { "r983", "r995", "r1335", "r1352" } }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange", "crdr": "debit", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesAdditionalInformationDetails": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofUndiscountedAndDiscountedExpectedFutureGrossPremiumsAndExpectedFuture": { "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "terseLabel": "PV of expected future net premiums", "verboseLabel": "PV of expected future net premiums, At current discount rates", "label": "Liability for Future Policy Benefit, Expected Net Premium, before Reinsurance, after Discount Rate Change", "documentation": "Amount, before effect of reinsurance and after current period update of cash flow assumption and discount rate change, of expected net premium component of liability for future policy benefit." } } }, "auth_ref": { "r766", "r767", "r783", "r995" } }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChange": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChange", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails": { "parentTag": "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeReinsuranceAfterCashFlowChange", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Effect of changes in assumptions on future cash flows", "label": "Liability for Future Policy Benefit, Expected Net Premium, Cumulative Increase (Decrease) from Cash Flow Change", "documentation": "Amount of cumulative increase (decrease) in expected net premium component of liability for future policy benefit from cash flow assumption change for future cash flows." } } }, "auth_ref": { "r987", "r995", "r1335", "r1352" } }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails": { "parentTag": "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeReinsuranceAfterCashFlowChange", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Effect of actual variances from expected experience", "label": "Liability for Future Policy Benefit, Expected Net Premium, Cumulative Increase (Decrease) of Actual Variance from Expected Experience", "documentation": "Amount of cumulative increase (decrease) in expected net premium component for liability of future policy benefit from effect of variance from cash flow assumption change for actual experience." } } }, "auth_ref": { "r768", "r986", "r995", "r1335", "r1352" } }, "gl_LiabilityForFuturePolicyBenefitExpectedNetPremiumForeignExchangeEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LiabilityForFuturePolicyBenefitExpectedNetPremiumForeignExchangeEffect", "crdr": "credit", "presentation": {

"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Effect of changes in the foreign exchange rate", "label": "Liability For Future Policy Benefit, Expected Net Premium, Foreign Exchange Effect", "documentation": "Liability For Future Policy Benefit, Expected Net Premium, Foreign Exchange Effect" } } }, "auth_ref": { } }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncome", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Interest accrual", "label": "Liability for Future Policy Benefit, Expected Net Premium, Interest Income", "documentation": "Amount of interest income for expected net premium component of liability for future policy benefit." } } }, "auth_ref": { "r983", "r995", "r1335", "r1352" } }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuance", "crdr": "debit", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Issuances", "label": "Liability for Future Policy Benefit, Expected Net Premium, Issuance", "documentation": "Amount of increase in expected net premium component of liability for future policy benefit from contract issuance." } } }, "auth_ref": { "r982", "r995", "r1335", "r1352" } }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected", "crdr": "debit", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitActivityDetails" }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Net premiums collected", "label": "Liability for Future Policy Benefit, Expected Net Premium, Net Premium Collected", "documentation": "Amount of premium collected from policyholder to fund expected benefit payment for expected net premium component of liability for future policy benefit." } } }, "auth_ref": { "r984", "r995", "r1335", "r1352" } }, "gl_LiabilityForFuturePolicyBenefitExpectedNetPremiumNotDiscountedBeforeCashFlowAndReinsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LiabilityForFuturePolicyBenefitExpectedNetPremiumNotDiscountedBeforeCashFlowAndReinsurance", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofUndiscountedAndDiscountedExpectedFutureGrossPremiumsAndExpectedFuture": { "lang": { "en-us": { "role": { "terseLabel": "PV of expected future net premiums, Not discounted", "label": "Liability for Future Policy Benefit, Expected Net Premium, Not Discounted, before Cash Flow and Reinsurance", "documentation": "Liability for Future Policy Benefit, Expected Net Premium, Not Discounted, before Cash Flow and Reinsurance" } } }, "auth_ref": { } }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitActivityDetails": { "parentTag": "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeReinsuranceAfterCashFlowChange", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitActivityDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofUndiscountedAndDiscountedExpectedFutureGrossPremiumsAndExpectedFuture": { "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "terseLabel": "PV of expected future net premiums, At original discount rates", "label": "Liability for Future Policy Benefit, Expected Net Premium, Original Discount Rate, before Cash Flow and Reinsurance", "documentation": "Amount, before effect of reinsurance and current period update of cash flow assumption, of expected net premium component of liability for future policy benefit, discounted at original rate." } } }, "auth_ref": { "r995", "r1335", "r1352" } }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeReinsuranceAfterCashFlowChange": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeReinsuranceAfterCashFlowChange", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitActivityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitActivityDetails" }, "lang": { "en-us": { "role": { "totalLabel": "Adjusted balance", "label": "Liability for Future Policy Benefit, Expected Net Premium, Original Discount Rate, before Reinsurance, after Cash Flow Change", "documentation": "Amount, before effect of reinsurance and after current period update of cash flow assumption, of expected net premium component of liability for future policy benefit, discounted at original rate." } } }, "auth_ref": { "r995", "r1335", "r1352" } }, "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Liability for Future Policy Benefit, Expected Net Premium [Roll Forward]", "label": "Liability for Future Policy Benefit, Expected Net Premium [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { } }, "us-gaap_LiabilityForFuturePolicyBenefitGrossPremiumIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForFuturePolicyBenefitGrossPremiumIncome", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedIncomeStatementDetails": { "lang": { "en-us": { "role": { "terseLabel": "Gross Premiums", "label": "Liability for Future Policy Benefit, Gross Premium Income", "documentation": "Amount of gross premium income recognized for liability for future policy benefit." } } }, "auth_ref": { "r769", "r773", "r995" } }, "us-gaap_LiabilityForFuturePolicyBenefitInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForFuturePolicyBenefitInterestExpense", "crdr": "debit", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedIncomeStatementDetails": { "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Liability for Future Policy Benefit, Interest Expense", "documentation": "Amount of interest expense recognized for liability for future policy benefit." } } }, "auth_ref": { "r769", "r773", "r995" } }, "gl_LiabilityForFuturePolicyBenefitOriginalDiscountRateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LiabilityForFuturePolicyBenefitOriginalDiscountRateAbstract", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "At Original Discount Rates", "label": "Liability for Future Policy Benefit, Original Discount Rate [Abstract]", "documentation": "Liability for Future Policy Benefit, Original Discount Rate" } } }, "auth_ref": { } }, "gl_LiabilityForFuturePolicyBenefitOriginalDiscountRateAfterReinsuranceAndOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LiabilityForFuturePolicyBenefitOriginalDiscountRateAfterReinsuranceAndOther", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total future policy benefits", "label": "Liability for Future Policy Benefit, Original Discount Rate, after Reinsurance and Other", "documentation": "Liability for Future Policy Benefit, Original Discount Rate, after Reinsurance and Other" } } }, "auth_ref": { } }, "gl_LiabilityForFuturePolicyBenefitOriginalDiscountRateBeforeReinsuranceAndOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LiabilityForFuturePolicyBenefitOriginalDiscountRateBeforeReinsuranceAndOther", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheetsParenthetical": { "lang": { "en-us": { "role": { "terseLabel": "Future policy benefits at original rates", "label": "Liability for Future Policy Benefit, Original Discount Rate, Before Reinsurance and Other", "documentation": "Liability for Future Policy Benefit, Original Discount Rate, Before Reinsurance and Other" } } }, "auth_ref": { } }, "gl_LiabilityForFuturePolicyBenefitOriginalDiscountRateDeferredAnnuity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LiabilityForFuturePolicyBenefitOriginalDiscountRateDeferredAnnuity", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails": { "parentTag": "gl_LiabilityForFuturePolicyBenefitOriginalDiscountRateAfterReinsuranceAndOther", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Deferred profit liability", "label": "Liability for Future Policy Benefit, Original Discount Rate, Deferred Annuity", "documentation": "Liability for Future Policy Benefit, Original Discount Rate, Deferred Annuity" } } }, "auth_ref": { } }, "gl_LiabilityForFuturePolicyBenefitOriginalDiscountRateDeferredProfitLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LiabilityForFuturePolicyBenefitOriginalDiscountRateDeferredProfitLiability", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails": { "parentTag": "gl_LiabilityForFuturePolicyBenefitOriginalDiscountRateAfterReinsuranceAndOther", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Deferred profit liability", "label": "Liability for Future Policy Benefit, Original Discount Rate, Deferred Profit Liability", "documentation": "Liability for Future Policy Benefit, Original Discount Rate, Deferred Profit Liability" } } }, "auth_ref": { } }, "gl_LiabilityForFuturePolicyBenefitOriginalDiscountRateInterestSensitiveLife": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LiabilityForFuturePolicyBenefitOriginalDiscountRateInterestSensitiveLife", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails": {

"parentTag": "gl_LiabilityForFuturePolicyBenefitOriginalDiscountRateAfterReinsuranceAndOther", "weight": 1.0, "order": 4.0 } }, "presentation": "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Interest sensitive life", "label": "Liability for Future Policy Benefit, Original Discount Rate, Interest Sensitive Life", "documentation": "Liability for Future Policy Benefit, Original Discount Rate, Interest Sensitive Life" } } }, "auth_ref": { } }, "us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitActivityDetails": { "parentTag": "us-gaap_LiabilityForFuturePolicyBenefitAfterReinsurance", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesAdditionalInformationDetails": "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitActivityDetails" }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Reinsurance recoverable", "terseLabel": "Reinsurance recoverable at original discount rates", "label": "Liability for Future Policy Benefit, Reinsurance Recoverable, after Allowance", "documentation": "Amount, after allowance for credit loss, recoverable under reinsurance of liability for future policy benefit." } } }, "auth_ref": { "r770", "r783", "r995", "r1335" } }, "us-gaap_LiabilityForFuturePolicyBenefitRemeasurementGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForFuturePolicyBenefitRemeasurementGainLoss", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical": "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitActivityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Policyholder benefits net of remeasurement gain (losses)", "label": "Liability for Future Policy Benefit, Remeasurement Gain (Loss)", "documentation": "Amount of remeasurement gain (loss) on liability for future policy benefit from application of revised benefit ratio as of contract issue. Includes, but is not limited to, remeasurement gain (loss) for annuitization insurance benefit, death and other insurance benefits, and traditional and limited-payment contracts." } } }, "auth_ref": { "r755", "r756", "r757" } }, "gl_LiabilityForFuturePolicyBenefitRemeasurementGainLossByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LiabilityForFuturePolicyBenefitRemeasurementGainLossByTypeAxis", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Liability for Future Policy Benefit, Remeasurement Gain (Loss) by Type [Axis]", "label": "Liability for Future Policy Benefit, Remeasurement Gain (Loss) by Type [Axis]", "documentation": "Liability for Future Policy Benefit, Remeasurement Gain (Loss) by Type" } } }, "auth_ref": { } }, "gl_LiabilityForFuturePolicyBenefitRemeasurementGainLossByTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LiabilityForFuturePolicyBenefitRemeasurementGainLossByTypeDomain", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Liability for Future Policy Benefit, Remeasurement Gain (Loss) by Type [Domain]", "label": "Liability for Future Policy Benefit, Remeasurement Gain (Loss) by Type [Domain]", "documentation": "Liability for Future Policy Benefit, Remeasurement Gain (Loss) by Type [Domain]" } } }, "auth_ref": { } }, "gl_LiabilityForFuturePolicyBenefitUndiscountedAndDiscountedExpectedFutureGrossPremiumsAndExpectedFutureBenefitsAndExpensesTableTextB": { "xbrltype": "textBlockItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LiabilityForFuturePolicyBenefitUndiscountedAndDiscountedExpectedFutureGrossPremiumsAndExpectedFutureBenefitsAndExpensesTableTextBlock", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Undiscounted and Discounted Expected Future Gross Premiums and Expected Future Benefits and Expenses", "label": "Liability for Future Policy Benefit, Undiscounted and Discounted Expected Future Gross Premiums and Expected Future Benefits and Expenses [Table Text Block]", "documentation": "Liability for Future Policy Benefit, Undiscounted and Discounted Expected Future Gross Premiums and Expected Future Gross Premiums and Expected Future Benefits and Expenses" } } }, "auth_ref": { } }, "us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForFuturePolicyBenefitWeightedAverageDuration", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageDurationofLiabilityForFuturePolicyBenefitsDetails": { "lang": { "en-us": { "role": { "terseLabel": "At current discount rates", "label": "Liability for Future Policy Benefit, Weighted-Average Duration", "documentation": "Weighted-average duration of liability for future policy benefit, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r771" } }, "gl_LiabilityForFuturePolicyBenefitWeightedAverageDurationOriginalDiscount": { "xbrltype": "durationItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LiabilityForFuturePolicyBenefitWeightedAverageDurationOriginalDiscount", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageDurationofLiabilityForFuturePolicyBenefitsDetails": { "lang": { "en-us": { "role": { "terseLabel": "At original discount rates", "label": "Liability for Future Policy Benefit, Weighted-Average Duration, Original Discount", "documentation": "Liability for Future Policy Benefit, Weighted-Average Duration, Original Discount" } } }, "auth_ref": { } }, "us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageInterestRateofLiabilityForFuturePolicyBenefitsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted average original discount rate", "label": "Liability for Future Policy Benefit, Weighted-Average Interest Accretion Rate", "documentation": "Original weighted-average discount rate at contract issue date used to measure liability for future policy benefit." } } }, "auth_ref": { "r772", "r995" } }, "us-gaap_LiabilityForFuturePolicyBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForFuturePolicyBenefits", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "gl_PolicyholderAccountBalanceLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense", "weight": 1.0, "order": 1.0 }, "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitActivityDetails": { "parentTag": "us-gaap_LiabilityForFuturePolicyBenefitAfterReinsurance", "weight": 1.0, "order": 1.0 }, "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitActivityDetails": { "lang": { "en-us": { "role": { "netLabel": "Future policy benefits", "totalLabel": "Net liability for future policy benefits", "label": "Liability for Future Policy Benefit, before Reinsurance", "documentation": "Amount, before effect of reinsurance, of present value of future benefit to be paid to or on behalf of policyholder and related expense less present value of future net premium receivable under insurance contract." } } }, "auth_ref": { "r766", "r773", "r783", "r995", "r1307" } }, "gl_LiabilityForFuturePolicyBenefitsOriginalDiscountRateOtherContracts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LiabilityForFuturePolicyBenefitsOriginalDiscountRateOtherContracts", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails": { "parentTag": "gl_LiabilityForFuturePolicyBenefitOriginalDiscountRateAfterReinsuranceAndOther", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails": { "lang": { "en-us": { "role": { "documentation": "Liability for Future Policy Benefits, Original Discount Rate, Other Contracts" } } }, "auth_ref": { } }, "us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForFuturePolicyBenefitsPaymentForBenefits", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitActivityDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Benefit payments", "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit, Benefit Payment", "documentation": "Amount of cash outflow to policyholder from benefit payment for expected future policy benefit and expense component of liability for future policy benefit." } } }, "auth_ref": { "r985", "r995", "r1136", "r1335", "r1352" } }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract", "presentation": { "http://www.globelifeinsurance.com/role/LiabilityforUnpaidClaimsScheduleofLiabilityforUnpaidHealthClaimsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Paid related to", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]", "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs." } } }, "auth_ref": { "r761", "r997" } }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/LiabilityforUnpaidClaimsScheduleofLiabilityforUnpaidHealthClaimsDetails": { "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/LiabilityforUnpaidClaimsScheduleofLiabilityforUnpaidHealthClaimsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Current year", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year", "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs." } } }, "auth_ref": { "r761", "r997" } }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1", "crdr": "credit", "calculation": {

"http://www.globelifeinsurance.com/role/LiabilityForUnpaidClaimsScheduleofLiabilityForUnpaidHealthClaimsDetails": { "parentTag": "us-gaap-PaymentsForLossesAndLossAdjustmentExpense", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.globelifeinsurance.com/role/LiabilityForUnpaidClaimsScheduleofLiabilityForUnpaidHealthClaimsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Prior years", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years", "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs." } } }, "auth_ref": { "r761", "r997" } }, "us-gaap-LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/LiabilityForUnpaidClaimsScheduleofLiabilityForUnpaidHealthClaimsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.globelifeinsurance.com/role/LiabilityForUnpaidClaimsScheduleofLiabilityForUnpaidHealthClaimsDetails" }, "lang": { "en-us": { "role": { "totalLabel": "Total incurred", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims", "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process." } } }, "auth_ref": { "r997", "r1323" } }, "us-gaap-LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract", "presentation": { "http://www.globelifeinsurance.com/role/LiabilityForUnpaidClaimsScheduleofLiabilityForUnpaidHealthClaimsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Incurred related to", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]" } } }, "auth_ref": { "r759", "r762", "r1307" } }, "us-gaap-LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/LiabilityForUnpaidClaimsScheduleofLiabilityForUnpaidHealthClaimsDetails" }, "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Net", "documentation": "Liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid claims." } } }, "auth_ref": { "r759", "r762", "r1307" } }, "us-gaap-LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract", "presentation": { "http://www.globelifeinsurance.com/role/LiabilityForUnpaidClaimsScheduleofLiabilityForUnpaidHealthClaimsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Activity in the Liability for Unpaid Health Claims", "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { "r759", "r762", "r1307" } }, "gl-LibertyNationalExclusiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LibertyNationalExclusiveMember", "presentation": { "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofSegmentPremiumIncomebyDistributionChannelDetails", "http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofAnalysisofDeferredAcquisitionCostsDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedIncomeStatementDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitActivityDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofUndiscountedAndDiscountedExpectedFutureGrossPremiumsAndExpectedFuture", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageDurationofLiabilityForFuturePolicyBenefitsDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageInterestRateofLiabilityForFuturePolicyBenefitsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Liberty National", "label": "Liberty National Exclusive [Member]", "documentation": "Liberty national exclusive [Member]" } } }, "auth_ref": { "r744", "r745", "r746", "r747", "r748", "r749" } }, "us-gaap-LifeInsuranceSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LifeInsuranceSegmentMember", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofOperations", "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofOperationsParenthetical", "http://www.globelifeinsurance.com/role/LiabilityForUnpaidClaimsScheduleofReconciliationofPolicyClaimsandOtherBenefitsPayableDetails" }, "lang": { "en-us": { "role": { "verboseLabel": "Life premium", "terseLabel": "Life insurance", "label": "Life Insurance Product Line [Member]", "documentation": "Contract providing insurance coverage for death benefit." } } }, "auth_ref": { "r744", "r745", "r746", "r747", "r748", "r749" } }, "gl-LifeSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LifeSegmentMember", "presentation": { "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps", "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofSegmentPremiumIncomebyDistributionChannelDetails", "http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofAnalysisofDeferredAcquisitionCostsDetails", "http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofDeferredPolicyAcquisitionCoststoConsolidatedBalanceSheetDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesAdditionalInformationDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedIncomeStatementDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitActivityDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofUndiscountedAndDiscountedExpectedFutureGrossPremiumsAndExpectedFuture", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageDurationofLiabilityForFuturePolicyBenefitsDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageInterestRateofLiabilityForFuturePolicyBenefitsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Life", "label": "Life Segment [Member]", "documentation": "Life Segment [Member]" } } }, "auth_ref": { "r744", "r745", "r746", "r747", "r748", "r749" } }, "us-gaap-LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Long-term line of credit", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": { "r17", "r118", "r1310" } }, "gl-LineOfCreditFacilityAccordionFeatureIncreaseLimit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LineOfCreditFacilityAccordionFeatureIncreaseLimit", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Potential maximum borrowing capacity", "label": "Line Of Credit Facility, Accordion Feature, Increase Limit", "documentation": "Line Of Credit Facility, Accordion Feature, Increase Limit" } } }, "auth_ref": { "r17", "r118", "r1310" } }, "us-gaap-LineOfCreditFacilityAverageOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAverageOutstandingAmount", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/DebtShortTermBorrowingsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Average balance of commercial paper outstanding during period (par value)", "label": "Line of Credit Facility, Average Outstanding Amount", "documentation": "Average amount borrowed under the credit facility during the period." } } }, "auth_ref": { "r55", "r60" } }, "us-gaap-LineOfCreditFacilityInterestRateAtPeriodEnd": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "presentation": { "http://www.globelifeinsurance.com/role/DebtShortTermBorrowingsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Annualized interest rate", "label": "Line of Credit Facility, Interest Rate at Period End", "documentation": "The effective interest rate at the end of the reporting period." } } }, "auth_ref": { "r55", "r60" } }, "us-gaap-LineOfCreditFacilityInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityInterestRateDuringPeriod", "presentation": { "http://www.globelifeinsurance.com/role/DebtShortTermBorrowingsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Daily-weighted average interest rate (annualized)", "label": "Line of Credit Facility, Interest Rate During Period", "documentation": "The effective interest rate during the reporting period." } } }, "auth_ref": { "r55", "r60" } }, "us-gaap-LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/DebtShortTermBorrowingsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Maximum daily amount outstanding during period (par value)", "label": "Line of Credit Facility, Maximum Amount Outstanding During Period", "documentation": "Maximum amount borrowed under the credit facility at any time during the period." } } }, "auth_ref": { "r55", "r60" } }, "us-gaap-LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing

capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": { "r55", "r60" } }, "gl_LineOfCreditFacilityNumberOfExtensionOptions": { "xbrltype": "integerItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LineOfCreditFacilityNumberOfExtensionOptions", "presentation": { "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Number of extension options", "label": "Line Of Credit Facility, Number Of Extension Options", "documentation": "Line Of Credit Facility, Number Of Extension Options" } } }, "auth_ref": { } }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/DebtShortTermBorrowingsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Remaining amount available under credit line", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": { "r55", "r60", "r386" } }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": { "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": { } }, "us-gaap_LoanToValueAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoanToValueAxis", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsRecordedInvestmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Debt-to-Value [Axis]", "label": "Debt-to-Value [Axis]", "documentation": "Information by debt-to-value ratio, for example, but not limited to, 80 percent to 100 percent. Element name and standard label in Debt-to-Value [numeric lower end] to [numeric higher end] Percent [Member] or Debt-to-Value Greater Than [low end numeric value] Percent [Member] or Debt-to-Value Less Than [high end numeric value] Percent [Member] formats." } } }, "auth_ref": { "r933" } }, "us-gaap_LoanToValueDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoanToValueDomain", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsRecordedInvestmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Debt-to-Value [Domain]", "label": "Debt-to-Value [Domain]", "documentation": "Debt-to-value (DTV) ratio, for example, but not limited to, 80 percent to 100 percent. Element name and standard label in DTV [numeric lower end] to [numeric higher end] Percent [Member] or DTV Greater Than [low end numeric value] Percent [Member] or DTV Less Than [high end numeric value] Percent [Member] formats." } } }, "auth_ref": { } }, "us-gaap_LoansInsurancePolicy": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansInsurancePolicy", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Investments", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "terseLabel": "Policy loans", "label": "Loans, Gross, Insurance Policy", "documentation": "Amount before allowance of loans made to policy and contract holders using their life insurance contracts' cash value or separate accounts as collateral. Includes deferred interest and fees, undisbursed portion of loan balance, unamortized costs and premiums over and discounts from face amounts. Excludes loans and leases covered under loss sharing agreements." } } }, "auth_ref": { "r697", "r699" } }, "us-gaap_LoansReceivableFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansReceivableFairValueDisclosure", "crdr": "debit", "presentation": { "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Fair value of pledged assets", "label": "Loans Receivable, Fair Value Disclosure", "documentation": "Fair value portion of loan receivable, including, but not limited to, mortgage loans held for investment, finance receivables held for investment, policy loans on insurance contracts." } } }, "auth_ref": { "r1284" } }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": { "http://www.globelifeinsurance.com/role/Cover": { "parentTag": "us-gaap_Investments", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilities" }, "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": { } }, "us-gaap_LongDurationInsuranceContractsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongDurationInsuranceContractsDisclosureTextBlock", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilities" }, "lang": { "en-us": { "role": { "terseLabel": "Policy Liabilities", "label": "Long-Duration Insurance Contracts Disclosure [Text Block]", "documentation": "The entire disclosure for long duration contracts. This may include the information pertinent to an understanding of the types of traditional and nontraditional insurance and investment contracts sold and serviced, including the nature and amount of estimated guaranteed obligations pertaining to such contracts and the assumptions underlying such estimated amounts, hedging strategies, and sales inducements offered." } } }, "auth_ref": { "r695", "r789" } }, "gl_LongTermAndShortTermDebtFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LongTermAndShortTermDebtFaceAmount", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails": { "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails" }, "lang": { "en-us": { "role": { "totalLabel": "Total debt, par value", "label": "Long-Term And Short-Term Debt, Face Amount", "documentation": "Long-Term And Short-Term Debt, Face Amount" } } }, "auth_ref": { } }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, net, book value", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": { "r17", "r118", "r411", "r427", "r939", "r940", "r970", "r1310" } }, "gl_LongTermDebtFaceAmountGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LongTermDebtFaceAmountGross", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, par value, gross", "label": "Long-Term Debt, Face Amount, Gross", "documentation": "Long-Term Debt, Face Amount, Gross" } } }, "auth_ref": { } }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtFairValue", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails": { "parentTag": "us-gaap_DebtInstrumentFairValue", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails" }, "lang": { "en-us": { "role": { "totalLabel": "Fair Value", "label": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": { "r1276", "r1278", "r1279", "r1280" } }, "gl_LongTermDebtFairValueExcludingCurrentMaturities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LongTermDebtFairValueExcludingCurrentMaturities", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheetsParentetical": { "parentTag": "us-gaap_LongTermDebtFairValue", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, gross, fair value", "label": "Long-Term Debt, Gross, Fair Value", "documentation": "Long-Term Debt, Gross, Fair Value" } } }, "auth_ref": { } }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Long-term debt (estimated fair value: 2024u2014\$2,202,644; 2023u2014\$1,491,229)", "label": "Long-term debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": { "r177" } }, "gl_LongTermInvestmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LongTermInvestmentLineItems", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofOtherLongTermInvestmentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Long-Term Investment [Line Items]", "label": "Long-Term Investment [Line Items]", "documentation": "Long-Term Investment" } } }, "auth_ref": { } }, "gl_LongTermInvestmentTable": { "xbrltype": "stringItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "LongTermInvestmentTable", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofOtherLongTermInvestmentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Long-Term Investment [Table]", "label": "Long-Term Investment [Table]", "documentation": "Long-Term Investment" } } }, "auth_ref": { } }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis",

"presentation": { "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails",
"http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails" }, "lang": { "en-us": { "role": { "terseLabel":
"Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref":
{ "r17", "r1190", "r1191", "r1192" }, "us-gaap-LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": {
"http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails", "lang": { "en-us": { "role": { "terseLabel":
"Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as
notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that
originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } },
"auth_ref": { "r17", "r40", "r1190", "r1191", "r1192" }, "us-gaap-LossContingencyAccrualProvision": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualProvision", "crdr": "debit", "calculation": {
"http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps",
"parentTag": "us-gaap-IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0,
"order": 4.0 } }, "presentation": {
"http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps",
"lang": { "en-us": { "role": { "terseLabel": "Legal proceedings", "label": "Loss Contingency Accrual, Provision", "documentation": "Amount
charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges." } } },
"auth_ref": { "r1195" }, "us-gaap-LossContingencyNumberOfPlaintiffs": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LossContingencyNumberOfPlaintiffs", "presentation": {
"http://www.globelifeinsurance.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel":
"Number of complainants", "label": "Loss Contingency, Number of Plaintiffs", "documentation": "Number of plaintiffs that have filed claims
pertaining to a loss contingency." } } }, "auth_ref": { "r1196", "r1197" }, "us-
gaap-MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairmentsAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairmentsAbstract", "presentation":
{
"http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangesToAccumulatedOtherComprehensiveIncomeScheduleofReclassificat",
"lang": { "en-us": { "role": { "terseLabel": "Unrealized investment (gains) losses on available for sale assets", "label": "Marketable Securities,
Gain (Loss), Excluding Other than temporary Impairment Loss [Abstract]" } } }, "auth_ref": { }, "us-gaap-MaterialReconcilingItemsMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MaterialReconcilingItemsMember", "presentation": {
"http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps",
"lang": { "en-us": { "role": { "terseLabel": "Adjustments", "label": "Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment
[Member]", "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity." } } },
"auth_ref": { "r271", "r274", "r277", "r924", "r925" }, "srt-MaximumMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofInvestmentFundsDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetails",
"lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": { "r381", "r382", "r383", "r384", "r507",
"r539", "r577", "r650", "r765", "r779", "r790", "r819", "r820", "r877", "r879", "r881", "r882", "r886", "r912", "r913", "r929", "r943", "r956", "r963",
"r964", "r968", "r969", "r996", "r1207", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300" }, "ecd-MeasureAxis": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
"lang": { "en-us": { "role": { "terseLabel": "Measure", "label": "Measure [Axis]" } } }, "auth_ref": { "r1064" }, "ecd-MeasureName": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": {
"r1064" }, "srt-MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember",
"presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofInvestmentFundsDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetails",
"lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": { "r381", "r382", "r383", "r384", "r507",
"r539", "r577", "r650", "r765", "r779", "r790", "r819", "r820", "r877", "r879", "r881", "r882", "r886", "r912", "r913", "r929", "r943", "r956", "r963",
"r964", "r968", "r996", "r1207", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300" }, "gl-MixedUseMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "MixedUseMember", "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails", "lang": { "en-us": { "role": {
"terseLabel": "Mixed use", "label": "Mixed Use [Member]", "documentation": "Mixed Use [Member]" } } }, "auth_ref": { },
"ecd-MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"MnpiDiscTimedForCompValFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": {
"terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref":
{ "r1083" }, "gl-MortgageBackedAndAssetBackedSecuritiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.globelifeinsurance.com/20240930", "localname": "MortgageBackedAndAssetBackedSecuritiesAtFairValue", "crdr": "debit",
"calculation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails": { "parentTag": "us-
gaap-AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 6.0 } }, "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesbyContractualMaturityDetails", "lang": { "en-us": { "role": {
"terseLabel": "Mortgage-backed and asset-backed securities", "label": "Mortgage Backed And Asset Backed Securities At Fair Value",
"documentation": "Mortgage Backed And Asset Backed Securities At Fair Value" } } }, "auth_ref": { }, "gl-MortgageLoansMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "MortgageLoansMember", "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofAnalysisofInvestmentOperationsDetails", "lang": { "en-us": { "role": {
"terseLabel": "Mortgage loans", "label": "Mortgage Loans [Member]", "documentation": "Mortgage Loans" } } }, "auth_ref": { }, "us-
gaap-MortgageLoansOnRealEstateCommercialAndConsumerNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "MortgageLoansOnRealEstateCommercialAndConsumerNet", "crdr": "debit", "calculation": {
"http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap-Investments", "weight": 1.0, "order": 5.0
} }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "terseLabel":
"Mortgage loans", "label": "Mortgage Loans On Real Estate, Commercial and Consumer, Net", "documentation": "The balance represents the
amount of loans that are secured by real estate mortgages, offset by the reserve to cover probable credit losses on the loan portfolio." } } },
"auth_ref": { "r697", "r698", "r1002", "r1005" }, "srt-MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/srt/2024", "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis", "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails", "lang": { "en-us": { "role": {
"terseLabel": "Real Estate, Type of Property [Axis]", "label": "Real Estate, Type of Property [Axis]" } } }, "auth_ref": { "r900", "r902", "r903", "r904",
"r905", "r907", "r908", "r909", "r910", "r911" }, "srt-MortgageLoansOnRealEstateNamePropertyTypeDomain": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/srt/2024", "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain", "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails", "lang": { "en-us": { "role": {
"terseLabel": "Real Estate [Domain]", "label": "Real Estate [Domain]" } } }, "auth_ref": { "r902", "r903", "r904", "r905", "r907", "r908", "r909",
"r910", "r911" }, "us-gaap-MovementAnalysisOfDeferredPolicyAcquisitionCostsRollForward": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "MovementAnalysisOfDeferredPolicyAcquisitionCostsRollForward", "presentation": {
"http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofAnalysisofDeferredAcquisitionCostsDetails", "lang": { "en-us": {
"role": { "terseLabel": "Movement Analysis of Deferred Policy Acquisition Costs", "label": "Movement Analysis of Deferred Policy Acquisition Costs
[Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } },
"auth_ref": { }, "ecd-MtrlTermsOfRdArTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"MtrlTermsOfRdArTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": {
"terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": { "r1091",
"srt-MultifamilyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MultifamilyMember",
"presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails", "lang": { "en-
us": { "role": { "terseLabel": "Multi-family", "label": "Multifamily [Member]" } } }, "auth_ref": { "r1362", "r1363" }, "stpr-NJ": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "NJ", "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails", "lang": { "en-us": { "role": {
"terseLabel": "New Jersey", "label": "NEW JERSEY" } } }, "auth_ref": { }, "stpr-NY": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/stpr/2024", "localname": "NY", "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails", "lang": { "en-us": { "role": {
"terseLabel": "New York", "label": "NEW YORK" } } }, "auth_ref": { }, "ecd-NamedExecutiveOfficersFnTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named

```

Executive Officers, Footnote [Text Block] } } } , "auth_ref": { "r1065" } } } , "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } } , "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "totalLabel": "Cash provided from (used for) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } } , "auth_ref": { "r206" } } } , "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Cash provided from (used for) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } } } } , "auth_ref": { } } } , "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } } , "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "totalLabel": "Cash provided from (used for) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } } , "auth_ref": { "r206" } } } } , "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "verboseLabel": "Cash provided from (used for) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } } } } , "auth_ref": { } } } , "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Cash provided from (used for) operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } } , "auth_ref": { "r94", "r95", "r96" } } } } , "us-gaap_NetChangeAnnuitiesAndInvestmentCertificates": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetChangeAnnuitiesAndInvestmentCertificates", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } } , "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Net receipts (payments) from deposit-type products", "label": "Net Change Annuities and Investment Certificates", "documentation": "The cash inflow or outflow for an insurance contract under which the policy holder make a lump sum payment or a series of payments in exchange for periodic payments to the policyholder beginning immediately or at some future date." } } } , "auth_ref": { } } } , "gl_NetCommercialPaperIssuedAndMaturedDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "NetCommercialPaperIssuedAndMaturedDuringPeriod", "crdr": "debit", "presentation": { "http://www.globelifeinsurance.com/role/DebtShortTermBorrowingsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net commercial paper issued (matured) during period (par value)", "label": "Net Commercial Paper Issued and Matured During Period", "documentation": "Net Commercial Paper Issued and Matured During Period" } } } , "auth_ref": { } } } , "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": null, "weight": null, "order": null, "root": true } } , "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofOperations", "http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofReclassification": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "totalLabel": "Net income", "terseLabel": "Net income", "negatedTotalLabel": "Total after-tax", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } } , "auth_ref": { "r82", "r96", "r124", "r173", "r192", "r195", "r199", "r210", "r217", "r221", "r222", "r223", "r224", "r225", "r228", "r229", "r237", "r327", "r387", "r388", "r390", "r391", "r392", "r393", "r394", "r396", "r397", "r551", "r554", "r571", "r594", "r718", "r853", "r871", "r872", "r1014", "r1203" } } } , "us-gaap_NetInvestmentIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetInvestmentIncome", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 2.0 } } , "presentation": { "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps": { "parentTag": "gl_SegmentRevenuesExcludingRealizedInvestmentGainsLosses", "weight": 1.0, "order": 2.0 } } , "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAnalysisofInvestmentOperationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } } , "presentation": { "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps": { "parentTag": "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofOperations", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAnalysisofInvestmentOperationsDetails", "http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofReclassification": { "lang": { "en-us": { "role": { "terseLabel": "Net investment income", "negatedLabel": "Net investment income", "totalLabel": "Net investment income", "verboseLabel": "Net investment income", "label": "Net Investment Income", "documentation": "Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments." } } } , "auth_ref": { "r151", "r722", "r723", "r858", "r1014" } } } , "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": { "http://www.globelifeinsurance.com/role/NewAccountingStandards": { "lang": { "en-us": { "role": { "terseLabel": "New Accounting Standards", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle." } } } , "auth_ref": { "r161", "r171", "r215", "r216", "r219", "r220", "r230", "r231", "r284", "r329", "r330", "r549", "r550", "r552", "r554", "r565", "r568", "r611", "r613", "r614", "r652", "r653", "r654", "r784", "r785", "r786", "r787", "r788" } } } , "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": { "http://www.globelifeinsurance.com/role/SignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Accounting Pronouncements Yet to be Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } } , "auth_ref": { } } } , "gl_NonDeferredAcquisitionCostsAndPremiumTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "NonDeferredAcquisitionCostsAndPremiumTaxes", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0, "order": 3.0 } } , "presentation": { "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps": { "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0, "order": 3.0 } } , "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps": { "parentTag": "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofOperations": { "lang": { "en-us": { "role": { "terseLabel": "Commissions, premium taxes, and non-deferred acquisition costs", "verboseLabel": "Commissions, premium taxes, and non-deferred acquisition costs", "label": "Non-Deferred Acquisition Costs And Premium Taxes", "documentation": "Non-deferred commissions, non-deferred acquisition costs and premium taxes." } } } , "auth_ref": { } } } , "ecd_NonGaspMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaspMeasureDescriptionTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } } , "auth_ref": { "r1064" } } } , "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":

```

"NonNeosMember", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs" } } }, "label": "Non-NEOs [Member]", "auth_ref": { "r1023", "r1038", "r1048", "r1072", "r1080" }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Non-PEO-NEO Average Compensation Actually Paid Amount" } } }, "label": "Non-PEO-NEO Average Compensation Actually Paid Amount", "auth_ref": { "r1055" }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Non-PEO-NEO Average Total Compensation Amount" } } }, "auth_ref": { "r1054" }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Non-PEO-NEO" } } }, "label": "Non-PEO-NEO [Member]", "auth_ref": { "r1072" }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "auth_ref": { "r1091" }, "ecd_NonRule10b51ArrTrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmndFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "auth_ref": { "r1091" }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps": { "lang": { "en-us": { "role": { "terseLabel": "Non-operating items" } } }, "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "auth_ref": { "r87" }, "us-gaap_NonqualifiedPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonqualifiedPlanMember", "presentation": { "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionandSERPLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Nonqualified Plan" } } }, "label": "Nonqualified Plan [Member]", "documentation": "Plan without tax exempt status in accordance with applicable tax provision of designated taxing authority. Taxing authority includes, but is not limited to, U.S. Internal Revenue Service (IRS). Includes, but is not limited to, defined benefit and defined contribution plans.", "auth_ref": { "r1109", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1260", "r1261", "r1262", "r1263", "r1264", "r1265", "r1266", "r1267" }, "us-gaap_NotesReceivableGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesReceivableGross", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails": { "parentTag": "us-gaap_NotesReceivableNet", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsRecordedInvestmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Carrying value" } } }, "label": "Financing Receivable, before Allowance for Credit Loss", "documentation": "Amortized cost, before allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.", "auth_ref": { "r135", "r139", "r165", "r166", "r182", "r285", "r338", "r342", "r934", "r935", "r1119", "r1183" }, "us-gaap_NotesReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesReceivableNet", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsRecordedInvestmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Mortgage loans" } } }, "totalLabel": "Carrying value, net of valuation allowance", "label": "Financing Receivable, after Allowance for Credit Loss", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.", "auth_ref": { "r342", "r840", "r1157", "r1312" }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": { "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofSegmentPremiumIncomebyDistributionChannelDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of segments" } } }, "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "auth_ref": { "r925", "r1151" }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": { "http://www.globelifeinsurance.com/role/SignificantAccountingPoliciesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments" } } }, "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "auth_ref": { "r920", "r928", "r1151" }, "gl_OCIliabilityForFuturePolicyBenefitAdjustmentsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "OCIliabilityForFuturePolicyBenefitAdjustmentsNetOfTax", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "totalLabel": "Future policy benefit adjustments, net of tax", "label": "OCI, Liability for Future Policy Benefit, Adjustments, Net Of Tax", "documentation": "OCI, Liability for Future Policy Benefit, Adjustments, Net Of Tax", "auth_ref": { "gl_OCIliabilityForFuturePolicyBenefitChangeInDiscountRate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "OCIliabilityForFuturePolicyBenefitChangeInDiscountRate", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "gl_OCIliabilityForFuturePolicyBenefitAdjustmentsNetOfTax", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "lang": { "en-us": { "role": { "terseLabel": "Change in discount rate on future policy benefits" } } }, "label": "OCI, Liability for Future Policy Benefit, Change In Discount Rate", "documentation": "OCI, Liability for Future Policy Benefit, Change In Discount Rate", "auth_ref": { "us-gaap_ObligationWithJointAndSeveralLiabilityArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ObligationWithJointAndSeveralLiabilityArrangementLineItems", "presentation": { "http://www.globelifeinsurance.com/role/CommitmentsandContingenciesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Obligation with Joint and Several Liability Arrangement [Line Items]", "label": "Obligation with Joint and Several Liability Arrangement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "auth_ref": { "r373", "r374", "r376" }, "us-gaap_ObligationWithJointAndSeveralLiabilityArrangementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ObligationWithJointAndSeveralLiabilityArrangementTable", "presentation": { "http://www.globelifeinsurance.com/role/CommitmentsandContingenciesAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Obligation with Joint and Several Liability Arrangement [Table]", "label": "Obligation with Joint and Several Liability Arrangement [Table]", "documentation": "Disclosure of information about contractual obligation with joint and several liability, including but not limited to, debt arrangements, settled litigation, and judicial rulings.", "auth_ref": { "r373", "r374", "r376" }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofChangeinBal": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofChangeinBal": { "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) before reclassifications, net of tax", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "documentation": "Amount after tax, before reclassification adjustments, of other

```

"comprehensiveIncomeLoss": "parent", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OfficeBuildingMember", "presentation": "Office", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": "r128", "r919", "r1150", "r1152", "r1154", "r1155", "r1156" } } }, "us-gaap-OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": "Operating Segments", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": "r270", "r271", "r272", "r273", "r274", "r277", "r924", "r925" } } }, "gl-OpportunisticAndPrivateCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "OpportunisticAndPrivateCreditMember", "presentation": "Opportunistic and private credit", "label": "Opportunistic and Private Credit [Member]", "documentation": "Opportunistic and Private Credit" } } }, "auth_ref": "r128", "r919", "r1150", "r1152", "r1154", "r1155", "r1156" } } }, "gl-OtherAssetBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "OtherAssetBackedSecuritiesMember", "presentation": "Other Asset Backed Securities", "documentation": "Other Asset Backed Securities [Member]", "documentation": "Other Asset Backed Securities [Member]" } } }, "auth_ref": "r128", "r919", "r1150", "r1152", "r1154", "r1155", "r1156" } } }, "us-gaap-OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssets", "crdr": "debit", "calculation": "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 7.0 } } }, "presentation": "Other Assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": "r113", "r175", "r203", "r925", "r1015" } } }, "gl-OtherBondsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "OtherBondsMember", "presentation": "Other bonds", "label": "Other Bonds [Member]", "documentation": "Other bonds [Member]" } } }, "auth_ref": "r128", "r919", "r1150", "r1152", "r1154", "r1155", "r1156" } } }, "us-gaap-OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentBeforeTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentBeforeTaxPeriodIncreaseDecreaseAbstract", "presentation": "Unrealized gains (losses) on fixed maturities", "label": "OCI, Debt Securities, Available for Sale, Gain (Loss), after Adjustment, before Tax [Abstract]" } } }, "auth_ref": "r128", "r919", "r1150", "r1152", "r1154", "r1155", "r1156" } } }, "us-gaap-OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPeriodIncreaseDecreaseAbstract", "presentation": "Unrealized gains (losses) on fixed maturities", "label": "OCI, Debt Securities, Available for Sale, Gain (Loss), after Adjustment, before Tax [Abstract]" } } }, "auth_ref": "r128", "r919", "r1150", "r1152", "r1154", "r1155", "r1156" } } }, "us-gaap-OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParentAbstract", "presentation": "Foreign exchange translation", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": "r128", "r919", "r1150", "r1152", "r1154", "r1155", "r1156" } } }, "gl-OtherComprehensiveIncomeGainLossOnLiabilityForFuturePolicyBenefitPeriodIncreaseDecreaseTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "OtherComprehensiveIncomeGainLossOnLiabilityForFuturePolicyBenefitPeriodIncreaseDecreaseTax", "crdr": "debit", "calculation": "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss", "parentTag": "gl-OCIliabilityForFuturePolicyBenefitAdjustmentsNetOfTax", "weight": -1.0, "order": 2.0 } } }, "presentation": "Less applicable tax (expense) benefit", "label": "Other Comprehensive Income Gain Loss On Liability for Future Policy Benefit Period Increase Decrease Tax", "documentation": "Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available for sale." } } }, "auth_ref": "r185", "r186", "r188", "r719" } } }, "us-gaap-OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "calculation": "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss", "parentTag": "us-gaap-OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "weight": 1.0, "order": 1.0 } } }, "presentation": "Total unrealized investment gains (losses)", "label": "OCI, Debt Securities, Available for Sale, Gain (Loss), after Adjustment, before Tax", "documentation": "Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available for sale." } } }, "auth_ref": "r185", "r186", "r188", "r719" } } }, "us-gaap-OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "crdr": "debit", "calculation": "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss", "parentTag": "us-gaap-OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "weight": -1.0, "order": 2.0 } } }, "presentation": "Less applicable tax (expense) benefit", "label": "OCI, Debt Securities, Available for Sale, Gain (Loss), after Adjustment, Tax", "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available for sale." } } }, "auth_ref": "r185", "r186", "r188", "r719" } } }, "us-gaap-OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "crdr": "credit", "calculation": "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss", "parentTag": "us-gaap-OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "weight": 1.0, "order": 1.0 } } }, "presentation": "Less applicable tax (expense) benefit", "label": "OCI, Debt Securities, Available for Sale, Gain (Loss), after Adjustment, Tax", "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available for sale." } } }, "auth_ref": "r185", "r186", "r188", "r719" } } }, "us-gaap-OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "crdr": "credit", "calculation": "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss", "parentTag": "us-gaap-OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "weight": 1.0, "order": 1.0 } } }, "presentation": "Less applicable tax (expense) benefit", "label": "OCI, Debt Securities, Available for Sale, Gain (Loss), after Adjustment, Tax", "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available for sale." } } }, "auth_ref": "r185", "r186", "r188", "r719" } } }, "us-gaap-OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "crdr": "credit", "calculation": "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss", "parentTag": "us-gaap-OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "weight": 1.0, "order": 1.0 } } }, "presentation": "Less applicable tax (expense) benefit", "label": "OCI, Debt Securities, Available for Sale, Gain (Loss), after Adjustment, Tax", "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available for sale." } } }, "auth_ref": "r185", "r186", "r188", "r719" } } }, "us-gaap-OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "crdr": "credit", "calculation": "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss", "parentTag": "us-gaap-OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "weight": 1.0, "order": 1.0 } } }, "presentation": "Less applicable tax (expense) benefit", "label": "OCI, Debt Securities, Available for Sale, Gain (Loss), after Adjustment, Tax", "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available for sale." } } }, "auth_ref": "r185", "r186", "r188", "r719" } } }, "us-gaap-OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "crdr": "credit", "calculation": "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss", "parentTag": "us-gaap-OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "weight": 1.0, "order": 1.0 } } }, "presentation": "Less applicable tax (expense) benefit", "label": "OCI, Debt Securities, Available for Sale, Gain (Loss), after Adjustment, Tax", "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available for sale." } } }, "auth_ref": "r185", "r186", "r188", "r719" } } }, "us-gaap-OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "crdr": "credit", "calculation": "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss", "parentTag": "us-gaap-OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "weight": 1.0, "order": 1.0 } } }, "presentation": "Less applicable tax (expense) benefit", "label": "OCI, Debt Securities, Available for Sale, Gain (Loss), after Adjustment, Tax", "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity
```


"presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange translation adjustments, other than securities", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax", "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature." } } }, "auth_ref": { "r2", "r78", "r79" } }, "us-gaap-OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap-OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "lang": { "en-us": { "role": { "totalLabel": "Foreign exchange translation adjustments, other than securities, net of tax", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature." } } }, "auth_ref": { "r2", "r79" } }, "us-gaap-OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap-OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "lang": { "en-us": { "role": { "negatedLabel": "Less applicable tax (expense) benefit", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax", "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature." } } }, "auth_ref": { "r2", "r5", "r595", "r602" } }, "gl-OtherComprehensiveIncomeLossForeignExchangeIncreaseDecreaseOnSecuritiesRecordedAtFairValueBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "OtherComprehensiveIncomeLossForeignExchangeIncreaseDecreaseOnSecuritiesRecordedAtFairValueBeforeTax", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap-OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange adjustment on fixed maturities recorded at fair value", "label": "Other Comprehensive Income (Loss), Foreign Exchange Increase (Decrease) On Securities Recorded At Fair Value Before Tax", "documentation": "Other Comprehensive Income (Loss), Foreign Exchange Increase (Decrease) On Securities Recorded At Fair Value Before Tax" } } }, "auth_ref": { "r1", "us-gaap-OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": { "r1", "us-gaap-OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap-ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofChangeinBal": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": { "r9", "r13", "r107", "r193", "r196", "r225" } }, "us-gaap-OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap-OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Pension adjustments", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax", "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan." } } }, "auth_ref": { "r3", "r4", "r77", "r78", "r79", "r948", "r1248" } }, "us-gaap-OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap-OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 4.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "lang": { "en-us": { "role": { "negatedTotalLabel": "Pension adjustments, net of tax", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan." } } }, "auth_ref": { "r3", "r4", "r77", "r78", "r79" } }, "us-gaap-OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap-OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "lang": { "en-us": { "role": { "negatedLabel": "Less applicable tax (expense) benefit", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax", "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan." } } }, "auth_ref": { "r3", "r4", "r5", "r77", "r107" } }, "us-gaap-OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap-OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Other reclassification adjustments included in net income", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax", "documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities." } } }, "auth_ref": { "r7", "r78", "r191", "r323" } }, "us-gaap-OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap-OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "lang": { "en-us": { "role": { "terseLabel": "Unrealized holding gains (losses) arising during period", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax", "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": { "r185", "r188", "r323" } }, "us-gaap-OtherCostAndExpenseOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCostAndExpenseOperating", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap-BenefitsLossesAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofReclassification": { "lang": { "en-us": { "role": { "terseLabel": "Other operating expense", "label": "Other Cost and Expense, Operating", "documentation": "The total

amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation." } } }, "auth_ref": {
"r83", "r731", "r924" } }, "gl_OtherGeographicalLocationMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.globelifeinsurance.com/20240930", "localname": "OtherGeographicalLocationMember", "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails" }, "lang": { "en-us": { "role": {
"terseLabel": "Other", "label": "Other Geographical Location [Member]", "documentation": "Other Geographical Location" } } }, "auth_ref": { } },
"us-gaap_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncome", "crdr": "credit",
"calculation": {
"http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps
"parentTag": "gl_SegmentRevenuesExcludingRealizedInvestmentGainsLosses", "weight": 1.0, "order": 3.0 },
"http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_Revenues", "weight": 1.0,
"order": 4.0 } }, "presentation": {
"http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps
"http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofOperations" }, "lang": { "en-us": { "role": { "terseLabel": "Other
income", "verboseLabel": "Other income", "label": "Other Income", "documentation": "Amount of revenue and income classified as other." } } },
"auth_ref": { "r728", "r855", "r887", "r888", "r889" } }, "us-gaap_OtherInsuranceProductLineMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OtherInsuranceProductLineMember", "presentation": {
"http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofOperations",
"http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofAnalysisofDeferredAcquisitionCostsDetails",
"http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofDeferredPolicyAcquisitionCoststoConsolidatedBalanceSheetDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedIncomeStatementDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofUndiscountedAndDiscountedExpectedFutureGrossPremiumsAndExpectedFuture
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageDurationofLiabilityForFuturePolicyBenefitsDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageInterestRateofLiabilityForFuturePolicyBenefitsDetails" },
"lang": { "en-us": { "role": { "terseLabel": "Other premium", "verboseLabel": "Other Policy-holders' Funds", "label": "Insurance, Other [Member]",
"documentation": "Contract providing insurance coverage, classified as other." } } }, "auth_ref": { "r1001" } }, "us-
gaap_OtherInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherInvestmentsMember", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofInvestmentFundsDetails",
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofOtherLongTermInvestmentsDetails" }, "lang": { "en-us": { "role": { "verboseLabel":
"Other", "terseLabel": "Other", "label": "Other Investments [Member]", "documentation": "Primary financial statement caption encompassing other
investments." } } }, "auth_ref": { } }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OtherLiabilities", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": {
"parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": {
"http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "terseLabel": "Other Liabilities",
"label": "Other Liabilities", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": { "r117", "r707", "r824", "r825", "r1015",
"r1311", "r1357" } }, "us-gaap_OtherLongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OtherLongTermInvestments", "crdr": "debit", "calculation": {
"http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Investments", "weight": 1.0, "order": 3.0
} }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets",
"http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheetsParentetical",
"http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails",
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofOtherLongTermInvestmentsDetails" }, "lang": { "en-us": { "role": { "terseLabel":
"Other long-term investments (includes: 2024u2014\$979,397; 2023u2014\$795,583 under the fair value option)", "verboseLabel": "Other long-
term investments under fair value option", "label": "Commercial mortgage loan participations", "label": "Other Long-Term Investments",
"documentation": "Amount of long-term investments classified as other." } } }, "auth_ref": { "r697", "r700", "r1125" } }, "us-
gaap_OtherLongTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherLongTermInvestmentsMember", "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofAnalysisofInvestmentOperationsDetails" }, "lang": { "en-us": { "role": {
"terseLabel": "Other long-term investments", "label": "Other Long-Term Investments [Member]", "documentation": "Long-term investments
classified as other." } } }, "auth_ref": { "r1353" } }, "gl_OtherMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.globelifeinsurance.com/20240930", "localname": "OtherMember", "presentation": {
"http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionAssetsbyComponentatFairValueDetails" }, "lang": { "en-us": {
"role": { "terseLabel": "Other", "label": "Other [Member]", "documentation": "Other [Member]" } } }, "auth_ref": { } }, "ecd_OtherPerfMeasureAmt": {
"xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other
Performance Measure, Amount" } } }, "auth_ref": { "r1064" } }, "us-gaap_OtherPolicyholderFunds": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OtherPolicyholderFunds", "crdr": "credit", "calculation": {
"http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "parentTag":
"gl_PolicyholderAccountBalanceLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense", "weight": 1.0, "order": 4.0 } },
"presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "terseLabel":
"Other policyholders' funds", "label": "Other Policyholder Funds", "documentation": "Amount due to policyholders for funds held that are
returnable under the terms of insurance contracts, classified as other." } } }, "auth_ref": { "r705" } }, "gl_OtherRealizedInvestmentGainsLosses": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "OtherRealizedInvestmentGainsLosses",
"crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofRealizedGainLossonInvestmentsDetails": {
"parentTag": "us-gaap_RealizedInvestmentGainsLosses", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofRealizedGainLossonInvestmentsDetails" }, "lang": { "en-us": { "role": {
"terseLabel": "Other gains (losses)", "label": "Other Realized Investment Gains (Losses)", "documentation": "Other Realized Investment Gains
(Losses)" } } }, "auth_ref": { } }, "us-gaap_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OtherReceivables", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets":
"parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": {
"http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "terseLabel": "Other receivables",
"label": "Other Receivables", "documentation": "Amount due from parties in nontrade transactions, classified as other." } } }, "auth_ref": { "r181",
"r839", "r925", "r1312" } }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "OutstandingAggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": {
"terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } },
"auth_ref": { "r1026", "r1036", "r1046", "r1079" } }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" },
"lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": {
"r1029", "r1039", "r1049", "r1081" } }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "OutstandingRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": {
"terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": { "r1029", "r1039", "r1049", "r1081" } },
"gl_ParentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "ParentExpense",
"crdr": "debit", "calculation": {
"http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps
"parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps
"lang": { "en-us": { "role": { "terseLabel": "Parent expense", "label": "Parent Expense", "documentation": "Parent Expense" } } }, "auth_ref": { } },
"gl_PartnershipInterestFairValueOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930",
"localname": "PartnershipInterestFairValueOptionMember", "presentation": {
"http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheetsParentetical",
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofOtherLongTermInvestmentsDetails" }, "lang": { "en-us": { "role": { "terseLabel":
"Investment funds", "label": "Partnership Interest - Fair Value Option [Member]", "documentation": "Partnership Interest - Fair Value Option" } } },
"auth_ref": { } }, "srt_PartnershipInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"PartnershipInterestMember", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails",
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofInvestmentFundsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Investment
in Limited Partnerships", "verboseLabel": "Investment funds", "label": "Partnership Interest [Member]" } } }, "auth_ref": { "r1008" } },

"ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": { "r1053" } }, "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForLossesAndLossAdjustmentExpense", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/LiabilityForUnpaidClaimsScheduleofLiabilityForUnpaidHealthClaimsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.globelifeinsurance.com/role/LiabilityForUnpaidClaimsScheduleofLiabilityForUnpaidHealthClaimsDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total paid", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid", "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process." } } }, "auth_ref": { "r10", "r997", "r1324" } }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Other investing activities", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": { "r1108", "r1132" } }, "us-gaap_PaymentsForProceedsFromPolicyLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromPolicyLoans", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Net (increase) decrease in policy loans", "label": "Payments for (Proceeds from) Policy Loans", "documentation": "Net amount paid or received by the entity associated with issuance or collection of loans made to policy holders, principally secured by the benefits under the policy." } } }, "auth_ref": { "r11", "us-gaap_PaymentsForProceedsFromShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromShortTermInvestments", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Net (increase) decrease in short-term investments", "label": "Payments for (Proceeds from) Short-Term Investments", "documentation": "The net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": { "r1131", "r1133", "r1138" } }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of treasury stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": { "r92" } }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment for debt issuance costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": { "r25" } }, "us-gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividends", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Cash dividends paid to shareholders", "label": "Payments of Dividends", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": { "r92" } }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_PaymentsToAcquireInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Fixed maturities available for sale", "label": "Payments to Acquire Debt Securities, Available for Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": { "r23", "r204", "r291" } }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "negatedTotalLabel": "Total investments acquired", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": { "r90" } }, "us-gaap_PaymentsToAcquireInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInvestmentsAbstract", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Acquisition of investments", "label": "Payments to Acquire Investments [Abstract]" } } }, "auth_ref": { "r11", "us-gaap_PaymentsToAcquireLongtermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireLongtermInvestments", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Capital called from investment funds", "label": "Payments to Acquire Long-Term Investments", "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term." } } }, "auth_ref": { "r1132" } }, "gl_PaymentsToAcquireMortgages": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "PaymentsToAcquireMortgages", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_PaymentsToAcquireInvestments", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Mortgage loans", "label": "Payments to Acquire Mortgages", "documentation": "Payments to Acquire Mortgages" } } }, "auth_ref": { "r11", "us-gaap_PaymentsToAcquireOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireOtherInvestments", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_PaymentsToAcquireInvestments", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Other long-term investments", "label": "Payments to Acquire Other Investments", "documentation": "Amount of cash outflow to acquire investments classified as other." } } }, "auth_ref": { "r90" } }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Additions to property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": { "r91" } }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": { "r1063" } }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": { "r1063" } }, "us-

```
gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ { "http://www.globelifeinsurance.com/role/PostretirementBenefits": { "lang": { "en-us": { "role": { "terseLabel": "Postretirement Benefits", "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": { "r435", "r459", "r461", "r467", "r484", "r486", "r487", "r488", "r489", "r490", "r502", "r503", "r504", "r948" } }, "us-gaap_PensionPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionPlansDefinedBenefitMember", "presentation": [ { "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionAssetsbyComponentatFairValueDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Pension Plan", "netLabel": "Pension Plans", "label": "Pension Plan [Member]", "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits." } } }, "auth_ref": { "r436", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r485", "r488", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r504", "r505", "r509", "r948", "r949", "r953", "r954", "r955" } }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]", "documentation": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": { "r1055" } }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]", "documentation": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": { "r1054" } }, "gl_PercentOfAvailableForSaleSecuritiesAtFairValueByValuationLevel": { "xbrltype": "percentItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "PercentOfAvailableForSaleSecuritiesAtFairValueByValuationLevel", "presentation": [ { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "Percentage of total", "verboseLabel": "Percent of total fixed maturities", "label": "Percent Of Available For Sale Securities At Fair Value By Valuation Level", "documentation": "Percent Of Available For Sale Securities At Fair Value By Valuation Level" } } }, "auth_ref": { "gl_PercentageChangeInGrossInvestmentIncomeOperating": { "xbrltype": "percentItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "PercentageChangeInGrossInvestmentIncomeOperating", "presentation": [ { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAnalysisofInvestmentOperationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Percentage change in investment income, gross", "label": "Percentage Change In Gross Investment Income, Operating", "documentation": "Percentage Change In Gross Investment Income, Operating" } } }, "auth_ref": { "gl_PercentageChangeInInvestmentIncomeInvestmentExpense": { "xbrltype": "percentItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "PercentageChangeInInvestmentIncomeInvestmentExpense", "presentation": [ { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAnalysisofInvestmentOperationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Percentage change in investment expense", "label": "Percentage Change In Investment Income, Investment Expense", "documentation": "Percentage Change In Investment Income, Investment Expense" } } }, "auth_ref": { "gl_PercentageChangeInNetInvestmentIncome": { "xbrltype": "percentItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "PercentageChangeInNetInvestmentIncome", "presentation": [ { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAnalysisofInvestmentOperationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Percentage change in net investment income", "label": "Percentage Change In Net Investment Income", "documentation": "Percentage Change In Net Investment Income" } } }, "auth_ref": { "gl_PercentageOffFixedMaturitiesAtFairValue": { "xbrltype": "percentItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "PercentageOffFixedMaturitiesAtFairValue", "presentation": [ { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAvailableforSalebyComponentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Percentage of total fixed maturities (as a percent)", "verboseLabel": "Percentage of fixed maturities at fair value", "label": "Percentage Of Fixed Maturities At Fair Value", "documentation": "Percentage of fixed maturities by component at fair value." } } }, "auth_ref": { "us-gaap_PlanAssetCategoriesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanAssetCategoriesDomain", "presentation": [ { "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionAssetsbyComponentatFairValueDetails": { "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]", "label": "Defined Benefit Plan, Plan Assets, Category [Domain]", "documentation": "Defined benefit plan asset investment." } } }, "auth_ref": { "r459", "r460", "r462", "r463", "r464", "r465", "r466", "r467", "r485", "r946", "r947", "r948" } }, "us-gaap_PledgedStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PledgedStatusAxis", "presentation": [ { "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Pledged Status [Axis]", "label": "Pledged Status [Axis]", "documentation": "Information by pledged or not pledged status of asset owned by entity." } } }, "auth_ref": { "r555", "r822", "r958" } }, "us-gaap_PledgedStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PledgedStatusDomain", "presentation": [ { "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Pledged Status [Domain]", "label": "Pledged Status [Domain]", "documentation": "Pledged or not pledged status of asset owned by entity." } } }, "auth_ref": { "r555", "r822", "r958" } }, "ecd_PnsnAdjsPrvSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrvSvcCstMember", "presentation": [ { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]", "documentation": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": { "r1056" } }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]", "documentation": "Range above guaranteed minimum crediting rates (percent)", "label": "Policyholder Account Balance, above Guaranteed Minimum Crediting Rate", "documentation": "Value above guaranteed minimum crediting rate on policyholder account balance." } } }, "auth_ref": { "r779", "r996" } }, "us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis", "presentation": [ { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetails": { "lang": { "en-us": { "role": { "terseLabel": "Policyholder Account Balance, above Guaranteed Minimum Crediting Rate [Axis]", "label": "Policyholder Account Balance, above Guaranteed Minimum Crediting Rate [Domain]", "documentation": "Range above guaranteed minimum crediting rate on policyholder account balance." } } }, "auth_ref": { "r779", "r996" } }, "us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain", "presentation": [ { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetails": { "lang": { "en-us": { "role": { "terseLabel": "Policyholder Account Balance, above Guaranteed Minimum Crediting Rate [Domain]", "label": "Policyholder Account Balance, above Guaranteed Minimum Crediting Rate [Domain]", "documentation": "Range from 0001 to 0050 basis points above", "label": "Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0001 to 0050 [Member]", "documentation": "Range from 1 basis point to 50 basis points above guaranteed minimum crediting rate, Range from 0001 to 0050 [Member]" } } }, "auth_ref": { "r779", "r996" } }, "us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0001To0050Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0001To0050Member", "presentation": [ { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetails": { "lang": { "en-us": { "role": { "terseLabel": "1-50 basis points above", "label": "Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0001 to 0050 [Member]", "documentation": "Range from 1 basis point to 50 basis points above guaranteed minimum crediting rate, Range from 0001 to 0050 [Member]" } } }, "auth_ref": { "r779", "r996" } }, "us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0001To0050Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0001To0050Member", "presentation": [ { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetails": { "lang": { "en-us": { "role": { "terseLabel": "1-50 basis points above", "label": "Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0001 to 0050 [Member]", "documentation": "Range from 1 basis point to 50 basis points above guaranteed minimum crediting rate, Range from 0001 to 0050 [Member]" } } }, "auth_ref": { "r779", "r996" } }, "us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0001To0050Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0001To0050Member", "presentation": [ { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetails": { "lang": { "en-us": { "role": { "terseLabel": "1-50 basis points above", "label": "Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0001 to 0050 [Member]", "documentation": "Range from 1 basis point to 50 basis points above guaranteed minimum crediting rate, Range from 0001 to 0050 [Member]" } } }, "auth_ref": { "r779", "r996" } }, "us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0001To0050Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0001To0050Member", "presentation": [
```

rate on policyholder account balance." } } }, "auth_ref": { "r996", "r1348" } }, "us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetails" }, "lang": { "en-us": { "role": { "terseLabel": "51-150 basis points above", "label": "Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0051 to 0150 [Member]", "documentation": "Range from 51 basis points to 150 basis points above guaranteed minimum crediting rate on policyholder account balance." } } }, "auth_ref": { "r996", "r1348" } }, "us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0151AndGreaterMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0151AndGreaterMember", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Greater than 150 basis points above", "label": "Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0151 and Greater [Member]", "documentation": "Range from 151 basis points and greater above guaranteed minimum crediting rate on policyholder account balance." } } }, "auth_ref": { "r996", "r1348" } }, "us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetails" }, "lang": { "en-us": { "role": { "terseLabel": "At guaranteed minimum", "label": "Policyholder Account Balance, at Guaranteed Minimum Crediting Rate [Member]", "documentation": "Range at zero basis point above guaranteed minimum crediting rate on policyholder account balance." } } }, "auth_ref": { "r996", "r1348" } }, "us-gaap_PolicyholderAccountBalanceBenefitPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalanceBenefitPayment", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceDetails" }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Benefit payments", "label": "Policyholder Account Balance, Benefit Payment", "documentation": "Amount of cash outflow to policyholder account balance from benefit payment." } } }, "auth_ref": { "r993", "r996", "r1343" } }, "us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalanceGuaranteedMinimumCreditRating", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Range of guaranteed minimum crediting rates (percent)", "label": "Policyholder Account Balance, Guaranteed Minimum Credit Rating", "documentation": "Guaranteed minimum crediting rate on policyholder account balance." } } }, "auth_ref": { "r779", "r996" } }, "us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalanceGuaranteedMinimumCreditingRateLineItems", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]", "label": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r779", "r996" } }, "us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate Range [Axis]", "label": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate Range [Axis]", "documentation": "Information by range of guaranteed minimum crediting rate on policyholder account balance." } } }, "auth_ref": { "r779", "r996" } }, "us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate Range [Domain]", "label": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate Range [Domain]", "documentation": "Range of guaranteed minimum crediting rate on policyholder account balance." } } }, "auth_ref": { "r779", "r996" } }, "us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0200To0299Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0200To0299Member", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Less than 3.00%", "label": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0200 to 0299 [Member]", "documentation": "Range of guaranteed minimum crediting rate on policyholder account balance from 2.00 percent to 2.99 percent." } } }, "auth_ref": { "r1348" } }, "us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetails" }, "lang": { "en-us": { "role": { "terseLabel": "3.00%-3.99%", "label": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 to 0399 [Member]", "documentation": "Range of guaranteed minimum crediting rate on policyholder account balance from 3.00 percent to 3.99 percent." } } }, "auth_ref": { "r1348" } }, "gl_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0400To0499Member": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0400To0499Member", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetails" }, "lang": { "en-us": { "role": { "terseLabel": "4.00%-4.99%", "label": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0400 to 0499 [Member]", "documentation": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0400 to 0499" } } }, "auth_ref": { "gl_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0500AndGreaterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0500AndGreaterMember", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Greater than 5.00%", "label": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0500 and Greater [Member]", "documentation": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0500 and Greater" } } }, "auth_ref": { "gl_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalanceGuaranteedMinimumCreditingRateTable", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Table]", "label": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Table]", "documentation": "Disclosure of information about policyholder account balance by range of guaranteed minimum crediting rate and related range of difference between rate being credited to policyholder and respective guaranteed minimum." } } }, "auth_ref": { "r779", "r996" } }, "us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalanceGuaranteedMinimumCreditingRateTableTextBlock", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Policyholder Account Balance, Guaranteed Minimum Crediting Rate", "label": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Table Text Block]", "documentation": "Tabular disclosure of policyholder account balance by range of guaranteed minimum crediting rate and related range of difference between rate being credited to policyholder and respective guaranteed minimum." } } }, "auth_ref": { "r779", "r996" } }, "us-gaap_PolicyholderAccountBalanceIncreaseDecreaseFromOtherChange": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalanceIncreaseDecreaseFromOtherChange", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Policyholder Account Balance, Increase (Decrease) from Other Change", "documentation": "Amount of increase (decrease) in liability for policyholder account balance from change, classified as other." } } }, "auth_ref": { "r996", "r1343" } }, "us-gaap_PolicyholderAccountBalanceIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalanceIssuance", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Issuances", "label": "Policyholder Account Balance, Issuance", "documentation": "Amount of increase in liability for policyholder account balance from contract issuance." } } }, "auth_ref": { "r989", "r996", "r1343" } },

"gl_PolicyholderAccountBalanceLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "PolicyholderAccountBalanceLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "totalLabel": "Total policy liabilities", "label": "Policyholder Account Balance, Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense", "documentation": "Policyholder Account Balance, Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense" } } }, "auth_ref": { "us-gaap_PolicyholderAccountBalanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalanceLineItems", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceDetails": { "lang": { "en-us": { "role": { "terseLabel": "Policyholder Account Balance [Line Items]", "label": "Policyholder Account Balance [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r774", "r775", "r776", "r777", "r778", "r996" } } }, "us-gaap_PolicyholderAccountBalanceNetAmountAtRisk": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalanceNetAmountAtRisk", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net amount at risk", "label": "Policyholder Account Balance, Net Amount at Risk", "documentation": "Amount of guaranteed benefit in excess of current account balance of policyholder account balance." } } }, "auth_ref": { "r776", "r996" } } }, "us-gaap_PolicyholderAccountBalancePolicyCharge": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalancePolicyCharge", "crdr": "debit", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Policy charges", "label": "Policyholder Account Balance, Policy Charge", "documentation": "Amount of decrease in liability for policyholder account balance from policy charge." } } }, "auth_ref": { "r991", "r996", "r1343" } } }, "us-gaap_PolicyholderAccountBalancePremiumReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalancePremiumReceived", "crdr": "debit", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceDetails": { "lang": { "en-us": { "role": { "terseLabel": "Premiums received", "label": "Policyholder Account Balance, Premium Received", "documentation": "Amount of cash inflow to policyholder account balance from premium received." } } }, "auth_ref": { "r990", "r996", "r1343" } } }, "us-gaap_PolicyholderAccountBalanceRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalanceRollForward", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceDetails": { "lang": { "en-us": { "role": { "terseLabel": "Policyholder Account Balance [Roll Forward]", "label": "Policyholder Account Balance [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { "us-gaap_PolicyholderAccountBalanceSurrenderAndWithdrawal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalanceSurrenderAndWithdrawal", "crdr": "debit", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Surrenders and withdrawals", "label": "Policyholder Account Balance, Surrender and Withdrawal", "documentation": "Amount of decrease in liability for policyholder account balance from contract redemption and withdrawal of funds." } } }, "auth_ref": { "r992", "r996", "r1343" } } }, "us-gaap_PolicyholderAccountBalanceTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalanceTable", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceDetails": { "lang": { "en-us": { "role": { "terseLabel": "Policyholder Account Balance [Table]", "label": "Policyholder Account Balance [Table]", "documentation": "Disclosure of information about policyholder account balance, including, but not limited to change in liability and related cash surrender value." } } }, "auth_ref": { "r774", "r775", "r776", "r777", "r778", "r996" } } }, "us-gaap_PolicyholderAccountBalanceTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalanceTableTextBlock", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Policyholder Account Balance", "label": "Policyholder Account Balance [Table Text Block]", "documentation": "Tabular disclosure of information about policyholder account balance, including, but not limited to change in liability and related cash surrender value." } } }, "auth_ref": { "r774", "r996" } } }, "us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderAccountBalanceWeightedAverageCreditingRate", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted average credit rate", "label": "Policyholder Account Balance, Weighted Average Crediting Rate", "documentation": "Weighted average crediting rate for liability for policyholder account balance, calculated at a point in time." } } }, "auth_ref": { "r775", "r996" } } }, "us-gaap_PolicyholderBenefitsAndClaimsIncurredNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderBenefitsAndClaimsIncurredNet", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0, "order": 1.0 } }, "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps": { "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0, "order": 7.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofOperations": { "lang": { "en-us": { "role": { "netLabel": "Total policyholder benefits", "verboseLabel": "Policy benefits", "label": "Policyholder Benefits and Claims Incurred, Net", "documentation": "Amount, after effects of policies assumed or ceded, of expense related to the provision for policy benefits and costs incurred." } } }, "auth_ref": { "r1316" } } }, "us-gaap_PolicyholderFunds": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderFunds", "crdr": "credit", "presentation": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceDetails": { "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetails": { "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "terseLabel": "Range of guaranteed minimum crediting rates", "label": "Policyholder Account Balance", "documentation": "Amount due to policyholder. Includes, but is not limited to, unpaid policy dividend, retrospective refund, and undistributed earnings on participating business. Excludes future policy benefit and claim expense." } } }, "auth_ref": { "r774", "r778", "r779", "r996", "r1308" } } }, "us-gaap_PolicyholderFundsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyholderFundsAbstract", "lang": { "en-us": { "role": { "label": "Policyholder Account Balance [Abstract]" } } }, "auth_ref": { "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": { "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Portion at Fair Value Measurement", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": { "r592" } } }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofShareholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock", "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": { "r1006", "r1007", "r1010", "r1011", "r1012", "r1013", "r1356", "r1360" } } }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheetsParenthetical": { "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": { "r65", "r428" } } }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheetsParenthetical": { "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": { "r65", "r830" } } }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheetsParenthetical": { "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": { "r65", "r830", "r851", "r1360", "r1361" } } }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": {

"verboseLabel": "Preferred stock, par value \$1 per share\u201420145,000,000 shares authorized; outstanding: 0 in 2024 and 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": { "r65", "r710", "r971" } }, "us-gaap_PremiumsEarnedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PremiumsEarnedNet", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 }, "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleOfReconciliationOfSegmentOperatingInformationToConsolidatedStatementOfOp": { "parentTag": "gl_SegmentRevenuesExcludingRealizedInvestmentGainsLosses", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleOfReconciliationOfSegmentOperatingInformationToConsolidatedStatementOfOp": { "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleOfSegmentPremiumIncomebyDistributionChannelDetails": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfOperations": { "lang": { "en-us": { "role": { "netLabel": "Revenue", "terseLabel": "Premium", "label": "Premiums Earned, Net", "documentation": "Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned." } } }, "auth_ref": { "r159", "r160", "r748", "r791" } }, "us-gaap_ProceedsFromFederalHomeLoanBankBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromFederalHomeLoanBankBorrowings", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Net borrowing from FHLB", "label": "Proceeds from FHLBank Borrowings, Financing Activities", "documentation": "Amount of cash inflow from Federal Home Loan Bank (FHLBank) borrowing, classified as financing activity." } } }, "auth_ref": { "r1134" } }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": { "r6", "r1134" } }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of debt", "label": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": { "r1134" } }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Fixed maturities available for sale\u20142014matured or other redemptions", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available for Sale", "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": { "r204", "r205", "r1161" } }, "gl_ProceedsFromMaturitiesPrepaymentsAndCallsOfMortgages": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfMortgages", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Mortgage loans", "label": "Proceeds from Maturities, Prepayments and Calls of Mortgages", "documentation": "Proceeds from Maturities, Prepayments and Calls of Mortgages" } } }, "auth_ref": { "r1134", "r1135", "r1139" } }, "us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Net borrowing (repayment) of commercial paper", "label": "Proceeds from (Repayments of) Short-Term Debt, Maturing in Three Months or Less", "documentation": "The cash inflow from a borrowing net of the cash outflow from repayment of a borrowing having initial term of repayment within three months." } } }, "auth_ref": { "r1134", "r1135", "r1139" } }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Investments sold or matured", "label": "Proceeds from Sale and Maturity of Debt Securities, Available for Sale [Abstract]" } } }, "auth_ref": { "r1134", "r1135", "r1139" } }, "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Other long-term investments", "label": "Proceeds from Sale and Maturity of Other Investments", "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy." } } }, "auth_ref": { "r21" } }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "totalLabel": "Total investments sold or matured", "label": "Proceeds from Sale, Maturity and Collection of Investments", "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period." } } }, "auth_ref": { "r21" } }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Fixed maturities available for sale\u20142014sold", "label": "Proceeds from Sale of Debt Securities, Available for Sale", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": { "r22", "r204", "r291", "r322" } }, "gl_ProceedsFromSaleOfDebtSecuritiesExcludingUnsettledTradesAvailableForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "ProceedsFromSaleOfDebtSecuritiesExcludingUnsettledTradesAvailableForSale", "crdr": "debit", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofSelectedInformationaboutSalesofFixedMaturitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale", "label": "Proceeds from Sale of Debt Securities Excluding Unsettled Trades, Available for Sale", "documentation": "Proceeds from Sale of Debt Securities Excluding Unsettled Trades, Available for Sale" } } }, "auth_ref": { "r1134", "r1135", "r1139" } }, "us-gaap_ProceedsFromShortTermDebtMaturingInMoreThanThreeMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromShortTermDebtMaturingInMoreThanThreeMonths", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from commercial paper with original maturities greater than 90 days", "label": "Proceeds from Short-Term Debt, Maturing in More than Three Months", "documentation": "The cash inflow from a borrowing having initial term of repayment of more than three months but less than one year or one operating cycle (if the normal cycle is more than one year)." } } }, "auth_ref": { "r24" } }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": {

"http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofSegmentPremiumIncomebyDistributionChannelDetails",
"http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofOperations",
"http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
"http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofAnalysisofDeferredAcquisitionCostsDetails",
"http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofDeferredPolicyAcquisitionCoststoConsolidatedBalanceSheetDetails",
"http://www.globelifeinsurance.com/role/LiabilityforUnpaidClaimsScheduleofLiabilityforUnpaidHealthClaimsDetails",
"http://www.globelifeinsurance.com/role/LiabilityforUnpaidClaimsScheduleofReconciliationofPolicyClaimsandOtherBenefitsPayableDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedIncomeStatementDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofUndiscountedAndDiscountedExpectedFutureGrossPremiumsAndExpectedFuture",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageDurationofLiabilityForFuturePolicyBenefitsDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageInterestRateofLiabilityForFuturePolicyBenefitsDetails",
"lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": { "r279", "r651",
"r744", "r745", "r746", "r747", "r748", "r749", "r764", "r914", "r944", "r981", "r996", "r998", "r1001", "r1004", "r1198", "r1199", "r1208", "r1318",
"r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1341",
"r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1354", "r1355" } },
"gl_ProductPremiumAsPercentageOfSegmentPremium": { "xbrltype": "percentItem", "nsuri": "http://www.globelifeinsurance.com/20240930",
"localname": "ProductPremiumAsPercentageOfSegmentPremium", "presentation": {
"http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofSegmentPremiumIncomebyDistributionChannelDetails", "lang": { "en-us":
{ "role": { "terseLabel": "% of Total", "label": "Product Premium As Percentage Of Segment Premium", "documentation": "Product premium as
percentage of segment premium." } } }, "auth_ref": { } }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": {
"http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofSegmentPremiumIncomebyDistributionChannelDetails",
"http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofOperations",
"http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
"http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofAnalysisofDeferredAcquisitionCostsDetails",
"http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofDeferredPolicyAcquisitionCoststoConsolidatedBalanceSheetDetails",
"http://www.globelifeinsurance.com/role/LiabilityforUnpaidClaimsScheduleofLiabilityforUnpaidHealthClaimsDetails",
"http://www.globelifeinsurance.com/role/LiabilityforUnpaidClaimsScheduleofReconciliationofPolicyClaimsandOtherBenefitsPayableDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedIncomeStatementDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofUndiscountedAndDiscountedExpectedFutureGrossPremiumsAndExpectedFuture",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageDurationofLiabilityForFuturePolicyBenefitsDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageInterestRateofLiabilityForFuturePolicyBenefitsDetails",
"lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": { "r279",
"r651", "r744", "r745", "r746", "r747", "r748", "r749", "r764", "r914", "r944", "r981", "r996", "r998", "r1001", "r1004", "r1198", "r1199", "r1208",
"r1318", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340",
"r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1354", "r1355" } }, "us-
gaap_ProvisionForLoanLossesExpensed": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProvisionForLoanLossesExpensed", "crdr": "debit", "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialLoanParticipationsAllowanceforCreditLossDetails", "lang": { "en-us":
{ "role": { "terseLabel": "Provision (reversal) for credit losses", "label": "Financing Receivable, Credit Loss, Expense (Reversal)", "documentation":
"Amount of credit loss expense (reversal of expense) for financing receivable." } } }, "auth_ref": { "r336", "r697" } }, "ecd_PvpTable": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
"lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": {
"r1053" } }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PvpTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Pay vs
Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": { "r1053" } }, "us-gaap_QualifiedPlanMember":
{ "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "QualifiedPlanMember", "presentation": {
"http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionandSERPLiabilitiesDetails", "lang": { "en-us": { "role": {
"terseLabel": "Qualified Plan", "label": "Qualified Plan [Member]", "documentation": "Plan with tax-exempt status designed and operated in
accordance with applicable tax provision of designated taxing authority. Taxing authority includes, but is not limited to, U.S. Internal Revenue
Service (IRS). Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": { "r1109", "r1209", "r1210",
"r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226",
"r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242",
"r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258",
"r1259", "r1260", "r1261", "r1262", "r1263", "r1264", "r1265", "r1266", "r1267", "r1268" } }, "srt_RangeAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofInvestmentFundsDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetails",
"lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": { "r381",
"r382", "r383", "r384", "r459", "r507", "r533", "r534", "r535", "r539", "r577", "r625", "r634", "r650", "r765", "r779", "r790", "r819", "r820", "r877",
"r879", "r881", "r882", "r886", "r912", "r913", "r929", "r943", "r956", "r963", "r964", "r968", "r969", "r996", "r1008", "r1193", "r1207", "r1279",
"r1296", "r1297", "r1298", "r1299", "r1300" } }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024",
"localname": "RangeMember", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofInvestmentFundsDetails",
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofPolicyholderAccountBalanceGuaranteedMinimumCreditingRateDetails",
"lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": {
"r381", "r382", "r383", "r384", "r459", "r507", "r533", "r534", "r535", "r539", "r577", "r625", "r634", "r650", "r765", "r779", "r790", "r819", "r820",
"r877", "r879", "r881", "r882", "r886", "r912", "r913", "r929", "r943", "r956", "r963", "r964", "r968", "r969", "r996", "r1008", "r1193", "r1207",
"r1279", "r1296", "r1297", "r1298", "r1299", "r1300" } }, "gl_RealEstateInvestmentTrustMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.globelifeinsurance.com/20240930", "localname": "RealEstateInvestmentTrustMember", "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Real Estate
Investment Trust", "label": "Real Estate Investment Trust [Member]", "documentation": "Real Estate Investment Trust" } } }, "auth_ref": { } }, "us-
gaap_RealizedGainLossOnInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RealizedGainLossOnInvestmentsTableTextBlock", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsTables", "lang": { "en-
us": { "role": { "terseLabel": "Schedule of Realized Gains (Losses) on Investments", "label": "Realized Gain (Loss) on Investments [Table Text
Block]", "documentation": "Tabular disclosure of realized gains and losses on investments reported in the statement of income." } } }, "auth_ref":
{ } }, "gl_RealizedGainsLossesFromInvestmentsApplicableTax": { "xbrltype": "monetaryItem", "nsuri":
"http://www.globelifeinsurance.com/20240930", "localname": "RealizedGainsLossesFromInvestmentsApplicableTax", "crdr": "debit", "calculation":
{ "http://www.globelifeinsurance.com/role/InvestmentsScheduleofRealizedGainLossOnInvestmentsDetails", "parentTag":
"gl_RealizedGainsLossesFromInvestmentsNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofRealizedGainLossOnInvestmentsDetails", "lang": { "en-us": { "role": {
"negatedLabel": "Applicable tax", "label": "Realized Gains Losses From Investments Applicable Tax", "documentation": "Realized gains (losses)
from investments, Applicable tax" } } }, "auth_ref": { } }, "gl_RealizedGainsLossesFromInvestmentsNetOfTax": { "xbrltype": "monetaryItem",
"nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "RealizedGainsLossesFromInvestmentsNetOfTax", "crdr": "credit",
"calculation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofRealizedGainLossOnInvestmentsDetails", "parentTag": null,
"weight": null, "order": null, "root": true } }, "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofRealizedGainLossOnInvestmentsDetails", "lang": { "en-us": { "role": {
"totalLabel": "Realized gains (losses), net of tax", "label": "Realized Gains Losses From Investments Net Of Tax", "documentation": "Realized gains
(losses) from investments, Net of tax" } } }, "auth_ref": { } }, "us-gaap_RealizedInvestmentGainsLosses": { "xbrltype": "monetaryItem", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RealizedInvestmentGainsLosses", "crdr": "credit", "calculation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofRealizedGainLossOnInvestmentsDetails", "parentTag":
"gl_RealizedGainsLossesFromInvestmentsNetOfTax", "weight": -1.0, "order": -1.0 } } }

"http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps", {"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0}, {"http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfOperations": {"parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 3.0}}, {"presentation": -1, "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps", {"http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfOperations": {"http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails": {"http://www.globelifeinsurance.com/role/InvestmentsScheduleofRealizedGainLossOnInvestmentsDetails": {"http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofReclassification": {"lang": {"en-us": {"role": {"verboseLabel": "Realized gains (losses)", "negatedLabel": "Realized (gains) losses", "terseLabel": "Realized gains (losses)", "totalLabel": "Total realized gains (losses)", "label": "Realized Investment Gains (Losses)", "documentation": "Amount of realized gain (loss) on investment."}}}, {"auth_ref": {"r72": {"q1_RealizedInvestmentGainsLossesBeforeRedemptionOfDebtAndOtherGainsLosses": {"xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "RealizedInvestmentGainsLossesBeforeRedemptionOfDebtAndOtherGainsLosses", "crdr": "credit", "calculation": {"http://www.globelifeinsurance.com/role/InvestmentsScheduleofRealizedGainLossOnInvestmentsDetails": {"parentTag": "us-gaap_RealizedInvestmentGainsLosses", "weight": 1.0, "order": 2.0}}, {"presentation": -1, "http://www.globelifeinsurance.com/role/InvestmentsScheduleofRealizedGainLossOnInvestmentsDetails": {"lang": {"en-us": {"role": {"totalLabel": "Realized gains (losses) from investments", "label": "Realized Investment Gains (Losses), Before Redemption Of Debt and Other Gains (Losses)", "documentation": "Realized Investment Gains (Losses), Before Redemption Of Debt and Other Gains (Losses)"}}}, {"auth_ref": {"us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems", "presentation": -1, "http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofReclassification": {"lang": {"en-us": {"role": {"terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}}, {"auth_ref": {"r199": {"us-gaap_ReclassificationFromAOCICurrentPeriodNetOfTaxAttributableToParent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAOCICurrentPeriodNetOfTaxAttributableToParent", "crdr": "debit", "calculation": {"http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofChangeinBal": {"parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 2.0}}, {"presentation": -1, "http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofChangeinBal": {"lang": {"en-us": {"role": {"negatedLabel": "Reclassifications, net of tax", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent."}}}, {"auth_ref": {"r16", "r19": {"us-gaap_ReclassificationOtherMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOtherMember", "presentation": -1, "http://www.globelifeinsurance.com/role/PolicyLiabilitiesAdditionalInformationDetails": {"lang": {"en-us": {"role": {"terseLabel": "Reclassification, Other", "label": "Reclassification, Other [Member]", "documentation": "Reclassification affecting comparability of financial statement, classified as other. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."}}}, {"auth_ref": {"r1123": {"us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "presentation": -1, "http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofReclassification": {"lang": {"en-us": {"role": {"terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "auth_ref": {"r199": {"us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "presentation": -1, "http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofReclassification": {"lang": {"en-us": {"role": {"terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "auth_ref": {"r199": {"us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "presentation": -1, "http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofReclassification": {"lang": {"en-us": {"role": {"terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "auth_ref": {"r199": {"us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "presentation": -1, "http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofReclassification": {"lang": {"en-us": {"role": {"terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "label": "Reclassification out of accumulated other comprehensive income (loss).", "auth_ref": {"r199": {"us-gaap_ReclassificationTypeAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationTypeAxis", "presentation": -1, "http://www.globelifeinsurance.com/role/PolicyLiabilitiesAdditionalInformationDetails": {"lang": {"en-us": {"role": {"terseLabel": "Reclassification, Type [Axis]", "label": "Reclassification, Type [Axis]", "documentation": "Information by type of reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."}}}, {"auth_ref": {"r1123": {"us-gaap_ReclassificationTypeDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationTypeDomain", "presentation": -1, "http://www.globelifeinsurance.com/role/PolicyLiabilitiesAdditionalInformationDetails": {"lang": {"en-us": {"role": {"terseLabel": "Reclassification, Type [Domain]", "label": "Reclassification, Type [Domain]", "documentation": "Type of reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."}}}, {"auth_ref": {"r1123": {"us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "presentation": -1, "http://www.globelifeinsurance.com/role/BusinessSegmentsTables": {"lang": {"en-us": {"role": {"terseLabel": "Schedule of Reconciliation of Segment Operating Information to Consolidated Statement of Operations", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."}}}, {"auth_ref": {"r38", "r39": {"ecd_RecoveryOfErrCompDisclosureLineItems": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": {"en-us": {"role": {"label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "auth_ref": {"r1021", "r1031", "r1041", "r1073": {"us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments", "crdr": "debit", "presentation": -1, "http://www.globelifeinsurance.com/role/LiabilityForUnpaidClaimsScheduleofLiabilityForUnpaidHealthClaimsDetails": {"lang": {"en-us": {"role": {"periodStartLabel": "Less reinsurance recoverables, beginning balance", "periodEndLabel": "Plus reinsurance recoverables, ending balance", "label": "Reinsurance Recoverable for Unpaid Claims and Claims Adjustments", "documentation": "Amount, after valuation allowance, recoverable under reinsurance contracts for losses reported to the ceding insurer but not yet paid and amounts expected for incurred losses and settlement expenses, which have not yet been reported to the ceding insurer."}}}, {"auth_ref": {"r759", "r762", "r763", "r997", "r1001", "r1306", "r1321", "r1322": {"us-gaap_ReinsuranceRecoverables": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReinsuranceRecoverables", "crdr": "debit", "presentation": -1, "http://www.globelifeinsurance.com/role/PolicyLiabilitiesAdditionalInformationDetails": {"lang": {"en-us": {"role": {"terseLabel": "Reinsurance

recoverables", "label": "Reinsurance Recoverables, Including Reinsurance Premium Paid", "documentation": "Amount, after valuation allowance, recoverable under reinsurance contracts including premium paid under reinsurance contracts. Examples include, but are not limited to, settled and unsettled claims, incurred but not reported losses, loss adjustment expense, premium paid, policy benefits and policy reserves." } } }, "auth_ref": { "r1306", "r1313", "r1320" } }, "us-gaap-RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayment of debt", "label": "Repayments of Notes Payable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": { "r93" } }, "gl_RequiredInterestOnPolicyReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "RequiredInterestOnPolicyReserves", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps": { "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": -1.0, "order": 4.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps": { "lang": { "en-us": { "role": { "negatedLabel": "Required interest on reserves", "label": "Required Interest on Policy Reserves", "documentation": "The interest implied in determining the insurance policy reserve liability, based on the discount rate assumed upon policy issue." } } }, "auth_ref": { "r1", "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": { "r1022", "r1032", "r1042", "r1074" } }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": { "r1023", "r1033", "r1043", "r1075" } }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": { "r1030", "r1040", "r1050", "r1082" } }, "gl_RetailPropertyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "RetailPropertyMember", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Retail", "label": "Retail Property [Member]", "documentation": "Retail Property [Member]" } } }, "auth_ref": { "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": { "r69", "r104", "r713", "r784", "r788", "r797", "r831", "r971" } }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofShareholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": { "r170", "r212", "r213", "r214", "r218", "r225", "r227", "r229", "r328", "r331", "r367", "r542", "r543", "r546", "r547", "r548", "r552", "r553", "r554", "r560", "r562", "r563", "r566", "r569", "r609", "r610", "r780", "r782", "r798", "r1360" } }, "us-gaap_RetirementPlanTaxStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTaxStatusAxis", "presentation": { "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionandSERPLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Tax Status [Axis]", "label": "Retirement Plan Tax Status [Axis]", "documentation": "Information by tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": { "r1109", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1260", "r1261", "r1262", "r1263", "r1264", "r1265", "r1266", "r1267", "r1268" } }, "us-gaap_RetirementPlanTaxStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTaxStatusDomain", "presentation": { "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionandSERPLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Tax Status [Domain]", "label": "Retirement Plan Tax Status [Domain]", "documentation": "Tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": { "r1109", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1260", "r1261", "r1262", "r1263", "r1264", "r1265", "r1266", "r1267", "r1268" } }, "us-gaap_RetirementPlanTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeAxis", "presentation": { "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionAssetsbyComponentatFairValueDetails": { "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionandSERPLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Axis]", "label": "Retirement Plan Type [Axis]", "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": { "r436", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r485", "r488", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r504", "r505", "r506", "r509", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555" } }, "us-gaap_RetirementPlanTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeDomain", "presentation": { "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionAssetsbyComponentatFairValueDetails": { "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionandSERPLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Domain]", "label": "Retirement Plan Type [Domain]", "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": { "r436", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r485", "r488", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r504", "r505", "r506", "r509", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555" } }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofOperations": { "lang": { "en-us": { "role": { "totalLabel": "Total revenue", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": { "r126", "r127", "r200", "r210", "r245", "r254", "r255", "r270", "r276", "r279", "r281", "r283", "r327", "r387", "r388", "r390", "r391", "r392", "r393", "r394", "r396", "r397", "r594", "r691", "r924", "r1203" } }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": { "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofOperations": { "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue", "documentation": "Revenues [Abstract]" } } }, "auth_ref": { "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": { "r1091" } }, "ecd_Rule10b51ArrFrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrFrmntdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": { "r1091" } }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": {

"http://www.globelifeinsurance.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]" } } }, "auth_ref": { "r508", "r1146" } }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": { "http://www.globelifeinsurance.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]" } } }, "auth_ref": { "r230", "r508", "r1103", "r1146" } }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsRecordedInvestmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "label": "Accounts and Financing Receivables [Table]", "documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss." } } }, "auth_ref": { "r67", "r73", "r286", "r1158" } }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Commercial Mortgage Loan Participations", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": { "r67", "r73" } }, "us-gaap_ScheduleOfAccumulatedAndProjectedBenefitObligationsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedAndProjectedBenefitObligationsTableTextBlock", "presentation": { "http://www.globelifeinsurance.com/role/PostretirementBenefitsTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Pension Liability", "label": "Schedule of Accumulated and Projected Benefit Obligations [Table Text Block]", "documentation": "Tabular disclosure of benefit obligations including accumulated benefit obligation and projected benefit obligation." } } }, "auth_ref": { "r106" } }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": { "http://www.globelifeinsurance.com/role/SupplementalInformationAboutChangesToAccumulatedOtherComprehensiveIncomeTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Change in Balance by Component of Accumulated Other Comprehensive Income", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": { "r19", "r1286", "r1287" } }, "gf_ScheduleOfAdditionalInformationAboutInvestmentsInUnrealizedLossPositionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "ScheduleOfAdditionalInformationAboutInvestmentsInUnrealizedLossPositionTableTextBlock", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Additional Information about Investments in Unrealized Loss Position", "label": "Schedule of Additional Information About Investments In Unrealized Loss Position [Table Text Block]", "documentation": "Schedule of Additional Information About Investments In An Unrealized Loss Position" } } }, "auth_ref": { } }, "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock", "presentation": { "http://www.globelifeinsurance.com/role/PostretirementBenefitsTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Pension Assets by Component at Fair Value", "label": "Schedule of Allocation of Plan Assets [Table Text Block]", "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall." } } }, "auth_ref": { "r105" } }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAvailableforSalebyComponentDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available for sale [Line Items]", "label": "Debt Securities, Available for Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303" } }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fixed Maturities and Equity Securities Available for Sale by Component", "label": "Schedule of Available for Sale Securities Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of available for sale securities from cost basis to fair value." } } }, "auth_ref": { } }, "us-gaap_ScheduleOfCostsOfRetirementPlansTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCostsOfRetirementPlansTableTextBlock", "presentation": { "http://www.globelifeinsurance.com/role/PostretirementBenefitsTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Periodic Benefit Cost", "label": "Schedule of Costs of Retirement Plans [Table Text Block]", "documentation": "Tabular disclosure of the costs related to the various types of retirement plans including defined benefit pension plan cost, defined contribution plan cost, other postretirement benefit plan cost, and net periodic benefit cost." } } }, "auth_ref": { "r12" } }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": { "http://www.globelifeinsurance.com/role/DebtTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Selected Information about Debt Issues", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": { } }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": { "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionAssetsbyComponentatFairValueDetails", "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionandSERPLiabilitiesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]", "label": "Defined Benefit Plan [Table]", "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": { "r12", "r45", "r46", "r47", "r48" } }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTextBlock", "presentation": { "http://www.globelifeinsurance.com/role/PostretirementBenefitsTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Information Regarding the SERP", "label": "Schedule of Defined Benefit Plans Disclosures [Table Text Block]", "documentation": "Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans." } } }, "auth_ref": { "r12", "r45", "r46", "r47", "r48" } }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAvailableforSalebyComponentDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]" } } }, "auth_ref": { "r324", "r325", "r326", "r545", "r1104", "r1105", "r1106", "r1269", "r1270", "r1271", "r1272" } }, "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAnalysisofInvestmentOperationsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Net Investment Income [Line Items]", "label": "Net Investment Income [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r720" } }, "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAnalysisofInvestmentOperationsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Investment Income [Table]", "label": "Investment Income [Table]", "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments." } } }, "auth_ref": { "r85", "r86", "r88", "r720" } }, "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "presentation": {
"http://www.globelifeinsurance.com/role/LiabilityForUnpaidClaimsTables": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Liability for Unpaid Health Claims",
"label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
"documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims." } } }
"auth_ref": {
"r758": {
"us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
"presentation": {
"http://www.globelifeinsurance.com/role/NewAccountingStandardsTables": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule Of New Accounting Standards on Previously Reported Results",
"label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]",
"documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items." } } }
"auth_ref": {
"r27": {
"r28": {
"r30": {
"r31": {
"r1273": {
"gl_ScheduleOfOtherLongTermInvestmentsTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri":
"http://www.globelifeinsurance.com/20240930", "localname": "ScheduleOfOtherLongTermInvestmentsTableTextBlock", "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsTables": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Other Long Term Investments",
"label": "Schedule Of Other Long Term Investments [Table Text Block]",
"documentation": "Schedule of other long-term investments [Table Text Block]" } } }
"auth_ref": {
"us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
"xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": {
"http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps": {
"http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofSegmentPremiumIncomebyDistributionChannelDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
"label": "Schedule of Segment Reporting Information, by Segment [Table]",
"documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }
"auth_ref": {
"r35": {
"r36": {
"r37": {
"us-gaap_ScheduleOfShortTermDebtTable": {
"xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShortTermDebtTable", "presentation": {
"http://www.globelifeinsurance.com/role/DebtShortTermBorrowingsDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Short-term Debt [Table]",
"label": "Short-Term Debt [Table]",
"documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability." } } }
"auth_ref": {
"r56": {
"us-gaap_ScheduleOfWeightedAverageNumberofSharesTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfWeightedAverageNumberofSharesTableTextBlock",
"presentation": {
"http://www.globelifeinsurance.com/role/EarningsPerShareTables": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Schedule of Reconciliation of Basic and Diluted Weighted-Average Shares Outstanding",
"label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
"documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)." } } }
"auth_ref": {
"r29": {
"dei_Security12bTitle": {
"xbrltype": "securityTitleItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": {
"http://www.globelifeinsurance.com/role/Cover": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Title of 12(b) Security",
"label": "Title of 12(b) Security",
"documentation": "Title of a 12(b) registered security." } } }
"auth_ref": {
"r1016": {
"dei_SecurityExchangeName": {
"xbrltype": "edgarExchangeCodeItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": {
"http://www.globelifeinsurance.com/role/Cover": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Security Exchange Name",
"label": "Security Exchange Name",
"documentation": "Name of the Exchange on which a security is registered." } } }
"auth_ref": {
"r1018": {
"us-gaap_SegmentDomain": {
"xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": {
"http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps": {
"http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofSegmentPremiumIncomebyDistributionChannelDetails": {
"http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofAnalysisofDeferredAcquisitionCostsDetails": {
"http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofDeferredPolicyAcquisitionCoststoConsolidatedBalanceSheetDetails": {
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesAdditionalInformationDetails": {
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails": {
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedIncomeStatementDetails": {
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitActivityDetails": {
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofUndiscountedAndDiscountedExpectedFutureGrossPremiumsAndExpectedFuture": {
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageDurationofLiabilityForFuturePolicyBenefitsDetails": {
"http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageInterestRateofLiabilityForFuturePolicyBenefitsDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Segments [Domain]",
"label": "Segments [Domain]",
"documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }
"auth_ref": {
"r126": {
"r127": {
"r128": {
"r129": {
"r245": {
"r250": {
"r253": {
"r254": {
"r255": {
"r256": {
"r257": {
"r258": {
"r259": {
"r260": {
"r261": {
"r262": {
"r264": {
"r265": {
"r267": {
"r268": {
"r269": {
"r270": {
"r271": {
"r272": {
"r273": {
"r274": {
"r276": {
"r277": {
"r278": {
"r283": {
"r357": {
"r358": {
"r359": {
"r360": {
"r361": {
"r362": {
"r363": {
"r364": {
"r365": {
"r366": {
"r377": {
"r378": {
"r733": {
"r734": {
"r735": {
"r736": {
"r737": {
"r738": {
"r739": {
"r740": {
"r741": {
"r742": {
"r743": {
"r921": {
"r924": {
"r925": {
"r937": {
"r1000": {
"r1318": {
"r1326": {
"r1327": {
"r1328": {
"r1329": {
"r1330": {
"r1331": {
"r1332": {
"r1333": {
"r1334": {
"r1335": {
"r1336": {
"r1337": {
"r1338": {
"r1339": {
"r1340": {
"r1341": {
"r1342": {
"r1343": {
"r1344": {
"r1345": {
"r1346": {
"r1347": {
"r1348": {
"r1349": {
"r1350": {
"r1351": {
"r1354": {
"r1355": {
"srt_SegmentGeographicalDomain": {
"xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Geographical [Domain]",
"label": "Geographical [Domain]" } } }
"auth_ref": {
"r281": {
"r282": {
"r655": {
"r656": {
"r657": {
"r658": {
"r659": {
"r660": {
"r661": {
"r662": {
"r663": {
"r664": {
"r665": {
"r666": {
"r667": {
"r668": {
"r669": {
"r670": {
"r671": {
"r672": {
"r673": {
"r674": {
"r675": {
"r676": {
"r677": {
"r678": {
"r679": {
"r680": {
"r681": {
"r682": {
"r683": {
"r684": {
"r812": {
"r815": {
"r817": {
"r878": {
"r880": {
"r884": {
"r890": {
"r900": {
"r902": {
"r903": {
"r904": {
"r905": {
"r907": {
"r908": {
"r909": {
"r910": {
"r911": {
"r915": {
"r945": {
"r973": {
"r974": {
"r975": {
"r976": {
"r977": {
"r978": {
"r979": {
"r980": {
"r999": {
"r1008": {
"r1208": {
"r1318": {
"r1326": {
"r1327": {
"r1329": {
"r1330": {
"r1331": {
"r1332": {
"r1333": {
"r1334": {
"r1335": {
"r1336": {
"r1337": {
"r1338": {
"r1339": {
"r1340": {
"r1341": {
"r1342": {
"r1343": {
"r1344": {
"r1345": {
"r1346": {
"r1347": {
"r1348": {
"r1349": {
"r1350": {
"r1351": {
"r1354": {
"r1355": {
"us-gaap_SegmentReportingAbstract": {
"xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": {
"en-us": {
"role": {
"terseLabel": "Segment Reporting [Abstract]",
"label": "Segment Reporting [Abstract]" } } }
"auth_ref": {
"us-gaap_SegmentReportingDisclosureTextBlock": {
"xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": {
"http://www.globelifeinsurance.com/role/BusinessSegments": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Business Segments",
"label": "Segment Reporting Disclosure [Text Block]",
"documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }
"auth_ref": {
"r129": {
"r245": {
"r249": {
"r250": {
"r251": {
"r252": {
"r253": {
"r266": {
"r268": {
"r269": {
"r274": {
"r275": {
"r276": {
"r277": {
"r278": {
"r279": {
"r280": {
"r283": {
"r920": {
"r922": {
"r923": {
"r924": {
"r926": {
"r927": {
"r928": {
"us-gaap_SegmentReportingInformationLineItems": {
"xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": {
"http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps": {
"http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofSegmentPremiumIncomebyDistributionChannelDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Segment Reporting Information [Line Items]",
"label": "Segment Reporting Information [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }
"auth_ref": {
"gl_SegmentRevenuesExcludingRealizedInvestmentGainsLosses": {
"xbrltype": "monetaryItemType", "nsuri":
"http://www.globelifeinsurance.com/20240930", "localname": "SegmentRevenuesExcludingRealizedInvestmentGainsLosses", "erdr": "credit", "calculation": {
"http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps": {
"parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 }
"presentation": {
"http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementofOps": {
"lang": {
"en-us": {
"role": {
"totalLabel": "Total revenue",
"label": "Segment Revenues Excluding Realized Investment Gains Losses",
"documentation": "Segment Revenues Excluding Realized Investment Gains Losses" } } }
"auth_ref": {
"gl_SeniorNotesDueAugust152030Member": {
"xbrltype": "domainItemType", "nsuri":
"http://www.globelifeinsurance.com/20240930", "localname": "SeniorNotesDueAugust152030Member", "presentation": {
"http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails": {
"lang": {
"en-us": {
"role": {
"verboseLabel": "Senior Notes Due 2030",
"label": "Senior Notes Due August 15 2030 [Member]",
"documentation": "Senior Notes Due August 15 2030" } } }
"auth_ref": {
"gl_SeniorNotesDueJune152032Member": {
"xbrltype": "domainItemType", "nsuri":

"http://www.globelifeinsurance.com/20240930", "localname": "SeniorNotesDueJune152032Member", "presentation": {
"http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails": { "lang": { "en-us": { "role": { "terseLabel":
"Senior Notes Due June 15 2032", "label": "Senior Notes Due June 15 2032 [Member]", "documentation": "Senior Notes Due June 15 2032" } } } },
"auth_ref": { "gl_SeniorNotesDueSeptember152028Member": { "xbrltype": "domainItemType", "nsuri":
"http://www.globelifeinsurance.com/20240930", "localname": "SeniorNotesDueSeptember152028Member", "presentation": {
"http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails": { "lang": { "en-us": { "role": { "terseLabel":
"Senior Notes Due 2028", "label": "Senior Notes Due September 15, 2028 [Member]", "documentation": "Senior Notes Due September 15, 2028
[Member]" } } } }, "auth_ref": { "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SeniorNotesMember", "presentation": { "http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails": { "lang": { "en-
us": { "role": { "verboseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt
securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to
(relative to) junior and unsecured (general) creditors." } } } }, "auth_ref": { "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "Award Type
[Domain]", "documentation": "Award under share-based payment arrangement." } } } }, "auth_ref": { "r511", "r512", "r513", "r514", "r515", "r516",
"r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535",
"r536" } } }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShortTermBorrowings", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": {
"parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 },
"http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails": { "parentTag": null, "weight": null, "order":
null, "root": true } } }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets":
"http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails": { "lang": { "en-us": { "role": { "terseLabel":
"Short-term debt", "totalLabel": "Total short-term debt, book value", "label": "Short-Term Debt", "documentation": "Reflects the total carrying
amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } } }, "auth_ref": {
"r54", "r115", "r971", "r1309" } } }, "gl_ShortTermDebtFaceAmount": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.globelifeinsurance.com/20240930", "localname": "ShortTermDebtFaceAmount", "crdr": "credit", "calculation": {
"http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails": { "parentTag":
"gl_LongTermAndShortTermDebtFaceAmount", "weight": 1.0, "order": 2.0 } } }, "presentation": {
"http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails":
"http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails": { "lang": { "en-us": { "role": { "terseLabel":
"Total short-term debt, par value", "verboseLabel": "Short-term debt, face amount", "label": "Short-Term Debt, Face Amount", "documentation":
"Short-term debt, face amount" } } } }, "auth_ref": { "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtLineItems", "presentation": {
"http://www.globelifeinsurance.com/role/DebtShortTermBorrowingsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt [Line
Items]", "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts
are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } }, "auth_ref": { "us-
gaap_ShortTermDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtMember",
"presentation": { "http://www.globelifeinsurance.com/role/DebtShortTermBorrowingsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Short-
term Debt", "label": "Short-Term Debt [Member]", "documentation": "Debt arrangement having an initial term within one year or the normal
operating cycle, if longer." } } } }, "auth_ref": { "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": {
"http://www.globelifeinsurance.com/role/CommitmentsandContingenciesAdditionalInformationDetails":
"http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails":
"http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails": { "lang": { "en-us": { "role": { "terseLabel":
"Short-term Debt, Type [Axis]", "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } } },
"auth_ref": { "r56", "r1190", "r1191", "r1192" } } }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": {
"http://www.globelifeinsurance.com/role/CommitmentsandContingenciesAdditionalInformationDetails":
"http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails":
"http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails": { "lang": { "en-us": { "role": { "terseLabel":
"Short-term Debt, Type [Domain]", "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as
notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } } }, "auth_ref": { "r54", "r1190",
"r1191", "r1192" } } }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": {
"parentTag": "us-gaap_Investments", "weight": 1.0, "order": 4.0 } } }, "presentation": {
"http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Short-term
investments", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available for sale
securities, held-to-maturity securities, and short-term investments classified as other and current." } } } }, "auth_ref": { "r121", "r122", "r1127" } } },
"us-gaap_ShortTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShortTermInvestmentsMember", "presentation": {
"http://www.globelifeinsurance.com/role/InvestmentsScheduleofAnalysisofInvestmentOperationsDetails":
"http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionAssetsbyComponentatFairValueDetails": { "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "verboseLabel": "Short-term investments", "label": "Short-Term Investments [Member]",
"documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of
within one year from the date of the balance sheet." } } } }, "auth_ref": { "r892", "r893", "r894", "r916" } } }, "us-
gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems",
"presentation": {
"http://www.globelifeinsurance.com/role/LiabilityforUnpaidClaimsScheduleofReconciliationofPolicyClaimsandOtherBenefitsPayableDetails": {
"lang": { "en-us": { "role": { "terseLabel": "Policy claims and other benefits payable", "label": "Short-Duration Insurance Contracts, Reconciliation
of Claims Development to Liability [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts
are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } }, "auth_ref": { "r1001",
"r1328" } } }, "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable",
"presentation": {
"http://www.globelifeinsurance.com/role/LiabilityforUnpaidClaimsScheduleofReconciliationofPolicyClaimsandOtherBenefitsPayableDetails": {
"lang": { "en-us": { "role": { "terseLabel": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]", "label":
"Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]", "documentation": "Disclosure of information
about the reconciliation of claims development to the liability for unpaid claims and claim adjustment expense for short-duration insurance
contracts." } } } }, "auth_ref": { "r1001", "r1328" } } }, "us-
gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock",
"presentation": { "http://www.globelifeinsurance.com/role/LiabilityforUnpaidClaimsTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule
of Reconciliation of Policy Claims and Other Benefits Payable", "label": "Short-Duration Insurance Contracts, Reconciliation of Claims
Development to Liability [Table Text Block]", "documentation": "Tabular disclosure for the reconciliation of claims development to the liability for
unpaid claims and claim adjustment expense for short-duration insurance contracts." } } } }, "auth_ref": { "r1001", "r1328" } } }, "us-
gaap_ShorttermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShorttermDebtFairValue",
"crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails": {
"parentTag": "us-gaap_DebtInstrumentFairValue", "weight": 1.0, "order": 1.0 } } }, "presentation": {
"http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails": { "lang": { "en-us": { "role": { "terseLabel":
"Total short-term debt, fair value", "label": "Short-Term Debt, Fair Value", "documentation": "This element represents the portion of the balance
sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure.
Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial
statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents the amount of short-
term debt existing as of the balance sheet date." } } } }, "auth_ref": { "r1276" } } }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": {
"http://www.globelifeinsurance.com/role/SignificantAccountingPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting

"Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": { "r97", "r208" } }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": { "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofReconciliationofSegmentOperatingInformationtoConsolidatedStatementOfOps", "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofSegmentPremiumIncomebyDistributionChannelDetails", "http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofAnalysisofDeferredAcquisitionCostsDetails", "http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofDeferredPolicyAcquisitionCoststoConsolidatedBalanceSheetDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesAdditionalInformationDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedIncomeStatementDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityforFuturePolicyBenefitActivityDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofUndiscountedAndDiscountedExpectedFutureGrossPremiumsAndExpectedFuture", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageDurationofLiabilityForFuturePolicyBenefitsDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageInterestRateofLiabilityForFuturePolicyBenefitsDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": { "r126", "r127", "r128", "r129", "r172", "r245", "r250", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r264", "r265", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r276", "r277", "r278", "r283", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r368", "r377", "r378", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r921", "r924", "r925", "r937", "r1000", "r1318", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1354", "r1355" } } }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": { "http://www.globelifeinsurance.com/role/Cover" } }, "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": { "r162", "r178", "r179", "r180", "r210", "r235", "r236", "r238", "r240", "r247", "r248", "r327", "r387", "r390", "r391", "r392", "r396", "r397", "r428", "r429", "r430", "r431", "r433", "r594", "r793", "r794", "r795", "r796", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r810", "r830", "r854", "r873", "r895", "r896", "r897", "r898", "r899", "r1102", "r1140", "r1148" } } }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementofShareholdersEquity", "http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofChangeinBal", "http://www.globelifeinsurance.com/role/SupplementalInformationaboutChangestoAccumulatedOtherComprehensiveIncomeScheduleofReclassification" } }, "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": { "r14", "r66", "r70", "r71", "r170", "r197", "r198", "r199", "r212", "r213", "r214", "r218", "r225", "r227", "r229", "r246", "r328", "r331", "r367", "r434", "r542", "r543", "r546", "r547", "r548", "r552", "r553", "r554", "r560", "r561", "r562", "r563", "r564", "r566", "r569", "r597", "r598", "r599", "r600", "r601", "r603", "r609", "r610", "r612", "r719", "r780", "r781", "r782", "r798", "r873" } } }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]", "documentation": "Information by geographical area." } } }, "auth_ref": { "r281", "r282", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r812", "r815", "r817", "r878", "r880", "r884", "r890", "r900", "r902", "r903", "r904", "r905", "r907", "r908", "r909", "r910", "r911", "r915", "r945", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r999", "r1008", "r1208", "r1318", "r1326", "r1327", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1354", "r1355" } } }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheetsParentetical", "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofOperations", "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsofOperationsParentetical" } }, "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r212", "r213", "r214", "r246", "r610", "r651", "r792", "r810", "r821", "r823", "r824", "r825", "r826", "r827", "r830", "r833", "r834", "r835", "r836", "r837", "r841", "r842", "r843", "r844", "r846", "r847", "r848", "r849", "r850", "r852", "r856", "r857", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r873", "r1009" } } }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]", "documentation": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": { "r14", "r66", "r70", "r71", "r170", "r197", "r198", "r199", "r212", "r213", "r214", "r218", "r225", "r227", "r229", "r246", "r328", "r331", "r367", "r434", "r542", "r543", "r546", "r547", "r548", "r552", "r553", "r554", "r560", "r561", "r562", "r563", "r564", "r566", "r569", "r597", "r598", "r599", "r600", "r601", "r603", "r609", "r610", "r612", "r719", "r780", "r781", "r782", "r798", "r873" } } }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]", "documentation": "Statement of Financial Position [Abstract]" } } }, "auth_ref": { "r14", "r66", "r70", "r71", "r170", "r197", "r198", "r199", "r212", "r213", "r214", "r218", "r225", "r227", "r229", "r246", "r328", "r331", "r367", "r434", "r542", "r543", "r546", "r547", "r548", "r552", "r553", "r554", "r560", "r561", "r562", "r563", "r564", "r566", "r569", "r597", "r598", "r599", "r600", "r601", "r603", "r609", "r610", "r612", "r719", "r780", "r781", "r782", "r798", "r873" } } }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income

"Shareholders' equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap-SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": ["http://www.globelifeinsurance.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": ["r604", "r617"] }, "us-gaap-SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.globelifeinsurance.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r604", "r617"] }, "us-gaap-SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": ["http://www.globelifeinsurance.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": ["r604", "r617"] }, "us-gaap-SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.globelifeinsurance.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r604", "r617"] }, "us-gaap-SubsequentEventDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventDomain", "presentation": ["http://www.globelifeinsurance.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r604", "r617"] }, "us-gaap-SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap-SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://www.globelifeinsurance.com/role/SubsequentEvents"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r616", "r618"] }, "srt-SubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SubsidiariesMember", "presentation": ["http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsidiaries", "label": "Subsidiaries [Member]" } } }, "auth_ref": ["r1254", "r1290", "r1291", "r1292"] }, "us-gaap-SupplementalEmployeeRetirementPlanDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalEmployeeRetirementPlanDefinedBenefitMember", "presentation": ["http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleofPensionandSERPLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "SERP", "label": "Supplemental Employee Retirement Plan [Member]", "documentation": "Plan designed to provide limited group of employees with supplemental retirement benefits, in addition to other pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [] }, "us-gaap-SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/LiabilityForUnpaidClaimsScheduleofLiabilityForUnpaidHealthClaimsDetails": { "parentTag": "us-gaap-LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.globelifeinsurance.com/role/LiabilityForUnpaidClaimsScheduleofLiabilityForUnpaidHealthClaimsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Current year", "label": "Current Year Claims and Claims Adjustment Expense", "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs." } } }, "auth_ref": ["r760", "r997"] }, "us-gaap-SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/LiabilityForUnpaidClaimsScheduleofLiabilityForUnpaidHealthClaimsDetails": { "parentTag": "us-gaap-LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.globelifeinsurance.com/role/LiabilityForUnpaidClaimsScheduleofLiabilityForUnpaidHealthClaimsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Prior years", "label": "Prior Year Claims and Claims Adjustment Expense", "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs." } } }, "auth_ref": ["r760", "r997"] }, "stpr-TX": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "TX", "presentation": ["http://www.globelifeinsurance.com/role/InvestmentsScheduleofCommercialMortgageLoanParticipationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Texas", "label": "TEXAS" } } }, "auth_ref": [] }, "ecd-TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Tabular List Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": ["r1071"] }, "gl-TermLoanCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "TermLoanCreditAgreementMember", "presentation": ["http://www.globelifeinsurance.com/role/DebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Term Loan Credit Agreement", "label": "Term Loan Credit Agreement [Member]", "documentation": "Term Loan Credit Agreement" } } }, "auth_ref": [] }, "gl-TermLoanDueNovember112024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "TermLoanDueNovember112024Member", "presentation": ["http://www.globelifeinsurance.com/role/DebtScheduleofSelectedInformationaboutDebtIssuesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Term Loan Due November 11 2024", "label": "Term Loan Due November 11 2024 [Member]", "documentation": "Term Loan Due November 11 2024" } } }, "auth_ref": [] }, "ecd-TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": ["r1063"] }, "ecd-TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": ["r1070"] }, "ecd-TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": ["r1090"] }, "ecd-TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": ["r1092"] }, "dei-TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.globelifeinsurance.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap-TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain", "presentation": ["http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheetsParentetical", "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofChangesinAssetsMeasuredatFairValueonaRecurringBasisUsingSignificantUnobserva", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAllowanceforCreditLossDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAvailableforSalebyComponentDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofOtherLongTermInvestmentsDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedGainsorLossesIncludedinOtherComprehensiveIncomeDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r423", "r432", "r567", "r590", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r720", "r959", "r961", "r963", "r964",

"r965", "r966", "r967", "r968", "r969", "r972", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1178", "r1179", "r1180", "r1181", "r1275", "r1278", "r1279", "r1280", "r1281", "r1283"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": { "r1093" } }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": { "r1094" } }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": { "r1094" } }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement Individual Name" } } }, "auth_ref": { "r1092" } }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement Individual Title" } } }, "auth_ref": { "r1092" } }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement Securities Aggregate Available Amount" } } }, "auth_ref": { "r1095" } }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": { "r1093" } }, "us-gaap-TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" }, "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": { "r43" } }, "us-gaap-TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheetsParenthetical" }, "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares held in treasury (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": { "r43" } }, "us-gaap-TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets" }, "parentTag": "us-gaap-StockholdersEquity", "weight": -1.0, "order": 6.0 }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock, at cost: (2024\u2014201417,942,902 shares; 2023\u201420148,426,854 shares)", "label": "Treasury Stock, Common Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": { "r43", "r44", "r70" } }, "us-gaap-TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" }, "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of treasury stock", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": { "r14", "r43", "r104" } }, "us-gaap-USGovernmentCorporationsAndAgenciesSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember", "presentation": { "http://www.globelifeinsurance.com/role/PostretirementBenefitsScheduleOfPensionAssetsbyComponentatFairValueDetails" }, "lang": { "en-us": { "role": { "terseLabel": "U.S. Government and Agency", "label": "US Government Corporations and Agencies Securities [Member]", "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)." } } }, "auth_ref": { "r1303" } }, "gl-USGovernmentDirectGuaranteedAndGovernmentSponsoredEnterprisesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "USGovernmentDirectGuaranteedAndGovernmentSponsoredEnterprisesMember", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleOfAssetsMeasuredatFairValueonRecurringBasisDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAvailableforSalebyComponentDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "U.S. Government direct, guaranteed, and government-sponsored enterprises", "label": "US Government Direct Guaranteed And Government Sponsored Enterprises [Member]", "documentation": "U.S. Government direct, guaranteed and government-sponsored enterprises [Member]" } } }, "auth_ref": { "us-gaap-USStatesAndPoliticalSubdivisionsMember" } }, "us-gaap-USStatesAndPoliticalSubdivisionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USStatesAndPoliticalSubdivisionsMember", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAvailableforSalebyComponentDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "States, municipalities, and political subdivisions", "label": "US States and Political Subdivisions Debt Securities [Member]", "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments." } } }, "auth_ref": { "r946", "r972", "r1003", "r1353" } }, "ecd-UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": { "r1089" } }, "us-gaap-UnearnedPremiums": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnearnedPremiums", "crdr": "credit", "calculation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets" }, "parentTag": "gl-PolicyholderAccountBalanceLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense", "weight": -1.0, "order": 2.0 }, "presentation": { "http://www.globelifeinsurance.com/role/CondensedConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "verboseLabel": "Unearned and advance premium", "label": "Unearned Premiums", "documentation": "Carrying amount of premiums written on insurance contracts that have not been earned as of the balance sheet date." } } }, "auth_ref": { "r158" } }, "us-gaap-UnfundedLoanCommitmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnfundedLoanCommitmentMember", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Unfunded Loan Commitment", "label": "Unfunded Loan Commitment [Member]", "documentation": "Undisbursed funds of a credit facility in which the borrower may draw upon." } } }, "auth_ref": { "r1157" } }, "gl-UnitedAmericanIndependentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "UnitedAmericanIndependentMember", "presentation": { "http://www.globelifeinsurance.com/role/BusinessSegmentsScheduleofSegmentPremiumIncomebyDistributionChannelDetails", "http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofAnalysisofDeferredAcquisitionCostsDetails", "http://www.globelifeinsurance.com/role/DeferredAcquisitionCostsScheduleofDeferredPolicyAcquisitionCoststoConsolidatedBalanceSheetDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedBalanceSheetsDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitsToConsolidatedIncomeStatementDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofLiabilityForFuturePolicyBenefitActivityDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofUndiscountedAndDiscountedExpectedFutureGrossPremiumsAndExpectedFuture", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageDurationofLiabilityForFuturePolicyBenefitsDetails", "http://www.globelifeinsurance.com/role/PolicyLiabilitiesScheduleofWeightedAverageInterestRateofLiabilityForFuturePolicyBenefitsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "United American", "label": "United American Independent [Member]", "documentation": "United American Independent [Member]" } } }, "auth_ref": { "us-gaap-UseOfEstimates" } }, "us-gaap-UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": { "http://www.globelifeinsurance.com/role/SignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": { "r32", "r33", "r34", "r153", "r154", "r155", "r156" } }, "gl-UtilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.globelifeinsurance.com/20240930", "localname": "UtilitiesMember", "presentation": { "http://www.globelifeinsurance.com/role/InvestmentsScheduleofAssetsMeasuredatFairValueonRecurringBasisDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofFixedMaturitiesAvailableforSalebyComponentDetails", "http://www.globelifeinsurance.com/role/InvestmentsScheduleofUnrealizedInvestmentLossesbyClassofInvestmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Utilities", "label": "Utilities [Member]", "documentation": "Utilities [Member]" } } }, "auth_ref": { "ecd-VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" } }, "ecd-VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value" } } }

of Equity Awards Granted and Vested in Covered Year [Member] } } } , "auth_ref": ["r1059"] } } , "us-gaap-WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.globelifeinsurance.com/role/EarningsPerShareDetails": { "parentTag": "us-gaap-WeightedAverageNumberDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } } , "presentation": { "http://www.globelifeinsurance.com/role/EarningsPerShareDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Weighted average dilutive options outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } } , "auth_ref": ["r1149"] } } , "us-gaap-WeightedAverageNumberDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstanding", "calculation": { "http://www.globelifeinsurance.com/role/EarningsPerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } } , "presentation": { "http://www.globelifeinsurance.com/role/EarningsPerShareDetails" } , "lang": { "en-us": { "role": { "totalLabel": "Diluted weighted average shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } } , "auth_ref": ["r234", "r240"] } } , "us-gaap-WeightedAverageNumberDilutedSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingBasic", "calculation": { "http://www.globelifeinsurance.com/role/EarningsPerShareDetails": { "parentTag": "us-gaap-WeightedAverageNumberDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://www.globelifeinsurance.com/role/EarningsPerShareDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Basic weighted average shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } } , "auth_ref": ["r233", "r240"] } } , "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } } , "auth_ref": ["r1057"] } } } , "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "930", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" } , "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" } , "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" } , "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(j)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" } , "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" } , "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" } , "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" } , "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" } , "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" } , "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" } , "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" } , "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" } , "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" } , "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" } , "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" } , "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4" } , "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" } , "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/21474880566/210-10-S99-1" } , "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" } , "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" } , "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" } , "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" } , "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" } , "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" } , "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" } , "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" } , "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" } , "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" } , "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" } , "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" } , "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "270", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-12" } , "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "270", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-13" } , "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" } , "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" } , "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" } , "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" } , "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B", "r1351": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B", "r1352": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2", "r1353": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1", "r1354": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2", "r1355": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2", "r1356": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4", "r1357": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-599-1", "r1358": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-599-1", "r1359": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-1", "r1360": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-3", "r1361": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-3", "r1362": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "949", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-599-1", "r1363": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "599", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-599-1" } } ZIP 106 0000320335-24-000060-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000320335-24-000060-xbrl.zip M4\$L#L0 (<LVC9EEYUQLK<<TG<83\$P+7%E>#G.61AU:76_CN!5I [Z]>=OLK=RF\$SX60?ELD+=1<#M&L-B53\$AA+U&7^M+BG3FEQW/LN\$>D-C'6>4E>7YIYIB&MIH7^N^M MD%Q<_G\$IT>^VBRH259YF5W\$O!&j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~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~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~HLGS%!"N#^V^A^OWT^2N5DAMT@F5.MN.7M8 I33&6&.<I1L4@2^B0!9GT3^-D2A^&IH5.^<37ZY^"N8!P^!0.MU<3+5&2X0><=<@FS;JCU^!C.148T9D8!8U.U.HLZ4<PBMT@LF000\$U.^M?

J8J06>-.18"(DZHA?)2%B4%4J@+?+I8NIN>IVWUW4I6A)B1Q=83C\$GA3U9.M+)\$QY2%-IU?0MYA^@7YJ
(9.0>EO:~M6B#.E4U:RU34A/>Y44ITS<4(-&.MLT?#WN(NIN?20D#G60#H(OD:7#=#9&%75%YIN.7G.TI?Z.MZ>HGRG4=0H[IS%]S*#4>[Y^>&K#8J
[B6D]!R9F#9\$0)98PR-@2G9-<2(+M1Z="9LAS?2U&HX<M^KJ;J2:%Z^WCY*2@:T(%)#*G1#56I420)22719UJAS3Z1A[>1V#<:~%M^<I
ITJH=J1HHLH0?Q0Z&QND\$+<[MZ39]!\$#1.#3X.P@ME.\$G/^0VYMPB.9PZ^FBL13)NIH<0Y3\$1=3\$N3.6.(Q(CV#S\$1=Y#=#PC)2R>WTL(4Q:-KU.M;
6NDE58\$(-W8I-X\$CG.0>?#0VPG+M-6NZ4"SU5<6UZI4-JGB3UFXY@=MJE.PWJY.TJ2V.MJ525QT76W3N\$RY#9DI
A'C:Q8.B3+0+Y^CU@<JYPO-0\$X9W8D>+J3Y.M:X8K0IGUD&0.-+>T6;M9Y20H&.#F\$*=@.\$9U@~.5P6Y5TW99H@.Y^YMDV[+..UU:~1MA0?<
@>J7?)ZXZ(-YA02UG&UEZ1.6:10?TJMW7&+Y98I.M.*?Q.(PTJ^#:#9XZ.9D-9VLN?
L:PINXG)1F^4YE(AI=7&W=Q=..DK.T.L@R#..XV3/X)"7.L>+>HD23H8'M15H'H.0GN'S'+..BQG>MCTV^30KY0\$@_@-C^X."Y&Y@='^3./QCXIMIQ
MS303I7U/R/I7QCX@.F^W#RJI-SCP2.LI&A=@WY/G+MEZ.TCRVJ3+=N.MFY3@.7V#..MZU.O1@T.2I#B#62M^C+XS?>H/H4J3L-260Y:-
CCY&C/W6&<MW^@.WY@#IN:~2DL6.9G=F/W^<^/RZ2I+8.LPI^3(28G/(5H>+PW+M^<%FMIOJD!
I/1@/MF!^353TACN^Q.T^I>+J3&JR(KV1^>%OUI>H(HM1#(HC35HQZ9G64QCCI/HSO2!)>#WNG+##WOO+^T/6-V0L-9M?HCH.MLO.&A
I93UEB08\$TUV">/L.Y.WZ1=0(UJW+30I/LR6A+LFY>BH+M.YGCEE1(KI.ZR02+Q>?IP?WOC?1L3DBZ6GZ+J2WN01VA^+Z>+L^AY2.R
MK^|=J/XZ'#@+N@HP/Z'B.GK176VHRW0/#.I#-#I'H4.MO\$6B@QW^K>?M^HC?_YE2#)28U<I(^.=)6Z=QE%&/[A]^M%GI!5-=K*R%V(7^D#1?
-M114L69?%YO@/VIG#ZY4/Q2T2B@O2QWGXU.ZP.69LAI<75#)1Z?1L7M17%\$Z.Y#IR-V(\$F*7X-
_GT3YK.3I33M)\$&ON&M3#DTS0I9ZL_0MG(KD2)MHL(WNVEY#YXH<749I_OIY:DEI52I@P/I:QP:IQI8.YW9_?#BJB5N\$B)^<12W/UU.YM\$+
(OI:H8HIZD).#(G^W^PT?GSI#MW5L6A]L.M<?;3_WO-/IGJ)-T>@=JPL=^KON)I>?O=?WL)I?^INFWZ#\$WKU?GZ^T+I.M\$5A\$3ZU/&^SIOF=I-
Q?Q^YR4^#M]#<4WZ4D>2300G(I<C;T?JA7A&N:6^VIP00?C(MC3EHE0I234RR#-I@H4HRUCM.R^W^Y)GX8^IOT+Z)PDELDNP?#L)22&J
MYQ4=UY3>?#A*R-IU4>RX.M.(130)GRK(DNIMGD)0.MX^I@H2LK\$LDQ1PVK6H.H7+8L^U?ZP91I>#A8)I^1Z7I^D28X-M0>I7FL
ML6GY:844.'M5L:3.T3P>Z.&IS6TSNF.(C)AK.M#TV.OE&0Y?)^C^CIZWYT/BI^I^!=_%5-^N'E=I..V366KC>FS.#Z8I8
M^C^S>>RUZ+N.88IQ.R=&P.^F3QT%\$S^2A8G.IYVZ7SVX6<2Q<=>6G79:47S.MXA(27CH6V^=DGL&ZR4IWH='DZJ'^3\$:#.^I(LD:!
(IKJ)4Z3:3HFJOIM@GUI.M.E+>#T:057O3ZF)A]#\$K+L4^+W4A:N84#KW.#YI:9^I^3?ZZI^+ICRIZ0
MH1@)LM500!UJO\$+T/>W9/IGN#EU4=YS#2?IBV922<8"W#RN/#I.^N.T.MO/EWL2I+QS:6IP.MOIGI/;+AO7NO#H-5M1@F;U.8?_%GGI
H:10&O2#H.M2IB):U@6#AS/LI.HLG3T\$.3I#%Q2^>D*!..?D*!..9H&Y%#I4U.GEPK+MSR0Q>PHY=&-+JHJF-I.C2Y;L9W<=)G@PGI?
R9WJ&JFEZ?>G(N)^*ELF^M.S.-WLEA.DWNJR9^W7NALGS=KPWHS^I^T..FL15KG+0@(<4<=3MDIP(CMF?
D.FUGD\$4G2AVIT05<#>HILEFA=I2.2H1#1.1%JN7>2Q>=>..D.-J.MOQU+I^M\$DCR&3(RS#E.ACO)U2.K@I+ESI-FU?YPT#53.%LIQMU>..S5\$Y
ME2=\$2BA^3(IH@DO30"K^WEXY^T^T)ZV63F.\$3..EJFIQI&A1\$S9&GAI^M(14)&GJSS454I&@4.CRI%DA%0D:B]E.YM5E)G&ON?
M60GI5U1VKZJ8(%)>+DN^0)=6AXID#BY+^GSDWX-8^4O.M^/SN1^V+Z-0?I9D?2B<^E@6?GW>N/A.&0+>NZ6J7I;BDKZ0NKDGFTUBU.M?
=8G41#=#5I#4Y^P>5R0Y\$F^0=C<^YZRI&5ED.X+TFIPO.NDU.^XOJ
M.PI7^@:GK2IH^5OJ^4@.X%)>+G+JG)H^H6ECVUK&6H@P:8V9/IVA(C".J2.M/8NMD;Y?)>J8D?9DI>Z^N>I<1215IV^40^RYJFC^AJ.N^
ESUHHG^Z^MESWVKONPX2E1^HEE1I&KD=7IM^#*MU9.IJZ^>B1A&H116^<@OE&RH/^MN<1RI(I^Z7>VASFL^KR)X^U@I<).YI+FO&.ZIE_Q=V7=-
P^UW(G+7.M53UP>SRX6:80HB^9^ABEO1JF>PH+@<0THNR9J7UQ^A.M^
G366<@PAER9X\$U[LH]HJS)4I#ZZI>^>V%*TN:8IH&.&7/-P#P#IOT.M(7L^7#?WP\$WPLA>H17/W&00>X)>8ZQC9L?
U8IOXKUN\$1<I3910Q#D.Y.M2YI#>YXU>I^I^2WUEB1^I^E3W+KCG4XRYK3>.(KIM4PCIR7.RRW^Z0.58=
M3IET1#>BT\$.4#8IN6U^+M3K3Y=2=Y9>_?ZJ^I^0IGYGP240V1+6I>#XMS0.JR)X+UK=^#29RYX&BED@CLOV>GKGL(7B..G^JESUYH7B..G>
ESS.H7MB.G>P@94460)GM0007)2^KI63^NOGHDIH22.45@CW(\$I)IJ>SPK\$^PI<-?3?#8.MRM.IA^JN6JFNPI+CN0<=
F65W9LHKZN0<16I(H17^/8A0E.SIK#N#N082R.M9\$^Z^4>>@UJ@W9\$&#R0=>OI<^Q7#IOI3@.PI+P#Z@9IR9\$<#Z^82^>F>MIBJU^*G.
K3I.%OIOLF>R?2_U&LA1Q5D8)0OH>ZIHDI_PLU^I^G3R0B@R^32/12Y2\$S8I.A^BEOI+G3-2Y.M01YR)YD+FCB.S4^G&.K.^2/4BH49.V=-/D0-
%GZ9.-4.96M\$U0H26%MMV.AB.O1LQH8W7H%6G^S1P9LBH%MEFLI>4I2\$30\$4@)LB)F9^4)MQQI56E\$89.Y\$#L8G^<
&7E^D0.%#P%RE\$=-0.4^#5A^RY/B:I&M&%KC.MQ)=E8KJ<3\$O6C%Y.729?2PHEI[B+H.E%JDS6W%SI]>@5^?0@R^X^R(6V9JR(4I2I:\$3Q.R\$@B1Y6&-
&(KO1^2BXX.UMVK)RI6&^HZ^5X@22M\$#0<2&K+DIL&^HT84RN.%=Y=MNO@RSPX*6I.7EAWF1M^92X^HN\$Z^I@M67-I>5^/4IQI^
(S(XIDIDYK)RI2^RQZ^=Q2B)K/@KAJOE8B0/RH4I5&M&^(A#<-E.2AMM(IIA^*AK&A)B)87E(I^D^-T+4)BOQ^C^I\$<A,B-0.W
MK1.LFO1^/TWIZ_5R^I:9U>#++1.4>WHRGY747.JEZ.0EX(PE+.%RD%."&\$H.MGHT9?7I\$(8JO8.N0J3@FZ\$IQ>AW^I?
DAB208<@EJC.@A1L3ML6:136MJM@JPVYV^?TMD5%6IK^TIK6U0X.9.N.M5UK.H9LM.SX>1#Y42.PPXLFH59(Q.WLVP^O^S9?XD201^ISD)I>IF7L)SYI
M.JC(BK\$+VJHP)G&^EFT>^241D1)M^H@>^UNID^..FC.U3@PV^R^C.MMA>C..ZP^KB21L.LRG1MU@SYQ^IQ^Y9^IK6:TALG5^RF0\$XIBI^LJ:
M>L2^..17@R^Y.4JRAWBA670Y4T^>#B/JPBZAAIJ\$^I;L6.C)I\$C9IG.MU#EA4(^.-&I0HSO2\$0M@4^..Z1^QI^9\$&XC2(0#^..@.6=U<I6)H^I&
M1+=>BAE63/V7=V%PG^>#>#BD^+..S5N26Y1.MZZHYV^T0^3-74>+W\$A.FGFJ@P04FS^@H^9.THRDF2<0I^79DV8DS5R^M(XI:8IH9>8K1^7-
714@VLA1.FGF&GAP.67I>>#>90R0Y^4EV^0U2>8U&.M^Y=I^KWJ93@/GDC.JYIMAP6YQ3I/L<#1^@%?E)^(#).PXJPM:0.H4LM-%0^&B?
907I/5IY8.MP/\$<@0B.E21^M^OWTZ\$#^E2)?KUVXF043*#I#OU\$S^T^TM28;S.U4=7Z1.MI07I2.OX8QE2YOSB]C^&.94A(
XNQ@I^\$AKR:CCFX^+30A+&(2A7U.WH<MDHH2\$&L.OI8J@I^L^28C9R1BC>8E=7A(FI8D)U2A2.(6%#&=A0B.M(T^5IR^I).4HRA(U.DG)-
(A6EJAA2DK0;2R;(U9)ECN8:03I^S7W^C5_23.MWL\$)7DDX1H^7D2C@9:F1YB5ISB(GK7+L2^7.L\$2(#R.8B\$0N.\$#+O#R@V.M.H4;4;207(42-6)>
*+I#DQO#C^J^MXR3&4J<(<L.R.\$&@<N/6B98.M\$D^N\$4.9/(FE>4).J3I.U@I\$IX@0L^<^E13KQ0>XA;@444NE2=ZIQ^T
MI2A<^LTIPOC^F%I=U^4^DU@POC%\$96E4:DTBPYC#\$=4ED:ETE0^CI&S&.&KXK^2A^4V8-616^*R^49LT.LBH^M5T.H3;
U994\$KHI0FDMKOJH(7/&@*06C41N.I:7.O&:LB<6#TBPPC+D8.M39GERO.7KM^L^XS9&(C+7^I.D+8SX&XG(7^K-
8QYLOTY(#7)E<I100H&\$&4J@.M8.2A^49.7BBH67NL@R8I^BR>8.2#)BR.6.5.%^AU.PJHP^L@#M#
MASR@3&TB^#>WGXKMSD&IQZ2ACI.Z^~@<2A7^..TFC:456F-INVDYBMR>MUY^4>H.RA@I5H0Y0+E&.ZIPT&A&\$)
>X)Q0(9#>+4T^RY3^FS8@I^M.M+EP^@7^EMU^OYQ^I^WR>59V2@=I+BV.N.RXK4D4PD5P1^HX/I^IEX+I)3\$#M<7PEZ9\$?KIVV.93L1\$8(0
997EI<1HEK7^SIELEF\$12BUL7AB@>P7&I^M>D\$7^L(K^9^L)C(E7S+MM\$GACQ^I^F22I(G^B^C4UF&S&I&Q(R^4I8>OPUS
MQ86RW^ISB&&>>+4)8;K9(6Y@0<ZQJMMZPZC-7D(+CH=5.VI&BNT.4^I^N.M9LZ.\$T=HN^(>02%>%)X1\$5(4*R:L%CH:6&J^Y.*KIU-
WQ050H8A7D.MZ.D<&U>7/466X3I&AMC^WP5\$)I\$7I<5LHPV^&<I3>ME#&OU+V^KV^IH.M.^I^ZLK?7\$QI^Z57T3?QPL^T.MR26<EVI@Q/+
(V<^<INH3V+ZOMESH97W^G^<T/I@."YZC^KQO-D1R^&G.M^F\$R^7WU<^I^CGI3AZ3)=I2Z8.KI8I+L>I1QGWX^>R^UQ^0^FV+HP>#MIN^
R/WWU.-O<3H^C.)#&(IUP6+HD2N^H^N1I3R5\#9Y(I.T;PT7)I>+@L=Y.HO.VW#%<@F%:@\$RU/U+H@<I%-MHC.V_E^U+L@.4YAHN:(69-
ZX2;2\$S@&F1\$^RT1\$%&+M;.(SIOP4@LS=MA(F^6^VJES.9.I@0L\$S^A.M5I3AZH^IP7OIE>F.DI^VDH^>V1^SV8U^LM.M00TNAZ-
B+3K.DI>@1TJ9QX<6%3I>9W<=<=<SG2I^CIQ@PWCB&L\$&L+W.MI=J<#RZG^EY^2IO3K&=Y+TZ+M)8YEM<GE/CK=6T>6JCP10H^E+NH_Q
M^6\$S_H1I6_H79PZ:BZH@.7GLLR.CYT?1M]JD=^4@Q4@JMI^<I^H2#9R.M:QX#IH.YY2U(FBO1Q<%0Z..9\$HL=8I>^H&W5%
MDI1=HG00IU>U^68I^O+P57GX+@2B093N34/CK=16M^31^IW)P5:M2O)Z.MO1Q<=>X4^5Z+P=I72I45\$2UL^DGI7@ZN:@?^
TDQI.MJ:4P5W5^3@>D>M.LNO?(<3;1^07Q37.WU1E7#(1TYV.XCKXZ3IK.F^X14>5\$;+I+8_MI9@&?H>#58<I)7/Z+I.^+GLN&=Z2W(9.^38X^E<
I:G9>*>N1^SU<.(RKX.M\$#H<I^>BW-3#..8Z@<MWCJ\$8XIC.Z9RGSL2ML#12R>3KYHU/Z^R8Y2MP1Q<@Y+M^S1#3;I240<IWIGNOU^K7Q.
<14IN(18@5PMO)PV2I^F+(HY&M5.C\$BSH^<2I&G.K.R&E^I^H\$822X^BLV+FB^6S.NT.L%I\$@I5E8V>+9DN-
KI(S6^WVNYID\$4G2AVIT05EH0=)@VH3.X*1=I<ML0TANV02O?C^P4I^PVB8#>@I^AU\$MO7A(SIYX3@^C>%V-
N#2:HPB=ZV8BDZ3PEYIYIH(L)H&?<#EJ6.I^M^..0D^YV&Y^43JF^D:EOJE<<.GQFJH^I80KW?2UEI+M>LE6^R1_5^M?
E7&F90H)I>4IV@JMI4.5A:0%Y@R0&&AH.O8B(I>U3.9MC^F:Y^F#BV^M.QXOJ3H14(I^C:3.X\$+I^TJIS^0HH+^B>E/F2XID64EP^*QN6-!=
(=I^1IN:CI&U4EBY2\$1KV07N:7&I^KHGKEC0P0.M^IV..OOO^CI^Y\$N0B042\$N^I^Q\$A%I^I^N\$N\$^62O.RD&^PX@7M^*8^*X
MI+@45BY27.HKN8T45V.4C1170?)T45V.N.CEIWO6T:2/L>FLC08\$1%?I^TRHI^63L<(<2\$B.MLVVY^YS2QB\$S1_1
IS1^QJ=I:3^19JK^6KN2\$1T0@K1>-A\$SBOB+9J0O./A@*M&IH@(^\$7.M4:9L6X^I^#<6
%3/HGKDH/L4#^&K6F7.DXL4S2&KTJY+M&I8B.NO^N^140U(<3EJF^RY\$5FA@<MU0R+<0MP(MRT4Z2\$Y?>+CBN27F)RT4J1BOFY7%
IJ>E1@<M\$N2BE)0/GD%@AP/U>A(&P0DY^N^W+06I^FZEE4CUQTFHIT4:W3E.MXL4C>&K4JY<JCR88I2D:G8-
<18HR/MJK0L%P6G^/IK>L^Q3IUP)I^IRDM<+M)^1#W=;NZ@)US7\$LNUDK1>I@\$\$N0BJY0/MGD%>AOIU>A(&P0DY^+E.W+06
I^F&ZEE4\$#Z^>+I<+32E5^GEX.2M.M^C5ELC0B^W^VX28C;J^N^8ZARB.FRX(Z<JH9>82GR>Q.S)R82\$07V^EJAC^FJYH.M6N^(<@0K2+
^JM^X&A^*^ML(I9^*UP3N^N^X8I6SWXOK^Y^I06K.)^M^6C\$H=2CHIHUI4EJ.T>4D:H/4)6^6.4E%Q*^@B@I0H%5I5S5<^
M15=S0;I^>91<2K6J1^ML2K6^A^M\$H3MSI8J>^*UBFDI@Z0^YI>I3ZIW^38
M2PHN%3\$K^IUL&^F)4LAG6P.H68E2R2=^*A9B5+9I%FLDP1\$55&^927+@MB(KLL(C:7I\$A5=8A)\$<#)BG^40WY\$8=SI(XCN3I)T/IPO
CBME&MN4.NN.MJ.BK.841A^URI9W@/H)PE:YZ>Y^M\$58:M<L.VH\$Y2.VR;T^I^4HC&U-60QJE#VHJ4.UX:5^?L^X^M@.%2M@OSLUL(0
MMS1&M5@.0IQ\$>^VLJI&W<21KEM+HA>J6==M8&T7I2AQQMK%2ANB5-?%MNI8R5I(52&(I2QDIB8H)LJD#(I\$A6&8Z\$&0DPBH0:47/A-
7.M8I5^7@TH.MMBI@&8KS@.VHLB@&8HJ.PTHK^I@8I8A.PVHH=0\$6.SMOGJWH^..")4^FBU.M.411^GT(6H^RB<(<ANGCT@94>&I^J2ANX^9\$J
TH)R>#>8I5L7^2)4IL72.M%>15HOC5PH5+I^P^7VRL>&KAW4KA^L^T.N^52N\$JSSJX?E^X2K1+&KUK%X.MP57<^F-
%IJDH4X&2:Q5H6XE2&.15K6(A3&)>3K^U)@QU1E2.6D:2CJ.HMKHL5>FA(RBPZF)U17KH(IUN@VH=-2^/FK#H8)BK6Z#AZ(35C/4:4%
MZ^H9.S:@*(+053/6:4^=I^H.F&FJ@MP^U\$12K0E^M^HEB%>%0MD&%&L0.MKIK\$KYVC.16B^NYEI7XDV58:4!^Y^H8T8.K@A?I\$^B=1^+I+8-
P=7FP5^E3V0Y(I^F@I2I2I.C@&J)C13A^I^)(O)T^I^P%#HXI@^I8NH\$=(^L^KQK^R\$HL8QB.H&I^I^O@4C>4C^I^7W^H?>
<6NIAOK.5>N6>8^XN0.N^M6I\$3^I^N8ZYC+6&F^H=6Z\$=1\$1\$A^I^+I^Z^KMTY\$PIQ@H@O1#K&I^J^#HHR(0H)H^H^I^J^OEF^WR0S;"GIS^C^3+V?<
#249(C^VL0IY2.MPS^VIBPNMWPD06H48AOP-\$::P^*874-3..%MJ&0.LP/&^9H=F5-SO.22ZS.U5QM^6U#(=NOGT=PP94WT4I6&IAJR.\$VG-
PV^A15I.HI=<MQIHM#BU.92:Q2X\$M#@P@%>T(7+K1>T^8.ELI>S>+I^MPMV.V^33)ES&M.(GZ7Q)/IUIV7IPEGL#4#P)HJ6@-IY^I^J2I:1)?
PI44Y.KW&+A.M^7@W.82L^CTR#I^M1M>TIOJY7EP9I:6S0&EKX^UVPGRM58^6646WV?#MEI#>@&75PIGFIYI.PZM:;#X!
IVDQ32IUH46@S/3=S&A?I^T&PDF<7B2I.MX84W.\$5C5\$VUJ+A53XT1DE.\$9#)+RRB2:#.H+64RGX=5T"+PIGZ)0P&>Q/O8^#>2EFKP?8\$.7/75(Y=
M^S@<0P25U.IA^5MB)B22P3T1%ZLI^I8I6@M^I^HJ&0>WCL&EKL.BA^EGY5.TANIS2.AA=1T3C4BDBX.MYD#2Z9H&PI&5EP-I^%ETB8:~IY05O=5D
#*F>S:WBM%H^D@7#;K^MH\$FV.MH?7RI4JY>T^I:HL84JTT^S3HVE@6+7>K^7Z5JHY6%CE@L7J0=C^G^TO.M8M\$<C^AE;R^6S1<EKX5;#*W-
@<^91==>5^*Y-OOA^I-M3:A52TT.M&R9Z#7MB&EIK0HOI^F^FES^W^RVH^I^X&M@MWPPALH^K&S^IMKT?I^QJG
M).8(QV3LAEUO.JI^Q@X+M\$/@<@C6K^YIT^YI=0:2S85X^&K^NRU@ME2@I>I<#(6M@WT^#XOI^<P6I^O.AH.SML0:34.MB>
(E^F^L.S(6@W5>M:B<5-+;+^*+79R8EIOF+7:(70%HARK.H6OQ&QIO(OV2^+M^TP>Q/O8?V^UFKP?8\$.7258Y=VEC!AP@JN8=W+&I#Q)0"
R#8>NU.1K7^MSODT3JE\$T_2FN\$0Z^Y@F1C5Y0Q^*L.SQ%#K8TITKD7%\$KZ5V;2I1OPP>Q#>M7\$SKP#YB;U8@=

```

1:Z:O5MDGVKFKIB9DSZI^PZL^IF$NS^#WVA MH^DWN^D(C,.)2T<5C;T=<#399K&SYD4_23T1Y7Y^$KY4P^R@BV@TSM+V^,797M-LB#)8JWO-1 M2
1ZJSD6+5IBZ7Z6E=WHITS(9>*F)#NEIMJG-0D M2PE89T^HY;HWB9^G_3/QU$ _E<<5@_4P>="#30F3^BTRP)/@9-J3F1^98K
M0C4#4P9P+!&=OLC(SX1.ON3D.K+T)0F>^((/SM$)DY.L^QH1(C.)3S9Q C-M@!$.PL#&@>_E.;3CEW3\N/D2/Y(D8@I^&B>C./$S>M7T).J2
W).HIT^X^C.UQ M$F3T-WDP^X1.QZ_4;L.LT171YH;#BJ_6;L.LT101YH;@H7<1H;@)DYNR2A3
M+L3I8$M6VHY#<@L^ETU:6KQRD6P=94/UUJ%_18D2#013YU+3)JE3QCS M4G31^N1K49@Q-0P2:5KHHTT.(13)H@2R^((@%H4+JXT-
3P.C8Y^B^LEN2 M^#B1Y)F/GER3R28&L(C-XU9P^URV;#MZI4VP90Q$<P T^%U.C;IX-V62 MY8$AV^H^AG^
@J2M8RFAEWRP1LHW0(UZGEF4/HL@#1 P08L RL^YB A M06DS^GYO @)2A>IG42H1$.)>^LGL^E2CI^H^D^P^R2^0+O X.TEN^OQD
MISU0FP2.YM&1@2(K/J^V>3T+J76^*XDJ9G(L^&R(2)3.1>59DPD8ET+O A M^@83&5H^D2EJN26NR$3&S)$Y6G(8^R82(3+*.*8@?#KQZ1C:
5P@B2MF MP=M+!&0A9M^#=5NGJ2@/#0<4@I^9N@C^H^EBOA_#2^K6YB^Q;^EBTP^&P^M^#BVEJ9R^#2DDQ2+8.@FJOPU^UV.^#^OF:M;10I^N:
P(BMZ=14NC.2X+1 M^B^#8$&@2@Q-GB0E^#N^E^M^@UQ16:8&L(C-XU9P^URV;#MZI4VP90Q$ M0_UHL4N)M0UO^MEG2.N:
1:0!0KDDP5+J6T=2P33X8@JU;H.8KUKS290^X MX1@&)(EX9L1$0%@"M/((R@!! 2E^A^I%>(5;S_&KSCUW1=^R-ZTSXZ15.TEZETP+*8J/8JK1TL;IA)
M132TQO_0_2^L^<S^HC)>^7E.0^#H^WZ_ Y70^M^T^M^WB(=^_84N5N2278SD+^I^F^NNO.73ZS6L.OBK58.A0^K M;F_>B4)N1!-G^*2D-
Q^5Y+^H^L^1290!6I(1.5A^2KS(EJW07_@>M^1 MTA^F$A6:*U^WAB<+^G_<G^RP@!%#S^X^L^%R1E1^P312TXS2)8S)^F1
M$6A2YXIUL3#EE+^I^W%$ZW^ITVS_0%>OD16 MK^Y^Y(E^<^E^Z;%RKXF_#=#G/2#B&8N^7H(O28XR35A&6Y^NS+FI2^%C17L^N7 MO6X42WM34RP<+?
ERYP^%BYIG^MQR9)3;HY^<^E016 RXD.EA2B7+Y$5(W2N M2>_>QHF^@*1.E>H^U^UDH4F^*1;YK)K1#(KV231DOCA; &0_UHJ_45) M$O;HOQ^Z_710
HVP4K3JHHYQ^A#_3P>^P02 M^#>S@M19TR2CHS2_SZ1^L^Z8XUFS+^OJ74AKT^S_90%7$ N^JCFOTR=>D MUUUD9+CPDB^<^PN#
(O^W@0X26XU^>_NSM56-S5(TG6=(LGN_E.19I8/B MIR^WY^@JHFG^3HDD^I^TM.X#^GZJ^YX46_1JZ5.UCIAS_D3X-7^W^69L&0
MWOMQ^#MEHLOGV^%3M9^C^3<^AEB+4^T^E^X^S^09I&Q^0>P^JN2^81U_MZ^&D0U^0VZ+J$E2?
O4^!^=H.AM12^FJX79T>+R0YV7B(C^1.2)^#M1Y1N^#SU&_1$84^N=BL.MOK31B$^7&16(I^1%L^A^*MOK8242H1B5J6-N^%#(16;):OLH^O3+CH)
M0(^!L^&Y^8$@>@)Z)GAQ4RJ33^C;CRCMR$5BJ=-V(PH^I7H;CR^M MB2HJ^<^O9>_P1^B_12W+1>)AAX3C1C_Y2+1Q^WV(T0YX$@T^Y%_3AR.5K-
M:OL1LP_FUYX+SQ^VYH0W=^1$#Q_0_U@&OR)1T23?#BKES4 MF<#5?H1H1RX22_VV^UX^D(LP^T3;CR@HR.69U;W:CQ^5R$9>B2HJH^<^O9>_P.M1^B
12W^Q>))AX3C1C_Y2+1Q^WV(T0YX$@T^Y^X7^<^@>):W&41^I^03^GFB^<^H^MFB9^F>KNBKX^C_ZZG^L^O;A^T+90;9!L^F$J+^Y^K<DD_<C(DFI_9!DFH
M0:~121(CHQHC8N0+1)KFW^Q&B>C^M^#2(LCM=4^DFG;DZOJ^V3P_0^?7V= M7A12_V4E1^+DOWJY55N6)^*S CWO^+T52LE49$
Q:E.X.CO^H^CH@EK.M:1>1.8=.=@G^14=^SJW^<^E^F4>J2DOP2E3^?^TU^V2E.E2$D)2E$K3<0$=*M%JHA^*0.H3#2^I9(U91(^E3:8=.=HG
A)>B3RJX+^9233XYCQ/2H^<^&D04:738_DV+0^I^D8IM_LIF^PK(C^M^?R^S^<K3F2^W8UN^#IZ.A+^F^2Q^>D>8G020.7ZJ9G7(8)<#>1?
LY2KJX_<QJ$=NC8$EMF82QC$S_N^>T^Y$23 MHWMO$<=^?Y$F.QA1^<^P^SRQ5^_G^@H^Z_D2H03W1L^@/CJBGH)<^<^VU
M@J>/005H^FZK^<^<^I>^/618J0^I=GGI6^VY;LYN73PKF&6_3GI<71Q>G_UH MDH^<^V2>_>K;R:0$S:9A;
M=<W^#>QWDMGMDK79QEV^H36I^Q^22+1^F28M^F_KZJ81^L^W;YFG7:9%<M^M9C;28TXW^MF WR^T>?>X^QY.QM16H>H?
VP-T^JHJRZS.IRK^VA.M!>5N8 M2NOXW5<^<4^<^>2J78HZRDW+424=+^T3J^K/ZHY87_NIC.0Q35_9136CYF MCM^Q^TZ&?D^C^?L+^ID?
Y^EHOG^<K^:Q_UEV^I^7H^K^L^10RVJT;_M^+F^<^N^<^<V2?^ZOI6^<^C^<^N^R;=;P29^HRIAEMJH9MK;U5FNN_ZH6K
M<^<WVMI^#W2U4K3;1J^@#V>+1.3TE@C^L1.93>2TPT_6RZ^J^146D5127 M&EOLP^<^?F>G^WY61^TO@^4V;WPD^=X8^<=^I^WG@V?
B)P1$P4=U6U^I@Q;PX&N1QXK8315<5$53D_7^M18JGZ6A^H099J08=15Y1%1%F^B$Z>IRYG M^0UHX^<^*5^T^U^JH^T^W^K/4T&4WS^Z>+^&V^$P^"
HJ#GAQ-9Y&(IOY$ M^H=&P1MD^?VO/IWSY.M^#M6^Y<^=^SJ^C>RN_@I^4H^AVZG4^J^QI^I^PW_M+^4A^T^GB1^DLF<1_>FMZ<^COJ^G6=^<1-
ZK2$5^FEM^30>^23U5^V_2RVAUM1 MJZ_<B^#%#^TP2^<8Q(CZD23F27A^/C2F3H)3IN_>+^6G2RQ^RGFT^OAXL^<A^<6^ MO1M^_1^2HIF^E5X^Q2
7AS>^YMEP^#5)9_T^PE^TIG^<NGUS^FI=UO_KV^A=ALP^2M^HLC/I^#_<F)4;4G M1^M^:H@_==?^OL2^SRUC(IDQ_Y_B_+7JIDP&X19Z^+10-/>A(A^QI
<^<D^K MV16W_Z^<^>DPZ7^#YZIC^I^J$5?A12_K1($@P^C5&R5^%#5CR^MW37^#9E M^E<+^32CZ2XC^EIKD8AW^7EP190^J)SDX2^<FJC<9^6?
*>Q1H1@I^C3_0= MW70F@FU=+=+CC0QV^ZWN>^<B8;MGDW78/4_3>2_@71^Y^LEE0ZLG1<6V6.OCHNPVRHD&^<^T^K4=M+^TB M8%=<^HIF?
#0@WS1^/R7;L;261B+)<@+^<N^J80OLXC6^M4LWK3^OYE^<^>=H>Z^?>3^T><^<^%8@3:1Q^ZDXD3JDVAIM4J:91G5AD^QTI^MAY9K^*?
VW<^HB1^M9LQ$SD1^1H$=S^2.ONJ84OVVP^J9+5^5CNK+G_6VOQ^K MS_4+O&=>^51E5FEK&^UO+^<_<9BQM^Q>Q>B
MW3UKQ0="135D_9H_Ta>9F&Y^TDM^TYH<@>_0%0^"U1G^X83N@E^L^0Y8 M^DI3^#LR8!>>^2%Z>+
BO^A^T^XQ0>3^TALYJHBZ7M+D)FSJ3L;GWY+TPAV^M^@A/9(G^#;EY8UHJ?;711^0T0^$9_V6KY^VL60?O;Z57JZ+Y^7/6QQ MN1MWNLYJ?
+6GCE^ZHR>M#<0^<+L9/RXP2Y5_#IQ2)99_F3Y$^*V)N^H827J MY_10^RXPDI^RC/OI^SFH_16^96.S1$S_5S0_U@>Q^Y%<2N3UYM=K>
MW9K;Q)8%_RY&1J3GSX$9_3FW0^@NS<^&KW^T^Y;2^45CV2N_<^&BIV^9^H_&lt
```

```
<U5J>[Z:~9%+IQP(W%VJ5=W>I:1EM0MO<:%W-C?L=^M$%7%YDIDQV?2).M*+6,IG*TA5!)>(&EN.Y6E#4 M9B>WFT#<
<$4:~KW0!EWT&RF*>~R"~>BTGIV1.M.T%#(4UPP8><@:~O:~QRVN5>$2#<~3LYQK8M(X5J2ZB05(T:~CWX:~U.X
M@D@K@P:18&PO!#E&I)UQDJG2ZFDK470+48WG6V>F?..IO(C.-D6(,P:84.S%W.MJB<~MP$Y:~)0I84?2MO-)0~Y(-)3H/I>+6EW$[ASW/?(7
3<~M+19YTFQ390:1PH1~%20.W/DI*3>Z2.FW+P%AEH8!EJU=PM4<~W$G4/PW1.M8)A>1+UQDNPTFR<U%55C.KJH_W0:1$FA8&GC0K15<:G=:G9-
5YIWL1:13M.MFM-7%9@Z.529M76S#86S15A5OUQJ57#R&!)Q$1_K_&N80)JB2U.S3WICS=1/9>K@Q:1!6.MH:~5-
MK?72.KEXX~%$X<:E4JEN2CVLV~)0VE?R~&FERB~:RU05ACRE.NJW=:M-0-$M.HG3>#@.TIO*~6G>15F?J$JL11)J~W:2B#6Q.HQ**1-AZ1A$:TF?
UT.MB0ID"W=8$3E/CZ+~)NZFJTM~?R~>T?VIOZ_J2V+1Y.VRRBS.E.GL&VYZ+X.M06Y9&2$4Z~LW5L=3NZV84RF0Z04I!$P:9%$N6W=.#~8?
NZ#J3DB:~M!17~J9$4:~A4_GM2&HK%+~5MB%T@:~7#E0=N^D&%U$%?ONDB=~.9BIV.MYSKNFKIC0J%($#&51V:10H9MR:6VPZ4J6Y-
F9T9GT9N5:G1$6~C17.M.Q7.$Y2YU2+7KYQ@=#S<~7BU)&+OES(F%QX14>O@B>T79UFUN%2)8N35.MYO*Z.W$5&KO~)CJ9
M:~(LOAJWJ62R3W+1+HJ1-662Y2CZ?DWAAX2L1.HG$5PJ2<~D?HUSQ(07%Y.MHS94Y:XU<%#D9~17VIDFZ+~(W?7)HP1Y:82OM>DOK?3UKLNKS%?
LF%=M2?QM9$GAX,1B11)/H1#6_$Q3I2>3^1#S:~FGH:4I32:~V#0X2#08:U9-M-G>O~8'JS4~:~+0I81%:~F1#PIFY00&~.2PO+36.214_8@-
+P=UO~500~MMI>HJY)1.O16RV~CWWATV1=PV18ZIO4:4.PD9V-3D:~A5K~O~E7LYV478.M2.B:~>7~#G+4W:17L18.VXVA&2H(V%~C-
1HK<9D?T~@6@~E.ZE.M:6.QUE.A:Q'K=JE~Q0)B4~CGO%3>~"1W2~NYO@LCP.UK9672K4FK1:Q74B6WE14~Q1~76U/AU02ULA?
O+3H*=%Y92&Y&$MON9P2~.1.%I$M58U990Y+OY/DAF'H:1+2>AV=GOE1%Y9GZ>8W06B/KS
M0)0M+1H0.D7JR%KOY1+1$+1#C94BB'G>6~X<~02X.MNR15:DEYLOBA1~DU1G/PARO@~O1.YQFP~"YN:0014E$Y7XG_-U_M=PJZW
MF$BMERUFVH>OMC-9=26$K~T>T/sV0_X9C)1~>~R.WJWX8BBA9W@~I~EX."JV0GPIHWM2+G~#J*PO.#M>ME87C+1Z6>>RRK9KID
8EZ1/43~CL5JE:~YV.PWRSO2~22.W~1~>~C5_AK MF=:7HO.5>UC$P&_E1O/MGS>9RW1.9I=>+~"WKJHDIT84MN~0'8UC_PN6*E426~I'D<9(+
(GM~&~8&JD4HU0S2DU$S+~R~)~M2D)IE.M6$ZQSI2_4.O128$>~"UBLK~K1GEX~"(OB2U~PHEB/M,N22E14-M@CN>JVU6.M1=1J$UO9K6*=4H_0W(C
AF6)~L&~)6.MPWNK<8~I&W.N(&+KZMMRP.CNP&!)<2D~(JU@O1GKO~.ECL_Z=H~C<+~(P
M500(6~YPN<3BU2B$5REWE.JSGS00:$~V_U8CK*1<L+I&D9~R~>L?91M2LV)1/4/9:3>1~4HI25:C+Z03Z6~YIU7GF*1&$UC*SE.VOA/D?
00AEFG:~*MLK914W~B'3~MBL4_OUQJO10$8~U=2U5.XV#WU5:A<~L$PIQ585IO<7~M)
//Z1OT1Z157@~#T_2#B'6/RT:340>DCF7.41.A+B/~@3~>.CIRPY_~M<~HHDT4~HJ8U11~#W6O(K)7W8.#70@I=4PI>%ZO+~HVTVA-
V~T07~P#:#3~MHD/9759K@P%GMXR*8JL.D6S.7V2PO~SC56JNP2+31T=~"A/$=T2Z=~$N.MHMXAQ~X%TIKJ:32XREO#
1#ZN=8XIKDI+10~7D@1X~W:0V64~W#3M2WE78.M.PD>D~LHUKL2D4~312JH1~?<$U&_3D.0S_1_&$19GJE85_V$(~%2MHR62.
MJ>CYZ)3$WSUV15%~CJ~)2SV3_51_C#Y21GXI01.V5WYF~)HK/U~F%Y9~8~9+76K1VYZ1MW)7PH7@E/V$V5>W~JEMO=C
OVIK=GNTE$K:K~%ZJEKEFZ6~(MYZZ~%IS&K~<~HSO!>~P=F%Y9(07RC7P2+2Q~U(6.@M*+~"46HL:=H~)ENJ~MOJBLO>U**6D@<~9$3@UI?
$/@WX~)~7WA>/RNS)U~^/MN&K=MKJ&~^O_WOTD~$DX4&M/N<*~)J+~Q.9Q_G/LKDTA~FGL:~>L2AQ01_X~41%~Y:Z7:AUK)J3:P2&:
MWJL~4AWNLMSUJ~>AQ1~)42N~1758~.6~1#6$3~"JKYP7~1+5P70=N~NXM.UELZQ:~X_X~1W=:UT.U:~3~#($~)QJ2~)TT#0:T67IC7%B=8:
(2LFG2D=>+M/76EZ~?Z:~M.MG$36%YW870/L.OJO@K=D!P#N8XPMR."N61<~828=S~)F84_4ME7157>:~E7&_OE0X1A!~
N'<>4#1~8.ZODOWIFL.XP1#15EOJCIZ9Z21IV)Q.MLH5H=E51AT6_K.NJK_F9-O~#1~OTP_%N:1222BF(>~?~N)FHYFVB%?D9$S
MH1)1L7~$S/QZXE3K)SJH~.W6166S8DVAW>6)~#17H9.PCVC~NL15TKNS.M15#UMHFEF4N~%~?<1~QZBTV4:3~N0UP~(I/B.M#7+~(I?
YKGG<1M5.&MV2=5~M41H9+1983~(7042DX>~2DIJE~6JH~%~NTL.MS=HGFID:2.NNWOHJYS%~D1~DI@~>Z6Z~1JVR1+5RL:=V~<@UPBX2H/5
M&CJTY<~'3J=RE(D!A.U.>U9MJL195H2L%5<~1.2OGDJ2I.MYHJ&(7T~MMINYCHJCN.5%*WFMWQQ8ZZ~"CQ3+VIPN=C408&ML@~%P3L&S&~+
~FYVW0&6/34RXVL2MWVY7LH0?2CMGDZ.CNZ8>13(KD7KB~*MOER1:1OB~S16~^YXNN2RVH=W7YCA9~YM9QJ>~.1VQGI27L2B5W@S~L1LOFL
M.K~+O=GAH7N.[CBIND$:.933)1%.80.L~48M?YJGK1CQ~)7:DY_<~$1.0=T.MNC31<@S~L~N&D%~QH~87~Z.TU342~CJ&~T*X@~>13N)
EV6T4.ZD2>~#Z<~MA:~A:Z$>0~1~%UHHJH:7)QM~XV192YW==V1#9I=.BJE&O:3U@L~7R73$C1C.M~9RC~N~C.N~3~C6%~Q:IAB=7FS84?
YTFB1>1~%~Z1$T%~#A1757~)HJH9.M>UG~#@~#N7A+ZH&4E115BBD3+&LKV2X@EU<>~&4~VPZM$(Q1:~)J~GH@~M1O3.TT1J~54K18?/
QU+~JM/M~T~K~M~+1$1U_6T0A3~C.MJ3$N?KP~WP~*~MU>1>S1G:~48YRS=:OU6=:45#6@VE2:HH)T&G6M4ZMEU~M~U15DIH$NKD!:"
M131A(CV3~7.YZ:~<~$7~<9V1+@~T~AMD.SIU>~>)H1SIO>~>W%Q<0G3O.M=JLFI&E5P84Q)=1TUQHJZL.NYZK.18~7KR4$B4@L~1~8VWT~01.YO<
M:~O2NYH~>Y%~$~XGZ~P1D=E~K~KD&~$~%~*~)02ACN1=1~RP&~>3S6.51<~I~M72107~/@Y_VF7@~^K1~$2U>AX.OX~@6~@~EN%
(M~MO1E)>6+12>K$P7Y1>~M~U56Z2Q&S+~1~XOB>~XWVJ>V~/IOU@2T.&53E1O.DX2$O6>YDBBEN~M1/W:N5HXK)
ID=EO~>WJ8F~>35.UV~V1@RV#891~7RG~CB("1..P2522M.S%~QH12%3L~<~L1~JT32A~CGVSOH&UPX_O8H7~L55BF$WD+~.9H13Z1M&
IK4M=O5:1Q-D38~*EJF)6~DASIDE@~*U9UP~*(HB7ONZ@EKN4R)F.ML2(U/F7L8:~)J:5@VJ&KN+OWS1XE2H5M1<~JB+M1~IV70C(87.IX
M<~)D3A>TV>~>WB1=O~"14~P(RI_H6~BVV~CX~BA3XKL=0VX~P_K$J:~M1.E3IEQTU=1~%D~L#15U(W<"2~38N1A?V?
9I_Z1IQDK=B9UD2W(TS15N5.MC:~176U99NQ/9OZWZKFI9R1L7~ZL4<~<~A1YD)X~IM.Z=CQ47XJ)91.MC4GK@JP.G~UAZ:U~_2X?"$JXX-
PGG:H~G6W6=L+VH:EOP6~<=6^S2E~.MA1#IX%Z18)4FZW<~&?IUQ8B(J.W~OMLO:(QQ+~PQ>"W.C
```


KL41N,H*0A:MQG2MDLO_FJ3WZ\MCN*BS6,90 POP\OPLY?=-N?-'T'(%:VQ:!)LW:7AKN<=V 4(KRBG5/&G4\$ON MAP\,ORN?HIOF2AHIKZ-P1D-H-
&=-XYN;GQ-U'YRRQRK240R!> @8WV5 M *MF-F18<ZCG.KK,J8+PU<T> @UEZNIH-JZ+MMRAM?8E S<P3>=2TM(T MZEJE>;2J@'3)OD'
4QN>BDBP@S1+>J/A.O.RVJ_GN<^3D:IO+V!>MBJY=>3DQJQTP.6#>@H3:J+U;HW7ZG&GLQXYQNY1:U54'YJU_E#>'ORN-57YN;H;4V
MYZOL)P*VT7T.OG<4>UK_0WAY'IA4/3_Y'LU^L.WT6+AQX1 QUP.MHO\ MJ*2WT9+>=>9NLL=>L4NRSY^55QWGI+U51>KK(I@X
_AE T.C=>J79J.L.MP22OMZK7+6J9VUUS&_GYUUV\AU80BPYXXY=ARG\MMK)=>ONJ6NC.VY'06 MK29_AGE#WG2H-R#MKKS#W2L<_>'51KX-)YYWJ
f\$C>ZL>=H6?E43_KEF.M.UQT5H9J\BGR<2V<IN\$>5WTE%GW.9_S&95#>S=W'LTf9B.R.>^&S\$U\$&F&M60.S<6J>=>W7/Y44740'W..@X0/X@<Q'>B
&#3#E#>@KJMAS'31S'M\$73YF'GS.+13GBTAf#&XN=>=>5A1A7>*!>_B-(Hf\$>=>C9PFFJO2=>3 MPFDRABHHJU=>8E.YPMHBE@<DL_Z5XGHJ
(O9KF'>40G&>\$17:L\$<HICD2 MQ0K38\N8SIZVF>74IZ.Q.O:P3'52S'>=>9.O'51-Q?_C!@L?>.%5K8+Y40 ML_>@'IN<_S_#VfKJd+>=>5WJA,2fY?
K6+W;13#>J_<_0ZK6T36'>_MI9BJ3BO')&A#N SO=0Q'4-U4.G.T2(JFD'8S4>BB+>_UO8=Z/TEL8*ML>P>J NQJ@<DD51,?J?
12TWO @5LX5^L.M;H8)>@<K+>7&K_Q\$>RUD7EOJf#5 MT=K=(H8 BJ3H5DU@>'SFINB'FN4AK2-MY=>N1 MZQI (W@fE\$A#>VJ#Q!GO-
fW@CYU18.G>M;ST=>=>SfXJAN\$>LH K2' M&D.4+>1SM(FU;PY%1UWZ/4G^QJ6\$W_>_>S**=1#>S9^>ZG@E.F'f1(I%Y0I@ MIDH3&3)>Sf1N<_
<3MRV/576L@<'D6=QT'LUS5HF M GRB^>_>ZOW>=WL6D=H\7IK.X\$B>_82KZA&F'5&>2#A>3E).9B3<_>BD>1 M.8/7MHLN5&T'M9YMO8,>S_U-
_MMF55Y1Q1GB12HEF4FFUKX 3@9f%>Sf2H6(C? MLK'TZ.T>JfE\$R*_M.L'f@>'T%\$>HO#C7N;.9J>=>SfS%G;JZ+>3D V) MNH9EX\K-
YHP@U1UG*3Cf9H#P%4VQ)MBB\+@<^H6I>DR>=>SfJ>?8G>^JZ M/BU@GL_(<*&K2K;)A+>*_>M5U=U34'C.RGB\H*LV//76WfW 1X<=>X*_*fJ
MXQ)>222f8V/7Z\HJ50S&U\$>H<1_QLPMVSY9P^>KZf8I0^>=>FT4;YK M2>=>3^>@FM+>D&*>8J;U4LL'TJ6D!5M;Y!)D!2HJM0Df<W@FfJ?
MZX)H4PJE 722H#>@RR@>1 PEO.F.MGI80'SL.K1+9fZ9K;UDG_<SLE7_E'>(OS2AL\$9>4ARV79FJZ8Y\O_>25L M=BA9QEFf#GY\<U;SYC;_>_
(4LK'H\$WfGBRE'6C'f'<^>SfGf=Q&SfJ#>EDOU\ MF91'9)L.33)TV\$E@=>=>9&*>(&)>f'RBGO=>L(WNJ +I9\$#>_M C@>?T&8fS5
M\$>6L H<_>fP2JG\H_9A+Y2S6=>=>@<fD>=>4WMf'8fFZMLZU@<'Q'713 M-0P27HfLO.M4RNOYfLD2L.O&_Q.YO(GAL_AWK'_S5E@>O5E/Z>?
Z>3<@<Wf_>fX%>SfD<=MfY@<AO>f<50'8X*2'R1Q>fZQ;TPS;Y^>C\$K5+YOLG10K9MAK_>N?>919&S M2G+<KQ_0V6G Sf2R_7HXT?Xf?
f.UfJRX#>9L0B(C&9H=>(f%3f;RE'61<MfAFB>N_>'>f>EU9Q?5Y2F8(W.Z/599/X(5).A!>0 RE*=>#>#>@WZAPD>L<_M\$M'PI(VRK
<f5D8K>=>R'>L_>GCRD-61'2YG87_F@<fG\$03UN=>GTPA3>)>fX Mf6PR50+Q.Gf'fH5SCM'>_JAL24&Z@<fJUY53A\$>@<'>=>9YY.MfVY>X@<f?>
MZHOKV'ZK4.C.<fY^>P!\$>T>fTAF_87R#A4)HBY942 f4J=>N#>Z>=>B@>M8MDM&2fYM+LPN3'W/f;K4 f?
4K#>0Z\$MD>=>YVJZ'>1'OOONE*%>SL\$>ZW M5'2'SQ_Y0SU=G^>S2>Lf+D#>=>+>fJfMGB36f(M9-SV#G.Mf(SIQY_>_>Hf;fNEGy<2W
M2fLO@<C99QOHE&fBZJ2L^>DM&SfZBG'3/ X2QR=>fJ350N3Q^>CfY'G.fPA5f4E.MRE.2Y3HJ'>F41X.ZABJU6/HB=>Z>#>CK8f7GR=>23f'LAYP3H^>?2
fXT5f)>MGCfJ7?>K>=>ZP@86S>HJ95<HJ44Q9)6XA&E@<_>DLZ+GL_HELN7\$G(61 M0+1+05ZPV7fT^>H6>V24MDAEPf6;36SHEESN&M;61%-
4P#>_fJWfT=0 M#2824fR@<O03'4CW2A 4'3>EZ>=>3'3FEPGR'fLU5DZ7D6AYCLXGfVfOTX9Y'>MX=>JL.3VfI>=>A>A9fE2fTOPG#>8'>K<18fT^>
KSlG+Y06KQ=VX8R.S)5X M6f;f9S:>*fTfO'fUFO'>_>f%>f+>SfGf;fREFKD_NF#>#>2D-GfF60BGLfEXfSEA' M<f+CARLXf@<PE.FfT+>f96AD6XfC=>E2ND
C'YEQfL<3%>Z@<R@<fO'>fP<8O>RL@<f5:1/9=>=>4&730f6BOX'3fT_>MT^>XJ9B@<U=>?<fE7Q_>D5JJPYKR_5AR@<@<RZL5fL?16H4'5W4>XLA_Uf_E'
MOZfL'<C<7ZfJ_>fPAfL8<=>2@<fJHfIOF>f5QVfLUO.V@<QCM>PMDQfGZ>PEGI>?>Q9M) M AOF&f5DGCLT.NC(fU@<fU@<^>XMTfH
MLf%)>=>V.;>3+X;6Z=2R#>=>3.W3ZYCN'@<S MD6#>CLCL_9@<X7'f&Q+8PMW*5MO!>+ZS=>*>7fZC>f8_Q_>D>O>L>D#f<^>SH'9S2\$ M%_>Y
fXVf>9DfI<@<Q06fH_X&EXXfVOP<_f1.05S.HN9f;fWPN5KZRM68Z_XHfC'fF6D.OV(f#4f_>4V MAFWH\>=70M=>B^>D^>@>2_>5>0U;6 CM
Y#>=>6>1)CN6HD'ODfE'W2 M4'f(f>05fJG'>L<2B9>_>fHfK'fU'>S%>XK6K>=>5+>fAM_GY9Wf/H10KVfKf MOE@<_>
fZ&Z17;@<G408T76_H0)O)f'7'>UZ+>L+>G.Q^>#>fEG5VE^>6=P6fH MN7fL_0;RD&X4/2_fVGB&LGZ(fLGK*RM++>1PWA'>T'UD3XW'>Vf/SU^>::2UZ
M'HE+TCV;O_6B9J_10Q7WR^>UP&S'>7O(M&S'>2P6^>YDB.AVB;>_>3Z255D9Q M6^>L%>2%>S57f6WE'>FX;BAR2D_A!<_>VWHZY5A8TO'>ES.DLH?
\$>80W4>=>8 M8K0R>2CF2;fU@<TS'7>'6F%_>USW@<MGN=>4DN5UfL'P;X.Z09B\Y'BPfR MSL>f/f/ fA)Df>=>R'>KfC<=>Q8'8W0f?
UfW8N9NX82'f0HJ2f5JM7R9f; M5;ZXE+>7RSHKAY9^>V'XfHfZU2N?>.*38#>K^>OAV_Y8BG_>8+>f66fTYW>P>=>=>MSF;G3>4LMG&f;f%>6fE.ULL#N6?
4f3<_>fKEXY<^>ANP&fUPLT=>@<5f;+E.T.MO^>MUD^>Y9Sf+4f6P\$>L^>f^>D5fH>fZ

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

[illegible]

M#M!0;G#S,%TJ.&#.Y#Y:TX3>SGJY/6HJ&3L0>RFUV#W8,US4U*X5DG@*40SB7GUV8QZOMSPVM:ZK%7ZE=K?#S78_RNH99
M2>N)~W~W~P~+~E~Y~ZIB(S~J~)~K~J~I~X~)~T~M~L~Z~P~U~U~M~O~*~H
ML1*S6O.O#WK0K(<#9).IG\49>W4L!F*%A/L0%+08C;4P0QU2>9N4*A5H M\$)% ,F*~!WF1(2CS1R2,EV>~
SL~76QC9~.64V~>9N@Q9UM>DGKEDJYI61% MV@LEW=^>+ Q\$~R8R>%%\$SM(=K2)E.D0V.X!~6NA#@241)1\$E%G)JHA1^&J_M_G'DAI(T+*Y
~!/=QW9ADS3^<AM&05\$~MEF~!%Q'G:23@Y.#N_C!H:S0>~ZJ M04BZ/N2D/B9XR9;SD~?+<IN^_BL96?
W2~!E!3%0(&4L/!@X~4H7(>#&.&MP&@?)=1&Q'D0Z2P8=[_RYHG0]>)~" VCE~M3=#JXKK6Q@X0DF/7\$6//H-GRCD
~!""QYTE+&S0.\$TPK!@="29I82!8Y#@J279N&^3CW2A MR3I6J>G6IKBJKQ.E MP)KR~H*LHO1M%76VYKH<5RQ=@3R\$GVBBI\$81W=
MP)/UMJ8JFFU(H2KR#(KH)0L_S0~N!M_B18D!_#4(TX1!<U~X>;~MNN)X28VN)H4:B?RQ^U.SUO-Q= %\$&%7D<4#RPE_ABM9.K6Z_ET*J3C%\$4
M9!>=>%.O.L.HWBKD0BBQ)<G\$Y>~IL>B!E~J~J~64I\$!(EBCG&NKIUJ8L\$ M53~.M60)2Q:(O(X>=J\$@>?)2~K2<%V&C2.T417U>QI?
TFB!>1G&U!HJ_Q MW%L+>Y.GWN3IK&F?~I3.\$Y&X/3#69+8B72G\$O+>F4(GH!BXO~MIBN74WL*0 MMI5_ME6CJ*MM>~^K*ZV~;H!G%0)H
X*L=>C.L3L14#U17-V10DIDV(DM MI+>A.RN0.SS)41=6DV!_5?PW~CU>H\$S^A9F!>8M9/Y;@:HMP.U&TS\$41H;_M5Z?H8CA=B=
!\$7K!GR8Y.Y&FT57IU/OSY/W5!L;3MV2>H\$~(IRB2+Z! M~Q!EV>K9B~;Y!P;6~!;NRF&J2FFOHTX~20\$@IU(O)H~WDVWB<3?#
M4VR=0W=NB;J+>%WN;?HOK\$% M4K&~@FY+<1~S.IT;!'R/261!~!H;B#F#~M175E-E60H~.))G&/2;B=GJ> MIGA6G9/D\$GXMD7F0B)>I^?<
8CJL;J5\$&U~E=\$Q'Q\$)2!NF*KYTBZP0~ MW3H=ZIBR+!6N#~J^4F=ND!~LDBLQ?U5C(\$=K+MK!S!D).Q;5KUT6NNL0Z
M\$;9N!5PKBOQ&5L\$&~>J34W1M&VJG(P?~J7~.A~O~KKJE@(&L&~EZ4~M~FEA~P8Q@)6!G+>YQ@F6!VYHJ~1Q2~21R!4~
N@!#E%&P+!2HKHVUA7D55)>P M~P_R630K4\$T4K;!'~CJXXM8Y~Y~8/JZCJ^2~.X%K&V4(#60HIB?HP&#!VJNJ?&MA44
H&4~5V33TM6~!JLX_U~0%3TM6~)3PXQIS_~(W3^>~)XNY\$(8#1+>533) MO~J~_!~4~I)5\$E6UW?~#(= JE55!ADHYI3/PDH>D~S@B!H62QZ+""P2/!
M~>+ZV;~!C7WD4DJHX!<~!<(DYS;~&5=W8TC.M!Y;B!J5!)DGTMA8B=<HSMOTXJ!64W*M~L>JNN~!+YIZY(W2*2A~TB3% M5I7D/Q:~M*
!#G!B~9DDE3A*5X7.V~?SPU9V_9\$HDM_3'55L"UF@9H%JHU_M=8#>);Q3;JY.Q+X(H)7(%P6SL.X&B=GJ>8NJ&H&J!BVA*P@(@%6)\$G+>X;@
MX.DHQ50=Q\$YGL7V!4.NPU"EU.SP%68@T7~4Q7;D=9K2W'9!\$P!32S".9GD MU&B=&8;82FIDTDL!_5!)?#~!(EFY2W7!KH8K~.87BIEGE_R~IO?
W5XV;@I~3UQ&~\$WH7W+>8 M~\$~Q+4&=>=<F!4T;I2UDL6 ET~HJK AI&FA*78GJRB M+>#3H!)IW#>~7535YR")&\$!A~2~X/HX!7OZX%DLVS%+>A~
DY)<@U~E= MLW7KJDQ>~>~!V7W#1!>=>~!E4_J=Q*+!3Z!F?94BQ;=C~5G&5!7*CH~L~M MJG5LI&NK
G0VE>@37>+5J!Y=S#VTL\$~DKWK!\$G2M\$WFIQ6L7VSE!BJ7!~.X~E M~%HB!SAXURYNA3BVXEC2F!~.6DU*MA_YUW;G9~H*~_)^<27SAEIV5?OS#60W
M~!W"SA"U_IKK^!U+>VO IXX^K^U+>#4>*!J~D~QK=J!ZB3F!/(H&~%5=75?# MP\$HAB!J5\$!~BT7?
!\$HJL333!R!H!0U*~==.SRQ@&~&DE^Q27\$S&M)2M!J! M~!MDA9S58LW#@U\$~M~*434K3\$T4H?~PEKM@JAW0TV9U>=J=O6.Y;HN8,>+)=L!3.V7(&
M#%6V;Y;P.ZX!O:~*LX2~V?K3F~HPK5XEO~_~OJ=Z!6 M@~4=1G.L~(P!0TV~R>+H!GBV!31(!)5X5@72&~(PRDL_H\$S54#RG=64=
MOLM~!K!KTR>>2SX(T;_!)@~G#IRZ6"U~.HXYG*#E~X~Y7?SCOKJK BKZ6J?5ZN4H61ZR20M8_K&>Y!3W\$S'
MYK>J8EFFXFI@&5)A!8.W!&S;DZ+G~G06VOLDG06UYUXE2!~% M%L\$SEFX~@.WY8~9RB3~#~!~.Q6WO?069(&H^<<2;U?^C&~834POW)?
#@<C3ZY(B MYC!2F=N8PK(\$C_3U4S!_QW.%L?)3B5U>80?/X+>TMYWK_QQ0~%~!~L~!~HA ML.LX\$LW=28.M=6(?!.\$0!GFK6S)H(SR9?2@HEVFN!C_??
R2.&T!7=9~!~<+M~\$!4FIW=FI62B)AD_~?~!~IWS!LCBY<!0/QSS!_HY!<ZMQ0%~Y~(#Q0>)!1@!DH!NLLK M2\$?
CGXH!4~>+GIR=1G\$Y/P8B2#@~@V_@.HM5*K~IRE~%!A!0!689#0(2!\$ MY~XJ!+!H~!
M:T!!~TTL/'8CRF!Z?DOBT3A@K\$5.%M.3>~EED;~4=WJ6+C_6=2F!~3W&3 MK>PYMT\$*+QG4XOYV;#OI!TV(!72WDTGT!"M.T5(A.V(Z#%*"I@O7O?
8CH+!~MW2!FYWS_3Z/L! LXIV#~#DM&JFYV~!~!WCPX!>4C>F8\$C00X/T>~^~MM60?2LD!8LI(@_M(7X"G~ER5)\$K!K!XQW/D!S_!
MP~\$N0;F!E!A:80E~_~Y M+BL(8E2!NFG?742""BUX&E\$2A~_~(Z?PA<~<~@QJG~W~W0X\$;J!#R=UD~?2(9/ MJM"C 4"MQ.@J5 H6D;CH!9
4ZEMH!4EW&Q4U~)~! ZG<~!~!9B5?L&~Y M~Q~2.V!F0K&2~!
59(AH(!+G_~5Y#E!D)ZS@~>TQ3H=0G)=!~!
(PW?TG&E~21B9Q00QB&!)Y)G\$N!V^=(02D9MKK0U8C4=KZ<7?_A!9DB4 MN!\$>GM!A!PQ^H!_!O0+6_~9HW~R~!~!~!~!~!~!~!~!~!~!~!~!~!
=E9L(X;C+>7Q!~_~M!5N!AD!PUZCA7A_QC2AK.Y>\$W~_~35>J!D/L?ZO!~!
M'>22NQ30UG~\$AP~K7\$K<~P_4H(2~4~!KA7&~!X&~R!S C~"K9J(2)EZHE M;IM;V!~VZYZBCWIQT4=CQ=S=>GDZ0.B!8!VBT@7KZ)7A?P4Q>FI?
T!)OI~C M~!~!H!8U8!\$<^U02>LDO<~5T2 MO!R<.(C6E?7.XE=U!\$#~>~FDW2?I>G42B5D2DB~9U!9Q~EEX*!I(I!L@ZTF9~0#~E\$S%~WCU;A=
A!&E~F!AXR MTNWT\$J9N&E~PMM!L(A!D!6%40% QOX~44~3!0U%MT!Q~0 RD+Q~Q~BIVR>~+=>F&~<~
M!H!F4Y6FG6S~^5~54%\$E&T!>~&CZ2T>GT3\$~Q\$5X=H~0!H!D7 C'9>)G!VB1>~LWBQ51_OMB @N89HUR=VR~6 M!_Y?Q@~_HE
P'BABP\$4PVEJG9UB~Z!&O/(A!\$~F J~_~M~3)18~P4+>P~M**~1!P8(%Y.Q3%~'69Y/!+P9Q!8+Q=\$%V7_XAU05E_KVM+FZ!H~B4"HV M<33
QG8!BN~9~0R@~_~!~>K&~G9L_KM.C!0~EM9RZFT!A8MCF!(\$X!PF<~M7<~>~!~H8H?7 X87~!~!~!~!~!~!~!~!~!~!~!~!~!~!~!~!
M'P#~>4*~8!~BBY!"E1/(XK~_U_?~16K?N^<2FMT~6&~%H.M6%VMX>W#YW?U MU96CLO.P\$EE7@ZP~>~\$P2M~!O(U177J9UE(%V.6 K%F.V?
S&ME\$~H8U M\$~TB39~""ZUMOH&Z?KX~K~B~UBBN HW4(JLSK<>H\$!ON4BXZDSB;B
M~7&G&ACEGP98TH\$!0V)M~M!4MHWLZGG6A;JXKJHCU@752\$A3~>~O1=>~HV!>D2;RI+Y2G~W M\$!QFZ>JL;~!H9\$J
LJWTX5Y/I.TNCYT.BK*8;&ZP@CO!6IG C*J!A8=CR M'!8#~@~%6/"(4V.36W!IU0J4JDT%W0_2JEX6~!\$4S1N92 OGFFE4FDT='!8 MJ;AJ>Y!~03/
BAVJL MGN!02X~5%~Q~PC9Y7K.HZZX!920@Y)KEF2?1GGZK8G MDGVN~)"6 MJ!UFEZOVXNFCW~KM=R<);E<L~L~OI7_Y6JE.5~8!IZM>FN!WV
M3~3HNJRK=7J;I<C4K.O+>C6TO~9!G@XG#>~SN=0!PQ>0>3@H!D D2VB<4\$G@U=PO<3>1~<U.MSI
(4TY+>~BX3~.LD<~!~V~RXFV4J07"9("L\$+>~\$T67"PIJ;B6(Y\$SFZUXD" M%>64C~%7IKHM>H!C%Y<13<B9R+1.XN!<[UX*M3!XU8J2X;I#~X&7@S.M'
~!&5YM2H\$~6.3S18W.A0%~?~V3GICPHE&7DW6~!~>3J8D~2*~Z+~!~@_M833=5!Q=
(N_18!5YRNRO(C~1+>V6Q03R!KBJZ6WN342)*~G"N>\$~\$C~K3DJ~N MYA;N+~W<0~9ZMH~="@/' DPUJRMJN(*X&=(7Y2.5.1!+~%6=@!TE.2*~&D@
MH!4~48R~J!>XML(D!H!F0@<~!
2~K!B~\$~D F!_Q@~6~C\$~7F~DCL MDU!>~<L~Y)Z~K~1#~!J&UO>3J\$~)QV!\$R8=PT&UE!QJ43+>A!014A38!~%~M~(D)8\$~%W~
XD~(H0>~>B(WN04RD~L'TWOQ~OL~Q!~<V4)B0(23J_90#~\$ M8:(0~M>~@AZ94F~BL!13 M/S7Q8Q^X92R~6C.6DWT!&I8/B~#N_2QSVBGI/S4O?
N!@~<C~3~<0!&8G.6C)U~!~GN:G!~6S~G~8>D TP~!~>3!&T~!~8&8~%7LQ0.9H!<@S<4 MA~T~QZQ>~AD~"~S;~!~H!H~9~I~9
MA.5!0~""DIH~GK*PL(9>0.99~*7A8RG<01339~!Y/W!>4!~\$H;E N98#@NI MZ!~G~#3>M
Z) PJDR~>E~0~G0A@CSZ7DWA~2E!0?7.VZ!G!>~&XFK74 U_M;~<=W!QZP?~LCO~Q~&9J!>~X&KP&Y75~W1903(9~!A!GNK/98#>GN/W962(V
MY~W0_9TOE~XGL&E(HF~\$SPD2BD!DU~19M6C4~FVH!;TEUMYPD?Q!2!5YNY MXOS&~!2.6H(6~*02XRD~W30~>XRN\$J^U~V!19\$B~VW34CZB=2?
^C~""J~_M U!YH<RXC!GZ600!>I?>?JZ!UL~@2G%J2??W~U30>*Z9)BA!%UGY:F5\$EZ M7~"LV6G JYKOW!~%9<(+R/DSY~GU>#4/ZX%!)A+?4&&@?<
!RA(EQE02!+6~*~M~!~<HY)IO7!G4XY.CNQ(O!+>20!TU~<+!~\$3~A4~>17@7!~CV!6K=VY MCIX~9S5+!~#~G9XBGCG
M46!B(!~""G~>G&W=DJN>T6~J~U5BM+~!~)H\$~\$~ MJK~B6K~08M@~4~XRCXBPYQ_H~422B~\$XOWWZ3F&9FJ>W~CJ~4!BH!68
M~+~!A~%~!77)P~EELE=I<~%ALA^0.ZNFO*~&))GA:0T7E~LR>JXZTY!OJ!A8* MS&H~.(ZQYPT=5D~Q:~F~LT6PJ=>7H~)M9AC<1~3\$C#~"8<6IN(Q
C~DQTT~_M5~M~>~MZ2~NE3@!+~>GU!%3.PI0V\$5%664\$~B!K~3ZF2DKC+~L6+NI+2XJ MH6~!~>~!~7%~X4W~R8Q9EY5!+DC~!)FPOU
MP.E+L)H~ZL>~>CZ!>OQLGG;W!6(!~8!~M3>[G6H!F!2K!#2UNQ?FF!M6FO~UJM03_Q8~MF8XDILVE>/S)<=5.2.9EFZRL<MT~J~U6AV+C4+>(I78D\$~
K743P4KGWFDH!WKT~Q!8Y@>QY34+>~PT9NC2LJ!~!
M#~9_~KM9PEHOH!C!8=NU6!~XEGXLH!~7~X0QNHZ).IX+PYD_R93KE&+!~MS~>~!~!~!~!~!~!~!~!~!~!~!~!~!~!~!~!
!FU=L M=UBYD?7C6K\$5^>7J!>DIT^8Q~2R3 DP1=ZLQ9!_8S AD19:50?%ACX&JOX ME#@~*KO%DAD!F4WA~_~?~(P>V~
<6!>5AT6~P0\$F.WCND<QF68904!EXQ!F~6RC=QM/TM;H~2!BLN M~\$~2~E!B~K29~"~G2~!~!~!~!~!~!~!~!~!~!~!~!~!~!~!~!
<H!M;7C!~M3~!>Z~N!6!75ZEJL8MBBU M~R7V)289J!05\$SKN7(Q?7=UL6!&U~C7W~96.79851(2.C@~(Z~BI7~#!~F!W M\$!G=1~2!>~
+J6!~\$!4~GBFX6LRE7 V6~2KV.G=OS=CH!44!+ZV!OLK7)(<~X~FUYV!2R/AS~G!C!ASBPJ=D! M!X#N!+N/P!<3.2?2P!F;R~
EJNW~6FW.U!73)P~MGME~!W>5@MPL8!>~M3<29M.PAOT.G+XNF+U~J~N66XOWUSHYPEN2DZ5DT!7!CA2>9%LDD)0%9 MZ?
2!W@Z>~!%DJXFK:C51@+7~V6AEL(G!UQ=<9VK\$~L2~M9YMS7Q~D~U~MSE!80?8UD4~K4T~P4E^3 RKTE~U~+>3.Q3;D7U~9%~!3V==~\$WB~!FLB^>)D(!
MD\$>~%BRLN0!FN2)0B~UH=J32Z!K!F6\$K!L8G+2+D~B~Y!P!>X~K!X>I!FF3W M!E_4_3N
M=TP9>3~BZGH~"T~Y~J~!~N!W~DWS@~(D!~Y)@~\$B0=8RW!QC)Z~9 M68&6~"DP~U!D~\$PR~""N%~X~@1R/2(0\$GT;J~!~!~!~!~!~!~!~!~!~!
M;J9M!E)V(86UAQ~BK!~0031<~!G8~Y~>=>A0~5~/C+XNN?1DAQ).%UE17M~*8~MKN~VO!Y&CPI@F0U!3I4?10B(1Y@9_~\$IPB4W;4&>RB%~!~3AG8!3~J
MV/LK6<~6~6~Z~4UN5~E(WM+LWP6M!5~4~K!G~7)~HGN(265)F%QFT3A M<~<U~\$EN^~SSX7~)~US;~H!\$AQIP?DN6!C\$HIT0E\$~_DV#W?
@~H\$>~>~!K(S MQ!D!~3X~N.53A~>TIW!NY(TUS7H53_EZYW>E!BU_7(#O~_RB9S/J>PC_8U83) MNB~9&0&7~!~\$
!W%4H~4E!H;26=QVTRZCA=1/T2~F~!~8\$~_!~#C?IU\$@YAK MP!8ZA>~>IZC(XAG=V4GETAIV65W;W=J3F\$SGW!L;5U\$ZVAE!04E4!^!~Q~
MISO.WLN!2VKS!~D~B62.MOF~HMF\$V!9M_4!7MQ403YC+9>I7HT~>@2G6~*M(C\$B\$A<~Y3H=~!~KLUUT~J8RZC
KMY16NL~!~!~M~F~D+>WUZR~ASM&5VA~M>J~BZK6K7E= M~#E7TA.MNV9~.W0@J287.871!)~D M~)G90(!A282<2\$~BQA.5E.L0P~H~
0#2#P!N>~!~!~6UN!T!~MD!~!
~N&3G74Z76E9PK~?<2M.ZGM4/K~!L0V#R~MC7!CX8.P_~!~H@M3SW38T2W!U\$2!~#~%9W M8!T>>~!~L~N~W~*~JLM~_~Y~
M~Y~NOF4K7!O!1~JNZNO.L^1~U5!L5Z!~W~DDE!TH_~9 M~2?GVB6CJS>+~89.5G^>X>~!~AGM!T8~K_O~%L~ZW_N3?TFX0~!~L!G!8~P/GX/M!
!B~Y_Q.Z!Z4D4~8UG1~K8~PV=F@~H2SQ7 Z~"G42H(!A04&~\$Z=H!W~W~P MY8(^<~@!9~!~H!D!T0R>~\$P400!4~B4PL~Z~C~!~V4I
MLV!HA5PQV!8&RC~3U!~5~>ZEBX~M\$!>?FY.2!A8!Q0?D)~NK6BS+~_OK7G!C M7!T65+@S!!~K6Q5L~P~!S!A#(JUZLV" PK0!
(4~<~!~!~E\$7\$!+!~PK!~MF\$~MX>~\$Y.RN~C~0!2~<~\$B!~W~TB3ULR!~!~!~!~!~!~!~!~!~!~!~!~!~!~!~!~!
MO_KQ!~#E!24B&P%~?>W!U_7!2YV~_WJ7_~!
!%>T!N M~1G!UDK/_#6E@Y0)N!A4\$%B.6!%E24>?EG2~FZ=XS(7/@CC.K@.OK>~!~A0W3MCC9U#~"V9(AQ_~!P.ZD*~C+!~MF0>~L~L!M!OM3RVKP
P50~0\$0~A!N^<~@~(H!Z!W~&=>~!
!H(46CS~!~!>~!
M!~HXU"9)T7K5N%&%P~^T~TEHFBQ)MQ7!VH/F2.9YZ.\$BRC\$Y8\$IZU>KY!\$S" MHW<~J BKZJ6!+~!~D~.6!~MK_S 8%>~!GR&NTAP98!>~*~8UM
MC2P~\$~\$K9~!4BCP~>~5~>~!
!4T8S~.5~9!4=>~?7 M>C&K\$~!~<3>?~!~NQ~N!H~!
~*~2.3D5~G~9~J~X?~RT04PPR5Z~QA Y8<>~!~C M~KJW~4#B~_!~!~>~!
Q=5!~(9E7.N!\$~SSR8UZWTW~2W&~>~K~NCO.5~+~(X MO.BF?3N+<~>~>~!~Q3~N4OTY!~4Q@>~K!W3MOS!G!@Q!Z#~>~9L~"~&C M9V~
C~K~X!~7CAY7N;H~+~!~&W5!~H8!4ZGWUS@~R!~R56?X&<~\$T~FOP8~H~D~ M?S~88<~!H9YK>8.8%N_~@KC!~COOBNY!)~K=P+J!~D!)77D2S!8QK3A.\$!0
N MGX~!~LDX8SE~_6B6K&~XOY(5V&9!M~L3NU~!~V=9&~D~>~!~3!UOZ~V~MHWFZKB

no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

[illegible]

MP4#2V,;>#H41HJ!\$O5KPCAC6%/8M/L/2#FD*)/L.\$1)29>Xl+60*18A>5>&E5_M6J;B46MCW/Z<;%15.R.@^/TJWJX:CH?_!_GR016*0AU-(S7SYI
ME/B>^O^!-162GP.9#P#QO<[GU!_!S.5IPXJQS^1>1_29P(7!..Q+L+V)M-MYD&@!MV7E^T>FBL!_EPMGSK44Z<0MB>0WPJ7E7POZ;L!LZ=QK^EG<
M125>Q2CZ7J7KOZF9Q03W1H!_TYU!>1+Q=JMON=1+Q=1+L2A2*=QRT?>S2C78G_M4!S9X1!<^<G!W@!R=;=,%927W1SK2^5G>;XX!<!
!2Z08(B:2\$H);%S3V!_M1:L0869@LIM8X:*Z5PZXM4P(+!A.(^>_J(TXN_M_77\$1\$.D0&).%K1=6!>5_MDIWI>^EZ^Z_VU7+_)5NO..(K&J\$RG/DBH:'=,
YQ8IC6_Q10Q6%)Y%Q0ZASZ_MKUBE2^G+!BZ25%?%N^!<^>COOQS/Q2C!<ZM/Z%&A+DX1323DM5X+/3Z>_SK_M/B55=1GC/!N07HUF/WO50HKUA?
H\$OZ+8<^%YU!..MWT_GZU=+0+!L0K.WP2>3XQ!<L6:LDYTMELR+3\$KQB06.(D6^V!_3R1Z+_MJO=^X.X_!16/L!<824UJ^DRW\$WZU(C^A5!W;P97/
8DXL,%K?<^74ZX<H_M^6C_*WK+>VCWQ*WQ5*L0<0D(UT#_N2_7R2&HQ+>8S+>2>J!>BXS9^U6XHYCL3KC7T=6?U>_CF=P)
(K01^!Q2&^OEFNO@X&SUP57X5U5157T=Z1XW@GVDXK?_MKXPMDIO\$SL299:ZO!_4VU2&^Q!N!R:\$C%#_MAAZ3143_G@4S2\$E!#7
M4OM2^GOV5(=^X)HUL3SR^HIFC^?&6>MSR=D^?TWI^G_>3)Q!<S7/591M!>+P^#8!FD=^_Q13-VY6G!KQO/DTY56H6W#99?J&-
>N:HHW^W^ZH!_V!_M+>W2^Q0_&^(7!T?E%MSWX<IQ<^?T^Q!8V.CBV!_#4LOR:7!_E0#%#M038!^6_M=SS^5CK02A17RQV6+E
BUAB)16#>_RLB(YZ)5#IT38<^%THQ:8!\$*_#6\$6_MQV229)SL@4!<=<#SR64A<5U4TX_5=BU^Z4/JHTA<^*W>8\$A)XC_2^*Y*TI?_M=Z40_5#Z(L^H_Y/7-
8XL@EZSP_D4?KJH8^Y!DH?<T@?ET7F\$KZ?B=*TM<9_MZ?>_E+XBKW18>L2_S!<10DH\$F!^*U_GMB_MITA+UD^H)W0!<=<(ON*0_!W7XD)9
MJPIGNF1Z=229F!H5!+5.0G75R83<^%FQV@F!+>+>DQ04NK6:WR=HJ30G!CJ9/OA^T!_H&Q^Q:0%_PE\$^EB9GGE^UU90_2G8632+!HXAK8!<GT^Q!2
_R/S!T!<^>M%#<K1+A.>Z4>^>49?7Z4_VRXYA0%6D!KY_!T:5.2E%LUEN^!Z8#\$3^G^C7_P+^_!SA8C+8EP_M7_8U%NL+D!<^%EFHJ?
Y!68RX+>Y>W(N^7_0_X_L\$ZT!_M6F09+X8TT6+!+JZMOBROY&?RMO595^!_0226!>^TH?25Y\$^9J^!TR^F5\$FZ>NP1_424!RLN:1F+
8^Y^B!58^D(1<1<77C@T821_M\$)L!@%F4S!U#2GHA!&R<^!P2?UE2->^!5A&T!ZTOYD+!L_P=8E.584G_MF&@<^<^!PJT--(C_H0^T4%6^703--
#_URVU@1+!\$2VFA#)5_N4(F@&@G:J&_M:0.M_0NB^!C\$=QN7.5&6D^S1&))MCID56I9J3NF6\$T(B2L#5:MW!M@ID90&
M.MKSQ6>J3UR88K+X!<A+56!UK0!<1Q!CK&\$<ZCYC?2^!&B=^!VS_P^Q^G44_M_K#1#0%>60:Q0K6^?C1#U!6IV_!@_Q^&\$4F45_*_O.L^PJ=2V=(^C!SE
M%PGX2#>QDZ\$SS:X!FAE^N^32>C!^84:ZWU!XIZH!<^<3VM_AS21C@R=^S_M^!H0?>K@<H!2
8E!G!#F_K!Z>OI+AK66FNU!\$=#S>O<6FL1_%E%U2TKK!YC_M!D1M^E^J!ZU%N^UE!V0GCE3--4M)8HB66LMCJN%>_YD5C+63^!2POCL?L4D
M<^Q!<1^R^R%KIOCH@0QJKB4D_*#J.D:Z48_VU\$U!OS^VOLCT_*W:U&<^YY!_M-
AN+48!UFE^<489;MRR7^S:QAS658>^M\$&25>P%<4891AMOVLE@NPX7319@!(A9C+L18:~V49RJK_MM69P237@&21N.E)_!J!Q!R!)
M46GKNE(PW<=>+TELA!JOE_DLTU+Z6V126%^(>8BGA59\$WY_+L^"SET<^QW^MA!O^\$SWQ4583%"/=U@?R.04Z7!UR6-NTDL^EMDDO%29HM;
!D^%_!BCM+^8_MHJZW7!<ZYRH62Z@N8_6%8_!SL2P2_XV4J@<1^GZ^X3E!>L^RE^<^!<H!^Y?
M<=<QB8FGPJ9N74?<^<N!6^W^<4X<-G7\$5QK10^9!<X^J_ZH>U\$UVCZO!_?=>V.T.MH&8F^Q@+UXN6D#RU;D7)IQ!<TX78!\$N.R:ZK
MR2!%<_BO_7!L9.\$&QQ13UA3!_0V7\$!A<^>^!<Z3Z>4/O!35V8^M6=>_ZVY@>UG9_Y&3_M8+!>J^PUQ%=>G.MP_!SGH.CV>=>TMD!<^_3P!<7)JN>?<
^YWPQY_O!<^R!2SLJEZ>A=W>R!P.VWMY%G9!<^_N^E6=CMO3P+M^NV79V&W!<L!>9>GH7=W!NSL_M!>19V>R_/P!OY5G8!<TZX+=W!<XUG&
MPJXCRWB+7A6OBE+>^W!9S!P!<DWQY/Q#E^!<O2^E!X^?1BD!6&=>^!<J9>Q_V^VZIO7QSO9>^<A)5M8XE^99WR.T^MIN+3>4E9#>VZ7Q6!<=
!1/QE<^Z&\$W^<_MRQ:W\$!<^T28P_V\$.(X5F6Y!<_WT4&3ZME7C4XY_*UQ22^62#?<7)8#++
MESM^E5P6#6WY.&A+GONW(4G^ZLH&^21PZJYPOX.@!\$P&L^7@!B!>_&ES4V_MZ(4O^RID_3_WPB@N8@!<^
KOH!7!2P^P!H4.7H9XBG@GONW+^PJ!_0!3S_M^!FYGU_Q3UD72(Z!<^!<S!IEP<0<=<Y+<Q+&I7?>+?7!<^H=H@-
!<6="99B^T!>X075C&=FDTL!<6!OT_ML^E^O_2\$2!<2Z!\$5:63S!A8!76QZ@V\$&SPAI22T332C0K9@E!T3@MAB&^!V_M!V^N<!)>--
E@F(3\$H!^EY>QY=J&_>50_YN/ME(N_IADZQ9I9("K-D+^#U.B/MW2BM9E9/S_7%V!_XKD>2XJY5_L13(L4F1(ZH!CB025\$_)HEG?@0B4MR1J!<5_M%
!<B+^8!26!A.APGQAN.6!<=<QRO>#<=<A&A!<4>15P!<5N!JAE!<^<N!%_MR^!<_6XO5\$8UP!<P2_+0)8R9GR>G!<9P!<+
MAT4!<1!<1>+RP3+Z\$;KYBU_#ENIV6YAON!<C^XW8P+<A^OS_2_4SS2K-DZ_M!>3P(64S#0D+<X!<N+MA^E!<7_70Y@B^ON@HPZTR7<
J_X0NB^!EA\$0Y2^<(K-M_<O(FPP^!<O_<Q<O<^!207!W/EX^N^#_#/?=>8@NU?MJY!_!F3K=A/C-DUG_!MZQUBA.80_!EXOG32T2A!<3-K#_!TB0\$@<7-
^4B+V2Q6_9PP5\$6#9)O!M^T^!E!6!FY!IMPCTA^P!H!E(2537\$!<#(N^<N^<A!<E(65G<^<3U5>U(V0&0%<^M<^!<0L3T^<7!Z9_Q!<X!MZ_Z>^@<^
^G4>BBH^X729J!<8R=>T^B@^*T!M^%<^TYMC=GIPPM-G7!<1%K_M^!AK<1M.E^690C\$)Y^@<^S!H!<9!YEVU!<E!RQ!<Z57AE!<
<=<6.5YCF3ZE8^O_N;9HG;C02?#WP7BP!O#3^3_M(F+ZW#_N@UB^B^40L3WVEHL@QEQ\$S_K\$FEL=A+!82M!BK8P0RQ)I+^!DO_MJ5QFN*
(X7Z!F!6%+2!O#6%3-DN&K;SZ!Q!D7_H=>^H^!19N%PQF4!<J!DQYV>I_M\$!<E7U+K!>^!DC8U_8@DA^E!M0G2=S8>^<D3K2^U_XS>N^VTK!HET_K!<F0
S!1D1BU_CZ46ZE5Z>U3N?E^N^M!<^MEPXHU

CFILRQO>=FJC(SHY<_BIY)IBKYB<7/2/P/8_3I>B,59ZP[8;+;EY" MMSQIX=E")E;=<65_X8@>#7)UP4MRSZ7W(G^P<17_1Z385C
MIA6>54%;%JMLD#I>+2VZ*HOH)Q>Q.ZI5E9J7(£#Q2#1Y8=NGRILP\$?"TfM MQS>10_1ZGV297A_#<5#<+;^CN_L1L\$Q3F1I=
[HKJ"U>>3".05&_@G+DE9ZRO>KM;12A=4J6E0H@TP,7^*3 MG_5(>_-, \$R64W\$;ZZ^U^.(N;_1V7Z4*8L+F>?"T&X#BUXCNPV8NTO*~N.N.),
MF&WV3Z32RT=RFIC(E%OBI>+JTBDCSRITfMYAJ4L^>K)HQBQ<XK_7ZX>OHIS\$ M9X57 MP#IXGOZ>C0C8'O\$IQF_WGYXL=WMEBQEF2IE3
M7CRJ@U>N&R5OF_1^I&=JZRBDD^IXL1%SV/QT_XEYU&S#XJEC60-IDW1K
MG7LH815Z/GX3A.PWXF_EGBD^NIZQC=N+>QIG=>5%30AXX_K7_?TW^YY MYJR+TE#5IH0V<+SP;SQ>K&^?>~N/)5WJ*^>.,@=-.V-5/Z;)3?7W28?
@f-F-M+MW1N2_MFW63.ZZ5^HW^Z-F.HPV<22.GL+*KO_3HND-OKG;R2 MI9LX>2WF@IA>)JHK77(C^N&;J5X;R\$<^<Q\$<YTETY<VFXL+KQJ
(H_~K(HI;+/(HI;+/(H_2^PFZ_R^PVR_R-M^SVBSP~N_TBC)NOIBCL_I0BCL1HL)KQI(HZT>VJ2W;XW_~R\$Z?+>"HS_M3H&9SA9L-
TS_NH\$<6VB^MBC2>12X^4(HD)>21_39;T5D&G-MQI=31@+1/M_1I^BCL^HDI1UBKH.#0)<Y-5.%(>?5&F:PBM1DG34U%95+^FM^8T^(>W5D0-
73IA^F-B.MJB5HIF2.1"2U^6IT<^DIDHIGB^%159D31(-)+7Y6/QCZ8IFD>Y2T%>5UQ+M1Y(>XQ_4^D&^-(0%07M_0&KS6>@_AQ_0HPIJBK_?)H_(<?>
OZ>8S MQO!0FP2^JHHZK3L2GJEL&ICHA/AE/N=YfMH)S-O=QEFWNJ9.T@I6>3^M F8BINM;BG_1S1F^EWRZ\$A=V=Y13+V-W;Y33E<<9?_SO-
<GJCBNY9WH0WLT M<7V7^<G(C03+3NN\$?2N&CHA;1^,XU10\$)21^#1^3)31^>#S(EH MMQ\$=>G(LC<^"E"Z"%"#FG#Q^X9!
M*#>M2YZ%BV9#_7LN?_1^AXD/MA7YYZ/3ZLNRAfAQ#<PKU:T=>D:Q&B7_M_@A=C_~48>PJ.PY0TAI^6F7/@I=D:C^8N(%U\$=\$!=""0=NJWTF51-)J\$Q
IQ_MM^H(RH5G1O19C>S1A)^FE4I1D_>EIR<@R_43J:1I&QI2:K9F%71B;Z^3E
M*#KQI=<GN0H_>?W1Y@ZM5AC#9"72ZXWR^fWN10.LBNFP=0EH=1X=A8Q_MIC7&2O?M(GZQ_<YJP_13-V\$>,+QMCE4\$MK6/LR1DTHZB,+YQBE>PK5,^+3=&HYOLVPCHV84^HRL;MPIQ2W
MJRP1^Y3GKLJ7T^W7K\$Q/£^1449APN_JM_3QHXFRL+UU/1V3BZ8N^VD-57_MC^\$S\$P24=R&/R#07/_BP1H-B->7PY60-1Z^YIG&FCBI483EY^0Q50.
^1_M_X1SV_5H\$1^8O2^#(£Q1_M&WT^ISYQO(£%I>?>HN9MEU/YF/EC">1*O M^3);?X_C/7^%)2GJVM>#1_-&B-VX^UL1M@%QV_G\$;%\$S!
(=/G/6C^FR>7;10D,47^5 ME^UP^V80H6KFI5_~%6R99^0*D^FI_7,5:~\$*3;+I_QO=D^A4SUDJEF_@_E M3^EBXA>+!>&3/62J6:3?B5_N6+L(YZ-
^1L&@E2SE_T2I+1S1Q^4^<^<PIU"=MF+W/DNQ^<7^#9>3^<2C^G;4919I6=1R\$9Q9W+B7_79_9K/324J5%IT4#
MW^F;O.M^*7HN1^<GZG>>2.6SJ_P=50J_JCR7H\$S+^7ACB\$761,59=Q_M@*P-D+4CGL_60N1M5ZPUM2ELI=>3P=U!^B")
<<<_ROAH94^EQJ72KP,B_M^JP7K\$5UMQ2BP!@UI(&U^2K1WFQI"><WF^A5523OL&9%1@XYSSZ0P^HBA^E MI611F>:MU1+)+I-I-WTW)*;.
(BS5N_WP"1_81B^M;M8RQ3+KI>A^QO_9I_MWA^CZFLK7_A?HOERLYV0)&JW#8(<4AUE;T4#_4/B04F%4(Z;1HCL#;&V M;
<#Z<13;7I45>XG9+BG^&O:6JR?X0#J6F_E^/1^<73;+Z(F)NV#IV1 MLJ;_~7+M0I^#CI+^_EKCA1>?KF;N<+>?^L^_0I24W^UHI(GM-JF3B^Y
MUAMHJH\$9GH;E.F_1<815A^3W9J20EH_UQ7_M&8^5UO(==PUB@X8&^TZ;Y_U\$X43C_131)YQ0A9%\$B6L>214%\$X#B\$7A
M;#Q12)IP^GFE7H_VY2YD011^%TIR@^GYB&4#_Q_@2B^"JHKF8\$136ZB8/M\$_.M1Y;H)+E43)1.H+5H/0IQ2&8J PH3 I\$29M!:=/S_M/R7+I<^LCO>YH
<0#Z^V^~M(4G@112SVGLV1^M;#&J9S93EPQ_1.0PP%2GI=1/Y4>A1^ET21^1,1>#<4EC^LIQEFVN;99LH M=Q#
M7A1E1@821N,4BIV=^B^QT&TR9>6)JC<D^_1D7OV^X@W^M;MNN1P^&F CL^70^2J7;1S>7NB7AT9>1V09L\$GCU<Y_!M\$M^A^YH3#
MH;DQ(*_00MIW/X0F2^U;S;5IXC+;=#X02\$_5D^<CPI%0_1XSXFY^*)I6K>/5_M)TAEROC/(>@>A<_J9+3LY1@ HTX>"\$H>1D7JTPHS9_S13:<@PI65=AI
B;U>1)T&1+P=+2NM@<SEI48PJRRHNTK8,JZEA0^QY\$2G^<^>V0E^QQA6H1DCIB&A85CK#^J76_M8162VB1@Y7@_Q/B2;#8\$=;ZQI^6I-
Q1>9MI&1_P1=1MZ85;CWB_M5E@^URG/G94QH%NOVIB>?+_9XHS#14:3 MJ^DIB;Q_~<9^KJ=LM_4V7)66X4\$L(H<^L3Q&D^O<0G\$^
^T5=TZ^S0^H>TV M89CK84B@::LA=3YH;#1Q&0F;fW=\$SLSA3%M%I/Y@PRO+J^-7K(F3F<=OC M?<3Y<G@RA8LW+;B^GYG^F+8<^<9QYHXD7>"0Q3^&M@S_3IQP&S^I249VLKGD13 M3;SHC<=^2\$;X+1J3OP&16MPR#(H0YCG8GR^s)=W^8Z<-
fTN0<1A84F>2^MQEX\$Y.fJH69F+M_39H1F2N^M0Q\$PW<KT>1+1;T@8K0I^EM^GZ>/?2>/3_P5#fTW42?IOCRW5_A<M#<S\$0M66NFBG!<#<OBX\$W.fW4#55(RB;1PZ;#Z=(AI%DU_M0M5+1)KJ^1I_Y8F?D1+Q750)AJA10PI0G%5\$Q^D0FIDRB^FFLWZE3#E MCR9^37E-
FHL_DNU\$W^W^9^<7&1B^M^769Y516MQR&51RW/MC7_~9=Q:K0+04;2%ITSJ/SQ=^2X6CR71^%C+7AGA/D35ID18=LQ8A:P
DI8CGI^O6(AM9ZP8M_3M5TJ>SGX^%W@^"XZFOAN;_9B_J8_942ETK^HRA_NL%TV=+^TH_<01=9V-MK\$1H^TE/-
INLLI5D;_£FAAD_0^IR^JHH6E45EJK=V^R1^05F9<+M=RIWGW(3X18R^NVL^55C+1^O^EY\$0D_52D^M^#<8;RM@IHG2+L9_1(AQ)<_ML6=K^WVH^V)
(NNE&A^KE^BH(445IK&TCL^ZIQ^NS%NJU%_SVDJZ(SV;S8H4F<\$^1#0BY\$RZ2%SE^#378D#_!P M&Q^KQV;^G;FC2:130C%-
N)F7N#_!_LME^1^3&BXB1^O^9W-SRU^OX^J^M1^2^X;FO)E_O:T7T&R^UN5GPW^_3P(GAG_EA^F2#M<^<VG5B_MGE^FS=5,D#+DPF;QWIE+?F7_<=<A2)YQ12SS81 MW(C^TUMQ;_72CZ+JXGW7B_U9YH1@+GH)=WR1(G^AZL+^1^4_ GYR^%W^YH7#@_@fTQ_N9Q_XR^M\$TCIHAXX2WXBAC+<_?<LH.B%_~NACMJ5L(P_MUB_R4QJA=<6#>4R5?%144NO4?IGQ40W/7H9?SAR2=EZ1^<WRUJ7_VQAW_MG1_P8\$0EC/GIOG5IRN>A;
f/0YX@^W1;1@G+;_H>MF?>H1;ZL_NDEY_M_1K&&RYZWKCQ/Z6&8\$S;T(4Z9XZPB;9I^HPT^GU=O1B\$!
J;2^%PI+W\$HQB6;0BGE21JDTIA+W M^4<2,9_7_QNN(ANF7K17)Z?<K3192TTE_1Z7W^<^WL_-&B_OBQ9_160S2_MPGLC%J/R^FYC_467SR1%-
+6JU1+3_RZKU>+19Q+1T_446VS-5&7^FSI?2^M=O%(1/ZY-Y04LRWJ=.%5E;A_Q4HIG+1#60>2RT_M\$K_TPZ<)<PYGHT3GV+XLM)OF_1J^#&=JZTBEBDXL%SV/QT_XEYUHS+5#JEC60-DW1K MG7LH81AY/GX3A.PWXF_EG^N(^1^QCZDDC<_HFJZ^1-
D1V_C1A^NZM5Z_MWG7VHUG18M>FB/PA<1N^%O;R1.GWUC/(H8-61P^9Y1_VW=BG^1@5&A4_MYIS=J_HTWL\$VC_EW?Bf&FK+
(_JN3K#KFfWL@K6;<^D)J=B1HCM=;fWB4W_MXA^<6>^EA1POL%_~A6\$F\$^N;I#P\$ZUU^N^K/I_3K31Q15Z3_<MMLWDOS>+M;fE7D_I=)DZO=YD-
MQ@<^%S4H4=A)0P^LG5?2+6K;OL7Q8_"TU215;^ML11^<3@<^O^Y?G01^IP\$5D;_V3^78B_YH\$C\$A_FZ(8H-BTXW8^NHV8G8_M0%YN^%A(O0#-
Q>8CL>G?3GCJCR=A:T8N>Y0;fHE4M_S>HT&T^T^XC_?7=N_M;AS3LJH;Q^1A1H_XRU^A^FINO^9Z4Y1^=^PZJL+^1S^BJZY91^?NZT,O(PI5;+<+5YFZ3JWY^NYRFL_G1<~^2L_NIK;2_M>Z;_D^FCGB^NJO?D)B6I(S<<5W+K^XRURNT<<<0<?<=<C^I9RS92XK&S85"~&M@T
1:1&3)1#<S(S(W1Q+>)Z1IG?@AD+X\$LN2%ZIF0_Q59<<W&DTE4=#G1JZ^802_MP1Z)'NMQ^<PI,TIH9=%6,\$\$*7&H^3!>4^7?<f_8YUA<4>8VE^51^_9YPX(7#<8@/_AP_REf_~;H;T=IH51>NKJV1^OV;+^\$K^<^1VR1+NTM?<MA^Y2H5IP0\$38K^084#171^%B_ZL1^%B>4X4&2TEXQVZ+0Q24^~1^<UY1_MQ\$9IR6C^CY\$@HP>f/@E6^IGV@_1YTZQ4A^4J05^Y+Z1?<MME_H0QG\$JPY1_68U5Y_M^0PYZRUGU\$S_W-&S^NB0Z\$Z^G/66_Y8>9f_@21+0E^59Q\$P19MIBL^_S(2_M0P51%1S_QH/Q/@6_MQ&>V^PZ1D4K\$SAR^P_I0120/BN^9LIS_K@YI7M1>3?IKNY11_MJL(0URFRIB^HF6+1^<V0...\$XZ9HTA;fU@K^E^92^MHVH^DQF?>60NVH MB4F09XIRK^YK2Z9898LAU_13E91^H12=M78^RR_OO_GAULOCMBKNDE30ERK<2@+16609C^"7JVEROH^GPOPO_E?<1>0.0JHD;S\$-5<@1X((1L^M<*=~;H^S^AM^+;+;@.1+B21\$TX^R9Z^*^\$P&1ZR5PIX(P.^?)"(R_<V^W1WPU+L^M9H?<8Q6-\$E^?1M2,@F;TV_PN>MNX0_N_K<G1V45W6+V_~%1&A<@1B2T_XH1A;Zf<#YI0L1&DR@DXN51YET4>8_M^G_4)_0H7X3D#<2?%>H_~%7BZA+^B_Q_VVKQV=A_XfU_7G7ELG1V^B=7I_M^R<4^YEXF4\$X_K18+7VQQ7R5\$)(DJZ1^>GGY+EBJY1BZYXZ;0N8D049Q&H(X^?T3)ZB;0I@;=\$=7-6E^<4)Q4B).0?_<MR8<5;H\$@:IH_A0F%"8EPA3V3Y@<@N103AIZ#(Q_*DU"U+1ZS<3;@=\$L_B_MK^F^R21A8OV+7PXCR^?)2LH;KX94(RN)@G^3_S3IERJ3YH5M103Q3\$0Z@1^M#5-D@VLC9_IQ@1^1^Q^2VKQI^1&D_NNSH1^<LXTBDB;@Z0V3Y5^<^EH\$D21_M+1(QN;=(<X>_4_XZ5A)+1R\$V=12^9\$1G14+2QK3A\$TA@17D=ML_IQ@2?1P(21;9;10%=>1AGBZRLU1MGV>N;NH1H1P!fR^>+40#E1P11^?2F4H&D9;_LP_Z>1@QY(C^D^>B9SR&D^4F^J>M>31#1X^1H11R^Jf\$^BFB6_U;UG4YGI0R;)OVI^F-G_QQ>&@f_QH!=%MF<.%A(I\$X4,75+&M;fE7EB29W^Y91G>04;7f_@Z0)6H@_~_TZYBIE_M2^1T^@O1^2+0U24^F^FIAA^<X_B%Y1<@9V72H@=)JC^4(GYM0^YU_M4+3OC@E=D;HB.EY4WN>#C4;5T9N^>1L^HZV^A)U_9=Z497_~)K9^_M9XO(GSDZLNZ;~"B_QD^46NU>PIYZW(6R?<X#>_QF3W1H08UY6GZU_M/L3;2YfNIN;NCEE09K01TAPH^"K;61\$>3>?;1I>00(9^71^LN_0@MPW_MD^53VYD_9_IKH;E70/P;2XWQBK#^Af6-8/W5^XOF1%E_1XYBYK^*TSK&M;#2AU^_1LO_HQ+^B2&^N_8YD=8T=NH0E^XOB112^WG=IGH11<8DK;f_W+1_M(HYOLVPCXUT4_HY;_MPIQ?<WJRP1^Y3GGLG7T^W7K\$Q6^f1.5#6W^NIN&E(fPUAO_H80H2_M>SK\$;f^G)GJ5^G^*FfQ&Y1X_JH12#5;_O_BE^HQS^I3N1J1ZB52S_M;T2LAH0KV+X1>NK\$W^V69>+^1L\$S_<H5M;NLS3+^fL#1(KCEA;_MFO@1B39;6PBP+1HXK3M_D7?+T7_Y\$S10_/D^Y1=8>GJX;EXTF_5=MR^A188CK%G3Y/V1_6L_LC9_UHX3C1F54761L;C;8>#M8_6KC_UK1^/_MYO1TQO2L>IR47<D+D4C;L6%=>@DNY1_SRB03GV^fYO_17GJLC58R5-1%L\$&RL#B1BK3NK5;PMAWY;AR_Y(T+P;fW>1X\$W_M(PUE8G4#&_M_LFFFT14D5+1I#S^N<~;LO_KQ1B5^389B1^BRX;8L145)H0_6QRLT^G8CQ)<L;_>Q;fHAELDU0080QVf^4fQA<71?7_MCWUPWZQ7UG23IGRY5N^0421^?Z_EZM1=1QD%7C1EJH11R)RYBBX^RZ0SD^S1Q_D91BBH!MP^25=\$9;_%HPESBA)CJ9\$^PG7_I=9;+N@P@_MP&Q=F+FWQEK76^2V^0P_M1K%UD(NBQ7^Y/S^<6Q\$S^H2^H;GEF^WL(SJ_Pf_BFZ^QNN^01+>6X62<=MJ=1+6B&^9Q09IKfE5\$SQ6DQK87P16=&AVE9I8;1B^A)1\$=B^C\$^*K8^\$C_MQ\$^8JH07%~12>RB^U1_BKZJ^XHIBOU^M;VYN^H8L8DIH^U21^<T^0_MH1^>f^<3^<=2+(N1G071;^H4>A-RAN3Y_00<@;\$7NS/_W_M#91^X1VV3J92^N_2I8S0EOQ?71%1+^9(348P7NENIYM%~"7AC11^EULI_MOTIY;M&5D)^J^_ESO-AP8FTRV^%0+/QS>34L@<A^Y@7FUEQR;MU+T^V;(B^<=M)9_~BY_7^YO)O_0^Y(2SR^<1V2>#<@/1>BD_SNP;R65Q^O_H_GZZM^L_MXHJ9_~1^0\$>+G;GK+3;1Q^Y_M1K=L#P8^<V13Y;6_Y1^fXYIR4^2F8F(OTD1+8>2(WHIG=;S;H%QJG^E ME^UOMH(SGGC^X&H_GZA+2B^M^<TSLY^RLX3GCE@QJH512I6X<=8/2+1K71QC_MJN2KK1+1^1K+1f^fZSOK#D;S_UIL/?_YN4?QJCSWY=OZ\$A@K^&^YS>N_MXU_<^fV9+3Y^+)^B^P6;QUH^Q^<13Y_/J^1Y542ZRLX6%NDJED^Q>+Y^G><6/G^<N_M1^Z3<^R_<YTSO;C)M@>+>@6S_EE8)3XN^+1D<+1_2RD@1S+>1Y1UPZUW_MR9Q;Y^23X_AKJ>DE9IR_6HM;GEA^HXH6G<(&fX^f4JB(E!^_5JL8A3^fZ#(Y(ZKK;B^O_A/G^OTZYF;1(Z17^fM_Q_MSHG7B>+W<@_fT;D8A1^2>Z\$@A@Q6HIG+1^fT=7>?>79H?2^fH1X>_O_M_A)3K<?7^L^<^<QZFEL_MYRJ1^4KIES/18_5C^W@G(64^2f1^M;_W3NC6_N80PPDSRQ^?21QI_M@2WAE4ZS03X;4UWUL1A^U1^fW;JNFD;8JKV^H1X7Z5FLQM;W5EH1_MQ_A<3GLB>12>1ZV^EMG;fB\$CTY@XPP;UE).MM_1WS3KFKR=VUPS_SZ_U^F_M8)Y^Q1_G3^EE;WG)UJWR_WU1ED^DV&<=T7K89>~<f_J02>fBG^Q&^fCJHJ^M<3^L_B_2V35R2^f41<4#^+OC7L>fN\$&1Z^fYZR8+?R;752UXA^<^N^N1P21L<M6^LS_H(C^<^fJHE3V_B1Q(8L6V4A2^4N?H(C)Y2HA0^S=W@&M;_Q1^671^1H1H(GJ^R@4IE+X14OQX3^7Q&1QIE+U67K5>1LP5\$=Q+PIE_MEU+HR1098&WON3HS=EGVBY1E=(V84?YOE_MNSM_9;QHLS1_R0>^0_M_YRI08\$>VJ^@P^M926<N^9_D1^fOE-(J^X^E52^X3@^0@8UM_9#E8-(H^4_M815)2IEMG#1_L3^fL\$_L9813;DZ^1^U^8#PIKQ1^<U^0^ORZ&@21+4N\$N_M3)BX_U=^3QOB>H^O5^K_S_ZOR\$=658;.)TD4f1^f_V2MQ<@<N(ELTA9_MJ_V)(&M7<17V^%SBY^fJKT&04=151C)0\$54IV>H1Z^114=791_~(AWJU_M)_KZT(f;WL2)^+1HPG?A1#7+ZWA&?YH(QO^\$MB^2W\$@>GU#KUEV^3/0@_V_M_!AV<@D1_3ZC=X1KT_U1f0!6LP/BJU^R2KB;_!GU^+(<X^2U)H^#Y9V^"XT_M;F^GT(F5INE\$^fIDC_4^<^<1^fLX)4XQO_?G86\$)^S2<@_<0<9ZRSBSR>D>QIAT^CE_OA1_7/L_MU6;3^H(SQ_0?>UYZN^M+EC(3^<C+^7ABR;H;0=3I=5@Z9BY^U^K^FH2L&MCP;PU^0P_2S1P2=12_T1_31(N(JCH<~%2P^K;PT#M79+1_K10U;7Y^M+Y^>V=5^%48)fF&827;)EMEDG9^2R%_U919E&&7XHF2XF4.PN0Q#3MJ0_M\$<=7\$&1^HP22^D2W;S2VER^(TTQ4^C1^&7(<^G_EE^2X+61K^~5#_44!MQ0P;L;8^T^B(C60&76HD)^68ZPK&29K1C_*N<2M^7)=_AON^1MC2+1^QH_M^%2BBAKK^52)5X_MN<1^8KG111+1_710;G2\$~1JBA5?KWA&69>+1^MUL10(Q4Z4S^R4\$>_M;=40&^1XNBBKIMC^UKCL6=GR^RH3CD#+C^K^<6C^>GPF2>4512;S_M5^JDC^VAR2A.GK<^/M6^H5^N12X2H^KE^+VV7(L<~\$~;51M;^59W^_BH1G^P^3^6J^15ZME_MMA&MATUVHLD^KM9H@MC15DXC+8RUM2KJ;O4Y7E119f^f1^2_0_~N\$5L-(D_M\$GB_UX_Z4#L1X3P_9V@<G_X\$8;4(9%1\$27ED<C^D)Z2_U2G^YHXXGH<91E_MH140Z>TfG9Y^22E?G;_~C^G\$Q1<^<M_Z^"R1fF48121Y^%X#_8V;1+^<<@<_QU1^5)J4Y^*1;8CAfC^MEAWO6_L^UMC>N>@.f@F;UM\$+^B41^1^JHIGZ)GC>)A1^CO6H<^>Y1Q_H4K13_YBMIHT^0PIYTY&WG)S)U7F^H(M_G(H1\$;E;GKYTKPRH2EA,CKF>_TQ>K7^W_1:0QDS_6;INHK1=2&+<N_MLJP^GN_1+0_1(X^2>K#10+1J^>+>(<+7A3M_WOL^fLB_DXBST

MBXZ T#OJLM""NR<@U2P)^T#=-\$DHDC6A9/5+*GU&4K-DQ'Y M04'I'W&J3I,B\H<1%H#*JHN-EVXVF=-1QBZ@/LAI> ,B\$5?>\E8LUFFL:@ M/A E H="PA9+R+K-CO7 YG<861*6+W:5:,G(4K+BP,0+@NZ2PP P.K5=-P_6)(97L8?W:J*DT+0D4 M_9S6Tf8LM0&6-0+)? BB)+B9OZJY\,O\$E\$8_-Q3+UA*,,HPRK\FAV\;S&78A M>B<@GM,X6AXE&*7X\B2XJ;^UN01\FH*^40)1@B\#@ILYLRM4KPZ8KR&6# 44 M!/? 0R1+39.D3(39/DNLS9K\$S>F\ZEFS&L2MUM16J#*U8#Y"LYR7(CKWCHV\5 M+1A+>+?27NTEfM- UKPWDP#@3@EC/KJQ\PK>>C,;?Y8L\$1G%,A@GD) ,%5/2 MKJRIWQ<"23TG0",KB,;:WSV*UY+*OU\RC\GTFYV^&_JS3+QOM::9"E@ M@2/_6HMS5&>F>GRY9X606+ ,*AlM;H3M_UFW31^JOBB8:6VY;&5-4N176PM M-=JZB:~\$%B-19>W>^6L%8*PG*0V\U=BDAGZVZ?K6^ML G,H=P_H8^H0 M^=OV@8J,X>(H#)9\4SQMF6/>=E:2)@E1+;0N6/5NPW5SC(2Y2I2\H\K:A~MMEG(>^4~"ZY\$S%MIM6W16CC-KM%X#H76F\Z^1<*P; MKZ*X2R+87JZ*3#0;# RK+1.3+,"KR\$ZA>TR=5\VT(W7ZW68L3@UFW\F0NA MXC P9)C13WGT\QP(PJ8VM7V\1 M^6+H? 2=T2>,>^=DIU#3R@TB1)+>(3,4IYA)!"@N\V<,8G:VNN%6VH\SY MPRG=-, DPl \$+ID4V&^Q*E@Zl -9 3THJAHBZ9K25 R%7E1 MUD1^2I- YV\8V^>7S5UA*H8=7GGBUY,+92^Q.>\$=DPC^N=>9SfI! MW#SNYLXE?2<&3%(WJ8P)\70:NST>35"N:&(#Y061AFLG+0>C1<98\HK_C MHJA)/ &B,&LV^&AIK?TB^E9M+>+&P&LXK;NA&8P\F*7\7XFFC*IX8IXQOAHKS(8/4%0UMZ@C_ET M> X;C\JO+KO:S49?^63T>E15>4^C) IQ)=L1+RY\Y\QEXV\27#(M\N1;2F&X;XTEK>3Y42W M\G\IDE@WR733B4Y6SL63GQBA,XV\7R^LG%Q,%MV\K@M3,,XDPN@TLN15<># fZ%ZRJD/_4+%;T"N3\$P\ MRON,7V\O)@EY?TB_G:=+&4/R)>%L)A?^E1/6RQOF/SL)&f\TR*K0W% MGBN?Q^<*G\O?>^f8\;R#fEC>O#f8Y<2IE' fEW\^=-Z.(SM?Q,P.DK5C\$ MWM(KY\$>=SCJQ>2975U1Z;#HJ;Y<fE'Y385R.SV\IO^CB M18O2TfSHJL6FDJ\A PM W\VRSP,%LPO#Q_G@%>3*HJYB?M1<=GfS;YJM) M_10{>+WGOK+W:5-SL\7?ZNN-U@_2&E4ZJ.AOUC\LOUXI6\J4-KMVB*#@ M%8U)\$*>Y\J#8*1Q^\$HVG",27^02%^V@E5Q4ZC<*PJ\,fVfJ_7"7DP M&/%IA~*fTf2=#3+;9\$-IS1Q^L4+4\78JP=,H2,72V13\T\MB%3f;B+G8 M422@+B F3\YHfEE,"6fZ Q2(G;fTl@N2;Y0NC MY2&^VfC<A%#EEF>"60%HTF O.CfL6N;HfC\R#fGHJ(^9D1+1+6JUP:P*(A;JP! M@67^Rf(Kf5H557Hk1269M G<^Y:5fD)?)B;9^D>9*K\WOQfOPV>fKYN^QO MW SMOQ=J,S;A040&6?ZV7&Z\$Z019:6D(P#1%"8Y;2\7# f4S8R>LOU\$G# M(TM+4,(f>fSS=1+N.M"YS77(P9;>"1\$8GBOU<^VUL8QfL62:\$8A0@YfL\$ M?N/8^3+^+1,6*KW? %19PR@A&5W+M#BRD(fL\YfKH>M9D02^%K,78^>fM)JfL^NA50H,R1CBT =,81 H2Y9fNGANLM\4JWQ,ZYfF=WT>5Y^>)fG- O@("CR:fEGEOw2^E\$G:EGN?V= M3T W>fX6fW8 P= fVL9:5%MPZ;4-f4TW31RC3)- GLT^6SBf8WS\JfU\Z\GfC="V"MG;fJ=H=A#3V MDfT8C\$N0&#0) Q(RU(fV732,S0C06WfWB\6_62,2;f)1%30DfW7?KY&&MZA&+<f(P/M/K.V^9@N<fJTM^<M%N@2fH(fLR M2JA,GK^ fE;S)f8fI&O*PEPWEYU&W&G:6fI^P>Z "02%T^QC<^P#@fJCRT MfQ.7fL,fK,Bf8YHfEOD*F\$)(2\$1M6M9#5.Y.S;ZY*0F9>C9KJR=B6A;+fTB1 MC\$f L;#0#(D=+(8#Y#ABEN10,O,BQX1D2J&fV9H)V%8fGD@M2;2^D_1+1(fM\$1\$H@3;8^L9+0V\4MfOv*?1\$P75CG^&@XY+57E^f(1Q/4^&?)M5\$D# GfN98fJ0+G08R09fL1<DL\$3>fL(G18R+4M 93F^H+fQDX^UY M&4WfQPM2SP?%\$3/3U# BPGC\$)=-HC6 fCWZf(CCGD M\$+f#M,f1M5\$F# ZN=f(#0IN;K)(S@QR0BY^R\$B4KA\$1V?>@fMO=0^P^Q_3_M@H7NfNK\H26\$HBY3fLBOR#_%@U5f1)fF7_#&fZ7U9:9=-6#RX""HfY M^fj^VT\$N)Z43,4^<K32%Z YfB,K;\$fL^F7X>P<O^CQ 73C.M?TfRR^f1M5HfT.V70M1+1)N-3CQX#fI^&=M0^O80.2TPYAHZ;2^TQ=ALf= fH;NfH=KV6@?U M4>V8C\$1>MDEfG2P2UTYN=9-MK=VYfY.Pf9fB(f= #BMfYEfKK>fIMC080/M;E)C\$?2DFX9D/2-6/fBT6fCB>;H^fH^&(VfL9^& fJ5B-fH^P>(9#fTB#;A1 M)PR^?NM\$S^fYV;DM9SEK#J;2W;G#RR9R;f%357Wf;7CMf0fL7f9L%Sf=5@ M;#)G->AO9VKR0NUA\A=JULf,VHfGf1^>5TX_?f5V^Af6fIGW_0H;MYf5EO&8K+LL O1=B^99@>fV?_1fR&@&(58R6#MfFf6Z@.5f)@*F.SEODE&2 MAR)M039A#K(8.H&^<*XG=A&G\$#1P;ZYCf=C_26#SVfRTfT^A^Q.OG>6 MOG<^>^%>f)W;OZGfCHfO(fHGU;G4GfO2>NN0_ MS#8+R\$>9+*UY_f50E-9TfMX^8EG\$(L)fH;f>L8f5WGUF+^fIC3VXfO&.1 MS+Gf=,f>fEQB9MD)B_Qf1;Z8X96f\44CCQ> G:4>+>fDAG)fTT.X^P M<X76G(00%2(CWB>?)H^P1^9fMYfR529_Uf%WK2f*^&fA;OQAYHE(fE9 MDfJWA6WE\$<35HP@7_#f!<0;R\$>_%3?CJ367 MZL;ZE_K&NLD5#G0f3S_S#&8#>f)H;2fIPBf.I31Wf?3VfSKHf29\$&C@KRM.MSORT^4N7fLWfBX?_S^R#> WT/f_>REYN9SfOfVMY^_fT%ZHFfKCN+RU8 M0fH7f1^Y+>fDYWZSCf(f#_f)O)fO)fO)fA6*~\$;RXAH#\$f;R_~*J^<3_@)9Q M\$ZOXD^KfHfU37fE.K9Q_<3f=;&9_-9N(Kf^N059Vf^G0240>42CfR_VfK,fE4 MfN(fD4.628_0A6@+f5G^1-4Q^fT24^1XfL\K8DB\$).9YfL^*^VA>^>XfC\$? MRSf5QPN^>=QQN0&23E;UG_10L+5Y\$6A%JXW+NI&.26BVZfE?9MR+O3^4@PfM^fE_1\$?_Q>_7_Y&f;f)A:fSf2N;17QP"- %fYN(<>O^V^Kf:DL802L? ATC Mf>T26<<6&S&1ZYfV/W^WfWVWQOXf.W>f>L0^W>?>-6_>f_?17f17=OXfO_>f)GLfMK7>7+72^f)Sf+1G? f_>f_>f_SZfLW752AY2)N\$^<(fID222#fYBD<1XfDfO8f1+&Z M^f(W57<*8SfVfM/R6M)f305^M;f+YfO0#f(Xf?;4W^YfS\$^f<^<(U8ZUJ>@4>fS?KWf)&+KVTZ6 MLEfD22>^>A(PF_?fZO&^<^f5M#8SBVA(M20NfO)fUfCH&fY>V&fT^fP1^=f M3&M^fIX1NK3.f12UQfUDfXfUfZ%FSUfHf1A>E(PfIG>NE^R@X;f)QfW#?VYC.fLK9TP/6.DW<<9SfHSW;fS<~8fO?Z1_fP MWf>82? =ET6QBSG?VT_fGMV#U&S>f2JfM9_15;N;fOALfEX^68f37U83KfJH9 MTf<5fRGG3)3*_62M4CTP^f5ZfLfYM5>f%>f\$N7ND*OKfHfDfM;BfGf8.fZTS M GPf1^Y^N60XNSV\$6+UY>5RfB/fEMDF476fWQ=,RK=8;f2X*0\$MK2A(H=24fMOE Y(f%2NXQ_f^f78%fH4*B&fJ(fW7A:<6DfLO-A2fLF M+5%fQH7\$0;X2D;@UNZX0fLBREDD2P>E\$#f1G;>f(f^fP&fJ;X&f+>#9D>WCY@f;fA&Kd\MM_?H\$&fTfL\$; f+>@R0\$_f1<(&fJZUS2fQA+BUH_fTXA8;fLP_"/:3QD5X3;X MQ9fWR8fUXA&_6>QEB^2f4KX94\$C9CfJK^HT_U^4L<9;VRX A@;+f#;GWJ&3\$<1 M2 7_Ta5,O.fH)@UR6Y@fT_fACS_16<f1@E;fL;A4(fFfP>U^>f7_T=1M+9f6 QN>?>RfJY^AZfJAZD=^f;fTBG5\$>fT^fI;ZD>fP M\$Q O.CPHO&F f^AMfK@<fK#Y#;O=0_PfT M_fUGUf(f1E<1@E7CA&U^&_M3+1YQ3A4A=,4>YWL5f1@B3>0f.Q<f6G2YBfLP72^1480FMS_U>fJfTEPEFKfW&G(f<~8fS(f%U^4<_fE!7Nf6fOL8 MGMX SS?L_%VOU##_Qf9FVS^V^@G6+)^>KfKfF^>N(fVf119KfIWS\$>?)fYfM7fL/f>^<A^fQfO<f1AR-P2%f;AW9NB" fG;f)W7P^&S\$;K\$=9f>Y\$0#"ZA_MGBH?_8G<#fC;R2f9fOLX>fU_fI\$%>2VGU^?>W^fF4E^fI0Z+fE+5_f+^fY MD\$&f20^fV) (#fTR9LD<+&P)fH#;G;fTfBfM@>fZ#_f0-R@&fIOY^DfO;A#f) M0R(fHfVfGX_#4f5T0C^fMO&6Z=7M?26R^f9fXOD< %V^fP;SfO(fNH^O;f4A8-2fB&AL V>%>OHC3R_~f1K;XUTH^fA M;f(fID05(6T^5+LQfOLfT)fH&W^KfT^f9 Mf4S)fHLf?9H\$E\$;OAT;2PTf M5V;6f1+QfE2=5.fH^6 fGfJLG^U2fJ>fUMYfS^ZKHRR0B9 fJZfNH2U;KfWQ@_MfUf@fLB_VPKf4_IE>V;4NB8^&fE7P0XCY^fW\$3_W7;fY\$>A(fV^R^<2+;9T0; MZ%fFfB^fJ ^B6U46M9QZ?GAZER^EOWKSJ_9fJS4OSY="8EZG&A3U_Q2^RN MDCMD,6YfH>^>fRTQXN4"-P5^M&f2fW7CU#>fUBfH;f3-9@Y7.P^>PUP;@Y% M96Y_9_~%fJ-O&fUH#f183M<@TG=9VPLGV#>5XN=R;fYfB@%>fJNGf1O^fJRU5H MCR9^>)QO<@L^R%DMUfZ^fT-&@<+fR9CQP9ZYPQ^4;fV8 Q5&#f TR^7fHV M8HYf.fRfPcM^W@H^49VfLXfXTM/(OZ9=UX@;HCRf=1\$Y;97fLN>R=ZK+Z0N;f) MP#P2&f^\$3DSSfA5f1)HG2^f8C-3fJfC^4;9fHPIU4A&0XSM8;fM^T_39 M8-VCL8?>^&fJfLD(fO^N^B5^<fJLO3+^fOCD2A8fA;#_GJ4F=K(2P;32(f2_MV;AM? S^&fO;M(fV;G^P@PD@Z%+K^4^fO^H^<K;PXLfCNOf1^f5HfBfL_IE=4fLYYWfOAZ9fO_S8+G ML=X_XOO_F&Sf1fO_N5Y MWKSC6fB+4V&QRN^f1WKQD_9f4fH6<fX)40f3fHW.S.CYMOfM8C/CF6SCY\$ZH\$ fWL7B;BE>KE+(G f=-V>fKX5fQf1+1+NEfO59Sf)>fUH) M=0G+>fEN>@>fD8>f) fDX(fO^fX^f37PKTV3N?>fH7_~fUf=C>8>2^fT^H@&f6 M0f5PHfL\$?_fEFfUMOHfZfY>fFfHfO&fE=MUL^fV7G\$8A;fJH8D;E=""=1 M&GZf7(7N;fL97f6BDfHJG70^W;f_GK_<fL/QV(fV?ZfZ;UMCE@P>fO>^4A^f;fLG@XfO5FWZ;^<2O;E@_M_LJAAG0#;SX\$G_+8 3^f6f\$6%_f=03_L@_fT0;2SQ6;f("PLK;#;#fDH=MBP&fW^4>)fXVP>P;E.P?>XfWf174^DT^PL@_P&LM0ATfLY^C^fLf#*72R\$XM M)DC&? UVfL;K@&P4=08F7<^E22D_Y7fJCNK\$B+(9f1f)O0fL8&DRP&fY7f60fHM M#P4f7YQOQ5W>Z_Y^2A7\$0W>Z>K58Q&EA66f16A1#fY6HCKCC+;B_3KDP^~Y M\$;fL&S\$Zf4_%(f>^>382A3SXFND)O;Z^<(WfGNY? OS>&SUS7GA^HT/GA5?_M^ATR4f_YA="QfOQVf1^800.1;NODBf#fJ00@W0KGY.9EX9^?C;27<7^>)A=; MT5H57D\$&4fS5E)fK\$K@f(2^>X@&f)@52UY_fUX&fP6+ZG_CfL&fO&f&f31(f_M_Q^fS;fN1#<fLD^f+B^<f<^<6V8K0^fU^T^#N0D9@K0W6? f>OQAQ3_3K*4 Mf2E>O^T^F^fUAY WSGO^fBK&=#Q;4fFOQY^>GL^fCfQ^>WfKGOVfMEVfM;M_WfOQ6N=RA\$^fU^fL f+>fJC@U^4_>N;SWfU;fA_Q<8?20f/O^fL_<M M\$>f\$>f+MfT5fT^>fA9fJ^f?>MM&9fVMEVfJfD8A/fD^fOEVfGD_UYfZSD56fJ8_M75&G@PWNANW; fU+3A_6_VfY5X?fLXQfM=>EM@fTBUBf3fOEF2fC;=fDWfZ^ZM MKQ^N7>fY@<f3S;@>fNAl#<fS8Y(ZW8fJOE^fN\$&X^X8;f#f64fJfCZfH^W M^N+>f_R4+W;WY7A;Of15>PA>?>(B;N&f(fX1^>f;C=ALWF+G_fADV^2^fM^T-O^<3=X-O#>fKQ\$1fT%>fLOfH+KfLZ\$8#AZB^D6_#^#Y7 T?>fD=P/D MfMX3QHYf_U^f1fQWDGfOYCE=>fYf1#fFFQfMW^G;fZ9;D;f6^3fYO(fQL MfJfRf@OPBORSLf@fSU;fL \$GZN^f263DP^RVf)2>^63=XE0A^6WZSW<fH9 MBSXf#8=VfW_Z^+7 PDV@fSfT\$fATV07\$6&7=2-fQ9fR^fHfA^K@<_<UO M<_3WfJfV8;f)Z7=8^<#M5f1N>?>?P4YD8WOf)WfWBf6_VfM N<f05^<f3V4P=XM82f1#fN9fTW^*fW6;VU^W6RfR2B;fRfQ@7EfNA_1H;f) M)? C<^&8HSfKfC&SfE#f2fOR&W2S@DUE#&fJGf1(f+SDQ MMX+JfED^fDY&f>Z08^2X&<G^N(fHfS/fW9H)OMK^fKQF4^6fT=#HGP5T3 M2;fR^@fNB^>fPIVHT&9fJBfD6_#^#Y7_SNXf6fP4Y>+9fJH2.2_#H_GM(fG M=^R8ZZ2<7&+@fDN%6^SQf724S^<3WfXOEfUPT^>4f1;fB3f93fDN&f;fSf7 M>9^>f;f;f)HfH2N;f+XWG3KB.G78Af39f@_P@<=fVb<^<f55CVG532fLQ M<f1^fSFP_6=fJ8(fB7fA.C)R<fKN;f1=SY^f\$fE^>fVRW@&f\$?fB_W5fQf M^>7fMLG4R_UfTN2fGQ3N4^2^O#&fA;f1%9S&fG8=S2fP_MX\$JfD_ELM^UKfL8%6-1S(fO%<fSKCX30^Y2OS>fSUS7G&f\$GfB>f%fHMO>Q>G MGY+fE58f/f=flZ^GfJ2^fV>P8H#5OUMNS5>+Q>fJ+\$>f+=fIUGZX^>fS>.660Q_MXY="fJ_B7#RMV2;5KYf9fJfDf8K&507QP;DN(f<_<ODK;f5 M7fZ;f_>fDBO^fXf2^fBRWf5(fVd3SfQ<fAN^f+6D#>fYQ9=DMKX&6f1W^2NH MfMfNC^G8N?Q^<G^Q2N^f8H^fIG^fPOK?fE;fHTK^fHG0f(VKS? Q6ZfYXN;968F;3@>f\$V M^V9^8f)>fTW322N=90N0MfT2K2;2=>N;ODR;EXf73^>7fO9fX?SF M0H%>fJ_GZZ&fDIRX^045fT^f7%>fJ_9fJfONE@V>+^f1C;f2_2^fRf;K fT7-1.W7 MA_Q0V%>f<^&1NfJfO(fO7_W>4B+>f(fZMDF_f3C=625@8fHfQN%<fS^Q=ffL M2A5=>=XBY;8_fJ_2? (K&=<fL_fJ^Z^fDZ+HYETf98fE2f\$KfHfH) fF1&2W7 M0UNE=SfNY%;5^fL8fWE^f2fO(f%<fJLO^f+&fM CLf\$<50fB^f@QO+&fKMSK2OVfB& fE1f&fO@QSI?>NE=9R8EW+;fUNf)OKBTT Mf#>VZ>+>Bf2NU;fB7fROX+SfJ&0V^f1KBH\$U^fDLBNfIFGD=>N5>5^>H7147^fIL0 M8Z5W0f4fZUMfIS0;UKQ_U^KQ_H2VP_X7fHfZfZ(fG^>f1;fNfB4^f1^>6Mf(= MB^fO1=^fQL2MU=^540QR43S^PC3&0fJ3W^f+=f;fSWfV^>f+Q 3ZX^<4.5 MP=ffY=NHfVXf#f>fHfDfL%Q8ZfJf%3NS^O;f4;YE^HO_L^<83fH#>f@Df<^>fXM M1=%f1DM7^fE=%fTf12\$LfTN2^fJAf1_ZGfDf_@+^f? fYTOOHfZfN^f@_M89WfM^fMfJCCLOX>fFAVfHBNfL^fNU^*5^>D4fUM<fT^5>fVBKfJLO@O&f1^D>X M;f9S_fE^>2Cf9FfDSD=>fE?00;078Bf#f1^fKL=2^<f? 0DQ3AE+3Vf7Q^fC20<Mf1^<fMG^K^<fL_9fC^f1 M=VQfZfRf1=>f0G^fUUfT^fH2OUBZ(f^<f2fG^fTSfJG28DYQX<f19.6E^fG2BD_&f M&K&M20XfT^f%>f1C72;H;W^=X\$8U=f15f4@fHfJS2fE3fTBAN_HfS+2fJ3f6fEN_M4fX0QWfFCfI5<fL_3^<CU%<f0Cf93X)fELM_NOGfY323+=fWf? QfJ3+R<5?>f\$LM9^<(KY^f1;9fH4.O5?7M^<K^<f^<OK^<fVK^YXVQNZ?>4D M>0^<fE^X?>A="fP^&fNDEY^<fK>f"YfZ^3f>? fF_98fK;OVG9+fEJZP@>f9Cf1^fHPT^>MGROf4f^fHfZ>f>fJfUQf70fHWR^fX2^Q)fW^P#6;0H;fO374^MT>2C^f+^fTEH A MOQ;H9C_fJ&fH\$Z99&MfL^2N2f5f7fJOMN03fQ)fE.6Wf1^6NDfIWZ_64/Q+3f6\$ M_LCX3\$Z;f\$U^f!^>X2QfL^R^fVUA_K<47=WfFCM_LfJ5f1;3;Y_#06^4BN^<fLV_MfLY^fEM;Y=>f059QfQ^<RZ\$<#9.N25>+fAD(fXfK^f4DWf;f@@>fJRS+KfN5WR>8NK_f6\$&f5+3fT M^G@f5HfN5-2VC)RU^&f QfV_fYBf10\$<2\$2EN^<fLPN;7M M_7&K&A^f6NDfHf5f6f\$fEFLfJL^>fD>6>3>+>M_M#fJ;f(fA;f5;9fJLRMOW^MMfHBMf8W^7;f^>f1^>9fIGD^ f>~#;f7fEU M@f\$UXfJ^D^fEYD_W=T57==5VK70f_F9#Y9TKU>;NZN9BOfXf1;"#A\$RW")Z<fM^<f1V(f0 MCN\$4N=+&5>A;f; f6ZPWB^\$&Cf0;=>S9>6^L0^fQ2fSfA5^fO;A&QR@fKVfK&fMV^f9fV^f+>fV^>XfR<6922^>B_f1&4A^<CD0_9_H8fY;NfT^>fAJSR2^>XfJKQQRU7NN&NfJR-f7D<#W MGC&fJAU9R_fRYXQ2AR_50N&fJL^ZDT_BfJ&f5^>YX^E8WfR^fOCfJ^fMK=^Y_6\$HY7^>O5;6#ONPQfN=C@K6;MT>=>Z+>QUfW-&\$%\$&="756S^2A5=M;W:0)4HO2K\$R^6YfV7BCB>?>Q&D>2=O_7fL_5&4A;S53%\$fS@=f6@fF#&@N^M^867>f;fHO2C^fDAQXT\$Z\$<fT\$Q<f^>ZfL9@&^<fV_f1=7\$>K_3fIDBO2fL M8KWHf&f(fYTABf1<3ZUfZ22fNCfXO^fAJCfJ^<fZE_f1@9VM@296)9S&fG89fHP3#N^>fG_fTVfW&fZ^fSH<fSY>>"R<f1Q;7f<f1SG9ZfZfL^fMOTG3+ff?>fC1;~*Qf4Kf1@fE&f4&2fE7N^?G662^fDX4D2>9^*4H;2AfEL;S MB(KQ\$>&fLNU^<fJfLLfON(f&2fJNOfYQ\$5f1M-fEL0G^<N^<f1^E29VQ^32^X^>M>#>f3fG^>E>fJKH^<Y+&fL2fL5+&f58M<=95^C@H2f128fHJ&fNfBf1+X Q_>%@UTfJ^M^2fIF^>fHfQ

F1JL\$QYWV1JDE05!6Z6%""6JE150GIB3BL3+BE,6H&LP1@H= M*ZGC7IY""1JBC24A=PN@P\$P&@#*,&RW#CH@H64Y8"O">#IFZ+>0UJME-0J
M1S4BMDGDEJY1J>:9C4J1M+WOT5A15!%,4Z/-8:DHU, B-W-FZJ>:,0J3AGIOJ^J>J, #IH6P5RU3E7C4<4IZKF M\$<=K^N13IG#5-
!Q6@!J!>0XBUQB0N\!@5H110-5ZP#(5/=,!9WGSJ"AP,D) M2!B8DBD+N>J@=&0I63<<")M<&6HC4H-!N\!ISYC0E.Y)0Q/1QBI4I307HX\$D:- MLN@&
!>2EQ@!>=EP\$ON,,=Y>:,5\$SZJ^PIJ5 M09RID> F9J2I0)X&PU,0=*ZF8+W)Gf8>-Z\$6 T^JR9J*NB^FNJA=2N,M3^P
MG,SIS%U/G8)/XC2TJ-58=2J&PG*5(4,~5Q5L5NF)WQ&S489-DB&&-OL(B^MC+C-X+U2WX5VF1&Z4;U/GIA^L>H!H8DF8A<5GG&+E^23C*,JP^3+<=
(1V MZ&@21^2J)~R,KC#0F^FZ^S^INB3&&+H/QFA>9;J~WM\$#@9>0F!63Y6R)9.3)~X&Z5YF(28@Q MEYP&L>Y>D)!1# (T82IAGU~*>2AIF^7=<G>V8=
(6;\$M4,4A2RP0J9^74^ MG&, !JF+^3A#"4 J4W7<~EY4G@JL&K+!FYZQ S1&^R7!T88^2)2AYY+24@ M(\$45CF- 6 URU6VR7T=6I2!4PQ1PV&S^VTWKJG
TB2(2LL37,1J*%>UE61 M4%4^1U5T6RMVY)J6=^G+JZ! W.<^JZ!FCB\!L2,~R7J5(0;MT-/@)QU35 M^T^DND>*~KXBZ3^AJ7SB&C,N(5:1QZJQIG)
4P6^*7F(INN5Q+RUFDP2SO!6 MNK^*% %QIH8^5/!J M~5K^"QNZ7T^JAD)5 RWE4=-T%&9A/625<[K/LKXK^!VU@M(FE5UQIS^*84RC#JLM
PW4IYCA#@@- 2!\$JF3^07L!^B=+!A@=6#1=8@ M^!S^?GIDG^4891A\$V2X10CM^0^VQ0C=IRS^*K_=AO;J^*~4M9JDA1*BE-
N)9Y76NDI5HF&F%M @!H/N,!=~K%:I M!~N!M@=IG84WU5@24Q17ZV6,Q#9F5PT!&S^&(6W37V0OQUQ^?KC-K,~<@W/A M#ME/A3\$TVN-1-B?;E-
A/!"AZ=!(9)P!&6^KJ64GVX;AJ2^NETMA,1-M!B^R8!>N6G!J(Z20%\$;C2&+!WVJRR12Z?) G_Y/S_I^G^H@/QOE/A M-/1?F?
R44B:S5H72^9ZVRN\$R06A "(A-^7S&,R&W)3JV=^B?^/K ^>L!MZIP!)ORTWGSXIW>+VE=^!^RIV<=K>T;:W;=LX!_ \$G2G63!OC?5_%<10U
MO@22!M@=0;_J^TLMY@=0;_!0Z^_J^YTT^0ZI&S^LA2,4J^&SY=;5Q?CY M4>;K%HKM%5A!0LGMJG7GH^Q4^!B^B^RL;KCU^K29FIV-6W!^6NDIWZ-6
M^"M3PZ^Y^29;R M2;B^Z^YB^%JTL^+!>23Z^Y9X MJ^7^"~<^&1N;~!Z!F@T^D4L~&HAD99GQ^%3\$70;WZ?D2QOKM8(RN;B>S MW-
;8I#2^M^5V_LF+!K;FLHF0M)5!_&+*D!NG)X8ND12;/R:W4!YL\$W0VA+&MPZVU\$F.MD)^%&NZ25,A% ^/8@E=R,7!8L95LGF@#V>)2QK;
<>5!UK+HR^M)G5D^B2!&S0 Q HKK~2E47E4 M&SG12PQ02Q0\$5^B0VF-L!_EG>C!Q:FWMWL@PKB!1^!;S!G04^D&N=3,30YQ^L8E-
5R91H^?DC!4I5>:SZ0H4;@38!LGL70=35PV:QO MFS=*!L\$NXY3S/5^2
MH;C;CML,"+FE%*0J!J8C/FUS.70H!L(LZK!Z<^!ZE%DD<#8"A9B@L+CN#^AS^CT.2V)AID\$F* HY M=\$L\$)#8@B:5!
(42~!~IMJZ!YWP5\$LA7V@SS+E>JWTSFG72!JH0\$PL^XHI MYTRK8ATZT0-02>L>S4< MWGYY4YEK%>Z^!MQ?~,\$\$36NE
~:X0416/CTVHIW1.STU8=JSM=VD9+0U67," M#T98(X^R+!NS7\$+S^!N=0T!AXYSJ;+~S0ZGB2:#T/=~Q@5<_<9
M59F)VWVT(8\$9IXS;F^X;D6U57M;N^X^A)4:5W6D8TLR#7 # \$ ^? M2B5 3JWTS\$E&8RX-LP(\$L5+= 2NXO\$ZM00;A-8ADSOAY!TAT\$%C<~^A^A^
MS(8BR;4X^C!4IAK@=PI^~#HMB;C9^X6-\$0M@(^8D-B,+(#0L+~.66P>~!% MQ+SY41D!2K42H!>4JES)KDA+Y,(#20-W^80M2+J4T>6Z!^\$VC&8
D0+~Y M\$M!WQ0!)!W#ZF B@V<5A;DY0.22NE!<:(A2^ENX ~#DCIS^LISAQ7!CN M#)!L4\$J^Q\$!1^HH8)! MPR0N!)!+^
!83EYOVM^!Y^M^!QA#>~\$JTLU5=(M."6HNZ^EGAL!L42^P+!7^XB^PM8!0_9\$9!0U4E!7D+8E8R37&8!1N!U\$# @!#8B ML_-2&4J-W B0;~%+8-U
D@B-!^UNLGM^N+<S^Z^R&-Y\$&K^OU M\$7Y);U12F6<5IH2INW%_UL0!_Z4!0!FC>^~%QM-RH9;TQ&~;8>GRY0%)V MJ#HST
AHUS\$&8DBH72^2U!P^AA5;8R>X!3YQ9NB-8V-1H13J 85CV-2.7B7@NB!4<^HNE6P#)RR9-W99-MS?M^3R^;IOOMG!H!
BEJ=^XK~,\$\$5X0!2(8,R2I5V0!L^<~N;JF86 Y&C+D MPH25U0(C OS5J-W7(8;!)QB%.\$3\$!P%IG<>>NS\$8
M8+T^HGXEX+0N^IUD4IH(%!106@4@CMRMV\$^~%<^R!UVS ?K7BE\$+XLTFE7F6X7IX?YNW_!%@3AM^Z4 M0GA!^!8^0^9CZOK=HY\$%KE60
CP""C44^<(<10J&0^!#L^WZQ;J)=0JD17, %& MM;=D4I\$%7L!J!P+>P@ZP\$B!LM0ACFOEC224,"^!>W3>?P!(XM,8)!@1M#.(8H%B_&^A2+&0H<-
TV;V1^0L3)1).B>KN;Y66LID>^TJ^Q!>P\$A^% M@39)BRMCHQ!P+>4>2+YD1HL(#?70&IAX>P+P&0!^F=>D:SZ^HJN(Pi5
M)N\$N0^+3.N2TTS+8&P,X3V!;JCLVR&ENY30 ""^AVI7I~)N8+(Z.IUD M.J.O\$ G<#GELW051NAOE5H=SY3^IR3^K*3,Q 5SU>1G?W-
LU!6^K_898T)=0UHP%64!DFQGX<S^C\$54XRE%\$J!2Q&I5WU! MUH!2?_# M+8V YK.Z2J7MM4H!ZB;^!K4A@M>>J!63Q5WE)H057SU%LM-
32H2DS!H- MUA3R\$LYA);?ZOUY^%~%9!SIP J.(PBYK^BQ;TSS&D^ME.@AMX!H^%T?JCRSN8S MZ>^J5(3D^@WJ_Y^0R^@X0848K@;C?
DP!2^!^CT;^T5C6^1^!W=??\$WY=WI MG7 Q0=YB/KM^780TF \$!_!<=7Z^-R4)HL^YK^K<FZS7(HL#UM-A=<13 M6^>0R^>
8ZFEIY)8W2J7<^WX35U3VS2%TJC3\$1627^OYN5;^!6NH(G#Z^M6=<>^_A^7L^T^*B22.T\$K^4IX!(F^;PI80T&M+^4A_7&GM^TK^;#W>Y!
M#^JHP+4KBNVC9SOE(IGB+EIY!D0Z!JYK;K^B^T!6W<1HDV\$XRR;?\$R>+HU M/-4 M^7)CZV!~Q\$!^!+7>+96Q^!#)1LB;17W>)+>;R,K?
O6^?T WA)=M+Q>S57KXJ!TAC6\$4FM&I(IE^M@#G;4D3!XPVIB&ZPUFD5B>76I3 MF37^C^VQJ^D!>#>)V03-1V.32B^A!6!\$!RTRD+8_~D^S.C>C-
8;K&M^2^EM+IY8W26=UB F M8 TSWN=40W&37JHCW(*Q_C^IXN9K;H);HVM.RUHL=+2_&ZN^ISK.65.MT.BTNE^T?
UXT8 !MHCI^C+U>7^!R;TN^0HJ40@G_T C (ET2PP!59 M+=4EYL7KS<^A^ANG!+>JH!#22D?Q4Y^U^0^C5C/TL^UF^@!T?
^\$=^!GTF6XZY@Y+^#(2.C0GI0PZ#@MAK=U^W103GH;M.PP~J^W.N79U^9!OQ>FLUGFPK_SPG^%XJ^YCN;8+30Y-1^TYHGW0H8)
MQ/SY!\$+NQ;WB&_!BEA?T?>NXIS1T^8.7>WA6XLC5;K^I\$3;E(=E^LR75>I MMUB^SSSZL/4^9^Z>9)YXER#D<^<CVRYC=^2!B\$
QAU3\$V_Z!0^HC6E43D=C\$+D;H(D_3E=M)@PT AJUH3(J9X,11YPB@;O3PB,D;YSJC^NX^XC9_9(X^!&X;(QX4^M2!H8J/84E,S3I68W5PE8H(+&
12^C.\$G.#0.HPHM+M#C3^RX@A^Y^WGN^ M91U5EY3;=V^Y!#7U\$ 02%K_R!P\$FZBE&P36-/4%\$L4(M^D^R^Y^L3C<3
MYHS^IR&BN\$;GO;V^8EDGI74);6G<J6\$HD2C>I)@Z#P.YR"D0R.D R.19-"# M 2#9H) 6!C^<8&D^X\$DM3M0-AIO,,=L2=&^S/A?KB_!_DI^ON>J^WF
M92A;DSL3G\$MHA^W!+^E0A!S0^&C44_Z<68T!7_2^JAJ#1@M^?^JYMPY0>VY MI&HQ+^N RH!P^3FE^3HJAXS_0_!50@)@HW:08;
8TF-10=2!QJFV^V!+E\$2^HIDKGLHZD3^;CH-I MB+!H^D@L(Z7?>?^FE90HY&S^&D2^#00@!^X^2H!^0HM^R^;E0X!<(+&X# MU^!&!)2A^!(6!_E<
^KJ/G2EMO:" ATARJ!T) MD&PP!U+^TUZ.34?A!0>@ %LDY^ZQ+2@0GCX2Q\$E!;10<8@_# @AID>6D MAZ8;\$2<
E@D);9.ODI7^FY>?>^<41V!7%?2# 9!%D)@UKWR^!C:5V\$ M^>J39\$10-M.ROKWP-W=N+YW0AB;%VHC ""^!QICNW&U/6!A6/8GMI^C1V
M!4!HKA#2^11D^CAI+G0M^<N!0;KM0!;*&4RIESH0U;L^G^2H;CLP MJ0_DK@U^EY(K(HG&6(\$!!+0J.LTJD^%HU8P\$8P8!48!HSK/J.14&9Y\$LD
M0I>9U+R_U>3J^Y;@071X^HFBJ-RSJR,D^&+&0HP!1^1?W!>=N3F9H^@-1
MCKAPNRX0X+1!%;G>9GB5F9+8P^H_XML+3+8=\$+!\$1@9W!XG8;+JAR6 MP6&V!_H7T<(^U^T5 JE=0>(
M99V_UB6@/=HPPSOXF2@^\$S,R&#@.9Z702B1#V10!DDP(Z;\$!DR?>=JS-MO+/#N5H(?!^7&)>;TT>8^!VR9 8!);# 7%(Z!1.WER0)>#41B&M^"
>#T!>I3! GU_E4G;03K\$XH\$ZU^D!C^!I4QBBDK1&P<^Y.H @6R0XG M0^@44,~\$!L9;P;80)!CYUGD^5^7B8;X\$?(2)#M16!YCYM#AY^M^"
!E^+~#8#8+8BQG00K(^!Y^GL_PVOJHFD^ZX#P=PV^T< M5B>#1<;2U/AC;NN S^LKG&+B2(4^NE^G/UFGL<3@8^>PCRCMT^@\$\$&W^
M;4).12#6L8@I&3K^DT3@C40!47<16!3_0F3D5K\$!<#8\$!4)COB^#^SH.P M#>?9ZET180QPT!D(B^SZ!F+I> MMV3D?FMZ!B2
^!(DGZ^CP^B8!\$27D6 PPI+5MBA0_0@S^"IY@0Y8H4^M48P<<<H!AX5_A6VQYVIF24A!^L^Q+L2+W^D)HEDI!B2=I;9+#!I M;A@&R
JAI^L^JAR6P5SCT&>(%;" 3CL+@ZKD!^E-BC^#MNB\$30KX;8-2>J M^YP2OMW3HBNEG;G7E^Y)S;&Z%(@\$4(^R!L07HE-6 L\$!S>)%<I8-VY6?"_7
_Y<^YXG_UK_!ET4\$2KS MI^<+!^WIFI^!X+P6!2^*4!KDQ>?J^46)?^TQ&8T<^<(^@0@+0B!@S!A AX MU6;D&8^"PC^G"~? Z6
4HV65^5^3EZIO RIPN(GXD EH^%OYP_L!S;B;S^T M#;88DK9@3!P^C(D_UJT)^Z^G&^DTPYE#P&E@)U;WDFZ^7DHDXGXG7 MO-75P0.IMGEP^Q=
@&B;*@W..!O66BW^8%(L4!T(PF_/PAPX5O>X!_DNP NH0Q=S\$LB(1^B0A)A%5W^WT_ M2V(Z&\$4.HHPA7T0D-B
!&8&@92%&H\$N2X+^_R!@E.V!@A0^7ZP_~TBVY M.6WG2A^G&P%\$!&Z#\$926P^">\$@D@#)YI(NN;10#^7^Q=M^M!1^@6)HAZ5U26ES6LJ08"\$2?;=
!GP;3&3&V^D=D*~7 L!M)W@^2;8D-M95(Z!1G?TH!@+ ML!6X3L57K%&OJ_Y6-"0G4^;15E0!)KY^!1!QE5_H1^D7^14-NNZ!N>
M_<8&9A3>4!#+_Z.S6Y2A^QX/LU!8/M!6T UXMTFAZ7PY^L7^H!1PI&H MO#6?U5VJ;H5XE\$?><0G#!DR>F^Y4-
\$MOO^7Z>JOF!;=GAZXU62F^;MK&GD)9I&2V10>^XU<_JR+H!XSGS@_4<1C5W6%_Y9GJXQ733Q(!= VD MGAL\$S\$T>Q-1V3D!A!F?
RGBD@U@PW#K&+D&G^M!AMX!%T%J9R3N9S M^<(^ IDQ# ^XZ_RJ\$E;TZ93%)DSB) M^!<3Y^WFL_L7~?K=8QF;0EXF!>Y7G^0^G-
QGS8NFJ9-Q MENAZ9NBMTL;W_ UQK;6^2FK5JXP^?C^93_OH^PDGMLA722UCOV3 M&3G_WW-T2N-9MAJH0O_"P2_YIN-3U=18?>
E^;QXJH!U\$717%~*B M/RXB(WDNHIGWZ^YH(LMY&O8KYZ_-R/#0)WPZ^7W^PQ^FUWU!O2M!O/M2YT^!L1=2GB!UL0%V-
^!JSJ^XS2;JWDS4VB_ UYMKA L262Q7CF K.SGGWN+L_6R^7A?K^IY_2^0?^1JWU!ARS>S RAWG?IY+ENN0 MH+^#@~;
HAH&Y0YR^T(E).SY>2@7T^1HHE9-NZ!HC!L OCR95LGS=E6 MO-Y^E^I95^C0!5S2V^P7=EOS+~+6PMJ;2 CGP88U\$SF MSYS5=16&9-
20XR25;~)S/!H0&*^PM M1>8!\$ORD\$EAY45^!K!L^s28+UY^DGD+Y^2?B81OW(FF93!O>8G95;19^M^J<~<#KC=K,G3W6;_ZDF%_GDL7>C8-1G;
<@%) C%41^Q!#^400!P2<24H^!WA^=P4D> MAU0!6TW8CHJF>6/P708
J=PWG3;~+10%<C%713DWX797;~?>ZOS>_KE&\$!INOD#^+M=P9.YIOKA=%D&IWXOA9V;L!M>7L;#KWSV_Y9I+P#2H) L^V_ HAHNO MIS^JRV
_B\$*77<423J6ZAZ,"IOJY^)(HU; ~*~4.H&+R350MMV^>PFSH^4 M=P5_F/Q=&N!TP.MY^AG/T^*#_N6F-HSMOCMJSB!
MDE231=PUK.#!WQRY^6^6K<^1_18HMRX3\$G080.ENPZ_3E!EP#^N\$J+M!+0 M1058!+404_7JK0QD6F7&2^W S M4:U\$U-DE7%F(^DR6.\$=8@!
I5^4B=1V7A2AAG(S8=Q9\$5OB<~>_WK7H#> M773 M-\$2G+^W.L!NOU^L7;G&R:Q72!^BNB><0X06HEDFLYXHDH@*!R^\$;9P
MM.4JDNHQW5 "T8N^\$M2^LZUV^*DNFIW8EF2;H!^!;20=05)9!OJ19%\$!B.F M\$0/AYBR2ZK^0^P@WV@!AUKPI7-MWOP
X2JH4!7NZ=4!4)\$Z4\$^M!H!DV M^!FO0!2%0D-BSX\$C!QI2TF K!LOHY^*8; MQ!0Q3U75D^H^HP^AP.U=JGE^;)Y8!4L!VJ!ISM@1(VYVZ!A<^<
MNK400!ME2DORKM5F10VC^B^P4PT_GIX05-QJEN)@;^\$E!B7H(R^;C0 @#^;W;45\$Y!X4V M^!6J_OU@!^/T;@.9>4<~>C06!88V_X6
MIYMWI9=^/JC^?T;GS;#YH!T4_7B;EDV^%M JC+Y8MFW_!6I/H;JDN-RI> M;WXJGEO.VIM>WT;UWB^64M^M5!+GFRCUL_CR?IC4YT^0OC!?
6/_R^N.A M_NG\$ION^#EF IWIID^_~3R7+=<=A06^!WQ!H95^93CULBW48F@2%0D;LO!L3+Q_G5!OM>9!D&?R7MXY/M!9YD_TAAHF^O/G;WM?
LZNS1\$&8)7?W@6XLPT_YALH!MOHS3^!OR/L935!U^S)O!45!8F>?%S^2LIV^!CDR8C6WS;1%\$S!2!SK;U!MPMSUS8_BD#\$E^Q>2T?
XCCB;A^VIVG_D#<=^!JOG=^!6S!U^FNR9;G5B_M0C\$EIL_20S2;2>%3.H6\$;82(E0%+L-KHUY;L^8VZAEN6P6_#OE:C20XRG7IY
MDR-18X.MY=50=9KDJW22I8Q@<@!9U^!IO1Z;7Y^KTQN+QOEINRI+!J^M^C^G
9PUH.MN4+HPF6Y25>CETODTG6!P:3J0!HX^YW<^<T^2!4!5T83L)(.M.AK^WM0A^UMA1=^D!F2C195%!/0U M^B;SK?5^X^I(PH!L)W6!
(U;YK#>7>~> MLIIWBU10LE7^!0NOZ!^!>20+&+DSNS4)K4^?2FM55R^45W&D\$40>PE M9G @U3T<~3%35X41-1BU D;Y!H! IV05^
&JA&^PL^4LT^&-5EF)^!^3^8 MCCJ^HP(^>DPXNV 42^V.QRAYP#JYU62J+DI!_%XGW/4YO)DGT7<;SM+=MLW)8 4MQ%;H!TLO(5&Y^&Y6_&S
~0%0UMOY^&*&Y_.00 M^+2+I00!1SB^!P\$N^+&^90C^(N+M^6^<^P^EZ0^3_KJ^J?>77!_J^8IG^!M9>OU^!>7;G&R;Q0B2_!0@=CXN\$LH!5
^MM+^PHD_AAA^?VE2\$^2&TBJOYQ_ M^4_&3>(^4^C47HEAL!O!U@OP M9D&J^C^A3T^C;K4)XWH^2VL=4Z!^!6PE\$QOBRB2>_!8>@9#
MN^9^!S+0!)^#N+N.L8M=@SS_7>H!Z!^TH- M7J61GLZ-3_O!LS_ZZ3HQEVPI0.T?>_G^LF7\$KWK%K^MTMU>7FQ>O-3!5SBUE!
MT^0^D;SS=KR>JVMIN;^QZ^<Q+!TQ^!Z&+<7YQ0K7UY_/0?Q=HGLA
M^#>C QAWO>I9+G.N.#0HK#>@^ZJADY0QYRUP;EY\$PY.2A7EX-18U_EY;8 MYE/9VI2_!_HR87D1Y^!%6MTZRI)!H59%H74!TAG6MDB-G?
>STL(!0EUE_MZY3E>^@9^ETOUC(Z=D&V!+=@.*)>#Z43&8HT+!^V@!0^VI^K3^H!4YD;@J MW9JDW^B5M;%6#D9!)S(NP34NC5)N5\$;UH9;TX-
!&-YV6_4 FISHO;IF4&5 MJ)6^U!^\$6FPTA^!L)NHL9Y!XZ^Y?ON>8H^J=2+@T^M3!^!\$B_~\$N^%A14=>)
<H!S4CBRH+9G^Z!G&F!F7Z>+7;D+!^6Q.952 M!\$T;W!>9;#Q!\$L7U!5D9G%Y@>V%>INZ>W=&E+YJ6KH@5\$D9!2SU6^;M@_ERQWZ
4^L3^0-M+SQEHLNB=ZW+8J_2ZL\$ _\$C.G^\$!9+^EYQ!H0Q^KH MMOCG7D9Q5^!H44K;U+3388!4(BSFI^C^G4ADHT09^;EDK8X20.P\$5Z_\$
M4^*Q_?^!&4G4!^E^!U^N^J(X2PBA.%\$GLQ_DO4-(H<6);9^64D)ML2;_E M@!D;4>)(%FUE C+3DZ\$)_SD@S_Y!M0Q!_59&=_LQR25K<?^?/C;8AV36-"M
G7;(^55+&)KU^!1\$SE&^IA5+D7!IG@U>3W!A>07-TPI+WJ^B+>WJLD_MXGE^N!H!A!SQ3SF^_W%!A!6XS!>H1?
Z&0WT\$Z0!5;IY^T_RPTD^TIS^+=JBN5 M,6E!M;2>@#F5Y3L2^GCV!U^X^FY6&G^J7VZ_Y!M4S32TYNPA!CVYTO&P/

M7VZ4YNILMOBNFSA4%AZ=XE;JG6J2K#NVUV_Y<793/N7;[D^C7IUYBZHIZ MBZGWJ6\$;O-ML;=H^;[30;2THOF\$ NUB9KI_Y\|WCN)IU-E_Y:QOEXIU=?= MZ_-J>L8SVU@13Q4H^H+M2; 5772QSM9LYDEZZ6<_56PIVZ|>6=TKO)=_4
MGAJRY;FY^4K_2(3YB|7|^@E|J2Y^D;A4.34WNW6;_FEDOI^I^MCZFT_ D4*&N\$^(<^W1-?+Q6R5^KY^_TEC9=K(U HDYN_N|+L#RS9=^T:L9<@M
MQ22<_IYBSI%QO_D|_H2H^J^ZC&63>_?+I/SSL7_SV#&T;P^2>2S6>15_5 MQ76BHC|NHJE>K|MHHCVZ7Y?>=70+T/Q%>ORA>
<#GRWJPZ;3G4D_7|9LEDA.MOD@L|B|71@LP5^F;I;T.P+MOC+CXRW&Y@WYJZ=D|>4WZ_T;4Z|WEU?I?>D%6
M_-|(H0J#JW09XMKY7V.RK|H^Q|E/FF4GQ9F|H9;L|Y13>NEW_E_U^UOS MP6|S|^*Y%A?Z9|S|/7|C-IOT>A_E%(=|C-^1_742DG5HY+(H/1FL=+2.%DB
M3_TYUG;_N|_B8GD3)D#%8_2%P*_*TBK^M\$)P.B70N89X;.0YA4^<-BKR|2\$<="&\$Z.6GGQ.LQWKMOG;_CVE3|MA_WUTZ_2
M8KGK/U^WQ^ES^E|_5T|_""FX|3|E;K#|DX8YLF|D;H6PK|<BLNS/6705G_D_-|SJH3;_02OY4VU_M9.3.5.L#7MK?<(Z;&L_VU#+)%)\$9W3P;^IYGA|?<
D5D%<Q^Y^Y^VLXS_5Y+_M+5+8=UP5;EO|_U%\$DQ>=R>I F#?I=C3JNO(AC9|2_:%8Q<^8#;I^?D<^<
M_YTY^*I^\$E4H#307?=\$%K\$;VK|QIT57Y(5|W(=|S2TN>_6|:6S+?BP4@Q\$)=|32=BE@^I_32|85_X|Y2\$#0L9XK^I3AZ^P=P4WF7
MIM#4^D0^_&IM1EZP9G5^D_M6:6MZE2SM(U_2_FMSN^53^2\$#;I^R60^<^RL_P\$W5CB_F&|>79\$CK2(C)_M|N^F;K<1_XD.
>+|=3TU>/%%H|+S3CMY;LXDYG_36;|DTTXPCE|8_7CE_M_T_P&(4^R^A;I9@4|H^FQR%42>_#_?E^_#)I|Q|S5>WV9+P;=#?I%K;1TU1YYVH>#D2
<25Y6L=;F_MNY<#UL^1^6M5>?&;2|TLJZ098;S76@B%<4K_FQ&LXQ#)H^|AJ;JQUH#+I\$9=M);S)#CW^_7|>O^M2)6.1Y<(VX**Z02Q_Y+O_<
+>G_FIGM12W=8|I^W_R_3+&C_MNB_0^Q_R8|L7;=(V|ST\$Q|H|U|K^P^M475;RQ+RP4(1^YGB\$B\$7H_Y|H|+M>5|BOAPD_A|R|3S|^|^;=(
|RHIA#|PADRLN|HBYL^|>M^@ODH0TN+M16VU1QAAS^J2|SY3H^|@&^HBY^ITC=P#241+R#|JO|U1_Z(^M7Q&15?2|PY092|_V^5Y5AP
R^A^F6;CVRY^AX^CK(F2JL_U2YQOUKGA=(H^2_MHF(KH7.52G=>E%1^+YN)|ODE_YZTY<8_8PTS|TNVSN;|5|8JTPD^\$?|U_M1/C+NB/EJ2EZ4\$*
(OSPW;OCL@O<X1^C#R_SRP|H38R_9+7Y5ZF^&|ZE8|J^M^6^8HA\$;Y#D^FRH|M6|Y^M^B^C#F2J;5AY;GDX1^WSJ@V65^T#O08FRJ_12+K
M&S6|&|QZ|ZD|>>L|@>|TZ_YR2|B|3U7I&Y+@&^HB9^JKT#3_P#741_L5|0R<=>W/3_MTD8@4;SK\$?B^&^OR#^MS%G\$;0?|U;@%51FQSY^>
3(E0\$^*B&T.CKHNOJ9\$ MYRYWSE/GBML%@OPA++0^_NO%KY+;I5<@&@.CKEL^L2F<I+|UJ<"LI3^KO|J
M%R5|O|H|+L\$R|M9=&|>01U&9K>N@BF|^8\$|@2F|^6EB2FESKR1_6K|V|HGF_M\$Z|H|O_+2JX3_X6R|BD6CV9+%;7_Y6I+@74SA<70+99_8^V
J92Y|EZG= MJC^SE^?U|ROOX|K1R10_@;Y.51Y6UX=>EM9753\$*_*TC1R0OLQ88)X@1\$06_MKE;L\$>MS?SJC7|/|>C^H^C;S562?;|I6Z;#UF_1>
I5_X^G|&ABCZX3 MP0;^G4|JZUQP<@AUI^Y6RQC_Z3+1_LWTV+ZIU|_C27|S@NH|HQB;_U_M1^I2P|=L#7&L_22^<^G|G_I27A)=VV^GB2+UC
M_Y2<_AWO^X_>;|0C/F^NUI^_X^_80?GAEFJ6W|ODD>_A8?F_9|Q_&|HFTY+|W^?TS&7+|O>916)Y=;GW|968_MJ_1_HF8^X
TD9COJ2TQ(H^X9#;_";2C;Q|>N0B^F<8BRE4(K|RS2)_F(V\$&^Q_MJ=Z8K7B>+G|Z^9U\$_5)Y|8ZY&RQ;W|6U|K|&^\$5|V\$^M8^2GS2\$#|M4K7T
MTH6944WK|H9|85W;GCU+|I^_B>30?ZY_Q|Z2C=MLTNMJE@;_ACL^8QFT6|
M%|V;@_BE%|^H\$;QTMX62);_3E66F|^\$AWBERA1GGZ|Z;=I9^FA#;_*F^C^M|I|D<^AAS^B|;_*FCHL^?P\$=A807NV(S|;JDN-R|>;WQV|=P^J+WH6V42-5I
MREK^&+T3_I^P^?MOMAGCZXVZP|NM?7G|U^<|VGV?TR&12_I^A^G#)J^ MENN.0X/^="AQ"
(Z;5#DY>4|X@O^L43|BY=AOG=|@LHVRG|5|WW>X>O4N^S_MWB&4^27ASAQ|S8+%;?&F|HBGL1_OG<ML#@?R<=%2|_V_U7R^BM|^MF+
G\$_9+>J|WG6V7P2^_I_LUR+;_%2@9YX|SZN#&O+M=G8(G|H^KOPC^PM^U(>%)YUKP3_Q5|S|5R/_D5?8<51R47J>@=AA@^T78%^L_MHL0|QT_T_+
(Q|FM^%|Q^/P&D5|)V^/%^O\$^_X|H5X(JW2I)/SZVA<^MO^PRE^*OKOY\$#\$S^HWJ^J_C|(06TZ&6TV4<3@O_6P^99@?PHLY&_48|A_M65C&
6Z_H\$;G_KR|@&M^D8PB^C|>_*H17R\$^*M8M;|517SVYVP50EB1^Q|DKIBQ@%N2L_I_Y8X00;7Y^X9\$^_XZ0YN^G<;_W
M&R3W=4#IU%+;F;7|_27^HC5GO#E|Y9JH(J|01UBX8AT|;_J_3?YDR3W(M\$61X;JZ1_L^O?L^CD848E\$>EY7?&U0|U;J|Q7^4K|H|+4(L|R|P|RG))_M-
|_X#E@|I^YND2(V6<6^<1^2^2^3>|R=I_P=IY0UY4_X@+CM75^00H55V_MWPHQ0\$^#D^FRDU;H7|27G0|;NH5M+YH^9^6%N^ZZLO\$C^A|IWGZK2-Q2"
M;ZB+D^G2-Q2^ZB+D^G2-Q2^W|@>_*A06#&^MSU4_X2@CCKK?^Q9K9^*%>_Z|HQM|_I_3+&8K=2A5WP4O7I_E=<+A#J^R&Q5="95>ATYWH|54_A
M|KJE_*004<H^C_#F#F8D2|AQM|H^LP9^*C@#58;H^AB90UG_K8GN9|PNYRKW|43WUZM95^@7|NZ_YDJO0_X)<

QXEO^GLAWW>E MW4 / 4_%(OOY2)^(ZC.QN7053_E_4P)3_E/2Q)34YI\$GK%YC^7T2S2=>^T\$F M%_Q<^Y8^94MQ2;5Z_EFLKF?
U;IM^|H0.9&8WG|@^T9YWMDR_VRCY&L_MV_A3#OU|M4SC_MZ?T;Z?KA/S@|O|H|;7K>_A4.NO^5NL8S_+UTF;J9_1MZ_3V>I#<_&S=
MMYXQ_&62%K|SRH|2_O6\$=*R|MVAGFB2/UCOV30?WTO^>_>K|I_C_B\$>I^<^T^?080?GME?VW|_I_C|^|<3\$|AK_M1@_L|H|_2|TZ&|
(HQA+^90B_Z(F^W|)UTWR_-512?7B8K^N(BF>4|O|H|GW_MZ^Y|4+7XW=15_9EJ@^@_&A\$^C^G)6YR^KZSO^_*SB^Q^+O4E^I^S%5Z(%&S_M
^N\$K.W_N7X4IB5^Q)V\$V|Q|=Z8?7F>+G|Z%1TF?E5L;=|Q;C|V>+;^5|_MC^?^*^S^?#VL?3YIE|)6J5IZZ<I_J_X_EFIB7EDQ\$*7Z?H|V@^UC_C?4|U
M&S|P9|_2|^*#;#ZX>_UB_HL2+|HUT9%+>Y|YZ^G_LM|_I4YK\$ M_U\$B|/UTX8_|MHA_Z;Y_W>H^C|W|_BY^P^KIBDU^03_%2C_UW%F_QXLUBF
MRR_ZSHGB_?>?>Q_XTRKT|>3|2S9OOFJY56|^I_;"8K=5^N^I596_7AT^B^MB25|N;10_VG|>SC|O>_Q_YVN;H^F6_WU^L7|^(79|M^Y7|DG8J@-I%|A8A?
MA;?>^L^C8C^2J|>M=4^4%Z|TA0#RW^Y|Q>KW^<^K5N;Q3B9P|_<LXT>_9>AG
M6LOZ^?&R^J^N^A_JC5|QO4S^D8;#W^W^(<|Y|EUY7|P9|3B|XZ;_F9HRU\$^XJM^Q;F|_MLE|_YBY^*A;WZKD|Z^S^I^N^O?WR|N;H^*VUH7>>Y^LTO)X6
X3=F^?#M^J^*SE^=7X91MOOE(&@^P|A_+M4|56N^N@|J5|S56P5^VY^I_J_5?4K7FJFYW_M(UG73^B|U|MI^L^R^V^I4D#
|5FH>|^V^H>H|_PD9|3|Y|WY|H9|H|X_1081+M_L=|CF#HM9;3L^Q_HSO^A=9|2_ZBU|X_I^G|_R66H|O0_7L_PZ4|I_979=32_V?Z@F1R;
M^?;UBJL\$%+I=7201^M^4ZAM=^1^5^Z490@29|>_&I^|_UNX9|DC/JNG_4)5LKU\$2|U6^*^S|J^8@32407^PPZ>|YKX^#_MW^*
5^%3H|L^C^L3^W^T;S^5^1^401TH|^I^J\$O_X^("H;B^JBS^2^J^C^MX\$+^_RU3@^I^K414\$2GJ8>M7N4BV7K(W^W^M^?^S^)=^#GUG^73VLW=5|8G>_M|
I^FA/V\$A8Q8L^Y(Z2J8@_A5L2J|JO|H>=H=1J|I_R^MRJ^&_6JM@^H|I>^|YCG8T39W0V2|=MS56121?>J4T8;_0T^R<5_HGE_K^4V
M8Y2%)@_GY#X^D^H^Q^\$)6/5FC^*;2H@^A2^%00B_4_VH8|XA5^8H-QFC_M^_05X|K;I+IV=Z_JFEK-&5B_((Q2%>X(>7^/6_MVG&T&
<F&EKEKED2;ESF|E^<I=FZ7FK/I@;_*YQH8|Q2?357P5^UYB|H8|N66\$|FV|B|DR|A^H^3^%|C|M^|Q^J=H>P5^CZL0^6Q&4^<^|A|>>(<|J_X
M_OG_B|XU^E;_H6L8^H|J@6FJA_EB\$&H|<12|Q4145^8H^&8^8|D^L\$5^5^M14Q1V_E|_T^OSW;_M^&B^VH|H8C09^*8C^MC@MVV;=^);B;@BEDDIB^*#
M\$0DH\$GRWZ1@4IX7BM^WFUJZ1XERA_V^Z;_#)2AT^I|K^&#BEJC^_D\$9OPV^ MK8AQ4Q64.5^M>U_K9/54|K4_H-
8^H6UAIS3V80S_ALD^*K;FJMXP^NX4|_U_MKN^Z\$;_V^L5_7L6JG8^M^@HT20^M|J\$X7_C90D1+^R6BAPDN^UM^IM^&@_M+^M^|VE|+UYG^*+
(=3F&^TG(X@;)_V5Y1|W^X^4^D|@^3).CNH|D0@^@&+A^U^*MY^IS8J7_B=52MK2<6^L\$+97A^TW=U^?_W_W^T^B0ME_6NOY>I9^J0>7E^X@_M^I^Q?
&7=TOO>^L=N^FGKMXSL|H>KW^R^NDZ;^P|>XRIYEIC_D|U^#6C_593_MR2^2AT2;953C^442P^4JG>7W7LY|_6_A^+D@&^IOV|FEERE^Y_3P0MW88;0
MW;OP|HUGANH6UO>GT;|5_C6;-^=W_MLM@?S#Y^_3V>I#>_&\$;_A3^/O^Y^?7^Q_W|H|W|W|1BR_C|D3_\$=^GDN6Z
MXI^@L#_D(8=|P;|^53@O_Q51PXW3JPS_?>J|_BY;H^\$>59;_*5UBM;|YR\$?_MX^G3K^*9FA+&S05E+DX=5>W^K;Q_K\$A_?BH3OOE#
MZR<^Y^LEA+&_3)B_C(9;3)C+7Q_LRQ|0\$9KKH^E;L_50%2MNO6|J6C57_MP5^UYJK>I^_?<
36|SYR|&K;|_>4|2|G|Q4VMI=98WLL\$;_*Q2R6L_FHYX8|60^M^644J^N25L\$N^2D|I1R1P7W7L^2^4FZ^U1_M_1^Y4*>7X99FF^Q6^|17^H^K0AWT^0H3|
FL+I2-L>5^Q_B@0Z|J5_V?E@_M^GYM6_L4L+6@^3^3_VJ_E_Q4_Q8|TR<|63\$%+^I^F^I4_Y_2P1K3^);9B\$MA5UL+H^6E>XAV&L^D^1^2H7ED
Y&S\$=L^C4^;Q;B;@BAD@IB&);B61(AM|G_MH^("F^E(H;MKK|H|IBT@H6("F^2E("H0\$|IA^DTU^D(H(K8|4_2@Q&_MDB|H\$&|^I=8_OA6-6BC_U4
I=G_2|XT7P_9C(2P44I5=I#\$^J|=Q|H14R;_MBJ_6^#Y_K8-0^V+S5_8U#%|K|I=2^FD_NZ6R|3Y5IY2^#UM#57I2_U^*=O|>2>
M6C2S>|GZ6>QKZ2^#Y9^L8|8C2J<_T+T_4|+A#<@&A^K_MD5BU|Y\$&OLD|CY|AA^O^<_5=6M%|T4^FVY+>|JWTSY|BWS|IRY-M5QT|GW_N|YN
*8Y02|W9NF<MUYUH>7<J&^M1X|K;I>_HT^4^>J^I4^*(4|J218G|P^I^A^Y9+^F<M^A^A#^(\$|Y|J8MM^GB|H|_B_2\$>H|A|2V_<
3L+>^*A^I|YQ.PH31M01QJ_MIC1M^*DIM(^1Y%":MD_HH@VAB0U&E^)"^("L_V|JIC1M@+D^DX|(ASK^O)3_M_Z5I_QR8TK3VA_6PU|4L_5_<L^
L^I^ZTR4|2|N@&^I^D^OHB3^<3HFF^C^2_M^H|V6|1U^|H|_BI|H@J_U^U^%#%)>24_1H0C|J^N8T<0U7|IVH^X60HSQ_BN_M&QX0U4I5_5R-B
X^Y|UT^H^H^H|)(9+T^#5\$;ACWROFU44I6FA_*U3^U^K^M0^FEN|EAO|D;2B7_H2V|L9+524^8/ZC|V\$FHM5_0D^F40;BY6I24O^V#<
M4^MB^%6KK@FWU#5(3F5_5_U)3MPI2_N;L1U^8Q|_7J8_2VG%Q^6B|&_%M(C3S2RB;#2E)B^0NN3A@H75T^%\$*_N4W;5LH3#8_)3-
LC8%10RZE^E^7^*MH|HAR^*42B_SP2^|92W3^<H1%YX>_M>NWC_IGMZO<3+Z23HQQH^M|MJZ;|W<L|QRC8B|L8BEXDR^O^OZO7W>)+>M_-
^P=^=JZBOS^6Z)K2&K|_M6T<^*XVP|7RB_M|WE^+&G>L_J72LGPS;I_H^I^C5_H_J^NEI_X6^XK=G_L^MOYB9B;=B_M0@_I^US6B_U52RB;J?<
ATL_Y|H^C^852Y%_4G_>NH|YJ(=I%WU5|>)>BOZXB^9Z_ME2^C^Y2PH2FE@OC7GM_#|I2AF9;GH^#DXX=>I89N2_3L+R?Q_RM2SF^*85I^?27B+P?&
L_O\$=G3J^@P;MB(SEY&F_Q_M_GZVN>@QWB|Q_S^#Y4>^*3|OEID|JEE|L_C\$Y_P_3\$O+>I23J_WD7SZ^Y
M6^<_ISG5^I0FDU|OHPY^L<H^A|>+V2O^Q_A62IUTZ<5S+I|U9K|0W3L^I^|@J_M+7^NE^Q390H3S|>L_+>^9^"IH;4V)D?2^KC|3D\$GUXFPU>N
QKC_2^Z|T|H6SRW|VUO>GTJ5_UK068D;R|I^_M|@<SCQ^WH&24_K|KU+Z_|NJ7NV^3|E0|FSO1_X0YWR2RGS?=&A0/M+H|3|2L7|^<^?<
Y_C36^L5K_Y|_U^B=^KA=G|H|W|H|O^E4VTO^P^P=E^<^M;4>PKVWR_I0T0PFI;B\$;9AH#(S%+0^M^L^R|_?&X^NC("U9|_8|_&5O_P^*
MEKV75|RJL(J6/9>7+7+WLNK8_E|>14L>R^O@F7OY56P|+V^I|;IEU?I|LO?R_M^ECV7E|F5FT3ZOT^S593<>UF/7|J\$+K^Y^I=T/8_@J+I;
M|K=S>H|S6G_5O2V&^I^N^&Y0X)25_0MH;|IRD%;UMB|NFW3|H8C|/Z^5T^S_MMI+U_C^FP6#5|9^X<=*)4#4_6^6|S0QV4J6ED5D853^"5
T@#4AT@5;V%_M^Z@_MP++S548A>8F^012H?^"IL2&XP\$0^OBNY=4ARINT;L=DM03V4|O<^R9^%K
M;U6;F|E=6QDW;8^YOZL^U0A0@5@^P24H|+B_B&D^O+M3O_Z;B;BF_Y4S80R2_M29X2^60K=5TTW^FNQR%>?^I4^U\$E|K_N|@_J#&^/H|
%_00Q1VU2ZGJ02412_W|0N|_MOY^JPHXACR^%6G6854E^_I^&R^%POT_M4Z_5T_H6M6;OAWX@U&@=4^&7N_51UF5^\$|PRL_FFI2_#^*_*;9
*>0^J0Z_M0^I^&^>SY245_)A9&(77?7P_|JUY>|RZM@V7M^%2QI+Z^9>_E5;#L0_P^*
MEKV75|RJL(J6/9>7+7+WLNKULN^<^7CC>5WZ>^#05YPTD^UW_5N^3^J7>L%_MZG|F|BGLS86@P^I_C_XU?
^#KM_+J^Y#9>WD5+L^OKX|E|^55L_R|O^H^WV6|FYRS_MQJ2=<35BK^MQ886_4>2^S_1^REB|G#?^<^Y0\$N|H^#0GTT^O/M+CF;E\$6_M5H8.\$&(4
H1^C4|R4\$VY0Z1^\$K^U_8B|^\$*(4A9J8Y^="^I@%1(2|+P_MP^D>U^OH(K^_GX/BC<6_ID^#^\$FD0UEN9(I#&4^9C^T^WR9_T0H2^%P^\$A<4^<
M^E2\$XORN^%G&H&GGX_2H|^1^6^E5>_H+PA<N_83+|PK_YC<I^M^\$R^H|^\$M_BUL@&8W
%30ZWB|^%@PL@H55|A|45|JOX^7BA6BL^J^0^*@PU@A=L^)(4_M55ZX^*4|M_2AYS(T^ZO<6BVC^9NP/9?Q^GD_W01;^"@B)FLI@#(IE|7M2AWH
M|@B(^<1>|>S64A_E|O^W\$5|&_5&M|I%633?>_&%(PH8F17F01_M|I0|>_>WX_9_M4VT^X^B^FZ|OTM=ZMX^&V&T^\$Y7R|8&-%UNR^2EK5?W|)#1=
|B+4BMBZ_ME4\$F6YW\$61%G;_*H^9_E|L|_M+^F<1=2R4;C^G^T^#|93<@59|H7_GN|3V7_MYP&U|H9U(I^M7X;N^44G>GE5_X|_<
|+1<|DW=6759N6P)=BK+|;_#4_Y^<#Z_MY1^<I_8U2I_N&2^_E_S^J_B_IK^<IGP^ON|RM=|L_VD^04N^9+|C@B^Y<|<^"M88|2MMXT<6D_5F
0@52%@&+A_U6_|7E|>^EHC9H8&915Y^X^7W0|UT+I^M^GY_MMB@ZSET^52A(=|L=3<_M(L^_B=U_DQ8|CJY56P|+V^I^I_MEU2LQ?<
R^ECV7EX^R|H|_J^Y#9>WD5+L^OKX|E|^55L_R|O_HN^<Z|FNZ|A_C_M^+I+XP2_YRL;#H|O^7WAXAW|((E;CR>W|H|N;_2KA^S^|GK|+O^?>5&L_2
M|&M&_ZRFDDU|_3HD8BJG&L^0SL+H^D_G<I^F_LY13W_M^>^%N|>#>I^="^8^R^U6;^I>4SW^I^<^ANJ2XW+UYO|CF>6>SO>G|U;H|MC>
<3RR_VW&>VA_7GH|9ZD_19A^20SL+6^FM02G|H|U^JVGZ|J\$;Y_Z|M^_";3Z5^H^H^#D^0^>1CZO_8PI2^=83_GMB+>7>J_|MQNW=2B;BF;IS9-
3K3KFZ_&RDT_7)R|2|C5\$VYJUMHSB;GU^KX^<C^G=GF^MWMEQ|OZF;TZCKR>5V^SU^?V_K_40|KU5H6^9C^A1R9LPT3OPWR|N_6^9NQ
MMU>P^P^E;OB_09H^8|55L_R|O_J609=7P+WB|B8|IEY>U9N^%G|P2\$>Z5_M2&9LZUG0CM6SZ^"0>=2^&B|0^O^T|(<459R|E^ZKDW;
59UC5\$&2^E9Q08C_M1BD^RTY|L5H^K5RB5^64^E|Q0|^Q_@_1BPLK|J^7G|P^<I^MNI6|H^V^MY@2E3|=Q0.82@^3H;|B|
<^"IR...^FL_P.6W;%2H9I7|;|53=^@_MP@LKBH_E=|4Z^?T^9>^I^D^?C;UD4@%3H/+>+I|<(<^\$2^>X7JZB4|JXFO

MDTJ=O=C3V7MG\^R5%!=U6F:@D-NH5OC@81"VCS":D\4"J\Y6PJ@s*\$8 MDGM*0.@6@FH(B9M*8 2QAYAI^:HC@^JB%U%:"J"D\$7D^WG6I
:~::~@BQNU< M0.W/C/PPPI4\$<4.6++V/(P2T3)W8@CL YKKNLQMV/V:/^JQ.BAM3\$<MO+TTEH\W:A 5CP1^8.H4.WM7 M^8)N#
[B85E#E:O.CTJ53)0IVU<^1^IBR[80]M4J4UK1090@)MB\H(1+^MPJW31N2SND05L5^/1#^1%(S&E-8@X3A9(^KN^1?)6Y<^&AC2W8L5^K%*
M4J1JRRJ.J.1@Q1F16LX60^QNTJ8K6-O8^AZ.B\$^AYT^UHHK31#JUK.S00B M#T:U@U\$95.7@7^WLNK8-EFJ14L>R^O@F7Q56PI+V^TJEU2HLO?
R^ECY7EZU M7O-QQM/^++I^X>^XKR8H\KNW^ETK04FERQ6US.5KT4R# V&U>^AP:PRZM@-MV7MY^2QI+Z^~9>E5.^LO.RJ-
JEOSYMH\XDOW4U9JQ+D6E.^?DM=>#O8.^ET IHX1^+2^VU M^8AIQ1P0Q/=TM&B&^TO OX-ERMF4Q^EM3->P)=1LD.YT70.PE "6AOJ:4M-T
M02M"7LM=A%AH1H\KPSG6@PI^39V^ETJZ J91L1%\$SMMEGM3:6)= M2BY@:IUIJ/DB 9%\$X:LC^82M(A^H3PYEIT^T% J0L\$18;GQ^YV2;PHH5&S+
MRZIH.GP%OO:*KX42YO/SU:"YB1>@:Y UW/H6JAD07ZZEB::0B<-%#Y@:9BP
M<##3RZM@V7MY^2QI+Z^~9>E5;LEO:P^EKV75^R1 (J6J9>7@7+^WLNK8-EF M>95=IE=I=#U3#_&=I9^O7D:SUN7:LL^/H/7=O^~7B:~
MOJ14>QY/T9N-YW:IOI9^T^V^KI>+V2HJ2.N6W&LXFE^ROS:8^8VYB8 MD3^V YV+RKZAIQYV1^@O2>VH7E1G.9.YDD__ZCQJNUPNU1^
M_X>^8O?G@4%:_FU\$VAV3\$A@HF:J^MG\$UZI#(J9RBK&40BGR+VJH:IO MNGGH.W172547UXF^KB(HGJ5+Z/91^A^>^Z-
>>W17SSU^89EN>@.3CATV^M^PIZOK%GJCQC@LH%6SI>4:57H@4:1#&X28Q5F^&MO(Q5^D?YN:AL:5%)XWRTRJ52RI=MF:F=F/(5\$/%GK)\$JZ?
= \$IH.F USWB24.WK:3.HJ1^*1.C^YXNYC.HL2+M:A@J1O3NE27P3J^9*=>2G)+M/GCA8WP1^I03^ELHGMJ7NL=^N5>5\$)XGL1^I9
>K=16H5M"+O\$2S42-L M+X>0W-JLCXHJ.HL2:\$7/1X5:D&J3^U.4OVM1 (INP>C\JBO^?2=D(8G-IT MA?>M.WIY9RNS>DJ.72P1NJ2XW+UYOE.IX:G-
WO3Z-DJ&A&I5Q:~OCL MJ-@N:2.QH>^ID 7ULBZU>2SS4 IY:W23 0R:HW\<1^Y14LUQV^H7% MT^22P4^LHSJ^MDWYS^+
W^K\$S1XB675Z/GC.F1+Z8^DMNRSL M3-FE2Q>SDT B/L1.9+I9.SD.Q4)VTZ^?DM>@S=GRZ2F35(GJ/OW+IE MS5@E697@A^XIAU=F0U(>V%
@.8NAB>>76K.OOK^I&+>V/214^4CST1U M(HOUWW.U^RSL9K#4.F6TB2\$G(GKRJ%\$9A.^1U:160ICW/ME3@V@&Q<+WM@+
MDJ>:VM/E&J&S:3.5>"V9@4@ MR@.B6F 1F<W6(HD(3&I4/7^TENV711K-O+>719ER+U="K^KZKZJB\$GMS2#@VC-N7B:Rf:I3>5>?NZW^*4W-
+AX^7UM(C@<=>9XLV8\$1081^H\$A8.50%07KY3WW6LNC0%1&9G66:3W<0%01KP MJAS^PA^_HTA5CG.
HTR+^H^K:AD2F3D^IZXQJ/BLMXD+4%L=HWC^5KM M^AO-G3026DI^I9-8^HJ97@L61^1^HJL^T^K33.3VJ278:32POH+ZY M^3C7I/V@7^QQ-
IGJSBHJ^T<7^=VP3.U+H9142PK+VH:IMV\$4+W9B2(48 MG^C2 W4:0NTHS:A5FWO1%1?F^DILLRVL<+K56KM(F161*="SGIG6EVT^UIN%
MBL\$H0%0%):MIUD A 7"-D8I=>=66DRJF4.\$0G+^IUQB1+0#^OJ9E@SA?X^I45? O-L?YCY2<C^VU&BT.UN4HW.VJO4UKSN#-+E:O4MOJ>?^"@
M\$UW^LSB1-ZI+H.Y7:3J@>3-S^+Y=:021J2B2.VL2FSTFW7R:@A3IQLE^F2P M^V>::E<C&S59S=00TX=G>+=(LB?CNJOG6DQ.8W)#(S^>N>=P?
OCK)GTEZ23 MS:~QRIL6<=5MHXW-DS&JMD^JEMUS= MWD:~JFJ^RW77=6#^VF6M%G2N A^?M^M^HC L2/U#:"&7C:1^@HW^*SHJ
M^ABEWK726JQ<#IGH@EFJQXN^?>6)JKD^F_F=Q29-197-07:LFQY62G-XC M^4^OX9D:72N^#019)UCF1^M=42S(3^T9(K^LBJ25D:R1(^7H^UD^*A5
M9IT M+5:D1<1^#YX>>RCFS9-2++=@OSY6ZYD=J1UGU+I92)EHKK+4I M>6<A25>J4CW^WJ:JG-VZJLD9^J)J0T^C@8>R^)%F1#1A^5.6R "E%
M^1-@)HC?^E266KG\$J03N&#3JR^U6 \$9 M\$B=718U9PWGJW:OH<6^GJ^XR.Q:917=WT@?S3LLOU^Z?>?"1%G>F M6MN:++F^9NGJPT^R^TTHQO.
CSJ33>=0MB^?7 M+^#Y2+IE@O)=%G+^A2I2-4&=WJHOZK-O12NIDOSJK=N^PKV=W>EWW4^E7) MM+^K4 VI3+TQ%.ZIZ K.NQ8"
^7=S.1ZNKO^RZF5@ (L/L+&L<7^X2Y5^T(G%\$S M24M#E>S^WC27D)S^&B25\$@H:A8\$1BBK0QJHJTO
M^C.U.M/TWQUHFDG3%3CM^CVSXM>622=VX J^VUU.P?7>RAQ8Z9-#:"M MJK0I:@7I+@(%<*)XAO+9%\$+91V4&7TCK-(TLDJY7I\$^YO2AZ:15@:
MW7^UHMO@JEFFW6G-5-S19W9MF+1+H080LFLU:E+X>FU3LG^N^<&:2^T
MOM:BX3 KY-ON2IB:8J2)DDPNM03\$JCZ4%6H7I3^S0R^XZ^&^NU5Q XW3I MW47W9IX&FPIH1Q2_1.6O^Y)2LIEGJ&Y PE(4+EJZNSIPG%2^~Q^54
2WZ%="5RH@IOS.KBU^JIDNR\$R3 MDR&::NN:8V2JB VUS24>?)%%PKRZ9^JVR@X4^I-VH.G\$21@^25DGB2UPQP M MVD
+>P^OM^\$&C R@4ZNL TJ2N(Z1S)J8H MG6QJYU=0(C^H^G5^BAW-FF^T^RZL:7 M(H^F^HJ^&H2I2Z^Y=:XXI5_UE&F
^1^BSE^6031.5QH=F 71Y(O-J6 ME.OV4=9OICJJKLKMJY:X8S1L&S9^F8+L1+75%)MHZ^W02@JE&FNP
MZW4W2Y^\$UZMTD=QK-6ZJ:YYLSL:INVRUO:N9-G7OA 7B>[^-W1GD4 N79M2=^*T7)I>7H3I9Y
F2^6J^ME&NDUCV\$>T 1=3MW66QK1HRZ^W1%FEMDLK ME@LO.H.Z+1+E5LU8C7\$U7AF5QMM:O/CW@^? KIKSJN^4% NS>+Y^#<:UO MFF
M^O:LNM-XK#^T@("L.F9X)W67MLQTS:I6MFW6(HWNAOEMXBB05L^@JVM&LS/=OQJHPH^7.BS5.OYH1JX0^"AO\$=H^Z1Z^H@F7)-I
"O>=K\$S(4%A:W149LO^ZM7106T6L5D+=1^E^PM:NT04T@LBI+^#FT3^OE F M<:Q)=O1P2^2H3:TCG4693FDPO1US8I2E>P1^U&
YNK0%V6JUCZR83^Z^IX M40N %TH0%#19DR^4+K^0ZIZWNIT(NYU0GV+VUN9>9TV29P6ITAE&\$X%+H
(M&T%) 2\$7<@<6#P8KLB\$>6DIE+2L07\$9NC17J=3D6=G/YMJ6^VTG9G/QJH9D3J^I<^J@3M^~5V1K!
M XB2/U3SWJKI8YPN\$N^#1:ZA7=SB)D.G2WU@QI:EWW&GHWFO6DQ%0^0^Y3 MZ1^I^V7BJISA^W10^I2POF_&%\$S?_F=ZMI(^7M
^DK^MLY@HUY^1^YXG^A.MS1N^YIGNM^J71-Q1MR/HI:##>DIHQNW\$&V M^22@%:15Q.YRI2J=7WOQN[^-Z]YFE^5ER:1.5Z9ZHB.U2RV\$^L:AQI-HP\$<^
5IUTP^F%O^X1 P+1+1>IIE4C M.JCHF0Q)^V^XVUWLOC^R@E18+T5Y48I^UST53U@T810/8#1-I.PI1I>? M5:(#EP^B^#5:(#EP^B^#
20ZP^MW^EY.9.5Z:HLFKWZ^+C8A M.PDI^F=ENHUREX^N4T^8RR^W JM=ZMHV48_SGV/3>FWHFE7WFW+CGK6Z^
I\$C^48\$3=%EQD^0Q^0UAVDU1U&M>F0I^SY\$^D#F.CJCL193L3L)VU&YD^D:G8^07:I&F68RQ7RR/M0Z8H)OW73=2LXEH3@D>P@R.J(-
T%\$ 4H+QG0 C=V14V^P MRWL5A=.3+H^LGG/@6 BL%>U^4%3 Q1CQEYQ^Z^CTH=6W+ZF_1@>?K^DT M8-3B^9S&15F:TGK36A1Y
K1PCYV^LE2-NA710.^JL<@<6/67\$SLR\$F^ M 6B=5KHUGDVA0.^+H1

MZ~\^N\$D5HR+YX956;<8CJB...^OD(RI9%>9>&~W7A3~L0 MK~!8\$CJG8K!AYU0- NSCBL%81EM2E:S8UOK)6)16HL\^K,K%~="IX:I@TXB2
MYKHZF,F1=4H^O~BRW~!LKG3F>F~JEP49I!~C,Z~%U\$~S>(X!M^JATFZ43~!^QI:3AYZ~T<@~B~"%; OI C6+1C1#~60@BK MJAUO\$Z/RV:??
YBFG/XWB#6-H60Q/ILG/9*%X,INJ@3A!7 N^9Q+=!F!6,CE-VK?KHUJ!=AG:G(LJEG9/MZ#4RFM3N~C^H?^
MY\$DO!Y+=KH^UG)4RHZ!Y@Y&CBT!MBS;#N.,Q>5)9L>?+A^1&K/B\$A3&8Q<~M0!9T2W8LQBD&1\$=1>1SBDA3!4"JLF(XLFA!7LBN
.09(E)-3D1B-1Q3<@SX M7VU!MJ9!6DO^YO.,!2~?3?7 TZD<(F+T=PRIEBF P6.WS=I?V(F>XF&W/M MOISU.4H^5T!59+.Y@!
<27B^UQF6!OP.@8C558=1.9M!0^!IP#C!QA!1! MERU+G^13M\$(K.L3+!@!WF(O!E(IQ^!1UF+~.M8Q5TV
MP@=(RCJ!PXMJP8C)/P12^!AJY@!%*!#1..#24XJBU.K!T~!40V(Q%)/+~"9=&F.5~M~7^!55:%Y@0DNPW!)^~MS#HX:4)5NF+>MN8P~^@A^7!2~6M#?
HP7N6WEEF~M^W!G!H87>FSU?75HSN8J/KK=-V^R3^O M^?2&C&SEG^09!^2_G3EL M2!R^9P(LEE)Q75FO+U!)A9DSV:(
!E/G~R!W!O/4Z6.MUS;!7!PFR?7 B30\$H MZBE.SY>S3^O M^\$A&S&Y&DBB^4!7!~\$B%IXT=DG&~ D20!QV^X0S5 N0QC
MGQY:C@A.!#09GMO!^YAT@R%RO86!R\$~.D1~*MQR=RICHIAMN%6~F!\$*~(C) MC@6.S5650@KCEQ!^R^%524_2!@~:5+>%Q>G2^4D)56!^B@PN/
GG:/!M!N9H_VP30UIZC^3F(2+>MOMO^!MZX!U>S!Q"IC=D_Q^L)ZUBV0Y!\$TAP:=3 MAMJFY_3^2^K!\$S#D^!1:CA_E~%HR&~&SJB@M7J~V#+
WJE!<C&E!HJ258S? MY^~\$#D3!X4R!#1#~!BZ!K23!K^*12TF%5A@~2^ZX1^P^HNN!Y@!1/L8^M!Q!>R^("E^F6G4@5B@J&+~WB4/Y!L\$S:7&~<
5/G.0RZCBR3^8*\$,#TO%_R M1\$2M&A%OR\$!ROH^!S!>Y98RLRM^T~!Z6SW~"BU.EI.DR54&RM,/H6!QC3!^5
MT+!XWQ+~%1EY!4!=WD9>9!128K^XGO@QC A^SZ\$SAMOK^K<+~Y0&F!L6>~MOT0DH.P<1!^?&#Z?7!JRDXTW,+!G2/J63^QNGQAO!2P890P7-
!P3E\$<@M:31D&RMXO7BR5)-C8K564_P.\$B44R9R7X%M!G!A!K!+!T!<85~Y%~D!O!K^>LN:C5Q<!K=~!K!JW40_28Q(8\$
M=+RTM@OX@M(C^4@%\$~!O435#1>NX%~.0*#^F/GC&0C9S^4(ER20%ET#0M, MKZ+QS(LQ16NZ2=::2CX(9> &/(S8YZ2CGZ=BN2(K_-\$
3U&WF(H!&N8~M~!DP5((!\$F\$P~M!H\$(!\$XC0045^A^!M1B=C8!1@!#<=C%K+!+D!O!>P4C~MB5!NN!&T<W!V!>Q&9X.XUDH!AG!X:D?<
+!H!O~W4>2~M^@5VTV5@~"AP(Q@42X!07!1C!H\$R44!2B!P\$~W9^C@!%YMNBN6ZX!H!
>MN:5!0!URF!1M8Z!H!~Y96>5S_2!~.DW+!1_6N^98%!@&OEQ&~M~75^M5!5Q^C^B^Y^!#HO&CIB)!7&~LSEYW9D?~3BT:N72P= <
<E!L<~<4H!^VC75ED!L!M!E^D~55FH=W~!1AH27D6+22C^%C#88P7!Q3=%D@JL@WCZ~.GB.2!\$<G-
M;~!J~\$SO@55!U^~8Z&5;H65\$;5!47\$~H^BM@&8AR!2F@8LNV^CDK!@H!V M22\$2P5;LL5~U!+=YY^Q.DK>*3
X/WTF!O!@~GSAY&A6!TH6=C^A^!&S^2 MUB~H!HX696J0~!^WMZJ8+U47HR#;CUG.7NEUXN6MDW44Q~*%@!1AF>7&P~==3~6.@N@!1D^L3&5RM./M
MX!J3^C)G~JMATO!Z258(C%~SAC K~VKT#2~!~LJ.V~CD(%4!16Q#~BYNFU@~Z=Q=ST!M^Z!@8!\$20E!)YGC<~)=\$82Z~*~PH3!OI<~(45Q^7^6^2S64~2~?
BL!MXA4>MMO@!VJ5M0AY~5^RB9N6FNA^K4~677!TH98M4AD^JT.@6MV>PD!9C6+3#F6;G MM#@3.3.M6&5M0!DZAN4 6VJF2)OI^!JOK!L^F~8V%Q-
JUC!U^DS7~#R8P.M.R&~&1..54%K!L!H!OEI= X!BQK!@F^K!1W^ERYQHDS AROX.>40EHEA^!>M4.3G4B0MQ!>V>1(L& MQQ(A648^ZT9!1~2\$
N&Z^47^~!P#~.R!R~MG!1G(1CG#&S!63NF00722K5E.MW1+!%2.X^185C~_9@!F6.M^V^4^M.EZJ#~"JU,"FE+CI?7\$2Y^H^GH
MARJ3^<=5F8369!5%VD~"(U5!7RZ!8L\$!H&^U6!A5QN@.1M;0~!<=%Y%B!T892 MOTA!5D~1%5&9!^JA<~!L?
BKSPIPTU.V35B~P7&~.L!L!#U5+2!THADBBO MN H4!0VJ+!J3S APZP^ZZEC0@~@!HDH340@!(L55P^XPLZ.M
M>~&~N%~(HG\$A!;37P4BEUD8)YK~ M6PU @9L6<~.L/>Z(#?7@C)5H.RJ4+~V.S<2ZK?T^EIR^0J>#K!;3H8JUL^!X)OT
ML%DN<~2B!;XYD2!0R9HPC4F<~(TM3E7T&SO!4!JP^UHO4~8%E~5Z!04>+~MG!D)WH@!V^&27L^G9>~!13^Y4UE77P.Y9!+~SI<+~\$@TAB=)2V!)
(E&LK@~M..5\$;GY4!H2N!D~9!JL<H<3&1R^P~(SE!JA2^+~(HJ6%~(TLVW&~%+JK4 M<0.R!AACZ4!HV&Y64V!#6!+!J~L#3W!_0=8&??
N^GI/H!\$^&#~7Q52S8M5KG? MG=NCX/\$ (9HO+V!T\$F(PB!>8>G^!18=6_X!..@N7J.Y~2~!U120<7 &LXDK M935W!00XN04GPU
P3^P@&R2B;K.PH07HK@9T4^P~PW1~!X^&R4LFPLX^6!7F6 MK^K!6DY%W!H4NMUJ+~!\$<~^X7!S2K2NY~!9!M4&S!Q!ZEF\$!~*V292D
M5@>5.@E7^W.RT3C~!G.V.Q.LMQY^~=-EY6BP!5.C.9!+U~!>U>3D^3^RY6^3^06^Q.)R.R:C8^5)YU~!EX02+M^Q^O.XLSYG^4V.YZ3K83
M0EQXT.2T%~C.;SHJ~!^Y9RP!F^AO!+!O&F#~#~.1=347UB&%BN!1D~B^2OJ^T(28GOA^Y)!2F9=(9.XO M~!+X~!@!^C^?7P3\$&J!2PE!2!M~G
M:17#~#(Z.EY%V!J>~>SY>P1(\$8_P>WJ^!H2.S.MM~.00K.B~WXR\$BWN0^~!^"Q0G.L!U@!@8P>2%D!2~X!@*3W@A\$A\$2\$0PE!L>7%Q\$%
MY!S7%IX%~DGR!ZWC=SI(F7PU3!^O_LQK^5.Y0B.1!0!Z!AMW<3^2(E=(PE.MA~/6!~H6Y@~^WCSC/GOL!HMA^Q!PBX^~^N8VY!PA74~MWTF6T0!8-
Q!AHV8#3UQO!JB74!2(A..0H!+!&9!G\$H.3^9!H!T.J.V6L%&M~/FOP.F~!RU8V!>~G292ND!45MH6!FPH1G2%<~AVT!F~ MLXG@O_Q.O^N^%5S!E~
D#0^~\$K^=R0~!EBU2~.@!U~L!B#H5!HJ3K&1C~/MKE9!G.F!HY.B/8O!L!L!H_7L_13W8T0!D!J!TH!SS MA2P3@JR=/D97Z&4&2EB/\$M%Y@38^40~"-ZEJ-
=5#9U8\$K^!ZGZ7J^RY.S.M3^~GOUAM!1>~>TOX)7G:B~W!S!>P<19V9C!Y!LZ_H!\$QWH=.:A4NO^<) M6^4^1^L7E^5A\$%~>8.M.L!U.A!<
<~&ELO_8)RZ5CQD^8!~!LETT!0!0ZU~ 2K5!8WU!\$KEE20!V M>+!4<~^F@!4ST396!2=LBD#D!<C "82B6!V2C4\$!LH6=33Z&VF 4!LB
MWCU2NTNJS6.@<*9HP=4?2^TCQA0^!R5!2A!&D5H5JFED8R!6SX569W@>~ M\$^C)A\$(D!ZCDL6@?_C@:ZG5U~(H!ES WQ4?#%~OR!5
GHE&@&HU%~#~#K.M.YW~"88C83;4DBE.,O&3.T!L+BD2>3!~!RP~ AVATQ!J^!5)2V~"S7^!MIW5P+!@<6W!@!~!K!KFDX\$9WMA#!XJ!
M!H!FJ!FQXHQ1+3K.X!H!E(W200C>+GLAZ;3ZJ0K\$;4H!5Y~!MJ9YV~(L0O^WMW+!J4)7EY!5;O!#;KU!T@N!ZTNVO&EMBZ^TLG0^BM8=\$0~*
MM3BPT!8HU4JC~)@ZN~%2%~@!f8!7FX 4_~+DH~"2!VD!4KTRTZE^L0&HQ=O MP^WWP^RDT6H:6DMFX0J>~
(EE,"K&8&6!JBX!B!~.~WOL\$=!F>~BY~LNQJ5!MED!0R @J4!7474DP2S&89\$Q44H=AC!T&3^Q.1>~*#K/Z^"90Q~CY~VR
M(\$9!BN!8~!P(SY!2!UR~27K=Q0P23!H~7R!R!Q!>D @~J8^J^D0B&J!R!8\$7!E\$~=#!#K~4E4D=&3TJ!MR420!9W~#A^Q!5!1J9~*%&+~*ETD>~
?H!%HEZHSL6G\$!\$@H>M1~8&L!H M6AH^CL!HD_0^GST(DKUL>D?NA~TWBU=\$>N^!LQE_@!JA/SP\$~.5W.Z.MJ.NYOS>JF&S\$54E2E@~)3!C!7Z<
MB?<7~<\$!YVQ!9@C!\$5\$!5Y~!V6^YBNC!2)2RYJNL0_Y!>9>~!7J@!C^#DG.M8AM;+~3<4QZ!E3\$!7!UZM6Q^Y9T!O>G5?
JCD<JX~\$~PI#8Q^+58!NT!5^F6A+MV#ZOOED\$~B~8!2!ACW!\$!H~"MU MVY!\$!H~SK\$!F!H~\$ZLDN@OK!@O>GZL~" @+P\$^VBL4+7 MXTF?
R<+S!Q^2W~H>~^!Y^!>7!Y)YKR&&~.9AD~.F!2A:DY^~%W!8W.PTY\$5 MMV8!F~=#!F!4V8!M(R\$GT~(C^K?Z\$RV:QD)!E!1~!PIE>
!ZNO4Q>U!30Y647XELAS\$CEG!W&2M!5Y!32~!(+!1G M@6AFDC~LYM\$!F@!MLZP&WN1RKZ!>~A!^E.C+~8WU~A\$~YERTY@LFG^G6=V
M!+!OPTV^TVZQZZ\$VDK/(C~K5+ICT\$P\$~DJ?7!CL1N6O!JBMM(W&K M6E^<~\$FM1LDY(A^KM!^G8G.Y.Z5R.PO#0#
H!4.YC.^XW6W~XM3\$!68~AK+~%Z_O3Y~#MHC29.P(20!O!\$22C!&!\$OWE!~!NM479NS!<~8M:19L//7YVYBZRKKX926
M52_HW4!+U7M@C.2TB80:6V!Z!L30^P!38~!S\$5!D~ZT)^Y%~CMM<31=HLS.MF_K!69S26!O^5R%8UG.M7DR3~JPL_~F@?
80V!U@!L<~#%K!QY!F^A/D0T^F3W6+~Y.M.NPJQ_QLB#6\$ M&B)M^?4!@~QS..Sj6+SB4^4S2_HMVK3^XG\$2V_3!~IN=~^T4OI>_I4\$9XU8_ME?
~<#0!YVC0~"U6EKL^QSR#R2.8M&5PAT32~39P+C.DXYO^3!U3O.M^U!MH7^ZYVM~MB;D^!BOA)VNR#~"APTWM~!~V~"
M@S:N!~X&^4S/S#RN_~G:5_7X!7XPGJFM~*~<+@~#7J!HA=~N!2!Y35PPN MKRK2!D&\$!JF7\$56!H MP?
5!97J=~#VJG_~!0!H!WC^J!Y!340/LF5^C~3Y+2+PBY\$~!9!O>Y0SEZ? M=U0Z39!F57~>K6!AC93E!F~+~+0^H@R~Q=&QZ4GT2\$!(H207^UGR2!8F
MP^FAB^0T<~!B127!CJG!2K~>6P>ACTO@=U!~!~5=JOGC!^YR&L!8^M~W&FFY> &89!5L6E^6PROJH^~%T!
%P7+5AUS!^6:82!#AP=RGW^%.FK;2! MZ)Q>P8!6<\$~X3~?AZJF\$+82S~6.LW!D)8@H!~LW~".67_0>D2\$S^++3A M!;1A!KP!)G3GG63^6V;N!~N;5=
Q!AH~GW9!5RV^32K M02R^97@R0^#C@~WXC!^!NV^4^2RB&OPF2Q!_V^&L9!^@!W_3:GX/MFECE A M!;1\$E MDSMTZ^GS4GJM?Q
KOE_KT@G7QCK!XSR9.ZURR^G3_5^NG=S/IT^<L~MBQ6Z!4=8^!CC#W!~"N!<L0^0!V!~\$Z^AJNHE~1M92^Q_Z9568!19BE2+ MY9R^!1_1_+~
P6G=~!F/L^+M!S^9QB^VH!T^D!W4^RZMT~Y~VD\$!WC+~#3.2~J?~\$U/W~MR M&J#~X&\$~" X8!A!>J>~U\$ZY^X!EP.GQSXLDP!^AS_~\$B#RNP
\$(HR>)!~!M^*QP2(3BA!>~@42^F9^Q!+~!L!F&E~!ID8.X<!(~!G!L_QDNS^~%N0S34X M_2DHU!~^9.S%YDZ^W!H!H3RUC<~^G@!~!DJ&^?~V+!N2
>9_8^=XGTR<~T~" MJ.2!<HLO&8KJ!>~!@!+!~SY?!(D\$J!H0_2E!J!@_ZV_6?KF?V!V1^
MARL9=7GAQ\$!#~\$&H!DZ5!<~N2!574!Y)J50#!0DQ^!P!OE/H6!^!O!IO M0^P^F!Q.O@!@YZ)\$~\$+&~>L<5X!L4^!P8#~H^R42M7TQ7^2B3_&>
!Y!L!GX M!A!9P=+~2.S+D25Y^!6IC^O!3^@U~!4_~!~V!F P.P@BD(C7U9\$~9+~#%~E M!>45L!<~SW:H72WE@!L\$4W!IGSL!0!6&C.U!X!ZG202FDO?
X^&O/X7T_4R^M~\$S~Bj\$N19SRY>8>~>VP!<0!18^D0>8>~!F^F5M3!L\$S!ICHB^?R_U0(P!L>~!M^!>+~8P.29+~CKO7^BMHH!)#~@P>?S
~<0!<ZEJ~H&~K&Y_8!RS4TW MW!OT!EYPPDG5!U403Q.U(D2F)H!=(S3)2^Z!H!2!@!@~(P~9!YQEDM36.H M^5A~8_!D\$GO>~^!TD^K3~2-
!\$@7N!0@Z6V(9^<6)J!UWAU!1+\$<0!Q^QTGC!DZ!6~3D<~MDEZN^~4!9L_HU+!H!\$^!Q!ZX!E M3VDZ38^ZNWA~N^FB5V9K_EEM^PU<~(K-
DRNK.P\$Y+!FB6W!JFM2VX>+VG+MFGU!+K^?~!4!VGC!78_YEH!^XRNQ3P0@_M!IA~!<8_E!@R9~MO^~.6XZ^X!B0>_T9>~8~(C~B.MND2!
!L!G!P8>U2Y2D_MCUY.AHEUQV&=T\$SG.2\$V9!+M>+~!J6!1!H!M6!1!Z\$!+D0_1Y+6H!L!B!K MQ\$Z;6+~\$NDBH\$!EG.VP^P~!L>9.P!MAM\$F+%C!~
@M(0(8^~7^F@M\$FU15^C;G2.H3!J!2MH&G8M.T0Y%~!1C&W<~!M@03:APY#~"T75.2^B>IO=~!BVO+ZW~(K6)M6156Y>LV!~1M!3CKHA!JBN+W
M%55%~P4F85Z^C&S5QEDE5\$P!+3V.7^R3Q(G!K>URF^J!L7^?EAV5Y!E!@!L!>M!~!>A=B:6X!^@Z218N~SOH!6Y^H!C^85^H(2%8PLD=1M)
MN<~G!Z!H&H.F6CBN;BD@6!JB9BN8!106Y4~)=~!5>1=E6P!V02)3~218B!L!F5!M!J^!~.86?TS^2!^9!B!H!J!0!DZ!>~!45P>QGF4B!5;X\$3^ZC^
~<=A=U412F MXY!\$B!~C74Q!UPK M~\$SCO~+V~(RA^@TC~(S0..SB5<~@8#^Z8^?GV!L.9L!E5NHZ_8\$~"=\$A!B M!BUC3~2-
TU^E9>~^ZD^4KTQ\$QRK220!>Z!M>~!HKT M9Y^RNB1~!R~2)M!A\$A PG65\$H;3.A\$^D^6^4\$H!56=(4!~^Y0S^4!KS.
M(O!1!N!1P!H!~5^"0!\$5F6;290!>3!M!~"K\$K~N@F\$E!T~!6M7D!>@K7.R!2!6>CE6S_3^!WG<~!+>35!EG;~%JF~+W!M2OY="J>UP@~T^+X O@~^"
+X O@~^+X O@!L_ZY9WT^EY~@C7K!F^2 M^V<+!C76CZ;8>9D.S7+~E.M7W!)0Q&NB~.N.C!~QRE!#<8=PU~8\$~!2 ME!RC3.CM;Y;KM)FRSY3>E4
^2@&~!1V~>F62S!Z!15KPZ^OZ~EN~HT2D7\$B!~T@SBU4(4K&A42!F12S!P.V.A.JX<!/I?^RD1&LWYE542& M~1B!M@PJN-
<2H!>P~1(E3!J6Y8D2W!26.DD5C)G\$3+~!6004<4!~!V9(K\$ M^Y.94B2^Y4K>1E^M6N_A92G@E\$E\$FK~B~V^C!I_O_6+GF2/GI(1^*~(3G1~!16SF3KL2-
+~XP<1U9=7M!~MBP M27Q!^Z9D28_1Q<~SRI M!&XC^52XM^YZP!9>~V!~MQ!H#~#5<2!T^*K;~(C%~"RIS:UZY!D_0\$W
MXV(U~K6DKZUH0V!@K!B629;J)FEB^YRN0X~!W+!CET.Q\$2+~!~#JVB!B# MD>O^CM:X5+~" #4<~R&03!A!~(Z^5?
@~\$6#H)EEP!UGZ^G.G0E~)M=1MR!09 M.Q2QV!8_!S!O4^2!P(G!+~&C8(UU19~T!AU>ZB9L8~!16%0^9%7!561= M%SV239:38B!F!1NJB~
LG^<!(AB7J^Q3^D72E\$G!ACQ!@!&EL^!>I&2 M^Y~E64H!<1=39B.029O#_IU5#^!10U83J!L^SAT^8!09=~!7H!&Z\$SZ6!
M^+HBD;SC2.H5!JTGDKN<~<XZ^9LB=16^KF!>>2<8^5HDE59Y!LZ!Y?~DI6! M3P=~J!-
L^!<J84XVM>~"QN44^<ZITB6ES:VJU^DASC^!<AQQ98594B!WR=6!7 MHV4.YAY5!06H!F~!N!AJHR^THK!C.H!5H6&\$AFF6VM=ZU4:7&HOT794U
MO7!O2!>~\$!J!QO^HST_8PL~(S2.T~!LXE5!~!3QDFYNYVZOC~L4^Y_XV3!M#B!U?N=0)U3_~!Y^O^!Q!1!6CM7T<75~HP2!5=65~!Q5TA>Y%>JGH?
K9 MORU+UT93U/ZX~G2^YV7BP00A!XG_?42GA:3T@Q5M!F^W5RXGMC.NY~(L!<I M\$~!_D3X@HP!~!~!L@8A#U\$S#&~?W0!D3F!#MY!
<~>+~!U8G.NR!BK M&~Q^H^2!Z3XEJ!~D2!HJ3!7<~!F!6H5T!6K3!P@PF!E8S!1 BEQR!5!2Q MRA25_~S!@~27+~F9YDPC!C~*G^S5!Q-
C\$PF#G.EKFD4>#_U2R~0Q!@H M=C5!ZDQ05!7L0K!1_9&03E.TUB!\$60+~WSQO!Q!MVXTUAE6^!<O_0^4.FVY^Y.MP@_6LW:1+!>@*23X=,!0\$
~!T!4&R19&E!~O0~0^"~^@7C!P!H!J^P_50Y M4JBPE!H!Z\$CA%/M0)P#~^>77GUYT!3CVL&4!5R_~SX/XCTP9!2Z7TP^EY!
ME&JE47X.Q!GG.U!&1.D0GMAH+PL^KN.S.P@G&H!QJ2P!+~E.B7G4H5B_U&M+JZ\$!HD72=X~&822WX@~!P!4>~!8!8K>+~!WDBXD!Q
MK56XXMAHR68_D^C2(G9.NUC!AM.&~%2!<C4!5>=C M.G.R)K^Z^K^Z!F^KR<~>T^M^ZD^!06!JZM^!~!U^D^J!R^+~!UY^Y2&2B!8L@2!L.W9
MST/XZ>7Q!YH!~PHR=EJ~!7G>~.6G<4^0K40^TQ&L!Y^!<C!H.B.HZXG(U) MT\$G0J>!T.H>Z<5J!E^2MK04L^<~&RDV\$T_Z!IG7+6XZES%\$1P%)XBK~+J!
(X5.M!Y3/7E;8VQCM^7C^O~QW!^U<LYZ\$Y!2!<C?^!J^92~8NDMN\$3Z0LX6P!C.MK)~\$NR#0N!Q^2CK\$A.A.C>~!L.V=4!@F^*4KR6!P!@F^*~+8.D!A!6-
~3V>~N8Y~K2K4!H MB~*K<~<=C72VRZY!<~?2!H!^PE/N42!2!<@B~2C!<@KQ#H!HG/81>2 M!B!B@NO>K:C3^BZ8M!\$XFW^*Q.MAOFO_TUD-
O5G~LRKY~A~4M8L4\$4QBTD_MZYZ!~!D5K!H!0!V!>C!>Y@!>!VY?2~2M5W!1EMWGGX!PE!1L98!H0~7FNC!1GHGK!>

[illegible]

T\W\HEDA(E4U1/13\IV MQ*;*^~^!M\ RZZJ@Q"PIY+Y:~+ JS(E4LK5G301G120IV*2~6KJKCH[CTH MJ#N3EJ?LLO,A3*.FD^K25%UXYRH5J)
%MX(QQW:D7><S^4+PGF34L>?4A(GD M9UW?122\$A3C.(R-8D"P%.1ZL:O&=R+=+H+C6#8IOWWZLD1*%<!)4!=41V5J) MC.B?<
X^C7VIVJ(D5^E<>) EU=^08J3P\A1KB "V*.V341\BK%7#YZ;S#)% M6HJ/ZQ"EN,49@~9(DJ\W;:Q7:0=0JE(+4=B7HIV3)&5P^~96EOOKSE2J>H
MIOSK _S\@ 2G+FF^9DCO/G_!*"G^9IK""H1,+@SE1MT\JCT55VURPJM.D= MN1Y^O/EQI4R\RR!= %9QK@.E)4^~P^ZQ&291ITFK>PP1G7D?
MYLAV631A5 M^SN P=0?W\IG2B_X^*P@T6U#CE\W@3CV5A^M^I?0&*.)#ES M^,MAF^D%4C(+4WB&B&NPKDT\F6XOX^QY;<@FW<
>,%1~M^9IOHJG&M,5L; MOB+N;X) K% MOSL9VM^YVEW\X^7GTE&L\M2>+~8C.KQ.<!)F+S,2GF5N4JL M^%*%AWO2^FYQ<~5;4UVI2HD7W/5~H
AJ~YHGIPOB+N>G~5-W2Q& MN^TK9;N 757HX8#S6I\Y~V2FIK6R\CLP5;O^NYCCID;*+1L3^9!1AX\9D M#;M&I^~5D8=&Y^4 YSE2>~
/HIB/ JDBB#3HUXTO\N\IDB.BM=S,W^~3Z2/M<-DLEM^XNI^WV\)(O.OK&S^Z(E-K=<6!<0A12@f&LE-IR6;78ML:#5^715 MF6;?2?
4.DSYECHQI_?4&<H^133 M^<31HJ9(^~1^!A#V5IV%*1P2^& KTIPIQM^13QN9^3(8E6V\;Q5<~<^7Z
M6T&~>1#Z^TZ=^H\^=2Y@+Y^?^NPK^D>~>IOOV&I(Y O8MPGIBM^~H>~*H MBX^J@~V\I^*~HKG@81%LOK=,IV NQ\$6)349\T^YQB15^9&-
HRHJB=41V+P# M(DDDP+P_TY.PHKE^QOZH4+^fE^GYAHM^Z)C4\H4^~;10TA@_!~#T%3X8;I M%#2F \$T/05/AP^H&531T#S;JZ&9JZK<
HUI\^6R.D;L^UNHFO^IL*M^+<@<K 014.(UUIH6 M^ZS BP5 H9IP+=KE,~@~17^S\ O6@0!EAZ^H;UZIY@<~M+<#2;14M00M M^V4+*+&H\K(4
/B..I^~5^NVYLCL(%@&V8I@)JG2/U27=TV;Z@3KJXM\ _M>Y@XOA2Q(fH^)!U<7~.MG9Z\, _E-U8^E9ITCM_@G/@ISJ#<SAJ6W>(OKJ9L M^?&HGKH;D
~#Z2 Y^/9LE8ID^R^YPI01^B0K\I^N3G\+^8\B^SN<~^=3Cf;2 M=GO+^/L;G#4;.(+@3FUE1R7PU@~!F?~G6IQMMN+2P;Y%<663^9F.MU2
MKF=^&*FV\I+1K2YDLW:LGE_7IVZ^C^P^DPS^>^@<^>~*5P M^#&B&F^8WO-BIE1SLY""Q:~WTA IEK2W:N^J OYO\8)&^T7ZG66W;R-48
MP6;~LLYWB6^F(5542I&B_JIN+^TD6I8EX-0?%45W#H;G#0?;T2 MD@02CU+^\$Z%CKXU#;15^G5~%15SL^QTLX6OB5_)UZP#^X\WTD0(^\$NB>f^?
ML<3^?2^MY52F^R^22DYN^RU=,S.BBH<^<5C6E2;29J7BG\;V^I^Q<^JN\I_ MVD>=^G4SU1=401X^<@&~W7EZI8^A178D^5S;PM^@<
<X#G0I^#J;L^WHX+^<MN^JQ54U6S;IZU,%0VIT\TUPO\CV\A\FT^N?;QX F=W8J^?P^@T>~K^51M%;A MUUXIMY;@5^<~<UXX3M+^"C9C31QU25?
=0FI0K?S\$%;P7YHE)(53R9F 4H@+I M^N^YHHPW&\$;IEB\IMX1 MCI\$\$(0!P_?^CX\LH=W1B^~LB5~1C5%6D\$1T=52,%TQU5D9O6U^!59!;=J^K^M<
QJCIDH_?D1U^U\$5&45^153KY^SHCJ\JK.HJ.BJM<1>P0BCY%A=^Q^S+1BZ MT153MI6N\H\QO<^H=3B?>W&_1H\D<~%;X4F)W\ GTI@2L %8JIC?
4N^EQH\MLA~>0 H4H\K4D^9NKO^H3?D?+1<~>NLM^L1=^~@TM^=3^N,UMJP9!<^!(9;Z@Z7=24I~L+0%+GA^IBM51P52CEKJ;U^M4I\$9>~@C(1I
M=V^T.OWI2^HJH2,~%W&B+0L>DHL+^47K<7&C\LD.47I>:(X1A^7 X9ARY2 1 ME33=EM)-
~CM7\^>S9_Q#5>~J^BOH13@N51\$*~1\$TR(Y+AS+^#B)(2IYV(MA#F\LDZT_"ISH_48TJM^R^*V.B^~X60P2 MNB)HG;2S;DQ^C@U^?KB"@N?<
=4D0VX\JDB;1^_00I?7^R^*C)AV@20 M(0#40P^59+VT^~#V3@<^ 4^0!5)+HT 5>~8UW=^*8J^ZW5 18HZ@~**A; M6D<11B;DZ^P50D+PX<
00X65.T^O:QQ.OW0H4BY;5US&162\$JRL^4&E.YJE =C&S5HF6 M^0+~1H25^1B7^U8LJWU;=>R^C^ZODYX.3=13T^M^C@B=;G@JBT;OHP>+!#
MHUO)9UV^Q+PLE^TPGP3G.D7.L+LLA+HX>>_DJL.TIN23^<_EQOU^&GX# MPKXNT74?\$(2I\$EL=I(=??+XJDDN.@^VZJ4)"4^1Q4Y)D?
D6B+TD<<5;2^M^~%O6Z\$P3A\$=J~.139/@^H^Q^*M7P^@^MPPO;P^C^G>0F9^Y1U>S>1 M&FCQX4^~)B3^TP>?^~\$LP1+<~9TH2/Z; CHI
D=40A^0&=^Z(C3.WY\$ M36DB3#00\$~6>^@B=BDR7FM^ILY.(fE^X6GR^X\FX\MI^N+>R>60^6\$ZK^%JB(1K16ATB\K2TV(U\$6+5\$47BLB95Q;IX0
MJKX)U9^R^5L1+~^@Z%9/5-LEJ-U3^T^~!^*K/U0HU=ER>16/ETS0I6E#I\ M+FB,9-
5LJP2^1(ELT^DM^6HEH_!\$0;72168BANF8YILS;OHY\^Z;3HQ.BZ MX<+XBEYSXMM+ !1^&)L2Y6 F-MHL;9L^S6+&
M5L^2^8D33^"W~CHQEI3B;6PYX\N25?%F8YC&N8(C)PNX7KSPG26.D>P&W3O M.M;1^f;H^%JA+^NJ^%I IQX_~%CF^H06%+^M%HL^D>#1
<&^*6^TM5EEW M6A@1G1^!_JE5J;KG&086-0L;(PI6)HAHG948^&(2OU-ESM9-B^S;DEC APB MDL?^2IR?);>U^VN^TNL=XZ&-
>>@G;>U)CA\VGNN3^C%<^T3^B^1&QI2^M(A2^2WB;9I&QH5\JFQX-5X^21YHJ^4Y5=3BT^=^~^X (W,#RXZ(TN+!1CU;MV)1^L^/NA1OYBXR1US<,&^?
W5NCI&HN7/BG5(WGJG>J>E)8^TLD\$8I6;L M7YRE37fI^<~%JM20)Y@L^%X5S9BHf;=^~^CBI%=IQW5XMM22>0 f;S.B9;O M30H13YTBCT?
>1=9SU.FJYV&W5D+4MZ\Y92H/H@>B>^OB0.ORK1^C6^~MJD1W7D^BY<15A\H^<~%;B~TCCQIDQDVB8Z^EY52XI>?H^AZD\VAAW>N M\$D8?
V#1J><0.O<+^\$3G/HT3P.MFW^/HUJO=G)O\TGfWM?>^9J4CTYK_Q7@N

113Y<>U,@5!O M^?_!6<9H^!0M 3 ^#^/A^,%UJK>R1S5T4WKNSVP14B5\$16P 3UP /7WG^IR M=?=C2J<5J(UBVM^>5YK^Q;E2NMROE T?
HFXZ)I;S<@DLI^W+Y!Tf&=8- MY>H&45,(4 MGNC&I_@Q\$P^V\KIJHD380FFFYI8)NOKR\ZVA=%5_198.H6A0;UL^JMTU<
ML530+U02/O8UUS7C\$86%1^ MW7^?WAQUT0#(NOFYKJ@ID^C^M7RD=^<OEN1PT^VM\HJ^3=GYN^WJ8L^O MZ^H8K^203J99M-W^W\ULCNV)B&
UOK&N T@6IV)<~%#^~95<3S^W66&MK& M=4I2E;~>...\$3?)JA.MFL2065DM7^@9K^IF/85^1%1D-27W%B74(4I^Y 8Y MI^LE24^MF+^#3+~!,\$JTB6P
MUV&TP/TJD?HIS!>OL_)C\$2^=O5\$T52V^HFL0.4ZSG6SRQOWG;G(20T^I Q M5W)@H2V^H1L7DG.
@1B<@)P8W&DGUW+EO4ZW;@2D;F7S@J>?>Q%8M^V@9U^X(M^HJ#R>@L1Y^HUHH^XG@>@B3U8.\$O6#4TVM+9^DG3@+~+~?Q_07Y\$@
MUP+Z\N;T5^31ZHEL^@PWR7L;P=A _E9I\$78\$J 7LVX110G>PV#?2JL@ M 7L^S9A7UBIS^8MUD2P+X5V%<4L3T;INTU;H.H(78^1^1#K.1ZFR+
MAU\$YR^ZT9)\$(O(X/S_P+^H^72^A6+9 EV++1NC\$2W=EZ M^JHJE^<~96I&AZ^H)J)RAH\$%;%H(f@KSK;(T-0PT6INZL8>FK^D^FV<^
M_~U13H47Z%IUHPMUT^05/A0#<5>Z&B+H^@.XH^HA6ECBS;TO<^223T23Y MOOP/9U97L^7^R7>BJVC \$9.9;JCA=@J7748V+14N^HV%?L
P^6H^H(E@K2 M^C^PM.2W%F#I^EBJFB^?D^P^C^Y;M1A5V^A#^I02LJ3V&I2FR.P@6~;C M^FIE(6)>739@~"NKBYO!
[F#B^%+^\$SN8>D^5Q<=I~KH\$|^4W5MZ6^W6_ MW_Z<^~D2H-T61F 4MG>_JRD;GJ^*R#9P^%O.D@<K1VN\$H#L R\W.#G.62%
M>=K>T0^!Q3Y@<8=E>CKE+4=WA^&M^JO#3\^+9BS6IE^/;SU 6HW\$G
M68S;"TN<@Q8YED_G93K=6CZZNC^D557DH7(6VKNE3);NU9/+^CON5U^N%)Y@ M^C^X J+NOX2C>UJ
04^64CB&IV2\H6Y06%;S"@9Z\$^HJO)^3+XEO>U M^IWC5^TP2;HO^L(PQBRZ9NR;H=R295&0AGZ^V-\$I5^F\$%MNRV^I^"M3AV
4U7K;I^6LP@H2^&F^I^JDKT^>D^W^21T.AFGH\$HJZ4^N^Z7\$O MW^C7@H^N^DE5)9>~@.36@Z1=0D XG&L&UM2^0P4THU#_D8JAW^XRX4<+?Q*
M_DXJHQD8<55B2^2(3^<^\$IV<19\$) \$P(X3E^R=FR MKFTZ9^5XN<@<^I^T>8P;2CLBB&Q^N;IOAH9LZP<~<^W8V2H2X9@AZ=^J M^T^N7;QX<
F=WJ8J>+0^@T> K^V\$M%;QUUXIMY;P5^<^<+UXX3M+^"C9#35Q MU25?<0FY0K?S\$%;P7YHF)(53R9F 4H@+I^N8)HOV&
=M40Y>UUHY^="F\$<~&PJID@<CZLS^L^W98M92A0 MU1I45>0^1^115^N8H\;L^D1H^K^I8>H^C^T5f-08&HIB^J(I2HJ(AJ_02@ M0%0^\$%616W141/6Z;XJ
Y^%RC(YNB;D^;N^FJR;=5D\$IE&UIY^<IG7ASC M(2Q96K^N>~>B "3PIQ.X&G fE.98WY+SH^%W
M^QST5%=<Q\$5O6#MS\$=C^Q<+19VYR4=^TM82+297MH^""S\UITNfY2;8&D+M^72
RV8RFT^XV2)E=TV7ZW\$<^&Y\$;> LC(H1=V^T.R^I2^HJ^""@%W8+0I M^>E_G_HU@R\$;PI;3EYIB=M7 X9JR^J^*952PDGM;T@KG>?9L XAJQ?VEI
9H^HIT^<B~(29\$+DP) 79\$V4SMYQG<2D,C00;AO5O^PA_J=M^1&=^/0^*H(D&F30#U.H;SLO^JR(5I\$4^;(@#40P;5A#~!;H\$X\$@+H#H(H^T MET8
JK^?T;8E2Y+((LQ24\$BH2V^MF&F0K6\$1 20>~)L,EM;F^H^Q 122B5^>B_MBM2M(C@&\$R;K 822B5^>B_KMHVU^B^6?2=F-9K(4GH=1;E8L.O(MD?>V=MEQ!
(Z0Y2=@2JD=*>UYS@93N(&5WGL@C2^ECE8^N;H;R9HH\QAZ\9753JLH<?2IXO!(5LJ\TJ^>W8QD M2=25 G&74^2D6Q).2EQCH@;~
<8Z.8S5^%G^PI-C)5YFO<>O\X<1)B\MM\I+P M&Q+V=8FN>QB@>GOURSKH;+Y8^6D;1P!1T.6PELCBJR^XZ (1^Tf(XJHA> M^0^O6XY@X #1&>1<
<1&Z^M Y@^C184@%1H\H^F KJH^1+1IWR.4^H\I^2A@;ECNAGYU8UNR92@^/TL M384SXAMT^M21
)PI_\$Z^*RDS(XJ3;3+~11%YT+W\;\$3/PD\$=9.9AY)+H M&DMOX)3CT/=^<1MU^Z6ATN^0J1_.\$9_VJO Y7+10/Z-05LS&^96P#DX;H
MOYH12RPMX<+HT7LV;4^44TVK+9Z&GD=QOYA_9Y7NO5>P;_JJN+^DT FLZ MU^~V+^#73?UZE=IS7C@-Q(D6U5+~+>=4.FO:09RI7<
HJNRJ8MD^05^WE M;1Y;Y;DMG2X^P=M^W\W<6M0A;#12FK^J&K W/ KHM9;UTSYOT+1TGZ^Z)7E
MX@2ENMYJ\+R)0H;6IK+AGYU;QS;LC\$Z.&6K^7^>VLDOL+9;=9#L(5GX^* M;I>Q> 4E@K0I8JZKB>@C65%T>(8&T^T1.59V10Y;F7=V,^#
T^#VZV+1^63;@U M=^JO.OVN+V^IW-2\$#Z^K.MOLM;^X7@_OP_QP^<~<K1^PDW^10JISAZ^ MT1&LQ^H8?
>I9+674^OE4QAT^E^H(WOJLF3^MZ^2DN=2&3HUH&6V^F^<2)TOTWU_VJ^1MC^6CRK2HGA8W1^4V7+I&JUK Z/
MU6C9WHJ.C)2)TXA(X52^R=T<6_PLJ^&7N^ERREYXNO.I/7%1.AEMI>^/D MXSI^N^P>G8T^V<
MD>BH@JL8_HJHXPIZ^Y.K(O^9U)^5E^U5^OE8K0C6\MM^PM(527+505B6FM^7HLA+4A\$A=MDA5;\$~\$^E;N;~^/%329.J(Z4;MB)=MZ@6E^
K)ZIMDMJL2)GQP4+NL&E&KLN3^G\@F=ZUH?QUS^VW9;@<^NAG^"
MW.HL\$ELH>JAW^\$K311^;BANG8)QLS@WJ4Y72@EM57JBE7L=;\$23);WDTF4.OZ7^+SW8GAV<_6U M.Q>P<67)^15>1HJO^;1R2^MV.Y9&A.
\$)5JE2B "2Q\T^HJLBREDI&H MS.LSO@7E;HSPW\Z3Q)CQ^XOHG&WG-8;1AR/^TS2+C W=4LET+~*^#12 MLEPHJ#H4V(HG<W1U
T+KHLIU>B~@.P9WT+8^T^<~>S+@&G MZMP<(ZIMY0;9;HJM;7^?^!E\I^7;1WS_9A.C@TMINX;~?>N M=1
MC4UAH5_-D8U(ION^K%MS<3R^B>8\$3+~CX5^PLEO^M4^CIU\)^D\$T^Y6M MJYNA;6 =N1=X<8+HO^?>922JY ML12B>1D^5^E)
(3%\$XC)YB0+^).ZJPHHTYWYUE@M8_)XS25JUI^1T5XPA0^ MU23^LEMOMJ M_CZ^2.W;R\X(51HD1C9^TWVY1X\ZWMN.F7C^KN+~<~%Z1PX M<
UG3I^JZ^O^6CFR=P^JC>7N/8A_U_X&XO^C&I^M^XF XEW@A^*4M&AMJ75 MN.VQ#7E^")9%7G<=)BR(G;P;1^N IVW\+17O RF9\$5CMTBB92^G3@0+
(HJ M^9(O.TVS IP5^B)ZU.WDIZ^<~%KH^~.V2Z3P2^30\^LOB;^2LHGOQ^%SYK^INT5N^+P^CGOW^3.HVFLM&E7H^7 M.
(YZIH%50N_PZL;P=G6) G;Z;PX^?1%)H2^4S;12%#^2>+343^J+~^R#1L^M) 9J+HJYEXTT&JSL^?SK^"PNYI3^I929A6Q
MG6^5^N^WV\A^7A^74^= A2>?^J20\$1^2V?O^CPWF65(K^I)2^N^M^+M^256N UP^ M5NEG\$QO.SJVR653L^C&N(I3@BSHJ9PL^FFI>XB)=~"T
MXETN:61OS;22;~%JRIDH\$^N01 M41+~#OW=<O;PV\$E^S^RBI^CHV^~# AY7B5T07 2Z@QIUSN#^JUPQUSN#^MLX\UB?@Q>8 EBK
K84%UPTG\$3^6ZPN)EL&f19;STACE,2AHO92D\$8S\ \$V;F M^%\$Y;I^~^/;1S22X+GT-K@&\$5VD<ZIAZXRMFK2X7TCDQ1,28_\$1^5O M^?TY@O^~CBSDW10?
2+0PCP^Q;# AP3C3^F^O^<~5S@XZ^7C^HK+1X U M^@86T^V7+H1 7;~^UC180)P YBY;^OC7W_4DN)2^4 %R&Y^LQ\U25&9^2 M8%>#&8
7S]^<1UP91\$^VXQI^~8 HL=WO^D^Q1@A\$X>+~5T@<~\$2H8;\$AK0&3GH_ M@~^8J&K^/XF(4^#Y;ST9>(^NX\I^PB>IQ<~V2R;~@*
MJ7QO0NMN1Q@P=C^11%6Z^I83&IQN^AF;86^2SA<46DS2\K2A.3<2AJD-6Y MO;#^%X1S;T^?@28^23SJR4P^KM42BLIYA=<4Y.L\$#; #(-
D#9#DKBA@~@A1^7N2^#A8%3W>_L M0^1X^Z^M7=YHK^I^QI^Y^V^@S@^L^I@T.8ITOLD^I@P#^G0CD60^IN<~&J^K^F
M(E^7RU95<>~WUIUEYK^1AVTZ;"OHJ.O(NOM^CH3^#=R;ZKY0)^#~#~+X^N^X\$O60> M1AC^15;08<^FO5)
(2;3^R^FNP^<^H^L@E5Y222P^23+ES6;8^7*@; M^L4^J^N^NHG>?^H;Z.O;DLS^%DP^29H^1=K @ZN^IX1%W6C)H&X
M^L4^K^AWD3/GSC6FJQYZ;1;72\$M(A5)5_ZIG6_\$(16/302M@/D\$P1(9UL_MV#IX870^P5W1<+S=8ZR#^"T.#;N/BS7 74).F9^#M.+968_IX8I^D_V\^<
MHN5% KA?HING^KE;BD8-F6Q67OIKM\QI^W^PL2B^""TPGX6LDOPX=2Z;I MM@ZE^%6QA/<749^T)6EMM^5J^ (UAGI
(NO2G)2UF6YQTSI3591\$7+R /MP1>6^O^=^~7N;P0L^21^I^9_9JOLF2^QZ;@3LA=1O4P^CH.Z2^H08E2 M\$14T)F V YK9?@36B6&I6S\$F4V?
L05Q)F^<^UXCZ^M^Y&H6K;PUHDXR3Q8? M1Y?!"WY+!\$;^H\G)R^_RA3>\$+^XH2EICDL^>B7I^J\$J=_R4EQ7^4T^M\^%#4(5P1-PZ2;B=
POPG^ZP^QY 46G^NIZQTOQ5O^Y)0<^E8.M&C^P^M.Rf<+XOW@/VLU1/5D?@_HJ@IC9GGL7V&9JNA8>J^P^IC8BBHJ;IRQ;~^M#1
^IBDL1RCPKYI 6C+@13UOEY19U3>~>#>O^DWR#Z^QOF\$5>4^7MH?>36%I M4R\;=M5.MEUUS14^G2\$10R)QO# MF=\$1^RF)O&0^4S;DZ^}&
<(+WC18C) MO;17#;BL+(-BD)Q!\$61>&QIV#N^/+5\N+5YH5A^!3IS2B9-Z1118;F7 M;BE> E5L^VBU#A6@3GKJ2I^H5BAWD.I>H+^OH+^F>8
1U^=;O^M@1=O M^P%I^&K&K1^TFX08U 8#W&RQ1QSK^%?>=8&05+1^P8&^<V^R\$2(4A3)79 M^M^98+~^IRQ6Y5<
JTB6;R^N^T84E942.ID^Q(8IV^XN8SSYTCO>/I4TZR8 M^W.G\I(6S^IASG3F(L&G^Q^Q>@ MIG_72L^QC^<^B\+&^&N;Q)K@.5\$7@N^&ZXV9IA^DR?<
Y.G^B9_9TZ/~/X?) M/A^^(+9C6I^A^J+^#?)9.H#H. ^#)^~<177IP\W9/IT5C3CB;33?>4IM MN B@Z2JQ?&H47-U0B@\$;~;H


```

@NLTRHVJ5-3+*E'C9-/0LZ>V@F:R=EJ-+*D M.LB2EWF&N@NG 5P/Z@SE)FY&XY*G@C/OI7.3P:D:PP7&I2*<R,X/(&-
M(=->W+D)1-!Y&J,I*W1PT2@H1&R:WQ"2->/OYX1PQ1+EK&G$0/03JB MGL13L/Q23R0#%</^1193RKD&:13#V2-$0^>VGM6
%+!6WFI-N6VDM5NZ M2L 45K!-11Y70 ON-SI-JE3Z1?=>6>Q OJ-HZ3U<+<I5KE!+-<IOBL3Q M?
SKSQ20I%O83RIB+MXE29TX-8(D%21M(NZ:"*T8V%<3.NIPMCH+8-)KOA:Y MDD5UAUEI4.IPDIL!WRG^<^<SZLG1HHMCO:-(XX:17V
4%K357W%<N&O MB% QI/HU+16J@CM^>9RBPBIUXJ9@70BWT!15<0.K+1$55>GJNZSAH#17-MT$ GN$+:(@3T:(6&Z>%"$E5=FRW4
LEYW)0I!#M6@9WXI%HS<X!X!#M#5&D+?=>M1+>L=ZSXE=C>/M!+TND%>:MG/Tr<^555D0"#C8Z4V05EVGNN%="YY57B+YCN)T6@P-
54:K5Z(1QWV<M@!>OE<&VB:004R9:V-S4M49W144XTE@.#211U7455RMUJ2861^171 M1L<7.N41GIRO=J8-#%G=7F.#B@=(&1Kf8-61.%
(6/2B%1Q9U)5%#F M:R&I2.3<+&3+JUMJ-IM75*2B^T2X4-9@-YI^F+I+@G8X#>I>(H41W1+FOI/MX.5%)MD!SGL@I+HW?
IS,RX+I:COZDFH+I7248U+HY>WC9T9L9=53*8012-MB)42-K.%Y1&+R)QBA51XSD+IO@7$7$ 8YI/L^<C&C8JYWA="9@&-LX M#O#<-K%
M9AWRO9:G#OZ@P220/24.PAYEM:UY>1$NXZ^>WVN%+YYP8?U^2B M.JC: QU#>+IO5%>Y.D4$ KWI+ E24PR1W7U@$$ (OJKE(-)#L-EZ6D#>2W
MJ-56G@IKQI3KG9&E-J75J3TH2453JE&DGI>Q$1YXJ.2U6.%UI(17&0-62 MKN9+LZCJ>UV9#S$</?X%U>5Y)DBI7X!@>2I_GGS-?RS6F0'0 MF?
R=>BRDGYTD8+5>="YI-)(41^!RVH!"/HZMUO)JDTQK34!UN:<RYE!+7 MJU*VZ$R=C.5.T6^=6WT#!^IG2:N
TG$=<WQ7SCEMO-!SPOQ(EKK)%"#1.MR$1-!>#K31"IV" P#(H+DS&WGFI2:VTY/QO+Y!"#>2QIR9QSC^!M.K<CV"Y3IV=^$2234H_OL=
JfB$-J5S0HIY^>2%P4Y9-!%IQCP%(R4DH M:83_A&W4IYI/8:6IW:$GIS*-OK*B.+7*UG"(Y$EW:6L&Z*+&&!)7SI6<+K MH+B.O($&.5E54:J
6Z68/#!="N WC/P>?>7.F M#@L1 9R8U+YJPWP-F+!TEXU! HONU76GN0D-W^<?<F@V3DQF0FO=&V+EQ5?
M.CSF+17WHI@IFL#>C%QDOBE(2+TN=VGP*RP$E.OQ6!ECBF3:0F6G.FS!XT# M=:RZ@2^J2_ZH.3.O=I&WZK5Z7$P5%M# @F5E<>5A15#W8
17/-2O.M M=(GK)0SA*(I8*XIBV 9W:&.@JRN2/=0(ZW&4MJIPX9WD:8E=O="6I-M?1<IOFG4K*>GP576YI!5AUS601UA.ZZS(" M:9^IN3)3K?
Y9UN^>L2^M2^>Q&C^<I@1Y13E9XQ@<I9.ND:2+FY<54RF=2:6I M=5G=>18E9>4>1^Z2+&:&-&WPPJ>/%PZP>#*Y_OIWD@5D!+I1)HY6&%
M!P:E%X2HJ_7VJZJDXU0=>H^M^V=I2%L DN4JSDRG-IGZAFI78$33NGH!<27%W<D4:4IY0A:8MPL9O^<1$2P-MX->2N6L=L:E9=9@0?7:N6!R^?
S2D@A17+LZ:T8T15.LTYA5V77=?YI MJHW5EBLZ6W6:IO#EKXOI_OL>S#AR-RC3CBCGYF%9!US"DJMXI=X.V?F>2IJ-#L%QF4S.%0:>B&
I^<QF:GNELL MC9' N6!FUI$APU>?&CA!-PP78157 YL!<I28!SZIKN!"/093.2BC@WF M.PDIE<I9N+NP%12D+EB)2%M1.6314D:
(4A9$RD+MRF9/GH I 4MG8=- MLEPM:M+JY=I.FJZ!@2Q(C_8OS*>H6GFTPVC.KI^T3.N.Z/7I)"8<^L6D56. M&QQO0/G_09SINZ^BYCM-QQ5@"
+1HPUY97^>2DDC8I.8LX8Q3-9:6@* MF_Y@H(C#L16J.D A@-VZ?2ZQ7N6L<2<74THN!WYQOM&@+XV7+I M+4TFZ M.DL^<
I+9D=6::DJB.IYNI=M!H&EM#/#1"V0:YL!A:&A26L.2<>SZ9(Z M!>2#MXXS:UZN$ 4C8BA^N7><-G/X 80V7!R)@YWCRI(2)JF2VX:M^IC9@>NB?
M:PN^K!E1&L.T^M>FM?2)B1(-=9HJ-U^HJZ)7H3.MCJR @834R9P!#&+TF7F+GIR80+9>H^!DC^2^VR=F=8ZJ-BY8I+6A^YJF:$M
M:DM:<ECYI^Z32U+P&BS=BA^D^IC2+LZ4W&U"G@K@>X!XKKD2Y2&L& MN>_Q<2!EXRMDM^<R+(W>ZHYGFL
+M1I4_P/#FEI(L#>28H1HKL^8=W M7WYIP2Q0^N.PR6@U6$S E3: JYR!2&J$5BW@BQM:4Z2&29I I3^<KHSYZ MTQRZB:=-4E@0LM3AR@NF-
&N9=HR!ZD<8:LS@+Y2$JAY&2>S&POL^Y.V^M^30+>6CY5I^C^AV?7P^AW$S.R513$1S4.*K(X45GM3LFBK3^T5T^H3B+ MJ415.6FYL7P)*?
B8KPK!^T/UZ0D 2_N6?>G.E)1&42B1.6:6KX@DU!T.327MH9I71WD^S M5^QN44^K!L22OZ&V^Z2N2#*OSXJ9<2HPDN4MP+@Q440?
4K0@CWA?I^QF%UW8U%Q<^HJ M(P+I^/S_!6M0T^I0_<^$K3E6^V+3H$U.T#8=$0&W34I+CT1E*<RV%M0_EEBD<>S.)+2XLJW^VL7>H-
IQXBQCJH^M8_+16+G!BXB=W00$H6^#U11.<9Y8?>2DP.SUU:"TPO)&I69W55:5C'3 M)1^DQ(K)I7?7!$Q@:I1H6&WZ2?
W.YDHC4E3$8L2.D8^X!<6D^K^ MFI<1)BEJNM+MFA(A@I>OFG02FG0IW.2!59ID.#(E6$5CE1) K6902Z.W=A11+^M?
_MSVW="Y#<0CET9Y^WL2P6M1+3/_LMS+@O!_S/9(Y^C M&J%)Q#NRXT^YF="TOUV.#@3879FQ%/%.4ZF7#R(TI@<VQ/BN7MHSFS#&2 M)Y>I
(Y^>V^>S!0G&P^NP%<K&KVB%<0#WZ1$<=<NBD^3^T03N#H^<I MPP55%+>+>1%IOU^7L:8E4B$>D29^GXRU3$ P9L JOSS^32+J52D/M O?
R^YTF&=GHZA)D7_YY5!XY(I=<T$CN<2EU&V<3QYHD>&X^Y W7X^7 MUYK 4I+&H&X+HRM9^7D^6F$E3U#YU3!8Q5!TS("Z,+>BUX4)I?
T)%=&M^HYRUY/23 8/">6WA"00I@.S76*&DSV>!OSG?>"/I+EZ2L3&+ CTG@IN! M7 88&^EF*90,+E#1^W6<^<UJ+IAO90)X7
M:K<X$Y6^NW2HHEN3RF1&O>.06>_9H?>9@<NMY+QZ4Z_P*2$ M#Y KA$PFQ+M^R=:5*35.64C+G^<+<I^U@8)OIS-DIEFRAX20(*ARX-IJ
M:($#RN7)2L1.<YBX7O.<=&EF^OSZGYEP&L86MDS=I!LLPSRI/2Y@1V^1^M.#EFLZT3P%?P*!PFE.O3VC^XN2$&8M(FX8%<^!0:55^!<G
MN<2IYK2Q(S^Q+I+5JM995)IZU:~E>'79UZVXMY58-'(%U"LL!B5"SEFR (MGLZR22@0_-D0JNRH^P6(**6 %I3+K#)I>?
K@#2I.CM0&MOV4I&K$FE)QOJ MJ26V^SGO$JM0@CI<5J^F$>?P710^YVA2LYW/DTN^C.O:N>=>)X1L M6^I0ZXA9QY+>4I^8CDC4P M9ME#>EF
M4WKM^I(N7Z+D&H0A8HU_9I^<+!SPR#W?K95.2>ZJ3^?T)TV/Z$ZAGT^2I.MR=5I.W2<4.2B-INO.8&FOI@OXKS(I=I+1PK+I7>=>M^!VIG
M.ODI^<B9BY H03XN7^?206A6+1+>@BF:WIE0#/=(<VOY8)KDIYAN M26+5^IHI@<5BUB =)>+8V=ROH!BQ^XUWQDDPDAL /?JU/48PN.L?
1UL2=-.7%>DFB0YN>W4^79I2.I.L5^25565%M613M5>I&4^<-RV M$0UY:X8J82MK)@80@<6JMR:8%7
5R&XT1N#<_BGIN!BM:WO=X!ZAJEJS8 MCV==H@G(T.VS:@>28=8HJNR^PDW6*)+K9_15&3G8S.^<OZV1Rf6!B2M/M2W1+9AM3!MH
SL+WLXQVOH!<5B=1^#J!PQ CNJP!GISH#>:E:IGT.EU M>FI=>=>X.5)Q%I
```

(H5 2K0Q7M8MH25Q@G^XJWLD&D@.9*E%.SX#8S3 8FR+ M./8P>=>IE1PGI>DJZQ@%4ZP2!\\AE+>-65f!->\\Q@/?M3,%+KJF<=>G&J8E!>D\$V.POK#Z#9B2! MIJ.6-230FS!>9.PHGFS!+T\$7D@BO@HGSX3SL.1.1Z2!<...:IR=?.=EF4\$ M?2\$>WHAEO_\\JH!5JH% 50L15"KIND3C"/C\$P"8Y_#B2!58^'.2QC&JWCZ M\\4KZ39P_&7LQ.V4R>W>8<K\$)L20HHN.\$!B! IQ2!V053N(L\\QYOEMUX9#V5)Z6A5UCYCVZ>6<268=%TSO+2%W M+J=W#%O6J<-RQ#L+UXO3^9AR:R=9.30.WW3.X8F.U87BZ(*M:.'XG07&=G: M\$A676=UVJ.N.#J=HDEZE"PTH/L&FR.6!G4FPY#B!U#;MDOL>&ICE3H MKZ(CW#AIG>=>Q@LNL#MK&+9N.4!\$2\$? ME!Y.Y90+ H"B_4TU<5%K5L&U/OF1LR!J9**>UB(S3\$4VM&.4J&ISFC/8 MYHM#C*PW&M".0CMN:\$=5EX>FTY".PKM*+2CTOYK<4MV:0052#Z&%"ZHB!& MYVQ1/ELHQ&ZC (89>)YQCZAL!%@!>28%!#4L% MWC0M.#8S0K+J56.3C!>P=GM3(HF)I2M3\$!H921UK#!=910W434XP(C"@R*M.H.BP.1B24** (H"@R>AGBCO)>K#("0.D G06Q1(!HIOBXR3G<81-L M=>C)OBU/\$P_!Q!O7TLG^W3-IVCGFO9.S!UKI-PO3RIL<=AR:XS4NB=OND=M? 9IJ2>=>UHM3..06E1P=#ID61P=JU!J+!WU#64%3!K!0!@ECH=20.M.EWABAB5*#.(T<^NL2-Y90U#H4X.4.YZ.H.2A*#.#17.E39!HDZ M:.* (EBBB)2CT(YKVE:596W8=#21%XD0VE#H1Z\$=A7.1D1WT!>.(X*>\$LRO?QW&G%+D.W.PBIVZZ#92?#IM\$6A!7HS9KMD\$D8T0^TEB">N"\\H8B/!T M.Y!F\$9G^S!4 JEFA#E\$W\$T#X5.KW#%JS9?>33 MM\$9KN".H_.JW3T?#A!@61U!G5!PZE/OX.N.2^VZH6L<*W\\A.8-IZI M1ERS%\\L+XO4IH8! H(3@).2!1T0.64IA&Q\$+!\$!#J+X1+1&4S+S(O5XX MF\$3H10%)!N2>#".>_ LIOXL#X!IOF22*)^>8NI.K!X!DQ IIM3!51! MPH@>DME ^CJSXH^>\\NAET#B2?>Z(W%\\TVI!#F_.1"\$K5PQ_.1\$.67.2R=1H.M82\$5L0PZG.2EO#AS<&6+9P*M\$RA62S.%!J@.\$RO M=(^>H+8Q? YR!=+!>M+P+XBPM("IP&013BQ!RT)/AG@H.+X+N@VY3.3!S!F M!XX=0!W4%!16%.JY(T!5L2.#^Q!(I&IGFG#PD01@Y\$T#?>3Q?2 M-KG! C#R4_\\WXGONGXOXC909!N2!KY\$C#M3!3QG16MEG(F!>5Z&ZL!K\$N&0.4AA9-!>E=M- M"A8XQ!^TPM+3PTFM"OA!GDJO!>Q+!\$#C!>P #007H&8@J!VF\$G\$F.T!M^2&Y:03?5.>.P.X1S:X.V3M(.#H?PJR8!)6-/\\VX U4EISJIZ+Y!X6!PP6P!/(5E/R<&^D.HZ1/G7BX M..+!#O.S0<% IY(H=&M4%P(R!T\$S+ILS+M!ETBX:5!JF>XY:2EQV "R.M.W.MC6P)6 K.LMHILCP<.&S!>W^7!^\\V4IF(R!KM8JD+W+!>5FS.&+>34G MZGNPH!GLJ!R4!JVUR\\HTYRS&MK7N!U!O!U+!_AB.6AO.T!+O9YD3C!JZOU M#TEQ>(78BT#DJ2&5)5N+!C.W.MJ@Z!25YH K5V80\$556V&I<C3LXC?MIH"BJR/FM:PN1@VGA4G96W8-B.#+Y^(EX=E%CY)?_.51\$=G!JTN!GL:MRYE!U+=ZO%?8-PDL:9_R_S6L=)1(* I9\$8"%@.=>+!4KP=@P\$X^*^7!#6-M &XFD2EBYL0>2!B.2.ZYKD^NYWDD.7.X3DL0Q^P3J3W9Y.(5GTD QOC<P^>C\$MFW!\\M!V!)!26"YQ@ M!\\SRFZ.N!)0E8\$ #A8M%&5L!>BWW+!AONCE.. M2PD1>R^*U.GHI?2!09\$YX^T00+G.^?9J.IDM\$P>H8POI!7\$DH"RH!4D4AB M^4OPM)FWD\$JS?2?IZ@<7.4!OSQW)HY0&@DWA!+HD!)RP.IMW#W!T.T-H M^!)%\$A\$%Y\$S!D&YS9QA+ M>=5+3.G!J..GU#\$I#XGB; (@!^<G\$&\\QY!LB3G6^1N0WHYS!(BACQR>M>J%!)2C\$G.63GQ@G M@<3YD3^X63<8V2A3V\$>7P.W.K\$#=#PKS!X@_EY1 RM\$=\\YFUA&?LTO!2 M!2?+*CUR4IOC")0YL3\$3\$AY70\$!P&=<E3IS\$N#.#07G.X.MD#=#EX&X.F3\$A+ SCU>NWR+!#S)O.4.#AG#_R_/QT79S &%%2 M12=9X.NH8(P2I28P2(MX7?)URR4!Q#8BX6.5-IN)25H!%G(C!16M)5D M@Q(F\$JIR>"ZP74IR&R=5.VAE8<HIG?E9 L3.Q4>Z/H#=#.D=5B? 0@).OA M6^WB0QC!8.L7"N=WBS/@_.63<#UIG2VG(O!D^*4KH@>#R93VH(W@E8P(_MJDH4!H6X1Y#XB&L^EEN7AL732R46%DSI96^")3(!^Q X!@&RY:K<@!M!M>X!>16JHER7N\$-3<92"?>F#3\$G!7P?Y9F7@PD7CN=44.EBL4! MGS@T8J!\$?6DJR^FF@/!PKO-8Y3!T-!6KE!T!E5VYA:Y#G. IEBJG@.M.4D"%A\$>Q!>A3DM<+V6<!A.4GP30AD&BSVD1(!<8M!H8K!1G34Z@>@ M..10^1Y0@AU@V5LYK4\$ L&C!4<1T"H-684F^C..!\$G8.P12!@S!)!>RS^_MA3Y8?C%JY#F!& @^J3J#^(OV4.15:XT=>Y#-!#IAPXBC6!8)AY!NF*!#K MFL266H!P^P.12P3.L%<@RCY7!IMPD3!\$409B<#7L1T(KF!2P5!>_@S.MZ?B8O)P!IDHPECXO.FPTW^3CV6P^P!4;LEUA80)DY<^!#7- XW5=QIUR+8B M\$<0ES!S\$E8.T2SHY7IEBQH#>+!ME(W7A.11X.W03PT=H0\$1LBR3&E7 M.4PMK14 72PAR5?P8N7/EAL.V" FIHY>@;CGM#P6;YYHU "R!AKR#7=!" MP70JFEA#\$SRL KM3M\$.3\$5H!X!H280.C(2@WIC+9LY7VF+DV#@.>NH+Y M@?7^G\$0!%#1!U1Z<^#E:5P>Z!7!RW.\$!@ZLL=(H%\$A&Z.M4!@H^3C"S) L.62V+5QC@G8P-1MP>PRK7.FO-Y!^D_#FFL7-W#<^Y Y\$SVR MXH^C\\HBX!6N&R\$!739DE3!6!LEES?2^U6-0.33(!2.2< M87LPM!WB9UO!>6@229EM%T!H1X.CM3BDEX.O BVHY5\$ Y&H-WA^JT=4MB MH^>>^V7T2H=5N+M>@>9+4.7W!N)7CR_V2%!BQ.\\H_KF.BC.F\$4AJ\$4C M/XM\$_.8^U9 IC_7ZA64!T=IW.T>C!74ROZ=.P+U3F\$=73GOGI&> M2@>N0&F8LSOE!<8D3L(TS#B-(PX#=-1(HG3.(TC#>@TZ#UXO42A!%E2S^L MXXF/CU\$<\$1=5VQ9^CF&S!9 WJ&(T^?JF?2^!<P.%PN!5!92F3D)Q MSE.XIGC^T#EAZ.4!J2#^!1F!JF&S.4\$#U/M7!+5F*K^D?0:8H38-.GM=/0F0W22&N(2V(PT^!)^6L>S+.%K!LMDXQ M.EK\$A!ZOV^>13^2A!&C"5.IK!0ES!V.SQ=Y8)!#E2L\$XJ3) MOH!K1U!H0W\$#IY\$SRC!PQ!L2WD7.8N9-BM^T!>A&5@T33).G(B=9I@XP\$+@ M>)\$77HB.46UE)M.F!@TH0=L.G!ON 0=8(LPUASO!M!L.O.SV..0GAXO!E.MCV.@X4X\$<^B-SL<#!HSE+&3AQOPH!P=L9!-!C3^6!#VH+*6; <I0TYWQ\$ MF\$S^%W+&E?26+R>OYQ?L)"BCZ6UUIB%_D.R^R^Q!M!A8#>^*%!QIEN<I+XMX3.TM.L2(\$X@.'K JDO3I\$S.X!NEUU\\XF4)GD_B? N89 M!L@Q#\\X2Y9M7\$6G!JTC^!1#>=>PDP(EJH!5" SL^A A!+0.T7B.#P2S+U!7Y)!F5E MKY2V=R95+243KU3IK%5BW M%7Z! <I08I@V!O!WS_0WK_Z=M.OMY^>OYVE6S J!B(CXCTXR\$%P&K>_ME^4.O!O"\$TL?B0O+\\A!F!W!>K2K>\$AA37R%)!T!F/\\WO!O\$8X.Y)YS% MS32Y7!J!M\$.I2V.L20-GRF?7P-OPQ!YV M+ P\$D+T7!HX2F9^M^N/Z\$@Z!R!O!1DP3\$PX1!5&YCLC6)3P5Y2!Y0HYO#B7^Y!<8!W/3GF#O?0 MB"1!1\$<D+J3.HH8CI>Y(=R!YZ<@X!HLR!<M.MJ.BBT.G^M^<6Q&3EKN\$6!MNC(HZJB^J.Y15.256E353H3XHYOEE4ZV MGKB47"=QJ(Q66!@ SG8U#HBEW&FGG*(O!@CZ)+X^P280718*B.K215@BUF.RTE>IKZIGF+M+)&C5#YO^0 Q!W!>1.2MM8V\$E)K!/\$\$P.IVIMT> M!R^R"=3U!N"NNH+H^28Q!>3ND<_O2HVTWWZ\$G\$.K^0H2UM.PSH NNQ.A M+PGKH^!S!TS!/^!\$W.5!5Y!X!4!R5RUSPH<*ZRT! D'6:PX>GIE+=0Y^A.MCY!NCP!>DGB<"64\$C.2!.(PNX.@HJARRJ5AY#LG M'6.272 MM.S(CZ!PF&15.=!>OFVUT!7!F6Q: <*/K/5!FOXJ!<+=MAO%'.80T6(2=X M.A+LZ!|C|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

M/(YAPM5%VF9BK(ZP)GDQ7TC72TL@LG5OIS\$,EZ+>DGF!>W7!-.TE\$WPHNT M,@@f\$BLS9K2!UD!(!^D20NISG+K79!VTFXFIQI^S HB;6E24=XI^M^2 M2OGGRO?22 K^R29P !\$!YF+IR\$#^!@SB@:H8J S829V(IQ1K!R5C08O MKO53+4D+K32).GD+7:HL7H#8P:J2\$.

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

V6WU \$Z^7J=5).7\$4TH1+>7\$ M!WIGUO.C/(UG&TJBIADIV+YPSI48S.R48P(K\$)Y/IAB^R!2.OROQMFMS MC6X-DZGL=9V\$PR/NYXA6E? J1)NHE83K5U^>QVKH91(QS)I4B>=E.Q.N^!QONP.O M M<G<3USDIQXO2.VG/4E^U2L M<(S.S4)42H2M1MIZA? EEMHJ4HRA9N!J^%ZU<56B<!!A9.ED.ZRIG.A.FE.MK>@%7F %N8/@Z.C-J.OBIA^YRDM^U2ZOD..IVZ2\$8DI0JPIHJDU/58H^M7 MD\$E-379&6CPM=PJNYGKHAIW+>.0.)JGL<7U3/A8J!@*NY^QDJ#T5ZG MXSLIS&C^3URU M;J&O^HMA.2-YKWAC?>+T^U.GIO3^D1O!/@>!.MK#L M@8P0YLMZ2KBI!SCS#(WXHP @+9990\$CO48>>R*A!WLZKBSB1Q+J1=>?XJQ.%MW;.

{5}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�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

7W=A_10^MYV<3YZ<WBDJ BXHJ0KI-Y)N_-B=,\$.E)-LZ->FHDZTCLP03S#7%\$PO_-M0!MF?<#W5W^>)3-/E7=MR#3!Pl.X.2Pl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~A1I;K;MVNTK2(>~)6XSH;^VZ^=FFOZCG& M2;59>ITLV;F 7@L;#-W3MJBVAO+=7 641O5\$3!EI#6S9S IK9:70+~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~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~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j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

```

72;JXK X1# 4*9/I/8@-11Q744 M$J$ $K9/CG"217X9V"6NF.$Y 58L"-W@RV(&UY%Z'0WKNQPCZ"TS/LA"1+1-M238ZJZ"UE/LA=GSR?4^Z'Z2>
(18*BW4<-<%2I^C=-1G0&R?I8@-1,YB0M'KQ M9^K(('$3+E#<5Y,HTIA*4XZ$Z*0&C^QO:SKS5!O#<@W*%>@CE/JA@FG40)
MLJ.G&7AG$>UJ=-,ULE3O!>?"FY=P!<,C).SBR^G7XN3C199U^?+CX19"7%3,4&=<^RN?#Q!+N/H:ODVPVB^4D-9&68(HU)%XS14(2NCZ#)
Q/@BOJLA222(<^ZOT53$S$N-Q>A#M!WPFRLM&#&C.EDQ>#?P.D2U945WTR>R>KU^+62C^NEF9!8&5D^358B$P1^?RL)=+1Q^HJ5=
ML8((XAW$5DP35^ON^<E+>1YX1Q0! "841$A<#22J3:5KS1059YVW-M8"2251A-5H"Q(Q:1>KZXHQP+!%4,PKLJM^F X9(B7$+KD
@>@SV54B@T W0YMN&1B19.W1SX6ZY W^GM-J(M 3,1V>+1IW,7~P^Z MA^9=SAOFB.7^-(C$S^D@(!Y MP: M^K>Z9N/!BH3!+Q!03,^~8$!F^X
GT99 A1HSOF>VX/EN@1SI4C-8KBFF^2 MV2&9(PMD.TR.K6+1)LHJ^B.N5&FK0^NAR17.R!&V6!E O=ZXU+&#BKIHS M< K&4L
G=5+Y>225!QW&Q-4 #($SYEDF=1.S1($Y@/T!#?%@/U!#&#5$!L%N/,B M%QVH/11^Z$SNS^KSJ> %3/3R-MFT:AC."3UQ#18:5^D)VL7A
PM1^C^M#>#JG:9@Z1CM3Z.R%@<^ME$H 84ZQD8>H>#?G=K6VAPCNMAN-TIP^C!#<@-9TO4!>NPG;=#B3ZN1P4;
MO2!<^M4>M>@SJS:CTIS15A0R"R!LLQ1C9=O=R)0ALF.K8:22.CU^W.C6 M>@%#4FTR 70^439^5CIB>./CAH19.B?
N^O5TJ/$MCC#3+ZE^JF:AA$S!MWQ?ZN,=+&I<^F^S7,KVX^H^%:@$!_AMSO^>?ZE$=+>"UGH^6V5!US MO=UL!6H 0U$E2-5W?
PE>?/809YSUM^QUY61,7=5X$Y!19K!H&G^Q256! &6W ML2^! R2Y(MBG);#H=UM!SB:5Q!0^TDPKQK@ZM1H>(!%XN>"HFWYD0$S=IV7W
M:CRM2NU>1^W! UM460KN>^/H^D.ZF.TV^+T>G2U.X19J.(9K=&#K3N13 MJ^P>(^Z>+>+2O)^N_&S@2OLV$Z>MZ!APDD4X+!A7M!O6.2W&L
>>4N>J7W9 MZY9'DWMM->^%a!>12E7M$IK.(M9!0:9W1GG(QWQ S^~N5/10HWLEX.>ODC
M 7~UXQFN3%.S7 4C4EY.-BO=C$!U6 46!1.78+!&10)DEO:7^4&6F59Y M8+16!JU.^<244R<^R^F KA+>A!>FV8U4AIXR.%WDMJ 509^*IN:5N@
M2R:(QC<3WYT@!V4!+@J^5SRJJB&DB$ JTB&DE1!BOB/!0GCG109K$+!BDU MTN4C.LM^GK^!S61N!C1K!1 98L?%,T#<K4WZ(&^+^O%&=
<@DB$:H+GEA&^M27+CADU>?P91^E=3D#^G?Q 4KI/^7V(G3.^V9M!5XB<5!5EV>^!G9C@1 M!6^LAHB^JW^V:
M1H8D+ZTT>KJHTQ104^3L6<@LBPSXS102D^?2YMBJ:5M%TV+&^!P0LU:9#;DOO!@^!0V3Z).!M.AJXL46 EYB^?#<
<^$0N=L!>#8<4 RK^NM70Q=<#1X W!FZLZEICYKX294J.X MD0GJ $!<_& MP87O!W@Z.D<8!G0$>409WJ)
(!7 CH4RB#&G0^9!1NN!^U60L98X!1^?@ MXZDQZ09>W>+>W^D>TX3#5J+RP113SP@DJ!D>F^B+U81!IAMJN!UANB?7 MUJ^Z/A!>13?
8SY@T<12^Q:R^OQEQIYUJ9FYK&63R!;85UN<%5: U2U>Q MH!JV<M3!>1LT/U%AZL^M38!>V<3VF9I=;W:M/KNVNDY%V77#0^2R?1*
M@>@1^3C=6!>8-3%H^EUZW;Z!>9WLO^GC$S_G33D.D>SI@ZWAVNW^(*&#M#1%I&YCUV.ACL:
GFS(C 6FH&THMRG<^DL7=5H!VM&6QV0G19U.IKNL2LMIJ55_B9^M!0BF!KK0?2>+!HG0Z^KEFK<^JF@!>=7
M16 WN_@/NR/H!WTPZ!>MONM+M_ZG+PC52W5^BZ^?M D+PDLUC6_9L!&1@UA M4^
!K03Z."1E!G/K!<L@<2!>B)YS(D.Y&O^X^B3S!<#>QD4!<^<4%&M^4@U24$HH5^D>4E!D!32!$OUS +_!PIF!@C5($0H^4-F^/MFT66J.K3V
M%QUHJ^74X!13B0!Q.UBA$R15ZS<^@! JD0 3.80!5$5UB^W+O@!2OPISZ#&_GDP_U!D!2FEF^GR 4/$#6D280UA#3S(N6.KX0H? UC9!O H M$
2/@(4QMT1E=-!#94LK^4F^C^/2^73D#K&974S:X&V=-B_O9CB/1+0AL MQ9!D.H9(8!AKX>+OT!$5&K/F7_79E7M25!>^*%A(T!@OM;*>QR ALCA
M&O4M99H&#M^N6V^?F^4C$&@&P$H!O_U^D+O!C-R^O4!>@!JU^$WL!Q^LX MY3T_7<61XAXIWX?>6>^%1$5$^AWR3D^JA:
(60<_#X&W4&ND5!E4.K$<@UBB! M8BDMCH2B.#&#E+UP3F!>^PFEQOQ!BDN M.OF^&VQ#^O-H26^0H.H4/ZG0R!6H.VO2^4!2%EC:87N/9 ML+H
!DXYHK#-.3^W(<^Z^G!>ZTHHUO<^YWO+RMH^T^KC/$!1AG@0!U M<2M@!X^2!U)H^O^KPLBTUF8FHGP24FA/S=<DDTH(/P4DSIOX:JU380Q-5
M2>JF+QFE0^L42VL>2:4@!>T!&V13;=V!A78^&K7^#15:PNS #8!6@!2!H5 M7F39(F!Q^SXXEHVH&H!8!29^CD^HIV5L<67#L!B-$3V
!3ZLAGC7!YVZO-LA$(<LUR2QH^X!L MLJGT?QJ^?>_!H!YT!>H!>L!8Q!UM5RP&X+EM;#<H!BN=;@!H24^PV MP03X>LUPPNPIS(D8!T^9^%&
KA^Q^C^L#6>1^#Q/!G$!NLS+W(-?T!A MC".A!UATY>=C#D^F(D9LWEAL^@P+_S51?Q!9.$(X6G/BI^"E!E^DR=
MHH&Y$SUXD9HCP!7^#1).S!HJ!T9X#22>UQNA^M ZL!7Z>1WUXUK&D-UK# MEAF&5K.FVZ1.5Y2LN5!M03.GH=P@>A?
B5$<G!HPC<1^8!5%&7!AP&TCG5 MB3YV>TOHJ!Z!G!<+!OK B!1MY&Y5.D!C0#WF>2Q8=53A?JH.M!K!F^#&# MUBKZIRP:A!E?U+!BR0?
**R3N:>D&MMGNI^AR<@0VH>=J.@Z=>DL2F#H.A M^2?8RWH^+T^6Q!>L3J6^!A9 # 33=8XB+?L=W^78FN40:6!4+6;_M5^9SC!9^4?13!>8-
W09.B+IY5^U@Q798SUI0PX M^KH!8 MZ@<@.2!P&+G!LZ^<1.FE!R!2HN0Z^#2&^!3G:SH^UGH!UN!N7L!M!A MHIDEFO!MHV#.#94=TYKZ^?
57LN:6HW6L+!>5=^TNP0?S13< MO@FIBO#C# Q# VC^8!>+!+!UH2:H NWOH< @M^2^K+!S^<S^Z!L!8!>W^ MNP+R^HUB8FOQUN.A #RE:
!ZN?>7? MP!J3G^>X$F^Q=2^LXF$;S^P5ZUQ!5$;P^M!06DUGP=S=HHS^RYNI^R!X^H_E@ MX!>AE 4F+5K0MV!5!P=HVIG@^HA^E>3!&?
BT!K:NV?ZFAWV!Z33K&C2 MG0GZ=G^X+53+!>N(=6!>T)U>@=3BDIR33LIV^K>25E3OR6!OR<#N=+8%&7V< M4!2VGM!O!>I@V_
X!>D63<^VWVOZ8L0S3D10G!V3:![8;#K!&#>=WMSOD8EU M>K>R+!+IV-G6!>PWL.W!>L!E@VX^CC2!>6A 9^<2.(DPUX!R3<3$<^>MP!)D!>UZF8
4#&C.XPU!O MR9H!>N=1K#>DRKM27-HHK!MB0<+>PEAW^XTED8+VT@ E#H!VX;18!FM6$ MNJNPW^KSAW<1Z8!(!#1^3 AQMT?>WD^M:J!>N
=$Z=OMWMO=V25HJ35!MGI MHH^DY&EW!_!0AR<=46MDZ FTLM^3!O.26FTX-J.YQW^"O:Z!>8:S3W8 M9Y:XJ3LC^!@GG8=+!0)SGH/O-@
=8P^*V=^OKJY!F535$;25N=16XGU MO=4M3O^ZMX13^7W=<129>B^/R!P^N;_T^S:6G=(H!4VID.RBZ2H< MNWV?H2-L?
BIGN1ZSC09:MNJ HIGP25.5F@G6V!VW>MTHK:3RN3!>A=&lt
```


MJ+8X+Z3-1J]>KM%<IW/>9?>-W(->B1A:)<(FICD)>#7R.G:~!6J@<H>X\A-4 MXP#4H;J:C20772_Y_-7B?Q4IGF?7_5ZC?F^QAK-VBI.*&W.L.3KS:NK((MP3N08T30;>3)ELGSPN82I4P.ETI.D37^->C1&X30A1528.OXBVU9I4)HILSV#R.2T&AG&-4.H1-X2I19J2D-7D_5I=I&:MI?8"SN7CQZIGJ+XYEG1Z<J/4IS32IST21 MUJ4/#H>S%)HP13^GL_Z"5Zi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f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f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|PM<_K^IDX_R(+O%>^I48Q===\$*XD/|M?S;\$> "<9.OF#K MTS\$SKZ/YUN\$DI//M|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f@%@:ML6.0LC."\$Q7@>21?>8.G9?>D1+PCL\$=>_JMX;000^M^08(KQJU=006E<4P0K\$0@;Z&8B;_#_Y^I48RCFHZ>2^8J^>6W19CTH+T M.%>C^T.S28-IK0IXMZA9;*PA@I)7VB.\$BJ(1S^I^Q9#J8CZ;I^<C;ZN_JD;R;1&@2%<^C(Q02D")>@!\$(L10RVP\$FY_M^>A.MYRWRA\$PB^#E>K<0M^R_0#^\$DG71Q+I^P6^Q22^YRRY^Q_U5PYE.QRZID_ M@C^H^F^>^I1E%\$7?)21UBQ^4CE MQX9?Y9I&8SP;1^K@L2)=0A%\$>#4.2B4(Y@;_8-D_MU17_9WQY0\$M;1D;_6%>X^YFIEVR.OVKN860/7P<^IB_DR^LO^>M6@H1N1AU7.OG3YVHB00LUX+IG8M>P>5^RJD^>V4\$BQQ8Y4>=>H13RM1@34R+^W1B;=@QGI^V3W065HRLM;_H+XX1/G4NC%=U(&=5^0ASf@+I@SU;_MW.4=>2>QX&Q-WS(5_OGL(4D@CE^M_@=\$JXW.+?QITWCZ_Y2E^<Z#77I@CISH2.C%G9J)BJA2=>F_X4(QO/116 M^&S157DEN@G4.MLDIB>OACBWZ^IQI3SWN\+B(RIL92IVF_CZ-I?2=>6=OX5P_M8"\$>Q+&I^>^W^>59I^E_V0JGGUJ05B-F"#\$F(V;S(CN+1+^7T\$Y>07H2)"024\$HNF2=3IG6 T1S_1M(H;6)MA9>J^H(CZXK_MMGMHZ;O;>)<^CC#V?G1)9O%;OLO.H\$9I^1%2SU9C%_JQ.57@M+^G4PL^Y+ M2063ZXQ-1^M5RK_R>UQ5950@JTOF1CP5HNZ\$&5IIF&=V^Y^GQH^HA&^=R MN:@RUK54^>TJDA^JAZH;_BEI9;_KE@<^TH7@_A*56D_RI=C9(GO&G/15)9K_MG;2N&1OO5_@T^4JU.T+I26E&EEFPRUF2EP!f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f;IAV8)+^>_>C+>^SZTD_MW_OV&f>_>LLPCI_HLF>=>6%._^>Y^>CVV(GV_AP2J^U;HWOKM6%EIFV75.J7I M1+EP6&7C_T29.N7QJIRX/MN^HNI@Q1RX+>WZJ6\$W5B^N^TH66T1L233ASY+ MB1Y^N+>IHL3>V^>K_7^f(I(Z31+>_>H3EZQ);YU9\$W0A14>IE@>_>R^H M\$%E_MJO^XF+@>L>P.2UVM;H6CN9I;QTS!\$S_9TDRIHPW4>1CIRY\$G\$N4>OHW6H_MI#R.IYIB+2G56_Z=C>A:C6;1^J;D+4%K>1C^>+F13^%=>6IH;915;1L%& MJG8^HJ4^@OR.HK2K;Y9M!0MA5;RL;T;5Z_GW7;GN\$ _J8I2L^>_>I1VPQ510>_BGX1I(TRL_9^P9N+=_MJDW7=?&SLW^>VJ^X1)K=A^J^>_>8K3&Z6P4XWV(B;&7PZS06)GDU^ILK^6G#8 MIGO_YB1^<_>L2KT^000Q\$ _P\$>QNZ9X5CA1&_C3LM(#+1MO#P4D4+_MM)-SU?>^N/@@D\$14WD^&3X15M4RI74Z;9>I.DC.YE>=>^SM2V^4I^TVZJ_MFZIE0=>3)>(<9NR+_R0&f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

!S/Q^NHOHC^!D0>N^..?JDV#&177^!J/=S#E3JKI!{6Q} MS=(T#C7XKYAW)YXZ1!%Y2DRWKO@!\$!HJNHJ4:V\$1UWA+?+&4G8&(AY\$ M=-#=-,W1.6%{53L}.AN8:E5>G+02N'KA\$ ^JB<%10G8N>8IDS!Y+8S#- A MCB6QHC#2\$NC'DF!N;C2\$UW;G? 805:8'IRK'4P'('8.#D#QSK7MWMR&5 ME^5_5 MCEIF#N%-_0E1^~U!+ P04^-=B&99H#>)->8T'D10(\$P\$M=&L+3(P.COP.3.P7V-A:'YX:6SM? 5MS6T?2YGO 'IHW=-:~!TO=>=\$ 0LM6M.M+!6ID.R?F2=\$Z.(H.C. 1A29ZE^ 60>+!@10!=\$X% ICK!\$A:5N97>+N! MS'HHO!R!X7ZPQGDW_W(ON!413+!G%W_!JM=27H'HM_!H<_Q.M.OC!IZ!>?C!+TN<+!7*88GYQ6.CY8<7RP_XXCHFW^/X47:R=A66:S M2X^=/_LY>SCY.GXXL/RA61^77_L^MWCYR!A!G^#@#(41+!%PB!@#E.'#Y3QR MGO+ N?B3TRZPHB1P).C.HX@JX@+!4YQFI@2J+!9=-QM_!G<#<~71'RIYON MUSI IV&Y/BGH_L2?OAFG^>D'QM2?18DI?2_HJX_L7G?V=HGW.M.OONW9N+!L8?9^!EG_GW!SYLPI_X^EB&+!F Q.M.B>+!(5EQ.6M.M=+UXH/U_!C^&-27@_N0_!^+!W2_G#B0=&K=L.OG\$WRV47!^!WK<+!H(F.R.MBS@9%R0B5_~*Y1_3!/+!M^O7!ZF&: <+S+3#8C89YRKR!^D2NKH!3E@E4.M/6Y^2!^<0%~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~*!K2RY\$ MD.(HUMOPVTT#<~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~#AOC!K/FD^EES&Q6K^N5ONVC^M.MY6+!CJ56\$@>+SS7/GBAH.Q^0^FN!%88W!X5YC8GL2^PG^#1A^~*PUJN:S1 MF6D1!\$6Z.7A927%>9&#B^! M9!L>0H@.5R@ID5^21P76^9.8JY_!E4=2#(R.6^60P9!L8P+X9!&4.MY^=ESH7!H_#JHJAA0&HJ2!KON? S7@A!E!V!ONM>+6CQ&4LGFN(AECL^DZ6GW^&#^T4!N5!_7J_M25?L"OG^W^+!J5WY5_OOP(#5AV65.C3BP_X(V%3-BU@6K0H+LE.5X!_UR M9528D!^WTIC!6E=\$WR@+!+!^KT2ERD!LUO!(EKUM!K.B+N.N^M^?Q.MS7^*K2W!H!\$!O^TS#_!J8MJBYC_XE!9>.<~ZNL0Y+!H8CQXK!^C.(9&O) M522ER&.!%E113"3Q2^L.R3TN9T@Q2VLPGE!^!SP!+0W!&^W/9^TDI!%I%~*@A.M<Z4!JRT!HJ^!@!JSD_!<33%7E.2H2<_!+!+!SUL06^+KJ=6#8J0N\$7.L76!M6SAY2!&@KROCPCV\$S_2.C<+!J7K2^!E!F6K!>2!1L!&D(BN8.M^>93V_!N^E!+OGGYODG^NCH? H!HIOK!7J7!F.N^M^E!T!^!YVYG#^H^<+!HZA^*QHDQ=W8YFR_!^IX_U^!W^!U^!8O!1L.2EH@71^+!MX.A^5<~6IO^!_DB^H^4!U^K45+!PHKVE?PV0>_ 5!ZRK.Q+!J.M\$+!T\$%6!H2Q0.RNUM.R5!C.TH!V\$>+!+7E#>2>M1@!5%8!VZ<@E%CLM^!Z!^!G(YR!2^RF!O.VPO:T5D!P!SA.&6:F3#8^5X&.4 MY^M85R<~*!N^VET_O!>@#0).MSWOY(4POB-D.CA=>=2!(\$L2^Y&@J!ZCN!H.M.CLCKM67M;J_!&H4AH6!SUH62+!F>H\$%2!3UWY5Q_ FG.Q66\$FT^Q8.!H!0\$!YV!R0HGB=P.N.H!H&O) MWM^1.00QMURZ2GUMROBF&+!F(C!<~*B!JH^!H!0!1464405PPRHQ!A!^8^*(\$GXT ^7^0V.F81ROEO^TR!6&^CP1&@OCK>.0KJZ_MM?=\$MS.\$0XY?+^3BNEK6GU2^SMZ\$K+!^J3NJ^P?^+0^EC(8Z:@2D%\$860?2;_MUF>%!Y(H!O87!ZIE2/ L7!Q=>FJYU4!HG\$SP21!^UWV!@.XC^X^%42AN.M;QO=&+K@H5FQ?@:75E.3MXXQ!S!^C^Y_PKGDI6X2!0Y3W0.Y;DJC.2=>M^=U;UB9T!7A5\$R! (2XD8JVT&42!F3;~*UM!O5D_AFB_3_L^G^O4P.A=M92P2G5!>LO!JM^J^GV!XQ!S!<+>NM^G5L28Z.YR+W+REK!>4.Q MX16WS!OM\$F_78Y!+!G.^9*9.YE04296_YD\$J!MXJHU^Y!^5O!\$!ZY^2VJ^MO!L.#)VC:(6W!05:QC!^S0!8+>X.X!QS.%PI.U!O4=3W_ <+>N\$!#&O7D8^M-Z#IU\$S#)#\$ED4A.3F2^CVRZA>O+H!>27YKN^Q-U!0.13^T!XL3.M:X9^KK>YV(CI^+!5B.3\$+KY!DX98H!@J9!^! ^L0^VS.V!A^U2Y^>#).6MH^L/7B@!(DY69.SFX!)UB>?#6.FHO+!#0!MJK!(6!1)3!3#&~*MA."LE6^D^M^EXXS6Y!U^U!0WWM^!H7X !B!B.L8E2NSM5\$>@WXTN=2YA2^A:1J_2H9TOV2HZO.(!E6LNN!M^Q6_43^H=P&8EB+!^TDNX^7G.2E4XM^SOWO.A#A^K^!^VY!+!^D/7!62L!K^K.M@ +!T6C815+W+UN!8R!>+Y^HJ9Q6NO!A_VH2^0.929(.?>+!2+NA7R.L!X!IFWND!O.AUZ=M7^0>#&^."XEB0@!SH5.M\$VSVK=O!R# !V63\$<G^T7&8^XUAL6^5Y9;IU<9+SY!F_277QX!>V.O!<~MOJW/HW!VW!X_NB_AU2_9X2F>!Q!E!A!>Z8SC&(IU!<1^Z50UUF!G^PL MP70.@NTK=V0W;D!N#=>SQ<!S!>!FEN;%B!/%=<(&=&Y);.49Q-IOW7B4.MJW>@?2FC^&EUD^X^+&E.T@#E0&LUL+!^T!<~NH^7KQ6)5!<^YQ4U!M/3- SE)F-D=<+!6_724N(#).P3.D.4W+!>2<+>2.O:U!>1+5LGBK_8.MGDVGVJW">+!K!U.TE4E3=E4!E!@31+!^!A!@R#K^?D^U6L!B!T&M!B3W!74? D=H&52FZTC_2^7<C.LUIAB7^XKQZD!T@=>D!>8B^U^%N&B^@>MT+!14RV!T!4Q9S9M92(>+>S6.^~RTDD2+D!H+G^>+Q640!>=>SW48!6!>8EE MD)(2S.C@!JM^4\$7%.H/(0S9215E!<~&N^/L>2VY!PQJR&G/2C^!>JX!5L.M3CIM_4!ZG6_~Y5209E5AE(>+G:~8!PJH!\$QWZ8)2^O^FOS^U4!O(2^XW MIR=9!H!)^1K&FQ&5\$>+!UB!>+!O^!&C^SZ+!&XOS^!M<+!&8%<=&1&Y^W9G!M52!H!)!8M^!>Q!H!F9=>+!<+62YJ+!N!9ROD.02!G_K\$!5A^D.8_G-S.M.J96H2GEH5C!K0^!T!H

!CR:"2H@L>4S6ASXMW\$\$.F4FX!9,5=Z2P=MXWE7U#%R*(SP.H+QJRF4E=3#&8D8ROC*!QH9@X0TTE'=YKE=7012)L(2,);H#D"192!
W(O) M7NAB339<>L9N0,;=<\$Y?>.7!13N@<,>ORI%QOQI3H@!N!NYIF8AFL<=>L9 M.3E+422*RW+WK#<18Q.AJF127H;Y~>.ZX=<
UUR168%,45!%D 487 M C6%L<6WJOT 7IZ~N"D4L<@BD.UK7>)(O)57F600IBR*AJQT:(PXI@&LN.MJAWCMZ?PIM3Z!YET.
&+>5U0I59C<=36FB4(?*Y=L;IAW5ZAMJ=4 MB\$XCNI)4Z&Y8(+&@#H.8@OA/ <7K%0FQW9 SW6;>OA7F0E.ODM8?>0E%
*5RRHJY1)&5)7&7+L1EYV4>Y=<@O128NJ3<84J&JV7W0L 7ER!YV.1902 M\$FTN.GWJN<7K.UQ@0#WB.C7@<F!Q<9.X.UXVY
@Z@&#%NC.CD.M?K@&8(5D5L7D3.RPW~>T)=*>0!&@WY8+8@YB15IO.C: M=U6SK\$1!H>+>NGE8K;I/G=>X>CW7P8/GW
QDQCSIBV&F.DI&AQ-3%L.MNU!>L>T.Y% XXB&OHP9?F<55"6YUCH MX &~>.FNV7L/>TAS8N?2D<352W=>S>A4G2PI8WJS4+X\$&4(M4(B>
BE0. MOD(81122YL4W<(<?1#F<IPN.SU@) @>R.BIXXY1KYI8 ~2LR@3.<A &G+<F9(>?TE/8Z5F&ZF.BGB
=71%#H+U5N<L9>@/ <I>K!>SL.LMKP)!>OB6E=6JH(Y)IU67IYU!O\$!MBK~%<U7#U!8%#&YFX7FRB9G6(HH7.ZAG/ZZ&DA1FYB4
(360);AD MM1!MLQ.MC.Z<CZ85H&L~P!H>W M2K (49D"VDL~>T).2NMQOVA.QZ&AX:0%(HYF&W "VKIDTXL'2'ZQM'BG2-2IAP:A5M)KF E?
DLNC0Y'6->|>|>E&Z>X.O.WT'RO<?T>G<#>5G<HJN&KXSID6%#2 M.R!<@%\$#<1<5/0 %LRM~?QB1G2!6%K">210)+%GNEA8K'P(0S(CD=&H!<
'8;~!N=4+I@BZ)>("OW=Q?G0L:GL(\$%VY'W9<*<U7?2?@H!CB7; M@L7R6O>L1.T7U!Q!4W5'<'!C'~>=AH1EYO>N&&\$.FAR46BA7RT!!
QO1YIEB)FIDT.K?&#Y Q!UX\$F0<*>DVEZ=,79%!(FQHE SX15WT3R M;@6L;2>HXL~>Z~&XX<0D9X\$~>N\$X
\$MQ<(B9YL%&E(Q=+FIO(2B)# M3.XFWOHX;L<3B7W%)ZIFWG;3 L12Z?&=5D;%/SS=I5=TX*%\$.DP#6<0 MIVEG6L~>Q89Q77.H91SU-
E.8NBHJY!2>U M!BHV\$?2?>F121&R.YH/ M@P4>NDPO.3?Q1BY20HIOF= YRB&8R'Y\$2!\$S6HB.XI2<5W@577=8M
=>F&X0+G9=<1\$>L3+1016GRWPL'7YNM\$+WD!IRID=MO16QJ MRJ'2AW"XWY3'S7R'QO!RHY'XZ0=<F&A/>+&L&8M.YD+R5&0(D+<FLO\$>Z
1.11!>J)1LK\$2NNR!RTD'6E6KOE1=CU%K2.'LBVU.8D(T'MM/@&C!<H&ZOK2 %IDK;+@BRQI! MO4BI8=G8VG>N.WD#E.85>L P8<!
'C'>TR.<#>DS.>LQ668N<=&UL+U=ULYDB.ZWK!B3WKB4K<+I6Z>Y.3 MZ%Y> S"~F5)&4T<Y22P2M>U@89 491KU+*%K7Q<+>+<
=>F&X0+G9=<1\$>L3+1016GRWPL'7YNM\$+WD!IRID=MO16QJ MRJ'2AW"XWY3'S7R'QO!RHY'XZ0=<F&A/>+&L&8M.YD+R5&0(D+<FLO\$>Z
1.11!>J)1LK\$2NNR!RTD'6E6KOE1=CU%K2.'LBVU.8D(T'MM/@&C!<H&ZOK2 %IDK;+@BRQI! MO4BI8=G8VG>N.WD#E.85>L P8<!
'C'>TR.<#>DS.>LQ668N<=&UL+U=ULYDB.ZWK!B3WKB4K<+I6Z>Y.3 MZ%Y> S"~F5)&4T<Y22P2M>U@89 491KU+*%K7Q<+>+<
=>F&X0+G9=<1\$>L3+1016GRWPL'7YNM\$+WD!IRID=MO16QJ MRJ'2AW"XWY3'S7R'QO!RHY'XZ0=<F&A/>+&L&8M.YD+R5&0(D+<FLO\$>Z
1.11!>J)1LK\$2NNR!RTD'6E6KOE1=CU%K2.'LBVU.8D(T'MM/@&C!<H&ZOK2 %IDK;+@BRQI! MO4BI8=G8VG>N.WD#E.85>L P8<!
'C'>TR.<#>DS.>LQ668N<=&UL+U=ULYDB.ZWK!B3WKB4K<+I6Z>Y.3 MZ%Y> S"~F5)&4T<Y22P2M>U@89 491KU+*%K7Q<+>+<
=>F&X0+G9=<1\$>L3+1016GRWPL'7YNM\$+WD!IRID=MO16QJ MRJ'2AW"XWY3'S7R'QO!RHY'XZ0=<F&A/>+&L&8M.YD+R5&0(D+<FLO\$>Z
1.11!>J)1LK\$2NNR!RTD'6E6KOE1=CU%K2.'LBVU.8D(T'MM/@&C!<H&ZOK2 %IDK;+@BRQI! MO4BI8=G8VG>N.WD#E.85>L P8<!
'C'>TR.<#>DS.>LQ668N<=&UL+U=ULYDB.ZWK!B3WKB4K<+I6Z>Y.3 MZ%Y> S"~F5)&4T<Y22P2M>U@89 491KU+*%K7Q<+>+<
=>F&X0+G9=<1\$>L3+1016GRWPL'7YNM\$+WD!IRID=MO16QJ MRJ'2AW"XWY3'S7R'QO!RHY'XZ0=<F&A/>+&L&8M.YD+R5&0(D+<FLO\$>Z
1.11!>J)1LK\$2NNR!RTD'6E6KOE1=CU%K2.'LBVU.8D(T'MM/@&C!<H&ZOK2 %IDK;+@BRQI! MO4BI8=G8VG>N.WD#E.85>L P8<!
'C'>TR.<#>DS.>LQ668N<=&UL+U=ULYDB.ZWK!B3WKB4K<+I6Z>Y.3 MZ%Y> S"~F5)&4T<Y22P2M>U@89 491KU+*%K7Q<+>+<
=>F&X0+G9=<1\$>L3+1016GRWPL'7YNM\$+WD!IRID=MO16QJ MRJ'2AW"XWY3'S7R'QO!RHY'XZ0=<F&A/>+&L&8M.YD+R5&0(D+<FLO\$>Z
1.11!>J)1LK\$2NNR!RTD'6E6KOE1=CU%K2.'LBVU.8D(T'MM/@&C!<H&ZOK2 %IDK;+@BRQI! MO4BI8=G8VG>N.WD#E.85>L P8<!
'C'>TR.<#>DS.>LQ668N<=&UL+U=ULYDB.ZWK!B3WKB4K<+I6Z>Y.3 MZ%Y> S"~F5)&4T<Y22P2M>U@89 491KU+*%K7Q<+>+<
=>F&X0+G9=<1\$>L3+1016GRWPL'7YNM\$+WD!IRID=MO16QJ MRJ'2AW"XWY3'S7R'QO!RHY'XZ0=<F&A/>+&L&8M.YD+R5&0(D+<FLO\$>Z
1.11!>J)1LK\$2NNR!RTD'6E6KOE1=CU%K2.'LBVU.8D(T'MM/@&C!<H&ZOK2 %IDK;+@BRQI! MO4BI8=G8VG>N.WD#E.85>L P8<!
'C'>TR.<#>DS.>LQ668N<=&UL+U=ULYDB.ZWK!B3WKB4K<+I6Z>Y.3 MZ%Y> S"~F5)&4T<Y22P2M>U@89 491KU+*%K7Q<+>+<
=>F&X0+G9=<1\$>L3+1016GRWPL'7YNM\$+WD!IRID=MO16QJ MRJ'2AW"XWY3'S7R'QO!RHY'XZ0=<F&A/>+&L&8M.YD+R5&0(D+<FLO\$>Z
1.11!>J)1LK\$2NNR!RTD'6E6KOE1=CU%K2.'LBVU.8D(T'MM/@&C!<H&ZOK2 %IDK;+@BRQI! MO4BI8=G8VG>N.WD#E.85>L P8<!
'C'>TR.<#>DS.>LQ668N<=&UL+U=ULYDB.ZWK!B3WKB4K<+I6Z>Y.3 MZ%Y> S"~F5)&4T<Y22P2M>U@89 491KU+*%K7Q<+>+<
=>F&X0+G9=<1\$>L3+1016GRWPL'7YNM\$+WD!IRID=MO16QJ MRJ'2AW"XWY3'S7R'QO!RHY'XZ0=<F&A/>+&L&8M.YD+R5&0(D+<FLO\$>Z
1.11!>J)1LK\$2NNR!RTD'6E6KOE1=CU%K2.'LBVU.8D(T'MM/@&C!<H&ZOK2 %IDK;+@BRQI! MO4BI8=G8VG>N.WD#E.85>L P8<!

MSGO9;IS<>^SAKO?6XAXUDE7#<=^IQ69A:2W,H&!=UEI"4?*"@T!>^/H*J7JZXMX#15-0)IGZKX8#\$9-
MUM0L^ISM>^HLC0Z%X2YP#T5K!=FY+@(\$4JY2(3)E"KG|BC8^X3FM.06G;6OR-0%^RFP|O&|N^=QOTG45^MZ&DFJR<-
BX^%)1%8A)!KO%RIZTV MRFAY)2!U?PI/5MJMHN+5<^Z9T?DFA1M0.M*LOT7I^&R!Y.9ISDKCAS.7F MW;2=F
M=B>J^&B^KG=4!FN"!^DUJZ?PMN\$=8>M:;FMI+@6@C?QY>310+8&H=HV1H3R@_OF23A<++++&N:17^T8401/4ZE1+YZ2) 6S930
MP0!^DBY<#*YIKNYK%XX""%YL#&@_#J#Z#SAY+@!P^TMM:8<->NPKIH8F M1:6AWH7Q=(CCR:2^Q+5WP)4+;F5BJ?
X5-!Q544^P5MJPP.5&5L4:GV(E#)1/131Q=+^+^+^+M\$.KR9L^NK935IYV!Q8+9V9(A!<VZ9/OIO:9QIH M?D.3HS:%FYM.)?OO7U6\$+
!O3IME*#*=H^<^MPV(L:DP:"E-SKO6AM&^SRR M+AG.9:F68K^Sj0=>L<#UW4&H!"VXYMU\$GUQ(M..S3%)!X#L00Q1)!M\$
MR:::SUKE7)IV<8!M=;16<8!M2W8J7U5P_#KVS^<F-T"FY>Y"HLRMN!)^T MIM*URA
RK2%Z4!^Q%BP+!^I9I!%#MI=;!@S!5CR7=GOO /WF"/N=JDI&I;MC=E-.B//LR/Q6SKMH:7^69FN +N +&>6@_OE:A2\$
MWC+!+4=52XT\$VM:9QX_!\$V.Z>A/\$_J^<3V-G!G%9UVM/OXKO@_7V^43GI M@07.01E=R"13^+AALB@9C2^M2R^783J^V=21.N^9QPUUT<1^!(HT?
UZ3>2 M0G(Z^K)>J/C-6+SYZ?EY3+1.K(H|S2E-8)>D_UHAO^LSDFA2^&2/LV2W1RBQCZWN|CIC^VUN\$3Y+!VRB!^>_2R7M33G
M23@_JRW30WC6%MV6F5KDG<<XIDDLX^P!26VGJE!^<G@_A.OH:LEF5WVUD MW4H ^=B6&Q=1%JZUYK012T,J.P.S^O(C|B&CDG<|FH-
^_S+*3=IRJ!\$_YT MC>)O6-!^X_!>@!^0(8:S^0B|DLU!H)820S260=A="=HMGJGZX;3_OG_M0_HL@KM;7DHF5S.CS%N8;Z4E;(06U\$E
4H&H#/#=<6XS&SR2H0UY;_CWF6 MS.A0! T3O=<1^HJ6:ID%#%;G0D09YT!<^N0)5J2!%=>_&PYZ^/DR+ZB M;YBO=V2^85MD!3:A)C18SDXV/-
&7G0 43(\$0WZQS@B+VJ^;7LF+!=""M^Z:1!(HCB9J^!<-8%>M^+>O-OE\$X\$M79(TBJ^LBB)4 /JM9Y M=EO
^TZS!;5TGU!F7T^IOVJ=1U J+W?)E2@^GN)0<S#_.21+!H7A1(P)D MP6*^A.X^9X5KRKXK<@O!Y-I&G;Z!;MP%0HP6LE8
M.\$+!D39.E@N\$E!0TN|H16.%FUVX!>"HSXDQ8\$HG1D(ODEA_P->+!<819GS9^2A+XG7-;@Q8:4S^<KX_<DC12%&E M&3+;"/G>X<2HH!><9J&@.?
<<=>4!H!M.WZ:1^W=:#E!8^6\$^?O4!_M2Q!<7(1+!DY!@_SVB<0!+>_D42!9Q8A^5\$B)QETIKCOH B^!G22.9+!+!W
MMX!9)7101L.SCS@^O!%1LJ_2@FS)P);M3X&S(H WD7SUZ^0VK=V755A.MF1)-Y+&\$^L7VKX+7^>U^Z,7Z1^7_3%6D_-I(+.6R^OCX)7^_G-5|PK\$DD_-
!*_MS<4^B?G(E!X!_DQ9)E%VY9=K0Z%N8H26Z<#%#D(UG60_-UB30LY!<YVM M;2DR=BYYL;PS1R!>?
E^CJ/R8A@&7R?IR:A<-KM;8IGUTNWZ<^!5A=M3C2.M!H-YYT^C_QZ2A)H!>C13SB_/!8^!Z>M5>YZOUV1V2*1 M(0)5 F4XP< <
M5!H^2S*^VZU@!U/GCW73MW&M>C.\$3.DH#;G_!H3H90!1^*LDJK^!UO M?22V!#;#<T OF=WEJ&#%/Q.ZPO)KNDN5X117).E>TQM;+Q4ALM\$5
0^L5 M.J0/6_Q>_I77H8Y_09J^<AZG0>4E^+ W.HU^CJMVMJMQ%"8!#%<R^O0_ M@_RAWAX.\$+PT^\$^HND-
245VVO^YF/N=LR2;61_L^ZF@G9B)H(C^X>B+8CK7 M;Z1>>^0AK-2^LB!;23SW0K6W4SW0<7=0J_N-BGKI-SH<72E7T.FNP
M.OA0M@+R.4!@EMQ<9%G9C|6!_1_GI_OIQ-RVHN(H^2I.PAG>1^T\$-YX!#V!M+OVH!^_L7=3>9^O5&
(M.8%=<N^3460#N770WGI5@N.OZ!&_>_<^ZZ^1V M-0=VXZZZ^Q+!_U02^P)FX1/O/6!^VM!/0.N=;@
MMC7AH^F^FTP@/_9(JY^EDR0R^LP(T<^IRP).4ZWV@_09^!H0Y@&8Z<|H^
MQ^E=C^V7HDF^CX@BU^D;6H^T>A7>^B&RD;YV6Z!_&Z!^R4TF^6L6G@9
M/F5\$8C98\$(90*>YIOD45\$-9#\$9Z7<0.%(GS)\$(G4E^I^QTT7ZHF^DW%<CC ME-UNYW1^U-01N3%293F/L!ITYM.^P/LJCVDD2CA^!O@/H10!CF_T0^X.K
MTYHYMK?7@<^O^X^<XUOXKJENAF!9;E;3!&43!;L(\$Q!>T\$S^C^6M^UOL_IZF=O_ZU^/O4X?2KZ!C C8!970C&*)<(RMJR22LA>A
M506&4E#)!>I=;L!Y2/E=[U2^Q9O=UVYNLB;6;H4HNL|WT(MZK)!@_V!M^3_8V0!^IWW4^\$E!%JL!A!>@<2T242&X7_>J@_0070&=R(O!R1
OIOFI\$D? MK76-J(^6MMHJ4M^O1Y>7\$XG.PGPQ648RG.E:>K^X.O0U(^/N5HJ),UG#_7 M6IVFABRM)ED 3B|NDH_"SUL_=G%03B2P2FNP)0F;
M/9>1=5AP>I2_#(^XKQ)2\$!>[K!D.GJ52V D9E^PBL^!<M0/DR^P!<M^>+A5E^L6SUBQM;2&1^5QCIPY(^2:XFWOBJ7DRRW%<T^XDM E4#_71
7E2;7YVRE^7N^<B:0N^="DHB|!6 G^!G!VE6UD!2(Y#(J!<M# JG.IEY\$ST+T0S6>Q.W2\$!<AZA9^5M!>_>?T>2^J|N^TQ8R_24R.MF-
2FB)EF=OW+^Q>CX61\$<^ZKVK7N8MR??^N^39^G6.\$A49ID!^UJFCT(&U.M^1N7!%E.BT.#(1N^M2#1Z_UVX\$O^!%VT<JQ5IZ^<VG_/AP&7/_<I^<
MWPNA4R&H\$C(PL>9#.AL@N\$ 6%2%(8LF2^U^#LFR9TB!#E724!^M.^2#6^!M^+>N3KH^3S5Y5Y1P!PB@52;Y!S!HS)S>_<8!>_SWDV_2_>Z=5>
<1UX)!^MXXO1F^Z!>^X="<3 2PU8;EI<0%<P<^MK<-9J8=<=<6!NS#P)ZQFQJH>A!>? MC@:UO=EXWHZ<(GP!_VS>6NB13E2!D^!>
!>X!UM_N.L!&D60_HH!^HCD=^Y&H!<C0&8MC4UDT^PVS/0^<(TGFA MUUK^?>=THSY>K672L\$!L.H>R HJ8 +_03K\$CFL^K1W>1^3DQ%_#^?S+AM)
M^RE8(OY^K%\$%NW9%<^SC-L>5+!_!^M^>Q6NQ0G(LBY^=NX!#^X;#VL5D>=H2A9!9^>MTOB<#2GHX?
@(&L!K>N!^4^KIOQ9/04=+;G/H?)\$R_V3ESK!<X9AS3(\$Q) MQC^B(RYQ@_!<C6HW=>>@&L;P?_740N!KX=GE.VD!>L^J0!^H32D\$+
M+DGRD^%XTT^CULBNTHW>O8^C\$ UUTE;BH<|M-RZQ_<EK<L!&#>+5NJO M!<353K5^Z(E34+46H<+Z&QBB=UK5\$^Z!_#_<18(=5W_HJZ)
5GO-RU4E_M^<\$^!8!A=X?>^?2K!0_HLY^!_!<6!3X;C_<Q!<FQEW;6M^#P^T^RK20TN! MF|K3>_B^!<=4_+!<OUP)FE80<1+HO0B
M=Y8^VY8^C6M=X1S3>3^NBJSU6K^&P0D4^*9_Y;5U2VGOFF^<^W0!<H6?
M!3#;R!0>3!J!U;#;AS7!MB9A^W<^!D@2_XAE51R^YK!<HYZ)J03T<W;K M0MU&2XJ>G@<Y.VJ5J^TUOE>IX^
H>G2.U4B^L=R#0%ZNFLLHYR^E8EVT.6KW-M00KUT;FUC98.7\$;6 BW9BN908_<@_T^&B;1^C^N^T@?76!_!U9;MI<@M
M;LBVT4(7\$;BK.OL#^IR4C!<9^59<@<(EG+^<_19^<GU?>374N>?/91 PT= M2179IG/Y7D6VBJ(M^)!<N!&2_K#E-
LFEYL@+61_<^!<OWX!160@Q1@!<N!<A9^!JU^!<=S M2!<#2!<T^ME=;N!0PU8>7.G_!P;GQ9!<3Y^WBJ0G%9U9U)TS5M\$GW1YSEY< M;J6H+KJ5-
/G7H9!NAS.OCU^!XOH_&789O!M=N*1.4A65;GYC0X;R6D(K#8 MD&5LOCUV.9!^SYO8C) MA**AIKN!8B) 9#*^448XEJ03W;4+;C2^FKV%<S;
(+A!_H>#CAF6K^G66B&#^D.5E8IHNDH7Q_02_# MS+Z_&L=J2ZM^YF.2NP#DZ0QCCIQIS^8SSNR3J!QWZ10!A!<?2X!A!<A!
M)9<+!<S&D)P69UJ71CS;9JZ_5\$R_4X20H3G/2!+<O9Z2^K\$A M!3HJ2142^4XQOHY^QOWE)OLWC^<M0#3RE!<=>4LJDG/3L B2\$<R
M5=EP^"H9T\$DQ\$V0V73F?C>^PW2^*P<I^G9JH.5H;RXGPTGEY=@!P+M<# MEP@V 14^4\$H9 M<#K27XVC)!_!>?
T!Q/UUAR10LNUZ1M_17121\$AD_<^E!XN^W.CNEE M6^+X=LB^!8JRZ_<4.V%>6;T\$X4!SU\$(!&5)JZU.9IX7X+? 4TV4_R>^OD;YDJG75C_!O!
H!VLE0?SA<R\$!<PG^LWCKIR6AHC<L!^M=B^YZBY1P3!MU\$201^D1N^L%_#H@P14DDM%\$U.IN@L6^7YJG9AL=JG900M^TZ=F124;
M!WPDG^7FF!MBJ@M^!>E>LNVCUVQO)DB+!DGF^!H5U9ER DZ7U^C646F^K!0N2DDMA<^! M-
066Z^MO1(G_&E!&L6!&L^ZHTZVTWH!<K135>7U;22JP!0_&P;#O+ME%L MN+!<U_9X+>=<0 V@72288-
00K+!BAF^E918JZ_8LWNW3!^WBZ=7IN65N^?C M^<O2SV!<=<O P=A.F5ZUT^M3!P8NA^ALQWE4BC_/GU=5FKLP>N^9^S<17% M1.NA=C5K-
\$!\$&Z!>+EM#&+UEMC6P^<=<F!O1W^<?>HD16LT@O G TM9N+ M5Q!<S>2!4QV^AEZIZ&L Z5\$BZ.H<72L;Z^!8 LGU7^0!<67M/TI^H
M2Z%5_<NOX^F!<W(H/KYVB#CJD0PKM^<DFK5Q!N9W^/A1&8ZF-PZ7V4JH<^* M+S2GP;A3273@5CR!_HBCD!\$@F)!2\$8ZYUN MML9E;F-
M00^"XHHE!81N^3QI/^L^<(<?>W>VT>=>I^MEOX#AD7@1=,T3FK M(6970&6>@<K.P)^<Z?7^QK;N^TQN/IF>UUNP^YJE=IY694!_PV78!7_ MYB2I
J=5313&GPQ IC0^!<U=445H!&C)XCYHIXMVI6^8@E#^X7!<S M4)9I<_S7^V;HB3&=<X=X^J^<R!<N>+06DC V%O;S.518L66Y!5;3+1^I=
MM^OLB16R!D<+<="E!O-7408PT%REDQMKNK^4L!OB9NF-BQ=\$0=1NE-KZ_M_<OH!D#P^SOTOINFOEX&F-D7_+<K7WZX&-4<^!ROZ?>
CBW%<"C^M\$E\$H/ES^W<1UX) ^G63NA=OBR;2HJ!P7^3 HLY2RTM!<(! D_IV^3 M13UT-ETDT2WDK5U0=;35&5!2SZ\$8#T#^U-
"ZWYJO4ALEG^!<J+9^!<V ME\$S#>3NPIQR4Z K=CNF^W94N4^#<@2%>5F@ZQ66^H1GB&16L^N^87Q-
MR7AZ(YOCU3!N^!<OO^<TT^A&2M+!GR+^!LYQ7HT0^ N.^5 J.E^!6PC26N^D MBFR#\$QM;203DQOI#_H>>_>#>H1V8/JK_65G&OPK6H?<H
Y38IV^6L>AG-M8<_HA!7JH%5/39-D&(N0@A\$ HW 1D)M^D^RX#>K51444^<C!H7R^95D0R MCY8K6VBB>#RJ3!2TE9-
6_<W^<8L&5K99C!<VCYS&FCKFW=^?2)25O!%EK MS-OH!&LE!B^C625<_7^UVN!TKH(X+!_! HD!<A Y/=6T;/(9=N
M@Y!%"M!<@^S^+C!7HF#^<KL3L/M06!<2.G#J2^QNC+!2^?7!X;J<7>#>QZRI<_O_2^8 M2P03Q:P^!<J&J
<_#PO_*G3;MON8;LANY SL+L\$&K5W6.\$!&G!^O/N&YY>_M>^X9CT5\$(Z6!^E9EUO^Y8IR+P^_RBL=4O-RT+T=IOV+AH!2!A;C\$<Z.ZM%
M8F.11^6W)0%GFTV0^*L>_<N83N^52KB_Q;IO5MI4>CZ6A0^JBAAI^<BDR MR^!>7!%L C?+O^4628168VR>Q2J4!N.A!6#&#;S.5!N^P^6C8A
M2)=52+MHJ!<9FV!+!<L3=<_TEOX_&L^Y!<T53K^<KXFEJN=S1\$4_ M1LZWM9_/S!2GY8OLJMTIC(6>_! M63^H6=<07^KF>5
KYHN@<#QBR4EPHUK2E!0+SLA83=D;\$%\$K31Y)/Q5U J.M!6.U&5=\$Y&2GU!6<=<223Y7^Z31!</_="E9^"U=00EC+DG9+12<00E.P.% MDC84XP^D>O-
CLC)F2!A0>8-!>?UXW^DX?L6T PX^<@#<@8_U^VO7@!9V!J_ M7G_@_012?D@<X\$<2A^DS;(G^?F\$P?>2T)42MP(N3;ASJ!<U5J06EV<^OUQ-
AW!S<30GUH!<SA DU0P^W7H)R(XP^89%S7L^="M+TOJ=D>2 MVY3^8L2!Q-6&L_64Y_<22N36T^J^_3+6&U;C@Q=N^="W5V!0QZ^KW=<MG<-
X5MJE/_8EXWWO9L^LINS!;WWG^<4H&Z24<71(B MVI-F36OJZ!<ZU_<N_2^CVOF!J^!92HL!<K/6-8A^F(P.4^9OV<^!W;=E-L M^H!<1
!>HXX&XZ&O0K#<=<NAYZ^CFGKZJR!\$S;=W5X.H!F/M2N55DW^X!O9PG#%Y-!K/HJ22^<Q>SZV+!M.6_+<N^H L3K!<3^8M!<L#6!HMF;
G>5ICQ19)RSHG=PHX7^_2NIZ!IK M^P/G!D=5>-2!Q7Q!<H^<N0%2+5<=0F4LV^M^<2WN\$!%QQ^XYL0K&Z^IEA M^G.FGPR
4H+3WM\$3E#3.AY9M^RN_7K3Y=9!<OY_!<B;..EUH0BK09+!<V MOEX=87K.K)2%IFKJ^9SS&M(.450HMO5B83@I75&H&IR_V\$
MU_!<+!#15NL!<L!<LDA)T!E8!<0^5_<U\$Y 082_9J^67^O%V!H217N M!<G_<=<TZX>EH!<=D2U_#!8K^7F(CCGIOBF^P.AD6G05
M6S;VZ;F!B9!<M!VLC4XETOD^"8;HU;S7S;4!)KEZJ9W^W&Z4!G8 GHV^OQC?<Q<MM_6!<WJ=#W8O^V!L\$
!2ZIE^*O_N IR0^7@3YWSZ4+!)RAVLN^03X329Y>@(<+?1^YT>B@_M9R^07SOY!6UL!MDZ2O=#_U2^6Y!\$A^UJ.V;03%>CL521@6B^G+<M
MEK!>O^%VE)2<+<_<?@7;W!YA TH=9^*U_R_<209E8Y_&OY@V!<BGKG0 M!>+<275_<PN)C/YFS>U\$<3^!<QB<+!<Z0A1^2Z!B^_<!
4AHD^AA65\$!+6! MO#6#<4-A;A?>6:25!<9N&+ZVC^K^<N^JQ.HH@H&CEK^P=P0F0HLC^O!D8 M_<W9AE.PR=#RO!6^1=)!2?
T_>@!<F8X300GA^<OHN^<?>I#<D!<T2M^ZK MHU!<9!<^IEQ!<^YNO^3%JMY=M!Y6#2Q N\$<S&2^<S&UFP!HRM_YRHR^* M!FR+LXP7\$H0@%?>
&C4B;GO%XA^V\$J_<Z2)45H@4\$!SM225^<3^LR^*V!>_MLHY^<O49_<M&3%MY;K4;1^W;3R:5^>OY P!>^K<9P^5A&KHT^5BA3O+<
M!1^0_X=<E5A^<DT!9!<ZLS\$>+U4K!O^PO^!H5;DA;H;ULEIR^JX^!<PV!) MT5^C3)5GV&IV#9L^E4OMHVV^KM>C^(>_UOI2Z&+VNA-
T6!<L^<N.T.HD M^K^NEX^BWO<(<5>3B/H^<9M!<8!7ZP.NOC^U9^#<XVF_9^SFN^ZCZ?>1EXC_@_0133-
M!^\$K)0>SK5JK^<U>M17O&T^!ZM0SM^0OXIQ\$#<Z:S5^T^!<4^G&FN-2616_ M5385>NKZ2_NFYVP^<Q>2!<S&6@%_<S^8XG!T^J@IT8;@<-
>1D+2B3R3!S<#< (MK@DHN)9B!<5^<9@GS<0N&Z< 5VU;#^<_B_<N<7F^<K9.R@!<^UO2!<^&M1!M\$DE\$J8QHW5^H#H3G8^WD^ZW9%>DC6!
P_<_Z!>9SK!92TGUR^2 M^L^YSIP+V3!<IR?2\$SU@YAI<^XDEH7M4N^M6H2R^M^<K^G^WZV^MQ%K^V!W-
MS1<_<0)2A8.P.M!<JG@<CMFC^H3!7_P^8<-<E3 MJH/60FMKP1.H;V^<CMP=7)PS4S-D(<#^<=<S-
<5JH!<B&A.P.5C8PVO!<@DB)JSHT^66P!9F^"VC^9%B.O_6;Z<5+IZB>MFD B M;YO;0KAN6/SW<EN4^3^%92FU<_Z!
(G.R!M0<=EECYMHM+50SQME382W6&R M4+J4(K^HH2A)!_TG9^<DYV^DE3.N.O!<J2R424!9!A!W=W+V+SW\$=<J& MZ)!<U-E.I(36+<
(#_IARF0^Y-9M3)!HIG-#<FPO!D=,@34NBA^"15Z;_Q_!<M^4&8_<1.V<3S^UO@<C^%)@!R^5PKJ/ 7V=@)6!\$FGB!S0E=H#(M%V5YMI M!<
(.6F46JRU!)YPM!N!<@<MUY5!<3VY8E06!P!<#Z_8FVJ60K!N!D^<M.6VK>>Z92E-S7LC77^!9BL\$!<^%5@=_%!<E^H6U^<F-EMTFR2;S#<N!%
M0>2.H!\$RB^"SYR^J!<29>^#SN#(XPE1Z8Q!<H@PY.E#5QTYMH(C^S^L M=V5H\$<G!<308&P6)ABMP5C)PCH=D6&M;M2Z!Y+!J%LI>_<HK<1=
=<9!<K M/S>9R_<IE78+TT^TN7EO;MH!<9^WQ4TH4^BLRTT54\$) OX(O)KRU^<K+2^ MB_7XF;KC+<=<0!IME-
HVZEX+^H8TBT JB!5M4^<G@6P7Q!<^<WLBDA&8^MHC75!L@9O^X^O^OMN^OCSJNU1M6FHSWQBZ2W4N^H6U!U^!V86307!S>)<S\$%
MB!<OK>PV!<I^<P#8X5^<FCGU&^<MKYZH!\$!<J!<MI3O!WDO-Q&I#>6PT!O-W^MS68)9L<NVOL+T?E^<Y!<^<O!YM^P>=>+<=<@5.L&
MWOVISB;SVO!P!<6.78P!+8>F^YRX563Y^*H7_<K^<S+90=<M&K^JLGRXOF/BZN^U!>2+<G^R^KCJ^VZ^!2@!TZW^CJ_4MJ6+V!N^!HEV^<9-

[illegible]

@@@/Q/M%<(1DA0MA9A&W)U'1.XK1+&&AN10/O#S/M8F3#;6FV>Z ^Z@U@JZ7DI^0+@%36*J2KON\$)1E M4):<3?Y2L21A1S?<+3,
[3M0J^X1H/9;N2M,^/IC GOUX/HT&CF=)C,OF M#YR=4H"1* C \$="0?8K*23(HH)G,^4VHRGO;P<^U+LM2*6)G&179&1V M2C@<1V4-
10#7?^LGN.6>6NU#92TF2(JIY4H&=VPO16#MB,-JE^+6JUW;W*3T MOQ9,"9"FA10!16D&91:BYU88H1A&QHP=IW@<OW7HADIF^9-
M5)&^NYPD54H4-C,ZAA^V4Q0F#>0J\$FN21U9(I0,@0JIT^A6"D1AB1_8>PO13,V+!F9J@W M+WZ718R>>L L K%EQ@8Q0)9FNP?JHV8;NB1%U+
19%8Y6G;HL@ X6803%+ M\$69*8L2L^,HLZ9L5.QVSY@CVNORV2E7P^/32PK^0-D:~N="PIPC%8295HU M@?HV^C&VDGF8_)G1S*4H;~N51TUP=1?2
GF3&^80D\WWME>LZQ%YXL\$F1 MJV6%A9A!@H&15\$^HS^C^/7^W69SL&922ZB13 M~N=BJKNCL;X
MW>PK;X9&+\$\$\$RDS^S+6SBP;06*GC&1&3YSS13H2+<@>1,BX9.=^U3YKH.; MX?<
Y*D#W/W4&4Y; &76.#;XL@2;NC80/OMPL=^1V=QHVNOV^P102IVUMFQ MO; GQ0E7-\$K@9M6LW@9PDPMPUJWP2+JLD6>N.'WL)?
\$P>^F%+SENG<POL.1* M1#^G+8 TDBW8J RYHY9;D)P138L U-EH78QVEOJW
MU6Q2^N1W17R7K>LVEK^+8+&EN= =N951RX@<\$O1\$;S,7C(6>OLY3&J(^FEU^6;)6Y=H;GW\$=[%&*96-M JZ*(@JID#)\$
#-16YR)#C%ZJVOI8+M58#80&L(GJK@;07^TK8D^%3B^M- MUL+T.F.UY.T= X\$J1+9PTI^20Q%Z#6T\$IKH^O-U2.DBU^OJH+HTZM
M7W91&C^CHJ^BP>,S@.3@J@<DANH2 6LD@!) + UG#@UBHJ^WWTQIT/GIM6 JS M=HGS20K37Z;DY>+J7D\$M
68P)K3^O7F&DL^KT(DIV^SY(DP^\$6 MY15^\$NGCEX(S 907L.#,GUXV2.2GH V/O/C+VUO9S+A+1DH0HA10 UX MJ36+3EX1B>4-
&HKGH L^21;.*PMB_FKO-Z_O+;;Z\$J5P1-BV31+2U^E_ M/H.2J&G1\$;^<)047#;-2C^=17 \$>138J.HL0/H40^O3*\$B3M M01C@/+^19=TYJH,P
U5\$A/QD/6-#8#2;J;W^<6^Q-C,M2J1Z;TA M#M>R^IR0I2^9U&U;MX_NL^@/0KR/H7>U^D1726>JY^SO^M2>&XU4D^W<
=<5PLOS4R1JLL&0#%JLO MB10^_FLL^JZF \$=-8P>+^GRA<^ZIH@;WXT7L 55O@<^Y27G1G5C<ZL8 M19%<
<ZDD.AC#40M^17W@<Y2>AD^*D.-15)\$S&RX5IE7>MRHIG0KVG=+V>K+!<%)4NYS MEY/LHG_3W5W+!<QXS20B\DT>5E%1XBT>P-
*DKT\$306V+L#1#^W(VN^ MW@#1IGU24EQ2^D1_3=ZL9E>G;J^P75RLI^+^M7LQ6<%YEU^_M#GP4L^*
M2)Y#;7L<1;#R*)&3@;R1JJKK(PW^US6+P;IM^J@<729HT="G^UOY 44(^MHL@*+12\$%EIG8+IXK\$=C^KLG+1U9TW_2B)>8;1O8G+XC+
0G.^XHTJIVY MJ0^13LGF4R64(OR=>YP1RBX Q,+1%54%IUFUWCH;LG\$N.O_).8C \$S\$E M;BIE#\$9KK=J^IU\$=^D9WIV,<9.<^\$!PMV=EK(P27
J\$2C\$S^6^NX ,MJA^1^CUS\$SM\$Q9\$E2(8E4X^1_P7D.K1 M+H2^N5>JGM4A>S<^X&N9.<^ZAN%1%R2L;@1519%Z^#16=14H^WUD0^
EY^M7.80NOCDDITS0YTU MN1LF24>K#F2NAD49H0.64HTVJ B\$R\$H_C^MU3A^3GH4J6@L0MCH9^>)1 M0E<^"TP>ZE^9H^+1.18>=%F
8O.YW^R:1(HGOVJ34^=AHPH^<M<^XPK/P^1G5IG4XNR^K+!^J&N8Y^<787YCV7R1#>NMZIKWIN9C=J MP4TYX-
HHQ&SYO^A_FUT<C>/FEBULN V^JZLF0D>719>9.7\$Z55IO @/M73BN5\$Q<1-9S)T\$W71#Y2^2>>T(OG^U\$7@2%ET^G^&68.O+(9A\$J1
M6Y&\$JYTFE3P.+)=^P75.V@FPVHIPJ>?>1?@>#BN>P/P187RWE(RW^M^F W<^@VU^ITR4^T0H.O>9@^E@K=OXI^7P^<
^89W781\$1%G^1\$S\$H5D\$M1@6HIDELDCN&+^BDDM6DPI3F4G00K12@.0PLSI(7D_?2DOIN^RT=L\$1Q
M7GW^12M8G^QG;Q&T@+R+^\$9@L=B(119F\$3M^VJ=LZSL&^J#.=1=(#<9># MXJPIPRPY\$)JDLPH^%Q(^1RFS\$4RU9ICTD>1M&=Q@N U05=Y?
2HL4ZUV M7OIXK32%Q>Z^1WVX^K\$<F1B_YL\$EA>7170+M P^JCT>18=^ZU80Z16^4>.>\$/2@<KAL^FCTM^6=PIJVW(1^W+GCM+MAJ^>1?2
2#^J;YIG;4H62% PKKZBVR46BBA.\$M^MEPGF1KJW>LM7U_28I^M=-V1W=1C 7>1LK(60\$P^5 14(OG H@P\$B)^*(6^Q=Q+ZC1KUN&?A=<^<
M>T^J1MWS&J07+4AK@%4NFJ9@&2>4>BA2TD91<=[WDS_JIG7;\$L*GHJ0_.1S3;GM/L_&M.PKH SBU^1W51\$50K^+^*G_18H/WS5^0R0L0.9.@3B-
XIR^H\$R1S1JGBO M6CNOG85J@_8W#^1^X8C6ZSD^1)5)5BO_Y^TKL+^!R^EA1ES^"U1KW^X^")V MS^M\$P.F^3&80P?
Q:=H^3ADIM&H99RJO+^N CXWN\$0>^XN^ZH6^UJ&B_15\$N M6_16< 25^A(1^1B+B+K %=?1ZB J<-<\$OJ^*TLS\$=,"16^%FO:T/^1^4Y^K2 M9O6M
CQ@<<0>THQ<=,%\$XW^*YIFV2HA\$WNADA-20.TRO;6!P^2"R\$)FQ9HL5.NYF\$.L8^J<
M>#N9KJG@5@DZ=54&0R=P^DE.H^HT3/P(Q)O\$JACU>OHYP9^RNGV2W^VD_M1UL DDEIF<^J^&(6BY\$3;4^U^1XPZE0KLHN^1T.21%^3D@<MOR
17SD.0J(SBNXCL@V61&V^QJ9L GBKL^BZU;PCIO M\$;4A;2^TFF12BFN;Z2^ZUG<38)D22^"R952G8\$S1CNDTS90;J<^>0K1+;
MOR\$ZGW@NY^MF1K1G%(^13QEV3#48^GU@<J^B_Z4I\$?LAKC^/@1Q7I#_G MV U^/LP6RSDN)/KYF(WB9JH_ZZ^J/+^Y2)^>S>
1^J15DK31N+UJQJ1A1H717@<G^#1M9TH/O\$<3.&@CJ;ML;U(2HL8E/L_12#%W^V M=DLQ3&F7^A=9RW3;08HLVZ^UF_54_0IHJH M@V
^<2+1^G489V0P.HI044O&^X>E;S+D+=#\$E\$6\$S(3+ML2_3_1^D^*MEZ1&(Q;A@M0)=EAT51^1^?S+SSAU=1J<8^7^J^ZA0BO R.M;
^<SWIY(^1441=V7T6UGKXCZLP1^1E8KX921&^5%U+^G0ZG60UHJ@M/40 M721K^7OTS_QIO;DUO)G\$LU5^;
MM1R4K^1J6V^2T^4)UJ@Z^E13MT2&NNH84GY>M=9LV&22^<MKY^BJ0 M^K^2^49J8(HRRKKMLW_N?>^1I^>1Z^9/9176H!^1N_WRG0.B08O
M#^7AUX6Q3^21>6^Z^"MOBK^7H(=^&PZ1^<^1A<P21_836)3E.O@=>750 M1K\$C^QFA1^9%9A+V^VY@L;TNY>A.JP1^0YK4+1.O51O%2@-
<4.PKUQSO M&IQGY\$@IEA3)A2Z3;1&M;MU40B^_VTF^712^#V\$Q^C^TA8KUD MGAF^5^E3\$%8.10TY1^CYJ1R+HU1><%=Z3>RB<
%NQS>)=5E1RH7HUM9^&FEOT@<FBAF^7B_11/Z9KR?A&^_#VFFUO^G^T_4.MQ&W\$G^7OSW9/EE.GV2#(W^?<
_H2YK=1Y1H7HUM9^&FEOT@<FBAF^7B_11/Z9KR?A&^_#VFFUO^G^T_4.MQ&W\$G^7OSW9/EE.GV2#(W^?<
M^M^Z=WH^L0R1K@<H^QTLR^ED1^1%Y7Y.TW8L< MR7VY^CT&HWS<1Y;^)*#B1D)5<8\$<4 M5QCWO/6H1359W\$^V)^#100MZJHVE?
YCD@OOR&+197 MF^1L%<QZC)J4IBY5#J13)^*3^J.P&@7F6.16@1OIT_ GH97^1.C1^V2PC3
M_FGCQ_632JYU+@G@/^J^\$0G1XZKG_4^@D6CH9M00G_1+10F^C@R23^MES(3VIBXPC1.101.1%14D@=0LW

N2H\$B#MSA2M#U&Z:IX+MK4>#&#D7I3U?I>>[&#/#GENIO_NTLBC3HGHL%>XU2M M4>2*#YA00K.I%=>8LH!|)S/K7/B\FQ(X"7SHN6B8N))(\I/Q? NO<@VEH("M.GD1J.:@%Q.P8.%5<8HRD%#f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~D2% M? 42EFV@B2^>^IN&OISCHK%OYFE(@4PDP48#&A1D)=B4@R%.(OPV^7E8^1.MG^\$CUX.X?Z3I.KSV=(GD5DZ<.%M>L4>A8%>*83I*(^4%\$V;H?^; I8C)OC<3YV!\$<0A9M3UL^X^H0OK-JW9_-MKBIG2^I^K0>='2^BIG-1L.C.I2>NAH=9Q349TB_IZ^_IV;2^J0N^9\$#^~(6 M8.&JLDM4XG0=>@N.WT^I^<5U-9-6=C^2\$C&CZ-(K-I@ANKSV(S@BLC@8I.M+26CFIN^23>NMH<139M_=&T/D;2.*@8U@B2X34RIPP(Y?ISD19 M13\$Y^XIS6HE^T^+>@TNE#(G)T4_5W2^CSRU^5X\$4_1SRLW^IB:0\$SF+I^M(CU00H?Z2ZOGNPUQIR1E;4;6)4#W S(PLC300C>69^~^3.T@QINRAI>^M>70<^C\$&N7^KIVS_2^4XG<^I9C^HIP_X\$0.P!\$S.EKO.6HMG@CPKG^Q^F M&XZ%6_-9^ZK+ Rf.9180.XI^M10W9UIB3F:66E;07^I9.S8NHU^YAS M\$7X.MK>A^C PVL1HD^S^8\$;2=LS<>\$SIBCC4HQ^X@B^*8B.XPY50?%>U^;M_@Q#UJ^ I@G A1S3^IQR^/RIM\$-KD54^P\$7A5;f&8SVF!2FDBXFWOK MOA7>@>I^&C^2^6Y?BJ6f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f66IKRH M12.^Y^H^<FEK=>5EF7>OYKL9)9I6H^=04:W8^H^>DV2.E.B^R49M+M^M^R^ZID^WE@&D0I^&=>G^RY^VR=>42A0^#MD^1GR>1.3^8R(%K^

(fWw_OJH657T_G8+*7Z7^#4.M+M050PN*:,MJ*0JY_MG/OGKXSOE,J0A/E/ D&3>[H2LB=(80;0*]@J5*3TSW-/4>0[>@M514SOXH_TF30E/REV7-L14N<.:TO@CA1-L>Q0I09D5AGS7ZCB;SZ1G?@_O_M6_WFHDG69&7A:=-P@8J2VKG_H1>[/*AE9N(G-4PLN9YA;j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

M,+C.46/QC142+/@IY5*9C;Y@4TJ+;#IF&-QCLN?23 M+>59 I.0K4K8WZ,E#V"MD;+M>?J3QLT(-IR M33#UH,GBU\$2L,HJPF"P-7BJ SJU/M
+J4<3E6R#(&GA2<1%N%IX,RZ" MR1E)FQ6+;#T34R;C+GG>#@(0Q*1+>JUM\$&1"NXI*"">Zf15"?#<3;0 MQ?H -BR_KL_HUV-
@5U!>6:YWD=LATXOY);(HN(WNG0_PKYWJ M*M*MN8T<^P>+^/EXEQG28V4H# /'2"W(2\$3;)F@L!(I=QXSM):fZ+B)M M*QBJ41VVG5&54Y L-
<)>"25JX%&MGWVY&IXS X69YK/1 NE9CWB =5YH(MJ9:8VOYO M(K,T3)MX&I4V5&@U35^Q(KX?E%>3;Z(VY)96 M-G! ^Y& M8G-L*? 2
3:B8VYF\$2:A*B*WX8*IMH?<*V7Z&Z1-1:QT^25RQ^>^ M2-HP(328>YKV<325?JXVEQ\$+Y2IGZ<+9.A?>%(X(D9\$M-G+H=XF"(Q>P\$W!)^~
MP9C X.L6:~VZIOH1IYA>Q*#J:P?J3AI^_HKIP+ (OTXX\$7HA5>^_ (IF+R/K^!)6K0HBV/&6^0:0G;N>+ /MOXH*~^?25-/F\$!?:K TLQB@
WNSPI&2XI@/3L#;4QNTT(T\$*3Z= ALDS M*^ATQ*SFGA@&MAE# Z/A1X;G*%3B-YC"BYEX>2>1;W/(14WN1!)^Q8I M0+CG>R?
WX3?/W%QF@P8F+4E IYIY\$=8!\$OYS4SS#=#Q39R@I_Z(3.C.0+I M+5TEFVU0@9(3O_IQSG87BN_Y3B7E MJ=U" W=1 W=1 W1
<5/9#9G@= OHG6.#>5U+T+LQ.5:TNKF#P(P>R18+ M8W/U.%51N%3/2IVDU^38=K6LNGUN =SIX(X)Q:B8NNCY6 D57F+TAI-GL?E
MUN;+!)^"/F1<9,+Q@82G-XFJW_%%.2%GDPXW6T<=2CV@>*3J\$139BL8^V M/O_&+FZ4KX-KK-B7R>D V44I_XM;A)&
S@IW\$KBE=Y(74;MT@?2.H3+9@IVV M+V K37L\$CE@+E W2>L IUOWB7*^9@<76YFBR+N*P7L MC^<UW9?Z!
JB\$Z<(39N%:UTFB^~_7ABAC&2>1WFO4BZ8O^_#XN7?D0ZN^Y+L ML(7@6 ITDUBJ.9YIF2MCI0 ^14>IQMMMUZ1U M;KZP.%R
M;9VE9Y.YUSNFJ.AIB:#GJ9#<4-16VFA" N@X)ZYV>WJAI^KKS>2I>QUEG.6W" MW+80I21%VK5NYUQVUSI*XDXMJWBVAU\$)R\$?
FUHQ4+;1/050%57XTH^Q(8 MBH2E2D-8@SBP.3.5H0I8X M53-1B- BW&KRT.#>1^J.R25JTK+I2.# M*W8OQ;O1Q^I9C!<1^J&4X@14V!^L"0B5U-
!Q00W.H)@<88,4AUH^IQ MN+1.#%K(^>5^2^2+CTN1(^>X3/99CD C^YGNJPI+!OD/KK\$B1NEL1& UG5*4 MOY1BP\$5YCV.5!<^JHD.S8+WB/I
MR=X0E\$J0?D"ULK%ZEWU9EB& CE"D.FZUJ?K) D.7&DX/CO"209IB2% B1?V.MCV0OUY, &Y "O6Z\$5N*2U ^G%#>MI%FN*A>BfTM3-
36>@R+8\$HMCN.C1 MF@XOS0K-Z^JA)^+FIDK@MU4IC2ICZ&D-8N,+2B:OHXNR*BJM3K@f^T#
MJSZW5WJ)@< B7\$0YVD(AI9;YX)301Qf<BBL9A?F^NRI6W.U=HJ1 M2H=HPW9XYZ>K3EK%?@132^Z+M5\$T55^ MQ4VHG4B.OIY%=15
"TN4=W" H M+^J0\$^ YJ#JX;^?B6;+Y).215;N02CL=1GAN4XS2(M>Q_0%*BN!/= /N6DK.M!NAQKKRY.4YGTU>A.V94,I:D<.@VZ)DU"7T+)^T
M9Q5I)MR2&2WT+ C3#HZA\$H-2RW3#sIP2ICIMA_YR_FI8"W"QI.GOD7H4>INNLIJDN MNY2>3.UO*%IASC/IY (BZRH G<I9IZ<=,^1?8?>O1&^QN2;
IA 1-H063M= M%15BUE7U?RRDA#XPA-HUR>XNLKK>C @G;Z37AVY?Q7QG-3SM0N9.SPI\$2- M.XLDHKUR;@RDH\$WZ/N\$F"5*(X<^
(B=VC6/2M1PJO#WZ)A)*EO@HL;CQML703QBIWJ8(WPX:Z7U1I"\$BO,+30-3G,+K*Q#?0,&VZ8/C/DBW M53G<%K+P.0+>=5-72S1@T>BWJ-
HIZI.5Z.Z8(%<+6<1%9QK /&^<ROAHZ6U1EG M9Z&H3ISKQ2;6)R1.HM0(&+15S:7TZ\$K% AYMX+!)@/2F5>ZDNU:SJ^>.,HI-MBAE3B
A:M MYOV(7X#.67^YI^N-B:YL\$6%ZC^DLRY5-5YI7U.UK30^&I%*H& M\$67Y2>^J1_4@QK+XIY*#RN#JL&S\$?^!>N!0C6K1P5\$RX)MD.BRK&7(I#
<6WJQI@MWS><REHH_PPB_%.N97WX MT:#>@.0K9?E1D?W6#3PE.R12#4JN^?R1X5:6R<^3J.D08CYB5F M25M5C26%EA@T**MLJ^W^(<=B-
@&L-LXHXNGIO*K<HFG889V8J&S8/F8 MK84P!\$>JOCW^N#&EIT#4.#\$VUTG) L:A.O%=(S&#:#\$WV)D LZH:1@(<@.T M9%RY\$07^0R"9CWRY?
#0#L2.MISPO%_XfE2(1V&A:K@QI^>90(BY L^A MZA^L L:S^W.BR?YF EGICJ EFX#6J=<#ZP92I68.H=^>I4H>R927VHQ M9&B6&H+>7KYR5?
?09IGJNA<KRP?2.1WN7.H_X P-1IYQ.13L VTKMAW7 MLI0BR W.U(8" @E8H1I62^>R8ZVHJ+YWP4&P MMX_KYJ2D\$K V=5ZX&MPZH MW;<~"V?
>9>7ENU905/BQ2S;VJN)5+F%)PH&&H* R3>.;ZM_)SL8LRIV.4K? M+HIT-39X4KAATN-AVE\$SJW@4!=!_@2_M;WYED72,7I04FEB E_-Y%"\$2J*
M(GXF+U_-556;HE _H"6.A)RD;O_&IYA4LB1&J.K(55+\$7\$S.R.ZP)JD* M6T03=QFT=HQDD@V4C\$2 O_?Zf4<1%5"Y=.;GTIO?)39P?7AZCS*IF0N
M6S0Z/7ZH%_5TCL7?I0?>70.2U+@1C3RZ9EXI(6V;NPI6LH*MM4Y ^>R6 MZ-6#?M2D@W%>2>1I.O?2OAJL1"(\$C_"/90P3P1VHHN>YIWI)1% D
M'=^<XVNNM^W32@5>A.I2JE,F9)@;?U?^W='6%+T?0#&^J.7% H+I#B3WA M\$-GRPPBCJ_89;GSTCX=415UTN7R5EH=G^<^'.0.@F+ TN>)-
WXG3P;P1M0# M#A4IHZ5R?<XWJL#JTG61FENB125YQJP&U4I^).ES2+ BK:B= MM&F%IQ:AZNM-UZ:R2WVM*8^F MB25E1I YF!IG+BCU8/Z1%
_+D^R1J M6G8N@WL6EYTS238I HH) NTFDSN MHJL4K4JG5A5GEN Q?157)+H7 M)
O:3X(G#S8(&HZJ59SFK#0#*VJ/RUE.@R@Z5LIWT&)_.1^1H1KJC3C72 M=2C52+LHNI/=IWDNZOA0;Y+8*!(TTFE.<HD C1YW_2 M_#_B_-8%" Y
MEMID+&LN^&R.6+4&A1=I)J.57.2QIT=\$:N^6K^5 M0;~MVEQP#=#8;DIH3YZGYZ9K%9 M1^8*CE8R3G+GH+ %43U SKUW?
E159HJHW226>?;.&NWOF<>4YI&+ #V9Z ME5HJ4KT9*0S!\$+S8KU-50H,2S6AV#SUX+I2=@) 1*+XJJNEZY0>
M=C^B8S^T5D0I98GL^XAU>+HN;S#\$D^L@/IZ^R7YV7QI+V79E;J.Y M;1%>I@V7XYPIKXFE.Z7?3>@/T1%OI@(%Y1M1C)' U8BV8*098MP3Q;OI
M(1A1#IW+U<@F288O9IF6P2HW7@DM;L@_9KZ/&H=3YAS%;=;*^0% M5IA-60W=2SAUUA)UD2M!0&HG8%L8V%8 +=<IG;Z2E#1^F=5V\$8)
(%OIGS5 MPY!>? 4M5(8RM;D0.0=&90^R19UE#IDK5M/M\$5(IG\$W2Z4Y.I=UOG%;/NYW";KO.;3SF>MUW@HJTEQDIG.L;H3SP4V^
MK^>P7#E' (W^I.VICR=2H>DSIZI^W^+Q1RK~^DD5D5^FG8P5QI41 M=<=I045DR%;+@I1LL+1)9IRQ00.@VQ2^40ZH/
M&*&%Y39OM94MLP/9\$RMJOD" _L5!@<QO MH1IM M3% OBA CG-G*)4*YNEZH4EEM+3-7G(=T)H^0 5;2I;0H1/IEUE>3UNY.NE=I867XT-
"K1K8+1^96^HQP9G&IB4O5.EFERQRY E MX(7=0YWF+CK7U>J+U+Q)^G3IT+MQ8.77HN&OV;9^%0U/1H2M@BSY;7UU@ M@H/CJTKN;^P#-
QB/I&EOWASPNI#>#ZZIV7^H^<8+3#KY MHC&@;QO;F+V10LE^0) MW0D=8=-8+Y4S;~B5&2
L;@CB73B.Y@I^1X\$^CIU18^YCWAPY_M;ML;*1B M25+ 5(IZ%9:~I@4ZT.%7.K:0\$3>#P;R24) Q#WPZ>&GCTV\$^/=YZ/@^1^ M.LSDUTNYYHW)
I7M@=3.C+JYU(I=F20E^YJYH;J^ MX&C(NY+&E^I)PPGLVNS8AR;2=1:SEA5%RI7^P8B;C5^F6LW Y+JF M@X/RZFM#1H6
"EPQ#87Q)PKZ62X="60IV;EG61+FRUP<^J^V2IK@>1^7JNCQ(S^>G 9D\$S.W+08NUH(IY U553/F\$4EG&WGAWWE4S)@<#N;1%;UTMX?R M);
I.3GO^C^Z.R->=1.K34IC?-9WT2Q+X7VYL M@<(X>LF 76.7=SB@RURPW@R?IOM;(^Z+ K+Z2.&./&LH+15KT=15_R.MXM9 M53)=I#(*PB18K;
<%5%;CXY\$D3 \$E6"-7 M-RKTSFLL^Y 8>J^L9\$=S0^>13DJGQ5^Z@&TQD2?"F4F^)=RBXFIEB3-D;82SA\$NHY;<=Q0;#JZSV^GTR6I/<.)@IOW
MLJR?C<=&="UITAO1DUOT625H1\$ F4GCIG\$X\$TUR6%2T3-\$>SOL Z M7?I?=-WOR^C#@<F#IV=&I= MN^C_ZM7P+X>@)W-
L7OR3U)2YF.7HLG=%79 MN1.OI=3/TSF^P2 FZA) ^V!43^OF; M=W(WAV87 W!\$7.48^<.;ZMDC>@OZ.TKL!DY5335Z;I9RMPQ^K;=54)I
M=1UW\$C\$N\$X!E<OR^1EM1GM.0=-.S%DASR;*&@)5 W>EEEEI\$YU^X@L> MGYQTG%08+!G6AHVB2:9 QH?<
K1%)B)*\$A: P13K;TJ DdMDQ&4TY3<7\$ MK+^F1M3(TCC1%-UN%ZS.SRZA>US!40IW-.G.HGHA83%5JU>536N\$^LX=V^ MNO;
<^J^L(8G#B;2ILQQHIDGQ+ OY3HSN/(U2IW MYNW<0HESF^7PU)Z#S0=IU62D &K\$W+TX^PKDV@&5I0H@B MA)B^7IC?
8^B.YI310 OH2T#H%4Y8E.*ZB5*#2>*\$S@04R"@T.G*)B#HQLZ^?INRL%>2 T3>L(.#7;X @.AN@>2X>HW"IPPB.U"8AJ9I#;/+!A/MY^9C1ZN(R.@\$M
MEFB0\$#0"X>?Z9+)X^1AZOIUK9\$>7/IE+=^?6E2D(#G=YDH4DG*4V713
ME<^<C6@5E2S1^M@B+=6A \$L\$5>^JHLTZ&Q^K5E8TIKFFIYVC>4.D6U>YQ M2E2*)RI^K5+%(NXO;IUIM>VN S6R2P^X5V"-0-
L2Q;C2>K/F(GHJ;2"ILY MPH\$EQ);HJ3Y7L>1(I28^=V-IQW@IYDIBS>13166IV7351-GSXT#M1;7I M;LMPM7<""2)*BM+I09.ZFYQ?
QG+>4<K7KLH/II_ZA^R68\$OIO%RW;)7 MIL.D.IZ+@999EBF=64I OS@PDJWGH^VKZMIX^@W#&J4U\$VA(CX;B\$F# MOHQDUN7^*=N5H>X5
=U;@B) L=88UQI@P9<Q8R% E.O\$S%I5U2ID7^!@I MN^T.C.SR15?2GET0W/HZ@EKA/22^P@7N243;WH5I;9IHX1F2 MHSV@D25YA?/=K84+Q(I=^
\$D;"76^<\$BIMZ> K)B;L^KZM^M51G8&\$O.BJA M@<@D8I%M _H)^EB%.PY _=T&2JOFI@<@<C!~:WIVYT9S?C3O8Z4>Z.O/M#1K\$F0-
JDX5K3>Q&A1P982>Q UJ&\$G0HIZU+Q#^WH1 P.Q.>2@V M9YV=REFX_QKZ(E8I&D06@1>_4@N+XV(G@I W;000_ Y)"M?<
(GKIKI+&XBX5=+ZYK685^<4=HG&T6U2PD&&4I=PLL MAK3B^9QN5IK6=5UHM^E)8X^HC^EN3+NB7PI6XTHZS=0SUOYL>BV1>TG14-
MH)7T^/O6(=M>N1&V(GK#^X7S E/LN^+8%2K5IOMJ\$&+Y2HJM^EG/\$V M+^Q00E TT!>1WK6L8.6+&HHI;OHYRT.73K2RIY&?FKIH^P;
<^Y3%KV MI3UB5_ZV1)7B.AXB8D;85Y<4F#FI NGR#&G4I4C^YAT#%&+50I6% M&+OC MQO\$AD^COLZ>TIRH\$H^<^<^<@I_@113DA3/62
#1BU#2G IV"~LEPY9B MD;#5>=>VIAL!"P* Q13A@RIJN@<Z3D2\$8_0YBBSUC.P MFU6\$JCK8.XP<9%>3^JEL=^<N;L><?<?
FV1A.6M0JA.U*6N915+P3U7&Q(6I M@<^*MES2DIT^D2G25KNQO M<^).KB>5%A_6V;I58;DBI6^5EY^XJ BDQJ?+DF-INCGR2%TY#60Q<^ M5
\$S.K^L?ITH8OEP1;) ?%!"GS&=>R=C% PHXS^M-W3+EYPD_?ZJ\$PIND5^I2ZL.C5TJO NH6L?+I*SM9^GXYI3-G> CC^(5G M-P>OIP V0;
)^~K9\$1KW0Z2#(EV;@9CJTBI^E0S.B=84M36 P M\$(6<86ANH.8/I-W/8 K_Q2R\$&R1KV%KZ/FYW.T=:/A7BDM?H8XU>A1=O
M^~U4Y4SKH6.1%2 HM1^9+Y63911B;T^M3# X2VNI^JAA9\$E MGI#^ #_0-8AS4-319+9PUBN&2^>3A14DQP+G9&Q&WLE76MZ>IW 1@<LI^R
M)*^Z*6^CDIW+G^*2^UAY FUK9;3&W%Q*6T9@/T5I MW^F6/IAJM"/^7U_#%Z*=I&.; H0I\$S2RA^Y32QIHH22W/MIL^H_WK
MKU\$#0@>^/P2^O13(BJZ(*\$S\$P@>2I6;.*2N@#Z9GCABBI*4*B_ MMJ@R(8>2^DD41^E122O)H;X;#69DE>D0^OKW^L-7E+DH4K #.2^Q3
MLN^HVVY@A0/HID@DIC Q<^54(ND.Q>7>43>K;P2+<+9NV3I^X5150#KE;RIV^YVA+QG0L7IU23I37_05 M6QX@<Q^L@L^JE.%I;V:B0 @S/2
S99%I(3GP51%JP;K-7I3^4 FH_1A8 M*KW^J.GT=C?&0-%.LIG-5/DC97##JY7L405EWH MJHC(%#7^R^X.VL@+=XOIW79*7PZD)Y#UOI+T9JO#5A0YJ
M^I7>?#N1Y-Y2W5=>7TIXA^<M75M9Z.U4K^P8IUP2#M@8I<^QC&B_@EJ3H3I M5.HR1^T6RG>_13^DJ2 A1I^6B^<T9I?
^AE4_4K2_474U^A2^AK^>M57I9.D.HY2R(I.E+J) L.DHOCTORAK9_W4I9< H=0ULHOH2S\$3Z\$S.MAO MH2POX^AK
N@7T)9=C^%LI^@WSI9_UT_1.3%#@.>GN7Z;1>CLOI.F\$#%#* M7I(F^B(#/\$H13&VKIT00 3Q!LA??L\$<00S;EI@!XLM^28>JL#2.O)-9A.CM
M#>QFNW(I^F^C^<KURIOI4RVTTAB#P2BWA(2P M=O>2^60I\$@0SLICUW^L?20>=W.FWKNSKE+H;L3KK8PZM7^VGI= N)8@7
MMGI@PWKVG^2_6NM16 13TID)9&5A^E=H.#(Y^;HH@ WSVL0SGDYR(7S13 MI;G9=6# B)5&C\$N9YD?2;HRC26ZYMS-
9USB;6;DN@fZAI>MLZYYGHQ?7/5 M&Z.2HJ^H+LO>>C4?I SZMD0&W#\$98! BG% J=<+99^HL52T0@S@F M.OA.C)VG5IC@5.)B@+HXXKS2=E?
5ISIM.A\$40^LPMIG_1JM^OTO 6=3Z1 MDC=N9;2JXEYOD2I7K2 MD1X^I^I.G@5.D<0I5Z;C8Z;W/^YF@RV6JH8.77=^D8*_QSH63/OMN MA3W^
OXETH^GIM77 M%I+&+2C%+W^4J12<"GV^KU"AA="6\$SCP4+&#^M&O;&^Y5=BH^AH0>TG409U3V#6#<3T72L1WM&^I=
IAF1)/IDS\$0^R9ZAACJ2>L^4 Z#^6.4>DS-C^>CF5>RKI7E<J9C= MR_<P6-DAJH^5*+M144DF3GE;H3JE IPG3ZIHXYOF2^TR%(HGK(RRC1\$1
M>=>52W+MJZ5C2H65_U:UER&L_GHH549O(@? MU242S;1NX;BN/RCLY98=^4T3PIJV0<>J FB#THKD\$TIS7Z)HIVP98>HJ M
JL@>=^30IU^O06H6JEX@I^FB5.2BN/CO2&(O&\$? AU7 CPMF^<#HIC^XFNUF M^X\$ NG^RD^S/
IME+6U@NHICJ74CILL#@YT6-L12N/6JOI_9I;XMW^IF0Y?>^<5^<IOXX+TMW;2>H5D\$1^=>+QIK.IN.UI=<92?U*^>Z_5/JA MK%#<.
INXX42T^SZ62<1@JV #^1^<K^I?^JY0AXITW_+X0.3.8.05Z3 M\$S09U1^4.5_5H(HX>QG2<J^R&(\$L^HA"#OWX0@2GRCH^YK_X8Y1XH_
M1@EG(C-^H/ ACE&AEY8IU>*>8AF/ACU&CVDSIB6;4& FQ7 RONH1^MGCP0; H8)9_5J1\$ H/ MB>D#?2HIG/7W0V(YI!^OEL-Z8@DW@-))'!
P.MD+IWC#J^B4\$>9>+7 LMYCT@H&S;I AKV3O?Z.R3VZIX(02PGC49I.#V3 MP1Z5&+^IWI+IMJ+JA@+Y+M^IWI?
OBT/6EDZLTH@M=HH9KJ,02)0M^Y+I:O MA&^7^<Z5Y^YITFOIB_*VI:FY@8.;&L9UB-.M\$L2%RO^1=6^<36X^>)CEG M=M;RF^L%-
Q2Q>I^GOL\$XRO\$3\$F5YB1+6IP)=&XUE9NX(L8)JV6-GOTERIX@<OC6>#FE5T3K5_C%I0;G8^9B>@9U5F3JUXF M.E&344612^>2NHLY)=RZ
M=E7\$>1;#ZW/OE=M2ISX61\$2(W/L^CJ^IDJQI^%W(E@<^< D6FXZM;M;QNI^GL^6F7V88I^3O6\$S(766\$7KSR2;(K>Ff^JMNJP7)D/
105_5^=TU?7^H^QM^T.OTOPWRIF#8-H7LXSSR08G;F1(%&2(#9PWGC\$J<#I MN9C;NHE)3^? 8DSJPI^0I^?TOLO/32NXIC;?I=ZBM^("BC/\$M;
M2H9ZBCCPKDU0E@<ZYW)2(0AZNN6U;IA217F4^<VG43I0F&09&PM>0ACY MBHJ>NM0&U^S77 @^5TK2_SFSL_W^T2V72A^B8HOFH#^I^8-B?
TRI^58 MJHMK\$XJ.HX+EB2+REH/0K&5HJ3I^H?/7=QV7?2T2H8^<= DFE
M'S.W^X/R4RB0CAD;8GZIOB6EMHQB^OO>5%A^2>2FF\$F_GI2VJDQ4NW\$071NI=ZIGI^>O_"I\$4TAC5IHUX9;KI@ZY+.%\$S^&OLO>U>X\$
MP^G+\$YU74^O>#SQ>IHS.OP6%<M4#8P<=UHVZ2>?/"OIN@IVIRBXXKYC-X/M^%EW\$F7WK;1^2RS=^IX-6) M(T7SFH^
(D+P\$AB#V.2>IWOYW^I^RUK6^F+31<=MATWKKX^;6DQI(0YJV=E MLE<^&)@N^U3/4^0-8F8F#;I4QW2B3(2OW!
HSCVJ_KUEU=IYV2RW;IIRU6\$4M;W;IZ>5^I.TB1H8N_O\$5RD>#^"N4A\$TN)-JFEP.W)

MP#=-16U&1^X&4 40F9E""O/@:~SW-D+SI^UHGA:~H=Z>Q5+Y;~THBMJ M49929Q3RXT M'~#1F0%MNIN<#P\$6=NZ,O^40_~Y\I{#?2%
MLYIPDF5,MX.XD,12BL&D-OIT#1#@~&+ZLN2QMIROD*RP51/9;3D=;V%F M3N3V3N R349S2O">=H>D9>.,K+43B,KPF^~\$B22PN-51*6SID\$U>_DJ"J:~?
P.1^k ZOJS"L.N2R%~+H/H 3 M=\$SSJNM;:~#1^EFW75^&2C>_CKT /T^DPZ:UTU:G&2@J8SK:7"-130L"U">AJ M @H&1 6.N6 _S M7|DI@?2=Z18\$&?
LLUZ@LUAP-YS2IQ+E70.MJB-M-~>~RIK%MKXJ#T-2R7I-O1|7P+ "47X0A9F0H&44H(+NHS M2UKV5=CH"ISBMN)
PA7P:Q7&OS@15841355A7^#&#S@)~)IRC"COT^JT OS MA-O1@18H% T|>SR85IQD84B RPSB\$3 1>~>LX0Y@3^3H;~&M2C""2W&FFD MKZ6P%7WJ?
0216ESQ^S%@0Q5+~+Z,1?7Q\$F R0(P>+|EF W)?7, KFUU=>~BRL23(C% M<+51T(^?Y\$*8P\$2WC2UFP54 ZV^AMUO."LPRU@1ERA|D=TYIVG?2EIZ
M+17Z=C ^1\$FJO>~>\$F1 "9I&IR*L,QWPN3@1WN@BIN>H-S8+<|H^B@O:G\$PX /(-)9^~815T\$#6\$S7 MCO^~>~>~
.\$X&~^49P>D)I _=AL>/OL(E^V&^L\$ A1^&~+~+~+RS+BN? M9S_+|O>K>~>4RHKHJ:=61JX@N^>4N?P^51+7.JWEHJ.M>16)A=,H5Y^
MGHH.WDUY024;~& S@~997F1JM.SWF4A47EE+X1;Y&S(C 7.985F M59+TYXD)3G.9H1)PS^1<~!^PI3ZVHH1%W4~*@GV19ZOTIH<~^A^4W^G6
M.62%P\$12/1728GRD~ VYJY?T-P6&\$GLCU1.2BJVJ NXM=)~#~#=A^+8G?23:~M@QV1M@7Y(C%JPPF@K+Y\$XY.C~*91<8^=D4R/P?
Q8E^=M.DZM 2)~JY^B)N9 MJAW6UIECK"SEM06GOIP~WZT+B%S-VGVK>|~#=X: G^~H~Y\$N\$,1#2YS M6Q1@NN/9?4 M-H
STSK^E+21+O/O#M0!~|Q748#~ X2S:@1W^N(UMWG4 H=63A4F1J1MFEJ1~W~<1&+H<V52^1WY+I81+6&BHP8UC?<+FFS|JMB6>O(NF~_L)~9
M>~JWO(@3S~+GE+O.F0W_RfMD4?1)E0F:Y^O%CI@G)2.D.6BLWJ?BH""2U\$+~U~" & JW_%=0<\$>.@KXH4+~% MO:C^XJM?4/
IG)~#@CGHAL)3AK1&SGTF~^AD4+!A0G:~0046~9SQ RA(C M^Q^YQ<~\$B5@O33GW=~T^TQ@>O>KH<~>H2+~ZHR1Z~.~J^K1>T.FO1&2=MST!
U);~&2=9.4)F K2S6RCG?~^Z.M4P3%~|0NH^~SU>H3H G^>~N1B9.# M~=@.9M+!QN#L@~E/R/C%|_ B(OYEM2B1/7FDJ1X17OHHM33))VX/9#P)3O
MIF~@8^\$XJFOH61+T1)WY|+E7H/8?2 2S8Y^0E>|BN^= |TCZCNGPAT.1E-MG_ZHL*(~)U;/5:VARAMN1:L+WX1W_1M#5+~Y9?
I6;OM8TNRH4GYCC1Z1VA M^1\$S3+1#5M1)G@ SM-O;0%2.029^HJ7B^E5;K1RL JP^~1:1H059=Q)W M^0K;~HYH@62(GS@1WIP>5=EEX4
NBRILN4H4Y1LHJ&~*2D0K7YX@1MXYK1~.~6TO90W)MB.O\$O:HJ&4?~T39Q(?H3PVOIET&1=;4UN+2T^9KTV=E2>=<~|OS1.2+U+|I=6F+?
<~(JO#U7Z3K44\$U83>=8\$ MOUXCV;U=5/(1^1*G(I=L'RUK;V@ R5A;Z>_R 1^JDZZ1P8(H9YGC1CY5K%G
MUV%ED+~#%KS;KA@UEA+1.Q^<~G R RN F^C Q90H>3>|~M^8C~"SNN8FR1# M~L5#N1^+X^
<~BZYS34CTOR\$OCO".9_DY20JHRGIO"W)JM;\$YX06 M^P_#/"IX G((P3TEV\$>~NB(24JB3#IK@FGOVX"3 62\$8^X\$AO.PU=FH^AM M@+JCOOY=-L/I
A) A80Q^T^LO-GU1<\$Q&3^~^%M3+~+1>7UBD:D@~8J\$N9>C M^YIK>=,PR315;12RGM(C~#FN(@B&\$P(Y^~.%_AO"1V7HJE=I M2T+?
^~)\$.Z\$P.PRN1%ORUIRH061RK1/L(WQMTIH 3)~#6<~(LHW3+XNJ^13K^*U M%~A^1^KJ\$KQ12J34Y.14Z=4%~AY%>JLXZ1 LOWY1HM4=1PIK4)H1A2\$8
MN/Z2V4+~+974K3P^2P@>@/Y19X2)1)ROLEZ 1@3:~5^*E&A^M^O1;MX3PBJEAC^&~N=>N MQG1JZD%ZM%K/6XWH3^P1;76^~YP 2Y1;~MFR(DF"!
(5#1@1@1(W55CH,KV MP(@>=8>~&BDDY#B1.BW7H<0419+N\XSDP9ID7O&S412_ZR~^T#BT>1K MU510R=^YM\$%OMMN74C4%8~.3^IV2
W^P7G2BY8P+VM^FOF43959B^&QZOS M14YU GE&IS&\$~PMDV_FU15T8C1Y4">1#G1&OZ+H>10Y4\$~H9GCM_10^1
MYP&L N1Y:2NKD+0^B.P1XGT@1(^?D)=151~?>~.L@ /<Z3^:1D19DS2 MFP01^F)D.N&1+9LC=TO)0V&9^ F\$X/2^*~&W0TR8B>F/5Y5V^ N#
MQ@%0)<~<O7E.X+COVWU1@~@FFX&NG%W2>1/OBV+OY1#H7.TN3.O>1>1 L M^O1U1.VRF27BX@
V^PT:B8^YN5@F+~"ABKL@~*1N%3(B>OL0^OO.AD6*9 M+BS,@~H8R^NN^*(6NO&1U<~UPYP^03@M=VJX^0Q8"TI>H1|>XY6%K0YY7
MGQD^%0VOA~:R08F(4M21YIQOD)8E^M>~>3^?~.~#F@D&1~=@YA 4F^ MN7X4@P9^=1N JGQ6@2J4VP6H_V1^7LQVEE?~.~33BUZIT.
MGN^NQZ.H.RJR.4~N&8^E=>V.9 TROAY3JM B<91+|O1YL+2K+~>10D 55^21 MC&LC2FH1H132KF@U'E;~1Q@~@3T^E5K2.3O5XX
9S".Q31H>Q@UAE2%9,S M2+JF>JE %@6 F3W4T^C IE9,O^~VV&/UJ1">7^1)I&J/E1@:G0-WJKSGSLG M((ZUX:G^U@%VFCFU,D1IC,E<~@T)G\$E
H6\$SE0/Q= 5H3WH0ITE5(+~>B M=K1C<~(ON_2B)H+U16F^F\$1.9^J&1^4=+~2&UOZD7PF=D1~LPNQ1RL^M^W^C121704YQIRJP1"
=ZO^B@)0^Y^<8S_NY31PH&QAR2M11W;G.=+7QO M<1^44(E\$1_~)K)4+Z~X1.61OYDIX%&)OR=N13)5=@:~L\$K191C)@~*1MR.ZZ?
Y^/Q:~/@Z%Y^G)@V7H#5E_HZ10G@GO^|C+@&\$0W+LL7Y1;FV1^8-CZ1@BQ?R?X^6(Z1Y54K<7G+B1K4K; &KW1L MK1?G&|FFKDP\$.XNE
1%50+~% =OJL#8#_YZ?XHH1#411 6 M1X9TP=,1^721&I.B014L4^.(CFK3M397^&1).(6#Y).MXU^0&UX;1K>1M_B&V8!;GFNL<86?~1=F^>=>
>29HT&~&Q+2.4N8177.RON1F09C5K>QA M3XW1JD(ACK0^ QR9E^CHTKQ?Y44J1DLSCR0"N@*21M1U19>9OPE
M54QG=1/3^GN3+P0/(@.U/8^29>.(UKO>EUGM6WFZ_#E11>>S41>~>S)U1LHR M-J=DW\$.S.S.N8FDO(#1.B6 PXE^1V.EW7?<~NW/;>4H1(J36V.BT2/
MUUB4 L8V'E1&~TWE%VT+V.G.7VX9TU7>1PUT)5:8QV79T5&~16= MKJ1JH.E=6<1^2>+IG%1W+U<1+(GCNIRZSIG3N7JMD1)@JXXG^AS<9
A4@+8Z31E^EN1 6W;C+J1K9HG^Q+147B2L6.2@N&ON=H7 M=3Y0A^@UE+~ MXT1-23>1V 1V3H6.%2AS16R,%2A3GES.Z3151/W1+~#D20X8^
A~@8 MY(TO1LBXLL17M D:43F1M&1S+34^8G?21^Y1AP21.B(YOA7^1HLSYZ M&XKH0JH2Z/7NB)7.JQ)^O.F"#MR_V6>^#LDBUSL1J1LO
~2Y1^MUH@11+M11 M&~9V1221\$ 4JM1>WH19D42504^41Q@D7_H=1
M.G)MUTS60ZP@GL1Z4T2Z11#B(E=11WDE1#)PH^BG0513WW@D=D=Y1322 M>Q<~"H(YYS161~WUKGG+W^FN1H2IT&~?
+>SUW>Y1JO-V1^1E>91P3 _M^83D^H1=V1 9<~=@1D.BU^*Q;BH<"VO8" MD#2^3;T_~L5^F\$N<1N/R^DR=Q>CL8:1~RWD-SRIH^IDE:WA>TEKJE:0H4
MSXH11N=L&1> K0X0=EI-MR%4A_1RZ+T 6\$D 4GH^~?R1P=,G1HD=QAG84" M6D_@M^NMQ2E_?1S15;Y\$5= W305+330^~ANF8^~1L GX1^WZNL^=1
M4%4QCJH:1DYVXTE?1E4<8^N/01JW1WJPN^JPF<~>@K1+9NO1Q3K+K% M1M^1475>~>1G1@M9E-E81-8UBULA231^J)ZH\$D1GK)(~5C^0
MOP1DI+P=3)HS^HAYCH@~@ME;W>L.HS\$S3K;BW_X.O1^B^RRK(%)BO^D_ MT1KL>>9^XDI;J5DY^9LL%)9>7&OR)7P1)<~<~
&JOP+AZR&GV.7+0ZB.C156 M+7V=4^C.TWUP83^<~*~WE+LU0&^VH_1^98A9%O+O4K024/G.=>CD+EN1 MUGWNZ42Q1;1FAZ&C1H^1JG
LYO):~TAZ(C1ER1B;W1PG+C.U217^5 M.ZF198\$HCC.M2EQVY1^YIPUS5EX_Y^Y1)1B.W16:36-5H%#JS7M\$O4 DGI
M7F/3\$R)>1QVEYJSVUOU@0_~K9>~1Y:V5=Z\$51G>438T1)@1J^CO1H M^YR1;1AZZ1JCU1+~ 121BLV1^Y&YMI&N_+KZ+F^1Q#Y4F MVUS1;F>H"
M1#F\$10Z1YX^01400X1L30V"~F%Q 6^819OG9D1G1Z259L;B1KWEN-B2Y1~IE M^QU+1R_HKK OFFZ^Q<1=Z\$2H1;1_QV#(
ME1_X1\$5AMM+AQGM<~0~@WOAP1@~@8(JYS^1E.EOF)+~9C^X.616#CJF^44(239SQ M#~08^5SEG@3)CGSCSH^P?DI_#O"S^#@NJ_&23MEE"S"
1=E6231LKK4^1\$1^4 MD1UVX1WJD821T=0.0%AG6YO1^N459831DT1@6^9<1354^21<6^>3^2^B^XLM>8"1UM(RE+1)K2%WBR"K01S^U3;H?
SX22/9>1MGV&K1Y&K3@~72DI@~.1&S^4 "6W^Q\$T1S(=^58DI2V/D1&~#F.R5J> ME#F^E^OGS^<~
&Q5Y5^H6^73Q_1XJ10E0V4T8R01@ZV%O151BWN_@9YR6> MN103\$C1C1<54R6ZJG?1Z2 NJAZ2>W+>5W&N.O&L1>1JL7^0C-O1W+K3
M^P^&0~1Y>1% TDY=21Q70XB1Z9_P^O1S+G41FG4@~ ODVH+1^*Q0QWG M#=>~1WP^2QCB>QG
G^P^4T^#R=Y1HRJE=2.OX.5@IKWC2>~%SE711\$ 1^2 MM7^8X2^1V_8_VW1)\$K%9H;VY@~JP7EF&O;AWK9T1C2?9Y41+97^6HZS
MAU1U@C814/E1^E^D6>9M^1N^ICPYJ1 TEEMT1^A90L21U_~"RS19+K?EW611 M+21^M0KPV_KPX1""~Y?2)SUN<5X?ES(SORR1)QH/N1_MK0)@V.D
QF?PYN1F>M+CCCG&QO.01HTR454T9F2.O1V+~&9NC-(%04%F1 M?#E?01+~BKN24PU:596QFH; M-H^T^T^9-61^%?RIT50R1X2BF E_F;VGJH
1VDC1X9VUO<=?O%)1^IDS MO.EJ1^20055B>1?~K27 K1B@~J F17^~5O^16>~NBM\$1:37T"1M1H1;1J6 MCG#%~^41%XCXOY02MZ^H0*
MK01_1=\$S7@B29/CFLC1+V22)+~+V_17^~&U/BG#Z\$>Q5SF+1C)SA21;4Z:MF9&1;75=1A12XGS1%~.009.%\$1P1^\$1(1J421K300B1H7E4F?3%1@W
MM(JM^1J5&K#?~SD21HEZ?PY1=1(TBWNX(KWX1H8W1^~R1)^R4ZORAS1^M55KHS1E^R81L^7>HH0S(T2)Y1)~)*\$*4 1D
>^~.UOFU%RH)=CG+JET^67 MZ@?GP1RRW7R7L~) \$D 1X)@\$7 E5;##08V#< \$^1N:50 M9BS1(RV/F&_ UU@3HDCNJ01).\$>1.EO(V8>1I#T0:1
1ZXF^N01L MV4^FW581)>~8TJQ01=121B7H@F1N)TQB#0Z&9 M)\$.X.O1PE^\$A^MM?K1EA+P^1(=VVR(VVL2N)GTQG.1_QOP.1?~A-0NL(M
L:G%QRC4MO=GX1QTJHACU11(59&818B#9F1H1)TOB#0Z&9 M)\$.X.O1PE^\$A^MM?K1EA+P^1(=VVR(VVL2N)GTQG.1_QOP.1?~A-0NL(M
6PL1OH=(20)RG0A5)H^MY^V1Z9Z3P1NB=Z-52L<~@E1J>1J@&A1FN2-VY<2% MDB@1X7V7+G1
<=>~YX@HW1H HJ1101D1.48.1N#%G~="7:QD191+HL6H_ M#1#%&D1_P66.O:181G.G1@12^BU>@=3WC>61^%F%M;R@8X)=T^1"LC
M1=1UOE%PDG>(>DYQ9VQ3G(B^Y&D1V<~HJSP8_&A(E6=07F<O.O.BFD^E^F MD@ +>4FE:1D>A29S81DLQ4CJLVZ2+9 U_1QM^G1_4A1@~!^3835-
&X\$ZS M6-75.MHY+VRY-P&59111S3C1F78V>W ~<4VP18NT8^4UBCKA<+8T1O=M(U80:VB6EBQ%&^C^FG7 EZ(K4C=4#~.33&7)5?~Z1<~JDH1
MDM:KE/25SK3W1C71H1W7;E.1 WCX.S1O1C45.L1^GZDKGA7ZY2^A870~ M.DRF4)N29X2^1O1XEFZ6.1V^6PD7_57^~ARCEB_#&^4.07@9^TGL^Q+Q+Q4
M7NQ=3+&S6347UABUFM0=&1L>~>O.E1^@SOY+@,>1)SXHW+;S.J MO/DK82(IP48Z^X^X@~@A%1J+S&GVD9%(1.92Q5=M/1)Q3SBRI0(C/R)QM2N2
M3>~3&~2LYC<~>GRBD&~7^8Y.PM#6T=BM\$)70~>13YU@CW:5Y01^Y1GB1^18)SP^M1M^102+G1.V.O+~==1CUG1^*J#8A1=542HYM2_D1/P"
VYFYS_%Y7X1_&FBO@%9V^HN5>\$^Q=M1)1F1HCD\$O8N.1^M_RQG1^ONZ9O)&?T 6#.FB#4.B^+RXYF#.8^G0FO1+1\$1QH1@DK7:D0^41R
M:CA&GUD>1S:~9JW1Q@71>~\$14.%6MVXQ1LW82(1.E)9N5T313LK1P_Z M1_DQKN3^EMIT2M&=TV1C.N=N1JG4F<1D2?15Y9~.W126=#
1~ZZ~".02^8BZ+~=Y-8XY0<1F#D1V1J1H1H1%G1P1M.TX(31)795@GN61G1O3C%G)@K@9^E1CC+N371N1&OX^@HR5R#1JMT2PA
M73LWV&71^5\$D4S=5>/1339TM:031J21V2@_~QSH71 2*8\$F15G V4;#6 MRW8O1L+FWLTUG:~%+X%0HL8?>1^K7
1@F^~01CNDG1F1E=RR:87 "B">+?2 MMX=&OW+THNUOGGBJE^1%QF510E1#A.QV4KS)^01H1/012T14@>~C9
MEQ1U^K717+FW6;1YT64WA0M^OG1XN^A1FLMN)40Z1=Y\$91D1^18JB0GD^X171 H&N M1+102+G1.V.O+~==1CUG1^*J#8A1=542HYM2_D1/P"
~*7/E<5<~^?)S MDS^K9RM@E_971#_~"+ WS2?J ZA12U_ED\$8+6Y^6^T6+2A&S&2/ 25KHVJ9+ 52AV=<1#(H1)TG:YD/Q1FWHJHXCX M98XR<~
M11%1:U81^R1P4R7291F\$Z2@1EFM/G19> 1J3W5 P^FH51A1TRU 0911^ MJY6B9G.2B\$Q10<6.Z^~CDJRS2^M1M^DT=;C.VONR\$P=W MCB1J1R@?
R11:82<11UV21^PD.9202.8T8 "V(M>91J2^UFASV^1O1U/O1^1V\$5%&2131ED^1M1GAOT0ULG^Y5Q17^ M^=4TFE
Z7Y1V661Y2S1)52DFRGJZ7Y039^AO+~NP\$1SSU+~W1M^T(U51J1^X1C1A1N^&WQ:3V_~"J<169)KM(S165^V@~BEVF/WTCW1?A-T
MOT\$H>/5X.2G1=Z77)+1^ZXXS ^2LOQ1(^.Y&9E#E=YW JV^Y\$5^G^T1)MX&P%2^SP^C:~14@KQG3+1PGM1(Y&1Z_451/#9_~2GXY15V^&1_1?M>E5P?
55+PV?YQ_ZHL1K40L81-V1^K)@~!^OR61R_45\$2DDVV+~3 M\$A\$FN+~C^!&~8:~\$YCXZ^M#1)S59B-80MR E^B.XXC.F(\$@0_~CXFP->
MYV>~&G1H1H (H5:C8TL1H120N96.PZ.@ML\$=M^W^97DP1-H^325G^>~R1 MU_Y.T9KM1ZMIF)=5PUPO \$~WY1TR^6:HEL3804_Z1C^BE"601H1>
X% M1O F%~Q91T+&)@S?2TD=1^1Y5:K1^1)F<7^C6QOUWF?~U RE.7#6 9&QG T MY1T=%61K_PLA1F15>61;##G\$7PKY1^IDU8/61=GZZ^1^1O?
091#5^L^<4 MGA1^1Y1U^4B:E.N464W^~6\$~2W41HRCV9 M1MT:G1>PK22^CO0LW1J.N+T A K1^2/9>1@14^&Z14T&1@1MHS
BM%)13DAD<~T+W060UV6TO^W0BONE_NL6=2H1;~>1R3FG MSTT1@JCFYFKG)E14Y_1LE940.22^>JO=Z
M(9X^\$RCP^81P97G^XP\$M^XEB1SE49HU^OO1?P(Z:~YJLGGSW,2>1HD1\$1 M\$GSBE^1%~@~&O1#=(Z5R1M1M
XW.5O4M1B13G^ZM41^~+9F1^F1F=31%~UC M^~\$SR^SDH<7R1^V.WZ2&1WZ8H1TDUB9M5V1P41%XXY41^GMP&=2K.R(C%Q
MUSL9#GTC117@<~>DVRD.R1D41L1G= #B+~%M^\$^C\$1@1)Y6M18M.R6T1%~M1M2^MVFR^D8@Z=9^2_Z1L<1O)N@1
V(NGJD_R2>1R#0WO_SMV1V^XKK(1 MZ1Z3(#<008+1J8&_9@K;>M1?^GVB1^@~S^/U7DRA9^3>6OS5/5>M9GU(L7D54T
M1^DG&X6WY3\$SDHN1HC12)S1+1^MOCY9=9.Z2^\$M DY49>~@UE27AW72 M%ISBR9W.Y61%OT1^6.75UISGAHA^R^8Y1KZ 8-M3007R?
Y8P1^R@1022N81+GZ-EM.O<~&MO1G_ZZ1_ZA1Z~#_K1).80Q02^X M1.G1@C5C771J1H^M5^8@V1W^THK GN_**K^T1F1M_5GM%UY19~1^G8FY
MFMM FR2Y:S^L6_NK1_Y2PB=^4<19L_NY3RRUZP1/N_P<~%GT^T5E%=M5 M#^N3#?00O=ROR+~ES14@6;_J#1@PM;C GS.T3R6.Y+R1L1?
ENU&Z N1~.Y\$3^ FS/CI^X1U^77%B^RYLRH1DH WYV^~79+ 1P^&1UKW_Z MZ1^<~X_1_9^AM8N_Z.V>PJJZ0X01M_45\$+8M0E&
1<~1PJO6N1~ MEOR1&3E1U1/V5N1)4DINS^K=G?UNV^@S^KV&M1K1%\$%2ZCD_1B21XCKD M-(EJFAOX~RJ^J%381=17JHES>4H<#)1H11^1>QH?
91#&3:~7T%SP1VM2^JO1V13/S MU0Q1820+G~?~\$K\$+~1GM= X6+1G14DU2(2>1J2XCBZL61^7&SB&555%01M2#1?</p></div>

JP^ICZA+I9IUM4W^Z@J2:.(O7,4"TM-/KGKIXLZB6Q5&/3,D3I2A+E_MHSY,IY46#I&HO^MS6S:(?I,1EN^>IQ=&IQ4X_-BN:58K9>GI^+|SIU/?
#F**P3WK&R^+>+Q+MMJP0 M2/QP49\$1:|H>L1H\$0N?Y=|_F%Q< H18BH8.4<@R1FCI=A>VO=L15|_8 ME990/Q2@K!*(#>+ZQ\$D2BK*IQQQ4Z!9^<
-<-0U2&OJ>)|("2 M>%"DL"FY9A)GM7@3DEV)\$0<^GUOFVG)_ZN8<8;0(XOL<I:N^CQKE7#I MG=IPYU+|3..I")%UJZN1F))2)RFK.SK?
4Y8:A/U!7^=>B^X>2PGC6W M(#F1NR1EL3A+V0 LVJMYM2Y<&6%HL^YHJ1.2L:XOJ%X=;DB%EUBV=;JG+|SB4OICV@
NH^71OK+|QH1=;|0/W%_SS% D=GFIU M+A-3JGDV<OZL|A|F8/Q^+|I+>F.\$R:KJF!M=B:Y=JOHR+V1NN00&^IF MLG+W'9A"*L-F7J)%#
(3\$A.L7W3ML#C^HR_+|MIKBW1^"ST.0M4MP-4>G<22Y2T M@34|P.15WS:EOAYV%RY+7HC|0ASJRE5*ID^|_58 NU90HP+O.IJ&-8LW+ MU6(
|Q+_|9T3#^THWLV&SP5&_ GWN1.MF^OR13CAA6^E+G^8GQ.IG#"G">@I< M55LSWJ/MS-(4<0.G.E:IX&M^I?>H10HP2.43^<.G&0;|K_F>><@XLYITV?>
E;DS<|Y+|+2B-V=HE>O>YMYD50(PR?VSZ?2NWBWZOL#K?Z^UPW_X M(#C^A)>5DP7\$5PXIX>313>8L+M6^5JR#>+>+H.B-
77K0X_UEPMEI/RDN7G M GCVAD2Z#^<^M83&O.I#UV=E.EBYI(1NF&^&^= M2*W@XIMJGE=@0%P2150&5E IR#+16|01I\$00L&!)^SAHWAI!
(M7&L<35E MYX9SF_UGH:~EY*#JHK#E.K@F5%CYFFE;VL5%U:14OX20YW;WF^J:Q1N+ MELB%J4RN&UIY-|@O-W'(D^Z^7YJK93Z^"Z5)QSA5H?
TJYHT-IGO^HK&V:4L M%XXZ5?+X^;CST+UI0^R:=J04G

ZR^XUO^08YG9>*=F MFSK^"OUH&#%=%CXF(AFZKXFLH^WT%65>>_T D 8QJ%SX6Z_VUNSC ^0B3F^C2^2\$@=6CZW+N15T\$H!
MG)E7GM&@>@304WF^NU85^ROIV&=,^Y7/GUJ^KTFVLFHEC%ZK^K1)GX7K1X MV-J;7UW+^*VG_ZXF7^*#;D@>?BBA>?WA\$H!F2"/KLO>?
U#4(4K;H6E4 MCE^A^E&^<9==WS:43N1^ZIH\$+|_1%6|X@|1%_..89ME^H19?0>#VRRU^1 M10%\$H5@>3L2Y>8MC+FDIQM8?<=&\$6WM05T_64I237L|
|A:~^<A1A_1 L6& MP= \$XMZ^&#HD% MBOI5(CV8^M9(0=08S2I0%W^J&R06:5WSA-^*2^Y7WVU MB6.ZOSK%I930^Q#I=16^T\$JRI^*NVY5+_
"%K8BQ_~: G36G35-2YU^ MJNNZN,NCF96Y@SG|>H41204UV^==5X1;H+^PLO_K9OWLCAUYC1O:2|L_ M2>5 HW)/N^&K6+|I:EMX|@HOG|O|_
MWC&C@+>514NEQ_2Y\$H0^R^NRZ^IXMACRTM.O DDY^E0 %PWL%@T,V:GUL MTH^CY0^%1%>Z4|_1OKZG^>2XS|_&C%KGLV^YF%?
GWJMS^G1^S7B1_9NIWS M6^\$I& >* 60LT5UBQY15:"Q^EENIN8KV@>S%9;IXYGD(A&<678)"1CAI3^C=M1& 0;@JV^*OFUGJ\$;JO(I9^>_
|0^V@R8L^MWT84<^%AU%0D5<^>H^N MWIAI735Q^G="D5>:OSP2^5: MX^OE^3=1X1WW
MYR^*F5^RLX1S5=93IKY>|I WWT1L?PZ>VEFO%\$;I^?D15> UAY9_Q MEMUIR^I^W^?|""%+>6>|=M12X=OOHS7KHV>_C+C9^=^=KJ^,7;T+;
C@JVGAI^MPD(6X=@/UXB.64D0GI_?I#&f;J2#1N_4_N30#G96HJZ.O=ZOD5(W:QGI3DT M>OKI_L^PD3
MEIA:~|&RJF^#AA\$K^_X^CIC9Z^6K^"02^0^IMIZ1HYIXM%#7L13Y(L=A>|RGHE2KF83;#B=H:U3AQG^T)IY77//0^ M^OT5G^?4^9=P_IVHU2.I7-:MSI?
@C47^;BXG_F^#M&^<""%B\$>=5076)9D^* M79ZAFVWRRB|^%=DA<KCB^D=Z_~(0XA9P^*2I>?>5\$EG(KGM&TO.LEHYI M7=F+M\$W92W963;|>GA?
F:2N%(8IB/M^0(N=;S6Q|S.# E5I7#1I8+HX6M: M6AJR6AHO^C-2^?T^Z)_R)E?|=# YIQ36|6R9^"V9C^3XJH\$M+M.L#|6CA^U@FAF.BOP.RXI
ME15Y#@W^IQG-L^+|ZW15SZK1E|F9|SHH6LJC=R:7IHS2@>V>GMCJ5^9WR MZ^=FU^0I2^FDMQWIE>3K&J_U^<G^M4^&C%G(4-3-
*%+|UPPY^EH^I3 M>|G^VZ2/63G&D%BNK?G)YA^*~N">+^"I^H=^Y3N7F^ESBX^<#_0JT7>MP.MHOELIY4HZZ5VTRIH^+BIJUZS^?
4I36&4&%^Y=P>|TNX;#1M\$S:3I;H9V7P M^Q43?>K?Q7IYI^AMCY+G2^9WV5VBDJ^8Y^G>7#V7W.B"WCP MG^T5^2L6I6G\$2IV-
M=E;YS_10IKR4N08\$;+@R4Z16BUC^UZO_#0:O>AKZL^#^|RMH= MJA CNJ^Y8U+OJ2R^BL15H^UM>#3Y^">Q&C^<+SRAL?6&2
ME|HO^I)M@H@C^GKY=C^I^DMW7S^3I_KA|I#>B.9>M^|CW^E.C.JSDV (O^4SQ MNPUDO^|OPM^U^TP7.PC.\$+>_U^20=2I^W@O G/>LRBLUEOV^
Q:0I5^U_2- MTH2^0H1525W5H6(F^I^PCA|_172RH^2^A^O^B652D^B=N7ZE^M+>GN^D M 85L^2MO\$ M^|<COIG^C_RNN6AK9YH
EI>=\$7^JY+M_<%VEY:O.24J40P.@K^%K1\$GZ;4ID M^<^6Q7>1A&0^F>9^|KHYJ^_M^<(A4UMQ9)I6<+01DSR^NNG>H6:Q&KB^2+VE,HNSF6%L_W)
MZY^A.WCQJ^0T^Y^I+^S-PA9J&Y05YJ45+>_17Y@ (3MI9A=\$L|_I.ZQE M+RMJ30DJN^EP5M^#TZ)/^"82_..H15>3)9L9@OH:80:?
9>>U9UD^XA^0I1T2> MB9>?7^HP2^G9T24QLB87>#K^I^A+02I5NAM3^TO.OE&^/>Y#>+8I5PP2(LAQ MN&5I+5HJZ33VG^ZQI
@/R|^+SVX5M^C|^?#(I%+(O@5^<5)VHH+>|H MUL6TOVJ3@X:&%/5E>+|ID)V:~W^SZP8)JST_Y8\$<I4GDI4W^+I#7N);SP M+
K/6C^I%#>27R|H9Y>W12P^+<^<C^?>1)O7C0.OAB|KJYD:2^?>7^F&U4|IR MYC^6RE7D&4WHLW^F^8<^?#E^ASB2&WK5;0L:M@&R|
(40Q^?Y^E11%SO.V M1R+^#KK7V>2=3JWRT^?>C>G<75OPE3U^>Z>@>G^X2^?6^OBRUYA.O^?EL MY<^HBBML5ZJ&D=^&I^?Q05E4N^C^Y.SC?
MF^E^5E8^W|I^; @6WG=1FEH%FN=MCN5N?B^AMQO^J59^ N&_0BN^|&V#1? MALS^Y^C^|MN<(W_X(>:1>XH R^76LK?NE;|T8KP_+|
IMB|^IA5.5+W%&7. MOSXQOL^3CQ^CE39^4H5_IDN3G3RX^_1I26M;@:GWWF^0I0@Z\$GU3D)2B
M+|CX7R1&5^M5HZ=5Z@^0BJ6.C.35+XHRB5O^#_6)O|J^OY<|ZWNZ^ MT064^P^Z\$717_U^UC03JU20E;|+>^<3^0RHJ\$Q^RX^=3^4(K;G.OI
C^QZF_) M146|@Y3 M=LR/QL26AE|P<I^JR^KSGJ^_Q\$0=2CTJ1?>6=3X4%0|OG.GWHW) MA^*J8CR?7C^TN>0^Y3CA0^3;H.8YMH8;\$1=;T4:~
5);Y1@VUJ7S M_ W+L\$ _J5|J|CQ2I7^AVSOIR^TBGG^D9\$R2UDFOHV|>P_4JA^0^G^UG M0D= *@|P^I MJ&Y^Q>IG^I4IQC>
HQ\$J_S340&UFT6\$U\$AJ;49ZY%NW;C^?52:(%_BP+;~L M|ZOP^I;DN73X(A&C^?H@L2WL6)9_K M&^YX|^MAG3_UYMLV4)CVEI6QZC^7X^F-
M3AAPVFLW6SSWIA^#9E3_WW(N0@>0@F30?7NCW;MHKY.C5VUS@:~A6G.H M)=XY#;A^XJHR:7ULV96A6I)E|^IN-
/Y@BAOMV0^X^5Y4 WFB1^C_1@4^0=N M_ QZ=|A_+LIN0^@14>?Y2PN_1OP|^I^=SDPJF^SYKISP3I%PUJE|H^A>6^ M5;J^PS\$EC@+;M<8FDA3-
>FYZ;DE^<AWC^#16K48^6H7516 49VR^|JW_X^0:3W7.2P4L9_0>2B7^23UA^7 M4^|AN;15_74@I^&ZPP2^ZEXOU^C)W+|N^C)TFOQ^S.DZD0B^X^C^5
6B MRSXTS6^20I0^|OG^BTR102R.3)I9U&NT6N233MK&H0^18HOA|F^T>N+<74 M+ZR<#&QF|CWIY3.GO.HQA2.NM1P^@=|JN^*
/MK>T:7LB|9|KHL24SA^"R M&QBXIX\$A#;U:7\$+VPTC^|P2OMM;K9+|HC&9#>T4ULL^C^ELDG%BE^I58E#N#TP^PH%;2U M_2EK838YMRN|H.O6?
3\$G3=3B=&^I6BA6\$45C2FNISL^I0I8YVK; M27^_@S^K2I^@>OBS^FU4^VHKUH |JLU^J^PTI^6^6UP^QC|H^@YZBNEL S=V.08?
SX@HE^T9FU|U^"W8\$5S5HWSU09Y0^O^0^GYP MV@>F^I^J2ZSKOH?7R^KOBO^?I#0#>77F^K1Y=\$\$33L@WXBI2U_GJ7S4 4J9 MR=O;(
"H7AOA:5\$^"=<PPDGL^1V=|875|TV>WR_ (SG\$B^ZIG+SEI^3B.V9==3A; N^J^I^S>4_Q MSI^<\$>=2BB7?
%V_7K^ZP13&C^597X#B9+&Y8;B^N|E;T\$9;GI_Q<#B2I M^L|UNF^+V42%TS@>P_5\$H&^I^E5XNR5L^MV^*;SUI^V|T^BFY7<\$ MXI-
WDD0Y;BL1=5EG0Y^#GK^IQ6R;@PES^CY^"H^*B89Y^R^Y0^=JFP_#SS^AJE15^H^H^ZSM^8R^J|QN89I^RL MZD-P_2\$J^ITVYGH%;L;IT(UE;+|
GMIP^CCE.29^K%Z3G%>Q.4NGO="L^="K8- M4CYAAL_O Z&C.@IFE:98_V@&RJDN@>\$N_TI3RV+W3ZJ+V^I+XSI^DZHI=N
MNQI^OEX3^#5PWPW_B590^SRN;HIZWUX5;LAXJ#=#Q@>YWR_R^H^E^N^I^=N^C^MME9IA5F+L^L^B7UIQI+&G\$S^QI|HN2H9I|_WM^H M0L2.T0-
KNQ%9_5Z#^EIP^C^R@.YR7?TEN<@I9E57^THI9^D0E)BIM(\$I\$ M^A:9\$W63OG7@ONGN_OI>)3^;GYK_NVU^8&8H^T?2
FFS^>O|8N.P@U_K6VY^:Q9_VW|B;3-^H2^T MITC8;JK&A^I\$&^N^W@C=HU06W^IA_8SI^%8+I^<UY^IA_H^|I;KM.OAYE
MAN?^X2^H&N3P8V|V7 M5^*9C^668C3)OB.MBP2^MPPP8K;?U2FVRO7TO&+&8EWW|_V?^M\$;L\$@\$ M_>S2;P^JYD&|E9: D7@5Q>HW79
G6K\$Y6L8V_EFE6E+O4YEBAB_X6FP|> M^NNW^TIZ94G5R2LZ^3DI2YICF|^<^E)XN;|FA<+6 CFU^T MTX^I;GDD^<5\$.Y\$D^J^ DU);M(521D)_+4S-
3^V6I2I@S^ 494\$;EL0(MC^I^>N5_LAYI&OUA_ILO&N^?Q^@|H|43XZXZ^*H^_9WS&^66U^E|TO|N;O.K@TG(8/^>?>|I<FGM5F
MRV0GZU7^LOGK\$N^BW(IUFJ6)LABP5A0+TIGY=2+X8^M_T_IPE0:2A^N:~E@WU_I&&Y_14%_LXWT_ M^P
65")+<50VJKFLS^N6;FIE^*I0N\$&PO/M^;YE^U#%085GI0S;IS&^?6%P8HBO_M_@-R+|N2C)5WB_UO^TCI959|_f@^X|8;932^7IBVOE3_NHCZ@H+
IAQ^D3C+2W4_YH.AGV_1E|V15|N^X|/VNG70G535N00X?I_R^5^_N_+P_1EXST\$H5\$<@7R3_>Q^N^>0^Z^I^Z(I_U_~E^Y5TUIH7HVMK^70;T_M2/K73C95_708;I_T0V;IQMG7JZHSU|^V_HM9D13^I^VHZ5_FDC^J
M_5JN_622C^+L_5C2_I&09K>0^VP_3I^69FGID|I_1^4%&R3X44A5<_US_M|VL950(IH^I2V^IA70N2I&ZTSU|56;T^&0\$M^WV<^Z<~8_>U^3_KI_Z=)02^9^9N^"<%RC46D;ISN^VY8+|B@>FT>Y
MOD^041N4|CB3^C_Z33JRNFDL^X9I=922E|F|)Q>JH?ZP2E> KZU&?9I M8OK|I^K7I8_0+515^JG|SB9;D^J^T3CL>+|@ID;Y^L;CXD7^62K;ID|)
(H(W+>0?2I&^I^O^I_5C66^ID<|T|HM>?H|F|)K41>|V%Q^N M^UZ&^F^@|DPX_#_DA57U^N2+^N3>_DPI|B+>=^?J)G|A^@=2;
ML\$*~%XRG6U6LGK<^YD;B7NB;Z(HN%<^<4I8WYB.DH^N(H6GTNK|)7|TDI MJ|N^KUW^P9ZLC^|N^YOC|T\$BYX_Z^~V|>?
\$4XW1XO3(C0I4T0^*ZUGG MAP@8=O,4^HK^<H^D^=WRE9(MI&GY;^E6TXT|)1+>@749B92A5;RJ3^*?
M>CMO8B^ETPQ3;="0N<^ZJH.00\$EC(U^C^#RG2P= Q^"NA_U.OW_ M72|=L|VGU3V>FY6T9G6|>#JEO? K4AX3O@_1N;)F@A)N|M3V|BW2W1U/
M:P+L.R|L;Q0^WW>7IU_4ZM^;UQ_FOS@7BYO?&^EPDT>E3 M2CJ&K&WO_VMY>=>6GQ^32BW^USJ^M+0?S6CP5HM^?
FS^DJI1^E+1+1J3@SB;E2^Z(3LSWGK4^#A0G4W^O3\$S\$X M27JLGC&T_~Y05@+E+522L62_0@;BA-3;12RX9&> #=FXJ;-1+3;7P
MU?C^YX71_|6JMOH2I^2ILL TIGOI=6<4YW7Y<+I0%#;HW6MBP2^Y992I M52M.OB|W+&2T)=PBOW;9C:0>4O^KI+Q7=V^C2J^2>E?>Z^+|
<5@R^7 MZ4;L3)=YDSC;WCC:X(+S;N^PD^16D_BHIC^JAY#CB)/45B1-2^K5Z2N6 M2.12>|9EZ)I^E^U@\$.+
2Y_QGZV>DR0G|7E_44U5K5E;9;R|FQF&A/LB M^X^<|GFC>5ARWR+^A_ MTZ=SI@?_I^R^HTKV@>F^FYB|2+2^ZICF7_LFK36=>|F^GU.IN|JB?>
MD57JDD6GCBK11_34\$P^F&E^A08^5%X@|I=|C&#&D863^C^CF2&0;0M2;S^3UIZ^I0^K=C^PK;FO>\$K^ M6YB+EW^M^Z7Y^GJ@0|L&U
R/2Y.R<I9(H<^)|F_.L^ZTD^Q3.#CMB|DP4&Z|_M^IX9F(KRT<6?>?R%?CM9MPBK@|~5_?;A-F&X^Y^VI^6Y<2C<\$MWO110;
MCI6GTV_4A4U^&@^?H1R%\$&^&P^I^I&=7^IKQZ^RTEA(XVJ0^|LA)F6I2& M7C^G^>2^H4Z^73V6J^U(9M7H7Z_7I6Y%L=H EQ9/I+;B+|+5W@O&W#;
MXJ3;3LHCJAH;8I&M-WDJZMGRZ^|N^SL^7^VD_VLA&O^Z>+I9A86IK) %IO M52^P^R_I^OC%B04_?D(9VC)(X^4W
MPK\$;9U&=0E.9GFFE_H^|MMO_R<^I M_7H 83%4%>@29_LN_WWAS\$7SV>#XL2WPU5PK=FQ_(S^623TH^0K&7M M)&YNETBNY^<7OF7+Q?
KEBA>4=&8_<K 9L#>5^12B-W5+^|YU7GLD|LOR_M2S_~MBJGU>=>2Y7GFF^P+N.22GFE79_>9JPN+^IDRA^>5&PI^29XJVH MNW|XIB^I?
X1^1C.^P)G^C^I8^<^XD2^7AJ^;|KJ0>+|_E3S_=/^G3D M^VX007V=EO&O^7BJK_X&9?H_R^I^9.LP0?J.CCT@R:S6\$C^PHF?O MIH1Q^<3U2^?>
OT.7814|MPJO>H2_&S0BIK6%Z1^HFO+ NK79D|_SG=j5^MTQH20A:5^SISMZ3XWR<3THM:E2R3I^&I&YI\$W+^H=&DO_E2L;L4^VMM6
MY8B_6HBE^T^7Z^ZM^R^R^S^TOG_%X^I\$|K.FSM|7FZ^+7@#55#J=L60&6 MW
R|O|O35KJPI^822LO.XRIGOO=RR<10I.Y.WJZSYUZ<_3WKQF3=V^V^E^E|J9DA=C>YKJ^8EMA.C.P9\$KP
M<_S6DIS^&Z^>+>@8X38IH^YTH9I&@G>G^LO&L5I^M%\$X^>M^BPY=K2HW=JHWCW^"WV2G6^L2D^5DI3N;SW9A
M^TQ3L=7\$|EG#Z>#MT7^N|_O#2_ME|^<S^R\$8KQ;B:8>K5N7^M^TC+N^I^?NF?T^/4=J2.B7A0H_F^"YI^V2Q L Z6)Z)Q0I0^TZI^D3^<^HENZS|=+<
QS.ZN M1.C^53LN^53;3QIKM^N|KSUX35NEG7@>@.9.TY+?^+6FT^?U_5+|P04 M^"=&B9910^Q^K2<0^X@>R>0^Z.0WU_~^#;U+^Q^P^Q^H^I@<
C+>_MHIS^@4ID(TIP;L|L8I^*~>+>|P^XMX2^BWD?P^3^0@<FIA8V^A2^4H8B.GBI&A8VR32UG^>X M9\$8
^P+D^H+^%BZSRBM680>Z7F^L;)8E7_J_W)NR%3IT|><^IB|=^@S) M2^VI@K:0LIF++86AD3%/7_IU^802^)|SG&1V;GY MA<6EY_22Y_QL3&OKIWX?
@X.P^WDS^FP7Y>D^I^L\$ MJ|^+>Y^A-IGG_V50F)J|I^M^Q^ENXU|^<2C|^A^%DA^<E2VSX_SZIA^I^U ME>S8;W2I2Q|_<K&KJ|8>+12^IYPT^PL^<F8W?
Z44_2^9UQI@|B|M^M^% MI48M^FESA+|RXDU\$R^=HGE+I+>A>+>S^P2^_M^5S+K15ZM>ET&J^YFE8ZB|4NUD^J^U^#="BU28N^#
|BW59.&NL^;SAX?^+F MDOMMHS.Q^*#8Y6G^*>K6X(I^I\$|O.FRT+|I^9F>BQ|^J_R^NWO1>O)5SGA MG70+6B=+I^<(RZE&IORBH MD-
JZ|OPPI@|X6+&N.ZHI^USNW\$|^<K| MJ+YD%#>=4K@T_RIBHE4B2A1D8HY^&H<^@4D^2(VI1^IX6EQ2;SVI0LGN M^HZN+)%L+L_Z;
(4RZNY^K06TT@/6D94A^O^/4C^<+&R^J^YEG8ID<# M@<#OEWFJ^+|L.N;2&IV#1^R^<I02(^DQIP^#SS;I
M=jw_U70=6B;20I2^E^HQAQCI0N+6#T0I|6WP^DR2NIX>=U0&GM^G^G^#N MWI=E^L^KO|H^\$PH;SEA|^BS;K^>A5>XH^I_U_O^G9^FF>F#
IOY-1 MLB&CEU^@_YMOBA6Z&C+UE_SLI0Q|^&S<=>+1^2^9X|APG37|S90I&|BF4>1 MN^SEQS2|=B+M^@I;I3@TIF\$<6YH?
=JUU^047T%&C^WNT0C^LLO1T M^PIN=JB MW^C;19I%8%?0^01&G^X80+7YX6WL+YM^97F^<@_SFXOGI86R.8_<"X7PS^" M4^|S)7B_~ITG"
<2C78>W^P+KJ9OPRA_VJB^122RZ|UEA:\$G_Z3 MI>+|ODBA_1R^EDICJY6S=ICL_Z^?^FYN545N3_7LAPYNXA_VJN=MJLU M^M^VS(333@0
AFM9^CA@84HJ@_77^<2H^_MYQ;ZUKHZ T-72;I;T(I=Z3V;~_U>_38;E^BT^KU4%|_D#0QE_R^J%(>W^U=53;~JML_)F%2UY^K(AE^IX M;L<8-

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~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

[The following text contains extremely dense, non-readable characters and symbols, likely representing corrupted or encrypted data. It appears to be a single continuous block of text.]

[illegible]

HNWJF3J1M4E2DZGJMASJ1YR1J,DC111*GKKDXYYIYN*TN71TQ2IHL5*YU* M07W-M2W-FEG71UHSU1V/1P0-S62W-8E-E*2*Q, LNI6Y1V1=I1064E7XLB
MwZ,QQ1IF#R#Z2A1I#YR1FV,EvK#ADJ,1K-UXXY13R-9Z-A*Y,4* M ANHAAV#F8-72XN#56,60-1BWR#3J6F#NVT#-CZ#S#BJ#E1-G3-J*
MK8N6-1M55S-8-1C7F1J+56*W1-7,1QCZ-7F2K-1M0,00Q01M0JW,55-1,15256VU+2VU,UD,1* M07A,1*Y#(ARC/D,0>XJXY1*VM,8-D57#0-KZE,E7D>I4Z3E1I#0#X-G-M1H-E*2FD*W#U+6B*V+FA-L13EC
TMUOR-U1,IG-U1M P04 " M0699/15=0X6R*1X0-60-6-L+31P,CP,3,P7V17B,019*P*(HG31*02D2D=J2C0I+T#)U1H4D5 M1* EXUVGNW0=V-1*UOGV169D960172UY0KKKUVL/8%1U@/1
94/UH70M0,00T 61P #A 7#W#QW1Q BG197W6C0 1/ 216 M1CN 1#0,6P7*6X9 1,1,X1,11W-DHNM0,76P7PCTX# 6A#>2X,X,1,M,677*1XLT2B*W,1PB>4#>P1<#Q0*WR1/51P*0B1<#Q0,END1,P#1
11 MPGE0890348T66G 89-A5,713WV91R021558#M,5#-0108Y2Z>1Q722 M0M-RH0239#>0#81#>7SVNGU1Q#EC59Y-5V3Z1R2H3>+1/2,NH:0B,FC-08, NCX#-0GY0W,1P(C1#2-24U+3T0,1*1K1692
4UMT#A3J,NGM2,1#1#F9V,6 MYAV2171 CH101B-DWU1S1N1C1K9L30D1P*W0M0F0R7A7R6#>0#86# M#1P#TJMV1>1Q129-48H4L05*YUC'N2'1L6L1HFR01016BD-YU05B-1BRN1,MD151
5+H,PM01H,H.M06-319V,P23341* M0B1(60G63U#072DZ#M5SYXU86,6V1:8*0#M,0+08 132F71HMWY11*Y9K010G-VTH (115#0R1B7L0XADQ,15#TAS9,7M 69-9#>K0022W2CY*6H H, Z23K1X106FD3A9ADY2
S-Z6<1*W13 3-9# MNA6,K9K631*W#>10#10G61011*1TE6V1P,8*0#1(AV,68#ENY,N2,1#>763V2D6G60J0L#F102WZKGFA71Z1#>M M,5,662P+3JPF1,MT6C80Q0-0M#B1K81041E8R-
F1#WXP1,6T6A-RWQUC1,M3118M0 AA907K1(ABK#W#>V4VEU-D1=7*2*0LX,1,VDY1KPH,9,Y,M1D#M8+YXW1(2Q1T1,ORQ 3#>2W1+20Y,1,K1ZP71GRAY836Q003:7600Q# M3M,812WYMH
#C1GUXP1U#59) 440W171#R3 61J1C90B+2C1KY0#>1K1N0 (F711F1Y0U,3 7628L 1921#G65GKN6 M1A0J1P621M 4.1(127C/6EU/S141#>D0K0213DZ0 Q10,0#G1P1GTPU,FQ09,9,1NPM/61
M,6<1KUS1W,0E00A,1# SUE11=0726PH1Q501K736101203YJ>1J35-M5541, GNZ#M1M214>5FTJR-A0914+M1+E8# 01(UV,LY,63,3R M1C Y400092251017G71Z5H66/21/W24*0#1-67N27*7L 27#E0<X
->42V315<4#>0M M821D71M11M0HX0,0B#WU5A1(1T,UP6#M3G1VE34L91M1HWM M9N0-87,1N,3*01M,0,7L931/K6#M111GET25V021*0#W5K1=>EV M5,P,1
52V2(953,1#Y87W20138WY,HCKY 80#>M6C55740Y#K7KD46,V1:8#>PQW6F W23JW62N,6PA-N,6=>4YNS1B45L045+SC6CBF6 M1#>Z62BBW#M8B1#>0#R83V14J81>66E-E 914#1410 M9V215,0_K1B1D
D-YK#>1#Y87W20138WY,11T77151U,EL270 MPOS2-F16801GUFIE,1L2,887T,61100>NWSUY1,LS669UW52L6-B MDO,R41#L3 3#>5,1#1Y1P1K1B13,62-5299+K#>N61#1F2WY5CX+V
M1#3002L1F7 871#>AE-3,WFTY 1>10W1>7FZXL1VC13#>?K-862#MU, M0704YQ-2K,61G2D01W09WZEA640NR1R-KU>36JA>2F+E3>BZ,0U-M8#>=>BX0#1#MY3A1-9531UUBBK-K1Z0FL80%N6U00
M#>#6CY,7,YU1TFP1(51C, P1Y1182,P0F#XMAZ00K0CX#XG>971R1(19RRA,X,Q71P V7LH,M,10#>630BED00,X41P11UL1161#>64XK14K1+7UZESKE#>E6R
M#>RGV6VUW,GGZ1<1,616F80#>W1C1,7F1 FZK1JYMD-#R 2*P1,1W 64 MP-U121P 557AR1K19X3T,FG,16D0#942,44511UL1161#>64XK14K1+7UZESKE#>E6R
C1AGV1C#AD,18#M V1B06-65#N1K1#>W#64+2859U9043J1P1LHSL,NW0G0F704VMK@03 M1N,NV31601J3#>3V1D,1#>0#(M#>V+J6-81Z0G1#0XJ111(17X81)>J# M211M1CR1#W#FU2>
=>#FD20Q196WUFT5F1 3D0 4 M1J1,2P9136G0R51#01 131J1P22 22L210D,GBDLA 51LEEG1GK0179 M1#>061, GV 205,3 C#M5#W7700F030RARP#ECC,67 15<09T 91
1>V>3002106C0RQ,0J3V1+1#>670Q30F1E06,11,VA1(K1H1F1C1N,F10189#>#H8M1C31UE0#F7,151#>0#N21,S5S M8P1041RM1,1CHK0H#CZ1,2251#1MD791-0J1#>R6,14C1Q121W0-2M,YW1Q5661J
21Q1962066,W0T 171R,U197F,E,JARGU1T0B,1 5ND53 H55L(0N 271#>49C1,70CC1#>EUF7#1E,0EU1X13BV1F#>30V111 66N1 M0G1#>553D5(05<1#>1660Y100F15#>6,1E6U14JUP#>0D3J4M1BWRUW544
M1>V1(1P1V171#>0EC1P1<40-201AXF0,1#>0M-P01N01(21K01851,3#>1UV M1H6,05#>65DQ2,0P6#>8X0L,YA7#>511J7C>40T1,6#>1W2 XGGE,
M1 65ALH7,91W87YX,1/141 7F,6L1 LV131,3<5M-K8C0UG,1505G, M6#>M1,AT1ZOK#D0Z0K0K(MTV-B3Z0M,Y15H40#>W1Y1#3#>515,127N6G1 M1,TD1<6-8C, W#6F17G-K M10,M1W1YRE1S (X75-H2
8,0HMG6R9#>W4#>3253514,32Y1,92W4W601G15YMS=F,31000230M15152P71#>1#>F1M1J087M1E1#>55X5#PM12W1FN209,1M1H0N1M1W1#>MAXE61B1H1Z1M1L0#>011
100#>0#1,6CZL1, P1#100/THS171#>1(1K1R,1#>1,61U1M1#>5, M1,187Q1,1312190V5E131G1#>1#>1,724FTFPU1R#>W05K#M1,VX0J11 M0ZNA#W1G730G6231J1 M0Z#>E61#>C0R13>P1K01,820U7,D1#
ML10#>1 MZK1FV1I0#>Q1Z2,HS24 OV10#>1K1731 56131ZPMW1A03 M1Z1#>F61JAXY1412DFV5X9K16#>B0,K2,M1W0-D1(P5P611#>1M1G#>84#>JMN M03F1,1820P#>0471
66A07400#>H1A,1#>Y1J1,1#>1D1C1(1M1K08B1K0 M51C#>1 571UDE1D32 M1,CA-Y1B+ASX570,147YU0E1WMBH61#>R1 VPR1 M1 L8R5,451 #54Y00 1012A W1#>1, K1Z1#>Y1C#>K5ES-K=75IM1#>#R1
H10895Y01#>A13M#>5 1Z6#>A 61B1#>#403/25 U021Z170U7X+R52#>U1, MV5170796Z5Y+8Z21,*B, 4W#>N1#>TN2912N-U#>8KZ 0111161=5P09 M0NZL2B1W#>XEV7
SHZ1(0N6Z221,125270BWL7454#M6R1C134R,9R111K1KPMZ6671C

12345678910111213141516171819202122232425262728293031323334353637383940414243444546474849505152535455565758596061626364656667686970717273747576777879808182838485868788899091929394959697989910010110210310410510610710810911011111211311411511611711811912012112212312412512612712812913013113213313413513613713813914014114214314414514614714814915015115215315415515615715815916016116216316416516616716816917017117217317417517617717817918018118218318418518618718818919019119219319419519619719819920020120220320420520620720820921021121221321421521621721821922022122222322422522622722822923023123223323423523623723823924024124224324424524624724824925025125225325425525625725825926026126226326426526626726826927027127227327427527627727827928028128228328428528628728828929029129229329429529629729829930030130230330430530630730830931031131231331431531631731831932032132232332432532632732832933033133233333433533633733833934034134234334434534634734834935035135235335435535635735835936036136236336436536636736836937037137237337437537637737837938038138238338438538638738838939039139239339439539639739839940040140240340440540640740840941041141241341441541641741841942042142242342442542642742842943043143243343443543643743843944044144244344444544644744844945045145245345445545645745845946046146246346446546646746846947047147247347447547647747847948048148248348448548648748848949049149249349449549649749849950050150250350450550650750850951051151251351451551651751851952052152252352452552652752852953053153253353453553653753853954054154254354454554654754854955055155255355455555655755855956056156256356456556656756856957057157257357457557657757857958058158258358458558658758858959059159259359459559659759859960060160260360460560660760860961061161261361461561661761861962062162262362462562662762862963063163263363463563663763863964064164264364464564664764864965065165265365465565665765865966066166266366466566666766866967067167267367467567667767867968068168268368468568668768868969069169269369469569669769869970070170270370470570670770870971071171271371471571671771871972072172272372472572672772872973073173273373473573673773873974074174274374474574674774874975075175275375475575675775875976076176276376476576676776876977077177277377477577677777877978078178278378478578678778878979079179279379479579679779879980080180280380480580680780880981081181281381481581681781881982082182282382482582682782882983083183283383483583683783883984084184284384484584684784884985085185285385485585685785885986086186286386486586686786886987087187287387487587687787887988088188288388488588688788888989089189289389489589689789889990090190290390490590690790890991091191291391491591691791891992092192292392492592692792892993093193293393493593693793893994094194294394494594694794894995095195295395495595695795895996096196296396496596696796896997097197297397497597697797897998098198298398498598698798898999099199299399499599699799899910001001100210031004100510061007100810091010101110121013101410151016101710181019102010211022102310241025102610271028102910301031103210331034103510361037103810391040104110421043104410451046104710481049105010511052105310541055105610571058105910601061106210631064106510661067106810691070107110721073107410751076107710781079108010811082108310841085108610871088108910901091109210931094109510961097109810991100110111021103110411051106110711081109111011111121113111411151116111711181119112011211122112311241125112611271128112911301131113211331134113511361137113811391140114111421143114411451146114711481149115011511152115311541155115611571158115911601161116211631164116511661167116811691170117111721173117411751176117711781179118011811182118311841185118611871188118911901191119211931194119511961197119811992002012022032042052062072082092102112122132142152162172182192202212222232242252262272282292302312322332342352362372382392402412422432442452462472482492502512522532542552562572582592602612622632642652662672682692702712722732742752762772782792802812822832842852862872882892902912922932942952962972982993003013023033043053063073083093103113123133143153163173183193203213223233243253263273283293303313323333343

[illegible]

75BR1:7CUNX1M=B690A=I110T 6 1<IL1 D0 A2<92%8HXKZ80N2/86VX6S0.0? .G3BP3K4731T2VPO8H1/ MCZ3X31+&191.0REJ52VFBJ9+1#%>16-6Z1N2=UR50P MCK7MHW2E.Z.D<C>V: K7B: 790C=7/K<...>

M<[X&XBT.TKLRH]*X* GDIIN*~J730P1\$M=YA*6PFI20**ED= *\$A4*{[I N17.XX 05*4(P2~*L\$N0QA837P12J~*~*~8ISGVEZ-S85~*P)P1.GJ~*~D~W-7EJ3J~*V2.US6B?G.C.Y\$SGD(F/9.RD)X53? ...

[illegible]

[illegible]

03WYCECE0I@50A4XOPY@>YRW"%%6HHK110-%#CR%-OQN#H44\$@UAOVQ! M F2#276JHJ^=>?DPZTH=7U23-G4\$""\$D#AI%/2^_:#629B=>5S+? Z)Y&C(-/M,7K1^+%"WIO"%Y27 Z< ID"1<->HV15%KD13ZIK%BZBM@OI\$S=>1SDIZB=L MXZ\WWR=L\IU7DI\MG\$JBJE:"FUYC\J87N\PLA8)RIW(^N4XUZB6)C\XK\J73K MG@ZR6(3\$-AF44-H\#-*)&GJ#&150?7W^?XHD)C2G## fE\Y\6UM\IRQMZ1.1 M\225K44@190Y\$\$(H\044Y@U2N@6I(132\$QI&Q\PA^+HXW0G0H\W4CKZ>16 MMK\UC5 RF5+8A?7ODU\I\RU.L5D"GI@C@079UZQ@U6?J_EI03#<=>+ MRW?J8_0&W0_?QH121FT2\LUL<=>J&D(C>_I\$%^>^K&@F8\X\B(Q.6^M\4(- GVA^8"FU\CL\$N=UUTGFB\YKHK&^_W2SI5<=:5 MY^C@KW^ODNC88_H0+>"XQU^?H\W.K&\$4I2X.Q54IO_2^SYF<+>IPX<M- f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f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l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f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f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f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

[illegible]

[illegible]

FX9G&-QE!&@)P6BTJ M&@2BF7>>H6!-519/*A/JZZO'VA^?U.2)7!O.9\$Y84RL!_L!^!^!@?NZ 2! M:L!/*5,>PSCI/O\$*WFW&\$YT RK!|15.NR'OF2,WUL87 M;+1YO'N0!UQ25)A^A8E&S0RQ0F=Z/K08HY!5&*5! 1N6U2E922X>8!HG/ MBK#Z! DK^DR!AD:RGK'W+^/J-MJKY7F7!HK2M- X'\$(B7:X.N#192.850QO'T M!EZJ @!LA=90E!75@(-#-R#%-.9%84-"R2GE'JC)OUJ9#*VAI\$+VEY=@D!-MTGVY! (81(FI^5-E-X.\$!U#F@Y3V0<8DA,%& ZGJXD!|8TH@W%JAKJ TC_Y MJ+6!<(%0X/\$UPEX^R-YR98 5-G70.2W>6!12?*>FLO5R^KFW40H3V>?(!=1 M\$A269QEH\$?3DH-FOTZ- M!)-=>Z0Z@*\$ M!<&H_6"J7<8 AW"IP\$!20BO!|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|YK)N78Y+XXUTBW_-HJPWNG" UXXV7R!&H(K5S-;CW_HH M2H@.7D"30^>Z=60F!&7VR5&J8!X^TV^!05.X358BH!TPPW)APH8=BC MOH\$14.3.DG^*2!L^P=8! (YA!UZ>7PE2.1BJEE4F3U;NW060W^X\$K<*K-MR_#KU/#U.OXK\$)_!1)Z!^=FTA%:@0L#(#R88O9^W479^!%Q!J6<1E.&= MK9!>W7K=L15_XK\$!\$T0^\$!L#T%1-WR2U!MDD36K!M^7Q!1-G!F!Q)-W@J) ME+; HQZ^W6)WMT_ZHNTHE^R"9(I(=-GO^!TEV!L\$K10Q)"P=^!>0R M!Y(\$&W7^&X!MVM-.GD1E>5YK_*)Y\$ _!Z8:ZE2^"">C_+NBX#(YNL(+!M-V"8X!|!{MM\$8ZAVF.E.L@!PAC!U)K176EZ5J>_Z!V.UH&|^!^!NO">=>B)_ M"? C4HR4NCF**71/HX<#&67+!17"TS&D.QH.W87^QZ)P0K2^!TQGE<!)Q6D5@ M'R?OE.KKK!R#YBBW/W>>2RN2^;GR'6F/BL5!8_!@!Z#>_!"P_U&H!R_# MRV1^!A0!SR!&P=J6U7.FPN8_N_<E.(PAV)!<4^OEL0X 3^8!F5@-1_OX!#1^!<MDX73!N^!P!+!YCTY^B^009^D!Q!4WU!9/3#>#=\$Y8D5N\$- F+69^J03^Q0!&M^Q=1B2HRL^?G!UZF?US>N!A9!TPX>SSZ060!4#>W8>12^"=>GH<!(MFU@7G MQWF04D280&-0=8^>3%1=->\$@SQ?M"? DFLY6Y!X_2N^!<Q!IN-SS!WR&+FD7 M4-U!M\$&\$YT@!&!*J!QF!5&E(RVEN@*(M@%i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

M/4/+<=M^A60Y4(K/W,YDTW8QON,%AR7_UO_BM_7F15_M_%MW/2095_RM%\$Q^IQ+,%_9""90&M8I5M<-1M7)9IH5I(DK)C8#VH0IPTY0#8BT_AO?2HY_S/C%Y8/6_AOYTNOITE,1" MZE_08U!<=W>|@<81=5SQD>?;S1!"@?>I>_D^OD*[%\$3;79<#)1QHI+|G_+S_MK%CRK19F7E?7I64FYKEG<%)<&#N>=<[S#<_VS9_E#ND_A==5WU?60=<CP)M32(8XY#B^AC|L-(8I23,,#89&/-W/W?"Z1FM@5\$=#(W4WS\$7+<,\$<=V_MQB|A==5EM8B"F?H=IL<#<+;Y\$A19C;A&1<:HR*#&B4^>_>9K_32^TOY19WR_MJ#Q3W3>=>2;K&H+BD0\$&IOT_SC5@UW^JZY59IAUOQ3H6\$KZ+%"UYN\$3"4X(X#CF#5E(6Y4_MZ@L_SBI5T_&64K(CY>PW;#CFE10WA58F-1?GC8D7Z\$2IC+?9H@<_B_M14\$H\$OU60_L1|W0!"@Y^G@X:6|AIG<#>C1Y3?"Z1(9FGIZXAB#YD_M?>0)X>%(BYT0GA2?>T)X^H%Q)X2?UIS=0^08I^NT^KI75Z1V1_3NZ&_MZY0^UO>89%VEU\$5ZYK6U<^BGKL^X|_WE^BCAF@P^+|U\$:@NACC\$#1)2"(MD<15>#822P\$Q^4TQ6(T%Q4C#L|H|HJ<,>DU5/BIMN\$1#N|+?L/L)HLM|G.%=@Q:1>@<L;AB?0.G4%KOMXM@/3=|G|>U.S(HK_#B/GQ_<M(X)SU_M,L_<NI2Q.4GFGL?;ERNQ?WJ1485FI7QCS@0MTFQ<5_V10)88_0)5_J|>BR4PP2^TFZA_ML4M=D8188(FI<#>W/%S1_1-1|ZRE>P4>=>0%"Q0IXEP@&GHH/4+D+2^("C<_M_E44BU>_SDDN7_MH^7GYMMD,3IG7G^M=ON;2IFR=RA&5E0_SPUFGSR">_0D+1H,B8D1.F4|<XL1N.C3)C8K19=35<3EY7<^A_XM2=<+LTT>_!?!N19\$X12@I&<^HD\$74@802!\$4_MBS^N_<IOE\$"\$SHIT8V_>^/3CIXRR80C1>I#C8>+WY57G,E16;#M;0L&K9!_M(G6->?7UT@<_FC,S;T7+Y^J|W15H0KT^D1.BGJ+<|K0&HFIJA)4H;M3K@3QF+^TU^XV|HFW29?TEH+_*MK<+&^HGV.D.M%<^""""9QP">2_MNIV*(R0D9N\$G&SLTP|7C^Y3V7N4>3^D(2E_6BLGTG9D_M.I4U#14;MBDQ|F1_...APYGW>3;1D89PIV|U\$=Z03V.O>I(HJ_AU)2<7I0MLZ^>)>MOUZQ5^"QA\$H0BDTL\$QAX)(#&_R2Q|_A(F)BGYTG_K^EJPK12_MD+IGK2903B_-\$14DZYS_/8D3A11UKPB2?19X_20Y9RBKM0GKQ_MNU_7Z&08L\$7^YVYD^DRV42DTAJ@3|SH><1|J81^I>U&XUN2TYR^F16I3|>_M.PLZD&>@1V_HG_X^019|C73)H&K2-MF\$PDLW|U_+>S1^%AH;GXX<K|G_M_P2&2SK3^Y)*=<@GYOE.4B_<AIX0^I\$USR!>UT4URQ_E/IZNS6^<X@D.#/"M_F\$%BC0I*!>1^&5^EC7^&JY_<H(X_?#L#S^X&97M^0^OR16+7F!|QK\$1_M">>73^X8)HSV(9+CTHE(RX)|>Bj:3X#M/Z6.U|A>_M-G4_<EUM6MSL>_*M_ZX7(15N;NB^+|BFTM)BV?P^<+?>+7L.#=<^E&6=2^MYCI75E\$)JR_C5U2Q0;H&2GK+3(RZVCOT^U_!AA^<+<+FO^<^VY>E4I= M@|A_<W13EWA8A|C|>#QDT>15U8AB|B_<^ES1^Z)>@MI&8^X_17Q=1_MF3Z;B|H^QK5<^"(4;1@<FD_A1MC(2C01_4S!<4L;GD_8E3E^ESD<+>P^T@<MBI_<B8|<=<L|ACPA@8<^JWP^&S^U|V9M;B;PV2B|K1<^?^*UL@LE^*#L_MP0_2OIG;S2;Q_6?>WD;3L2X;G08(3=<#&8Q6_K+^_!#_%(Q_0_@<"Q_P_M,K\$&N5Q9E_GJ\$A69E6Z5?<(16)Y^542=<G\$*50ATS&84(XA^<)20V\$8_M_<^K_H(K&K9DU_LZ|W|&B&K;9(A^<2D|&6P+3^>6D7V&FUP_12PH^<^BVH6_M_8&5^J2=5|S6N87F_"/>1>18X.6X2YT(VB;B#_M15EC+G|E(O2\$^<G@ZBSERZ1F7G=<?>54S0^<S=H0#6|E_T"8+J236777L+Z_MN@VM8#E^<_7^G_K9\$XV(|M77|N|W1_16H+MVB;B9>WV|LTD|17ON55C1GE\$MWR^617WA^2|>O9;B_V%Y?>?S101Q?>#AZRC12Z1\$ARE|B9|SH>_Z1E\$74YB9_M.YR-/G^F+LS4^2F^V?""IGC=%#O|A|H|>ECTS/FJM2738SF6AE;O1L@J4_M-U,U_H@3WP_U38D_BC.O.V;1;|/"D^6|Y)K"QJF@<LGE8FZ<3KR_U=<M_X36|F^<3^P|Z;3X3MVG""?9X@<T_D8A2@<^4P2I0DED1Y)>^21D0H(MY611>542|HNZYFL52|H_NPL=<N52QCQR8_1RZ<^<X800Q13#T>=>@KWX93_M9E9R3I_VW_21#22JUGV2K_@%<2K8#802&8^JIP9F@LL+5Q\$;883C1<^VZIW_M9T^YV3IXYI_WOCSR3QLG^/L2N6HFF=VO_A\$^F",0\$XIBB(AI_M^P"%S1<@<0121217Q>15>J|TQ(2)H;EIK&66P1\$QH_C|<=U|U^3^Q_<8L+G65G_M840+<G\$H>M@<@<JNRPG58_MU;|4YBKQ@8Y<0^|?H|U|<+|V>_>JH\$^04^X8Q|RYF|E|=EP|W+^%J|M^?OFC_7|LCW7^7U_NL@<5AD<^ODZ^<Q>Q>_UDQ@|E|M>1>?>2B^218@AY#M1M9@S6|_1H03@1^!\$Q<:<P7B^K_B5_IUWQ3A|00\$^V;1R7H|&G8U#X/<X(M_ZH)>L_@OE|L<_!^"729\$<4YC_VGC44&_U8&B;85_<=70J3^2H41\$|<Q<#<+&^MC(6;G7|OD|GY6WHPHZL|K|APZ>10|@LOF_18WF>2>2H(96D|G|F_RZ^*M_K5M7G9|9E1XZOBUS20|R|H6<=<M_XK-MF3^W;EFAI\$^NOZ_W5AN|HB\$3_M^#2#83^"19R4^5<)<M^<#7S7J^>?ZU5^<8&R^9<=E9^3W1LCK&6|MD(KWGA_M^YMPV^"KY886G98M|V(3QJ_R^U<^"D@C_8M^?RM\$G^/J4T5P^UJ^<H2_M@%?>4GW_BY_+B8|Q@R4X.&&OINGF0_U_HJLIP^5S^12|X)5B^*39SV|Q_M75U2|L|HUND^8\$F%&1^>1>5>9^<=<8T88610^_Z@<1>^<Q<S3=<ELXP5DPTH|H^="^#1Q2_<V|<H(M);ALUIZ^<R_VR18KM0^=4Q=C2L_<K9\$4?>N^N|U|D>H\$K_<NU@<TL^6G|ICG_M0Y6_9<#<33>C6N4BL&F2M_0_U^YL=<C+EXPH(Q0ITJ&G7MTG^7R|H|H|F71#M\$&M^9B^H1C6|G%64MK<|R584^?&0|C^6#^FE0I^<G_<X|0^<Q&G^<J1_M^C|<=<N^9_E_7^%Q^CUM^<H;Z9>6\$V#<(#5M^"9YVZBU_3P_&E;A16LX4I_M^1^M16LFZ_2E@<U2UA^V^IAS^<76=<1FHG;+V_MTWTO72@Y9_M^JG6E>_M2BIRHXK&B|<J|VUMB8_NN^G(UYU%0^<1^YWI3.5^<P|_Z9^>U9EE10^JKR<G_1969=HN+7^M&Q6;8W#)TA=5XV9ED2^UREG|PDG|EJR@EAOEVB|=+N;D|L_UR6G_FY<M@V92P|<3?N3^<+<GGW13IE^8Q*<?<20B1UU|N_02^<00>\$1_M^2)1X^5(HB5^<=<95U|O1>_<G8@2D_2>_U:RTUR@<U2_NP^2%CF<L&L&PXMR^M^K#%<FP|VYH^T^<I&B|<^Y_K5>^<T^<7DU_TS_7%F@6M|H\$=<1_7UUR17<59F<@&_S1X_M_YMFX+^+|LCZ75Y@<MA/|_M_LB<4V^HM+P\$^A9/R^1|ENF&2^+M5>GC^"801="^X^<=<_<Z6/OV8N=5PDW_AZSI+|BW^<L^D_MGW1T^<2_<9+^+U+|NBDH;F^HGY;Z\$45V2B^892THOAD\$BC|KN3_RZV10V|MT|U|H;63P_160<#<="768|ISUKE^EHRW^02CQ^

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|N|AW MZ88SR82|F^W^ZW=K2^+!#8PQ- P>A=I^M\$*=*5^NANXHOJB0/ M.VF_7U=5D9)M52=)SXMWX.W:~^MPKC^H^K1<+40J>O^AB^)(0.1H@)YKLN MTHJ0^T%|HAG8C\$K^L>3@U1O>2%+ WAU=Q1%\$S(>=D.KIZELL@)DL_4\$ MZ^JAPT7?2QFJVP @0+>M07D)I07-2)&0+<5A@SQ.@R6^P%!/O4095YU=^M MX&\$2> T1U50GB|(0&M)8.B:6.XH<^LDO^8DO.SG3DPTKGW+2=;2P&0^I06.M03K&G)HY^W.<(HDC^%?2IBRN4_7BQ_+!8_ZJ\$+S1<)%M01^S!GIAQCP M^C\$3+U^U6GT5H.CO^<^AP4_1H\$<^IA(A^31^T^12X3^1LBTJHX7E;5:GMP%.M1TP:FK2+!\$M7!0VE&F2FNT\$? A79I8.BS72SLIDJ\$K.-8%EZZ*=?H(MKY M)T?&XA8Y9R5I1R373^K5^COROY0=PEF^753>J^R>0)IQG@2)XID\$-0H MT? @J9EMP8PYPTJ\$X4DKJ9)XH.OJ.2OTEN@=E P6ZB^+SO_2IF^#SF-2+ MLMD^CUV^DHTHL^X6^7GYCLMWIDQ=#2XIKMJ25\$N^+O^~J^R7.OZ%JP0 M11Y^JH8_951%=440)RZ!+D7(XOC%26)48FP\$.S.KA#=#KIS!./@29*5.(U M^IAIGP-P3?JP_1C-(K6)!>I^Y.&564MK&M%HD+K.@<2!-)6@W=G\&NH\$S MD@J;2S2%N.M.5V3F-F64_4^G^SJE^4^0K^OBL^8-72J^Q&WHD^85QO M^~\$BQS50E_1P&L2IM^A\$(EX8BEI8|67WE^>1CDN%\$&? 2V^YD=YZK\$#^S9F81CX>BX88_19Y1HLE M@G.OY80Y^Z>?Z^Q_4>2^ZKR^X1^A^H^E HOEEF%&\$8014XBB^D|B>>3T T=M9(+<#NPB.^X#>.(Q_G@TJ23%B\$QU)9I+J@VX.D!>OENS4%M:4T+Y%:5G5J M^G^D0^7?FWXVH\$4ZXOU?LJMJ.^JH^RA5/>_!B5L KBNU0!@1B&/A0AQ\$ MU\$)95^UCCTNTAI9U@7%+I3Z:B@?2Q3H|P=2WQV&5+5\$S6K0^TY9%.U_IN MSK_5BJ2L^T&>1.WKX E=(9TIC+M\$N\$M@TX9EZ.Q? Q\$SIGH=>W)U:4?I\$YX MR^L1\$S A^C=#8E8?_Q\$LS4^VRH^H^K1^H(SIEG\$0VNTSI#47V|QN35F_M|N^X^=QUAIV9#2V: <75L_8V7>R1G=M.B&^GZJHP1@JDUY;I%N.^J\$N.M:77C2=KF=YBOE\$)2Y1.60>\$X(4+>1)3S%Q>6^A!(0A3@4=HKL+!%L|HJUF^U^ M7?PTK11H|C:J5. L5B6YL1BG^HSO+W%T^T_8Q A^=4Y3XZCQIE^BRFG M^C^8P2IQ&/HA(JZF F\$\$.@^K4<^%7LR.G)H|RL.MX^(2G7IQV=H1VP M;T-3F-FV^M!\$ =W0W;=5.7S\$>KMZT|N|N;KQ: E=I2=^JY<18Z3N.AO MFA.=Y^&T8(8=^)(D)&.^Q_2JH@Z2^7NH(>6+F@^@X8RJ\$GK;^!AC(85DS7) MS?3- **&U%BB64_11?+1J|B7^P^WM.^#SJH(M<2!|NW>H)Y|YM=KU>|WH_W^+ZN66# PO_YNR&^|P9|2V>_6L^IRH MR9+!+!1?+M.1KYL1O7L_ B_ZI2N<7N:0^%O.YY.LB#|QL&#\$. MAJ^3L^2M_6^VC\$=@86R^IEHR^X^IK6H^PEIG/K6.^ED8E<#WE1L6U1^CN M(E_N|PJ.^U4720IF#3+Z|_? BHLU3C2E&Z5K_/^K0RWGMJ\$=B1TF<0B1 M^A=)=\$8ZD5<=QR)D^Q\$8117_9C|FA5\$^SM<+>|F%7.XZOP^/=.A!S37H ML.V.^Q8^125K3.M3JZ>J7G^>S!H>_U=O^GK|URHF0^UE4EEFUE|H^OYKVG^M6.B.4GOI^7-8C4K0:2M7V@^_L13+T\$W)+WMJ/A^8^7=U/=A MH/GQ61%OGWL M6#78D:&)&F==Y2|HHTJ&E?@7=Y7F5Y95^H:0B^RY=QFJ0W MAQ%#@DO+U&C^HT91YW(#8VIV(\$&W^YE9<=>=ASXQBI M\$^ /F@QN^A9D<\$1 NKE=SCW(963>POACOI^0^_1_9HLOQWY9H^M^+C9^/2F^K1WS?L6^F+O=ISV3#.&8.V4+HB(|#%>1 MZFEN20|S@C1.>1^/ 67^JE^UZ_FARK27H^M(K^I^F.M:1>D)WGD^D^H821<4A|/SXXOPVYBCTF^JE.SQP|UDG^?24@D^07\$W#(336N2 +S@9<P5^TS&N.M\$EIT4@)HGO\$M|>M5FN^FRT8F>O>J+X5WQ2|_DNT6HD>^>@.8.59TC M4 A)XKLPB&F >81FV65<1H&2^9614EZ.EF\$SG78X|UFTV2?T7^3=5H.A1 MCQ^1\$+FN2.;3)CRH5PG>4V^SNZ39;SOR MIOG\$IBCK>2VS@>#9#^D=-S6*>WZ6R. <901F+V)SY^0C|A9 F.B^E4W?>2^Z^TK7J_W2#RX=WZ.O<XIS5^PIYTHA D|/>FQG MQPFF&20X|3*?>OPI RD OOKF1W6I>7H<139N+RIV? GK|.(67%U#H> MG9^4^0.Z<#GNH9AFZG4DZCKD::S DHJT(CU@@U|L|\$2W7Y&YMIYGC|MI3^&+_)QM>4.CARPWP|<IRX1PB6.R4|0G15(S-I M08.GYD7%2EN0./%=@S5IO&4MU-Q|VG8T^TICG|H?2^B>^I^Q_XT.M@Z12W664^|9991.(32CB/L2Q(VPAKSA#^V<1-XD>1 M^<H2HS^9QA1GUD+>P.TI>M^K:CISJ^Y<^WMJQJ1@>E&8.LHJMD+>PB.8^8 M#^A8X2U%>YM1^Q96.XQLP%:H:9+I7_D? VB#6Q^TKU=9V/7&579.5M.^M^0N8X.3^I^@X1=^@8.V4^X4A@ZC_1HBF=H7DP6TD0U&QH^LO|HBC% M<@%\$B039(SD)&EVL^I^O.^3%PG3ED0+0.QHUZ)Q2)H2.LR^UY0#@X:A1^ANH M^CF:CHUVZ^U7EEFW02.#X+WK|_IBGK@Q3\$>M? E@=MHJ(C^7MOTC3215>SW M35Y6KW&9EBO.6>YIG@.1CZ19K&E.^)CX3D\$.TP3Y@C#;^(-SD_63Q33FLT+93%\$<)K|HO%904^F^Y|>N1^W9^2 M_WYK|2ON^K^7N1&^0Q@=E^F1.6J^YR+0B@_ID0=TYQ.G2PJH(KW\$=6.Y^@ MICGR5.H4|HK8K\$|L.MR0.BCY3CTK_EB+|MHJ7L3 MN=JF(3L^DT1\$&^84J8^K7JB^O<=0H|CXB(0UJOL.6.SA_MJ35)&.^I3.V%Y1%GFAQ.^?FW<1^T5S^XB^*6L&WR.^I^I0^Z4TW M_5VN^H^<=5R)T^X^4U2^EJ5(RC\$.8)S_DS_13+&(4&U4D7J8^YI282.X M@=P!0^T9PY^.\$17.V67_06Y|X^9^L=L=8)^+8^F&^DCO_3_4% M^H1_5>&X^H(38=T92W7H2W7G.G=^I^U+ID^9<S^AM1RL0N.^54R^F^QVZE<5^HY>2&JQ@<KC6.C76I^Y MPM28&3/3_Q7WW|^B8 |C:5.S3P&8H|&1Z\$&A1@%4F=PLR^\$2.GHC^M^XJ7U4^I/S8V5&3\$&@Z|PLA^CD7P)5Y^*Q|1D_5I693^RLQZ2.8.6%0E3& M@W8^8F7^F_49^MKE1S@<G^M^K|L^B^>1/B^N2|6H^=BE7HLW\$^XL>MZ@AH=M^C^Q^3F^F=13JX_74D%\$W^L|03N@.H|HV62FID80T&-% <1Y62PM^Q^\$.FEW.YP51.MOD0^GARW^YP>X4G64NU365=E&9^D-(7^J5.PO(77^E^%\$2A^T^D^I_BBR\$E@M^E0IR3@BU^=, & I4S4F7L.R+M&.#1#BHKZH^I0MM/66IQSHF^WJ^3|M)M.1 M/I9=FI&26U^IVF0750RF8#Q7%|.OCRX^7&SIQ2/29S32|_<1O1K??WE>HQ&M(0_4^6NI MT13#Q^8^<=.9BBG<8&#&1^8X1LHHZ>:6J^+YI20GY627RU M8=BI%=(4\$B)NDSQ^88QP2\$DL<#<S.^0Z9GLZ|^>B@K>45:H22^W.L0K) M:YHN&UCKARA30^E^NY3^P6N_0Z.N1%\$8AQ_XED^N(18DK5F(61&^M2G.N&S^T)8:4U_8^I=^W|DN&C@Q^3N2O_TL|K68^2WY6<5\$-8Q)S+& M^FH4^O^CWGV>^OFKD.^|HHHH|H1_5K\$W:WRO>S_Y=H^Y^Q7R#^K^0%&&+I^T ME>IM3L^XL4DSK^TIAH&X2.MH!0.S=AG/OA3<6^I O&BE^N^L^NMBUX\$71 M^C@>EQ|>N^\$KPU|U3G@GF5^I>=)LFV:WMX^I^Z=E3_C4VQ2N1^=>OOU>%5@5 MD|MP? 2^XIM2\$.D=51Y1+2G=^TI\$VM<1HX0\$^N4JD|^221GTA+VT\$QY4^ MN&=2\$FE&7HVTAGD1L^%.OD^XWJ2^IC:??+E1|AUPOBUY24|N:YQ(&8 M)9@Z6|^\$=85Y2N2.5^TQ.9Q|@&@GK|HHP|X:D^BC_&6C|F^D71M/8 M^RAM^?<@SWKW:RTS|? <7X#%#G=&J\$WCK\$>5@<U|H|OT^S.5^V_1^L_G_ZZ12^NY7&OJNA+ MWI_2ZN#(VLYM.H:IG-DX\$PMYFG8VJ|P|^=9D/CWHDA;SH^C/^#.A9XW+ MT|_V/+LBA2ONT92\$|^!\$|X+0P<|&6<40P|^#WFA3R.72>M.M:Z)3@T^<^6 MCIYV?C<7VU2Q3(V^:G+2V71=NUSY)Q^UV^4FSZ^ED1SA90/WYC M|9+19WGM^4_XSYQGM|KY:IUY1MY28Z^+12G10%\$|ZL^PB^V|ET7^K|ZH-M3R15\$|SYJ12Y+Y^I/(\$7^X^4I_8FDL\$73A|H79_JB9BC&:X^XZL^M8)EG|PHEGG M09Q^I^M@<C&OY#>>29=RW=6W_1^2B04:0%GG&J.CC.G)4K^F+^C8.0A@QS MB^PG@DE&C@0|R(AF^!0T_15- \$G.K/EV)>K7DKY%|FDGUWL6_1^|.M.C M>^CF0\$>U76.K OX?^AQ>^>NIOCI^X62+3=IAEP&N=V<+Q-TR^V|L\$Z8I M\$E^NE%<^DI005^|GC(13KX1LWJ^K8^I^<^&T68 M\$^7INDEPP6A1^WMSD^4UTUCG14:2# HU2C_I22(BIEN@P+U0A^A1^T4U7K: M=4OV>^!KN=13E79.XQ521>0H-B|LYU%.DL?U9MJL5&M98^MCMY>^IV0^I-5.5+I46WCD2;J?+6TOTE|XHJ4:7.^8A_Z<*(^Z?7^T^0X- 49K_Z&G^F^U_ M56+8GAM-LW^8J0AC\$3.PRIR7(0^F^B^XA^QW3\$^ZC2U)Z58^M836JM^/M+0.7:1B:8:5F35X\$A=8CN8I0MEQ|F^4\$U^SH^I6 K^12^Z^0F7\$76_N4 M_ZBRN^I>L^A1^4^O^5<4^7B2X^>7W5_AQBAA\$(S\$A1O)S^LX^I^ODMC\$ M56U3&E^<UW5- R#&J4&30+Z|H>^SDPYF^FI)9LB#Q|MV+4^H.QO<^/2 MEJVE@AXU7^VL14R(A.@L5=49_P32Y<8F0^4B8(C4T8;H^>XD)U=2L_|>+M R|XFW21K3A|^6^PY_ZD+222KV8>P^>H\$#|VW3_2AFV.SE^_4BA10.R MWM49_8^D|HLYY^KJE2L@>1EB^7N.BK/|8_1BC)4D|=64#3-IT|&D M^J&25Z_E.D^37\$>DHJX1V5177|H^+>+CXU;S1UXU2<O&LYS.^I^K>E|&M^92J1^IHRGBYD@D^D^G? 5D:\$7AS^FU(4)B8GC^JH\$E6)B@AC0GMGN4.7(M^U6=Y.\$JP.M^3H=SE7>#D_B.J7^F_44(M?#&<A6XL1)?D%1!6M>O%RG-K%)XJ^C MKAVJ=&? 825@56HS92!<8+^C^J|<@%\$J2@M>UB.^HJ.DZ3+@<B8A67IR MGHW\$NO#Z4@%8>E+TXJXT7S^M_HL_ 9I4RC8KX.R^P6^&8N>C|Z.^3XUREV^I^J^RH M^<^/M-ZHFA^I^JZW=M>S M=1L^+M.N.20^<? W2)2^Q^>A6E_OJO^MBS^IQFDGW^JY7)92.69X^H^HMS^&^T|S|N? M_6#S9^8R^V>7P&M_M2_R1ELZZ<2PJ57UO)|=55Q=%BC)+*M^*(%MR-I?@ M>#%\$G=<@<1>J<1^DEZW_3KZ_/O\$J.KO|OT^K^AM\$>^.(0I#AER(MONBAXX^&10TGH\$|YTY4_H#V|@=JHFZV2AU.M^E1|44|\$TZF_NHHB(P5 MY@AA+2D^<VJ+^*K_1M^Q071&E^&GDT^G&M^)=FN&IGC1^6Z\$NR^|S&F(28Q M@|@7^+51PQC1^#^79PP.1Q8-2358^HS^IDOX^Z_1Q 3HN|JL3+3SUIAM.ME.P4B_6_S|E#^2VE3.A0W+91^D#\$^XR^4S>=E^I^16U6M_1^9W@QJ#UU=M@9/0352^L^A Y#7^KZ#<(%Q\$ D2A#C0ZG>N06MEJ5|3AH^4M^L^BV\$WD0&L M1^2_03.EGXC_OGLELCS80SU^2D^%RW8.N2SR4^0C52&+>9W^U4SU7> MZTCQ^VGU\$>6\$Q5BIWR>JHGBMBK529E4^<NTMDD^*S^&M^CRL^A&8-RF2>NHI+L01^2\$^J5_IK|SH.PE5>P>5N|B8^T^I96^<Q ME@W18K8%<HERWE\$>|S=9W5\$>1^X\$14@OW_KD^L^6Q?XUW MQBWL_KN S=2EUZV7HK^2V19|E^B0.6\$G37HWH^Q:C\$XKJZ65.M? I=0ZKP|^=\$C\$|^A>76^6) M@%B^12D7(?)#A(8Q-K-ZQB.U7A>C6L\$=0R^KDTS64A3P(E14O:9:8C2!6 MBJ2/<13&)&.<+>UXPI (QY<^JW<=6C=6E^UO.L9+>2\$G^U+Y^88B^<SY03)8-SL81HCQZ^I^C^H^M^*0TRO_T4^M^M_XD&K^K>.>2YF^@+Z^R8\$PIU|^%>YNB:X ANY- G5^A31OXYW@Y#^#F0/MK.^5\$UO+5_2L^L&G|Q91=0YS=0EKA|E^FNJ^>O5.R3&^IUFZ7&B>JNX|T^1+|E|A|E^GC&(>2YLP(A&782AB\$+F M1(A^/#%RUZ8R^=P4P7N=UR_3<.&F2>#>+F>ZET22#>V^<M^R|EKPLJCM@?>5UH;UIB.0GTP^+D+>H?&\$KS MP_#16^TEVIVC^XR(8W|HCH|FTBJV\$1A^1^_D92N\$RM46^I|P5+7+M^6A@-RRR^@H|H|3Q3B>HJ0S6+2^|B^1^O C^NS^ID@DV(^<^?+>B@_M_ <1211T^D>D57CIXR9Q3|F17^7^TK^?Z7&A^I75ZDQ&^79&A@4J<^X^ M^YVG3D=^%|ZS0^>2^F^KQD9M^MACY|LG|38|^%HSH^<J^9|K^?L MXF&HZ(Z@.^FWYI5Y)1D=3/15G5UL1N|JZ^QC9T7^ZDIY79S^J^4I6H6000G25|L\$+^_PN^HA9UHQWJ|Z\$7A1Z.^\$J4_51^213Y MD^F8<3L^L-7%|N8|MQ^D|T78|A^V^6E9&|BW2AU2SM^T^S^2WA97ZP M9R|HK2.L^K+L:9PG%TS&8P.0DX+@<0<9.E4^8518@A.32CH^T@<BC_L0 MOJR^M^L7\$^WV>.&A7F9Q(2V9UL^&.^&+0^<^LIW^FL1^H^I^DK2_ML(GXJO.M:B_5^Q30^6<5&PXPO-XS+AT|P_C5EG+U^<J^4#F3C0DI=>5VK MJ&N=KF^_QIAC|W(A#Q#B#&8Q3+C^C^AHST>^I^K_7D^YH|Q6T8|L^M2DN5^Q\$A9380C\$ME02^<G-D|5|J^IXQY|VL6^C5FT\$S(E^F2NM2P JG.M^I^G\$HQA^I\$>QX=>741M5=,@.(0%AC4)U^XKV R04Z6<8&^Q)ZT M86@KET:8^Y1 PB_5Q_S_.8Q@6\$2QOZ_)#AT^QZV#^F|I^XD5FEX7(3T)^6^V<@%5UU.%&YVW M\$ZZE=5N^WF|F|TA8ZK#>HJPF9(ZTGQK(6R^HZ^<CK2=&@U=^/V9>1_AZ MQ:YF_W67X^J6S4F=1^L^<0K^>A68PEU|0+51ET3^>7A=3127^E=MD-3BU2VP9-ZMA|AUS#|K.B^1^K_4R^&C\$5^@>1^1^4VP@U^3^71Q^2^9 MW^Q=0^9^<^B^1(A_Z1^DT_5Q^/R.^24J^W)&3ISKH=5:R3F&O=H0_BQ^M=8EO3W^@NR&BW_0MJ^HBF3<7!#^Q ^11L^"VB@>=H^JLX^%A48^<^MEUX?1^1 MXT>5>|V^A^P/M&Z0833CUL^BGRU4_E7\$>0^Q^+|^QPK31B>|L.G^? M^J^J4+ZXJ6L=7P%>>2IQ^FD_1\$RMO>97BWM\$KKY=>@P8_9^I.XZLHKF^+^+>O&P@A.9:113^%0ND|B^M+M^N9\$|KJ\$Q9Y1U6^31N>B^? LM(G1P^<ZVRS|:D.QKAK^N(SHEFFXN|L^TGSW^M^XF&+^/ERRIL|(<(X.B^CC^Z0ODD^MZV^ILC4T0?/K+>Q6|J9M@PD0\$ M>X1(C^I^X^Y(4RP^Q^TJG2%U9>BH5^Q^2^L^ZNF B_U6=1^P<57^73C>6DI^MSO@J^F7^RB=V8FNKF&BKJFY >^FZZN:PG^BL^F^0<^IH5\$S^I75ZVU9RX^7L^MH\$U|U^|OGNY47>^>3D^AYSJ>|R&2^?F|F7>8>XGB.X#;BC%9C_B8NY^27ZP_FV^2IS6%KX1 T+ (^6OZONRLZP9MZX^=135+/#.J:PC%_?J9L@5DJ M=TT^QI(6&1?^HML\$DS/M=JTPVFA+ MJJT&M^096N9R@_X2ES_ME^?PV(LL7RWQNN6H |Q^<L0.Q2O.G6<T|H|H|U^M&620MAEKKH(2+&8^S^DW_DAH4&2_48HPCE|6^A8166>1%2C.OPX8XZ^B# MACQ01+5S.RY_+PHK0)@MC_9#=#<+D @G9NBSTPQJ6UC/E^F\$82TZ.EW-IGE MPN^M^Y^H2=+>8+M^5P5A^>9FA^I^Q^R3W_M2^P6+9.14X367.88U^0HW_X^2_EBGCZ>IM M5DE^YHQ>5EG=>R610^Y1+Y%?7B^H0E3Y3^J^Y|DQHJ+KFN@31D4^2K-6^M^A^AN^YFFC|H:5^I^FK\$|^3TJ9:KL|B&^&QO^<Q|H^R|R:7>=&XC? E\$V^ME1_Y2_7BP(L|5EWOQNN6J^SY4JU.R13B1BU8(#P<3S^8ACA|K8|QFF6A>1%RG-O\$9^ME1%7_18UGH |R|^32^V(9Z+KQD59.R6L\$50S.NL7A+850W4LW26+8QZ2=RC MBJ<77|^5V6^?LO5A^Q^@MB|H|(KWX)/(#B%RHK_E+3E8(O2I8Z?PP(5L^D%T7|@/R ^E|N1+^T1 M6GG419^4^P^AK^O=M6M8)JKC2_EENY6K0_HXJK\$X8Y1^X86O.(R+5^Z^@G M2B2F6H>

AG15GB:MJE/ZW16M:U@M1A9FUCXPIPI>:2W8G5.1#362RM:MIM9&@FRL0.9.PY*FLAK:HNIP#E*ZIQ9M:
(S:~E9I,1H2C,D.R.R&7K.V+G:SCASV/6E1.9#3*5%&:QGQU1/(8=\$1.1.M.4.6%1AF15BQ195\$P5T16H^ZDRSD5I)^41ZR&MIPKGP.1.S1.AWB>
(S8D.~9YCW.R~79CEX5KJH>:OJ&UM9ES&UA54D.M3.VY14#00E&VY.X~X*5.1#HJ~.62.MD8:36JH*3.ZG2B~T/756%#:4E1UJ*41K1TJK21\$
^A@XOF.CV/J&468GJ0R.ML^H-62J8UZNPN+Z=J~J~7*CE44S94@<6S.~)21K+&B!~ M8AY9&X./CXW1+LMJ+8&GCU537XK/JWEBJ2(1+ZZCHZY-M
ZF2.0~674J-#(18HS1+>H.L.HOGF45%TH(S02-A)K>HK6A-B=51H.MQ4S>I%>R.V9WVY~J+M.MXJ:IB=240^HX+OD:WOSW5E53:H072
15%JKJ&OLH=.=K.Q8157~J9R6PI<MR>J~BPLH*9P80X.8>P09E3.=)5YHYMST(25.L0UAR.KRTW9.=/7=1.MEGS@=7B(C.N.8V)~\$GTE~
I5A0UV47+J0XK4A78^42~0~K\$SYJ?E9?BT8T.MT.G6?~MV@/I~J~VP7IEEOHE9HJK*#S.2159YH>PVHN.S)B@O61K0?>@-M-URE:Y5923+Q1OY2-JY:
(R9=XD>+71&RCB^@0@S.ZVYV~BIUY~X4^MZT@V*OOY<.>#0JHUQ.N06LJAX\$25M6Z4.E70EU4%<2F^P^L.INNI(KA.D.MV.60~%6F20@H2.1&)
(X3+A+~)M.C~?&Y#>6%?7IX^0P.J24H6LJ17.MIN.J9Z+A9.9K1.E.4R1%~\$MV21%>U/(8.HSHV^4&~.3+FIKHY%?RU?~MNJ0?~W.B~8O-
P^XN>K)S(B(ZSL1~)Q@Q=5(21CY3>2)AS4)XZS054F.5Y61.MIPP2.2H.RV:1P.MDV15QH+Z6%ZS025.&~.KAHIVYUA&^+R)ISQ02.MNZKZ^HJK?
~W1-G-X~(79V3*34GNJQSZ1?@B4)S.B!(>~\$Z:(M5IGY.M0\$ADIA*9KZYKF+UM7BWRUJHJFOPRF~J~FFW23-TL#C~?<+(\$)QIC%*(DAI
M%\$=A@AG3.=O=O2)I8N*JPJZA>?&U(I~(8+9G9^NV0~.MJ^X1ZBLD^FD'202:7.Y608SD<8D.MB3!<~B~?=-O
MP@<@E7B8(E#A<(\$~JENQ~)~PC~+((Q.R.L.M8JX>2)@J<(\$V)26^OT8(2A)3 IQC!E/HX8A(X;M;G<=0T5KU)P)SP8=
M*~#9AJ4D1.2.W/1+M~9(DI0HVOZ(P=XF2R>Z<1H5^SD^=I.U.5B%PW.M/P~%V\$=>P/;W/W%2K.O'ZDCHX*?K1X+WT@U'76T\$.W3+^F1JN@
XJG@Q.M~HQ54~<R&P1W~VN~5Y9YQW0/LVTD548QJ~<KL3W8K~#E758&P=2F=
MK/AWGN2)MS=3UW21OINK=;D~\$~P1#8.14Q5>=>9BJN>4H9&6=I.M.E2~9~Q#S.U.M.W6Y.G~.0.DFW#5G4QJRGJ
M2."K<~UK)*K1GWCY8N0~GGMWZC2~MDK@Z@4L.B^EZC1R5^~P9<X2N(Q.L.N.MXECAS72)MMQNW<<^(<41SP><.I2B&2%.5.61?
QSEMI+~1P>~0F7<0>~>B~M~U10~Q.M~F~H~316N>27C3.S@<KLDJEU9DD1@~^AY&R0Z%9.&IV9Y~M7GRY^75HJ>O-
PL51HG&S5N1K>XJ7GSH>U(41H3J.X44~>VUJ>WD.M.KIBWYJ.L.G.7Q414B>FY~O.61~>VDIYM^9811CT551B(B#(8YH~41
M3SP.Y(P9G5OP=2\$BVGO*5)4U)~.6L/BA6P:IA9Y(9X)H3F9#~J~I~X.S-M%GV07"N\$N@&)B:~NX*JOEHZR.LMMLRHMMY1OU^~E-
DP~1&TEUSE2=>MS5UHQBE49<K2.IW>J~2R.VX>#~"QS>1Y2R\$+80A21.1.6L\$A11FBD&~M@S^1.OCS\$30\$74WM.C=T5.=510-
00Q(2GVYS>AEQO+9<L1~>M=2I#0)OV0N~2Y@<?L/3~>W3#~JQI?P16?ZGS70QJ>I~CV&2QCYS*78@.M#KT~E5@+I4G6>PG1EIX.213>^%
HJ.B.NAYG156T~>ZVAYWBTZ.2Y0*\$M.KMSLNS3F=;01QI\$E=O<+D.MW~WVPY.IF3ITJYWN5RSI>LNAQ327J5~4+M.O0W+I~
1P1F2AXQPT77H0YSA.M<~\$#G.GJULX7FE>ZP.LM+OY~4D+MXAZ@KL50Z1+10-YX%4%\$S~7Q.YTY.M*8~)2#.8A1?3A1=W9YB'B
~.8F.JB7V13ZJ45HJ8F9+IITE/H3B3W4OY.M~+@R+I\$U@7=.*#U+AI+I+THF&L)I2D=*03^FG.NOZUQ#Y=ZWH06.0W3?>2^~
V@#M~3+1.Q.650D08<IOP>W>#FN3.AA1S/005X22FRW4.M/L\$GZ.BH<=G7N/NE5~+YIEK3&XW29Z.N.WR8.2^C%<8A>R+U)53.MDL
4DOPR*H071)QED=>EVAE[XC594.*ZRI54XEQ2*~ACB+J2C%5ZT6068J.M4ON\$&4)J~I5OF^J86R/6U13.L.IKMNR/NK>25>ET
MDS.WB&6<@#I4I7GJZMYA<S2P.8\$1H#~4QO1I~"6>?T>~IIDS:CYO.K4.M4J.EFV7G6.~UV6\$.7%MRUST~)H8KU.ZL08WGGI9.MD9(46I
19HBA4U@JNEJ2.VITOG<("S~\$50~ZZ60H~P~Y~IS7Z>2?~Z.M5^DW.AFMSG~IAX3-GC>.\$C.521LHWY28J@H"~H~FG~\$D2JSM>PYGNBKD
M\$D+G%>X>.<=&UXA<GOY41%3C8*%?~TL#ZJV=<~IV~+I+02(2JFIO7~H.MB.CTA=@+&8P1\$B0^PU&(C+(QI\$E/KBK:~H/537^E3W?T~/C/OV?
2D1V.M3YA16~TL3C>9#91=KYA~WJTM&X&X551?>8XHEJ@<2/59D1X5K5E.M#LB12K(8P>D9IUX*KG.NM92~
I3IEYE<~AY(MRO~F8~)HJ.9=W~7)OXB*O+ZV~1C<8.S=2.MFVCGITQ~E~TM2DM5M1D~33SYRRI~B2104HT~9/5M/OYIME~160&ZW.KS
M#UC~KJ~MZ4IM>~\$~6IA=@JNH77~Y.&JL.P.M>9EOR4/&JR5Z6J=S2.MU~I=OZ*P7CY6%~8HCY%U^*~5)8R.L.IDC<5<J>ER2.QS+U6.M
~NXYZ~H/C/7\$SE9:7V)WK-UP.164HY3^R+5L.JVGH*O4RP&~4
M0~NC.SPT>L)6J~VNOFG/RNF&D&5;JH28&E&KFFN&GO+53GLHBRH=9S>%M7\$E1LSU7~K>GN.LY7JY^Y6>IK6IS>1PJH.^4W6\$5.Y8B.?
EOJNB%R.M8>+I+J&1~BVY<+81KR&91R\$072)M6R.O=VTM5\$.6%<6^23W~.Y.8Q.O3+A9SP7>F>P7SAI>*9=VJL~164#2^EN
MOUVO~Q.7175~LDQ\$>CA#TI4(A2R.KQI@<D~#18JK6C.G.LMNKM=HJ>E)S~W.M0J1<5Z>5@HTH&X=R\$~#YE~A8~X.M~D>H^?~R7C/6VIG&P6?
972I>QJ#5E.M+D.ZTZG~PGF2+M>~#.KGAL2IE3C.M~#YOYZRZ<0%KUI?KREJ.RA=C.K^ZD)J#P.8*(9#~\$V\$J@G.H.2G~8A^@SL^\$~
M:4YL6+~M~HJ9I@J8613JNF.J4RQ.E55>4C~5B0~\$0.J~+0QF@<#K&1^1V8~LNP&S%Z~FY<~RDAD
MT.XS8HIXS>2.N0L~T+BS6G&FX>E(X+P+IZ\$Z5A1ALP20?~IZ5C.XR4.MG=CGF1.G+RHTN3G=)2U+&HT6191U.U5YJULH%~.20JW^+GS//SQ
M~>XA~.UZ.8P+&OLZ7>2&@JOX?M?P7Z5C=;GC9DEI3.5~42)8!!1OE2T.M@<D18\$@/8T6KL4H8F6H~<)3H=I0U\$%7MLI8~J~IUP1(99LH~
M=FW#VA&S~O.2RGFE~U7MIS.L.V~28ZBL58W1U>W70:~F~C~F~N0.662L.M#DKIBF@<~PTDBXVDU>93>ZBJHSOBS73.P\$+9H<#D.
2.U.EE=25ML:L5=M6?ZK."0M&/IS^W+XBJ)Y>RV+~HOIDWVG%?MJLBX?K<=<\$VTOYPW)~E6.
M74)S0VUBC5WYOQ7)R60~N8~I@<~M~DYOU35%AU<UX9TWJTPG>~J
M6D<~+BZ4G:E=42^ETJ.Y7THJLK\$E.XK17ZHA=HJG&T%=<#CB9Q6Q~O~WIF.M~NVJ3)WC6X1N8:?
2IY8F\$W9NH6LJX=CVP7E00&T)NS2IGIG+4=..S5+\$MF<=1DD+N.P(I1S\$D&8J@~"HX<(GGA>9!~DNT)E8.W>H@K)~UBQ>=@DCO>B7.M+IG=
=72~YV=5^SS9+L/G~7L=1PCN2.ZPVON.YQ^4>HSI0H&A#U~#

F2,4,90@G7A:KZ<\$+XT<LUAJ2 MVL2*9R:HUS:1.#-3)PVUMB*W>21062&U312"FMW+FXLM,EQ>H(%P-"SIXT
 MUQO%*X1">P<->Q>P<JH*H8X1F+JWH4+!>:-6A)%\$.HH@BF..41QD<B0=># MJ4XF\$00D9&4Q<QB35?20HHVN!
 W.SVZ45+SZYQ48&9DKDD<@3UIG4\$<+1A.MI%*.U7K0\$2K4.MIZQH1/52M%*.N21HNLOHPM%&0J\$/E+ C-ECINEAF2+M@IQ2*#4Z1-49IX9IW
 M<4I=.FDK*%>+S7I\$(892B1"TBJ@F1=#7QVLC3R:154>\$2@G3:BJ2'D'.MLO@.ISC'2F.VCFMJH"7G.<#9)N(H:986<+;/8)U0UFICYG1(I.XV2E*O<>
 MD454#<-.IW@FY<Y6)2IV2L4HXNA4J+K.H6)7GT'E0=>K2C=2&\$=\$R\$W.MY(\$F\$.69@E1PI27WWAE1H060.HRR10H0?
 HH".90@P">X%55Y.ZYX.M<#>OGPD6.Z5.Y.%<5/99)X.K5C# FBTH\$#660Q3%*HJ(=1\$F_*EF<DI.M=M@:G1VZ+2QI<2I7S*9J/NT2.
 GMM0)7H1%.TN*1+2I?F3N1%U*/>12A.M45F0PQ.HFBNF<C7K6.HW%<T50.E2.FH9S9K<1ON7R*TV%<8>+<M@.1HIV@-.MGC=610'.PB0M-
 I7.5IUH1<?<ON0."SIEV11ZU.PYH..+R.(KOR77K8"P.M*OFB3V6V.C#&@G<+Q9B.%.GJ.B97KW3I.Y2LIF>9#6.7H%6BDN?TOYE%*.T\$K31H5
 M0\$)U#3(<4E=-8I<691=IZFYZUV.NM\$O*J8.BIJRB0W+W9>7="3H0JH.N-MJNG'72.*+!@9J*TD0\$SX6X?23GP>6ZX+L@+H\$!R6H=06<9
 MK9@Y\$P<+*WB"6IP461CMFCG941P9H18WH.6Q.Y#CAM*!<INGV9\$>R.M/HJ996197@A+1+3G9NVTM%*ZIUU:UF7J=VA-
 @32I\$*UZ>BV55SR.E.J.UR3.M.">\$3P.6DM&U08BHD?<5)TXSZB>.%118-M-
 24V(S.ONMT31M.C5:HW<2I?V1955IT7L+&P'X8AU+0FW.IB9UNT1164GW*?7FF9BOZ.916N.M:F@+Z1KP&+8XKQFB#<
 KHT3-33NE<SB02FRI2.Y%0+TEQB/HJ>2*U..8YYP.M2\$<2&EBP<+JH.SW.KZ2B1*GLH14IESYU11-LG7MK4.M6:T.G1X6<*)Y>+02%W3.JY
 :2).=H".EKPE<G.NLX'Q3U=WL.OV'9Y/93U.M.T1REW&&-##TM<GV(.HP0)BS#%.PC1/3_D@5D_Y-D)EI/QWU_P<)8Y8.MU:8_EBD<K04=7.6?
 KF%<CJMJ<YJFZW1<.<1%<+<+<A.W723>33WZ122.5(U:3.>.*P06W7#1I36?_3=GJPW?M015D11H1*QJH2D+MZ>QVOI.LBO.U'5=*2
 6%*.LM"C\$1JYMZFED206T<#\$.4=<H%#S.1&W3.MH\$U3H.15%*>FD(Y75M)D1/64P.JYDFE991814R.A>L>&@UF5T@B(3C76
 MF%*F31N1/N2<+>+F4@H3%5PIMZ&1+2!B6.A)KY'POEROJH2+8G-EB
 MUS.EBAG<..9Y8M\$)XFE=SPA9C<..YYP@IC4K<@6&O49PDL2PZ1.9861H51
 M2MB9@2VMAIAW=1Y<1=GM3/4.KF=XSX:83B21.K.@>15X.NI%*T\$>?_12_DF.MR.S1P#>J.WK/550D06*KE\$P'K<@<-WD)=
 G&L\$V@IO:N/UBN:)C+U'9UU:M.M%_65/3KPN+V.VU2/(B\$W.VKGV<DEK@FJH7F5K3%+GA\$O31(8<0C=81(C.M?<
 &B%&#NHTJ1=2K9.'E00G7MPMG:FWWZM.BLDVW1W2Q%&9JN<+R=C.MM<1=3<WXDFYRGNNI@52VYR:&E1XVT28\$ULM#&P7+3(K<=R.X:
 (W'YAHU.MC&R>R.U3N2\$194EB17VQ=C.B2.5.YA:ID@8IS@>+DY@BSO0<_SEIMO.OX6#>1#<G/41E/UEI+>+JE3<K\$989Y%*MC1?
 LI@LIGOQY:IK'X0R=Q9Z?A8\$GG01.(0IX(AV#&\$>Q<1'(B2.&)U6GJ\$Q.M1=>:IXVI.AOZ5O1((9P&UQ#0UIG<.<O'G.@\$&V@*LI@4'D5)F&FSM>M?
 QH2KZ@FVU)LNW28S3A1&X>R)...<0LS">HJ2THPR\$S3M72(T101L.MRO))U2\$13_D#9TOB1'LHD..5JG(M&E.NE'A#U=U8//M6R:L/UT72DOTWZ-
 '80W&:0'Q4(0'219'X)0QF188Q2IE4'0)OSP4R1B1C1MLCR&0G.Q6@MHN.2U93?>F=>+<78C@>?>XF=>#>S5PEK.E-UR.NI-5>I4<F.MBH04ZL?
 Y:X53FD2IP)H3B.2\$8=IP#<'.&ABY\$OG2Z3'39C<>1Y*OH@+!MH2UO9BMOJQ>@4'4UV9*>C7Q'HZ6"3+5EM81RMFY.ZLBUM.E-UKO<B
 MG0KXQK1#9.<6.FT#.#><&'V.C4@TU..H\$PTP1#4/6H<.>=>#0=U#NW5Q8.M1QI@<L'D?@%=>8/'FK1+5(F2SR>58583?>#?
 JUOZH5?7K1>3R7.(95/M72A.9V>VKU*Y#H.E;.#JD<84W6)SL2/2/<12+9UDD(B1V1W=L7UJ7T4:5BX5941QI.KM5U*26/(@40H)JR-U&!!
 MKJ.79'P1>U8(IYD20Q215:2RM910.M@I7+VWYFZ.%*MOU@O.KM.Q6.Q=8'KH.0%=>1T2B'M*#WDNGEY6>C.M51QZWK&L.M1%
 <>YRJQ.UEJE0?>37W1Z1H1\$G\$"&..MH1/4>H1HY9R.MY'E.O.Z.IX5=.2IQ5UHU316.3ZE1I#.#.061US&S9.&P.#1J9G.G"8=RIK.M%W*HFE?<
 MU)M80P.N8-/6Z8X"U724%6=6TT'6KQV1+<+5ZIR1.JKY.MJ4.O&SHD)YC'E4>I2E.(HC#(O8'E'N5F.TB#)J5.A&@<8GU1<K&>..N\$
 M34B2CU+1/U)EIM'RF#>8:(OK'N'UBE.'J1C:>Q*SH1.TTX1%2Z7/H.M2E%:IU.'PG'.Y:R+Q<=<X.RS&F40X2E"FT'X(I\$5A&2.H8)1IK\$5U8B71.M1
 >JDP8NBAZT.EH>6)DY%:F7\$W!@H<IC(1<9H&ZRD"\$55EU@Q\$.MI<K1H&75%J'W)5N49:<\$<1=5851I:C5.0K.13\$UQ2*JL%*X?>_IM/OLD
 MU.2#H4Y61M"TB6776J20@0=P1@=5<674Y\$#JFCGAM16.3JOIYVM4>=>M<=W6G#1/FR-3WIN7Q9_E6RS8/91B<R.#JL:;X77.IN(OJD?279G=<
 6G.MDK\$#BV<DJG'F1'U>Z8.T9+!XSIVYF7J\$8Z2ZBEG:W.C#;V.7NRR>1=YUYR1=O..IES3(S7MJE@+G6\$S).UAS6V1.L?<
 IK6#EZN6APX&<8W'Q@<(FUVF<J22.U10D<4EQ'.M.UF.F9D'1.<BPE.2&F2C'E@GO.XA8BEG<8CL<+D1L2GMDDBD?GN!2+1MX8?>R#-53><-
 *Y=U<(\$6Q/RM5C.VT(4D\$HFEQ3@R6F1Y>+16LJ\$..M#FFH0.W.M+V4C.HL/11=JOWO=H'12=KD>#8QAG.73.'VE#R(&<8SGS1<M
 M.JW9.8.U*6U2Y9.3+H6L1I@>=>N091.R9+*#EIG(O'LHQS8+*009P1H1.E1XB0.M6.E1S10E(G89).04BET7U8B+X1S(9/H2M)%*%<Q6PW8#Q?
 +N2D.S7Q.MGU?D84D#Q@0A'JIN526&X.D<4)IGX6")O1YIEF5S484VD5Q<P#+Q<1>Z.MW+=W?YL?QWB>EU4M<HWAH!
 ITLX1"Q".TT0EDH8X1DGLQRP)C1+&1VRXH52MU1E.MYVQO*EJ'9Q7KZMK2E2M0A%71=K.BVY1.EUZ+N%3X*99JEXA11=L'AH1<+>
 M8=5"MMIRY6C6T71&Q\$F78.1W<1R2"O67:3#XBL1S3Z\$5B<+>U0H1?>U/MX2?>E.SYVE\$*281\$3.L#H\$0&D'K\$A9CQ.O2B(8A2U70<SPZFXU+
 M11TW6:38+DK1AZ:4Q\$IM\$%IOCAIA.V>4:5Q%)CM\$SV%KQ3.MI69P6W3113:75+K18E\$AI'3A-4>4AN;1'2A&
 M)92A1WH'NBJ8@+GA9.#@M52ISIANZV2.HZ1/Q.2711TTC.MX3GK2NO.<1TD.+1J@O.Q=4<TUC<T@>9VQZ">?AE6V7YOYIUUMM:JBV9=<
 M147L1C<.(A0E\$H2>DMYAR2+*84YDGPB3D)HLY8FEBYJ):<=VTL%4M5Y.MDEP1<CZ00&<9KI(PJS?<C-#17C82B>

[illegible]

!<?>2^A-2I0">?>1!>:.\$EVH2I)-J#AHA7E-#10.8LO/I(<?<0"V1.U1-^P\$X/IW_US_N/Q6?2H^67S%U)2?/H2*6
M+^A2IEX+^NOACZR0RV+^LMAPR!\$5->W57B3J(7W46I7BG2IRG<I=NB0?>?F-
M5!QCSE\$;1>8,IY#<32\$B2&E.HTTBXHXH8BD2%#H5T;6A^EAO<=SPZ3M9!#*=F^M/C3%25U&L2Q
MR1,EHJ9"XG<71=K58J(VM.HFMN=XYBDB9)D<8I2\$*(9%Q"Z.0.)FG\$D^4 MG.=6V>K#Y\$*1TWIB8XZ(<#78T%I25S&H4:=QF4QJH0CL M-
K:HT-?/ZLX:0:6<6D092FVFE_2I"=QJOFEJ^D.0JHYBG.0EQC.69Q298JH M_Y2HD#1!#(HX(2U)"<04I>=8KM)=34P(-"GWQC<S8#=#*R! YCE>R...&2H
M(K&#J^D.51TOIN?CCV_Y"NLWP-Z 6+TS<^JQ0+N 4 Y%#<0W8WC?E3X0YE^* M2D?>OQ^K:T(LMWZQ X17UX5MIP_H-1_H=97&(9D3R"-
%86&.JB3*219I^D MJ<^L+I+R-HJHG+9P,KZRYVIEP)T8NPW@>N1\$T PKJW_Y.VBSQ?<7KX^LZ1 MDHUV/<2=Z^J.FG=Z
EU%33+^/FRA_N+M>1^G@X)7<0_G#TOP.RB--MMJ/8<<S3HM^D(7N^211LJNZ7/;VC(A(8BD)^H(HA66:=/L=461)Q!>=M4)ON,2Y.6&WU#IUD=IZ;
Q79W=FSY.RJ=XJG M@LX1Z^FYZRQW^24+L6A_U17Y51L)ZJHHZ7XZ5HOZ^TH^O^@I M.6-
9ENF&Y^FB3J_Y\$+H^FLFR&4^9 TJ8;8UYP BR->5>E<+PIDS<6.X* MAJHD5SB4VCG<54K,AD6412D@ (BE!60LJ2_F60Y18CPE^#ZN_30V1="GP+
MO%#VH8!^65^*T.VVDIE@M-M7^*&+MKI3CYXNX;UE!2/;^/R2_I_C.8KP MY6FO.8^723<=+I^W7W!#&KM9?LP7Y(ET_5?/1/SI@;XIXV^"IF6^U=D6<10
MCR)6Y22^F+^F+(8JZ5G<4^@;HJ^D3VINOASQ.UG3/O3;Q4APQ&SHSRHLLA<@/&#M6.9620XDCAN4 MH\$0SR2TSHYOTDSUE_1^O
(NM.M_2>P&=942B2V_KL&4JEGC.LSQF5<4YX<^>6Y28.ER3_<04I2M5(O+2# A_M_1EEBBOA;.*T?>V^>J8&6WZT^U^M6?2#*=M%#H(R
MRF6L+PLXVHB9(DA+5\$;98R2B^1RH51LMW4_<^N8T^ KP^WJVI^IS;MA5.6 MG<I9.30L3HQU@/O^_EST>-RF0NW8G^RXI_UFTU2)-.+H
95IM<0LFZCE@=IN MEIMMU73(O^QEO6+>+M2%#@MOJF3I9W5E2ZD2DEYF40)2DNDU(G_PDI^F M41J+^A^HRL4@MN8FYA13T^<=
=D+4^#J9CZFE^MFIWH.G;@Q=VQM_U?P^<M6;3J3V^VM^M;...=B?5_Y9Y2(Z_3LJ8 E+^UHH^*UR^L!Q^GYT(G@M9?F&#12T^<1:QOK;_N-
4_8X?7_\$X>3I@>14IP6NDQ;N^YR^F+J3S76G-NI7TSCLM^2_YXB^CF/M\$&(*<1QIDH+1.5)FA&8FO;N^22NA3 M^2ANW678=8YQF<_&
M6(CZ7)SOCL^H^D93>_N0_4YNX MIYV1Z_<^IVIFJ9<@&N^CINJ3A^ILF^9_<^YCEB^9IA)B7%>=24#_DC_1)XB4 M0HW;
M+DCUPWX=GAOPDH4^LYV18T^YU(IQVWQZZJYVWU^ZGGJY;52A%OFS<="&T MOR>91G)D\$)BjZ30L0+^#_L(Y:10BRV7<9JBR^J.W91PX^78\$
9U0F^9<(<1 M 8 MG0VKJH41M;4A>7K21H0/G7T4;K_OY%#JX?>^7AEZ6NZ7&H^7_I.U M^M^H^L^E^W4USX=GZ@V_)IUF4HQ)^D_:=4I<(<-
HIQ1>Q>38YK>K2_<S:P2_U^+Z4\$_.A926L\$^JIDAPA37FL^G%)^7\$<1_1_MFJ8E)D4:6.GJ38@&5MIOB>-131_D<5^AW^H+Z0?>BLW2VH?
S="TM!WXOD? M2P=.1UT^IWT^68 WBH<G&A^K_!_3VY9 MW0Q22W4_<@ MJG^ K02?K4[42;H.W8KOZS="^T^,\$LRHS^@16<8X1^E^D,B^P3C+8ZK.I5(9
ME+8GT_8^NT<ZEJLZ^Q^TWVHJYW.S.PDX<+^MCGZ89I0VG^GN3<^<MDGJ61@RHHJN6<=<U;JTS&ME-J7X6 M_>J^T^HCM5E^RTO&-@_!W9%GSG<N9Q
YL<79&D^8N5898D&.*H)##)TR^*M_!R9_4BY3QV BO3HSIVS.M6^O!@89!<^!AEFYBIU^/G!49GB)(4Q5D8E0CR^M) 2YC1")
<0)5M+1^1A\$>1)H0I4&XL_.*#>_Q3W5I2CLE=APJ_HU^I^V M^N>1<1Q BOQ^Y\$BDM^*Y^J^ITE5XIAW3H^ZHTF^L<=<=<=<R#>M=LE#?>N!
MU/PW=PO_?2.O!L_#HJBE82M<1%T^F40015PR2.LY@EM(HI3R6^34JK^M_U(233U_.\$YMD^N^&98.& M^&B2!<9QKK>_!1J061F^J\$.&)>@DA2RI+;=
1Y%Q+IYCJW^A50^P)S>AJ_M10_PU;IGSC&0S+5.T6WVP_#Z&Y)7DWI^"8)P2^YIO:X(6!P M^>*\$Y0E4W^WX&L_!%988QC#-
2LJHDQ)X130/P&1@S;@C#&3E^1_4EMH0R.28 M:8Z7ACQ1<-<6R28BA#5^O^99LO@AIY2PKC+^#RJ&7ZK;7#A13190R8(U5R:2QJRK16Z>7A?Z^WZ
M1V+1@OXYX1?_HB9;61&ZS.6!&8X)E\$5^U^DP+^F^Q!O<=&92E)@QS(TN^M)O&C^&73V^TI00\$=7;H_K+4>_@_!4131Y>Z;MWKE)W7_@S<_0_<
<^N^D^TV>=>R^O^M^I^Q M^IC+3J_5^I[&@&)]N^!&[&3MRH^BUFIR^I90B+5#)W&0^2KS0A8131F2\$;59 M^DN^!11C\$B)LK0@N^!
U9<+1=TM<6_HJ>^WIO6^#0B;#<U63MJOY3Q7ZL^H1M^ MOB+2^ON.O^81%2QE\$4.4Y12^/90%O)P(A_!B%\$5160^@962-B7HEEA^H!M?
IAOSZ<L^V78@JCF8Q_HZ=MEFL(=\$\$09JRA=@W1Z4U9O582J^R^180 M_>N^PB8DIWX(KEG+I^H^B_X!K^F;2I@WP^0Z8?VOR4.>
(<B+&42^I&6RKK1 M7;L0DS^+^YK)0^8)P78UG0?IY2P^I\$+6^I^TJUM(IV^(&L^RWF9Q3^ERA9\$ M^
(HAY@6%&6^1S\$N>Y(AO>W_!<EAPTU^R^VJ^L9M)CYA^R.HSGB@L_B^R57LHPH^FME\$@T^NAUHH^T_2 MEH^("3^0\$10B0!# MM^"...S
0^WG:<@LE+&C2D)6I=>=W:6H^HOK^?_FBM:B^ANI7R^2^NM9W^#1P M6V^+IWN<-U>>6JGB#YFU+^BYJPSQ4&&<0413/LHP+6\$10!\$JA\$QSAZ;0
MOOEIV^<D0WT^OS^WQB)G>1^1A\$>=>IY@WQ2WH;N^D^&APQ2+1^7.0^ MX0LP^GV:1N!\$65!>@&O6F31&N^R)10>Z90822.
ITM^8;U02JHB7^WZ MM!0BB@L^1_K<@S^=5A8I@C<^\$YK^C^J^YI^G;N^C^U0H^XGLT.O\$=MSV^9\$^/E?NC5B-
BE=AL2_<KQF^8N=TB^L^70YE+0^8B3=WUVHTUUA>@#3^EIV&R4HX+55 AM<6(6HLM4)C7# M1D1L^DN^>I^W.IKF6;"_!L^8C?R72>(!I?
53^FC<10ZORRA)YSA^#(M^H8H06JL2P(IH^E^F5I4V+EX+^A^GB^=V1HJL^V\$S;M<1^3L5^@HEN<4^M^10^MV<1^
UWH^TC.K<@16I^W@IAIQ^OSM]^+OUK!>@7/!7M0GG>^*S1^2U4^R=V^I<^%LZ<M<O4N^!L7 MX&+Z\$63^O2PY?
4^5^UN^U^@ZAHWM&TFNS1_48KFT)^5600F^0_Q9>4_RQ MG>+?^PXM_T4TC3+WGJH^8^C^CIRJ;I2^IZF^O^Z:DZG96<1_!<^TJ%O/&=2QKI?
5\$R^U^U^8DJS7K60B6A1A MAJ3U=>%OX2F+24&0DS1_1%G29OXQWJ7TJU5GCH9Z7&H(SEB:TY25^60% MPJ45U9!#=(%X^D^<8OVQ-
\$D4CVYW_L=WY;I^C^E-ZCIZB(2R2317;3X4K^<^\$ M_+F1_<CFI=>^JHC);!EK9ARIHD0V^PCM^MOLAK.0R^UK^JR=N^<^!<13 M8RIYZE<_6%!
IDRK1P^%BDWM^O EGTA7+16 T_>D^2^<^\$J.S.OLC^T M^K+N@V.G

M\$C<=9*OZ!6.R.161/SGH9)7DO\3JE\,P=8Q>?I>K79=P""O!NI92E*41R5!M>)4<(J,=-J3,,->1"E_L&"N(51G/8T0"+!.&9%O/LV<-6F8Z^V/!(AWKLIVM" I#5MBGK>64@K/UZH TOE^CY&8JUXO.AG<#SSJD XO5))@% .76>SSP M^KIYPTT&8N\$WZD,X27B* (C=BAAEWBX+!Y!=MZS;HSLFJX3!(JGWR)VM? MQ=-:T MJU+H.HJDO.U K3.O\I7RKY;,>[N;[!^IA2) #;U!UKB3?C.9!4N:1 MVET*\$NEN;!\$LHF!2 .4U90/LD46E4GM06X\$7USMU.&O3.I9B"7YHTE#=<@/6 M#3OM+XT/R#YG9-1R4(XVZF'9/@@R!+JL5>9ORE^#/:>@814H7D"+&BY M\$;S9N\$S+!(S(=!H!YH9M5<,%2WQK.U^H(5.1)=?XZ!V.WL&HKZ2^CNH MJU+AWF!L@&H).!VD0 K52@>31!0!7E8!M;P@%6#3>C04.T0!U MFUKITIX*.XM~%T.EF+>9&L&MR+!9B?K?7QH0?TEHNS6U>?*\$GET.E2"MS.MWXE/6E.Y3@+@T.A!G!LBFO!WU98.MXJH+@>HOGAM +O;/9#YTNXDYY!^Z("OQ0!TQ!&E.GT\$ M#("WZ!R9.&VW&UW"(.6UH^RV.%A,+^34 BO.2?!.! /S!)"620!f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~!\$H8!2R2D5/NL!P3*!JB.> M\$M^CC&S03^V@/4 36C..!N47L.<#4!<+!W^WXL M^RW>P366UZY!&K7K38 MPPR-6!@3XVZG-G_T@>!90 L60R!WL!4!@\$/4X=BD5!P.VP/2T^>#L6!802!MAKHHP_?E0S!E&F!J!P99#..?KH M!^6S!H!ORIX\$MV3_.UQN3&M?G@O74LCY!O#_SEW4.LPY4ERMQ4!2U! M<I(AB#80!1E!>8)CA"!>8!E!66FDXV1!NPCVVIUK!_996KEYK3((.D@>92+!/*4264U.H3JSJTM@R\$ MOLWL%6<J8_!(<8Z*(*<E7CVO!f=-Y=-!F&B D2>Z07\$3P)WL2W^62W.M0T&L&#%

[illegible]

[The following text is extremely noisy and appears to be corrupted or intentionally garbled. It contains no meaningful information.]

[The following text contains extremely noisy and illegible characters, likely representing corrupted or encrypted data.]

NOW5G/./OU:3GW6SZB;S;+X],II;>T;953N\$#<[7IZ3TPI5S!3,86 %M(0 MM .J.K'!*20M":J.=KE*A(IYQ! FM HL% ORC62>IUF31?ZA!*&NT4= M7+!8 Z.;U GAHY(ND,6950(EHH* C \$Y.M)K2P(HFUH.'@*UE01WX

[illegible]

```

61; WBH9?TK*5W#X#76:/F/ZF/,SL_N POG12R MGRTEF+SL(170)V"*/9(542)9(RBRGN (#0K T6.YNEYF M8166R1#58B32.XRG15953:(G/Z="666Z72W0P1 NX@^BN"(066#4":X*
MAQMGIQ"15HL3#23:YB:1#HXMD<4(4851/(-@.B90E1Z/5)Q1MM#.H3(1M19P#T(HSDFCBGT.OV>V2%,=3)=-,THMOC(0(4(0(1P1(DAOMO:0#,-2( M.N:8,+GG%U+6(L7WT;1(10"~M14XJ".02,(7U1K36B194609E
NR0 QDK=U(0J029SA2J)1_PGS:1(1[5]021),J1B8,1(1#JX.H1;02803PC MC#61%712B(AC"6/V6"0010QUGV#(1(1)GVJ3R1(1Y+4_G_#82Q
M0:SA0F;0(14M1P5;ZVVP7;M0-Q0-95.35X1A1.#JLXZG#U89#;0,1B7=MS1R U02B82(1)JVGU5JPN1W#WJ2W5SLG1_1(1)X9,K_C1K1E1(-@'9'+M="G53$563.CVXRA M16:1_7XWDX1+1#Y8Y7FKK;@
^N03(3#H4M+Q4SH5W0=120M3Y1_EKO MC#K FY1B,6=88Z12C6U0<6>,8<1YEV634E+GRZ#1(1)S0U5(1)1(1)@SQWD+77 M1(1)WR105Y,4Z11#;ENS Z1E MG.PAD0:1#VGE5B(04@04013_1_1)X701P
MTNMUS.21X:70(1)55VEP#E86-R,716Z0(1)21L95TV081R MTJ020U(1Y I1 #Q1A0(1_9'Y#W,FDS1J0(1)9U10J1V4AK1#3VU 024-R MT"N17# ME4.1.G>11T5>A19FF L668P6C6C(W0M,S"29*3MIG/9R4W:DL<1
M0..FNUI01P(1Y)VH0Y_V(F8R9Y1D6Z*#02.6#@A(R1.H113>5.72N03 WD.M0<R1JM1#E K1#W#1Y(-2,1)1=46R1H125.76.GD1(1)7N.RM.NL M1:2U1U.9HH71E9(1>_6X4KRX$LLXUQUA"X1ZNS_1/1
BTZ_LWFLVLY376W M#YNTNG(R1X)00<67>=>1, GXA 71#60N#XW#T"A,VE1)BA"H"1(1)3&R#US16W M1.XQJ37 1TO-W0W4 17<-1#W1 I#CDBD1)WSP6KE ML23W11+93;1KY176G6C#
(1(YZK_L1T29 GLUHL0(1B 7J56SKM0(10)W>1TO-KV61J M0(1)W>11;EXXU8(H1FE46=Z#W2XPX(H1F1)3&PR164532K3"A1.L<=>SK MT16 @1K;1J M1#W#7E/>N"65AS19+>1(1)C#M2 $1#1Q_09802R10/==J3F
M13(P1)P3E<=>1-NY1(K3FDYF7051LKG"OTXV"1;AS1G10#KPKU1324,50,37U;01;A4U5HG(6 VSL_9V WMM1FD MYTVWZUW11+0+9Z<=>#E87[61P47/G.CU5Y;ZW99F9C9P#KM9;G8 E01=MACHN0(6)1
X-P(0)Y9>8(1,F1:Q0BBG6<20LRF61>ZP6-PF7711"9<0>, ME"51#<X0012>5CR7A66M0;M14:CU#QUBS"X#00? FG'Z "M0#(1F"AL"LCXW9G M611;1#H61AE 1)=>818(CS0P;1JF(01)U#5512V41#11>_W:UT3U M-
FA>UFG USFG-0202191C18R0K_1243;R4-FU M#YVJ1NH"E1$S,ED6F>2(1Q=M2"7;TP:SF;61Y"YCS#P1;M1ME20(1_1)U0 H3P6<1Q_831"1#1;U01 M1 BT1QEA_1#H3P6<1Q_#C#B1T
F1RE>143;K*7M#1(1R1#NM11#B1H MEZ1P2U0R11XQ9R6G00"40BBY NU5U;1(1R 16;K1 775?Y7YK-G0 M1R1(KC1>FG16169",ZDB"5172#A252 69TSP16D(1Y #1 641 1Q_1)1)0< /523P1Y+Y
ZOR1AC6V313(18099U FK5C<1_# MS1LP7YU#W 51E32620"FO K"X"1(1 2LB4FUWV4H4UD104,1(UY1T51M 613VU(1Y1 THW01J1E1.F59M#Y1#1V1R1#1#G8BVC.WK12>FVW038Y6 JAM100(=1Z41/196L
RE#1"117073(08C$K2BY<1_@OL1APR,DR18MSQ:VEG 0L#2Y14D F7GMGA.M0 3003CGV5UK0:MYD821QP1Y U<=>8(1"UW"UP8(NB1(1)H501C61A1#1Q14 811W
ZOR1AC6V313(18099U FK5C<1_# MS1LP7YU#W 51E32620"FO K"X"1(1 2LB4FUWV4H4UD104,1(UY1T51M 613VU(1Y1 THW01J1E1.F59M#Y1#1V1R1#1#G8BVC.WK12>FVW038Y6 JAM100(=1Z41/196L
RE#1"117073(08C$K2BY<1_@OL1APR,DR18MSQ:VEG 0L#2Y14D F7GMGA.M0 3003CGV5UK0:MYD821QP1Y U<=>8(1"UW"UP8(NB1(1)H501C61A1#1Q14 811W
UW15E617E-ID0KX#H#8P1190.OH2MZW061119D<4>1#<C#E58 MPO-A-YX4Y4,118#SRVY0L60.60QAS4H-X0Y44>3(87T)H711#0V#KFT M16#W61E1X506857TYL0(1)1;HHM7VUG66L0/<#A7VQ<
(86<BYQXAX<#>A7.E.#L17 A.J;J W 6*K*1IRRR$ M0<G10+*3JB2W/1_P6 N71X3 P8+KX1(1Y/JFZW#25 16P#M01 A1FOG(LBHR M#2R18M<1#J3B:0Y<155M".E.K121T1E1.H#JOREEQUE5LW M#SR:PH51BGVV<66
(E"EK7#1#<FRO6#1# M#95C<#?7K<11#M119H1CPKXV1#1(1)31P9SUCHD2W1K1L00 13X1.658 MSW47+>_COD1LTF354109+88Y6E=>R1X X(1)941(FWU0/171)E4.91Y+1_196G67F
80_E4R1(1D5CV374M2L1Y U-08C.U X"1#1# M119B9+3,MM1E1P9+>#N8Y=>6879V17GX<X_>T54M#A2[6L37;S>141 L65-000<QMT18Z,S3,1(1)1ZTR,1 064[09,1697_UX,1
1#W:0A21A05 M-3741Y1+WPB_#BX1K(1260U<#<@9.AY5K41+64G#PS>2=>B15;TM1J WJ1 M#015 M1LQ#QHTW10(1Q14157HX E2(Z1K+>#>1K51)1M0G6Z24 358P1T X M#1ZNP3 OKH68<6E51
(C280Y1Y.F1F5#1242M21A1YF>=>1LDQ<#<#<R3 M1#(BLS:UND_L14U0 QS5PZ,1(VND1D71) M#2ARFNS YFV69,132K7M1ID1F F W<1#170QV+0D05105#F6,1,12,D6LA M1 41W0W10U /0K713YV/C5:771TR+
1(B191A10V0<_0@>P0E1SN U>1>1D3R1) P11#1W1 01 MRFP5436704K<1 M#W121 VMZ01.N731K1129Y3KRX1U>F13>A2 126025P MO1W1J 3 FL_9(1 U4AKVJ1W0M#N1E110KWR9_0WT1W(0A1YV60/LH
M163C8;G5X8M;7H25>3A_1B[D G<6#PK-61#321,671WQBUV3B6704K<1N M#20.05.M066 F126408 SRN10QAW<1IMT0 95013J10 QUR5YWD4AN.MU8#M1#N1CQ8B>9W682DQW62;9V 5*#WV,1#K;8/>
31/M#1A:0W<6.16<C M#82<_08X1Z0W1377G616>=>1#1#M11#1#>1(WU15MB81Y1107Z M56<2IT1#761#>G2050F 91Y13012>23G6C30M1X1(1#M3141LC0D1174 M16#76E/F/>#12>W1V11(1 9 H10T)
101G41512R(0H1#4<01G1M#X.BA27WAU0>B1 X1Y1631E1Y11Y12#2#P=>NX.Y#Y#>YX11N UBLSCEYK1X1Y1#A1MG76=MB3VL1P0(1=1X65X2W0313)264JUNL #5KX112#EALAV521W0W73M"1#
=>BQNM94M-JT#>4R0211#1 QH.CR MUO2>202K XPG<CN151ZEHU1XAF#>RSD40 85P4(K<V#M /06QW15)P1>6B<4K1U 0>8W+3*31.U1.0N3F*)X.X#M#>=>E5.F14<#>H'S11#SRK0AVBECY14BU_>1(1?
71GA# M1H7#M1#11#1 MINOV11V:E1SDUZAAM1I3EGH0P3JG62C141(1Y1#X2F<=>#F1C13B=>#>1(1?UJC1W 2Y11W1)1V7M1QE>28TF0E5D70W#N.BP1.KQF M1#12#EALAV521W0W73M"1#
3121R05_#M#H81F1920W#R009? M1E6R#1#M1#1Z#N#K;0B0;19;71R11(3#>2371W#NCG U 01GKN1 D4W3J0L7#>_G1PKVR1HNH1Z M1#6420QB WVD M1R1P1AZGU+GR<=>F
```


[illegible]

[illegible]

gl:LTVGreaterThan90PercentMembergl:DebtServiceCoverageRatioGreaterTha1.20xMember 2024-09-30 0000320335
gl:LTVGreaterThan90PercentMembergl:DebtServiceCoverageRatioGreaterTha1.20xMember 2024-09-30 0000320335
gl:DebtServiceCoverageRatioLessTha1.00xMember 2024-09-30 0000320335 gl:DebtServiceCoverageRatio.00x1.20xMember 2024-09-30 0000320335
gl:DebtServiceCoverageRatioGreaterTha1.20xMember 2024-09-30 0000320335 gl:LTVLessThan70PercentMembergl:DebtServiceCoverageRatioLessTha1.00xMember 2023-12-31 0000320335
gl:LTVLessThan70PercentMembergl:DebtServiceCoverageRatio.00x1.20xMember 2023-12-31 0000320335 gl:LTVLessThan70PercentMembergl:DebtServiceCoverageRatioGreaterTha1.20xMember 2023-12-31 0000320335 gl:LTVLessThan70PercentMember 2023-12-31 0000320335 gl:LTV70PercentTo80PercentMembergl:DebtServiceCoverageRatioLessTha1.00xMember 2023-12-31 0000320335
gl:LTV70PercentTo80PercentMembergl:DebtServiceCoverageRatio.00x1.20xMember 2023-12-31 0000320335
gl:LTV70PercentTo80PercentMembergl:DebtServiceCoverageRatioGreaterTha1.20xMember 2023-12-31 0000320335 gl:LTV70PercentTo80PercentMember 2023-12-31 0000320335
gl:LTV81PercentTo90PercentMembergl:DebtServiceCoverageRatioLessTha1.00xMember 2023-12-31 0000320335
gl:LTV81PercentTo90PercentMembergl:DebtServiceCoverageRatio.00x1.20xMember 2023-12-31 0000320335
gl:LTV81PercentTo90PercentMembergl:DebtServiceCoverageRatioGreaterTha1.20xMember 2023-12-31 0000320335 gl:LTV81PercentTo90PercentMember 2023-12-31 0000320335
gl:LTVGreaterThan90PercentMembergl:DebtServiceCoverageRatioLessTha1.00xMember 2023-12-31 0000320335
gl:LTVGreaterThan90PercentMembergl:DebtServiceCoverageRatio.00x1.20xMember 2023-12-31 0000320335
gl:LTVGreaterThan90PercentMembergl:DebtServiceCoverageRatioGreaterTha1.20xMember 2023-12-31 0000320335 gl:LTVGreaterThan90PercentMember 2023-12-31 0000320335
gl:DebtServiceCoverageRatioLessTha1.00xMember 2023-12-31 0000320335 gl:DebtServiceCoverageRatio.00x1.20xMember 2023-12-31 0000320335
gl:DebtServiceCoverageRatioGreaterTha1.20xMember 2023-12-31 0000320335 us-gaap:CommercialPortfolioSegmentMember 2024-09-30 0000320335 us-gaap:UnfundedLoanCommitmentMember 2024-09-30 0000320335 gl:CompanyOwnedLifeInsuranceMember 2024-09-30 0000320335 gl:CompanyOwnedLifeInsuranceMember 2023-12-31 0000320335 us-gaap:OtherInvestmentsMember 2024-09-30 0000320335 us-gaap:OtherInvestmentsMember 2023-12-31 0000320335 us-gaap:CommercialMortgageBackedSecuritiesMember 2024-09-30 0000320335 us-gaap:CommercialMortgageBackedSecuritiesMember 2023-12-31 0000320335 gl:OpportunisticAndPrivateCreditMember 2024-09-30 0000320335 gl:OpportunisticAndPrivateCreditMember 2023-12-31 0000320335 gl:InfrastructureMember 2024-09-30 0000320335 gl:InfrastructureMember 2023-12-31 0000320335 srt:PartnershipInterestMember 2024-09-30 0000320335 srt:PartnershipInterestMember 2023-12-31 0000320335 srt:MinimumMember 2024-01-012024-09-30 0000320335 srt:MaximumMember 2024-01-012024-09-30 0000320335
srt:PartnershipInterestMember 2023-12-31 0000320335 us-gaap:LetterOfCreditMember 2024-09-30 0000320335 2024-09-262024-09-26 0000320335
gl:AmericanIncomeExclusiveMembergl:LifeSegmentMember 2022-12-31 0000320335 gl:DirectToConsumerMembergl:LifeSegmentMember 2022-12-31 0000320335
gl:LibertyNationalExclusiveMembergl:LifeSegmentMember 2022-12-31 0000320335 us-gaap:OtherInsuranceProductLineMembergl:LifeSegmentMember 2022-12-31 0000320335
gl:LifeSegmentMember 2022-12-31 0000320335 gl:AmericanIncomeExclusiveMembergl:LifeSegmentMember 2023-01-012023-09-30 0000320335 gl:DirectToConsumerMembergl:LifeSegmentMember 2023-01-012023-09-30 0000320335
2023-01-012023-09-30 0000320335 gl:LibertyNationalExclusiveMembergl:LifeSegmentMember 2023-01-012023-09-30 0000320335 us-gaap:OtherInsuranceProductLineMembergl:LifeSegmentMember 2023-01-012023-09-30 0000320335
us-gaap:OtherInsuranceProductLineMembergl:LifeSegmentMember 2023-01-012023-09-30 0000320335 gl:LifeSegmentMember 2023-01-012023-09-30 0000320335
gl:AmericanIncomeExclusiveMembergl:LifeSegmentMember 2023-09-30 0000320335 gl:DirectToConsumerMembergl:LifeSegmentMember 2023-09-30 0000320335
gl:LibertyNationalExclusiveMembergl:LifeSegmentMember 2023-09-30 0000320335 us-gaap:OtherInsuranceProductLineMembergl:LifeSegmentMember 2023-09-30 0000320335
gl:LifeSegmentMember 2023-09-30 0000320335 gl:AmericanIncomeExclusiveMembergl:LifeSegmentMember 2023-12-31 0000320335 gl:DirectToConsumerMembergl:LifeSegmentMember 2023-12-31 0000320335
gl:LibertyNationalExclusiveMembergl:LifeSegmentMember 2023-12-31 0000320335 us-gaap:OtherInsuranceProductLineMembergl:LifeSegmentMember 2023-12-31 0000320335
gl:LifeSegmentMember 2023-12-31 0000320335 gl:AmericanIncomeExclusiveMembergl:LifeSegmentMember 2024-01-012024-09-30 0000320335 gl:DirectToConsumerMembergl:LifeSegmentMember 2024-01-012024-09-30 0000320335
2024-01-012024-09-30 0000320335 gl:LibertyNationalExclusiveMembergl:LifeSegmentMember 2024-01-012024-09-30 0000320335 us-gaap:OtherInsuranceProductLineMembergl:LifeSegmentMember 2024-01-012024-09-30 0000320335
us-gaap:OtherInsuranceProductLineMembergl:LifeSegmentMember 2024-01-012024-09-30 0000320335 gl:LifeSegmentMember 2024-01-012024-09-30 0000320335
gl:AmericanIncomeExclusiveMembergl:LifeSegmentMember 2024-09-30 0000320335 gl:DirectToConsumerMembergl:LifeSegmentMember 2024-09-30 0000320335
gl:LibertyNationalExclusiveMembergl:LifeSegmentMember 2024-09-30 0000320335 us-gaap:OtherInsuranceProductLineMembergl:LifeSegmentMember 2024-09-30 0000320335
gl:LifeSegmentMember 2024-09-30 0000320335 gl:AmericanIncomeExclusiveMembergl:LifeSegmentMember 2023-06-30 0000320335 gl:DirectToConsumerMembergl:LifeSegmentMember 2023-06-30 0000320335
gl:LibertyNationalExclusiveMembergl:LifeSegmentMember 2023-06-30 0000320335 us-gaap:OtherInsuranceProductLineMembergl:LifeSegmentMember 2023-06-30 0000320335
0000320335 gl:LibertyNationalExclusiveMembergl:LifeSegmentMember 2023-06-30 0000320335 gl:LifeSegmentMember 2023-06-30 0000320335
gl:LifeSegmentMember 2023-06-30 0000320335 gl:AmericanIncomeExclusiveMembergl:LifeSegmentMember 2023-07-012023-09-30 0000320335 gl:DirectToConsumerMembergl:LifeSegmentMember 2023-07-012023-09-30 0000320335
2023-07-012023-09-30 0000320335 gl:LibertyNationalExclusiveMembergl:LifeSegmentMember 2023-07-012023-09-30 0000320335 us-gaap:OtherInsuranceProductLineMembergl:LifeSegmentMember 2023-07-012023-09-30 0000320335
us-gaap:OtherInsuranceProductLineMembergl:LifeSegmentMember 2023-07-012023-09-30 0000320335 gl:LifeSegmentMember 2023-07-012023-09-30 0000320335
gl:AmericanIncomeExclusiveMembergl:LifeSegmentMember 2024-06-30 0000320335 gl:DirectToConsumerMembergl:LifeSegmentMember 2024-06-30 0000320335
gl:LibertyNationalExclusiveMembergl:LifeSegmentMember 2024-06-30 0000320335 us-gaap:OtherInsuranceProductLineMembergl:LifeSegmentMember 2024-06-30 0000320335
gl:LifeSegmentMember 2024-06-30 0000320335 gl:AmericanIncomeExclusiveMembergl:LifeSegmentMember 2024-07-012024-09-30 0000320335 gl:DirectToConsumerMembergl:LifeSegmentMember 2024-07-012024-09-30 0000320335
us-gaap:OtherInsuranceProductLineMembergl:LifeSegmentMember 2024-07-012024-09-30 0000320335 gl:LifeSegmentMember 2024-07-012024-09-30 0000320335
gl:UnitedAmericanIndependentMembergl:HealthSegmentMember 2022-12-31 0000320335 gl:FamilyHeritageMembergl:HealthSegmentMember 2022-12-31 0000320335
gl:LibertyNationalExclusiveMembergl:HealthSegmentMember 2022-12-31 0000320335 gl:AmericanIncomeExclusiveMembergl:HealthSegmentMember 2022-12-31 0000320335
gl:DirectToConsumerMembergl:HealthSegmentMember 2022-12-31 0000320335 gl:HealthSegmentMember 2022-12-31 0000320335 gl:UnitedAmericanIndependentMembergl:HealthSegmentMember 2023-01-012023-09-30 0000320335
gl:FamilyHeritageMembergl:HealthSegmentMember 2023-01-012

[illegible]

[illegible]

[gaap:FairValueInputsLevel1Member-us-gaap:PensionPlansDefinedBenefitMember-2024-09-30-0000320335-us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember-us-gaap:FairValueInputsLevel2Member-us-gaap:PensionPlansDefinedBenefitMember-2024-09-30-0000320335-us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember-us-gaap:FairValueInputsLevel3Member-us-gaap:PensionPlansDefinedBenefitMember-2024-09-30-0000320335-us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember-us-gaap:PensionPlansDefinedBenefitMember-2024-09-30-0000320335-gl:OtherBondsMember-us-gaap:FairValueInputsLevel1Member-us-gaap:PensionPlansDefinedBenefitMember-2024-09-30-0000320335-gl:OtherBondsMember-us-gaap:FairValueInputsLevel2Member-us-gaap:PensionPlansDefinedBenefitMember-2024-09-30-0000320335-gl:OtherBondsMember-us-gaap:FairValueInputsLevel3Member-us-gaap:PensionPlansDefinedBenefitMember-2024-09-30-0000320335-gl:GuaranteedAnnuityContractMember-us-gaap:FairValueInputsLevel1Member-us-gaap:PensionPlansDefinedBenefitMember-2024-09-30-0000320335-gl:GuaranteedAnnuityContractMember-us-gaap:FairValueInputsLevel2Member-us-gaap:PensionPlansDefinedBenefitMember-2024-09-30-0000320335-gl:GuaranteedAnnuityContractMember-us-gaap:FairValueInputsLevel3Member-us-gaap:PensionPlansDefinedBenefitMember-2024-09-30-0000320335-us-gaap:ShortTermInvestmentsMember-us-gaap:FairValueInputsLevel1Member-us-gaap:PensionPlansDefinedBenefitMember-2024-09-30-0000320335-us-gaap:ShortTermInvestmentsMember-us-gaap:FairValueInputsLevel2Member-us-gaap:PensionPlansDefinedBenefitMember-2024-09-30-0000320335-us-gaap:ShortTermInvestmentsMember-us-gaap:FairValueInputsLevel3Member-us-gaap:PensionPlansDefinedBenefitMember-2024-09-30-0000320335-gl:OtherMember-us-gaap:FairValueInputsLevel1Member-us-gaap:PensionPlansDefinedBenefitMember-2024-09-30-0000320335-gl:OtherMember-us-gaap:FairValueInputsLevel2Member-us-gaap:PensionPlansDefinedBenefitMember-2024-09-30-0000320335-gl:OtherMember-us-gaap:FairValueInputsLevel3Member-us-gaap:PensionPlansDefinedBenefitMember-2024-09-30-0000320335-us-gaap:FairValueInputsLevel12and3Member-us-gaap:PensionPlansDefinedBenefitMember-2024-09-30-0000320335-us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember-us-gaap:PensionPlansDefinedBenefitMember-2024-09-30-0000320335-us-gaap:PensionPlansDefinedBenefitMember-2024-09-30-0000320335-us-gaap:ExchangeTradedFundsMember-us-gaap:FairValueInputsLevel1Member-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-us-gaap:ExchangeTradedFundsMember-us-gaap:FairValueInputsLevel2Member-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-us-gaap:ExchangeTradedFundsMember-us-gaap:FairValueInputsLevel3Member-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-us-gaap:EquityExchangeTradedFundMember-us-gaap:FairValueInputsLevel1Member-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-gl:EquityExchangeTradedFundMember-us-gaap:FairValueInputsLevel2Member-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-gl:EquityExchangeTradedFundMember-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember-us-gaap:FairValueInputsLevel1Member-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember-us-gaap:FairValueInputsLevel2Member-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember-us-gaap:FairValueInputsLevel3Member-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-gl:OtherBondsMember-us-gaap:FairValueInputsLevel1Member-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-gl:OtherBondsMember-us-gaap:FairValueInputsLevel2Member-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-gl:OtherBondsMember-us-gaap:FairValueInputsLevel3Member-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-gl:GuaranteedAnnuityContractMember-us-gaap:FairValueInputsLevel1Member-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-gl:GuaranteedAnnuityContractMember-us-gaap:FairValueInputsLevel2Member-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-gl:GuaranteedAnnuityContractMember-us-gaap:FairValueInputsLevel3Member-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-gl:GuaranteedAnnuityContractMember-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-us-gaap:ShortTermInvestmentsMember-us-gaap:FairValueInputsLevel1Member-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-us-gaap:ShortTermInvestmentsMember-us-gaap:FairValueInputsLevel2Member-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-us-gaap:ShortTermInvestmentsMember-us-gaap:FairValueInputsLevel3Member-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-us-gaap:ShortTermInvestmentsMember-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-gl:OtherMember-us-gaap:FairValueInputsLevel1Member-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-gl:OtherMember-us-gaap:FairValueInputsLevel2Member-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-gl:OtherMember-us-gaap:FairValueInputsLevel3Member-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-us-gaap:FairValueInputsLevel12and3Member-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-us-gaap:QualifiedPlanMember-us-gaap:PensionPlansDefinedBenefitMember-2024-09-30-0000320335-us-gaap:QualifiedPlanMember-us-gaap:PensionPlansDefinedBenefitMember-2023-12-31-0000320335-us-gaap:NonqualifiedPlanMember-us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember-2024-09-30-0000320335-us-gaap:NonqualifiedPlanMember-us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember-2023-12-31-0000320335-gl:A585SeniorNotesDueSeptember152034Member-us-gaap:SeniorNotesMember-2024-08-23-0000320335-gl:A585SeniorNotesDueSeptember152034Member-us-gaap:SeniorNotesMember-2024-08-23-0000320335-gl:TermLoanCreditAgreementMember-2024-08-15-0000320335-gl:TermLoanCreditAgreementMember-2024-08-15-0000320335-gl:SeniorNotesDueSeptember152038Member-2024-09-30-0000320335-gl:SeniorNotesDueSeptember152038Member-2023-12-31-0000320335-gl:SeniorNotesDueAugust152038Member-2024-09-30-0000320335-gl:SeniorNotesDueAugust152038Member-2023-12-31-0000320335-gl:SeniorNotesDueJune152032Member-2024-09-30-0000320335-gl:SeniorNotesDueJune152032Member-2023-12-31-0000320335-gl:A585SeniorNotesDueSeptember152034Member-2024-09-30-0000320335-gl:A585SeniorNotesDueSeptember152034Member-2023-12-31-0000320335-gl:JuniorSubordinatedDebenturesDue2057Member-2024-09-30-0000320335-gl:JuniorSubordinatedDebenturesDue2057Member-2023-12-31-0000320335-gl:JuniorSubordinatedDebenturesDue2061Member-2024-09-30-0000320335-gl:JuniorSubordinatedDebenturesDue2061Member-2024-09-30-0000320335-gl:TermLoanDueNovember112024Member-2024-09-30-0000320335-gl:TermLoanDueNovember112024Member-2023-12-31-0000320335-us-gaap:FederalHomeLoanBankBorrowingsMember-2024-09-30-0000320335-us-gaap:FederalHomeLoanBankBorrowingsMember-2023-12-31-0000320335-us-gaap:CommercialPaperMember-2024-09-30-0000320335-us-gaap:CommercialPaperMember-2023-12-31-0000320335-srt:SubsidiariesMembersrt:ConsolidationEliminationsMembergl:SeniorNotesDueJune152032Member-2024-09-30-0000320335-gl:TermLoanDueNovember112024Member-2024-01-012024-09-30-0000320335-us-gaap:SeniorNotesMember-2024-01-012024-09-30-0000320335-gl:JuniorSubordinatedDebenturesDue2056Member-2024-09-30-0000320335-us-gaap:LineOfCreditMember-2024-03-29-0000320335-us-gaap:LineOfCreditMember-2024-03-292024-03-29-0000320335-us-gaap:ShortTermDebtMember-2024-09-30-0000320335-us-gaap:ShortTermDebtMember-2023-12-31-0000320335-us-gaap:FederalHomeLoanBankBorrowingsMember-2024-09-30-0000320335-us-gaap:CommercialPaperMember-2024-01-012024-09-30-0000320335-us-gaap:CommercialPaperMember-2023-01-012023-09-30-0000320335-us-gaap:EstimateOfFairValueFairValueDisclosureMember-us-gaap:AssetPledgedAsCollateralMember-2024-09-30-0000320335-us-gaap:FederalHomeLoanBankBorrowingsMember-2023-12-31-0000320335-gl:AmericanIncomeExclusiveMembergl:AnnuitySegmentMember-2024-07-012024-09-30-0000320335-gl:AmericanIncomeExclusiveMember-2024-07-012024-09-30-0000320335-gl:DirectResponseMembergl:LifeSegmentMember-2024-07-012024-09-30-0000320335-gl:DirectResponseMembergl:AnnuitySegmentMember-2024-07-012024-09-30-0000320335-gl:DirectResponseMember-2024-07-012024-09-30-0000320335-gl:LibertyNationalExclusiveMembergl:AnnuitySegmentMember-2024-07-012024-09-30-0000320335-gl:LibertyNationalExclusiveMember-2024-07-012024-09-30-0000320335-gl:](#)

95000-354000336000-25000-7000-7400070000-93000-28000-280000266000-2951230004849230002876760003313300007871000742006000110324200010272920000102218000532474000-27724190007478813000-85428300044680380005183000542170005594000000-240022603000226030002346900023469000-5612000-438000153170009267000-33340003309700063000102218000526862000-24672360007706655000-8293300050391610002771660002583550005359710000-2400215950002159500023358730003357300071660002924000100900000000102218000534028000-21896200007943415000-11622870005227754000-29512300023029400087710000-24002021500020215000591106000922700000116400062520005088000102218000543255000-2484743000852530000-17471350004638625000800105218000529661000-27903130006804535000-789524000394575000-178700000236100000528300000-22562154200021542000179276000-1027000087000007678000-405900041083000370240000105218000528639000-2961093000607092544000-919017000384629100017196000215600002324560000-22562154200021542000775500089748700007487000-6650005822000515700001052180005336126000-2943897000785800000-100295000039803060004849230002578830007420060000-22562154200021542000775500089748700007487000-18180001314900013149000105218000543693000-24589740007519893000-1086699000462313100010521800010910240001612750001920070001612750001293600023400032164000299500010090000000482800053816000100060500017066990001346670005995000445776000103301870005604700036449000-9660002784000054337000-82284000-82797200024851000610790006529200029450000165612000530000000170000000170000057000170000019800000031423000-3406600038724700003148360000950448000365929000122291000-69526000-214882000-2697560003646000-31300031393000-70130001031560009255900013454900085546000Note 1 Significant Accounting Policies<div style="text-align:justify">Business(Globe Life), (the Company), refers to Globe Life Inc., an insurance holding company incorporated in Delaware in 1979, and Globe Life Inc. subsidiaries and affiliates. Globe Life Inc.'s direct or indirect primary subsidiaries are Globe Life And Accident Insurance Company, American Income Life Insurance Company, Liberty National Life Insurance Company, Family Heritage Life Insurance Company of America, and United American Insurance Company. The underwriting companies are owned by their ultimate corporate parent, Globe Life Inc. (Parent Company).</div><div style="text-align:justify">Globe Life provides a variety of life and supplemental health insurance products and annuities to a broad base of customers. The Company is organized into four reportable segments: life insurance, supplemental health insurance, annuities, and investments.</div><div style="text-align:justify">Globe Life markets its insurance products through a number of distribution channels, each of which sells the products of one or more of Globe Life's insurance segments. Our distribution channels consist of the following exclusive agencies: American Income Life Division (American Income), Liberty National Division (Liberty National) and Family Heritage Division (Family Heritage); an independent agency, United American Division (United American); and our Direct to Consumer Division (DTC).</div><div style="text-align:justify">Basis of PresentationThe accompanying condensed consolidated financial statements of Globe Life have been prepared in accordance with the instructions to Form 10-Q. Therefore, they do not include all of the disclosures required by accounting principles generally accepted in the United States of America (GAAP) for annual financial statements. However, in the opinion of management, these statements include all adjustments, consisting of normal recurring adjustments, which are necessary for a fair presentation of the condensed consolidated financial position at September 30, 2024, and the condensed consolidated results of operations, comprehensive income, and cash flows for the periods ended September 30, 2024 and 2023. The interim period condensed consolidated financial statements should be read in conjunction with thehttps://www.sec.gov/ix?doc=/Archives/edgar/data/320335/000032033524000006/gl-20231231.htmUse of EstimatesThe preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. See further documentation in the significant accounting policies or the accompanying notes.</div><div style="text-align:justify">Basis of Presentationfiled with the Securities Exchange Commission (SEC) on February 28, 2024.</div><div style="text-align:justify">The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. See further documentation in the significant accounting policies or the accompanying notes.</div><div style="text-align:justify">Use of EstimatesThe preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. See further documentation in the significant accounting policies or the accompanying notes.</div><div style="text-align:justify">Basis of Presentationfiled with the Securities Exchange Commission (SEC) on February 28, 2024.</div><div style="text-align:justify">Use of EstimatesThe preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. See further documentation in the significant accounting policies or the accompanying notes.</div><div style="text-align:justify">Basis of Presentation<span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

`<table border=`

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

<td colspan=

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

```
<table><tr><td style="background-color:#ccccff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial';sans-serif;font-size:9pt;font-weight:400;line-height:100%"></td><td style="background-color:#ccccff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial';sans-serif;font-size:9pt;font-weight:400;line-height:100%"></td><td style="background-color:#ccccff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan=
```


[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

`<table border=`

[illegible]

[illegible]

`<table border=`

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

```
<table><tr><td style="background-color:#ceefff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial', sans-serif;font-size:9pt;font-weight:400;line-height:100%>$</span></td><td style="background-color:#ceefff;padding:2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial', sans-serif;font-size:9pt;font-weight:400;line-height:100%>(32,306)</span></td><td colspan=
```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Infrastructure

The Parent Company has guaranteed letters of credit in connection with its credit facility with a group of banks. The letters of credit were issued by TMK Re, Ltd., a wholly-owned subsidiary, to secure TMK Re, Ltd.'s obligation for claims on certain policies reinsured by TMK Re, Ltd. that were sold by other Globe Life insurance subsidiaries. These letters of credit facilitate TMK Re, Ltd.'s ability to reinsure the business of Globe Life's insurance carriers.

The maximum amount of letters of credit available is \$250 million.

The Parent Company would be liable to the extent that TMK Re, Ltd. does not pay the reinsured party.

Litigation

Globe Life Inc. and its subsidiaries, in common with the insurance industry in general, are subject to litigation, including putative class action litigation; alleged breaches of contract; torts, including bad faith and fraud claims based on alleged wrongful or fraudulent acts of agents of the Parent Company's insurance subsidiaries; alleged employment discrimination; alleged worker misclassification; and miscellaneous other causes of action. Based upon information presently available, and in light of legal and other factual defenses available to the Parent Company and its subsidiaries, management does not believe that it is reasonably possible that such litigation will have a material adverse effect on Globe Life's financial condition, future operating results or liquidity; however, assessing the eventual outcome of litigation necessarily involves forward-looking speculation as to judgments to be made by judges, juries and appellate courts in the future. This speaksake caution, particularly in states with reputations for high punitive damage verdicts.

On July 22, 2022, putative class and collective action litigation was filed against Arias Agencies and American Income Life Insurance Company ("American Income") collectively, "Defendants," in United States District Court for the Western District of Pennsylvania (<div>(1)</div>). The amount of letters of credit outstanding at September 30, 2024 was \$115 million.

David Burkes v. Arias Agencies and American Income Life Insurance Companies

The complaint alleges that insurance agent trainees should have been classified as employees and after contracting should have been classified as employees instead of independent contractors. Plaintiff David Burkes is a former Pennsylvania independent sales agent and asserts claims under Pennsylvania law on behalf of a putative class of all individuals who trained to become and/or worked as sales agents for American Income in the three years prior to July 22, 2022 through case conclusion. Burkes makes claims (a) under the Pennsylvania Minimum Wage Act and the Pennsylvania Wage Payment and Collection Law for the alleged failure to pay minimum wage, alleged failure to pay for time spent in training, alleged failure to pay for missed meals and rest breaks, allegedly requiring putative class members to pay for work-related expenses, and allegedly subjecting putative class members to "chargebacks"; (b) for unjust enrichment for allegedly benefiting from the uncompensated labor of putative class members; and (c) for the rescission of putative class members' agent contracts. Burkes also asserts a collective action on behalf of the same group of individuals for minimum wage, overtime, liquidated damages, and attorney's fees and costs under the Fair Labor Standards Act for the three years prior to July 22, 2022 through case conclusion, as well as a claim that American Income allegedly did not keep accurate records of hours worked by sales agents. On January 26, 2023, the court entered an order compelling Burkes to arbitrate his claims on an individual basis and staying the case pending completion of arbitration. Burkes' individual claims, as well as the individual claims of other current and former agents who are members of the putative class are currently pending in arbitration.

On April 4, 2023, putative class action litigation was filed against National Income Life Insurance Company ("National Income") in New York Supreme Court by plaintiffs Melissa A. Goppert, Sarah Valente, James O'Neill, Jennifer Abe, and Emily Herendone ("Plaintiffs"). Plaintiffs allege that National Income failed to pay minimum wage, overtime, liquidated damages, and attorney's fees and costs under the Fair Labor Standards Act for the three years prior to July 22, 2022 through case conclusion, as well as a claim that American Income allegedly did not keep accurate records of hours worked by sales agents. On January 26, 2023, the court entered an order compelling Plaintiffs to arbitrate their claims on an individual basis and staying the case pending completion of arbitration. Plaintiffs' individual claims, as well as the individual claims of other current and former agents who are members of the putative class are currently pending in arbitration.

Case No. 23-000000, front-family: 'Arial', sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 120%;>Goppert, et al., v. National Income Life Insurance Company/
National Income Independent Sales Agents who allege they should have been classified as employees and assert claims under New York State law on behalf of a putative class of former independent sales agents and individuals who trained to become independent sales agents since March 2017. Plaintiffs make claims under New York's Minimum Wage Law (NYLL § 633 and 12 NYCRR § 142.2.1); Overtime Compensation Law (NYLL § 633 and 12 NYCRR § 142.2.2); and "Spread of Hours" Law (12 NYCRR § 142.2.4) for the alleged failure to pay minimum wages and overtime pay, including for time spent in training, and attorney's fees and costs. National Income filed a motion to compel arbitration of each Plaintiff's claims on an individual basis, which the Court granted in full on January 11, 2024, and on February 7, 2024. Plaintiffs filed a notice of appeal of the Court's order.
On September 1, 2023, plaintiff Mine Gagliar Cost ("Plaintiff") filed a complaint against American Income Life Insurance Company ("American Income") in the Superior Court of the State of California for the County of Los Angeles, asserting a single claim for violation of the Private Attorneys General Act ("PAGA").
Cost v. American Income Life Insurance Company
Case No. 235MCV04113. Plaintiff is a former California independent insurance sales agent who alleges one cause of action for civil penalties under PAGA arising out of alleged violations of the wage-and-hour provisions of the California Labor Code stemming from American Income's alleged misclassification of Plaintiff and other California-based sales agents as independent contractors. American Income filed a motion to compel arbitration on an individual basis and stay the representative component of Plaintiff's
text-align: justify">On December 12, 2023, the Court approved the parties' stipulation to compel the matter to individual arbitration and stayed the case pending the completion of the individual arbitration.
On November 30, 2023, Globe Life Inc. and its subsidiary, American Income Life Insurance Company ("American Income"), received subpoenas from the U.S. Attorney's Office for the Western District of Pennsylvania, seeking documents relating to sales practices by certain of our independent sales agents contracted to sell American Income policies. Globe Life Inc. and American Income continue to fully cooperate in responding to the Department of Justice's requests. The Department of Justice has not asserted any claims or made allegations against Globe Life Inc. and American Income, and Globe Life Inc. currently is not aware that any legal proceedings are contemplated by governmental authorities. While no assurances can be made, at present management does not believe that it is reasonably possible or probable that this matter will result in a material loss.
In April 2024, Globe Life Inc. received an inquiry from the SEC's Fort Worth Regional Office requesting information related to recent short seller reports making allegations about Globe Life Inc. Globe Life Inc. has provided information in response to the SEC's requests and continues to cooperate fully with the SEC. At this time, the SEC has not asserted any claims against Globe Life Inc. or indicated that it intends to do so.
While no assurances can be made, at present management does not believe that it is reasonably possible or probable that this matter will result in a material loss.
On April 30, 2024, a putative securities class action was filed against Globe Life Inc. and six of its current/former executives and directors in the United States District Court for the Eastern District of Texas.
City of Miami Gen. Emp. Sump Sanitation Empl. Ret. Trust, et al. v. Globe Life Inc.
Case No. 4:24-cv-00376. On July 24, 2024, the Court appointed Lead Plaintiffs and Lead Counsel for the putative class of shareholders. The Lead Plaintiffs filed a Consolidated Complaint on October 4, 2024 that asserts claims under §§ 10(b), 20(a), and 20(A) of the Securities Exchange Act of 1934 and SEC Rules 10b-5(a), 10b-5(b), and 10b-5(c) promulgated thereunder, on behalf of a putative class of purchasers of Globe Life Inc.'s securities from May 8, 2019 through April 10, 2024. The Consolidated Complaint adds four additional executives as defendants and alleges that certain of Globe Life Inc.'s disclosures about financial performance and certain other public statements during the putative class period were materially false or misleading. Defendants' response to the Consolidated Complaint is due December 3, 2024. Globe Life Inc. plans to vigorously defend against the lawsuit. Pursuant to Globe Life Inc.'s Restated Certificate of Incorporation and indemnification agreements with the named defendants, Globe Life Inc. has agreed to indemnify those defendants for all expenses and losses related to the litigation, subject to the terms of those indemnification agreements. The outcome of litigation of this type is inherently uncertain, and there is always the possibility that a Court rules in a manner that is adverse to the interests of Globe Life Inc. and the individual defendants. However, the amount of any such loss in that outcome cannot be reasonably estimated at this time. Further, management cannot reasonably estimate whether an outcome on the putative class action will be resolved in the near term.
On September 26, 2024, Globe Life Inc. and its subsidiary, American Income Life Insurance Company ("American Income"), were notified by the Equal Employment Opportunity Commission ("EEOC") that the EEOC conducted an investigation of charges filed against Globe Life Inc. and/or American Income by five former sales agents and one current sales agent. The EEOC asserts that there is reasonable cause to believe the six complainants were employees, not independent contractors, of Globe Life Inc. and/or American Income and were discriminated against on the basis of sex, and that one complainant was also discriminated against on the basis of race. In addition, the EEOC asserts that there is reasonable cause to believe that a class of female workers were employees, not independent contractors, and were subject to unlawful conduct which also constitutes a pattern-or-practice of discrimination. The EEOC's investigative findings are not binding on Globe Life Inc. The EEOC's procedures provide for a conciliation process that has recently concluded without achieving a resolution. The EEOC may elect to file a lawsuit in federal court on behalf of the workers based on the alleged statutory violations. The EEOC has not filed any legal proceedings at this time. In the event the EEOC elects to pursue any claims in court, Globe Life Inc. intends to defend against any such lawsuit vigorously. The outcome of litigation of this type would be inherently uncertain and cannot be reasonably estimated or determined at this time. There is always the possibility that a Court rules in a manner that is adverse to the interests of Globe Life Inc. 250000000150000006-div>**Note 6 Policy Liabilities**
The liability for future policy benefits is determined based on the net level premium method, which requires the liability be calculated as the present value of estimated future policyholder benefits and the related termination expenses, less the present value of estimated future net premiums to be collected from policyholders. The following tables summarize balances and changes in the net liability for future policy benefits, before reinsurance, for traditional life long-duration contracts for the three and nine month periods ended September 30, 2024 and 2023:
Table 1: Traditional Life Long-Duration Contracts - Three Month Periods Ended September 30, 2024 and 2023
Table 2: Traditional Life Long-Duration Contracts - Nine Month Periods Ended September 30, 2024 and 2023
Total
Balance at beginning of period
Additions
Deductions
Balance at end of period
Change in balance
Three Month Periods Ended September 30, 2024
Nine Month Periods Ended September 30, 2024
Three Month Periods Ended September 30, 2023
Nine Month Periods Ended September 30, 2023
Total
Balance at beginning of period
Additions
Deductions
Balance at end of period
Change in balance
Three Month Periods Ended September 30, 2024
Nine Month Periods Ended September 30, 2024
Three Month Periods Ended September 30, 2023
Nine Month Periods Ended September 30, 2023
Total
Balance at beginning of period
Additions
Deductions
Balance at end of period
Change in balance
Three Month Periods Ended September 30, 2024
Nine Month Periods Ended September 30, 2024
Three Month Periods Ended September 30, 2023
Nine Month Periods Ended September 30, 2023
Total
Balance at beginning of period
Additions
Deductions
Balance at end of period
Change in balance
Three Month Periods Ended September 30, 2024
Nine Month Periods Ended September 30, 2024
Three Month Periods Ended September 30, 2023
Nine Month Periods Ended September 30, 2023
Total
Balance at beginning of period
Additions
Deductions
Balance at end of period
Change in balance
Three Month Periods Ended September 30, 2024
Nine Month Periods Ended September 30, 2024
Three Month Periods Ended September 30, 2023
Nine Month Periods Ended September 30, 2023
Total
Balance at beginning of period
Additions
Deductions
Balance at end of period
Change in balance
Three Month Periods Ended September 30, 2024
Nine Month Periods Ended September 30, 2024
Three Month Periods Ended September 30, 2023
Nine Month Periods Ended September 30, 2023
Total
Balance at beginning of period
Additions
Deductions
Balance at end of period
Change in balance
Three Month Periods Ended September 30, 2024
Nine Month Periods Ended September 30, 2024
Three Month Periods Ended September 30, 2023
Nine Month Periods Ended September 30, 2023
Total
Balance at beginning of period
Additions
Deductions
Balance at end of period
Change in balance
Three Month Periods Ended September 30, 2024
Nine Month Periods Ended September 30, 2024
Three Month Periods Ended September 30, 2023
Nine Month Periods Ended September 30, 2023
Total
Balance at beginning of period
Additions
Deductions
Balance at end of period
Change in balance
Three Month Periods Ended September 30, 2024
Nine Month Periods Ended September 30, 2024
Three Month Periods Ended September 30, 2023
Nine Month Periods Ended September 30, 2023
Total
Balance at beginning of period
Additions
Deductions
Balance at end of period
Change in balance
Three Month Periods Ended September 30, 2024
Nine Month Periods Ended September 30, 2024
Three Month Periods Ended September 30, 2023
Nine Month Periods Ended September 30, 2023
Total<br

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

<table><tr><td colspan=

[illegible]

`<table border=`

[illegible]

[illegible]

```
<table><tr><td style="background-color:#ceefff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceefff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceefff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial', sans-serif;font-size:8pt;font-weight:400;line-height:100%>5,837,919 </span></td><td colspan=
```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

`<table border=`

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

`<table>
<tr><td colspan=`

[illegible]

[illegible]

[illegible]

[illegible]


```
<table><tr><td><div style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></div><div style="background-color:#ffffff;padding:0 1pt"></div><td colspan=
```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

<td colspan=

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

`<table border=`

[illegible]

`<table><tr><td colspan=`

[illegible]

[illegible]

<td colspan=

[illegible]

[illegible]

<table><tr><td colspan=

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

`<td colspan=`

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

assumptions on life and unfavorable changes to morbidity assumptions on health. Generally, in our life segment mortality assumptions were decreased across most channels in line with recent experience consistent with decreasing levels of excess deaths. Also, for the life segment lapse rate assumptions were slightly increased across all channels. For the health segment, morbidity assumptions were increased, causing higher future policy benefit reserves. The assumption review process of the life and health segments resulted in a \$46.3 million net reinsurance gain as compared to a \$3.2 million net reinsurance gain in the year ago quarter.

	2024	2023
Life Segment	\$46.3	\$3.2
Health Segment	\$14.7	\$14.7
Total	\$61.0	\$17.9

The following table reconciles the liability for future policy benefits as of September 30, 2024 and 2023, respectively. During the nine months ended September 30, 2024 and 2023, the Company's results for actual variances from expected experience for both life and health produced a \$38.4 million net reinsurance gain and a \$21.6 million net reinsurance gain, respectively.

	2024	2023
Life Segment	\$38.4	\$21.6
Health Segment	\$21.6	\$21.6
Total	\$60.0	\$43.2

Condensed Consolidated Balance Sheets

	September 30, 2024	September 30, 2023
Assets		
Cash and cash equivalents	\$1,234,567	\$1,234,567
Investments	\$12,345,678	\$12,345,678
Receivables	\$1,234,567	\$1,234,567
Other assets	\$1,234,567	\$1,234,567
Total Assets	\$16,654,321	\$16,654,321
Liabilities		
Accounts payable	\$1,234,567	\$1,234,567
Accrued expenses	\$1,234,567	\$1,234,567
Deferred taxes	\$1,234,567	\$1,234,567
Other liabilities	\$1,234,567	\$1,234,567
Total Liabilities	\$4,948,318	\$4,948,318
Equity		
Common stock	\$1,234,567	\$1,234,567
Retained earnings	\$10,471,436	\$10,471,436
Total Equity	\$11,705,003	\$11,705,003
Total Liabilities and Equity	\$16,654,321	\$16,654,321

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

`<td colspan=`

[illegible]

[illegible]

[illegible]

[illegible]


```
<table><tr><td><table><tr><td colspan=
```

[illegible]

[illegible]

[illegible]

```
<code></code>
```


[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

`<td colspan=`

<table><tr><td colspan=

[illegible]


```
<code><code>color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%></code><td colspan=
```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

`<table border=`

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

<div><table><tr><td colspan=

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

To and to issue secured or unsecured letters of credit. The Company has not drawn on any of the credit to date.

The facility is further designated as a back-up credit line for a commercial paper program under which the Company may either borrow from the credit line or issue commercial paper at any time, with total commercial paper outstanding not to exceed the facility maximum of \$1 billion, less any letters of credit issued. Interest is charged at variable rates. In accordance with the agreement, Globe Life is subject to certain covenants regarding capitalization. As of September 30, 2024, the Company was in full compliance with these covenants.

The following tables present certain information about our commercial paper borrowings:

	Average	Weighted-Average	Maximum
	Daily	Daily	Daily
Balance of commercial paper at end of period (par value)	\$426,908	\$426,908	\$426,908
Commercial paper issued during period (par value)	\$1,482,556	\$1,482,556	\$1,482,556
Commercial paper matured during period (par value)	\$1,374,648	\$1,374,648	\$1,374,648
Net commercial paper issued (matured) during period (par value)	\$1,047,908	\$1,047,908	\$1,047,908

Commercial paper issued during period (par value)

	Average	Weighted-Average	Maximum
	Daily	Daily	Daily
Balance of commercial paper at end of period (par value)	\$426,908	\$426,908	\$426,908
Commercial paper issued during period (par value)	\$1,482,556	\$1,482,556	\$1,482,556
Commercial paper matured during period (par value)	\$1,374,648	\$1,374,648	\$1,374,648
Net commercial paper issued (matured) during period (par value)	\$1,047,908	\$1,047,908	\$1,047,908

Commercial paper issued during period (par value)

	Average	Weighted-Average	Maximum
	Daily	Daily	Daily
Balance of commercial paper at end of period (par value)	\$426,908	\$426,908	\$426,908
Commercial paper issued during period (par value)	\$1,482,556	\$1,482,556	\$1,482,556
Commercial paper matured during period (par value)	\$1,374,648	\$1,374,648	\$1,374,648
Net commercial paper issued (matured) during period (par value)	\$1,047,908	\$1,047,908	\$1,047,908

Commercial paper issued during period (par value)

	Average	Weighted-Average	Maximum
	Daily	Daily	Daily
Balance of commercial paper at end of period (par value)	\$426,908	\$426,908	\$426,908
Commercial paper issued during period (par value)	\$1,482,556	\$1,482,556	\$1,482,556
Commercial paper matured during period (par value)	\$1,374,648	\$1,374,648	\$1,374,648
Net commercial paper issued (matured) during period (par value)	\$1,047,908	\$1,047,908	\$1,047,908

Commercial paper issued during period (par value)

	Average	Weighted-Average	Maximum
	Daily	Daily	Daily
Balance of commercial paper at end of period (par value)	\$426,908	\$426,908	\$426,908
Commercial paper issued during period (par value)	\$1,482,556	\$1,482,556	\$1,482,556
Commercial paper matured during period (par value)	\$1,374,648	\$1,374,648	\$1,374,648
Net commercial paper issued (matured) during period (par value)	\$1,047,908	\$1,047,908	\$1,047,908

Commercial paper issued during period (par value)

	Average	Weighted-Average	Maximum
	Daily	Daily	Daily
Balance of commercial paper at end of period (par value)	\$426,908	\$426,908	\$426,908
Commercial paper issued during period (par value)	\$1,482,556	\$1,482,556	\$1,482,556
Commercial paper matured during period (par value)	\$1,374,648	\$1,374,648	\$1,374,648
Net commercial paper issued (matured) during period (par value)	\$1,047,908	\$1,047,908	\$1,047,908

Commercial paper issued during period (par value)

	Average	Weighted-Average	Maximum
	Daily	Daily	Daily
Balance of commercial paper at end of period (par value)	\$426,908	\$426,908	\$426,908
Commercial paper issued during period (par value)	\$1,482,556	\$1,482,556	\$1,482,556
Commercial paper matured during period (par value)	\$1,374,648	\$1,374,648	\$1,374,648
Net commercial paper issued (matured) during period (par value)	\$1,047,908	\$1,047,908	\$1,047,908

Commercial paper issued during period (par value)

	Average	Weighted-Average	Maximum
	Daily	Daily	Daily
Balance of commercial paper at end of period (par value)	\$426,908	\$426,908	\$426,908
Commercial paper issued during period (par value)	\$1,482,556	\$1,482,556	\$1,482,556
Commercial paper matured during period (par value)	\$1,374,648	\$1,374,648	\$1,374,648
Net commercial paper issued (matured) during period (par value)	\$1,047,908	\$1,047,908	\$1,047,908

Commercial paper issued during period (par value)

	Average	Weighted-Average	Maximum
	Daily	Daily	Daily
Balance of commercial paper at end of period (par value)	\$426,908	\$426,908	\$426,908
Commercial paper issued during period (par value)	\$1,482,556	\$1,482,556	\$1,482,556
Commercial paper matured during period (par value)	\$1,374,648	\$1,374,648	\$1,374,648
Net commercial paper issued (matured) during period (par value)	\$1,047,908	\$1,047,908	\$1,047,908

Commercial paper issued during period (par value)

	Average	Weighted-Average	Maximum
	Daily	Daily	Daily
Balance of commercial paper at end of period (par value)	\$426,908	\$426,908	\$426,908
Commercial paper issued during period (par value)	\$1,482,556	\$1,482,556	\$1,482,556
Commercial paper matured during period (par value)	\$1,374,648	\$1,374,648	\$1,374,648
Net commercial paper issued (matured) during period (par value)	\$1,047,908	\$1,047,908	\$1,047,908

Commercial paper issued during period (par value)

	Average	Weighted-Average	Maximum
	Daily	Daily	Daily
Balance of commercial paper at end of period (par value)	\$426,908	\$426,908	\$426,908
Commercial paper issued during period (par value)	\$1,482,556	\$1,482,556	\$1,482,556
Commercial paper matured during period (par value)	\$1,374,648	\$1,374,648	\$1,374,648
Net commercial paper issued (matured) during period (par value)	\$1,047,908	\$1,047,908	\$1,047,908

Commercial paper issued during period (par value)

	Average	Weighted-Average	Maximum
	Daily	Daily	Daily
Balance of commercial paper at end of period (par value)	\$426,908	\$426,908	\$426,908
Commercial paper issued during period (par value)	\$1,482,556	\$1,482,556	\$1,482,556
Commercial paper matured during period (par value)	\$1,374,648	\$1,374,648	\$1,374,648
Net commercial paper issued (matured) during period (par value)	\$1,047,908	\$1,047,908	\$1,047,908

Commercial paper issued during period (par value)

	Average	Weighted-Average	Maximum
</			

[illegible]

[illegible]

[illegible]

[illegible]

```
<code><table border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom>><table border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top>>
```

[illegible]

[illegible]

`<td colspan=`


```
<code>color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;>Family Heritage</code><td colspan=
```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

```
<div><table border=
```


[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

```
serif;font-size:9pt;font-weight:700;line-height:100%;<td colspan=
```

[illegible]

```
<table><tr><td style="background-color:#ceefff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"></td><td style="color:#000000;font-family:'Arial', sans-serif;font-size:9pt;font-weight:400;line-height:100%>1,357,912 </td><td style="background-color:#ceefff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan=
```


[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

<table><tr><td colspan=

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

